<SEC-DOCUMENT>0001640334-15-000301.txt : 20151112
<SEC-HEADER>0001640334-15-000301.hdr.sgml : 20151112
<ACCEPTANCE-DATETIME>20151112172343
ACCESSION NUMBER:		0001640334-15-000301
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		11
CONFORMED PERIOD OF REPORT:	20150930
FILED AS OF DATE:		20151112
DATE AS OF CHANGE:		20151112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nemus Bioscience, Inc.
		CENTRAL INDEX KEY:			0001516551
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				450692882
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-55136
		FILM NUMBER:		151226002

	BUSINESS ADDRESS:	
		STREET 1:		650 TOWN CENTER DRIVE, SUITE 1770
		CITY:			COSTA MESA
		STATE:			CA
		ZIP:			92626
		BUSINESS PHONE:		(949) 396-0330

	MAIL ADDRESS:	
		STREET 1:		650 TOWN CENTER DRIVE, SUITE 1770
		CITY:			COSTA MESA
		STATE:			CA
		ZIP:			92626

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LOAD GUARD LOGISTICS, INC.
		DATE OF NAME CHANGE:	20121107

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LOAD GUARD TRANSPORTATION, INC.
		DATE OF NAME CHANGE:	20110324
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>nmus_10q-09302015.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: pubco1
    Document created using EDGARfilings PROfile 3.6.1.0
    Copyright 1995 - 2015 Summit Financial Printing, LLC.  All rights reserved.-->
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif" bgcolor="#ffffff" text="#000000">
<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">UNITED STATES</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">SECURITIES AND EXCHANGE COMMISSION</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Washington, D.C. 20549</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">FORM 10-Q&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">(Mark One)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">&#160;</div>

<table id="41e38d5441b748b5aa589743c0f6d039" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 4.16%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">[X]</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 95.84%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 100%" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">For the quarterly period ended September 30, 2015</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">or</div>

<div><br>
</div>

<table id="79a40f0f616546ef823dcbf34ec43a57" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 4.16%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">[&#160; &#160;]</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 95.84%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">For the transition period from ____ to _____</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">Commission File Number: <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>000-55136</u></font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: right">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center"><u>Nemus Bioscience, Inc.</u></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">(Exact name of registrant as specified in its charter)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: right">&#160;</div>

<table id="5cbce132253a4494b06c85b1cd4e43fc" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-VARIANT: normal; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; FONT-STYLE: normal; BORDER-BOTTOM-COLOR: ; WIDTH: 50%">
<div style="TEXT-ALIGN: left"><u>Nevada</u></div>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-VARIANT: normal; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; FONT-STYLE: normal; BORDER-BOTTOM-COLOR: ; WIDTH: 50%">
<div style="TEXT-ALIGN: right"><u>45-0692882</u></div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 50%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">(State or other jurisdiction</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">of incorporation or organization)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 50%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">(I.R.S. Employer</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">Identification No.)</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: right">&#160;</div>

<table id="f03e83251f214b8da609cda10ac4f41a" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; FONT-VARIANT: normal; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; FONT-STYLE: normal; BORDER-BOTTOM-COLOR: ; WIDTH: 100%">
<div style="TEXT-ALIGN: center"><u>650 Town Center Drive, Suite 1770, Costa Mesa, CA 92626</u></div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 100%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">(Address of principal executive offices) (Zip Code)</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: right">&#160;</div>

<table id="bb6221b001a64a99a47f09ef8cfa1b66" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-VARIANT: normal; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; FONT-STYLE: normal; BORDER-BOTTOM-COLOR: ; WIDTH: 100%">
<div style="TEXT-ALIGN: center"><u>(949) 396-0330</u></div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 100%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">(Registrant's telephone number, including area code)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">________________________________________________</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">(Former name or former address, if changed since last report)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Indicate by check mark whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <font style="FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#61560;</font> Yes&#160; <font style="FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#61551;</font> No</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: right">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160; <font style="FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#61560;</font> Yes&#160; <font style="FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#61551;</font> No</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: right">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Indicate by check mark whether the registrant is a large accelerated file, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#160;</div>

<table id="70dac70c057647b582fe0022c2025d37" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.77%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Large accelerated filer</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 4.12%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Wingdings; TEXT-ALIGN: left">&#61551;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 41.24%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 24.74%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Accelerated filer</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 4.12%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Wingdings; TEXT-ALIGN: left">&#61551;</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 25.77%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Non-accelerated filer</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 4.12%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Wingdings; TEXT-ALIGN: left">&#61551;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 41.24%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">(Do not check if a smaller reporting company)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 24.74%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Smaller reporting company</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 4.12%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Wingdings; TEXT-ALIGN: left">&#61560;</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: right">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160; <font style="FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#61551;</font> Yes&#160; <font style="FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#61560;</font> No</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: right">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">As of November 12, 2015, there were 19,278,163 shares of the issuer's $0.001 par value common stock issued and outstanding.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
</div>

<div>&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center"><a name="TABLEOFCONTENTS"><!--Anchor--></a>TABLE OF CONTENTS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#160;</div>

<table id="0b35ea315a6249cd9b5216c98f820198" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 100%" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">PART I&#8212;FINANCIAL INFORMATION</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 12.48%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 78.14%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 9.38%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>

<tr style="HEIGHT: 14px">
<td style="VERTICAL-ALIGN: middle; WIDTH: 12.48%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Item 1.</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 78.14%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><a href="#Item1.FinancialStatements">Financial Statements:</a></div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 9.38%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">4</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 12.48%">&#160;</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 78.14%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><a href="#NEMUSBIOSCIENCEINC.ANDSUB">Consolidated Balance Sheets as of September 30, 2015 (Unaudited) and December 31, 2014</a></div>
</td>
<td style="VERTICAL-ALIGN: middle; TEXT-ALIGN: right; WIDTH: 9.38%">&#160;4</td>
</tr>

<tr style="HEIGHT: 18px">
<td style="VERTICAL-ALIGN: middle; WIDTH: 12.48%">&#160;</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 78.14%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><a href="#CONSOLIDATEDSTATEMENTSOFO">Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2015&#160; and 2014 (Unaudited)</a></div>
</td>
<td style="VERTICAL-ALIGN: middle; TEXT-ALIGN: right; WIDTH: 9.38%">&#160;5</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 12.48%">&#160;</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 78.14%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><a href="#CONSOLIDATEDSTATEMENTSOFC">Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2015&#160; and 2014 ( Unaudited)</a></div>
</td>
<td style="VERTICAL-ALIGN: middle; TEXT-ALIGN: right; WIDTH: 9.38%">&#160;6</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 12.48%">&#160;</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 78.14%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><a href="#NOTESTOTHEUNAUDITEDCONSOL">Notes to the Unaudited Consolidated Financial Statements</a></div>
</td>
<td style="VERTICAL-ALIGN: middle; TEXT-ALIGN: right; WIDTH: 9.38%">&#160;7</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 12.48%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Item 2.</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 78.14%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><a href="#Item2.ManagementsDiscussi">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></div>
</td>
<td style="VERTICAL-ALIGN: middle; TEXT-ALIGN: right; WIDTH: 9.38%">&#160;21</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 12.48%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Item 3.</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 78.14%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><a href="#Item3.QuantitativeandQual">Quantitative and Qualitative Disclosures about Market Risk</a></div>
</td>
<td style="VERTICAL-ALIGN: middle; TEXT-ALIGN: right; WIDTH: 9.38%">&#160;25</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 12.48%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Item 4.</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 78.14%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><a href="#Item4.ControlsandProcedur">Controls and Procedures</a></div>
</td>
<td style="VERTICAL-ALIGN: middle; TEXT-ALIGN: right; WIDTH: 9.38%">&#160;25</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 12.48%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 78.14%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 9.38%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 100%" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">PART II &#8211; OTHER INFORMATION</div>
</td>
</tr>

<tr style="HEIGHT: 18px">
<td style="VERTICAL-ALIGN: middle; WIDTH: 12.48%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 78.14%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 9.38%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 12.48%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Item 1.</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 78.14%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><a href="#Item1.LegalProceedings.">Legal Proceedings</a></div>
</td>
<td style="VERTICAL-ALIGN: middle; TEXT-ALIGN: right; WIDTH: 9.38%">&#160;26</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 12.48%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Item 1A.</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 78.14%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><a href="#Item1A.RiskFactors.">Risk Factors</a></div>
</td>
<td style="VERTICAL-ALIGN: middle; TEXT-ALIGN: right; WIDTH: 9.38%">&#160;26</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 12.48%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Item 2.</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 78.14%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><a href="#Item2.UnregisteredSalesof">Unregistered Sales of Equity Securities and Use of Proceeds</a></div>
</td>
<td style="VERTICAL-ALIGN: middle; TEXT-ALIGN: right; WIDTH: 9.38%">&#160;26</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 12.48%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Item 3.</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 78.14%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><a href="#Item3.DefaultsUponSeniorS">Defaults Upon Senior Securities</a></div>
</td>
<td style="VERTICAL-ALIGN: middle; TEXT-ALIGN: right; WIDTH: 9.38%">&#160;26</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 12.48%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Item 4.</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 78.14%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><a href="#Item4.MineSafetyDisclosur">Mine Safety Disclosures</a></div>
</td>
<td style="VERTICAL-ALIGN: middle; TEXT-ALIGN: right; WIDTH: 9.38%">&#160;26</td>
</tr>

<tr style="HEIGHT: 17px">
<td style="VERTICAL-ALIGN: middle; WIDTH: 12.48%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Item 5.</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 78.14%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><a href="#Item5.OtherInformation.">Other Information</a></div>
</td>
<td style="VERTICAL-ALIGN: middle; TEXT-ALIGN: right; WIDTH: 9.38%">&#160;26</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 12.48%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Item 6.</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 78.14%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><a href="#Item6.Exhibits.">Exhibits</a></div>
</td>
<td style="VERTICAL-ALIGN: middle; TEXT-ALIGN: right; WIDTH: 9.38%">&#160;26</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">2</div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div id="DSPFPageHeader" style="WIDTH: 100%"><a style="FONT-STYLE: italic" href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>
</div>

<div>
<div>&#160;</div>

<div>
<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 12pt">FORWARD-LOOKING STATEMENTS</div>

<div><br>
</div>
</div>

<div>
<div>Statements in this Quarterly Report on Form 10-Q that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. In some cases, you can identify forward-looking statements by terminology including "anticipates," "believes," "can," "continue," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "should," "will," "would" or the negative of these terms or other comparable terminology. Factors that could cause actual results to differ materially from those currently anticipated include those set forth in the section titled "Risk Factors" including, without limitation, risks relating to:</div>

<div><br>
</div>
</div>

<div style="TEXT-ALIGN: left">
<table id="32106339889f450eb7ba0ed7acd6bd33" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; VERTICAL-ALIGN: top; WIDTH: 18pt; align: right">&#183;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; WIDTH: auto">the results of our research and development activities, including uncertainties relating to the discovery of potential product candidates and the preclinical and clinical testing of our product candidates;</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left">
<table id="7285f61815b14f48bd8641462066af57" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; VERTICAL-ALIGN: top; WIDTH: 18pt; align: right">&#183;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; WIDTH: auto">the early stage of our product candidates presently under development;</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left">
<table id="b0c74daa8d294ba4a1cdb54226d30d43" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; VERTICAL-ALIGN: top; WIDTH: 18pt; align: right">&#183;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; WIDTH: auto">our need for substantial additional funds in order to continue our operations, and the uncertainty of whether we will be able to obtain the funding we need;</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left">
<table id="9bacba79677e485d9d05c0c48d688702" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; VERTICAL-ALIGN: top; WIDTH: 18pt; align: right">&#183;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; WIDTH: auto">our ability to obtain and, if obtained, maintain regulatory approval of our current product candidates, and any of our other future product candidates, and any related restrictions, limitations, and/or warnings in the label of any approved product candidate;</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left">
<table id="9b401289187248aab542f6d9abde2cd3" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; VERTICAL-ALIGN: top; WIDTH: 18pt; align: right">&#183;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; WIDTH: auto">our ability to retain or hire key scientific or management personnel;</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left">
<table id="805cea178c514023b4e2ce0782159f0d" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; VERTICAL-ALIGN: top; WIDTH: 18pt; align: right">&#183;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; WIDTH: auto">our ability to protect our intellectual property rights that are valuable to our business, including patent and other intellectual property rights;</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left">
<table id="77557427f62440419d3ff5ec43b03f97" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; VERTICAL-ALIGN: top; WIDTH: 18pt; align: right">&#183;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; WIDTH: auto">our dependence on the University of Mississippi, third-party manufacturers, suppliers, research organizations, testing laboratories and other potential collaborators;</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left">
<table id="3e9b76c10e2d445d8264b697bc9d83b1" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; VERTICAL-ALIGN: top; WIDTH: 18pt; align: right">&#183;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; WIDTH: auto">our ability to develop successful sales and marketing capabilities in the future as needed;</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left">
<table id="7020e06e5255417c828b55d11a0e5e9d" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; VERTICAL-ALIGN: top; WIDTH: 18pt; align: right">&#183;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; WIDTH: auto">the size and growth of the potential markets for any of our approved product candidates, and the rate and degree of market acceptance of any of our approved product candidates;</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left">
<table id="b6ac80956bdc496690b76d87477f9e5d" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; VERTICAL-ALIGN: top; WIDTH: 18pt; align: right">&#183;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; WIDTH: auto">competition in our industry; and</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left">
<table id="f0777d48c41748a2aa410be515f19073" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 18pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; VERTICAL-ALIGN: top; WIDTH: 18pt; align: right">&#183;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; WIDTH: auto">regulatory developments in the United States and foreign countries.</td>
</tr>
</table>
</div>

<div>
<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">We operate in a rapidly-changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. The forward-looking statements included in this report speak only as of the date hereof, and except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to actual results or to changes in our expectations.</div>
</div>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">3</div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div id="DSPFPageHeader" style="WIDTH: 100%"><a style="FONT-STYLE: italic" href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">PART I - FINANCIAL INFORMATION</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">&#160;</div>

<div style="MARGIN-BOTTOM: 0.1pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 0.1pt; MARGIN-RIGHT: 0.1pt"><u><a name="Item1.FinancialStatements"><!--Anchor--></a>Item 1. Financial Statements</u></div>
</div>

<div>&#160;</div>

<div><a name="NEMUSBIOSCIENCEINC.ANDSUB"><!--Anchor--></a>

<table id="bee7bd0d3e994a93bd6ba802651c072d" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 100%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">NEMUS BIOSCIENCE, INC. AND SUBSIDIARY</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 100%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">CONSOLIDATED BALANCE SHEETS</div>
</td>
</tr>
</table>
</div>

<div>&#160;</div>

<div>
<table id="08b6b1b7ccd0479c98e1f94f54dddbe8" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="8">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">ASSETS</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">(unaudited)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"></td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">September 30,</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">December 31,</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">2015</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">2014</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">Current assets</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"></td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"></td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;Cash and cash equivalents</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">4,342,722</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">207,330</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;Restricted cash</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">37,500</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;Prepaid expenses</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">95,548</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">64,489</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; PADDING-LEFT: 9pt; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;Other current assets</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">31,110</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">36,580</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; PADDING-LEFT: 18pt; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 9pt">&#160;Total current assets</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">4,506,880</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">308,399</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#160;Property and equipment, net</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">16,046</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">21,354</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#160;Other assets</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; PADDING-LEFT: 9pt; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;Deposits and other assets</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">18,594</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">18,594</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; PADDING-LEFT: 18pt; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 9pt">&#160;Total other assets</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">18,594</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">18,594</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; PADDING-LEFT: 18pt; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 9pt">&#160;Total assets</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">4,541,520</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">348,347</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div>&#160;</div>

<div></div>

<div>
<table id="7688c5f2061747bc89396232bde9604b" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="8">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">(unaudited)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"></td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr style="HEIGHT: 16px">
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">September 30,</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">December 31,</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">2015</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">2014</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr style="HEIGHT: 16px">
<td style="VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#160;Current liabilities</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"></td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"></td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 1%; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;Accounts payable</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">132,234</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">409,497</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 1%; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;Accrued payroll and related expenses</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">144,723</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">45,566</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 1%; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;Accrued license and patent reimbursement fees</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">90,216</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">119,428</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 1%; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;Accrued expenses</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">177,081</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">125,799</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 1%; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;Stock subscription liability</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">100,000</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 1%; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;Provision for conversion of Series B preferred stock</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">75,488</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; PADDING-LEFT: 1%; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;Income taxes payable</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">800</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; PADDING-LEFT: 4%; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;Total current liabilities</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">619,742</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">801,090</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#160;Noncurrent liabilities</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 1%; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;Deferred rent</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">3,221</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">805</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; PADDING-LEFT: 1%; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;Series B warrants</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2,892,392</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; PADDING-LEFT: 4%; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;Total noncurrent liabilities</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2,895,613</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">805</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr style="HEIGHT: 12px">
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; PADDING-LEFT: 4%; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;Total liabilities</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">3,515,355</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">801,895</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#160;Commitments and contingencies</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 1%; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;(Note 3)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr style="HEIGHT: 18px">
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Redeemable Convertible Series B Preferred Stock, $0.001 par value,</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 1%; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;20 million shares authorized;&#160; 5,000 issued and outstanding as of September 30,</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 1%; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;2015 and none issued and outstanding as of December 31, 2014, net of</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr style="HEIGHT: 14px">
<td style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 1%; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;$411,661 in issuance costs; $5.0 million liquidation preference as of September 30, 2015</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1,620,459</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#160;Stockholders' deficit</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 1%; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;Common stock, $0.001 par value; 236 million shares authorized;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 4%; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;18,078,163 issued and outstanding as of September 30, 2015 and 16 million</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 4%; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;issued and outstanding as of December 31, 2014</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">18,078</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">16,000</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 1%; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;Additional paid-in-capital</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">5,723,888</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2,257,771</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 1%; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;Warrants</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">731,036</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">190,000</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; PADDING-LEFT: 1%; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;Accumulated deficit</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(7,067,296</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(2,917,319</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; PADDING-LEFT: 4%; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;Total stockholders' deficit</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(594,294</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(453,548</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; PADDING-LEFT: 4%; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;Total liabilities and stockholders' deficit</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">4,541,520</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">348,347</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div>&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">See accompanying notes to the unaudited consolidated financial statements.</div>

<div>&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">4</div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div id="DSPFPageHeader" style="WIDTH: 100%"><a style="FONT-STYLE: italic" href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>

<div>
<table id="a9484ef06ae34249b02523ed23856b12" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr style="HEIGHT: 18px">
<td style="VERTICAL-ALIGN: bottom; WIDTH: 100%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">NEMUS BIOSCIENCE, INC. AND SUBSIDIARY</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 100%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center"><a name="CONSOLIDATEDSTATEMENTSOFO"><!--Anchor--></a>CONSOLIDATED STATEMENTS OF OPERATIONS</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 100%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">(unaudited)</div>
</td>
</tr>
</table>
</div>

<div>&#160;</div>

<div>
<table id="dc4618fd52fa4f7cb46719a4e160a64e" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;&#160;&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Three</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Three</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Nine</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Nine</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;&#160;&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Months Ended</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Months Ended</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Months Ended</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Months Ended</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;&#160;&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">September 30,</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">September 30,</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">September 30,</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">September 30,</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">2015</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">2014</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">2015</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">2014</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"></td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"></td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"></td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"></td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">Operating expenses</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"></td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"></td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"></td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"></td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 2%; WIDTH: 52%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Research and development</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">152,288</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">195,000</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">232,862</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">195,000</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; PADDING-LEFT: 2%; WIDTH: 52%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">General and administrative</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">744,004</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">662,613</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2,929,799</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">835,634</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 52%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; PADDING-LEFT: 5%; WIDTH: 52%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Total operating expenses</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">896,292</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">857,613</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">3,162,661</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1,030,634</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 52%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 52%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">Operating loss</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(896,292</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(857,613</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(3,162,661</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(1,030,634</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 52%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 52%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">Other expense</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 2%; WIDTH: 52%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Change in fair value of conversion rights</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; PADDING-LEFT: 2%; WIDTH: 52%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;of Series A preferred stock</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">286,000</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">986,000</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 52%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 52%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">Net loss before income taxes</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(1,182,292</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(857,613</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(4,148,661</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(1,030,634</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 52%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; PADDING-LEFT: 2%; WIDTH: 52%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Provision for income taxes</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">500</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">905</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1,316</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">905</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 52%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 52%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">Net loss</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(1,182,792</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(858,518</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(4,149,977</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(1,031,539</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 52%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 52%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr style="HEIGHT: 22px">
<td style="FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; WIDTH: 52%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div>Basic and diluted loss per common share</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(0.07</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(0.08</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(0.25</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(0.12</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div>
</td>
</tr>

<tr style="HEIGHT: 16px">
<td style="VERTICAL-ALIGN: bottom; WIDTH: 52%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; WIDTH: 52%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div>Shares used in computing basic and diluted loss per share</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">17,062,366</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">10,502,609</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">16,519,854</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">8,805,766</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div>&#160;</div>

<div>&#160;</div>

<div>
<div style="TEXT-ALIGN: center">See accompanying notes to the unaudited consolidated financial statements.</div>

<div style="TEXT-ALIGN: center">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">5</div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div id="DSPFPageHeader" style="WIDTH: 100%"><a style="FONT-STYLE: italic" href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>
</div>

<div>
<table id="a464e317e6e1448eb800f96dcbfb78d0" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 100%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">NEMUS BIOSCIENCE, INC. AND SUBSIDIARY</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 100%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center"><a name="CONSOLIDATEDSTATEMENTSOFC"><!--Anchor--></a>CONSOLIDATED STATEMENTS OF CASH FLOWS</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 100%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">(unaudited)</div>
</td>
</tr>
</table>
</div>

<div>&#160;</div>

<div>
<table id="a9b0e5dcabdb460daaf86c0abcfae481" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Nine</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Nine</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Months Ended</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Months Ended</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">September 30,</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">September 30,</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">2015</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">2014</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"></td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"></td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">Cash flows from operating activities:</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"></td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"></td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 1%; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Net loss</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(4,149,977</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(1,031,539</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 1%; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Adjustments to reconcile net loss to net cash</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 3%; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">used in operating activities:</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 3%; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Depreciation</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">7,290</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">344</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 3%; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Stock-based compensation for employees</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">263,985</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr style="HEIGHT: 12px">
<td style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 3%; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Amortization of warrants and stock issued for services (1)(2)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">529,016</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 3%; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Change in fair value of conversion rights</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 3%; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;&#160;&#160;of Series A preferred stock</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">986,000</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 3%; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Changes in assets and liabilities:</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 3%; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Restricted cash</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(37,500</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 3%; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Prepaid expenses (1)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">25,800</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(23,758</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 3%; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Other current assets</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">5,470</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 3%; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Deposits and other assets</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(64,970</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 3%; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Accounts payable (2)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(267,264</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 3%; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Accrued payroll and related expenses</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">99,157</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 3%; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Accrued license and patent reimbursement fees</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(29,212</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 3%; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Stock subscription liability</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(100,000</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; PADDING-LEFT: 3%; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Accrued expenses and other liabilities</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">52,899</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">167,355</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; PADDING-LEFT: 5%; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Net cash used in operating activities</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(2,614,336</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(952,568</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">Cash flows from investing activities:</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; PADDING-LEFT: 1%; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Purchases of property and equipment</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(1,982</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(12,389</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; PADDING-LEFT: 3%; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Net cash used in investing activities</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(1,982</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(12,389</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr style="HEIGHT: 18px">
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">Cash flows from financing activities:</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 1%; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Proceeds from common stock issuance, net of $3,920 issuance costs</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">721,069</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1,989,980</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 1%; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Proceeds from Series A preferred stock issuance, net of $7,700 issuance costs</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1,442,302</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;-</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; PADDING-LEFT: 1%; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Proceeds from Series B preferred stock issuance, net of $411,661 issuance costs</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">4,588,339</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; PADDING-LEFT: 3%; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Net cash provided by financing activities</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">6,751,710</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1,989,980</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">Net increase in cash and cash equivalents</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">4,135,392</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1,025,023</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Cash and cash equivalents</font>,<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"> beginning of period</font></div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">207,330</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; PADDING-BOTTOM: 4px; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">Cash and cash equivalents, end of period</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">4,342,722</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1,025,023</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left">Supplemental disclosures of cash-flow information:</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Cash paid during the period for:</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; PADDING-LEFT: 1%; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Interest</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 76%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; PADDING-LEFT: 1%; WIDTH: 76%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Income taxes</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">116</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">905</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div>&#160;</div>

<div>
<table id="2995a3f5e2c7419d920259ce3ece2114" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 100%; BACKGROUND-COLOR: #cceeff" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left">Supplemental disclosures of non-cash financing and investing activities:</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 100%; BACKGROUND-COLOR: #ffffff" colspan="2">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 7.64%; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">(1)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 92.36%; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">During the nine months ended September 30, 2015, the Company issued 200,000 warrants to purchase shares of our common stock for consulting services. The warrants were valued at $417,875. The Company also issued shares of common stock for consulting services valued at $168,000. Such amounts were recorded as a Prepaid Expense and are being amortized over the service period.</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 100%; BACKGROUND-COLOR: #ffffff" colspan="2">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 7.64%; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">(2)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 92.36%; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">The Company issued 6,000 warrants at an exercise price of $2.50 to a service provider in exchange for extinguishment of $10,000 of trade accounts payable owed to this vendor.</div>
</td>
</tr>
</table>
</div>

<div>&#160;</div>

<div>&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">See accompanying notes to the unaudited consolidated financial statements.&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">6</div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div id="DSPFPageHeader" style="WIDTH: 100%"><a style="FONT-STYLE: italic" href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>
</div>

<div><br>
<div style="WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); TEXT-ALIGN: center; FONT: bold 10pt 'Times New Roman', Times, serif; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">NEMUS BIOSCIENCE, INC. and SUBSIDIARY</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt"><a name="NOTESTOTHEUNAUDITEDCONSOL"><!--Anchor--></a>NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">(Information as of and for the three and nine month periods ended September 30, 2015 and 2014 is unaudited)</div>
</div>
</div>

<div>
<div><br>
 &#160;</div>

<div style="MARGIN-BOTTOM: 5pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-TOP: 5pt">1. Nature of Operations, Business Activities and Summary of Significant Accounting Policies</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; TEXT-ALIGN: left">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt">Nature of Operations and Basis of Presentation</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal; TEXT-ALIGN: left">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">Nemus Bioscience, Inc. is a biopharmaceutical company that plans to develop and commercialize therapeutics from cannabinoids through a partnership with the University of Mississippi. The University of Mississippi ("UM") is federally permitted and licensed to cultivate cannabis for research and commercial purposes. Unless otherwise specified, references in these Notes to the Unaudited Consolidated Financial Statements to the "Company," "we" or "our" refer to Nemus Bioscience, Inc., a Nevada corporation formerly known as Load Guard Logistics, Inc. ("LGL"), together with its wholly-owned subsidiary, Nemus, a California corporation ("Nemus"). Nemus became the wholly owned subsidiary of Nemus Bioscience, Inc. through the Merger (as defined below).</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">Nemus Bioscience, Inc. (formerly LGL) was incorporated in Nevada on March 16, 2011. Nemus was incorporated in California on July 17, 2012. Our headquarters are located in Costa Mesa, California.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">As of September 30, 2015, the Company has devoted substantially all of its efforts to securing product licenses, raising capital, and building infrastructure, and has not realized revenue from its planned principal operations.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt">Business Activities</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">On October 31, 2014, pursuant to an Agreement and Plan of Merger, dated October 17, 2014 (the "Merger Agreement"), LGL,&#160; Nemus Acquisition Corp. ("Acquisition Sub"), Nemus Bioscience, Inc. ("Name Change Merger Sub"), and Nemus, Acquisition Sub merged with and into Nemus and Nemus survived as a wholly-owned subsidiary of LGL (the "Merger"). Immediately after the Merger, LGL changed its name to "Nemus Bioscience, Inc." by merging with Name Change Merger Sub.&#160;Pursuant to the Merger Agreement, each share of Nemus common stock outstanding totaling 12,880,000 shares was exchanged at a 1:1 conversion rate to LGL shares and when combined with the 3,120,000 shares of LGL common stock outstanding, amounted to 16,000,000 total shares outstanding upon completion of the merger.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">The Merger is being accounted for as a reverse-merger and recapitalization. Nemus is the acquirer for financial reporting purposes and LGL is the acquired company. Consequently, the assets and liabilities and the operations that will be reflected in the historical consolidated&#160;financial statements prior to the Merger will be those of Nemus and will be recorded at the historical cost basis of Nemus, and the consolidated financial statements after completion of the Merger will include the assets and liabilities of LGL and Nemus, the historical operations of Nemus and the operations of the Nemus from and after the closing date of the Merger.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Use of Estimates</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles ("U.S. GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">7</div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div id="DSPFPageHeader" style="WIDTH: 100%"><a style="FONT-STYLE: italic" href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>

<div style="WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); TEXT-ALIGN: center; FONT: bold 10pt 'Times New Roman', Times, serif; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">NEMUS BIOSCIENCE, INC. and SUBSIDIARY</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">(Information as of and for the three and nine month periods ended September 30, 2015 and 2014 is unaudited)</div>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Liquidity and Going Concern</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">The Company has incurred operating losses and negative cash flows from operations since our inception. As of September 30, 2015, we had cash and cash equivalents of $4,342,722.&#160; The Company anticipates that it will continue to incur net losses into the foreseeable future as it continues to advance and develop a number of potential drug candidates into preclinical development activities and expands its corporate infrastructure which includes the costs associated with being a public company. Without additional funding, management believes that the Company will not have sufficient funds to meet its obligations within one year after the date the consolidated financial statements are issued. These conditions give rise to substantial doubt as to the Company's ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">The Company plans to continue to fund its losses from operations and capital funding needs through public or private equity or debt financings, strategic collaborations, licensing arrangements, asset sales, government grants or other arrangements. However, the Company cannot be sure that such additional funds will be available on reasonable terms, or at all. If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result. If the Company is unable to secure adequate additional funding, the Company may be forced to make a reduction in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Cash and Cash Equivalents</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The carrying value of those investments approximates their fair market value due to their short maturity and liquidity. Cash and cash equivalents include cash on hand and amounts on deposit with financial institutions, which amounts may at times exceed federally insured limits. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Restricted Cash</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; TEXT-ALIGN: justify; MARGIN-TOP: 3pt"><font id="TRGRRTFtoHTMLTab" style="FONT-SIZE: 5.14pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">A deposit of $37,500 as of September 30, 2015 was restricted from withdrawal and held by a bank in the form of a certificate of deposit. This certificate served as collateral for payment of the Company's credit cards.&#160; Restricted cash as of December 31, 2014 was $0.</font></div>

<div style="MARGIN-BOTTOM: 3pt; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt">Fair Value Measurements</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last is considered unobservable, is used to measure fair value:</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">
<table id="993003d147f94d70bec0ac452e8ad809" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 20.45pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 51.55pt; align: right">Level 1:</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">
<div>Valuations for assets and liabilities traded in active markets from readily available pricing sources such as quoted prices in active markets for identical assets or liabilities.</div>

<div>&#160;</div>
</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 3pt; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">
<table id="bb317b4e12db4022b358618a3c154304" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 20.45pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 51.55pt; align: right">Level 2:</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">
<div>Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</div>

<div>&#160;</div>
</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 3pt; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">
<table id="29a82f255cb4439986943ccda306a7ba" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 20.45pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 51.55pt; align: right">Level 3:</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 0.1pt; MARGIN-TOP: 3pt; TEXT-INDENT: 35.9pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 0.1pt; MARGIN-TOP: 3pt; TEXT-INDENT: 35.9pt">The carrying values of our financial instruments, including, cash and cash equivalents, prepaid expenses, accounts payable, and accrued expenses approximate their fair value due to the short maturities of these financial instruments.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 0.1pt; MARGIN-TOP: 3pt; TEXT-INDENT: 35.9pt">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">8</div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div id="DSPFPageHeader" style="WIDTH: 100%"><a style="FONT-STYLE: italic" href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>

<div style="WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); TEXT-ALIGN: center; FONT: bold 10pt 'Times New Roman', Times, serif; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">NEMUS BIOSCIENCE, INC. and SUBSIDIARY</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">(Information as of and for the three and nine month periods ended September 30, 2015 and 2014 is unaudited)</div>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Property and Equipment, Net</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">As of September 30, 2015, property and equipment, net, was $16,046, consisting primarily of computers and equipment. The Company had $21,354 of property and equipment, net, as of December 31, 2014. Expenditures for additions, renewals and improvements will be capitalized at cost. Depreciation will generally be computed on a straight-line method based on the estimated useful life of the related assets currently ranging from two to three years. Maintenance and repairs that do not extend the life of assets are charged to expense when incurred. When properties are disposed of, the related costs and accumulated depreciation are removed from the accounts and any gain or loss is reported in the period the transaction takes place.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount exceeds its estimated future undiscounted cash flows, an impairment charge is recognized by the amount by which the carrying amount exceeds the fair value of the asset.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">The costs incurred for the rights to use licensed technologies in the research and development process, including licensing fees and milestone payments, will be charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where there is an identified alternative future use. No cost associated with the use of licensed technologies has been capitalized to date.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Income Taxes</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">The Company accounts for our deferred income tax assets and liabilities based on differences between the financial reporting and tax bases of assets and liabilities, and net operating loss carry forwards (the "NOLs") and other tax credit carry forwards. These items are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the period that includes the enactment date. Any interest or penalties would be recorded in the Company's statement of operations in the period incurred.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">The Company records a valuation allowance to reduce the deferred income tax assets to the amount that is more likely than not to be realized. In making such determinations, management considers all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. As a result there are no income tax benefits reflected in the statement of operations to offset pre-tax losses.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">The Company recognizes a tax benefit from uncertain tax positions when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Revenue Recognition</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">The Company has not begun planned principal operations and has not generated any revenue since inception.</div>

<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">9</div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div id="DSPFPageHeader" style="WIDTH: 100%"><a style="FONT-STYLE: italic" href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>

<div style="WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); TEXT-ALIGN: center; FONT: bold 10pt 'Times New Roman', Times, serif; WIDOWS: 1; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">NEMUS BIOSCIENCE, INC. and SUBSIDIARY</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">(Information as of and for the three and nine month periods ended September 30, 2015 and 2014 is unaudited)</div>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Research and Development Expenses</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">Research and development ("R&amp;D") costs are expensed when incurred. These costs may consist of external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, third-party manufacturing organizations and consultants; employee-related expenses, which include salaries, benefits and stock-based compensation for the personnel involved in our preclinical and clinical drug development activities; and facilities expense, depreciation and other allocated expenses; and equipment and laboratory supplies.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Stock-Based Compensation Expenses</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">Stock-based compensation cost is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period. We use the Black-Scholes option pricing model for estimating the grant date fair value of stock options and warrants using the following assumptions:</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">
<table id="9fd1b5dabbd04854853bc9f424b1b118" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 20.25pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; VERTICAL-ALIGN: top; WIDTH: 27pt; align: right">&#183;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">Exercise price - We determined the exercise price based on valuations using the best information available to management at the time of the valuations.</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 3pt; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">
<table id="5a8b4ba53f4c415a9071ab6b16d695ae" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 20.25pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; VERTICAL-ALIGN: top; WIDTH: 27pt; align: right">&#183;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">Volatility &#8211; We estimate the stock price volatility based on industry peers who are also in the early development stage given the limited market data available in the public arena.</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 3pt; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">
<table id="0289636245724c8eac15cdc4d64d19bd" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 20.25pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; VERTICAL-ALIGN: top; WIDTH: 27pt; align: right">&#183;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">Expected term - The expected term is based on a simplified method which defines the life as the average of the contractual term of the options and warrants and the weighted-average vesting period for all open awards.</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 3pt; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">
<table id="c2c3fe7e12b14414927e07e1f751744e" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 20.25pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; VERTICAL-ALIGN: top; WIDTH: 27pt; align: right">&#183;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">Risk-free rate - The risk-free interest rate for the expected term of the option or warrant is based on the average market rate on U.S. treasury securities in effect during the quarter in which the awards were granted.</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 3pt; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">
<table id="373bbb98e00a4931be2341a7bd8f3f30" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 20.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; VERTICAL-ALIGN: top; WIDTH: 27pt; align: right">&#183;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">Dividends &#8211; The dividend yield assumption is based on our history and expectation of paying no dividends.</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt">Stock-Based Compensation for Non-Employees</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">The Company accounts for warrants and options issued to non-employees under ASC 505-50, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Equity &#8211; Equity Based Payments to Non-Employees,</font> using the Black-Scholes option-pricing model. The value of such non-employee awards are periodically re-measured over the vesting terms and at each quarter end.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt">Segment Information</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">The Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") No. 280, "Segment Reporting" establishes standards for reporting information about reportable segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group ("CODM"), in deciding how to allocate resources and in assessing performance. The CODM evaluates revenues and gross profits based on product lines and routes to market. Based on the early development stage of our operation, we operate in a single reportable segment.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">10</div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div id="DSPFPageHeader" style="WIDTH: 100%"><a style="FONT-STYLE: italic" href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal; TEXT-ALIGN: left">
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">NEMUS BIOSCIENCE, INC. and SUBSIDIARY</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">(Information as of and for the three and nine month periods ended September 30, 2015 and 2014 is unaudited)</div>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt">Comprehensive Income (Loss)</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company is required to record all components of comprehensive loss in the consolidated&#160;financial statements in the period in which they are recognized. Net income (loss) and other comprehensive loss, net of their related tax effect, arrived at a comprehensive loss. For the three and nine months ended September 30, 2015 and 2014, the comprehensive loss was equal to the net loss.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt">Earnings per share</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">The Company applies FASB ASC 260, "Earnings per Share." Basic earnings (loss) per share is computed by dividing earnings (loss) available to common stockholders by the weighted-average number of common shares outstanding. Diluted earnings or loss per share would include the dilutive effect of awards granted to employees under stock-based compensation plans, if any. There were no dilutive awards outstanding at September 30, 2015.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-TOP: 3pt">2. University of Mississippi ("UM") Agreements</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">In July 2013, the Company entered into a Memorandum of Understanding (MOU) with the UM to engage in joint research of extracting, manipulating, and studying cannabis in certain forms to develop intellectual property (IP) with the intention to create and commercialize therapeutic medicines. Nemus will own all IP developed solely by its employees and will jointly own all IP developed jointly between Nemus and UM employees. The term of the MOU agreement is five years and the parties agree to negotiate separate Research agreements upon the identification of patentable technologies as well as any deemed to be a trade secret. The agreement may be terminated by either party with three months written notice to the other party.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">On May 15, 2014, the Company entered into an Option Agreement in which UM granted us a three-month option for conducting due diligence to exclusively license a suppository dosage form containing Dronabinol Hemi succinate and other esters ("NPC 4718").</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">As a result of our due diligence, on September 29, 2014, the Company executed three license agreements with UM pursuant to which UM granted us exclusive, perpetual, worldwide licenses, including the right to sublicense, to intellectual property related to UM5050, a pro-drug formulation of tetrahydrocannabinol, or THC for products administered through each of ocular, oral or rectal delivery. The license agreement for the field of oral delivery also includes rights to UM 1250, a bio-adhesive hot melt extruded film for topical and mucosal adhesion application and drug delivery.&#160; The license agreements contain certain milestone and royalty payments, as defined therein. These licenses also require the Company to reimburse UM for patent costs incurred related to these products under license. In the case of the ocular license the Company was required to reimburse sunk patent expenses of $70,678 in February 2015; this amount was reflected in accrued license and patent reimbursement fees as of December 31, 2014. These license agreements will terminate upon expiration of the patents, breach or default of the license agreements, or upon 60 days written notice by the Company to UM.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">On October 15, 2014, we signed a renewable option agreement for the rights to explore other routes of delivery of UM5050 not yet agreed upon and/or in combination with other cannabinoids or other compatible compounds. There was a one-time up-front option payment and the option period was for six months expiring on March 31, 2015. On September 29, 2015, the Company exercised its right to renew for an additional six months under the same financial terms and conditions.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">11</div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div id="DSPFPageHeader" style="WIDTH: 100%"><a style="FONT-STYLE: italic" href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal; TEXT-ALIGN: left">
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">NEMUS BIOSCIENCE, INC. and SUBSIDIARY</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">(Information as of and for the three and nine month periods ended September 30, 2015 and 2014 is unaudited)</div>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt">&#160;</div>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 0.1pt; MARGIN-TOP: 3pt; TEXT-INDENT: 20pt">On July 1, 2014, the Company entered into three additional Option Agreements, pursuant to which UM granted Nemus three-month exclusive options for conducting due diligence on the following three cannabinoid extracts to exclusively license them for the purposes of obtaining FDA approval and commercializing the extracts:</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 0.1pt; MARGIN-TOP: 3pt; TEXT-INDENT: 20pt">&#160;</div>

<div style="TEXT-ALIGN: justify">
<table id="c4f938d47bd34e11a569690bbe28d98a" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 20pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 27.35pt; align: right">1)</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">UM 1490 &#8211; transmucosal delivery of cannabinoids</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify">
<table id="8b6816df1ddb45e18aa1c789873ccb93" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 20pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 27.35pt; align: right">2)</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">UM 5070 &#8211; treatment for methicillin-resistant <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Staphylococcus aureus </font>(MRSA) infections</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify">
<table id="cae4107c99794962ae0022d797a3e3fd" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 20pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 27.35pt; align: right">3)</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">UM 8790 &#8211; ocular delivery of cannabinoids</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; MARGIN-RIGHT: 0.1pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; MARGIN-RIGHT: 0.1pt; TEXT-INDENT: 36pt">In March of 2015, in lieu of a license agreement, the Company entered into a research agreement with UM to begin studies concerning the medical utility of cannabinoids as anti-infective therapeutics for MRSA.&#160; The fee payable to UM under the agreement is based on the achievement of certain milestones in the project. The Company recognized $18,673 and $66,747 of research and development expense for the three and nine months ending September 30, 2015 which represents work completed to date under this contract.&#160; The agreement also grants an exclusive option to license the technology from the University within 180 days from the commencement of the agreement. Either party may terminate the agreement with 30 days written notice.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; MARGIN-RIGHT: 0.1pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 0.6pt; MARGIN-RIGHT: 3.8pt; TEXT-INDENT: 35.9pt">In July of 2015, the Company entered into a research agreement with UM to begin studies concerning research and development of cannabidiol (CBD) formulations.&#160; The fee payable to UM is based on the achievement of certain milestones in the project. The Company recognized $37,119 of research and development expense for both the three and nine months ending September 30, 2015 which represents work completed to date under this contract. The agreement also grants an exclusive option to license the technology from the University within 180 days from the commencement of the agreement. Either party may terminate the agreement with 30 days written notice.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 0.6pt; MARGIN-RIGHT: 3.8pt; TEXT-INDENT: 35.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 0.3pt; MARGIN-RIGHT: 0.2pt; TEXT-INDENT: 35.8pt">In September of 2015, the Company entered into a research agreement with UM to advance NEMUS' lead proprietary cannabinoid-based therapy (UM5050) developed for the treatment and management of glaucoma into an optimized once-daily treatment formulation. The fee payable to UM is based on the achievement of certain milestones in the project. The Company recognized $21,496 of research and development expense for both the three and nine months ending September 30, 2015 which represents work completed to date under this contract. The agreement also grants an exclusive option to license the technology from the University within 180 days from the commencement of the agreement. Either party may terminate the agreement with 30 days written notice.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 0.3pt; MARGIN-RIGHT: 0.2pt; TEXT-INDENT: 35.8pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">3. Commitments and Contingencies</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Lease Commitments</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">The Company leased temporary headquarters facilities under a month-to-month operating lease agreement. This lease was terminated effective December 31, 2014. Monthly rent expense under this lease was $2,060.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">On September 1, 2014, the Company signed an operating lease for laboratory and office space at the Innovation Hub, Insight Park located on the University of Mississippi campus. The lease term commenced on October 1, 2014 and expires on December 31, 2017. There are annual escalating rent provisions and two months of free rent in the agreement. The total cash payments over the life of the lease are divided by the total number of months in the lease period and the average rent will be charged to expense each month during the lease period. The monthly amount charged to rent expense is $9,000.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">In October of&#160;2014, we signed a lease agreement for our corporate office headquarters that consists of approximately 4,087 square feet located at 650 Town Center Drive, Suite 1770, Costa Mesa, CA 92626. &#160; The lease expires on October 31, 2016 and our monthly rent is $5,373, payable in equal monthly installments with annual escalations.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">12</div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div id="DSPFPageHeader" style="WIDTH: 100%"><a style="FONT-STYLE: italic" href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal; TEXT-ALIGN: left">
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">NEMUS BIOSCIENCE, INC. and SUBSIDIARY</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">(Information as of and for the three and nine month periods ended September 30, 2015 and 2014 is unaudited)</div>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">Total net rent expense related to our operating leases for the nine months ended September 30, 2015 and 2014 was $170,931and $6,844, respectively. For the three months ended September 30, 2015 and 2014, total net rent expense was $56,680 and $6,294.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 0.2pt; MARGIN-TOP: 3pt; TEXT-INDENT: 35.9pt">Future minimum payments under the non-cancelable portion of our operating leases as of September 30, 2015 are as follows:</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 0.2pt; MARGIN-TOP: 3pt; TEXT-INDENT: 35.9pt">&#160;</div>

<table id="c98a3663e9fb4d61887fffb1ae4a9ea5" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">For the year ending December 31,</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2"></td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 88%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">2015</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">43,900</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 88%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">2016</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">165,700</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 88%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">2017</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">85,900</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 88%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">2018</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 88%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">2019</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 88%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Thereafter</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 88%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Total</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">295,500</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Independent Contractor Agreements</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">The Company has entered into independent contractor agreements with individuals that are operating in the capacity of our management team, or that are serving in an advisory role. Certain agreements expired once the individuals became full-time employees. Independent contractor expense for the nine months ended September 30, 2015 was $90,000 and for the nine months ended September 30, 2014 was $353,000. Two of these contractors accounted for 30% and 15% respectively of our total expenditures for the nine months ended September 30, 2014. There was no significant independent contractor expense as a percent of our total expenditures&#160;for the nine months ended September 30, 2015.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Legal Matters</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">General Litigation and Disputes</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">From time to time, in the normal course of our operations, we may be a party to litigation and other dispute matters and claims. Currently Nemus is not party to any litigation, dispute matters or claims. Litigation can be expensive and disruptive to normal business operations. Moreover, the results of complex legal proceedings are difficult to predict and our view of these matters may change in the future as the litigation and events related thereto unfold. An unfavorable outcome to any legal matter, if material, could have a materially adverse effect on our operations or our financial position, liquidity or results of operations.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Government Proceedings</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">Like other companies in the pharmaceutical industry, we are subject to extensive regulation by national, state and local government agencies in the United States. As a result, interaction with government agencies occurs in the normal course of our operations. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from any government investigation or proceeding. As of September 30, 2015, the Company had no current proceedings or inquiries.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt">Change in Control Severance Plan</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">In February 2015, we adopted a change in control severance plan, in which our named executive officers participate, that provides for the payment of severance benefits if the executive's service is terminated within twelve months following a change in control, either due to a termination without cause or upon a resignation for good reason (as each term is defined in the plan).</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">13</div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div id="DSPFPageHeader" style="WIDTH: 100%"><a style="FONT-STYLE: italic" href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal; TEXT-ALIGN: left; MARGIN-TOP: 3pt">
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">NEMUS BIOSCIENCE, INC. and SUBSIDIARY</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">(Information as of and for the three and nine month periods ended September 30, 2015 and 2014 is unaudited)</div>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">In either such event, and provided the executive timely executes and does not revoke a general release of claims against the Company, he or she will be entitled to receive: (i) a lump sum cash payment equal to at least six months of the executive's monthly compensation, plus an additional month for each full year of service over six years, (ii) Company-paid premiums for continued health insurance for a period equal to length of the cash severance period or, if earlier, when executive becomes covered under a subsequent employer's healthcare plan, and (iii) full vesting of all then-outstanding unvested stock options and restricted stock awards.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-TOP: 3pt">4. Stockholders' Deficit and Redeemable Convertible Series B Preferred Stock</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Common Stock</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">On July 17, 2012, the Company issued 7,770,000 shares of common stock with no par value and warrants (see first paragraph under warrants below) to its founders and one board member in exchange for the services provided to establish Nemus, valued at approximately $1,000.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">In June of 2014, the Company sold 1,800,000 shares of common stock with no par value and warrants for a purchase price of $900,000 (the "June 2014 Stock Purchase Agreement") to a group of private investors. See additional discussion on warrants below.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">In August of 2014, the Company sold 2,200,000 shares of common stock with no par value and warrants for a purchase price of $1,100,000 to a group of private investors. See additional discussion on warrants below.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">In October of 2014, the Company issued 1,110,000 shares of common stock with no par value to eighteen individual investors that had participated in a prior entity founded by Nemus' then current president. Such entity has been insolvent and not operating since the inception date of Nemus. The issuance of these shares was in exchange for the signing of a release of claims against the Company, its President, and the former entity. The Company recorded a general and administrative expense of $466,200 in the fourth quarter of 2014 to reflect the fair market value of the common stock issued in exchange for the release of claims. The fair market value of the common stock issued was determined via an independent third-party valuation conducted as of October 31, 2014.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">In January of 2015, the Company sold 241,663 shares of common stock with par value of $0.001 for a purchase price of $724,989 to a group of private investors.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">In March of 2015, the Company issued 24,000 shares of common stock with par value of $0.001 to a third party in exchange for services to be performed related to raising additional capital. The Company recorded a prepaid expense of $168,000 in the first quarter to reflect the fair market value of the common stock issued and is amortizing this expense over the contract service period which is one year. The fair market value was determined utilizing the Company's closing stock price as of the commencement date of the contract service period. For the nine months ended September 30, 2015, the Company amortized $113,806 to general and administrative expense.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">In August 2015, in conjunction with the Series B Preferred Stock sale (discussed below), the Company raised $5.0 million at $1,000 per share resulting in the automatic conversion of the Series A Preferred Stock to common stock. This resulted in the conversion of 580,000 shares of Series A Preferred Stock at $2.50 per share to the equivalent of 1,812,500 shares of common stock.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">14</div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div id="DSPFPageHeader" style="WIDTH: 100%"><a style="FONT-STYLE: italic" href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal; TEXT-ALIGN: left">
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">NEMUS BIOSCIENCE, INC. and SUBSIDIARY</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">(Information as of and for the three and nine month periods ended September 30, 2015 and 2014 is unaudited)</div>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Preferred Stock</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">The Company has authorized 20,000,000 shares of preferred stock with a par value of $0.001 per share.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>Series A Preferred Stock:</u></font>&#160; In April 2015, the Company sold 250,000 shares of Series A preferred stock with par value of $0.001 and 50,000 warrants to purchase the Company's common stock for an aggregate purchase price of $625,000, or $2,50 per share&#160;to a group of private investors. The shares of preferred stock automatically convert to shares of common stock either at (i) a subsequent equity financing of at least $1,000,000 or (ii) October 1, 2015, whichever is earlier. The warrants are exercisable at a price of $5.00 per share and expire five years from the issuance date. In May 2015, the Company sold 150,000 shares and 30,000 warrants and in July 2015, 180,000 shares and 36,000 warrants under the same terms and conditions.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">The Series A preferred stock issued also has a "down-round" protection feature provided to the investors if the Company subsequently issues or sells any shares in a round of equity financing of at least $1,000,000 prior to October 1, 2015 in which the shares of common stock to be acquired are at a price less than $2.50 per share. The Company is required to issue additional shares of common stock to the investors in an amount such that the subscription price paid, when divided by the total number of shares issued will result in an actual price paid per share of common stock equal to such lower price. This conversion occurred as discussed above in conjunction with the Series B Preferred Stock financing totaling $5.0 million and resulted in the conversion of 580,000 shares of Series A Preferred Stock at to 1,812,500 shares of common stock.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 12pt; TEXT-INDENT: 36pt"><u>Redeemable Convertible Series B Preferred Stock</u><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>:</u></font> In August 2015, the Company sold 5,000 shares of Series B Convertible Preferred Stock and warrants to purchase 6,250,000 shares of the Company's common stock for an aggregate purchase price of $1,000 per share resulting in gross proceeds of $5.0 million.&#160; Each share of preferred stock is convertible into 1,250 shares of common stock which results in an effective conversion price of $0.80 per common share and can be converted by the holder at any time. The Series B preferred stock issued also has a "down-round" protection feature provided to the investors if the Company subsequently issues or sell any shares of common stock, stock options, or convertible securities at a price less than the conversion price of $0.80 per common share. The conversion price is automatically adjusted down to the price of the instrument being issued. See additional discussion in Note 5 below. The Series B shares have liquidation preference over other preferred shares and common stock and have voting rights equal to the number of common shares into which each holder's preferred stock is convertible as of the record date. The preferred stock has no dividend rights. If dividends are declared on the common stock, the holders of the preferred stock shall be entitled to participate in such dividends on an as-if converted basis. The warrants are exercisable at a price of $1.15 per share and expire five years from the issuance date. See additional discussion regarding these warrants in Note 6 below.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">In the event of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary, Series B preferred stockholders receive an amount per share equal to the conversion price of $0.80, subject to down-round adjustment,&#160;multiplied by the as-if converted share amount of 6,250,000 common shares, totaling $5.0 million.&#160; If upon the liquidation, the assets are insufficient to permit payments to the Series B holders,&#160;all assets legally available will be distributed in a pro rata basis among the Series B&#160;holders in proportion to the full amounts they would otherwise be entitled to receive. Any remaining assets are distributed pro rata among the common stockholders.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">Subject to certain trigger events occurring, the Series B preferred stock holders have the right to force the Company to redeem the shares of preferred stock at a price per preferred share equal to the greater of (A) 115% of the conversion amount and (B) the product of (1) the conversion rate in effect at such time and (2) the greatest closing sale price of the Common Stock during the period beginning on the date immediately preceding such triggering event and ending on the date such holder delivers the notice of redemption. Such triggering events include:</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">
<div style="MARGIN-BOTTOM: 3pt; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">
<table id="5a2b48051c72401281a4e68e9542d0cf" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 18pt; align: right">-</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">Failure of the Series B Registration Statement to be declared effective by the SEC on or prior to the date that is ninety days after the Effectiveness Deadline;</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 3pt; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">
<table id="9aa5697466584f0aba287195ce3c7fc7" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 18pt; align: right">-</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">Suspension of the Company&#8217;s common stock from trading for a period of (2) consecutive trading days;</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 3pt; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">
<table id="3574d16ac8544f66a866f55eb19edd95" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 18pt; align: right">-</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">Failure of the Company to deliver all the shares of the common stock or make the appropriate cash payments in a timely manner upon conversion of the Series B Preferred;</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 3pt; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">
<table id="efa5485a941341dba3261c48abc95c07" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 18pt; align: right">-</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">Any default of indebtedness;</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 3pt; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">
<table id="d93c08687c61458585237bc8fdf16638" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 18pt; align: right">-</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">Any filing of voluntary or involuntary bankruptcy by the Company;</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 3pt; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">
<table id="a00b954615f34fa38b8d11caa9556cb7" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 18pt; align: right">-</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">A final judgment in excess of $100,000 rendered against the Company;</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 3pt; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">
<table id="e2d1425ace7249bea58f5de3f0db324a" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 18pt; align: right">-</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">Breach of representations and warranties in the Stock Purchase Agreement;</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 3pt; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">
<table id="1cf1f406bb194198a1f4b91938b62c90" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36.1pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 18pt; align: right">-</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">Failure to comply with the Series B Certificate of Designation or Rule 144 requirements.</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; MARGIN-RIGHT: 0.3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; MARGIN-RIGHT: 0.3pt">As certain of these triggering events are considered to be outside the control of the Company, the Series B preferred stock is considered to be contingently redeemable&#160;convertible and as a result, has been classified as mezzanine equity in the Company&#8217;s balance sheet presentation.</div>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">15</div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div id="DSPFPageHeader" style="WIDTH: 100%"><a style="FONT-STYLE: italic" href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">NEMUS BIOSCIENCE, INC. and SUBSIDIARY</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">(Information as of and for the three and nine month periods ended September 30, 2015 and 2014 is unaudited)</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">&#160;</div>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Warrants</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">On July 17, 2012, the Company issued warrants to purchase up to 3,000,000 shares of our common stock to its founders and two advisors in consideration for services provided in the start-up of operations. The warrants are exercisable at a price of $1.00 per share and expire on June 20, 2023. The Company valued these warrants utilizing the Black-Scholes valuation model and they were determined to be of nominal value given the start-up nature of the Company's operations at the time of grant.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">In conjunction with the June 2014 Stock Purchase Agreement, the Company issued warrants to purchase up to 450,000 shares of common stock to a group of private investors. The warrants are exercisable at a price of $1.00 per share and expire on June 12, 2020. The Company valued these warrants at $85,500. This amount was recorded as warrants and was reclassified from the total consideration received for both the common stock and warrants purchased.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">In August 2014 as part of the June 2014 Stock Purchase Agreement, the Company issued warrants to purchase up to 550,000 shares of common stock with an exercise price of $1.00 per share that expire in August 2020. The Company valued these warrants at $104,500. This amount was recorded as warrants and was reclassified from the total consideration received for both the common stock and warrants purchased.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">In March 2015, the Company entered into an agreement with a financial advisory and public relations consulting firm which included the issuance of warrants to purchase up to 90,000 shares of common stock with an exercise price of $2.50 per share with a term of five years. These warrants were in exchange for services performed beginning in the first quarter and were subsequently issued in April 2015. The Company estimated the warrant value to be $67,950 utilizing the Black Scholes option pricing model and amortized $9,225 for services provided through September 30, 2015.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">In April 2015, the Company entered into an agreement with one of its investors to provide advisory services on all matters including financing. In conjunction with this agreement, the Company issued warrants that vest immediately to purchase 100,000 shares of common stock with an exercise price of $5.00 per share with a term of ten years. The Company estimated the warrant value to be $326,000 utilizing the Black Scholes option pricing model and recorded this amount to general and administrative expense for the quarter due to the immediate vesting.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; TEXT-INDENT: 35.9pt">In April 2015, the Company issued to a former service provider <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; BACKGROUND-COLOR: #ffffff">in exchange for</font> payment of its outstanding invoice warrants that vest immediately to purchase 6,000 shares of common stock with an exercise price of $2.50 per share. The Company estimated the warrant value to be $10,000 which represented the value of the trade debt extinguished<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; BACKGROUND-COLOR: #ffffff">.&#160;</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; TEXT-INDENT: 35.9pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">In April 2015, the Company issued 50,000 warrants to purchase the Company's common stock in conjunction with its Series A Preferred Stock financing. The warrants are exercisable at a price of $5.00 per share and expire five years from the issuance date. In May 2015, the Company issued 30,000 warrants and in July 2015, 36,000 warrants under the same terms and conditions.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 0.3pt; TEXT-INDENT: 35.9pt">In June 2015, the Company issued to a service provider <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; BACKGROUND-COLOR: #ffffff">in exchange for consulting</font> services warrants that vest immediately to purchase 10,000 shares of common stock with an exercise price of $5.00 per share with a term of five years. The Company estimated the warrant value to be $14,700 utilizing the Black Scholes option pricing model<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; BACKGROUND-COLOR: #ffffff">.&#160;</font></div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 0.3pt; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 35.9pt">In August 2015, the Company issued 6,250,000 warrants to purchase common stock in conjunction with its Series B Preferred Stock financing. See further discussion in Note 6 below.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 0.4pt; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 35.9pt">In August 2015, the Company issued 187,500 warrants to purchase common stock to its investment banker in exchange for services rendered in conjunction with the Series B Preferred Stock financing. The warrants vest immediately and have an exercise price of $1.15 per share. The Company estimated the value of the warrants to be $86,250 utilizing the Black Scholes option pricing model and recorded this amount to offering costs as an offset to Additional Paid-in-Capital.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; TEXT-ALIGN: left; MARGIN-LEFT: 0.4pt; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 35.9pt">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">16</div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div id="DSPFPageHeader" style="WIDTH: 100%"><a style="FONT-STYLE: italic" href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">NEMUS BIOSCIENCE, INC. and SUBSIDIARY</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">(Information as of and for the three and nine month periods ended September 30, 2015 and 2014 is unaudited)</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">&#160;</div>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">The Company's board of directors considered various objective and subjective factors, along with input from management, to determine the fair value of the warrants, including:</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">
<table id="566e0d6168ad4a3584463119bd53c279" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 20.25pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; VERTICAL-ALIGN: top; WIDTH: 27pt; align: right">&#183;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">Contemporaneous valuation prepared by an independent third-party valuation specialist effective as of June 30, 2014, October 31, 2014, and April 1, 2015, and August 20, 2015,</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 3pt; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">
<table id="a44fe765ac0f49f5af55938b7979ae74" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 20.25pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; VERTICAL-ALIGN: top; WIDTH: 27pt; align: right">&#183;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">Its results of operations, financial position and the status of research and development efforts and achievement of enterprise milestones,</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 3pt; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">
<table id="7730aadd69e34c538ba0f6c84e06b9a0" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 20.25pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; VERTICAL-ALIGN: top; WIDTH: 27pt; align: right">&#183;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">The composition of, and changes to, the Company's management team and board of directors,</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 3pt; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">
<table id="ce0655ad177f468ea79569c10b4345b2" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 20.25pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; VERTICAL-ALIGN: top; WIDTH: 27pt; align: right">&#183;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">The lack of liquidity of its common stock as a newly public company,</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 3pt; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">
<table id="9cac77aa8f9b49438149054d0b10c05d" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 20.25pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; VERTICAL-ALIGN: top; WIDTH: 27pt; align: right">&#183;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">The Company's stage of development, business strategy and the material risks related to its business and industry,</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 3pt; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">
<table id="830e42f3a08948abb41fcd48412765e0" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 20.25pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; VERTICAL-ALIGN: top; WIDTH: 27pt; align: right">&#183;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">The valuation of publicly-traded companies in the biotechnology sectors,</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 3pt; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">
<table id="34928e8e4f054e5bb1ee78f7b8f07188" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 20.25pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; VERTICAL-ALIGN: top; WIDTH: 27pt; align: right">&#183;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">External market conditions affecting the biotechnology industry sectors,</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 3pt; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">
<table id="d61b928bfc1d4cea83ee919cb0c065a3" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 20.25pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; VERTICAL-ALIGN: top; WIDTH: 27pt; align: right">&#183;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">The likelihood of achieving a liquidity event for the holders of its common stock, such as an initial public offering, or IPO, or a sale of the Company, given prevailing market conditions, and</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 3pt; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">
<table id="406bc7a8bd49449bbe47410b7b341ae2" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 20.45pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; VERTICAL-ALIGN: top; WIDTH: 27pt; align: right">&#183;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">The state of the IPO market for similarly situated biotechnology companies,</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 3pt; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">
<table id="bbbf2248e5ff4fab976f39a73a1c83c2" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 20.45pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; VERTICAL-ALIGN: top; WIDTH: 27pt; align: right">&#183;</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">Discussions held with bankers, potential investors, and preliminary term sheets received as part of management's capital raise efforts.</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">There are significant judgments and estimates inherent in the determination of the fair value of the Company's warrants. These judgments and estimates included the assumptions regarding its future operating performance, the time to completing an IPO or other liquidity event and the determination of the appropriate valuation methods. If the Company had made different assumptions, its warrant valuation could have been significantly different.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">Stock Option Plans: 2014 Omnibus Incentive Plan</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">The 2014 Omnibus Incentive Plan (the "2014 Plan") was adopted to provide a means by which officers, non-employee directors, and employees of and consultants to the Company and its affiliates could be given an opportunity to acquire an equity interest in the Company. All officers, non-employee directors, and employees of and consultants to the Company are eligible to participate in the 2014 Plan.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">On October 31, 2014, after the closing of the Merger, our Board of Directors approved the 2014 Plan. The 2014 Plan reserved 3,200,000 shares for future grants.&#160;As of September 30, 2015, options (net of canceled or expired options) covering an aggregate of 1,180,000 shares of the Company's common stock had been granted under the 2014 Plan, and the Company had 1,180,000 options outstanding and 2,020,000 shares available for future grants under the 2014 Plan.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">17</div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div id="DSPFPageHeader" style="WIDTH: 100%"><a style="FONT-STYLE: italic" href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">NEMUS BIOSCIENCE, INC. and SUBSIDIARY</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">(Information as of and for the three and nine month periods ended September 30, 2015 and 2014 is unaudited)</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 3pt">&#160;</div>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">Options granted under the 2014 Plan expire no later than 10 years from the date of grant. Options granted under the 2014 Plan may be either incentive or non-qualified stock options. For incentive and non-qualified stock option grants, the option price shall be at least 100% of the fair value on the date of grants, as determined by the Company's Board of Directors. If at any time the Company grants an option, and the optionee directly or by attribution owns stock possessing more than 10% of the total combined voting power of all classes of stock of the Company, the option price shall be at least 110% of the fair value and shall not be exercisable more than five years after the date of grant.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">Options granted under the 2014 Plan may be immediately exercisable if permitted in the specific grant approved by the Board of Directors and, if exercised early may be subject to repurchase provisions. The shares acquired generally vest over a period of five years from the date of grant. The Company granted options to purchase 1,180,000 shares through September 30, 2015, under the 2014 Plan.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 3pt">The following is a summary of activity under the 2014 Plan as of September, 2015:</div>

<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
</div>

<table id="16428ede6362438f877ea7d6c1a4ae89" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: middle; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: middle; PADDING-BOTTOM: 2px" valign="bottom" colspan="2"></td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="10">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Options Outstanding</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: middle" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Shares Available</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: middle" valign="bottom" colspan="2"></td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: middle" valign="bottom" colspan="3"></td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: middle" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Weighted Average</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: middle" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">for Grant of</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: middle" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Number of</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: middle" valign="bottom" colspan="3"></td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: middle" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Exercise</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Options</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Shares</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Price per Share</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Price</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 52%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; TEXT-INDENT: 10.05pt">Balance at December&#160;31, 2014</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1,470,000</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1,730,000</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">0.42</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">0.42</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; PADDING-LEFT: 4%; WIDTH: 52%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Options granted</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(130,000</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">130,000</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div>$&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1.15 - $3.00</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.29</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; PADDING-LEFT: 4%; WIDTH: 52%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Options exercised</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">-</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; PADDING-BOTTOM: 2px; PADDING-LEFT: 4%; WIDTH: 52%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Options cancelled</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">680,000</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(680,000</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">0.42</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">0.42</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; PADDING-BOTTOM: 4px; WIDTH: 52%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; TEXT-INDENT: 10.05pt">Balance at September&#160;30, 2015</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2,020,000</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1,180,000</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">0.42 - $3.00</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">0.63</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
</div>

<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt">The weighted average remaining contractual life in years of the options outstanding as of September 30, 2015 was 9.18 years.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">Aggregate intrinsic value is the sum of the amounts by which the quoted market price of the Company's stock exceeded the exercise price of the stock options at September 30, 2015 for those stock options for which the quoted market price was in excess of the exercise price ("in-the-money options"). As of September 30, 2015, the aggregate intrinsic value of options outstanding was $147,000. As of September 30, 2015, no options to purchase shares of common stock were exercisable.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt">Stock Based Compensation Expense</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">The Company recognizes stock-based compensation expense based on the fair value of that portion of stock options that are ultimately expected to vest during the period. Stock-based compensation expense recognized in the consolidated statement of operations includes compensation expense for stock-based awards based on the estimated grant date fair value over the requisite service period. For the nine months ended September 30, 2015, the Company recognized stock-based compensation expense of $263,985 which was recorded as a general and administrative expense in the consolidated statement of operations. For the nine months ended September 30, 2014, stock-based compensation expense was $0.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">The total amount of unrecognized compensation cost related to non-vested stock options was $1,477,143 as of September 30, 2015. This amount will be recognized over a weighted average period of 4.14 years.</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">18</div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div id="DSPFPageHeader" style="WIDTH: 100%"><a style="FONT-STYLE: italic" href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt">
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: normal; TEXT-ALIGN: center; MARGIN-TOP: 3pt">NEMUS BIOSCIENCE, INC. and SUBSIDIARY</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: normal; TEXT-ALIGN: center; MARGIN-TOP: 3pt">NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: normal; TEXT-ALIGN: center; MARGIN-TOP: 3pt">(Information as of and for the three and nine month periods ended September 30, 2015 and 2014 is unaudited)</div>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt">Valuation Assumptions</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">The fair value of options was estimated at the date of grant using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company's common stock for similar terms. The expected term was estimated using the simplified method as permitted under SAB No. 110, since the Company has no recent exercise or forfeiture history that is representative of options granted during the year.&#160;The expected term represents the estimated period of time that stock options are expected to be outstanding, which is less than the contractual term which is generally ten years. The risk-free interest rate is based on the U.S. Treasury yield. The expected dividend yield is zero, as the Company does not anticipate paying dividends in the near future. The weighted average assumptions for employee options are as follows:</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">
<table id="79dfe170e8fd4dc8b7948cccd20d6929" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 75.06%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 2px solid; WIDTH: 24.94%" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">For the Nine Months Ended&#160;&#160; September 30,</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 75.06%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 2px solid; WIDTH: 12.96%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: right">2015</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 2.02%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 2px solid; WIDTH: 9.96%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: right">2014</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 75.06%; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Dividend yield</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 12.96%; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">0.00%</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 2.02%; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 9.96%; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">NA</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 75.06%; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Volatility factor</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 12.96%; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">75.00%</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 2.02%; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 9.96%; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">NA</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 75.06%; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Risk-free interest rate</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 12.96%; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">1.68-1.85%</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 2.02%; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 9.96%; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">NA</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 75.06%; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Expected term (years)</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 12.96%; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">6.25-6.50</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 2.02%; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 9.96%; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">NA</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 75.06%; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Weighted-average fair value of options granted during the periods</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 12.96%; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">$2.69</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 2.02%; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 9.96%; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">NA</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"></div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">5. Provision for Conversion of Preferred Stock</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt">Series A Preferred Stock Conversion Liability</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 0.2pt; MARGIN-TOP: 3pt; TEXT-INDENT: 35.8pt">In connection with the Series A preferred stock financing, the Company recorded a liability related to down-round protection provided to the stockholders in the event that the Company does another offering of common stock greater than $1,000,000 at a price below $2.50 per share. The down-round provision expires at the closing of a subsequent financing round or October 1, 2015 whichever is earlier. With the assistance of a third-party valuation specialist, the Company valued the conversion liability pursuant to the accounting guidance of ASC 820-10, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Fair Value Measurements</font>, as of the closing date of the first round of financing which was April 1, 2015.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 0.2pt; MARGIN-TOP: 3pt; TEXT-INDENT: 35.8pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 0.1pt; MARGIN-TOP: 3pt; TEXT-INDENT: 35.9pt">As of June 30, 2015, the Company re-evaluated the likelihood and valuation of a potential down-round given that management has been actively pursuing capital raising efforts. In the absence of any definitive agreement, the Company calculated the fair value of the conversion feature to be $700,000 by determining the highest probability of a per share price in the next anticipated round of financing, after considering all discussions with bankers, potential investors, and preliminary term sheets. This amount was booked as a current liability as of June 30, 2015 and was charged as a non-operating expense for the period.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 0.1pt; MARGIN-TOP: 3pt; TEXT-INDENT: 35.9pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 0.1pt; MARGIN-TOP: 3pt; TEXT-INDENT: 35.9pt">In July of 2015, the Company increased its down-round provision by $286,000 based on the closing of an additional round of 180,000 Series A shares<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>by determining the highest probability of a per share price in the next anticipated round of financing, after considering all discussions with bankers, potential investors, and preliminary term sheets. This amount was charged to non-operating expense for the three months ended September 30, 2015.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 0.1pt; MARGIN-TOP: 3pt; TEXT-INDENT: 35.9pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 0.2pt; MARGIN-TOP: 3pt; TEXT-INDENT: 35.8pt">As of August 21, 2015, upon the closing of the Series B Preferred Stock sale with proceeds totaling $5.0 million, the Company issued 1,232,000 additional shares of common stock at $0.80 per share thereby eliminating this liability of $986,000 and offsetting it to Additional Paid-in-Capital. This amount was calculated by determining the difference in per share pricing between the Series A Preferred Stock financing of $2.50 per share and the Series B Preferred Stock Financing of $0.80 per share multiplied by the 580,000 total shares included in the Series A offering.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 0.2pt; MARGIN-TOP: 3pt; TEXT-INDENT: 35.8pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 0.2pt; MARGIN-TOP: 3pt; TEXT-INDENT: 35.8pt">
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt">Series B Preferred Stock Conversion Liability</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 0.2pt; MARGIN-TOP: 3pt; TEXT-INDENT: 35.9pt">As of August 20, 2015, in connection with the Series B preferred stock financing, the Company recorded a liability related to down-round protection provided to the stockholders in the event that the Company does another sale or issuance of common stock, stock options or convertible securities where the share price is below $0.80 per share. With the assistance of a third-party valuation specialist, the Company valued the conversion liability pursuant to the accounting guidance of ASC 820-10, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Fair Value Measurements</font>, as of the closing date of the financing. The Company also performed a review of the conversion liability in conjunction with ASC 815, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Derivatives and Hedging/Contracts in Entity's Own Equity</font>, and determined that the liability requires bifurcation and re-measurement to fair market value at the end of each reporting period. The derivative was valued at $75,488 and was booked as a current liability as of September 30, 2015. The value of this embedded derivative was determined utilizing a with and without method by valuing the preferred stock with and without the down round protection.</div>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 0.2pt; MARGIN-TOP: 3pt; TEXT-INDENT: 35.8pt">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">19</div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div id="DSPFPageHeader" style="WIDTH: 100%"><a style="FONT-STYLE: italic" href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal; TEXT-ALIGN: left">
<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: normal; TEXT-ALIGN: center; MARGIN-TOP: 3pt">NEMUS BIOSCIENCE, INC. and SUBSIDIARY</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: normal; TEXT-ALIGN: center; MARGIN-TOP: 3pt">NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: normal; TEXT-ALIGN: center; MARGIN-TOP: 3pt">(Information as of and for the three and nine month periods ended September 30, 2015 and 2014 is unaudited)</div>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">6. Series B Warrants</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">In conjunction with the Series B Preferred Stock financing, the Company issued 6,437,500 warrants that are exercisable at a price of $1.15 per share and expire five years from the issuance date. The warrants were valued at $2,935,800 utilizing the Black-Scholes pricing model and the following assumptions:<br>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 0.1pt; MARGIN-TOP: 3pt; TEXT-INDENT: 35.9pt">
<table id="d2b686eb6987452bb297eeeec0efa484" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 75.06%">&#160;</td>
<td style="VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 2px solid; WIDTH: 24.94%" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">For the Nine Months Ended&#160;&#160; September 30,</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 75.06%">&#160;</td>
<td style="VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 2px solid; WIDTH: 12.96%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: right">2015</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 2.02%">&#160;</td>
<td style="VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 2px solid; WIDTH: 9.96%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: right">2014</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 75.06%; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Dividend yield</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 12.96%; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">0.00%</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 2.02%; BACKGROUND-COLOR: #cceeff">&#160;</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 9.96%; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">NA</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 75.06%; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Volatility factor</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 12.96%; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">70.00%</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 2.02%; BACKGROUND-COLOR: #ffffff">&#160;</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 9.96%; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">NA</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 75.06%; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Risk-free interest rate</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 12.96%; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">1.75%</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 2.02%; BACKGROUND-COLOR: #cceeff">&#160;</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 9.96%; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">NA</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 75.06%; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Expected term (years)</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 12.96%; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">4.61</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 2.02%; BACKGROUND-COLOR: #ffffff">&#160;</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 9.96%; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">NA</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; WIDTH: 75.06%; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Weighted-average fair value of warrants granted during the periods</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 12.96%; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">$0.46</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 2.02%; BACKGROUND-COLOR: #cceeff">&#160;</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 9.96%; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">NA</div>
</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 0.1pt; MARGIN-TOP: 3pt; TEXT-INDENT: 35.9pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 0.1pt; MARGIN-TOP: 3pt; TEXT-INDENT: 35.9pt">The warrants are exercisable in cash or through a cashless exercise provision. The Series B warrants also have a "down-round" protection feature provided to the investors if the Company subsequently issues or sell any shares of common stock, stock options, or convertible securities at a price less than the exercise price of $1.15 per each warrant. The conversion price is automatically adjusted down to the price of the instrument being issued.&#160;The Company reviewed the classification of the warrants as liabilities or equity under the guidance of ASC 480-10, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Distinguishing Liabilities from Equity</font>, and concluded that the Series B warrants should be classified as a liability. The Company then applied the relative fair value allocation methodology for allocating the proceeds of $5.0 million received from the Series B financing between the conversion liability and the warrants with the residual amount being allocated to the Preferred Stock. As such, the warrant value as of September 30, 2015 was $2,892,392 and will be subject to fair value re-measurement at the end of each reporting period.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 0.1pt; MARGIN-TOP: 3pt; TEXT-INDENT: 35.9pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-TOP: 3pt">7. Income Taxes</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">At September 30, 2015, the Company had net operating loss carry forwards ("NOLs") aggregating approximately $4,023,000 which, if not used, expire in 2035. The utilization of these NOLs may become subject to limitations based on past and future changes in ownership of the Company pursuant to Internal Revenue Code Section 382.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 0.2pt; MARGIN-TOP: 3pt; TEXT-INDENT: 35.9pt">The Company records a valuation allowance against deferred tax assets to the extent that it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Due to the substantial doubt related to the Company's ability to utilize its deferred tax assets, a valuation allowance for the full amount of the deferred tax assets has been established at September 30, 2015. As a result of this valuation allowance there are no income tax benefits reflected in the accompanying statement of operations to offset pre-tax losses.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 0.2pt; MARGIN-TOP: 3pt; TEXT-INDENT: 35.9pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">The Company has no uncertain tax positions as of September 30, 2015.</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">8. Subsequent Events</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt; MARGIN-RIGHT: 0.1pt">Restricted Stock Awards</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left; MARGIN-TOP: 3pt; MARGIN-RIGHT: 0.1pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN: 5pt 0.3pt 5pt 0.2pt; TEXT-INDENT: 35.8pt">Restricted stock awards ("RSAs") are granted to our board of directors and members of senior management and are issued pursuant to the Company's 2014 Omnibus Incentive Plan. On October 20, 2015, a total of 1,200,000 RSAs were granted to members of the Company's senior management and board of directors with a fair market value of approximately $900,000. These RSAs vest from one to&#160;three years from the grant date.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN: 5pt 0.3pt 5pt 0.2pt; TEXT-INDENT: 35.8pt">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">20</div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div id="DSPFPageHeader" style="WIDTH: 100%"><a style="FONT-STYLE: italic" href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>
</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left"><u><a name="Item2.ManagementsDiscussi"><!--Anchor--></a>Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</u></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; TEXT-ALIGN: left">&#160;</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 12pt; TEXT-INDENT: 36pt">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our&#160;with our financial statements for the nine months ended September 30, 2015, the year ended December 31, 2014, and the year ended December 31, 2013 together with notes thereto.&#160;&#160;In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors, including, but not limited, to those set forth under "Risk Factors" and elsewhere in this Quarterly Report on Form 10-Q.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-LEFT: 0.2pt; MARGIN-TOP: 12pt; TEXT-INDENT: 35.8pt">Unless otherwise provided in this Quarterly Report,&#160; references to "we," "us," "our" and "Nemus" in this discussion and analysis refer to Nemus Bioscience, Inc., a Nevada corporation formerly known as Load Guard Logistics, Inc. (&#8220;LGL&#8221;), together with its wholly-owned subsidiary,&#160; Nemus, a California corporation (&#8220;Nemus&#8221;). Nemus became the wholly owned subsidiary of Nemus Bioscience, Inc. through the closing of a reverse merger transaction (the &#8220;Merger&#8221;) pursuant to which a wholly owned subsidiary of LGL formed solely for the purpose of the Merger merged with and into Nemus and LGL changed its name to Nemus Bioscience, Inc.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-LEFT: 0.1pt; MARGIN-TOP: 12pt; TEXT-INDENT: 35.9pt">The Merger is accounted for as a reverse merger and recapitalization, with Nemus as the acquirer and LGL as the acquired company for financial reporting purposes. As a result, the assets and liabilities and the operations that will be reflected in the historical financial statements prior to the Merger will be those of Nemus and will be recorded at the historical cost basis of Nemus, and the consolidated financial statements after completion of the Merger will include the assets and liabilities of LGL and Nemus, the historical operations of Nemus&#160;and the operations of the combined enterprise of LGL and Nemus from and after the closing date of the Merger.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">Overview</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 0.2pt; MARGIN-TOP: 12pt; TEXT-INDENT: 35.9pt">We are a biopharmaceutical company focused on the discovery, development, and the commercialization of cannabis-based therapeutics, or cannabinoids, through our partnership with the University of Mississippi, or UM.&#160; UM has held the only contract to cultivate cannabis for research purposes on behalf of the Federal Government since 1968, and it has significant expertise in cannabis cultivation and the extraction, separation, process and manufacture of cannabis extracts.&#160; We are currently UM's sole partner for the development and commercialization of drugs derived from cannabis extracts, or cannabinoids, and the realization of this partnership will depend on the successful navigation of the complex regulatory framework for the cultivation and handling of cannabis in the United States.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">Recent Events&#160;</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 12pt; TEXT-INDENT: 36pt">On September 29, 2014, the Company executed three license agreements with UM pursuant to which UM granted us exclusive, perpetual, worldwide licenses, including the right to sublicense, to intellectual property related to UM5050, a pro-drug formulation of tetrahydrocannabinol, or THC for products administered through each of ocular, oral or rectal delivery. The license agreement for the field of oral delivery also includes rights to UM 1250, a bio-adhesive hot melt extruded film for topical and mucosal adhesion application and drug delivery.&#160; The license agreements contain certain milestone and royalty payments, as defined therein. These licenses also require the Company to reimburse UM for patent costs incurred related to these products under license. In the case of the ocular license the Company was required to reimburse sunk patent expenses of $70,678 in February 2015; this amount was reflected in accrued license and patent reimbursement fees as of December 31, 2014. These license agreements will terminate upon expiration of the patents, breach or default of the license agreements, or upon 60 days written notice by the Company to UM.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 12pt; TEXT-INDENT: 36pt">On October 15, 2014, we signed a renewable option agreement for the rights to explore other routes of delivery of UM5050 not yet agreed upon and/or in combination with other cannabinoids or other compatible compounds. There was a one-time up-front option payment and the option period was for six months expiring on March 31, 2015. On September 29, 2015, the Company exercised its right to renew for an additional six months under the same financial terms and conditions.</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">21</div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div id="DSPFPageHeader" style="WIDTH: 100%"><a style="FONT-STYLE: italic" href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 0.1pt; MARGIN-TOP: 12pt; TEXT-INDENT: 20pt">On July 1, 2014, the Company entered into three additional Option Agreements, pursuant to which UM granted Nemus three-month exclusive options for conducting due diligence on the following three cannabinoid extracts to exclusively license them for the purposes of obtaining FDA approval and commercializing the extracts:</div>

<div style="TEXT-ALIGN: justify">
<table id="9def7c1b722e41c4bee2687af2875306" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 20pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 27.35pt; align: right">1)</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">UM 1490 &#8211; transmucosal delivery of cannabinoids</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify">
<table id="0c5b25b0493a47edbdd639f39a99d390" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 20pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 27.35pt; align: right">2)</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">UM 5070 &#8211; treatment for methicillin-resistant <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Staphylococcus aureus </font>(MRSA) infections</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify">
<table id="fe7b530e97dd4eed80e4536f81326b02" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 20pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; WIDTH: 27.35pt; align: right">3)</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; WIDTH: auto">UM 8790 &#8211; ocular delivery of cannabinoids</td>
</tr>
</table>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 12pt; MARGIN-RIGHT: 0.1pt; TEXT-INDENT: 36pt">In March of 2015, in lieu of a license agreement, the Company entered into a research agreement with UM to begin studies concerning the medical utility of cannabinoids as anti-infective therapeutics for MRSA.&#160; The fee payable to UM under the agreement is based on the achievement of certain milestones in the project. The Company recognized $18,673 and $66,747 of research and development expense for the three and nine months ending September 30, 2015 which represents work completed to date under this contract.&#160; The agreement also grants an exclusive option to license the technology from the University within 180 days from the commencement of the agreement. Either party may terminate the agreement with 30 days written notice.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN: 12pt 3.8pt 12pt 0.6pt; TEXT-INDENT: 35.9pt">In July of 2015, the Company entered into a research agreement with UM to begin studies concerning research and development of cannabidiol (CBD) formulations.&#160; The fee payable to UM is based on the achievement of certain milestones in the project. The Company recognized $37,119 of research and development expense for both the three and nine months ending September 30, 2015 which represents work completed to date under this contract. The agreement also grants an exclusive option to license the technology from the University within 180 days from the commencement of the agreement. Either party may terminate the agreement with 30 days written notice.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN: 12pt 0.2pt 12pt 0.3pt; TEXT-INDENT: 35.8pt">In September of 2015, the Company entered into a research agreement with UM to advance NEMUS&#8217; lead proprietary cannabinoid-based therapy (UM5050) developed for the treatment and management of glaucoma into an optimized once-daily treatment formulation. The fee payable to UM is based on the achievement of certain milestones in the project. The Company recognized $21,496 of research and development expense for both the three and nine months ending September 30, 2015 which represents work completed to date under this contract. The agreement also grants an exclusive option to license the technology from the University within 180 days from the commencement of the agreement. Either party may terminate the agreement with 30 days written notice.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">Critical Accounting Policy and Estimates</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 0.1pt; MARGIN-TOP: 12pt; TEXT-INDENT: 35.9pt">Our Management's Discussion and Analysis of Financial Condition and Results of Operations section discusses our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments, including those related to revenue recognition, accrued expenses, financing operations, and contingencies and litigation. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The most significant accounting estimates inherent in the preparation of our financial statements include estimates as to the appropriate carrying value of certain assets and liabilities which are not readily apparent from other sources.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 0.2pt; MARGIN-TOP: 12pt; TEXT-INDENT: 35.8pt">During the quarter ended September 30, 2015, there were no significant changes to the items that were disclosed as our critical accounting policies and estimates in Note 1 to our financial statements for the year ended December 31, 2014 contained in our Form 10-K as filed with the SEC on March 27, 2015.</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">22</div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div id="DSPFPageHeader" style="WIDTH: 100%"><a style="FONT-STYLE: italic" href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 12pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Results of Operations&#160;</font>&#160;&#160;</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">For the three months ended September 30, 2015 and 2014&#160;</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 12pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Revenues.&#160;</font>&#160;&#160;&#160;To date, we have not generated any revenues, and do not expect to generate any revenue from the sale of products in the near future.&#160;&#160;</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 12pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Operating expenses.&#160;&#160;&#160;</font>For the three months ended September 30, 2015, our total operating expenses were $896,292 as compared to $857,613 for the three months ended September 30, 2014. The increase in operating expenses was due primarily to an increase in general and administrative costs consisting of consulting and professional fees in the three months ended September 30, 2015, as discussed below.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 12pt; MARGIN-RIGHT: 7.8pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>Research and development.</u></font> Research and development expenses for the three months ended September 30, 2015 were $152,288 which consisted of license fee renewals and contract R&amp;D fees incurred by the University of Mississippi for the three outstanding research projects (MRSA, CBD formulation, and glaucoma treatment optimization).</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 12pt; MARGIN-RIGHT: 7.9pt">For the three months ended September 30, 2014, our research and development expenses were $195,000 which consisted of license fees payable to the University of Mississippi to obtain the rights to certain cannabinoid extracts and delivery mechanisms.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 12pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>General and administrative</u></font>. General and administrative expenses for the three months ended September 30, 2015 were $744,004 which primarily consisted of consulting fees and professional fees associated with our costs of being a public company.&#160;By comparison, our general and administrative expenses for the three months ended September 30, 2014 were $662,613 and consisted primarily of professional fees in order to prepare for becoming a public company along with fees paid to advisors.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 12pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Other income and expenses.</font> For the three months ended September 30, 2015, the Company had non-operating expenses of $286,000 which represented a change in the fair value of the conversion right related to the Series A preferred stock issuance. This loss was estimated by determining the highest probability of a per share price in the next anticipated round of financing after considering all discussions with bankers, potential investors and preliminary term sheets. This amount represents the incremental value of shares that would be required to be issued to the preferred stockholders in the event of a subsequent down-round financing.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">For the three months ended September 30, 2014, other income and expenses were $905.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 12pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Net Loss.</font>&#160;For the three months ended September 30, 2015, we had a net loss of $1,182,792, as compared to a net loss of $858,518 for the three months ended September 30, 2014. We expect to incur net losses for the foreseeable future.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">For the nine months ended September 30, 2015 and 2014&#160;</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 12pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Revenues.&#160;</font>&#160;&#160;&#160;To date, we have not generated any revenues, and do not expect to generate any revenue from the sale of products in the near future.&#160;&#160;</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 12pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Operating expenses.&#160;&#160;&#160;</font>For the nine months ended September 30, 2015, our total operating expenses were $3,162,161 as compared to $1,030,634 for the nine months ended September 30, 2014. The increase in operating expenses was due primarily to an increase in general and administrative expenses consisting of consulting and professional fees in the nine months ended September 30, 2015, as discussed below.</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">23</div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div id="DSPFPageHeader" style="WIDTH: 100%"><a style="FONT-STYLE: italic" href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 12pt; MARGIN-RIGHT: 7.8pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>Research and development.</u></font> Research and development expenses for the nine months ended September 30, 2015, were $232,862 which consisted of license fee renewals, option expenses, and contract R&amp;D fees incurred by the University of Mississippi for the three outstanding research projects (MRSA, CBD formulation, and glaucoma treatment optimization).</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 12pt; MARGIN-RIGHT: 7.9pt">For the nine months ended September 30, 2014, our research and development expenses were $195,000 which consisted of license fees payable to the University of Mississippi to obtain the rights to certain cannabinoid extracts.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 12pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>General and administrative</u></font>. General and administrative expenses for the nine months ended September 30, 2015 were $2,929,799 which primarily consisted of consulting fees and professional fees associated with our costs of being a public company.&#160;By comparison, our general and administrative expenses for the nine months ended September 30, 2014 were $835,634 and consisted primarily of professional fees in order to prepare for becoming a public company along with fees paid to advisors.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Other income and expenses.</font> For the nine months ended September 30, 2015, the Company had non-operating expenses of $986,000 which represented a change in the fair value of the conversion right related to the Series A preferred stock issuance. This loss was estimated by determining the highest probability of a per share price in the next anticipated round of financing after considering all discussions with bankers, potential investors and preliminary term sheets. This amount represents the incremental value of shares that would be required to be issued to the preferred stockholders in the event of a subsequent down-round financing.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">For the nine months ended September 30, 2014, other income and expenses were $905.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-TOP: 12pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Net Loss.</font>&#160;For the nine months ended September 30, 2015, we had a net loss of $4,149,977 as compared to a net loss of $1,031,539 for the nine months ended September 30, 2014. We expect to incur net losses for the foreseeable future.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-TOP: 12pt">Liquidity and Capital Resources</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 0.1pt; MARGIN-TOP: 12pt; TEXT-INDENT: 35.9pt">We had cash and cash equivalents of $4,342,722 as of September 30, 2015, as compared to $207,330 as of December 31, 2014. This increase was attributable to the completion of our Series B Preferred Stock financing which resulted in gross proceeds of $5.0 million. We anticipate that we will continue to incur net losses into the foreseeable future as we continue to advance and develop a number of potential drug candidates into preclinical development activities and expand our corporate infrastructure which includes the costs associated with being a public company.&#160; Without additional funding, management believes that we will not have sufficient funds to meet its obligations beyond one year after the date the consolidated financial statements are issued. These conditions give rise to substantial doubt as to our ability to continue as a going concern.&#160;&#160;</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 0.2pt; MARGIN-TOP: 12pt; TEXT-INDENT: 35.8pt">We have been, and intend to continue, working toward identifying and obtaining new sources of financing. No assurances can be given that we will be successful in obtaining additional financing in the future.&#160;&#160;Any future financing that we may obtain may cause significant dilution to existing stockholders. Any debt financing or other financing of securities senior to common stock that we are able to obtain will likely include financial and other covenants that will restrict our flexibility. Any failure to comply with these covenants would have a negative impact on our business, prospects, financial condition, results of operations and cash flows.</div>

<div style="TEXT-ALIGN: left">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;If adequate funds are not available, we may be required to delay, scale back or eliminate portions of our operations or obtain funds through arrangements with strategic partners or others that may require us to relinquish rights to certain of our assets. Accordingly, the inability to obtain such financing could result in a significant loss of ownership and/or control of our assets and could also adversely affect our ability to fund our continued operations and our expansion efforts.</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">24</div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div id="DSPFPageHeader" style="WIDTH: 100%"><a style="FONT-STYLE: italic" href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>

<div style="TEXT-ALIGN: left">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; During the next twelve months, we expect to incur significant research and development expenses with respect to our products. The majority of our research and development activity is focused on development of potential drug candidates and preclinical trials.</div>

<div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 0.1pt; MARGIN-TOP: 12pt; TEXT-INDENT: 35.9pt">We also expect to incur significant legal and accounting costs in connection with being a public company. We expect those fees will be significant and will continue to impact our liquidity. Those fees will be higher as our business volume and activity increases.&#160;</div>

<div style="TEXT-ALIGN: left">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;We anticipate that we will need to hire additional employees or independent contractors for our new laboratory at UM. We also anticipate that we will need to purchase or lease additional equipment for the Company's headquarters and laboratory facilities.</div>

<div style="MARGIN-BOTTOM: 3pt; MARGIN-TOP: 3pt"><br>
</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-TOP: 3pt"><u>Off-Balance Sheet Arrangements</u></div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-TOP: 3pt">&#160;</div>

<div style="MARGIN-BOTTOM: 3pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-TOP: 3pt; TEXT-INDENT: 36pt">There are no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left"><u><a name="Item3.QuantitativeandQual"><!--Anchor--></a>Item 3. Quantitative and Qualitative Disclosures about Market Risk.</u></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Not applicable.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left"><u><a name="Item4.ControlsandProcedur"><!--Anchor--></a>Item 4. Controls and Procedures.</u></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Evaluation of disclosure controls and procedures.</font> We maintain controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management including our principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosures. In designing and evaluating the disclosure controls and procedures, management recognizes that any control and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">We conducted an evaluation, under the supervision and with the participation of our principal executive and financial officers, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based upon their evaluation and subject to the foregoing, the principal executive and financial officers have concluded that, as of the end of the period covered by this report, the disclosure controls and procedures were effective at a reasonable assurance level.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Changes in internal controls.</font> Management determined there were no changes in our internal control over financial reporting that occurred during the fiscal quarter covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">25</div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div id="DSPFPageHeader" style="WIDTH: 100%"><a style="FONT-STYLE: italic" href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">PART II &#8212; OTHER INFORMATION</div>

<div style="TEXT-ALIGN: justify"><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify"><u><a name="Item1.LegalProceedings."><!--Anchor--></a>Item 1. Legal Proceedings.</u></div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">To the best of our knowledge, we are not a party to any legal proceedings that, individually or in the aggregate, are deemed to be material to our financial condition or results of operations.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left"><u><a name="Item1A.RiskFactors."><!--Anchor--></a>Item 1A. Risk Factors.</u></div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Investing in our common stock involves a high degree of risk. Our Annual Report on Form 10-K for the year ended December 31, 2014 includes a detailed discussion of our risk factors under the heading &#8220;Part I, Item 1A-Risk Factors.&#8221;&#160; There are no changes from the risk factors previously disclosed in our Annual Report on Form 10-K. You should carefully consider the risk factors discussed in our Annual Report on Form 10-K as well as the other information in this report before deciding whether to invest in shares of our common stock. The occurrence of any of the risks discussed in the Annual Report on Form 10-K could harm our business, financial condition, results of operations or growth prospects. In that case, the trading price of our common stock could decline, and you may lose all or part of your investment.</div>

<div></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left"><u><a name="Item2.UnregisteredSalesof"><!--Anchor--></a>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</u></div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">On July 3, 2015, the Company sold to four investors 180,000 shares of Series A Preferred Stock and warrants to purchase 36,000 shares of the Company's common stock at an exercise price of $5.00 per share for a term of five years in exchange for aggregate proceeds of $450,000, or $2.50 per share. The issuance and sale of such shares was not registered under the Securities Act, and such shares were issued in reliance upon an exemption from registration afforded by Section&#160;4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated thereunder.&#160;The Company relied on the exemption based on representations given by the investors.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">On August 20, 2015, the Company sold to fifteen investors 5,000 shares of Series B Convertible Preferred Stock and warrants to purchase 6,250,000 shares of the Company&#8217;s common stock<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> at an exercise price of $1.15 per share for a term of five years in exchange for aggregate proceeds of $5,000,000, or $1,000 per share</font>.&#160; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">The issuance and sale of such shares was not registered under the Securities Act, and such shares were issued in reliance upon an exemption from registration afforded by Section&#160;4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated thereunder.&#160;The Company relied on the exemption based on representations given by the investors.</font></div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">On August 25, 2015, the Company issued 187,500 warrants to purchase common stock at an exercise price of $1.15 per share for a term of five years to its investment banker in exchange for services rendered in conjunction with the Series B </font>Convertible <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Preferred Stock financing. The issuance and sale of such shares was not registered under the Securities Act, and such shares were issued in reliance upon an exemption from registration afforded by Section&#160;4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated thereunder.&#160;</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left"><u><a name="Item3.DefaultsUponSeniorS"><!--Anchor--></a>Item 3. Defaults Upon Senior Securities.</u></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">None.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left"><u><a name="Item4.MineSafetyDisclosur"><!--Anchor--></a>Item 4. Mine Safety Disclosures.</u></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Not applicable.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left"><u><a name="Item5.OtherInformation."><!--Anchor--></a>Item 5. Other Information.</u></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">None.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><u><a name="Item6.Exhibits."><!--Anchor--></a>Item 6. Exhibits.</u></font></div>

<div><br>
</div>

<table id="77b9d55958d04e638534a9beb1246571" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 10.42%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">31.1</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 89.58%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><a href="ex-31_1.htm">Certification of Principal Executive Officer, pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934</a></div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 10.42%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">31.2</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 89.58%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><a href="ex-31_2.htm">Certification of Principal Financial Officer, pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934</a></div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 10.42%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">32.1+</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 89.58%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><a href="ex-32_1.htm">Certification of Principal Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 10.42%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">32.2+</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 89.58%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><a href="ex-32_2.htm">Certification of Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 10.42%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">101.ins</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 89.58%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Instance Document</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 10.42%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">101.sch</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 89.58%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">XBRL Taxonomy Schema Document</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 10.42%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">101.cal</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 89.58%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">XBRL Taxonomy Calculation Linkbase Document</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 10.42%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">101.def</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 89.58%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">XBRL Taxonomy Definition Linkbase Document</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 10.42%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">101.lab</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 89.58%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">XBRL Taxonomy Label Linkbase Document</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 10.42%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">101.pre</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 89.58%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">XBRL Taxonomy Presentation Linkbase Document</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;+ </font>Furnished herewith and not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.</div>

<div style="MARGIN-BOTTOM: 0.1pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 0.1pt; MARGIN-RIGHT: 0.1pt">&#160;&#160;</div>

<div><br>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageNumberArea" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">26</div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>

<div id="DSPFPageHeader" style="WIDTH: 100%"><a style="FONT-STYLE: italic" href="#TABLEOFCONTENTS">Table of Contents</a></div>
</div>

<div><br>
</div>

<div><br>
</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center"><a name="SIGNATURES"><!--Anchor--></a>SIGNATURES</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">In accordance with the requirements of the Securities Exchange Act of 1934, the registrant duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#160;</div>

<table id="212cdc2d623e4f5bada9254091e9ede2" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 48.95%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 38.55%" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">Nemus Bioscience, Inc.,</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">a Nevada corporation</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 12.5%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 48.95%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5.2%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 33.34%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 12.5%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 48.95%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">November 12, 2015</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 5.2%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">By:</div>
</td>
<td style="VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 2px solid; WIDTH: 33.34%">&#160;<font style="FONT-STYLE: italic">/s/ Brian Murphy</font></td>
<td style="VERTICAL-ALIGN: top; WIDTH: 12.5%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 48.95%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5.2%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Its:</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 33.34%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Brian Murphy</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Chief Executive Officer</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">(Principal Executive Officer)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 12.5%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#160;</div>

<table id="12526f7df3474098b8365b21fcb0b53e" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 48.95%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">November 12, 2015</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 5.2%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">By:</div>
</td>
<td style="VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 2px solid; WIDTH: 33.34%">&#160;<font style="FONT-STYLE: italic">/s/ Elizabeth Berecz</font></td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 12.5%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 48.95%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5.2%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Its:</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 33.34%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Elizabeth Berecz</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Chief Financial Officer</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">(Principal Financial and Accounting Officer)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; WIDTH: 12.5%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#160;</div>

<div><br>
</div>
</div>

<div>&#160;</div>

<div id="DSPFPageNumberArea" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">27</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex-31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: pubco1
    Document created using EDGARfilings PROfile 3.6.1.0
    Copyright 1995 - 2015 Summit Financial Printing, LLC.  All rights reserved.-->
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif" bgcolor="#ffffff" text="#000000">
<div style="TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 0.2pt; MARGIN-RIGHT: 0.2pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 0.2pt; MARGIN-RIGHT: 0.2pt"><u>Exhibit 31.1</u></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Certification of Principal Executive Officer,</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Required By Rule 13a-14(A) of the Securities Exchange Act of 1934, As Amended,</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">As Adopted Pursuant To Section&#160;302 of the Sarbanes-Oxley Act of 2002</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">I, Brian Murphy, certify that:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<table id="c7754022a2274ab8a63fa364abe19e3d" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.31%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.32%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">1.</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 87.36%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">I have reviewed this quarterly report on Form 10-Q of Nemus Bioscience, Inc.;</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<table id="4f10725dbebb44e0b1702b145a1a186c" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.31%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.32%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">2.</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 87.36%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<table id="f8a2225be9d541e48fa8c06fe8053c25" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.31%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.32%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">3.</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 87.36%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<table id="ac44f76389ea41bc87681196fb5e96c7" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.31%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.32%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">4.</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 87.36%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<table id="16f809241ebf42b5b542e164de7c2963" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 12.63%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.31%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">(a)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 81.06%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font> to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<table id="4de3ee7fbf244ce08b0135f36637e06a" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 12.63%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.31%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">(b)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 81.06%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>
</td>
</tr>
</table>

<div><br>
</div>

<table id="ba00eb9865154c5ead8d7fff62878a24" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 12.63%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.31%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">(c)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 81.06%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font></div>
</td>
</tr>
</table>

<div><br>
</div>

<table id="4a5d411ef35845ad92fca29cf454e695" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 12.63%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.31%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">(d)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 81.06%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</div>
</td>
</tr>
</table>

<div><br>
</div>

<table id="21b00b22939748d884c6daf174572f4d" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.31%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.32%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">5.</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 87.36%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<table id="6f95337a4a474e64be3a09181a568b30" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 12.63%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.31%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">(a)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 81.06%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">All significant deficiencies and material weaknesses <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font> in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<table id="e5772ef611a2494b838facd204b4ea32" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 12.63%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.31%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">(b)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 81.06%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div><br>
</div>

<div>Date:&#160;&#160;November 12, 2015</div>

<table id="369f229dc0e44b96961efe9417116b5f" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 28%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 20%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 35%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 12%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; WIDTH: 28%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left">&#160;/s/ Brian Murphy</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 20%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 5%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 35%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 12%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 28%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Brian Murphy</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Chief Executive Officer</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 20%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 5%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 35%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 12%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex-31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: pubco1
    Document created using EDGARfilings PROfile 3.6.1.0
    Copyright 1995 - 2015 Summit Financial Printing, LLC.  All rights reserved.-->
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif" bgcolor="#ffffff" text="#000000">
<div>&#160;</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left"><u>Exhibit 31.2</u></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Certification of Principal Financial Officer,</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Required By Rule 13a-14(A) of the Securities Exchange Act of 1934, As Amended,</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">As Adopted Pursuant To Section&#160;302 of the Sarbanes-Oxley Act of 2002</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">I, Elizabeth Berecz, certify that:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">&#160;</div>

<table id="8ce52cf42fcd405db472fe53d7534ccd" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.31%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.32%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">1.</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 87.36%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">I have reviewed this quarterly report on Form 10-Q of Nemus Bioscience, Inc.;</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">&#160;</div>

<table id="6a438c92ea9f46928071c49b1b8040ea" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.31%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.32%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">2.</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 87.36%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">&#160;</div>

<table id="74cd58991f864149a1e85edb68dd66c1" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.31%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.32%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">3.</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 87.36%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">&#160;</div>

<table id="cc621700f2de41e4a61c09443c5853fa" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.31%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.32%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">4.</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 87.36%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">&#160;</div>

<table id="f422901d2b604d3ca644dabe5dc778e7" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 12.63%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.31%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">(a)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 81.06%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font> to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">&#160;</div>

<table id="1bda9212231349648c11c3913aeb6c89" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 12.63%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.31%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">(b)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 81.06%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>
</td>
</tr>
</table>

<div><br>
</div>

<table id="5230a900113942fdaa7d78cdac0a60be" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 12.63%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.31%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">(c)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 81.06%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font></div>
</td>
</tr>
</table>

<div><br>
</div>

<table id="6483b938b6d047a18ea1f43062185e88" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 12.63%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.31%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">(d)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 81.06%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</div>
</td>
</tr>
</table>

<div><br>
</div>

<table id="749336ebedc64ba7a9c66f03c8f972c1" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.31%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.32%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">5.</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 87.36%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">&#160;</div>

<table id="9b78981054234ec9af9236304d92d433" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 12.63%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.31%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">(a)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 81.06%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">All significant deficiencies and material weaknesses <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font> in the design or operation of internal control over financial reporting <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font> which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">&#160;</div>

<table id="a1dd96316fd24fa5a1eb9d7ca3a0c0b6" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 12.63%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.31%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">(b)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 81.06%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</div>

<div>&#160;</div>

<div>&#160;</div>

<div>&#160;</div>
</td>
</tr>
</table>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Date:&#160; November 12, 2015</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">
<table id="0b4ee9ad756c482a99b7065a39dff148" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; WIDTH: 34.74%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left">/s/ Elizabeth Berecz</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 12.62%">&#160;</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 5.26%">&#160;</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 34.74%">&#160;</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 12.64%">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 34.74%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Elizabeth Berecz</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Chief&#160;Financial Officer</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 12.62%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 5.26%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 34.74%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 12.64%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ex-32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: pubco1
    Document created using EDGARfilings PROfile 3.6.1.0
    Copyright 1995 - 2015 Summit Financial Printing, LLC.  All rights reserved.-->
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif" bgcolor="#ffffff" text="#000000">
<div style="TEXT-ALIGN: left">&#160;</div>

<div style="TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left"><u>Exhibit 32.1</u></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Certification of Principal Executive Officer, pursuant to 18 U.S.C. Section&#160;1350,</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">In connection with the Quarterly Report of Nemus Bioscience, Inc. a Nevada corporation (the &#8220;Company&#8221;) on Form 10-Q for the period ending September 30, 2015, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), Brian Murphy, Chief Executive Officer of the Company, certifies to the best of his knowledge, pursuant to 18&#160;U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</div>

<div><br>
</div>

<table id="0ed88716cb2c4c8dad3a5dd4f2e8d85d" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.31%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.32%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">(1)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 87.36%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</div>
</td>
</tr>
</table>

<div><br>
</div>

<table id="cf61e0050d4043248fbe83c3442c3853" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.31%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.32%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">(2)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 87.36%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</div>
</td>
</tr>
</table>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<table id="81796a7b9051428898ce4cb25e361f89" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; WIDTH: 34.74%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left">/s/ Brian Murphy</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 12.62%">&#160;</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 5.26%">&#160;</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 34.74%">&#160;</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 12.64%">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 34.74%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Brian Murphy</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Chief Executive Officer</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">November&#160; 12, 2015</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 12.62%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 5.26%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 34.74%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 12.64%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>ex-32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: pubco1
    Document created using EDGARfilings PROfile 3.6.1.0
    Copyright 1995 - 2015 Summit Financial Printing, LLC.  All rights reserved.-->
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif" bgcolor="#ffffff" text="#000000">
<div style="TEXT-ALIGN: left">&#160;</div>

<div style="TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left"><u>Exhibit 32.2</u></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">Certification of Principal&#160;Financial Officer, pursuant to 18 U.S.C. Section&#160;1350,</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">In connection with the Quarterly Report of Nemus Bioscience, Inc. a Nevada corporation (the &#8220;Company&#8221;) on Form 10-Q for the period ending September 30, 2015, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;),&#160;Elizabeth Berecz, Chief Financial Officer of the Company, certifies to the best of his knowledge, pursuant to 18&#160;U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</div>

<div><br>
</div>

<table id="b9fd8e3c93b64d8aa0f6dc309396e1f8" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.31%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.32%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">(1)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 87.36%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</div>
</td>
</tr>
</table>

<div><br>
</div>

<table id="b52419b8635649c1a5716803426a6d89" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.31%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 6.32%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">(2)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 87.36%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</div>
</td>
</tr>
</table>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<table id="a85385becd264c6f8400251bf6a63e4e" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-COLLAPSE: collapse; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; WIDTH: 34.74%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left">/s/ Elizabeth Berecz</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 12.62%">&#160;</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 5.26%">&#160;</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 34.74%">&#160;</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 12.64%">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 34.74%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Elizabeth Berecz</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Chief&#160;Financial Officer</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">November 12, 2015</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 12.62%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 5.26%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 34.74%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: middle; WIDTH: 12.64%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>nmus-20150930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!-- Generated using Ez-XBRL version 7.3.0.6 [11/10/2015 11:15:57 PM] -->
<!-- Based on XBRL 2.1 -->
<!--XBRL Document Modified with Ez-Editor Version 1.4.0.0 on Friday, November 13, 2015 12:10:52 AM -->
<xbrli:xbrl xmlns:nmus="http://www.nemusbioscience.com/20150930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2015-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31" xmlns:us-types="http://fasb.org/us-types/2015-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr">
<link:schemaRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:type="simple" xlink:href="nmus-20150930.xsd"/>
<!-- Context Section  -->
<xbrli:context id="Context_As_Of_17_Jul_2012T00_00_00_TO_17_Jul_2012T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-07-17
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jul_2012T00_00_00_TO_17_Jul_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FoundersAndMemberOfBoardMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nmus:FoundersAndMemberOfBoardMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-07-01
</xbrli:startDate>
<xbrli:endDate>
2012-07-17
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jul_2013T00_00_00_TO_31_Jul_2013T00_00_00_AgreementAxis_UniversityOfMississippiAgreementsMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="nmus:AgreementAxis">nmus:UniversityOfMississippiAgreementsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-07-01
</xbrli:startDate>
<xbrli:endDate>
2013-07-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AgreementAxis_StockPurchaseAgreementJune2014Member_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="nmus:AgreementAxis">nmus:StockPurchaseAgreementJune2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Aug_2014T00_00_00_TO_31_Aug_2014T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-08-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Aug_2014T00_00_00_TO_31_Aug_2014T00_00_00_AgreementAxis_StockPurchaseAgreementJune2014Member_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="nmus:AgreementAxis">nmus:StockPurchaseAgreementJune2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-08-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>

<xbrli:context id="Context_Custom_01_Sep_2014T00_00_00_TO_29_Sep_2014T00_00_00_AgreementAxis_OptionAgreementMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="nmus:AgreementAxis">nmus:OptionAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-09-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-29
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-07-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AgreementAxis_IndependentContractorAgreementsMember_ContractorAxis_ContractorOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="nmus:AgreementAxis">nmus:IndependentContractorAgreementsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="nmus:ContractorAxis">nmus:ContractorOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AgreementAxis_IndependentContractorAgreementsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="nmus:AgreementAxis">nmus:IndependentContractorAgreementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:SeriesBWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AgreementAxis_IndependentContractorAgreementsMember_ContractorAxis_ContractorTwoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="nmus:AgreementAxis">nmus:IndependentContractorAgreementsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="nmus:ContractorAxis">nmus:ContractorTwoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-09-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-10-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_BusinessAcquisitionAxis_NemusAcquisitionCorpMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nmus:NemusAcquisitionCorpMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-10-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_BusinessAcquisitionAxis_NemusAcquisitionCorpMember_LegalEntityAxis_NemusBioscienceIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nmus:NemusAcquisitionCorpMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:NemusBioscienceIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-10-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-10-01
</xbrli:startDate>
<xbrli:endDate>
2014-10-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_BusinessAcquisitionAxis_NemusAcquisitionCorpMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nmus:NemusAcquisitionCorpMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-10-01
</xbrli:startDate>
<xbrli:endDate>
2014-10-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Jan_2015T00_00_00_TO_31_Jan_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-01-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2015T00_00_00_TO_31_Jan_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Feb_2015T00_00_00_TO_28_Feb_2015T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember_AgreementAxis_OptionAgreementMember_BalanceSheetLocationAxis_AccruedLicenseAndPatentReimbursementFeesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="nmus:AgreementAxis">nmus:OptionAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">nmus:AccruedLicenseAndPatentReimbursementFeesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-02-01
</xbrli:startDate>
<xbrli:endDate>
2015-02-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2015T00_00_00_TO_31_Mar_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-03-01
</xbrli:startDate>
<xbrli:endDate>
2015-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-04-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-04-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-04-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-04-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-04-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-04-01
</xbrli:startDate>
<xbrli:endDate>
2015-04-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-04-01
</xbrli:startDate>
<xbrli:endDate>
2015-04-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-04-01
</xbrli:startDate>
<xbrli:endDate>
2015-04-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_May_2015T00_00_00_TO_31_May_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-05-01
</xbrli:startDate>
<xbrli:endDate>
2015-05-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_May_2015T00_00_00_TO_31_May_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-05-01
</xbrli:startDate>
<xbrli:endDate>
2015-05-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-06-01
</xbrli:startDate>
<xbrli:endDate>
2015-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Jul_2015T00_00_00_TO_31_Jul_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-07-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jul_2015T00_00_00_TO_31_Jul_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-07-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jul_2015T00_00_00_TO_31_Jul_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-07-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_21_Aug_2015T00_00_00_TO_21_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-08-21
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Aug_2015T00_00_00_TO_21_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-08-01
</xbrli:startDate>
<xbrli:endDate>
2015-08-21
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-08-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-08-01
</xbrli:startDate>
<xbrli:endDate>
2015-08-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_0ME_01-Aug-2015T00_00_00_TO_21-Aug-2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>

<xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-08-01
</xbrli:startDate>
<xbrli:endDate>2015-08-21</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-08-01
</xbrli:startDate>
<xbrli:endDate>
2015-08-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-08-01
</xbrli:startDate>
<xbrli:endDate>
2015-08-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_AgreementAxis_ResearchAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="nmus:AgreementAxis">nmus:ResearchAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember_AgreementAxis_ResearchAgreementMember_MonthAndYearOfAgreementAxis_March2015Member_LegalEntityAxis_UniversityOfMississippiMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="nmus:AgreementAxis">nmus:ResearchAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="nmus:MonthAndYearOfAgreementAxis">nmus:March2015Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:UniversityOfMississippiMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember_AgreementAxis_ResearchAgreementMember_MonthAndYearOfAgreementAxis_July2015Member_LegalEntityAxis_UniversityOfMississippiMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="nmus:AgreementAxis">nmus:ResearchAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="nmus:MonthAndYearOfAgreementAxis">nmus:July2015Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:UniversityOfMississippiMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember_AgreementAxis_ResearchAgreementMember_MonthAndYearOfAgreementAxis_September2015Member_LegalEntityAxis_UniversityOfMississippiMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="nmus:AgreementAxis">nmus:ResearchAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="nmus:MonthAndYearOfAgreementAxis">nmus:September2015Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:UniversityOfMississippiMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_AgreementAxis_IndependentContractorAgreementsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="nmus:AgreementAxis">nmus:IndependentContractorAgreementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_AgreementAxis_StockPurchaseAgreementJune2014Member_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="nmus:AgreementAxis">nmus:StockPurchaseAgreementJune2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmus:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_AgreementAxis_ResearchAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="nmus:AgreementAxis">nmus:ResearchAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_RangeAxis_MaximumMember_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:SeriesBWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember_AgreementAxis_ResearchAgreementMember_MonthAndYearOfAgreementAxis_March2015Member_LegalEntityAxis_UniversityOfMississippiMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="nmus:AgreementAxis">nmus:ResearchAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="nmus:MonthAndYearOfAgreementAxis">nmus:March2015Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:UniversityOfMississippiMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember_AgreementAxis_ResearchAgreementMember_MonthAndYearOfAgreementAxis_July2015Member_LegalEntityAxis_UniversityOfMississippiMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="nmus:AgreementAxis">nmus:ResearchAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="nmus:MonthAndYearOfAgreementAxis">nmus:July2015Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:UniversityOfMississippiMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember_AgreementAxis_ResearchAgreementMember_MonthAndYearOfAgreementAxis_September2015Member_LegalEntityAxis_UniversityOfMississippiMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="nmus:AgreementAxis">nmus:ResearchAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="nmus:MonthAndYearOfAgreementAxis">nmus:September2015Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">nmus:UniversityOfMississippiMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_OmnibusIncentivePlan2014Member_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmus:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_OmnibusIncentivePlan2014Member_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmus:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_AgreementAxis_StockPurchaseAgreementJune2014Member_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="nmus:AgreementAxis">nmus:StockPurchaseAgreementJune2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmus:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nmus:SeriesBWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2015T00_00_00_TO_20_Oct_2015T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_RestrictedStockMember_TitleOfIndividualAxis_ManagementAndBoardOfDirectorsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmus:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">nmus:ManagementAndBoardOfDirectorsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-10-01
</xbrli:startDate>
<xbrli:endDate>
2015-10-20
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_12-Nov-2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2015-11-12</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Jan_2015T00_00_00_TO_31_Dec_2014T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmus:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<!-- Unit Section  -->
<!--
I~1\FVPHexeD5678YReqi>MrlsywiI~\FVP6459c444c555cT{h>EF847:;;1665818J981=E=H17<86=<G=F4=: -->
<xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>

<xbrli:unit id="pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit>
<xbrli:unit id="Advisor"><xbrli:measure>nmus:Advisor</xbrli:measure></xbrli:unit>
<xbrli:unit id="Investor"><xbrli:measure>nmus:Investor</xbrli:measure></xbrli:unit>
<xbrli:unit id="Segment"><xbrli:measure>nmus:Segment</xbrli:measure></xbrli:unit>
<!-- Element Section  --><dei:EntityRegistrantName contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">Nemus Bioscience, Inc.</dei:EntityRegistrantName>
<dei:EntityCentralIndexKey contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">0001516551</dei:EntityCentralIndexKey>
<dei:TradingSymbol contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">nmus</dei:TradingSymbol>
<dei:CurrentFiscalYearEndDate contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">--12-31</dei:CurrentFiscalYearEndDate>
<dei:EntityFilerCategory contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">Smaller Reporting Company</dei:EntityFilerCategory>
<dei:EntityCommonStockSharesOutstanding contextRef="Context_As_Of_12-Nov-2015T00_00_00" unitRef="shares" decimals="INF">19278163</dei:EntityCommonStockSharesOutstanding>
<dei:DocumentType contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">10-Q</dei:DocumentType>
<dei:DocumentPeriodEndDate contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">2015-09-30</dei:DocumentPeriodEndDate>
<dei:AmendmentFlag contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">false</dei:AmendmentFlag>
<dei:DocumentFiscalYearFocus contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">2015</dei:DocumentFiscalYearFocus>
<dei:DocumentFiscalPeriodFocus contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">Q3</dei:DocumentFiscalPeriodFocus>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">207330</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">4342722</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">1025023</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:PrepaidExpenseCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">64489</us-gaap:PrepaidExpenseCurrent>
<us-gaap:PrepaidExpenseCurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">95548</us-gaap:PrepaidExpenseCurrent>
<us-gaap:OtherAssetsCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">36580</us-gaap:OtherAssetsCurrent>
<us-gaap:OtherAssetsCurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">31110</us-gaap:OtherAssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">308399</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">4506880</us-gaap:AssetsCurrent>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">21354</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">16046</us-gaap:PropertyPlantAndEquipmentNet>
<nmus:DepositsAndOtherAssets contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">18594</nmus:DepositsAndOtherAssets>
<nmus:DepositsAndOtherAssets contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">18594</nmus:DepositsAndOtherAssets>
<us-gaap:OtherAssetsNoncurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">18594</us-gaap:OtherAssetsNoncurrent>
<us-gaap:OtherAssetsNoncurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">18594</us-gaap:OtherAssetsNoncurrent>
<us-gaap:Assets contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">348347</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">4541520</us-gaap:Assets>
<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">409497</us-gaap:AccountsPayableCurrent>
<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">132234</us-gaap:AccountsPayableCurrent>
<us-gaap:AccruedSalariesCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">45566</us-gaap:AccruedSalariesCurrent>
<us-gaap:AccruedSalariesCurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">144723</us-gaap:AccruedSalariesCurrent>
<nmus:AccruedLicenseAndPatentReimbursementFees contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">119428</nmus:AccruedLicenseAndPatentReimbursementFees>
<nmus:AccruedLicenseAndPatentReimbursementFees contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">90216</nmus:AccruedLicenseAndPatentReimbursementFees>
<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">125799</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">177081</us-gaap:AccruedLiabilitiesCurrent>
<nmus:StockSubscriptionLiability contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">100000</nmus:StockSubscriptionLiability>
<nmus:ProvisionForConversionOfPreferredStock contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">700000</nmus:ProvisionForConversionOfPreferredStock>
<nmus:ProvisionForConversionOfPreferredStock contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">75488</nmus:ProvisionForConversionOfPreferredStock>
<us-gaap:AccruedIncomeTaxesCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">800</us-gaap:AccruedIncomeTaxesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">801090</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">619742</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesNoncurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">805</us-gaap:LiabilitiesNoncurrent>
<us-gaap:LiabilitiesNoncurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">2895613</us-gaap:LiabilitiesNoncurrent>
<us-gaap:Liabilities contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">801895</us-gaap:Liabilities>
<us-gaap:Liabilities contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">3515355</us-gaap:Liabilities>
<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">1620459</us-gaap:PreferredStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">16000</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">18078</us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">2257771</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">5723888</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:WarrantsAndRightsOutstanding contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">190000</us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:WarrantsAndRightsOutstanding contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">731036</us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:WarrantsAndRightsOutstanding contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="USD" decimals="0">2935800</us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-2917319</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-7067296</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-453548</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-594294</us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">348347</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">4541520</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_30_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="shares" decimals="-6">20000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="shares" decimals="-6">20000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="shares" decimals="INF">5000</us-gaap:PreferredStockSharesIssued>

<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="shares" decimals="INF">5000</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Jan_2015T00_00_00_TO_31_Jan_2015T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="shares" decimals="-6">236000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="shares" decimals="-6">236000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="shares" decimals="-6">16000000</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="shares" decimals="INF">18078163</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_BusinessAcquisitionAxis_NemusAcquisitionCorpMember" unitRef="shares" decimals="INF">16000000</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_BusinessAcquisitionAxis_NemusAcquisitionCorpMember_LegalEntityAxis_NemusBioscienceIncMember" unitRef="shares" decimals="INF">3120000</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="shares" decimals="-6">16000000</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="shares" decimals="INF">18078163</us-gaap:CommonStockSharesOutstanding>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">195000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">195000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">152288</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_AgreementAxis_ResearchAgreementMember" unitRef="USD" decimals="0">18673</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember_AgreementAxis_ResearchAgreementMember_MonthAndYearOfAgreementAxis_March2015Member_LegalEntityAxis_UniversityOfMississippiMember" unitRef="USD" decimals="0">18673</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember_AgreementAxis_ResearchAgreementMember_MonthAndYearOfAgreementAxis_July2015Member_LegalEntityAxis_UniversityOfMississippiMember" unitRef="USD" decimals="0">37119</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember_AgreementAxis_ResearchAgreementMember_MonthAndYearOfAgreementAxis_September2015Member_LegalEntityAxis_UniversityOfMississippiMember" unitRef="USD" decimals="0">21496</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">232862</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_AgreementAxis_ResearchAgreementMember" unitRef="USD" decimals="0">66747</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember_AgreementAxis_ResearchAgreementMember_MonthAndYearOfAgreementAxis_March2015Member_LegalEntityAxis_UniversityOfMississippiMember" unitRef="USD" decimals="0">66747</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember_AgreementAxis_ResearchAgreementMember_MonthAndYearOfAgreementAxis_July2015Member_LegalEntityAxis_UniversityOfMississippiMember" unitRef="USD" decimals="0">37119</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember_AgreementAxis_ResearchAgreementMember_MonthAndYearOfAgreementAxis_September2015Member_LegalEntityAxis_UniversityOfMississippiMember" unitRef="USD" decimals="0">21496</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">662613</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">835634</us-gaap:GeneralAndAdministrativeExpense>


<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">744004</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">2929799</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:OperatingExpenses contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">857613</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">1030634</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">896292</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">3162661</us-gaap:OperatingExpenses>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">-857613</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">-1030634</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-896292</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-3162661</us-gaap:OperatingIncomeLoss>
<nmus:GainLossOnConversionRightPreferredStock contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-286000</nmus:GainLossOnConversionRightPreferredStock>
<nmus:GainLossOnConversionRightPreferredStock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-986000</nmus:GainLossOnConversionRightPreferredStock>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">-857613</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">-1030634</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-1182292</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-4148661</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">905</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">905</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">500</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">1316</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">-858518</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">-1031539</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-1182792</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-4149977</us-gaap:NetIncomeLoss>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD_per_Share" decimals="2">-0.08</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD_per_Share" decimals="2">-0.12</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD_per_Share" decimals="2">-0.07</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD_per_Share" decimals="2">-0.25</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="shares" decimals="0">10502609</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="shares" decimals="0">8805766</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="shares" decimals="0">17062366</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="shares" decimals="0">16519854</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:Depreciation contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">344</us-gaap:Depreciation>
<us-gaap:Depreciation contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">7290</us-gaap:Depreciation>
<us-gaap:ShareBasedCompensation contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">263985</us-gaap:ShareBasedCompensation>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0" id="Footnote-2_1">529016</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0" id="Footnote-1_2">23758</us-gaap:IncreaseDecreaseInPrepaidExpense>
<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0" id="Footnote-1_3">-25800</us-gaap:IncreaseDecreaseInPrepaidExpense>
<us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-5470</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
<nmus:IncreaseDecreaseInDepositsAndOtherAssets contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">64970</nmus:IncreaseDecreaseInDepositsAndOtherAssets>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0" id="Footnote-2_2">-267264</us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">99157</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
<nmus:IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">29212</nmus:IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees>
<nmus:IncreaseDecreaseInStockSubscriptionLiability contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">100000</nmus:IncreaseDecreaseInStockSubscriptionLiability>
<us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">167355</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
<us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">52899</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">-952568</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-2614336</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">12389</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">1982</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">-12389</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-1982</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">1989980</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">721069</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">1442302</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">1989980</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">6751710</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">1025023</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">4135392</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:InterestPaid contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:InterestPaid contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncomeTaxesPaid contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">905</us-gaap:IncomeTaxesPaid>
<us-gaap:IncomeTaxesPaid contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">116</us-gaap:IncomeTaxesPaid>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="shares" decimals="INF">200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
<nmus:NoncashValueOfWarrantsIssued contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">417875</nmus:NoncashValueOfWarrantsIssued>
<us-gaap:StockIssued1 contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">168000</us-gaap:StockIssued1>
<nmus:WarrantsIssuedInExchangeForExtinguishmentOfTradeAccountsPayable contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="shares" decimals="INF">6000</nmus:WarrantsIssuedInExchangeForExtinguishmentOfTradeAccountsPayable>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_17_Jul_2012T00_00_00_TO_17_Jul_2012T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Aug_2014T00_00_00_TO_31_Aug_2014T00_00_00_AgreementAxis_StockPurchaseAgreementJune2014Member_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">2.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00" unitRef="USD_per_Share" decimals="2">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">2.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD_per_Share" decimals="2">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD_per_Share" decimals="2">2.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_AgreementAxis_StockPurchaseAgreementJune2014Member_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="USD_per_Share" decimals="2">1.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<nmus:ExtinguishmentOfTradeAccountsPayableOwedToVendor contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">10000</nmus:ExtinguishmentOfTradeAccountsPayableOwedToVendor>
<us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 5pt; margin-bottom: 5pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;1. Nature of Operations, Business Activities and Summary of Significant Accounting Policies&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Nature of Operations and Basis of Presentation&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Nemus Bioscience, Inc. is a biopharmaceutical company that plans to develop and commercialize therapeutics from cannabinoids through a partnership with the University of Mississippi. The University of Mississippi ("UM") is federally permitted and licensed to cultivate cannabis for research and commercial purposes. Unless otherwise specified, references in these Notes to the Unaudited Consolidated Financial Statements to the "Company," "we" or "our" refer to Nemus Bioscience, Inc., a Nevada corporation formerly known as Load Guard Logistics, Inc. ("LGL"), together with its wholly-owned subsidiary, Nemus, a California corporation ("Nemus"). Nemus became the wholly owned subsidiary of Nemus Bioscience, Inc. through the Merger (as defined below).&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Nemus Bioscience, Inc. (formerly LGL) was incorporated in Nevada on March 16, 2011. Nemus was incorporated in California on July 17, 2012. Our headquarters are located in Costa Mesa, California.&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;As of September 30, 2015, the Company has devoted substantially all of its efforts to securing product licenses, raising capital, and building infrastructure, and has not realized revenue from its planned principal operations.&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Business Activities&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;On October 31, 2014, pursuant to an Agreement and Plan of Merger, dated October 17, 2014 (the "Merger Agreement"), LGL,&amp;#160; Nemus Acquisition Corp. ("Acquisition Sub"), Nemus Bioscience, Inc. ("Name Change Merger Sub"), and Nemus, Acquisition Sub merged with and into Nemus and Nemus survived as a wholly-owned subsidiary of LGL (the "Merger"). Immediately after the Merger, LGL changed its name to "Nemus Bioscience, Inc." by merging with Name Change Merger Sub.&amp;#160;Pursuant to the Merger Agreement, each share of Nemus common stock outstanding totaling 12,880,000 shares was exchanged at a 1:1 conversion rate to LGL shares and when combined with the 3,120,000 shares of LGL common stock outstanding, amounted to 16,000,000 total shares outstanding upon completion of the merger.&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;The Merger is being accounted for as a reverse-merger and recapitalization. Nemus is the acquirer for financial reporting purposes and LGL is the acquired company. Consequently, the assets and liabilities and the operations that will be reflected in the historical consolidated&amp;#160;financial statements prior to the Merger will be those of Nemus and will be recorded at the historical cost basis of Nemus, and the consolidated financial statements after completion of the Merger will include the assets and liabilities of LGL and Nemus, the historical operations of Nemus and the operations of the Nemus from and after the closing date of the Merger.&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Use of Estimates&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles ("U.S. GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates.&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Liquidity and Going Concern&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;The Company has incurred operating losses and negative cash flows from operations since our inception. As of September 30, 2015, we had cash and cash equivalents of $4,342,722.&amp;#160; The Company anticipates that it will continue to incur net losses into the foreseeable future as it continues to advance and develop a number of potential drug candidates into preclinical development activities and expands its corporate infrastructure which includes the costs associated with being a public company. Without additional funding, management believes that the Company will not have sufficient funds to meet its obligations within one year after the date the consolidated financial statements are issued. These conditions give rise to substantial doubt as to the Company's ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;The Company plans to continue to fund its losses from operations and capital funding needs through public or private equity or debt financings, strategic collaborations, licensing arrangements, asset sales, government grants or other arrangements. However, the Company cannot be sure that such additional funds will be available on reasonable terms, or at all. If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result. If the Company is unable to secure adequate additional funding, the Company may be forced to make a reduction in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs.&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Cash and Cash Equivalents&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The carrying value of those investments approximates their fair market value due to their short maturity and liquidity. Cash and cash equivalents include cash on hand and amounts on deposit with financial institutions, which amounts may at times exceed federally insured limits. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk.&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Restricted Cash&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-size: 5.14pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;A deposit of $37,500 as of September 30, 2015 was restricted from withdrawal and held by a bank in the form of a certificate of deposit. This certificate served as collateral for payment of the Company's credit cards.&amp;#160; Restricted cash as of December 31, 2014 was $0.&lt;/font&gt;&lt;/div&gt;
&lt;div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Fair Value Measurements&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last is considered unobservable, is used to measure fair value:&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;
&lt;table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="width: 20.45pt;"&gt;&lt;/td&gt;
&lt;td style="width: 51.55pt; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;Level 1:&lt;/td&gt;
&lt;td style="width: auto; text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;
&lt;div&gt;Valuations for assets and liabilities traded in active markets from readily available pricing sources such as quoted prices in active markets for identical assets or liabilities.&lt;/div&gt;
&lt;div&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;
&lt;table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="width: 20.45pt;"&gt;&lt;/td&gt;
&lt;td style="width: 51.55pt; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;Level 2:&lt;/td&gt;
&lt;td style="width: auto; text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;
&lt;div&gt;Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/div&gt;
&lt;div&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;
&lt;table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="width: 20.45pt;"&gt;&lt;/td&gt;
&lt;td style="width: 51.55pt; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;Level 3:&lt;/td&gt;
&lt;td style="width: auto; text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 35.9pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.1pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 35.9pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.1pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;The carrying values of our financial instruments, including, cash and cash equivalents, prepaid expenses, accounts payable, and accrued expenses approximate their fair value due to the short maturities of these financial instruments.&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Property and Equipment, Net&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;As of September 30, 2015, property and equipment, net, was $16,046, consisting primarily of computers and equipment. The Company had $21,354 of property and equipment, net, as of December 31, 2014. Expenditures for additions, renewals and improvements will be capitalized at cost. Depreciation will generally be computed on a straight-line method based on the estimated useful life of the related assets currently ranging from two to three years. Maintenance and repairs that do not extend the life of assets are charged to expense when incurred. When properties are disposed of, the related costs and accumulated depreciation are removed from the accounts and any gain or loss is reported in the period the transaction takes place.&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount exceeds its estimated future undiscounted cash flows, an impairment charge is recognized by the amount by which the carrying amount exceeds the fair value of the asset.&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;The costs incurred for the rights to use licensed technologies in the research and development process, including licensing fees and milestone payments, will be charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where there is an identified alternative future use. No cost associated with the use of licensed technologies has been capitalized to date.&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Income Taxes&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;The Company accounts for our deferred income tax assets and liabilities based on differences between the financial reporting and tax bases of assets and liabilities, and net operating loss carry forwards (the "NOLs") and other tax credit carry forwards. These items are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the period that includes the enactment date. Any interest or penalties would be recorded in the Company's statement of operations in the period incurred.&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times,;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;The Company records a valuation allowance to reduce the deferred income tax assets to the amount that is more likely than not to be realized. In making such determinations, management considers all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. As a result there are no income tax benefits reflected in the statement of operations to offset pre-tax losses.&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;The Company recognizes a tax benefit from uncertain tax positions when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position.&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Revenue Recognition&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;The Company has not begun planned principal operations and has not generated any revenue since inception.&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Research and Development Expenses&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Research and development ("R&amp;amp;D") costs are expensed when incurred. These costs may consist of external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, third-party manufacturing organizations and consultants; employee-related expenses, which include salaries, benefits and stock-based compensation for the personnel involved in our preclinical and clinical drug development activities; and facilities expense, depreciation and other allocated expenses; and equipment and laboratory supplies.&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Stock-Based Compensation Expenses&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Stock-based compensation cost is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period. We use the Black-Scholes option pricing model for estimating the grant date fair value of stock options and warrants using the following assumptions:&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;
&lt;table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="width: 20.25pt;"&gt;&lt;/td&gt;
&lt;td style="width: 27pt; font-family: symbol, serif; font-size: 10pt; vertical-align: top;"&gt;&amp;#183;&lt;/td&gt;
&lt;td style="width: auto; text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;Exercise price - We determined the exercise price based on valuations using the best information available to management at the time of the valuations.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;
&lt;table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="width: 20.25pt;"&gt;&lt;/td&gt;
&lt;td style="width: 27pt; font-family: symbol, serif; font-size: 10pt; vertical-align: top;"&gt;&amp;#183;&lt;/td&gt;
&lt;td style="width: auto; text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;Volatility &amp;#8211; We estimate the stock price volatility based on industry peers who are also in the early development stage given the limited market data available in the public arena.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;
&lt;table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="width: 20.25pt;"&gt;&lt;/td&gt;
&lt;td style="width: 27pt; font-family: symbol, serif; font-size: 10pt; vertical-align: top;"&gt;&amp;#183;&lt;/td&gt;
&lt;td style="width: auto; text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;Expected term - The expected term is based on a simplified method which defines the life as the average of the contractual term of the options and warrants and the weighted-average vesting period for all open awards.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;
&lt;table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="width: 20.25pt;"&gt;&lt;/td&gt;
&lt;td style="width: 27pt; font-family: symbol, serif; font-size: 10pt; vertical-align: top;"&gt;&amp;#183;&lt;/td&gt;
&lt;td style="width: auto; text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;Risk-free rate - The risk-free interest rate for the expected term of the option or warrant is based on the average market rate on U.S. treasury securities in effect during the quarter in which the awards were granted.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;
&lt;table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="width: 20.35pt;"&gt;&lt;/td&gt;
&lt;td style="width: 27pt; font-family: symbol, serif; font-size: 10pt; vertical-align: top;"&gt;&amp;#183;&lt;/td&gt;
&lt;td style="width: auto; text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;Dividends &amp;#8211; The dividend yield assumption is based on our history and expectation of paying no dividends.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Stock-Based Compensation for Non-Employees&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;The Company accounts for warrants and options issued to non-employees under ASC 505-50,&amp;#160;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;"&gt;Equity &amp;#8211; Equity Based Payments to Non-Employees,&lt;/font&gt;&amp;#160;using the Black-Scholes option-pricing model. The value of such non-employee awards are periodically re-measured over the vesting terms and at each quarter end.&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Segment Information&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;The Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") No. 280, "Segment Reporting" establishes standards for reporting information about reportable segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group ("CODM"), in deciding how to allocate resources and in assessing performance. The CODM evaluates revenues and gross profits based on product lines and routes to market. Based on the early development stage of our operation, we operate in a single reportable segment.&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Comprehensive Income (Loss)&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company is required to record all components of comprehensive loss in the consolidated&amp;#160;financial statements in the period in which they are recognized. Net income (loss) and other comprehensive loss, net of their related tax effect, arrived at a comprehensive loss. For the three and nine months ended September 30, 2015 and 2014, the comprehensive loss was equal to the net loss.&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Earnings per share&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;The Company applies FASB ASC 260, "Earnings per Share." Basic earnings (loss) per share is computed by dividing earnings (loss) available to common stockholders by the weighted-average number of common shares outstanding. Diluted earnings or loss per share would include the dilutive effect of awards granted to employees under stock-based compensation plans, if any. There were no dilutive awards outstanding at September 30, 2015.&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
<nmus:UniversityOfMississippiAgreementsTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;2. University of Mississippi ("UM") Agreements&lt;/div&gt;
&lt;div style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;In July 2013, the Company entered into a Memorandum of Understanding (MOU) with the UM to engage in joint research of extracting, manipulating, and studying cannabis in certain forms to develop intellectual property (IP) with the intention to create and commercialize therapeutic medicines. Nemus will own all IP developed solely by its employees and will jointly own all IP developed jointly between Nemus and UM employees. The term of the MOU agreement is five years and the parties agree to negotiate separate Research agreements upon the identification of patentable technologies as well as any deemed to be a trade secret. The agreement may be terminated by either party with three months written notice to the other party.&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;On May 15, 2014, the Company entered into an Option Agreement in which UM granted us a three-month option for conducting due diligence to exclusively license a suppository dosage form containing Dronabinol Hemi succinate and other esters ("NPC 4718").&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;As a result of our due diligence, on September 29, 2014, the Company executed three license agreements with UM pursuant to which UM granted us exclusive, perpetual, worldwide licenses, including the right to sublicense, to intellectual property related to UM5050, a pro-drug formulation of tetrahydrocannabinol, or THC for products administered through each of ocular, oral or rectal delivery. The license agreement for the field of oral delivery also includes rights to UM 1250, a bio-adhesive hot melt extruded film for topical and mucosal adhesion application and drug delivery.&amp;#160; The license agreements contain certain milestone and royalty payments, as defined therein. These licenses also require the Company to reimburse UM for patent costs incurred related to these products under license. In the case of the ocular license the Company was required to reimburse sunk patent expenses of $70,678 in February 2015; this amount was reflected in accrued license and patent reimbursement fees as of December 31, 2014. These license agreements will terminate upon expiration of the patents, breach or default of the license agreements, or upon 60 days written notice by the Company to UM.&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;On October 15, 2014, we signed a renewable option agreement for the rights to explore other routes of delivery of UM5050 not yet agreed upon and/or in combination with other cannabinoids or other compatible compounds. There was a one-time up-front option payment and the option period was for six months expiring on March 31, 2015. On September 29, 2015, the Company exercised its right to renew for an additional six months under the same financial terms and conditions.&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 3pt; margin-bottom: 3pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 20pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.1pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;On July 1, 2014, the Company entered into three additional Option Agreements, pursuant to which UM granted Nemus three-month exclusive options for conducting due diligence on the following three cannabinoid extracts to exclusively license them for the purposes of obtaining FDA approval and commercializing the extracts:&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 20pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.1pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;
&lt;table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="width: 20pt;"&gt;&lt;/td&gt;
&lt;td style="width: 27.35pt; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;1)&lt;/td&gt;
&lt;td style="width: auto; text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;UM 1490 &amp;#8211; transmucosal delivery of cannabinoids&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;
&lt;table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="width: 20pt;"&gt;&lt;/td&gt;
&lt;td style="width: 27.35pt; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;2)&lt;/td&gt;
&lt;td style="width: auto; text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;UM 5070 &amp;#8211; treatment for methicillin-resistant&amp;#160;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;"&gt;Staphylococcus aureus&amp;#160;&lt;/font&gt;(MRSA) infections&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;
&lt;table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="width: 20pt;"&gt;&lt;/td&gt;
&lt;td style="width: 27.35pt; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;3)&lt;/td&gt;
&lt;td style="width: auto; text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;UM 8790 &amp;#8211; ocular delivery of cannabinoids&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-right: 0.1pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-right: 0.1pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;In March of 2015, in lieu of a license agreement, the Company entered into a research agreement with UM to begin studies concerning the medical utility of cannabinoids as anti-infective therapeutics for MRSA.&amp;#160; The fee payable to UM under the agreement is based on the achievement of certain milestones in the project. The Company recognized $18,673 and $66,747 of research and development expense for the three and nine months ending September 30, 2015 which represents work completed to date under this contract.&amp;#160; The agreement also grants an exclusive option to license the technology from the University within 180 days from the commencement of the agreement. Either party may terminate the agreement with 30 days written notice.&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-right: 0.1pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 35.9pt; letter-spacing: normal; margin-right: 3.8pt; margin-left: 0.6pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;In July of 2015, the Company entered into a research agreement with UM to begin studies concerning research and development of cannabidiol (CBD) formulations.&amp;#160; The fee payable to UM is based on the achievement of certain milestones in the project. The Company recognized $37,119 of research and development expense for both the three and nine months ending September 30, 2015 which represents work completed to date under this contract. The agreement also grants an exclusive option to license the technology from the University within 180 days from the commencement of the agreement. Either party may terminate the agreement with 30 days written notice.&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 35.9pt; letter-spacing: normal; margin-right: 3.8pt; margin-left: 0.6pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 35.8pt; letter-spacing: normal; margin-right: 0.2pt; margin-left: 0.3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;In September of 2015, the Company entered into a research agreement with UM to advance NEMUS' lead proprietary cannabinoid-based therapy (UM5050) developed for the treatment and management of glaucoma into an optimized once-daily treatment formulation. The fee payable to UM is based on the achievement of certain milestones in the project. The Company recognized $21,496 of research and development expense for both the three and nine months ending September 30, 2015 which represents work completed to date under this contract. The agreement also grants an exclusive option to license the technology from the University within 180 days from the commencement of the agreement. Either party may terminate the agreement with 30 days written notice.&lt;/div&gt;</nmus:UniversityOfMississippiAgreementsTextBlock>
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div style="font: bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;3. Commitments and Contingencies&lt;/div&gt;
&lt;div style="font: bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Lease Commitments&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company leased temporary headquarters facilities under a month-to-month operating lease agreement. This lease was terminated effective December 31, 2014. Monthly rent expense under this lease was $2,060.&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;On September 1, 2014, the Company signed an operating lease for laboratory and office space at the Innovation Hub, Insight Park located on the University of Mississippi campus. The lease term commenced on October 1, 2014 and expires on December 31, 2017. There are annual escalating rent provisions and two months of free rent in the agreement. The total cash payments over the life of the lease are divided by the total number of months in the lease period and the average rent will be charged to expense each month during the lease period. The monthly amount charged to rent expense is $9,000.&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In October of&amp;#160;2014, we signed a lease agreement for our corporate office headquarters that consists of approximately 4,087 square feet located at 650 Town Center Drive, Suite 1770, Costa Mesa, CA 92626. &amp;#160; The lease expires on October 31, 2016 and our monthly rent is $5,373, payable in equal monthly installments with annual escalations.&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Total net rent expense related to our operating leases for the nine months ended September 30, 2015 and 2014 was $170,931and $6,844, respectively. For the three months ended September 30, 2015 and 2014, total net rent expense was $56,680 and $6,294.&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 35.9pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.2pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Future minimum payments under the non-cancelable portion of our operating leases as of September 30, 2015 are as follows:&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 35.9pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.2pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;table align="center" style="widows: 1; text-transform: none; text-indent: 0px; width: 100%; font-family: 'times new roman', times, serif; letter-spacing: normal; font-size: 10pt; word-spacing: 0px; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="vertical-align: bottom;" valign="bottom"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;"&gt;For the year ending December 31,&lt;/div&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;" valign="bottom" colspan="2"&gt;&lt;/td&gt;
&lt;td style="text-align: left; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width: 1337px; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;2015&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 16px; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;43,900&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width: 1337px; vertical-align: bottom; background-color: #ffffff;" valign="bottom"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;2016&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 16px; vertical-align: bottom; background-color: #ffffff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #ffffff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;165,700&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width: 1337px; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;2017&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 16px; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;85,900&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width: 1337px; vertical-align: bottom; background-color: #ffffff;" valign="bottom"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;2018&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 16px; vertical-align: bottom; background-color: #ffffff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #ffffff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width: 1337px; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;2019&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 16px; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width: 1337px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;" valign="bottom"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Thereafter&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 136px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width: 1337px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Total&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 16px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 136px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;295,500&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Independent Contractor Agreements&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company has entered into independent contractor agreements with individuals that are operating in the capacity of our management team, or that are serving in an advisory role. Certain agreements expired once the individuals became full-time employees. Independent contractor expense for the nine months ended September 30, 2015 was $90,000 and for the nine months ended September 30, 2014 was $353,000. Two of these contractors accounted for 30% and 15% respectively of our total expenditures for the nine months ended September 30, 2014. There was no significant independent contractor expense as a percent of our total expenditures&amp;#160;for the nine months ended September 30, 2015.&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Legal Matters&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: italic 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;General Litigation and Disputes&lt;/div&gt;
&lt;div style="font: italic 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;From time to time, in the normal course of our operations, we may be a party to litigation and other dispute matters and claims. Currently Nemus is not party to any litigation, dispute matters or claims. Litigation can be expensive and disruptive to normal business operations. Moreover, the results of complex legal proceedings are difficult to predict and our view of these matters may change in the future as the litigation and events related thereto unfold. An unfavorable outcome to any legal matter, if material, could have a materially adverse effect on our operations or our financial position, liquidity or results of operations.&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: italic 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Government Proceedings&lt;/div&gt;
&lt;div style="font: italic 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Like other companies in the pharmaceutical industry, we are subject to extensive regulation by national, state and local government agencies in the United States. As a result, interaction with government agencies occurs in the normal course of our operations. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from any government investigation or proceeding. As of September 30, 2015, the Company had no current proceedings or inquiries.&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Change in Control Severance Plan&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In February 2015, we adopted a change in control severance plan, in which our named executive officers participate, that provides for the payment of severance benefits if the executive's service is terminated within twelve months following a change in control, either due to a termination without cause or upon a resignation for good reason (as each term is defined in the plan).&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In either such event, and provided the executive timely executes and does not revoke a general release of claims against the Company, he or she will be entitled to receive: (i) a lump sum cash payment equal to at least six months of the executive's monthly compensation, plus an additional month for each full year of service over six years, (ii) Company-paid premiums for continued health insurance for a period equal to length of the cash severance period or, if earlier, when executive becomes covered under a subsequent employer's healthcare plan, and (iii) full vesting of all then-outstanding unvested stock options and restricted stock awards.&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div style="text-align: left; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;4. Stockholders' Deficit and Redeemable Convertible Series B Preferred Stock&lt;/div&gt;
&lt;div style="text-align: left; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold italic 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;Common Stock&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold italic 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;On July 17, 2012, the Company issued 7,770,000 shares of common stock with no par value and warrants (see first paragraph under warrants below) to its founders and one board member in exchange for the services provided to establish Nemus, valued at approximately $1,000.&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;In June of 2014, the Company sold 1,800,000 shares of common stock with no par value and warrants for a purchase price of $900,000 (the "June 2014 Stock Purchase Agreement") to a group of private investors. See additional discussion on warrants below.&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;In August of 2014, the Company sold 2,200,000 shares of common stock with no par value and warrants for a purchase price of $1,100,000 to a group of private investors. See additional discussion on warrants below.&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;In October of 2014, the Company issued 1,110,000 shares of common stock with no par value to eighteen individual investors that had participated in a prior entity founded by Nemus' then current president. Such entity has been insolvent and not operating since the inception date of Nemus. The issuance of these shares was in exchange for the signing of a release of claims against the Company, its President, and the former entity. The Company recorded a general and administrative expense of $466,200 in the fourth quarter of 2014 to reflect the fair market value of the common stock issued in exchange for the release of claims. The fair market value of the common stock issued was determined via an independent third-party valuation conducted as of October 31, 2014.&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;In January of 2015, the Company sold 241,663 shares of common stock with par value of $0.001 for a purchase price of $724,989 to a group of private investors.&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;In March of 2015, the Company issued 24,000 shares of common stock with par value of $0.001 to a third party in exchange for services to be performed related to raising additional capital. The Company recorded a prepaid expense of $168,000 in the first quarter to reflect the fair market value of the common stock issued and is amortizing this expense over the contract service period which is one year. The fair market value was determined utilizing the Company's closing stock price as of the commencement date of the contract service period. For the nine months ended September 30, 2015, the Company amortized $113,806 to general and administrative expense.&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;In August 2015, in conjunction with the Series B Preferred Stock sale (discussed below), the Company raised $5.0 million at $1,000 per share resulting in the automatic conversion of the Series A Preferred Stock to common stock. This resulted in the conversion of 580,000 shares of Series A Preferred Stock at $2.50 per share to the equivalent of 1,812,500 shares of common stock.&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold italic 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;Preferred Stock&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold italic 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;The Company has authorized 20,000,000 shares of preferred stock with a par value of $0.001 per share.&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;u&gt;Series A Preferred Stock:&lt;/u&gt;&lt;/font&gt;&amp;#160; In April 2015, the Company sold 250,000 shares of Series A preferred stock with par value of $0.001 and 50,000 warrants to purchase the Company's common stock for an aggregate purchase price of $625,000, or $2,50 per share&amp;#160;to a group of private investors. The shares of preferred stock automatically convert to shares of common stock either at (i) a subsequent equity financing of at least $1,000,000 or (ii) October 1, 2015, whichever is earlier. The warrants are exercisable at a price of $5.00 per share and expire five years from the issuance date. In May 2015, the Company sold 150,000 shares and 30,000 warrants and in July 2015, 180,000 shares and 36,000 warrants under the same terms and conditions.&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;The Series A preferred stock issued also has a "down-round" protection feature provided to the investors if the Company subsequently issues or sells any shares in a round of equity financing of at least $1,000,000 prior to October 1, 2015 in which the shares of common stock to be acquired are at a price less than $2.50 per share. The Company is required to issue additional shares of common stock to the investors in an amount such that the subscription price paid, when divided by the total number of shares issued will result in an actual price paid per share of common stock equal to such lower price. This conversion occurred as discussed above in conjunction with the Series B Preferred Stock financing totaling $5.0 million and resulted in the conversion of 580,000 shares of Series A Preferred Stock at to 1,812,500 shares of common stock.&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 12pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 12pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&lt;u&gt;Redeemable Convertible Series B Preferred Stock&lt;/u&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;u&gt;:&lt;/u&gt;&lt;/font&gt;&amp;#160;In August 2015, the Company sold 5,000 shares of Series B Convertible Preferred Stock and warrants to purchase 6,250,000 shares of the Company's common stock for an aggregate purchase price of $1,000 per share resulting in gross proceeds of $5.0 million.&amp;#160; Each share of preferred stock is convertible into 1,250 shares of common stock which results in an effective conversion price of $0.80 per common share and can be converted by the holder at any time. The Series B preferred stock issued also has a "down-round" protection feature provided to the investors if the Company subsequently issues or sell any shares of common stock, stock options, or convertible securities at a price less than the conversion price of $0.80 per common share. The conversion price is automatically adjusted down to the price of the instrument being issued. See additional discussion in Note 5 below. The Series B shares have liquidation preference over other preferred shares and common stock and have voting rights equal to the number of common shares into which each holder's preferred stock is convertible as of the record date. The preferred stock has no dividend rights. If dividends are declared on the common stock, the holders of the preferred stock shall be entitled to participate in such dividends on an as-if converted basis. The warrants are exercisable at a price of $1.15 per share and expire five years from the issuance date. See additional discussion regarding these warrants in Note 6 below.&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;In the event of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary, Series B preferred stockholders receive an amount per share equal to the conversion price of $0.80, subject to down-round adjustment,&amp;#160;multiplied by the as-if converted share amount of 6,250,000 common shares, totaling $5.0 million.&amp;#160; If upon the liquidation, the assets are insufficient to permit payments to the Series B holders,&amp;#160;all assets legally available will be distributed in a pro rata basis among the Series B&amp;#160;holders in proportion to the full amounts they would otherwise be entitled to receive. Any remaining assets are distributed pro rata among the common stockholders.&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;Subject to certain trigger events occurring, the Series B preferred stock holders have the right to force the Company to redeem the shares of preferred stock at a price per preferred share equal to the greater of (A) 115% of the conversion amount and (B) the product of (1) the conversion rate in effect at such time and (2) the greatest closing sale price of the Common Stock during the period beginning on the date immediately preceding such triggering event and ending on the date such holder delivers the notice of redemption. Such triggering events include:&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;
&lt;div style="text-align: justify; margin-top: 3pt; margin-bottom: 3pt;"&gt;
&lt;table style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="width: 36pt;"&gt;&lt;/td&gt;
&lt;td style="width: 18pt; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;-&lt;/td&gt;
&lt;td style="text-align: justify; width: auto; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;Failure of the Series B Registration Statement to be declared effective by the SEC on or prior to the date that is ninety days after the Effectiveness Deadline;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="text-align: justify; margin-top: 3pt; margin-bottom: 3pt;"&gt;
&lt;table style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="width: 36pt;"&gt;&lt;/td&gt;
&lt;td style="width: 18pt; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;-&lt;/td&gt;
&lt;td style="text-align: justify; width: auto; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;Suspension of the Company&amp;#8217;s common stock from trading for a period of (2) consecutive trading days;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="text-align: justify; margin-top: 3pt; margin-bottom: 3pt;"&gt;
&lt;table style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="width: 36pt;"&gt;&lt;/td&gt;
&lt;td style="width: 18pt; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;-&lt;/td&gt;
&lt;td style="text-align: justify; width: auto; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;Failure of the Company to deliver all the shares of the common stock or make the appropriate cash payments in a timely manner upon conversion of the Series B Preferred;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="text-align: justify; margin-top: 3pt; margin-bottom: 3pt;"&gt;
&lt;table style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" id="efa5485a941341dba3261c48abc95c07" class="dspflisttable" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="width: 36pt;"&gt;&lt;/td&gt;
&lt;td style="width: 18pt; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;-&lt;/td&gt;
&lt;td style="text-align: justify; width: auto; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;Any default of indebtedness;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="text-align: justify; margin-top: 3pt; margin-bottom: 3pt;"&gt;
&lt;table style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" id="d93c08687c61458585237bc8fdf16638" class="dspflisttable" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="width: 36pt;"&gt;&lt;/td&gt;
&lt;td style="width: 18pt; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;-&lt;/td&gt;
&lt;td style="text-align: justify; width: auto; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;Any filing of voluntary or involuntary bankruptcy by the Company;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="text-align: justify; margin-top: 3pt; margin-bottom: 3pt;"&gt;
&lt;table style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" id="a00b954615f34fa38b8d11caa9556cb7" class="dspflisttable" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="width: 36pt;"&gt;&lt;/td&gt;
&lt;td style="width: 18pt; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;-&lt;/td&gt;
&lt;td style="text-align: justify; width: auto; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;A final judgment in excess of $100,000 rendered against the Company;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="text-align: justify; margin-top: 3pt; margin-bottom: 3pt;"&gt;
&lt;table style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" id="e2d1425ace7249bea58f5de3f0db324a" class="dspflisttable" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="width: 36pt;"&gt;&lt;/td&gt;
&lt;td style="width: 18pt; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;-&lt;/td&gt;
&lt;td style="text-align: justify; width: auto; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;Breach of representations and warranties in the Stock Purchase Agreement;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="text-align: justify; margin-top: 3pt; margin-bottom: 3pt;"&gt;
&lt;table style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="width: 36.1pt;"&gt;&lt;/td&gt;
&lt;td style="width: 18pt; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;-&lt;/td&gt;
&lt;td style="text-align: justify; width: auto; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;Failure to comply with the Series B Certificate of Designation or Rule 144 requirements.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="text-align: justify; margin-top: 3pt; font-family: 'times new roman', times, serif; margin-bottom: 3pt; font-size: 10pt; margin-right: 0.3pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: justify; margin-top: 3pt; font-family: 'times new roman', times, serif; margin-bottom: 3pt; font-size: 10pt; margin-right: 0.3pt;"&gt;As certain of these triggering events are considered to be outside the control of the Company, the Series B preferred stock is considered to be contingently redeemable&amp;#160;convertible and as a result, has been classified as mezzanine equity in the Company&amp;#8217;s balance sheet presentation.&lt;/div&gt;
&lt;/div&gt;
&lt;div style="text-align: left; widows: 1; text-transform: none; text-indent: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;
&lt;div style="text-align: center; margin-top: 3pt; font-family: 'times new roman', times, serif; margin-bottom: 3pt; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold italic 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;Warrants&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold italic 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;On July 17, 2012, the Company issued warrants to purchase up to 3,000,000 shares of our common stock to its founders and two advisors in consideration for services provided in the start-up of operations. The warrants are exercisable at a price of $1.00 per share and expire on June 20, 2023. The Company valued these warrants utilizing the Black-Scholes valuation model and they were determined to be of nominal value given the start-up nature of the Company's operations at the time of grant.&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;In conjunction with the June 2014 Stock Purchase Agreement, the Company issued warrants to purchase up to 450,000 shares of common stock to a group of private investors. The warrants are exercisable at a price of $1.00 per share and expire on June 12, 2020. The Company valued these warrants at $85,500. This amount was recorded as warrants and was reclassified from the total consideration received for both the common stock and warrants purchased.&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;In August 2014 as part of the June 2014 Stock Purchase Agreement, the Company issued warrants to purchase up to 550,000 shares of common stock with an exercise price of $1.00 per share that expire in August 2020. The Company valued these warrants at $104,500. This amount was recorded as warrants and was reclassified from the total consideration received for both the common stock and warrants purchased.&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;In March 2015, the Company entered into an agreement with a financial advisory and public relations consulting firm which included the issuance of warrants to purchase up to 90,000 shares of common stock with an exercise price of $2.50 per share with a term of five years. These warrants were in exchange for services performed beginning in the first quarter and were subsequently issued in April 2015. The Company estimated the warrant value to be $67,950 utilizing the Black Scholes option pricing model and amortized $9,225 for services provided through September 30, 2015.&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;In April 2015, the Company entered into an agreement with one of its investors to provide advisory services on all matters including financing. In conjunction with this agreement, the Company issued warrants that vest immediately to purchase 100,000 shares of common stock with an exercise price of $5.00 per share with a term of ten years. The Company estimated the warrant value to be $326,000 utilizing the Black Scholes option pricing model and recorded this amount to general and administrative expense for the quarter due to the immediate vesting.&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: left; widows: 1; text-transform: none; text-indent: 35.9pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;In April 2015, the Company issued to a former service provider&amp;#160;&lt;font style="background-color: #ffffff; font-family: 'times new roman', times, serif; color: #000000; font-size: 10pt;"&gt;in exchange for&lt;/font&gt;&amp;#160;payment of its outstanding invoice warrants that vest immediately to purchase 6,000 shares of common stock with an exercise price of $2.50 per share. The Company estimated the warrant value to be $10,000 which represented the value of the trade debt extinguished&lt;font style="background-color: #ffffff; font-family: 'times new roman', times, serif; color: #000000; font-size: 10pt;"&gt;.&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div style="text-align: left; widows: 1; text-transform: none; text-indent: 35.9pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;In April 2015, the Company issued 50,000 warrants to purchase the Company's common stock in conjunction with its Series A Preferred Stock financing. The warrants are exercisable at a price of $5.00 per share and expire five years from the issuance date. In May 2015, the Company issued 30,000 warrants and in July 2015, 36,000 warrants under the same terms and conditions.&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: left; widows: 1; text-transform: none; text-indent: 35.9pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; margin-left: 0.3pt; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;In June 2015, the Company issued to a service provider&amp;#160;&lt;font style="background-color: #ffffff; font-family: 'times new roman', times, serif; color: #000000; font-size: 10pt;"&gt;in exchange for consulting&lt;/font&gt;&amp;#160;services warrants that vest immediately to purchase 10,000 shares of common stock with an exercise price of $5.00 per share with a term of five years. The Company estimated the warrant value to be $14,700 utilizing the Black Scholes option pricing model&lt;font style="background-color: #ffffff; font-family: 'times new roman', times, serif; color: #000000; font-size: 10pt;"&gt;.&amp;#160;&lt;/font&gt;&lt;/div&gt;
&lt;div style="widows: 1; text-transform: none; text-indent: 0px; font: medium 'times new roman'; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: left; widows: 1; text-transform: none; background-color: #ffffff; text-indent: 35.9pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; margin-left: 0.3pt; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;In August 2015, the Company issued 6,250,000 warrants to purchase common stock in conjunction with its Series B Preferred Stock financing. See further discussion in Note 6 below.&lt;/div&gt;
&lt;div style="widows: 1; text-transform: none; text-indent: 0px; font: medium 'times new roman'; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: left; widows: 1; text-transform: none; background-color: #ffffff; text-indent: 35.9pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; margin-left: 0.4pt; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;In August 2015, the Company issued 187,500 warrants to purchase common stock to its investment banker in exchange for services rendered in conjunction with the Series B Preferred Stock financing. The warrants vest immediately and have an exercise price of $1.15 per share. The Company estimated the value of the warrants to be $86,250 utilizing the Black Scholes option pricing model and recorded this amount to offering costs as an offset to Additional Paid-in-Capital.&lt;/div&gt;
&lt;div style="text-align: left; widows: 1; text-transform: none; text-indent: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;
&lt;div style="text-align: center; margin-top: 3pt; font-family: 'times new roman', times, serif; margin-bottom: 3pt; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;The Company's board of directors considered various objective and subjective factors, along with input from management, to determine the fair value of the warrants, including:&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: medium 'times new roman'; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;
&lt;table style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="width: 20.25pt;"&gt;&lt;/td&gt;
&lt;td style="width: 27pt; font-family: symbol, serif; font-size: 10pt; vertical-align: top;"&gt;&amp;#183;&lt;/td&gt;
&lt;td style="text-align: justify; width: auto; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;Contemporaneous valuation prepared by an independent third-party valuation specialist effective as of June 30, 2014, October 31, 2014, and April 1, 2015, and August 20, 2015,&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: medium 'times new roman'; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;
&lt;table style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" id="a44fe765ac0f49f5af55938b7979ae74" class="dspflisttable" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="width: 20.25pt;"&gt;&lt;/td&gt;
&lt;td style="width: 27pt; font-family: symbol, serif; font-size: 10pt; vertical-align: top;"&gt;&amp;#183;&lt;/td&gt;
&lt;td style="text-align: justify; width: auto; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;Its results of operations, financial position and the status of research and development efforts and achievement of enterprise milestones,&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: medium 'times new roman'; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;
&lt;table style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="width: 20.25pt;"&gt;&lt;/td&gt;
&lt;td style="width: 27pt; font-family: symbol, serif; font-size: 10pt; vertical-align: top;"&gt;&amp;#183;&lt;/td&gt;
&lt;td style="text-align: justify; width: auto; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;The composition of, and changes to, the Company's management team and board of directors,&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: medium 'times new roman'; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;
&lt;table style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" id="ce0655ad177f468ea79569c10b4345b2" class="dspflisttable" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="width: 20.25pt;"&gt;&lt;/td&gt;
&lt;td style="width: 27pt; font-family: symbol, serif; font-size: 10pt; vertical-align: top;"&gt;&amp;#183;&lt;/td&gt;
&lt;td style="text-align: justify; width: auto; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;The lack of liquidity of its common stock as a newly public company,&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: medium 'times new roman'; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;
&lt;table style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="width: 20.25pt;"&gt;&lt;/td&gt;
&lt;td style="width: 27pt; font-family: symbol, serif; font-size: 10pt; vertical-align: top;"&gt;&amp;#183;&lt;/td&gt;
&lt;td style="text-align: justify; width: auto; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;The Company's stage of development, business strategy and the material risks related to its business and industry,&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: medium 'times new roman'; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;
&lt;table style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="width: 20.25pt;"&gt;&lt;/td&gt;
&lt;td style="width: 27pt; font-family: symbol, serif; font-size: 10pt; vertical-align: top;"&gt;&amp;#183;&lt;/td&gt;
&lt;td style="text-align: justify; width: auto; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;The valuation of publicly-traded companies in the biotechnology sectors,&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: medium 'times new roman'; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;
&lt;table style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="width: 20.25pt;"&gt;&lt;/td&gt;
&lt;td style="width: 27pt; font-family: symbol, serif; font-size: 10pt; vertical-align: top;"&gt;&amp;#183;&lt;/td&gt;
&lt;td style="text-align: justify; width: auto; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;External market conditions affecting the biotechnology industry sectors,&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: medium 'times new roman'; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;
&lt;table style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" id="d61b928bfc1d4cea83ee919cb0c065a3" class="dspflisttable" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="width: 20.25pt;"&gt;&lt;/td&gt;
&lt;td style="width: 27pt; font-family: symbol, serif; font-size: 10pt; vertical-align: top;"&gt;&amp;#183;&lt;/td&gt;
&lt;td style="text-align: justify; width: auto; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;The likelihood of achieving a liquidity event for the holders of its common stock, such as an initial public offering, or IPO, or a sale of the Company, given prevailing market conditions, and&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: medium 'times new roman'; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;
&lt;table style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="width: 20.45pt;"&gt;&lt;/td&gt;
&lt;td style="width: 27pt; font-family: symbol, serif; font-size: 10pt; vertical-align: top;"&gt;&amp;#183;&lt;/td&gt;
&lt;td style="text-align: justify; width: auto; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;The state of the IPO market for similarly situated biotechnology companies,&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: medium 'times new roman'; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;
&lt;table style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" id="bbbf2248e5ff4fab976f39a73a1c83c2" class="dspflisttable" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="width: 20.45pt;"&gt;&lt;/td&gt;
&lt;td style="width: 27pt; font-family: symbol, serif; font-size: 10pt; vertical-align: top;"&gt;&amp;#183;&lt;/td&gt;
&lt;td style="text-align: justify; width: auto; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;Discussions held with bankers, potential investors, and preliminary term sheets received as part of management's capital raise efforts.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;There are significant judgments and estimates inherent in the determination of the fair value of the Company's warrants. These judgments and estimates included the assumptions regarding its future operating performance, the time to completing an IPO or other liquidity event and the determination of the appropriate valuation methods. If the Company had made different assumptions, its warrant valuation could have been significantly different.&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold italic 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;Stock Option Plans: 2014 Omnibus Incentive Plan&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold italic 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;The 2014 Omnibus Incentive Plan (the "2014 Plan") was adopted to provide a means by which officers, non-employee directors, and employees of and consultants to the Company and its affiliates could be given an opportunity to acquire an equity interest in the Company. All officers, non-employee directors, and employees of and consultants to the Company are eligible to participate in the 2014 Plan.&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;On October 31, 2014, after the closing of the Merger, our Board of Directors approved the 2014 Plan. The 2014 Plan reserved 3,200,000 shares for future grants.&amp;#160;As of September 30, 2015, options (net of canceled or expired options) covering an aggregate of 1,180,000 shares of the Company's common stock had been granted under the 2014 Plan, and the Company had 1,180,000 options outstanding and 2,020,000 shares available for future grants under the 2014 Plan.&lt;/div&gt;
&lt;div style="text-align: left; widows: 1; text-transform: none; text-indent: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;
&lt;div style="text-align: center; margin-top: 3pt; font-family: 'times new roman', times, serif; margin-bottom: 3pt; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;Options granted under the 2014 Plan expire no later than 10 years from the date of grant. Options granted under the 2014 Plan may be either incentive or non-qualified stock options. For incentive and non-qualified stock option grants, the option price shall be at least 100% of the fair value on the date of grants, as determined by the Company's Board of Directors. If at any time the Company grants an option, and the optionee directly or by attribution owns stock possessing more than 10% of the total combined voting power of all classes of stock of the Company, the option price shall be at least 110% of the fair value and shall not be exercisable more than five years after the date of grant.&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;Options granted under the 2014 Plan may be immediately exercisable if permitted in the specific grant approved by the Board of Directors and, if exercised early may be subject to repurchase provisions. The shares acquired generally vest over a period of five years from the date of grant. The Company granted options to purchase 1,180,000 shares through September 30, 2015, under the 2014 Plan.&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: left; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;The following is a summary of activity under the 2014 Plan as of September, 2015:&lt;/div&gt;
&lt;div style="widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: medium 'times new roman'; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;table style="widows: 1; text-transform: none; text-indent: 0px; width: 100%; font-family: 'times new roman', times, serif; letter-spacing: normal; font-size: 10pt; word-spacing: 0px; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="padding-bottom: 2px; vertical-align: middle;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2px; vertical-align: middle;" valign="bottom" colspan="2"&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2px; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 2px solid; vertical-align: middle;" valign="bottom" colspan="10"&gt;
&lt;div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;"&gt;Options Outstanding&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2px; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: middle;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="vertical-align: middle;" valign="bottom" colspan="2"&gt;
&lt;div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;"&gt;Shares Available&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: left; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="vertical-align: middle;" valign="bottom" colspan="2"&gt;&lt;/td&gt;
&lt;td style="text-align: left; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="vertical-align: middle;" valign="bottom" colspan="3"&gt;&lt;/td&gt;
&lt;td style="text-align: left; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="vertical-align: middle;" valign="bottom" colspan="2"&gt;
&lt;div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;"&gt;Weighted Average&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: left; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: middle;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="vertical-align: middle;" valign="bottom" colspan="2"&gt;
&lt;div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;"&gt;for Grant of&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: left; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="vertical-align: middle;" valign="bottom" colspan="2"&gt;
&lt;div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;"&gt;Number of&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: left; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="vertical-align: middle;" valign="bottom" colspan="3"&gt;&lt;/td&gt;
&lt;td style="text-align: left; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="vertical-align: middle;" valign="bottom" colspan="2"&gt;
&lt;div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;"&gt;Exercise&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: left; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-bottom: 2px; vertical-align: middle;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 2px solid; vertical-align: middle;" valign="bottom" colspan="2"&gt;
&lt;div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;"&gt;Options&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2px; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 2px solid; vertical-align: middle;" valign="bottom" colspan="2"&gt;
&lt;div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;"&gt;Shares&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2px; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 2px solid; vertical-align: middle;" valign="bottom" colspan="3"&gt;
&lt;div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;"&gt;Price per Share&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2px; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 2px solid; vertical-align: middle;" valign="bottom" colspan="2"&gt;
&lt;div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;"&gt;Price&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2px; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color: #cceeff; width: 790px; vertical-align: middle;" valign="bottom"&gt;
&lt;div style="text-align: left; text-indent: 10.05pt; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;"&gt;Balance at December&amp;#160;31, 2014&lt;/div&gt;
&lt;/td&gt;
&lt;td style="background-color: #cceeff; width: 16px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; width: 16px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; background-color: #cceeff; width: 137px; vertical-align: bottom;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;1,470,000&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; width: 16px; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="background-color: #cceeff; width: 16px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; background-color: #cceeff; width: 136px; vertical-align: bottom;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;1,730,000&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: right; background-color: #cceeff; width: 136px; vertical-align: bottom;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;0.42&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: right; background-color: #cceeff; width: 136px; vertical-align: bottom;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;0.42&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color: #ffffff; padding-left: 60px; width: 729px; vertical-align: middle;" valign="bottom"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Options granted&lt;/div&gt;
&lt;/td&gt;
&lt;td style="background-color: #ffffff; width: 16px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #ffffff; width: 16px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; background-color: #ffffff; width: 137px; vertical-align: bottom;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;(130,000&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: left; background-color: #ffffff; width: 16px; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;
&lt;/td&gt;
&lt;td style="background-color: #ffffff; width: 16px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #ffffff; width: 15px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; background-color: #ffffff; width: 136px; vertical-align: bottom;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;130,000&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: left; background-color: #ffffff; width: 15px; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="background-color: #ffffff; width: 15px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #ffffff; width: 15px; vertical-align: bottom;" valign="bottom"&gt;
&lt;div&gt;$&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: right; background-color: #ffffff; width: 136px; vertical-align: bottom;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;1.15 - $3.00&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: left; background-color: #ffffff; width: 15px; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="background-color: #ffffff; width: 15px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #ffffff; width: 15px; vertical-align: bottom;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: right; background-color: #ffffff; width: 136px; vertical-align: bottom;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;2.29&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: left; background-color: #ffffff; width: 15px; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color: #cceeff; padding-left: 60px; width: 729px; vertical-align: middle;" valign="bottom"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Options exercised&lt;/div&gt;
&lt;/td&gt;
&lt;td style="background-color: #cceeff; width: 16px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; width: 16px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; background-color: #cceeff; width: 137px; vertical-align: bottom;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; width: 16px; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="background-color: #cceeff; width: 16px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; background-color: #cceeff; width: 136px; vertical-align: bottom;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; background-color: #cceeff; width: 136px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; background-color: #cceeff; width: 136px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-bottom: 2px; background-color: #ffffff; padding-left: 60px; width: 729px; vertical-align: middle;" valign="bottom"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Options cancelled&lt;/div&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 2px; background-color: #ffffff; width: 16px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 16px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 137px; vertical-align: bottom;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;680,000&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 16px; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2px; background-color: #ffffff; width: 16px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 15px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 136px; vertical-align: bottom;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;(680,000&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 15px; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 2px; background-color: #ffffff; width: 15px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 15px; vertical-align: bottom;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 2px; background-color: #ffffff; width: 136px; vertical-align: bottom;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;0.42&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 15px; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2px; background-color: #ffffff; width: 15px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 15px; vertical-align: bottom;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 2px; background-color: #ffffff; width: 136px; vertical-align: bottom;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;0.42&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 15px; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-bottom: 4px; background-color: #cceeff; width: 790px; vertical-align: middle;" valign="bottom"&gt;
&lt;div style="text-align: left; text-indent: 10.05pt; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;"&gt;Balance at September&amp;#160;30, 2015&lt;/div&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 4px; background-color: #cceeff; width: 16px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 16px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 137px; vertical-align: bottom;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;2,020,000&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 16px; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4px; background-color: #cceeff; width: 16px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 136px; vertical-align: bottom;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;1,180,000&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4px; background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: right; background-color: #cceeff; width: 136px; vertical-align: bottom;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;0.42 - $3.00&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4px; background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: right; background-color: #cceeff; width: 136px; vertical-align: bottom;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;0.63&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;div style="widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: medium 'times new roman'; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: medium 'times new roman'; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;The weighted average remaining contractual life in years of the options outstanding as of September 30, 2015 was 9.18 years.&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;Aggregate intrinsic value is the sum of the amounts by which the quoted market price of the Company's stock exceeded the exercise price of the stock options at September 30, 2015 for those stock options for which the quoted market price was in excess of the exercise price ("in-the-money options"). As of September 30, 2015, the aggregate intrinsic value of options outstanding was $147,000. As of September 30, 2015, no options to purchase shares of common stock were exercisable.&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: left; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold italic 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;Stock Based Compensation Expense&lt;/div&gt;
&lt;div style="text-align: left; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold italic 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;The Company recognizes stock-based compensation expense based on the fair value of that portion of stock options that are ultimately expected to vest during the period. Stock-based compensation expense recognized in the consolidated statement of operations includes compensation expense for stock-based awards based on the estimated grant date fair value over the requisite service period. For the nine months ended September 30, 2015, the Company recognized stock-based compensation expense of $263,985 which was recorded as a general and administrative expense in the consolidated statement of operations. For the nine months ended September 30, 2014, stock-based compensation expense was $0.&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: left; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;The total amount of unrecognized compensation cost related to non-vested stock options was $1,477,143 as of September 30, 2015. This amount will be recognized over a weighted average period of 4.14 years.&lt;/div&gt;
&lt;div style="text-align: left; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold italic 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: left; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold italic 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;Valuation Assumptions&lt;/div&gt;
&lt;div style="text-align: left; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold italic 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;The fair value of options was estimated at the date of grant using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company's common stock for similar terms. The expected term was estimated using the simplified method as permitted under SAB No. 110, since the Company has no recent exercise or forfeiture history that is representative of options granted during the year.&amp;#160;The expected term represents the estimated period of time that stock options are expected to be outstanding, which is less than the contractual term which is generally ten years. The risk-free interest rate is based on the U.S. Treasury yield. The expected dividend yield is zero, as the Company does not anticipate paying dividends in the near future. The weighted average assumptions for employee options are as follows:&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: left; widows: 1; text-transform: none; text-indent: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;
&lt;table style="width: 100%; border-collapse: collapse; font-family: 'times new roman', times, serif; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="width: 1141px; vertical-align: middle;"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #000000 2px solid; width: 378px; vertical-align: middle;" colspan="3"&gt;
&lt;div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;"&gt;For the Nine Months Ended&amp;#160;&amp;#160; September 30,&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width: 1141px; vertical-align: middle;"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #000000 2px solid; width: 196px; vertical-align: middle;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;"&gt;2015&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 30px; vertical-align: middle;"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #000000 2px solid; width: 152px; vertical-align: middle;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;"&gt;2014&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color: #cceeff; width: 1141px; vertical-align: middle;"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Dividend yield&lt;/div&gt;
&lt;/td&gt;
&lt;td style="background-color: #cceeff; width: 196px; vertical-align: middle;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;0.00%&lt;/div&gt;
&lt;/td&gt;
&lt;td style="background-color: #cceeff; width: 30px; vertical-align: middle;"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="background-color: #cceeff; width: 152px; vertical-align: middle;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;NA&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color: #ffffff; width: 1141px; vertical-align: middle;"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Volatility factor&lt;/div&gt;
&lt;/td&gt;
&lt;td style="background-color: #ffffff; width: 196px; vertical-align: middle;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;75.00%&lt;/div&gt;
&lt;/td&gt;
&lt;td style="background-color: #ffffff; width: 30px; vertical-align: middle;"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="background-color: #ffffff; width: 152px; vertical-align: middle;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;NA&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color: #cceeff; width: 1141px; vertical-align: middle;"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Risk-free interest rate&lt;/div&gt;
&lt;/td&gt;
&lt;td style="background-color: #cceeff; width: 196px; vertical-align: middle;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;1.68-1.85%&lt;/div&gt;
&lt;/td&gt;
&lt;td style="background-color: #cceeff; width: 30px; vertical-align: middle;"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="background-color: #cceeff; width: 152px; vertical-align: middle;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;NA&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color: #ffffff; width: 1141px; vertical-align: middle;"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Expected term (years)&lt;/div&gt;
&lt;/td&gt;
&lt;td style="background-color: #ffffff; width: 196px; vertical-align: middle;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;6.25-6.50&lt;/div&gt;
&lt;/td&gt;
&lt;td style="background-color: #ffffff; width: 30px; vertical-align: middle;"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="background-color: #ffffff; width: 152px; vertical-align: middle;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;NA&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color: #cceeff; width: 1141px; vertical-align: middle;"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Weighted-average fair value of options granted during the periods&lt;/div&gt;
&lt;/td&gt;
&lt;td style="background-color: #cceeff; width: 196px; vertical-align: middle;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$2.69&lt;/div&gt;
&lt;/td&gt;
&lt;td style="background-color: #cceeff; width: 30px; vertical-align: middle;"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="background-color: #cceeff; width: 152px; vertical-align: middle;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;NA&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<us-gaap:PreferredStockTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div style="font: bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;5. Provision for Conversion of Preferred Stock&lt;/div&gt;
&lt;div style="font: bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Series A Preferred Stock Conversion Liability&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 35.8pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.2pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;In connection with the Series A preferred stock financing, the Company recorded a liability related to down-round protection provided to the stockholders in the event that the Company does another offering of common stock greater than $1,000,000 at a price below $2.50 per share. The down-round provision expires at the closing of a subsequent financing round or October 1, 2015 whichever is earlier. With the assistance of a third-party valuation specialist, the Company valued the conversion liability pursuant to the accounting guidance of ASC 820-10,&amp;#160;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;"&gt;Fair Value Measurements&lt;/font&gt;, as of the closing date of the first round of financing which was April 1, 2015.&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 35.8pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.2pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 35.9pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.1pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;As of June 30, 2015, the Company re-evaluated the likelihood and valuation of a potential down-round given that management has been actively pursuing capital raising efforts. In the absence of any definitive agreement, the Company calculated the fair value of the conversion feature to be $700,000 by determining the highest probability of a per share price in the next anticipated round of financing, after considering all discussions with bankers, potential investors, and preliminary term sheets. This amount was booked as a current liability as of June 30, 2015 and was charged as a non-operating expense for the period.&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 35.9pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.1pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 35.9pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.1pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;In July of 2015, the Company increased its down-round provision by $286,000 based on the closing of an additional round of 180,000 Series A shares&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/font&gt;by determining the highest probability of a per share price in the next anticipated round of financing, after considering all discussions with bankers, potential investors, and preliminary term sheets. This amount was charged to non-operating expense for the three months ended September 30, 2015.&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 35.9pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.1pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 35.8pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.2pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;As of August 21, 2015, upon the closing of the Series B Preferred Stock sale with proceeds totaling $5.0 million, the Company issued 1,232,000 additional shares of common stock at $0.80 per share thereby eliminating this liability of $986,000 and offsetting it to Additional Paid-in-Capital. This amount was calculated by determining the difference in per share pricing between the Series A Preferred Stock financing of $2.50 per share and the Series B Preferred Stock Financing of $0.80 per share multiplied by the 580,000 total shares included in the Series A offering.&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 35.8pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.2pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 35.8pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.2pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 3pt; margin-bottom: 3pt;"&gt;Series B Preferred Stock Conversion Liability&lt;/div&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 3pt; margin-bottom: 3pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 35.9pt; font-family: 'times new roman', times, serif; font-size: 10pt; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.2pt;"&gt;As of August 20, 2015, in connection with the Series B preferred stock financing, the Company recorded a liability related to down-round protection provided to the stockholders in the event that the Company does another sale or issuance of common stock, stock options or convertible securities where the share price is below $0.80 per share. With the assistance of a third-party valuation specialist, the Company valued the conversion liability pursuant to the accounting guidance of ASC 820-10,&amp;#160;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;"&gt;Fair Value Measurements&lt;/font&gt;, as of the closing date of the financing. The Company also performed a review of the conversion liability in conjunction with ASC 815,&amp;#160;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;"&gt;Derivatives and Hedging/Contracts in Entity's Own Equity&lt;/font&gt;, and determined that the liability requires bifurcation and re-measurement to fair market value at the end of each reporting period. The derivative was valued at $75,488 and was booked as a current liability as of September 30, 2015. The value of this embedded derivative was determined utilizing a with and without method by valuing the preferred stock with and without the down round protection.&lt;/div&gt;
&lt;/div&gt;</us-gaap:PreferredStockTextBlock>
<us-gaap:IncomeTaxDisclosureTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div style="text-align: left; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;7. Income Taxes&lt;/div&gt;
&lt;div style="text-align: left; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;At September 30, 2015, the Company had net operating loss carry forwards ("NOLs") aggregating approximately $4,023,000 which, if not used, expire in 2035. The utilization of these NOLs may become subject to limitations based on past and future changes in ownership of the Company pursuant to Internal Revenue Code Section 382.&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 35.9pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; margin-left: 0.2pt; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;The Company records a valuation allowance against deferred tax assets to the extent that it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Due to the substantial doubt related to the Company's ability to utilize its deferred tax assets, a valuation allowance for the full amount of the deferred tax assets has been established at September 30, 2015. As a result of this valuation allowance there are no income tax benefits reflected in the accompanying statement of operations to offset pre-tax losses.&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 35.9pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; margin-left: 0.2pt; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;The Company has no uncertain tax positions as of September 30, 2015.&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
<us-gaap:SubsequentEventsTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;8. Subsequent Events&lt;/div&gt;
&lt;div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: left; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold italic 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; margin-right: 0.1pt; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;Restricted Stock Awards&lt;/div&gt;
&lt;div style="text-align: left; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold italic 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; margin-right: 0.1pt; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: left; widows: 1; text-transform: none; text-indent: 35.8pt; margin: 5pt 0.3pt 5pt 0.2pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;Restricted stock awards ("RSAs") are granted to our board of directors and members of senior management and are issued pursuant to the Company's 2014 Omnibus Incentive Plan. On October 20, 2015, a total of 1,200,000 RSAs were granted to members of the Company's senior management and board of directors with a fair market value of approximately $900,000. These RSAs vest from one to&amp;#160;three years from the grant date.&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
<us-gaap:UseOfEstimates contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Use of Estimates&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles ("U.S. GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates.&lt;/div&gt;</us-gaap:UseOfEstimates>
<nmus:LiquidityAndGoingConcernPolicyTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Liquidity and Going Concern&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;The Company has incurred operating losses and negative cash flows from operations since our inception. As of September 30, 2015, we had cash and cash equivalents of $4,342,722.&amp;#160; The Company anticipates that it will continue to incur net losses into the foreseeable future as it continues to advance and develop a number of potential drug candidates into preclinical development activities and expands its corporate infrastructure which includes the costs associated with being a public company. Without additional funding, management believes that the Company will not have sufficient funds to meet its obligations within one year after the date the consolidated financial statements are issued. These conditions give rise to substantial doubt as to the Company's ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;The Company plans to continue to fund its losses from operations and capital funding needs through public or private equity or debt financings, strategic collaborations, licensing arrangements, asset sales, government grants or other arrangements. However, the Company cannot be sure that such additional funds will be available on reasonable terms, or at all. If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result. If the Company is unable to secure adequate additional funding, the Company may be forced to make a reduction in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs.&lt;/div&gt;</nmus:LiquidityAndGoingConcernPolicyTextBlock>
<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Cash and Cash Equivalents&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The carrying value of those investments approximates their fair market value due to their short maturity and liquidity. Cash and cash equivalents include cash on hand and amounts on deposit with financial institutions, which amounts may at times exceed federally insured limits. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk.&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
<us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Fair Value Measurements&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last is considered unobservable, is used to measure fair value:&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;
&lt;table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="width: 20.45pt;"&gt;&lt;/td&gt;
&lt;td style="width: 51.55pt; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;Level 1:&lt;/td&gt;
&lt;td style="width: auto; text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;
&lt;div&gt;Valuations for assets and liabilities traded in active markets from readily available pricing sources such as quoted prices in active markets for identical assets or liabilities.&lt;/div&gt;
&lt;div&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;
&lt;table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="width: 20.45pt;"&gt;&lt;/td&gt;
&lt;td style="width: 51.55pt; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;Level 2:&lt;/td&gt;
&lt;td style="width: auto; text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;
&lt;div&gt;Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/div&gt;
&lt;div&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;
&lt;table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="width: 20.45pt;"&gt;&lt;/td&gt;
&lt;td style="width: 51.55pt; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;Level 3:&lt;/td&gt;
&lt;td style="width: auto; text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 35.9pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.1pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 35.9pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.1pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;The carrying values of our financial instruments, including, cash and cash equivalents, prepaid expenses, accounts payable, and accrued expenses approximate their fair value due to the short maturities of these financial instruments.&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Property and Equipment, Net&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;As of September 30, 2015, property and equipment, net, was $16,046, consisting primarily of computers and equipment. The Company had $21,354 of property and equipment, net, as of December 31, 2014. Expenditures for additions, renewals and improvements will be capitalized at cost. Depreciation will generally be computed on a straight-line method based on the estimated useful life of the related assets currently ranging from two to three years. Maintenance and repairs that do not extend the life of assets are charged to expense when incurred. When properties are disposed of, the related costs and accumulated depreciation are removed from the accounts and any gain or loss is reported in the period the transaction takes place.&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount exceeds its estimated future undiscounted cash flows, an impairment charge is recognized by the amount by which the carrying amount exceeds the fair value of the asset.&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;The costs incurred for the rights to use licensed technologies in the research and development process, including licensing fees and milestone payments, will be charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where there is an identified alternative future use. No cost associated with the use of licensed technologies has been capitalized to date.&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
<us-gaap:IncomeTaxPolicyTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Income Taxes&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;The Company accounts for our deferred income tax assets and liabilities based on differences between the financial reporting and tax bases of assets and liabilities, and net operating loss carry forwards (the "NOLs") and other tax credit carry forwards. These items are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the period that includes the enactment date. Any interest or penalties would be recorded in the Company's statement of operations in the period incurred.&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;The Company records a valuation allowance to reduce the deferred income tax assets to the amount that is more likely than not to be realized. In making such determinations, management considers all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. As a result there are no income tax benefits reflected in the statement of operations to offset pre-tax losses.&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;The Company recognizes a tax benefit from uncertain tax positions when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position.&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
<us-gaap:RevenueRecognitionPolicyTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Revenue Recognition&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;The Company has not begun planned principal operations and has not generated any revenue since inception.&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Research and Development Expenses&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Research and development ("R&amp;amp;D") costs are expensed when incurred. These costs may consist of external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, third-party manufacturing organizations and consultants; employee-related expenses, which include salaries, benefits and stock-based compensation for the personnel involved in our preclinical and clinical drug development activities; and facilities expense, depreciation and other allocated expenses; and equipment and laboratory supplies.&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
<us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Stock-Based Compensation Expenses&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Stock-based compensation cost is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period. We use the Black-Scholes option pricing model for estimating the grant date fair value of stock options and warrants using the following assumptions:&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;
&lt;table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="width: 20.25pt;"&gt;&lt;/td&gt;
&lt;td style="width: 27pt; font-family: symbol, serif; font-size: 10pt; vertical-align: top;"&gt;&amp;#183;&lt;/td&gt;
&lt;td style="width: auto; text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;Exercise price - We determined the exercise price based on valuations using the best information available to management at the time of the valuations.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;
&lt;table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="width: 20.25pt;"&gt;&lt;/td&gt;
&lt;td style="width: 27pt; font-family: symbol, serif; font-size: 10pt; vertical-align: top;"&gt;&amp;#183;&lt;/td&gt;
&lt;td style="width: auto; text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;Volatility &amp;#8211; We estimate the stock price volatility based on industry peers who are also in the early development stage given the limited market data available in the public arena.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;
&lt;table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="width: 20.25pt;"&gt;&lt;/td&gt;
&lt;td style="width: 27pt; font-family: symbol, serif; font-size: 10pt; vertical-align: top;"&gt;&amp;#183;&lt;/td&gt;
&lt;td style="width: auto; text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;Expected term - The expected term is based on a simplified method which defines the life as the average of the contractual term of the options and warrants and the weighted-average vesting period for all open awards.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;
&lt;table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="width: 20.25pt;"&gt;&lt;/td&gt;
&lt;td style="width: 27pt; font-family: symbol, serif; font-size: 10pt; vertical-align: top;"&gt;&amp;#183;&lt;/td&gt;
&lt;td style="width: auto; text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;Risk-free rate - The risk-free interest rate for the expected term of the option or warrant is based on the average market rate on U.S. treasury securities in effect during the quarter in which the awards were granted.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;
&lt;table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="width: 20.35pt;"&gt;&lt;/td&gt;
&lt;td style="width: 27pt; font-family: symbol, serif; font-size: 10pt; vertical-align: top;"&gt;&amp;#183;&lt;/td&gt;
&lt;td style="width: auto; text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;"&gt;Dividends &amp;#8211; The dividend yield assumption is based on our history and expectation of paying no dividends.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
<nmus:StockBasedCompensationForNonEmployeesPolicyTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Stock-Based Compensation for Non-Employees&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;The Company accounts for warrants and options issued to non-employees under ASC 505-50,&amp;#160;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;"&gt;Equity &amp;#8211; Equity Based Payments to Non-Employees,&lt;/font&gt;&amp;#160;using the Black-Scholes option-pricing model. The value of such non-employee awards are periodically re-measured over the vesting terms and at each quarter end.&lt;/div&gt;</nmus:StockBasedCompensationForNonEmployeesPolicyTextBlock>
<us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Segment Information&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;The Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") No. 280, "Segment Reporting" establishes standards for reporting information about reportable segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group ("CODM"), in deciding how to allocate resources and in assessing performance. The CODM evaluates revenues and gross profits based on product lines and routes to market. Based on the early development stage of our operation, we operate in a single reportable segment.&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
<us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Comprehensive Income (Loss)&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company is required to record all components of comprehensive loss in the consolidated&amp;#160;financial statements in the period in which they are recognized. Net income (loss) and other comprehensive loss, net of their related tax effect, arrived at a comprehensive loss. For the three and nine months ended September 30, 2015 and 2014, the comprehensive loss was equal to the net loss.&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
<us-gaap:EarningsPerSharePolicyTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Earnings per share&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;The Company applies FASB ASC 260, "Earnings per Share." Basic earnings (loss) per share is computed by dividing earnings (loss) available to common stockholders by the weighted-average number of common shares outstanding. Diluted earnings or loss per share would include the dilutive effect of awards granted to employees under stock-based compensation plans, if any. There were no dilutive awards outstanding at September 30, 2015.&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
<us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;table align="center" style="width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; widows: 1; -webkit-text-stroke-width: 0px;"  border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="vertical-align: bottom;" valign="bottom"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;"&gt;For the year ending December 31,&lt;/div&gt;
&lt;/td&gt;
&lt;td style="vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;" valign="bottom" colspan="2"&gt;&lt;/td&gt;
&lt;td style="text-align: left; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width: 1337px; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;2015&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 16px; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;43,900&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width: 1337px; vertical-align: bottom; background-color: #ffffff;" valign="bottom"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;2016&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 16px; vertical-align: bottom; background-color: #ffffff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #ffffff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;165,700&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width: 1337px; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;2017&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 16px; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;85,900&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width: 1337px; vertical-align: bottom; background-color: #ffffff;" valign="bottom"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;2018&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 16px; vertical-align: bottom; background-color: #ffffff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #ffffff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width: 1337px; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;2019&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 16px; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width: 1337px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;" valign="bottom"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Thereafter&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 136px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width: 1337px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Total&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 16px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 136px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;295,500&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;table align="center" style="width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; widows: 1; -webkit-text-stroke-width: 0px;"  border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="padding-bottom: 2px; vertical-align: middle;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2px; vertical-align: middle;" valign="bottom" colspan="2"&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2px; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="vertical-align: middle; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" valign="bottom" colspan="10"&gt;
&lt;div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;"&gt;Options Outstanding&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2px; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: middle;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="vertical-align: middle;" valign="bottom" colspan="2"&gt;
&lt;div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;"&gt;Shares Available&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: left; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="vertical-align: middle;" valign="bottom" colspan="2"&gt;&lt;/td&gt;
&lt;td style="text-align: left; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="vertical-align: middle;" valign="bottom" colspan="3"&gt;&lt;/td&gt;
&lt;td style="text-align: left; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="vertical-align: middle;" valign="bottom" colspan="2"&gt;
&lt;div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;"&gt;Weighted Average&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: left; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: middle;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="vertical-align: middle;" valign="bottom" colspan="2"&gt;
&lt;div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;"&gt;for Grant of&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: left; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="vertical-align: middle;" valign="bottom" colspan="2"&gt;
&lt;div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;"&gt;Number of&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: left; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="vertical-align: middle;" valign="bottom" colspan="3"&gt;&lt;/td&gt;
&lt;td style="text-align: left; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="vertical-align: middle;" valign="bottom" colspan="2"&gt;
&lt;div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;"&gt;Exercise&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: left; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-bottom: 2px; vertical-align: middle;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="vertical-align: middle; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" valign="bottom" colspan="2"&gt;
&lt;div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;"&gt;Options&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2px; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="vertical-align: middle; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" valign="bottom" colspan="2"&gt;
&lt;div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;"&gt;Shares&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2px; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="vertical-align: middle; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" valign="bottom" colspan="3"&gt;
&lt;div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;"&gt;Price per Share&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2px; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2px; vertical-align: bottom;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="vertical-align: middle; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" valign="bottom" colspan="2"&gt;
&lt;div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;"&gt;Price&lt;/div&gt;
&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2px; vertical-align: bottom;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width: 790px; vertical-align: middle; background-color: #cceeff;" valign="bottom"&gt;
&lt;div style="text-align: left; text-indent: 10.05pt; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;"&gt;Balance at December&amp;#160;31, 2014&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 16px; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 137px; text-align: right; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;1,470,000&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size:
 10pt;"&gt;1,730,000&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;0.42&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;0.42&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width: 729.25px; padding-left: 60.75px; vertical-align: middle; background-color: #ffffff;" valign="bottom"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Options granted&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 16px; vertical-align: bottom; background-color: #ffffff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 137px; text-align: right; vertical-align: bottom; background-color: #ffffff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;(130,000&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 16px; vertical-align: bottom; background-color: #ffffff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #ffffff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;130,000&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; vertical-align: bottom; background-color: #ffffff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;" valign="bottom"&gt;
&lt;div&gt;$&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #ffffff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;1.15 - $3.00&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; vertical-align: bottom; background-color: #ffffff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #ffffff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;2.29&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width: 729.25px; padding-left: 60.75px; vertical-align: middle; background-color: #cceeff;" valign="bottom"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Options exercised&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 16px; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 137px; text-align: right; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width: 729.25px; padding-bottom: 2px; padding-left: 60.75px; vertical-align: middle; background-color: #ffffff;" valign="bottom"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Options cancelled&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;
 vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 137px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;680,000&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 136px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;(680,000&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;" valign="bottom" nowrap="nowrap"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 136px; text-align: right; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;0.42&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 136px; text-align: right; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;0.42&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width: 790px; padding-bottom: 4px; vertical-align: middle; background-color: #cceeff;" valign="bottom"&gt;
&lt;div style="text-align: left; text-indent: 10.05pt; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;"&gt;Balance at September&amp;#160;30, 2015&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 16px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 137px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;2,020,000&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 16px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 136px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;1,180,000&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;0.42 - $3.00&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #cceeff;" valign="bottom"&gt;
&lt;div style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;0.63&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;" valign="bottom" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div style="text-align: left; widows: 1; text-transform: none; text-indent: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;&lt;br class="apple-interchange-newline"  /&gt;
&lt;table style="width: 100%; border-collapse: collapse; font-family: 'times new roman', times, serif; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="width: 1141px; vertical-align: middle;"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #000000 2px solid; width: 378px; vertical-align: middle;" colspan="3"&gt;
&lt;div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;"&gt;For the Nine Months Ended&amp;#160;&amp;#160; September 30,&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width: 1141px; vertical-align: middle;"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #000000 2px solid; width: 196px; vertical-align: middle;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;"&gt;2015&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 30px; vertical-align: middle;"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #000000 2px solid; width: 152px; vertical-align: middle;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;"&gt;2014&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color: #cceeff; width: 1141px; vertical-align: middle;"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Dividend yield&lt;/div&gt;
&lt;/td&gt;
&lt;td style="background-color: #cceeff; width: 196px; vertical-align: middle;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;0.00%&lt;/div&gt;
&lt;/td&gt;
&lt;td style="background-color: #cceeff; width: 30px; vertical-align: middle;"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="background-color: #cceeff; width: 152px; vertical-align: middle;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;NA&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color: #ffffff; width: 1141px; vertical-align: middle;"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Volatility factor&lt;/div&gt;
&lt;/td&gt;
&lt;td style="background-color: #ffffff; width: 196px; vertical-align: middle;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;75.00%&lt;/div&gt;
&lt;/td&gt;
&lt;td style="background-color: #ffffff; width: 30px; vertical-align: middle;"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="background-color: #ffffff; width: 152px; vertical-align: middle;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;NA&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color: #cceeff; width: 1141px; vertical-align: middle;"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Risk-free interest rate&lt;/div&gt;
&lt;/td&gt;
&lt;td style="background-color: #cceeff; width: 196px; vertical-align: middle;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;1.68-1.85%&lt;/div&gt;
&lt;/td&gt;
&lt;td style="background-color: #cceeff; width: 30px; vertical-align: middle;"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="background-color: #cceeff; width: 152px; vertical-align: middle;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;NA&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color: #ffffff; width: 1141px; vertical-align: middle;"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Expected term (years)&lt;/div&gt;
&lt;/td&gt;
&lt;td style="background-color: #ffffff; width: 196px; vertical-align: middle;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;6.25-6.50&lt;/div&gt;
&lt;/td&gt;
&lt;td style="background-color: #ffffff; width: 30px; vertical-align: middle;"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="background-color: #ffffff; width: 152px; vertical-align: middle;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;NA&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color: #cceeff; width: 1141px; vertical-align: middle;"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Weighted-average fair value of options granted during the periods&lt;/div&gt;
&lt;/td&gt;
&lt;td style="background-color: #cceeff; width: 196px; vertical-align: middle;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$2.69&lt;/div&gt;
&lt;/td&gt;
&lt;td style="background-color: #cceeff; width: 30px; vertical-align: middle;"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="background-color: #cceeff; width: 152px; vertical-align: middle;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;NA&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
<nmus:NumberOfSharesExchanged contextRef="Context_Custom_01_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_BusinessAcquisitionAxis_NemusAcquisitionCorpMember" unitRef="shares" decimals="INF">12880000</nmus:NumberOfSharesExchanged>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_17_Jul_2012T00_00_00_TO_17_Jul_2012T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">3000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AgreementAxis_StockPurchaseAgreementJune2014Member_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">1800000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_31_Aug_2014T00_00_00_TO_31_Aug_2014T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">2200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_31_Aug_2014T00_00_00_TO_31_Aug_2014T00_00_00_AgreementAxis_StockPurchaseAgreementJune2014Member_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">550000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_31_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">90000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_30_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00" unitRef="shares" decimals="INF">100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_30_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">6000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">10000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_31_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">6250000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_AgreementAxis_StockPurchaseAgreementJune2014Member_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">450000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:PropertyPlantAndEquipmentDepreciationMethods contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">Straight-line method</us-gaap:PropertyPlantAndEquipmentDepreciationMethods>
<us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">two to three years</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
<nmus:TermOfMemorandumOfUnderstandingAgreement contextRef="Context_Custom_01_Jul_2013T00_00_00_TO_31_Jul_2013T00_00_00_AgreementAxis_UniversityOfMississippiAgreementsMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember">P5Y</nmus:TermOfMemorandumOfUnderstandingAgreement>
<nmus:NumberOfLicenseAgreements contextRef="Context_Custom_01_Sep_2014T00_00_00_TO_29_Sep_2014T00_00_00_AgreementAxis_OptionAgreementMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" unitRef="License_agreement" decimals="INF">3</nmus:NumberOfLicenseAgreements>
<nmus:NoticePeriodForTermination contextRef="Context_Custom_01_Sep_2014T00_00_00_TO_29_Sep_2014T00_00_00_AgreementAxis_OptionAgreementMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember">P60D</nmus:NoticePeriodForTermination>
<nmus:NoticePeriodForTermination contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember_AgreementAxis_ResearchAgreementMember_MonthAndYearOfAgreementAxis_March2015Member_LegalEntityAxis_UniversityOfMississippiMember">P30D</nmus:NoticePeriodForTermination>
<nmus:NoticePeriodForTermination contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember_AgreementAxis_ResearchAgreementMember_MonthAndYearOfAgreementAxis_July2015Member_LegalEntityAxis_UniversityOfMississippiMember">P30D</nmus:NoticePeriodForTermination>
<nmus:NoticePeriodForTermination contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember_AgreementAxis_ResearchAgreementMember_MonthAndYearOfAgreementAxis_September2015Member_LegalEntityAxis_UniversityOfMississippiMember">P30D</nmus:NoticePeriodForTermination>
<nmus:ReimbursementOfSunkPatentExpenses contextRef="Context_Custom_01_Feb_2015T00_00_00_TO_28_Feb_2015T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember_AgreementAxis_OptionAgreementMember_BalanceSheetLocationAxis_AccruedLicenseAndPatentReimbursementFeesMember" unitRef="USD" decimals="0">70678</nmus:ReimbursementOfSunkPatentExpenses>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">43900</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">165700</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">85900</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">295500</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
<nmus:PercentageOfContractorExpensesForTotalExpenditures contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AgreementAxis_IndependentContractorAgreementsMember_ContractorAxis_ContractorOneMember" unitRef="pure" decimals="2">0.30</nmus:PercentageOfContractorExpensesForTotalExpenditures>
<nmus:PercentageOfContractorExpensesForTotalExpenditures contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AgreementAxis_IndependentContractorAgreementsMember_ContractorAxis_ContractorTwoMember" unitRef="pure" decimals="2">0.15</nmus:PercentageOfContractorExpensesForTotalExpenditures>
<us-gaap:AreaOfLand contextRef="Context_As_Of_31_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00" unitRef="sqft" decimals="0">4087</us-gaap:AreaOfLand>
<us-gaap:OperatingLeasesRentExpenseNet contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">6294</us-gaap:OperatingLeasesRentExpenseNet>
<us-gaap:OperatingLeasesRentExpenseNet contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">6844</us-gaap:OperatingLeasesRentExpenseNet>

<us-gaap:OperatingLeasesRentExpenseNet contextRef="Context_Custom_01_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">9000</us-gaap:OperatingLeasesRentExpenseNet>
<us-gaap:OperatingLeasesRentExpenseNet contextRef="Context_Custom_01_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00" unitRef="USD" decimals="0">5373</us-gaap:OperatingLeasesRentExpenseNet>
<us-gaap:OperatingLeasesRentExpenseNet contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">2060</us-gaap:OperatingLeasesRentExpenseNet>
<us-gaap:OperatingLeasesRentExpenseNet contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">56680</us-gaap:OperatingLeasesRentExpenseNet>
<us-gaap:OperatingLeasesRentExpenseNet contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">170931</us-gaap:OperatingLeasesRentExpenseNet>

<nmus:SharesAvailableForGrantOfOptionsOpeningBalance contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">1470000</nmus:SharesAvailableForGrantOfOptionsOpeningBalance>
<nmus:SharesAvailableForGrantOptionsGranted contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">130000</nmus:SharesAvailableForGrantOptionsGranted>
<nmus:SharesAvailableForGrantOptionsExercised contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" xsi:nil="true"/>
<nmus:SharesAvailableForGrantOptionsCancelled contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">680000</nmus:SharesAvailableForGrantOptionsCancelled>
<nmus:SharesAvailableForGrantOfOptionsEndingBalance contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">2020000</nmus:SharesAvailableForGrantOfOptionsEndingBalance>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">1180000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_01_Jan_2015T00_00_00_TO_31_Dec_2014T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">1730000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">1180000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">130000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_RangeAxis_MaximumMember_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">1180000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">680000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<nmus:OptionsOutstandingPricePerShareOpeningBalance contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">0.42</nmus:OptionsOutstandingPricePerShareOpeningBalance>
<nmus:OptionsOutstandingPricePerShareOptionsGranted contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_OmnibusIncentivePlan2014Member_RangeAxis_MinimumMember" unitRef="USD" decimals="2">1.15</nmus:OptionsOutstandingPricePerShareOptionsGranted>
<nmus:OptionsOutstandingPricePerShareOptionsGranted contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_OmnibusIncentivePlan2014Member_RangeAxis_MaximumMember" unitRef="USD" decimals="2">3.00</nmus:OptionsOutstandingPricePerShareOptionsGranted>
<nmus:OptionsOutstandingPricePerShareEndingBalance contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_OmnibusIncentivePlan2014Member_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">0.42</nmus:OptionsOutstandingPricePerShareEndingBalance>
<nmus:OptionsOutstandingPricePerShareEndingBalance contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_OmnibusIncentivePlan2014Member_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">3.00</nmus:OptionsOutstandingPricePerShareEndingBalance>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">0.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_01_Jan_2015T00_00_00_TO_31_Dec_2014T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">0.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">2.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="4">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="4">0.7500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" xsi:nil="true"/>

<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_RangeAxis_MaximumMember_AwardTypeAxis_EmployeeStockOptionMember">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">2.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<nmus:TermOfWarrant contextRef="Context_Custom_01_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00">P10Y</nmus:TermOfWarrant>
<nmus:TermOfWarrant contextRef="Context_Custom_01_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">P5Y</nmus:TermOfWarrant>
<nmus:TermOfWarrant contextRef="Context_Custom_01_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">P5Y</nmus:TermOfWarrant>
<nmus:NumberOfAdvisors contextRef="Context_As_Of_17_Jul_2012T00_00_00_TO_17_Jul_2012T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="Advisor" decimals="INF">2</nmus:NumberOfAdvisors>
<nmus:ValueOfCommonStockCalledByWarrants contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AgreementAxis_StockPurchaseAgreementJune2014Member_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">900000</nmus:ValueOfCommonStockCalledByWarrants>
<nmus:ValueOfCommonStockCalledByWarrants contextRef="Context_As_Of_31_Aug_2014T00_00_00_TO_31_Aug_2014T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">1100000</nmus:ValueOfCommonStockCalledByWarrants>
<nmus:ValueOfCommonStockCalledByWarrants contextRef="Context_As_Of_31_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">67950</nmus:ValueOfCommonStockCalledByWarrants>
<nmus:ValueOfCommonStockCalledByWarrants contextRef="Context_As_Of_30_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">10000</nmus:ValueOfCommonStockCalledByWarrants>
<nmus:ValueOfCommonStockCalledByWarrants contextRef="Context_As_Of_30_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">326000</nmus:ValueOfCommonStockCalledByWarrants>
<nmus:ValueOfCommonStockCalledByWarrants contextRef="Context_As_Of_30_Jun_2015T00_00_00_TO_30_Jun_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">14700</nmus:ValueOfCommonStockCalledByWarrants>
<nmus:ValueOfCommonStockCalledByWarrants contextRef="Context_As_Of_31_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">86250</nmus:ValueOfCommonStockCalledByWarrants>
<nmus:ValueOfCommonStockCalledByWarrants contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">67950</nmus:ValueOfCommonStockCalledByWarrants>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="Context_Custom_01_Jul_2012T00_00_00_TO_17_Jul_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FoundersAndMemberOfBoardMember" unitRef="shares" decimals="INF">7770000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="Context_Custom_01_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00" unitRef="shares" decimals="INF">1110000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="Context_Custom_01_Mar_2015T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="shares" decimals="INF">24000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
<nmus:ValueOfShareExchangedForServices contextRef="Context_Custom_01_Jul_2012T00_00_00_TO_17_Jul_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FoundersAndMemberOfBoardMember" unitRef="USD" decimals="0">1000</nmus:ValueOfShareExchangedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_3ME_01_Jan_2015T00_00_00_TO_31_Mar_2015T00_00_00" unitRef="USD" decimals="0">168000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_01_Jan_2015T00_00_00_TO_31_Jan_2015T00_00_00" unitRef="shares" decimals="INF">241663</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_01_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">50000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_01_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_01_May_2015T00_00_00_TO_31_May_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">30000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_01_May_2015T00_00_00_TO_31_May_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">150000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_01_Jul_2015T00_00_00_TO_31_Jul_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">36000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_01_Jul_2015T00_00_00_TO_31_Jul_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">180000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_Custom_01_Jan_2015T00_00_00_TO_31_Jan_2015T00_00_00" unitRef="USD" decimals="0">724989</us-gaap:StockIssuedDuringPeriodValueNewIssues>

<nmus:ValueOfWarrantsIssued contextRef="Context_Custom_01_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">625000</nmus:ValueOfWarrantsIssued>
<nmus:ValueOfWarrantsIssued contextRef="Context_Custom_01_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">1000</nmus:ValueOfWarrantsIssued>
<nmus:ValueOfWarrantsIssued contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_AgreementAxis_StockPurchaseAgreementJune2014Member_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">85500</nmus:ValueOfWarrantsIssued>
<nmus:NumberOfInvestor contextRef="Context_Custom_01_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00" unitRef="Investor" decimals="INF">18</nmus:NumberOfInvestor>
<nmus:MinimumIssuanceOfSharesInEquityFinancing contextRef="Context_Custom_01_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">1000000</nmus:MinimumIssuanceOfSharesInEquityFinancing>
<nmus:MinimumIssuanceOfSharesInEquityFinancing contextRef="Context_Custom_01_Jul_2015T00_00_00_TO_31_Jul_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">286000</nmus:MinimumIssuanceOfSharesInEquityFinancing>
<nmus:MaximumIssuancePricePerShareInEquityFinancing contextRef="Context_As_Of_30_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD_per_Share" decimals="2">2.50</nmus:MaximumIssuancePricePerShareInEquityFinancing>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">3200000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">2020000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
<nmus:PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="2">1.00</nmus:PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants>
<nmus:CommonStockVotingPercentage contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="2">0.10</nmus:CommonStockVotingPercentage>
<nmus:PercentageOfFairValueOptionPriceAtDateOfGrants contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="2">1.10</nmus:PercentageOfFairValueOptionPriceAtDateOfGrants>
<nmus:MaximumExercisablePeriodOfFairValueOfOption contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember">P5Y</nmus:MaximumExercisablePeriodOfFairValueOfOption>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_Custom_01_Oct_2015T00_00_00_TO_20_Oct_2015T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_RestrictedStockMember_TitleOfIndividualAxis_ManagementAndBoardOfDirectorsMember">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember">P9Y2M5D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="0">147000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">0</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">263985</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">1477143</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">P4Y1M20D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
<us-gaap:OperatingLossCarryforwards contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">4023000</us-gaap:OperatingLossCarryforwards>
<us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">37500</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
<us-gaap:DeferredRentCreditNoncurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">805</us-gaap:DeferredRentCreditNoncurrent>
<us-gaap:DeferredRentCreditNoncurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">3221</us-gaap:DeferredRentCreditNoncurrent>
<us-gaap:DerivativeLiabilitiesNoncurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">2892392</us-gaap:DerivativeLiabilitiesNoncurrent>
<us-gaap:DerivativeLiabilitiesNoncurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="USD" decimals="0">2892392</us-gaap:DerivativeLiabilitiesNoncurrent>
<us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">37500</us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities>
<nmus:ProceedsFromSeriesBPreferredStockIssuance contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">4588339</nmus:ProceedsFromSeriesBPreferredStockIssuance>
<nmus:SeriesBWarrantsTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div style="font: bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;6. Series B Warrants&lt;/div&gt;
&lt;div style="font: bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;In conjunction with the Series B Preferred Stock financing, the Company issued 6,437,500 warrants that are exercisable at a price of $1.15 per share and expire five years from the issuance date. The warrants were valued at $2,935,800 utilizing the Black-Scholes pricing model and the following assumptions:&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 35.9pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.1pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;
&lt;table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="width: 1123px; vertical-align: middle;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 396px; vertical-align: middle; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="3"&gt;
&lt;div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;"&gt;For the Nine Months Ended&amp;#160;&amp;#160; September 30,&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width: 1123px; vertical-align: middle;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 195px; vertical-align: middle; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;"&gt;2015&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 51px; vertical-align: middle;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 150px; vertical-align: middle; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;"&gt;2014&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width: 1123px; vertical-align: middle; background-color: #cceeff;"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Dividend yield&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 195px; vertical-align: middle; background-color: #cceeff;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;0.00%&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 51px; vertical-align: middle; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 150px; vertical-align: middle; background-color: #cceeff;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;NA&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width: 1123px; vertical-align: middle; background-color: #ffffff;"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Volatility factor&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 195px; vertical-align: middle; background-color: #ffffff;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;70.00%&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 51px; vertical-align: middle; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 150px; vertical-align: middle; background-color: #ffffff;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;NA&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width: 1123px; vertical-align: middle; background-color: #cceeff;"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Risk-free interest rate&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 195px; vertical-align: middle; background-color: #cceeff;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;1.75%&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 51px; vertical-align: middle; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 150px; vertical-align: middle; background-color: #cceeff;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;NA&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width: 1123px; vertical-align: middle; background-color: #ffffff;"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Expected term (years)&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 195px; vertical-align: middle; background-color: #ffffff;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;4.61&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 51px; vertical-align: middle; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 150px; vertical-align: middle; background-color: #ffffff;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;NA&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width: 1123px; vertical-align: middle; background-color: #cceeff;"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Weighted-average fair value of warrants granted during the periods&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 195px; vertical-align: middle; background-color: #cceeff;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$0.46&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 51px; vertical-align: middle; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 150px; vertical-align: middle; background-color: #cceeff;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;NA&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 35.9pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.1pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 35.9pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.1pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;The warrants are exercisable in cash or through a cashless exercise provision. The Series B warrants also have a "down-round" protection feature provided to the investors if the Company subsequently issues or sell any shares of common stock, stock options, or convertible securities at a price less than the exercise price of $1.15 per each warrant. The conversion price is automatically adjusted down to the price of the instrument being issued.&amp;#160;The Company reviewed the classification of the warrants as liabilities or equity under the guidance of ASC 480-10,&amp;#160;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;"&gt;Distinguishing Liabilities from Equity&lt;/font&gt;, and concluded that the Series B warrants should be classified as a liability. The Company then applied the relative fair value allocation methodology for allocating the proceeds of $5.0 million received from the Series B financing between the conversion liability and the warrants with the residual amount being allocated to the Preferred Stock. As such, the warrant value as of September 30, 2015 was $2,892,392 and will be subject to fair value re-measurement at the end of each reporting period.&lt;/div&gt;</nmus:SeriesBWarrantsTextBlock>
<us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;"  border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr&gt;
&lt;td style="width: 1123px; vertical-align: middle;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 396px; vertical-align: middle; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="3"&gt;
&lt;div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;"&gt;For the Nine Months Ended&amp;#160;&amp;#160; September 30,&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width: 1123px; vertical-align: middle;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 195px; vertical-align: middle; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;"&gt;2015&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 51px; vertical-align: middle;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 150px; vertical-align: middle; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;"&gt;2014&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width: 1123px; vertical-align: middle; background-color: #cceeff;"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Dividend yield&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 195px; vertical-align: middle; background-color: #cceeff;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;0.00%&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 51px; vertical-align: middle; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 150px; vertical-align: middle; background-color: #cceeff;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;NA&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width: 1123px; vertical-align: middle; background-color: #ffffff;"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Volatility factor&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 195px; vertical-align: middle; background-color: #ffffff;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;70.00%&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 51px; vertical-align: middle; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 150px; vertical-align: middle; background-color: #ffffff;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;NA&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width: 1123px; vertical-align: middle; background-color: #cceeff;"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Risk-free interest rate&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 195px; vertical-align: middle; background-color: #cceeff;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;1.75%&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 51px; vertical-align: middle; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 150px; vertical-align: middle; background-color: #cceeff;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;NA&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width: 1123px; vertical-align: middle; background-color: #ffffff;"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Expected term (years)&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 195px; vertical-align: middle; background-color: #ffffff;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;4.61&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 51px; vertical-align: middle; background-color: #ffffff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 150px; vertical-align: middle; background-color: #ffffff;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;NA&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="width: 1123px; vertical-align: middle; background-color: #cceeff;"&gt;
&lt;div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Weighted-average fair value of warrants granted during the periods&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 195px; vertical-align: middle; background-color: #cceeff;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$0.46&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 51px; vertical-align: middle; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 150px; vertical-align: middle; background-color: #cceeff;"&gt;
&lt;div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;NA&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
<us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;Restricted Cash&lt;/div&gt;
&lt;div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-size: 5.14pt;" &gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;A deposit of $37,500 as of September 30, 2015 was restricted from withdrawal and held by a bank in the form of a certificate of deposit. This certificate served as collateral for payment of the Company's credit cards.&amp;#160; Restricted cash as of December 31, 2014 was $0.&lt;/font&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="Context_Custom_01_Oct_2015T00_00_00_TO_20_Oct_2015T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_RestrictedStockMember_TitleOfIndividualAxis_ManagementAndBoardOfDirectorsMember" unitRef="shares" decimals="INF">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="pure" xsi:nil="true"/>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="pure" decimals="4">0.0000</us-gaap:FairValueAssumptionsExpectedDividendRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="pure" xsi:nil="true"/>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="pure" decimals="4">0.7000</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="pure" xsi:nil="true"/>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="pure" decimals="4">0.0175</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember">P4Y7M10D</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="USD_per_Share" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="USD_per_Share" decimals="2">0.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<nmus:NumberOfWarrantsIssued contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="shares" decimals="INF">6437500</nmus:NumberOfWarrantsIssued>
<us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants contextRef="Context_Custom_01_Aug_2015T00_00_00_TO_21_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD" decimals="-5">5000000</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>

<us-gaap:SharesIssued contextRef="Context_As_Of_31_Jul_2015T00_00_00_TO_31_Jul_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">180000</us-gaap:SharesIssued>
<us-gaap:SharesIssued contextRef="Context_As_Of_21_Aug_2015T00_00_00_TO_21_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="shares" decimals="INF">1232000</us-gaap:SharesIssued>
<us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants contextRef="Context_Custom_01_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD" decimals="-6">5000000</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
<us-gaap:NumberOfReportableSegments contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="Segment" decimals="INF">1</us-gaap:NumberOfReportableSegments>
<nmus:OptionsOutstandingPricePerShareOptionsCancelled contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">0.42</nmus:OptionsOutstandingPricePerShareOptionsCancelled>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">0.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>


<us-gaap:ConversionOfStockSharesConverted1 contextRef="Context_0ME_01-Aug-2015T00_00_00_TO_21-Aug-2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">580000</us-gaap:ConversionOfStockSharesConverted1>

<us-gaap:PreferredStockRedemptionTerms contextRef="Context_Custom_01_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember">(A) 115% of the conversion amount and (B) the product of (1) the conversion rate in effect at such time and (2) the greatest closing sale price of the Common Stock during the period beginning on the date immediately preceding such triggering event and ending on the date such holder delivers the notice of redemption.</us-gaap:PreferredStockRedemptionTerms>

<nmus:ConversionRate contextRef="Context_As_Of_31_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_BusinessAcquisitionAxis_NemusAcquisitionCorpMember" unitRef="pure" decimals="0">1</nmus:ConversionRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember">Black-Scholes pricing model</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed>
<nmus:FairMarketValueOfSharesGranted contextRef="Context_Custom_01_Oct_2015T00_00_00_TO_20_Oct_2015T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_RestrictedStockMember_TitleOfIndividualAxis_ManagementAndBoardOfDirectorsMember" unitRef="USD" decimals="0">900000</nmus:FairMarketValueOfSharesGranted>

<!-- Footnote Section -->
<link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<link:loc xlink:type="locator" xlink:href="#Footnote-2_1" xlink:label="lab_Footnote-2_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-1" xlink:from="lab_Footnote-2_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="2.0" xlink:to="Footnote-2" xlink:from="lab_Footnote-2_1"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-1_2" xlink:label="lab_Footnote-1_2"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-1" xlink:from="lab_Footnote-1_2"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-1_3" xlink:label="lab_Footnote-1_3"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-1" xlink:from="lab_Footnote-1_3"/>


<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-1" xml:lang="en-US">During the nine months ended September 30, 2015, the Company issued 200,000 warrants to purchase shares of our common stock for consulting services. The warrants were valued at $417,875. The Company also issued shares of common stock for consulting services valued at $168,000. Such amounts were recorded as a Prepaid Expense and are being amortized over the service period.</link:footnote>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-2">The Company issued 6,000 warrants at an exercise price of $2.50 to a service provider in exchange for extinguishment of $10,000 of trade accounts payable owed to this vendor.</link:footnote>
<link:loc xlink:type="locator" xlink:href="#Footnote-2_2" xlink:label="lab_Footnote-2_2"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Footnote-2_2" xlink:to="Footnote-2" order="1.0"/>
</link:footnoteLink>
<nmus:NoticePeriodForTermination contextRef="Context_Custom_01_Jul_2013T00_00_00_TO_31_Jul_2013T00_00_00_AgreementAxis_UniversityOfMississippiAgreementsMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember">P3M</nmus:NoticePeriodForTermination>
<xbrli:unit id="License_agreement"><xbrli:measure>nmus:License_agreement</xbrli:measure></xbrli:unit>
	<nmus:IndependentContractorExpense contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_AgreementAxis_IndependentContractorAgreementsMember" unitRef="USD" decimals="0">90000</nmus:IndependentContractorExpense>
<nmus:IndependentContractorExpense contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_AgreementAxis_IndependentContractorAgreementsMember" unitRef="USD" decimals="0">353000</nmus:IndependentContractorExpense>
<us-gaap:SharesIssuedPricePerShare contextRef="Context_As_Of_21_Aug_2015T00_00_00_TO_21_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:SharesIssuedPricePerShare>
<nmus:DownRoundProvisionsExpirationTerms contextRef="Context_Custom_01_Apr_2015T00_00_00_TO_30_Apr_2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">&lt;div&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;either at (i) a subsequent equity financing of at least $1,000,000 or (ii) October 1, 2015&lt;/font&gt;&lt;/div&gt;</nmus:DownRoundProvisionsExpirationTerms>

<us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="USD" decimals="-6">5000000</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
<us-gaap:CostOfServicesAmortization contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">113806</us-gaap:CostOfServicesAmortization>
<nmus:AmortizationOfWarrantServiceCost contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">9225</nmus:AmortizationOfWarrantServiceCost>
<xbrli:context id="Context_3ME_01-Oct-2014T00_00_00_TO_31-Dec-2014T00_00_00"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2014-10-01</xbrli:startDate><xbrli:endDate>2014-12-31</xbrli:endDate></xbrli:period></xbrli:context>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME_01-Oct-2014T00_00_00_TO_31-Dec-2014T00_00_00" unitRef="USD" decimals="0">466200</us-gaap:GeneralAndAdministrativeExpense>
<xbrli:context id="Context_1ME_01-Aug-2015T00_00_00_TO_31-Aug-2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-08-01</xbrli:startDate><xbrli:endDate>2015-08-31</xbrli:endDate></xbrli:period></xbrli:context>
	<us-gaap:ConversionOfStockSharesConverted1 contextRef="Context_1ME_01-Aug-2015T00_00_00_TO_31-Aug-2015T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">580000</us-gaap:ConversionOfStockSharesConverted1>

<xbrli:context id="Context_0ME_01-Aug-2015T00_00_00_TO_21-Aug-2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-08-01</xbrli:startDate><xbrli:endDate>2015-08-21</xbrli:endDate></xbrli:period></xbrli:context>
	<us-gaap:ConversionOfStockSharesIssued1 contextRef="Context_0ME_01-Aug-2015T00_00_00_TO_21-Aug-2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">1812500</us-gaap:ConversionOfStockSharesIssued1>
<nmus:ConversionPrice contextRef="Context_0ME_01-Aug-2015T00_00_00_TO_21-Aug-2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD_per_Share" decimals="2">0.80</nmus:ConversionPrice>
<nmus:StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants contextRef="Context_Custom_01_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="shares" decimals="INF">5000</nmus:StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants>
<us-gaap:ConversionOfStockSharesIssued1 contextRef="Context_Custom_01_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">1250</us-gaap:ConversionOfStockSharesIssued1>
<nmus:ConversionPrice contextRef="Context_Custom_01_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD_per_Share" decimals="0">1000</nmus:ConversionPrice>
<xbrli:context id="Context_As_Of_31-Aug-2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-08-31</xbrli:instant></xbrli:period></xbrli:context>
	<nmus:MaximumIssuancePricePerShareInEquityFinancing contextRef="Context_As_Of_31-Aug-2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.80</nmus:MaximumIssuancePricePerShareInEquityFinancing>
<xbrli:context id="Context_1ME_01-Aug-2014T00_00_00_TO_31-Aug-2014T00_00_00_AgreementAxis_StockPurchaseAgreementJune2014Member_StatementEquityComponentsAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nmus:AgreementAxis">nmus:StockPurchaseAgreementJune2014Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-08-01</xbrli:startDate><xbrli:endDate>2014-08-31</xbrli:endDate></xbrli:period></xbrli:context>
	<nmus:ValueOfWarrantsIssued contextRef="Context_1ME_01-Aug-2014T00_00_00_TO_31-Aug-2014T00_00_00_AgreementAxis_StockPurchaseAgreementJune2014Member_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">104500</nmus:ValueOfWarrantsIssued>
<xbrli:context id="Context_1ME_01-Mar-2015T00_00_00_TO_31-Mar-2015T00_00_00_StatementEquityComponentsAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-03-01</xbrli:startDate><xbrli:endDate>2015-03-31</xbrli:endDate></xbrli:period></xbrli:context>
	<nmus:TermOfWarrant contextRef="Context_1ME_01-Mar-2015T00_00_00_TO_31-Mar-2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">P5Y</nmus:TermOfWarrant>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_01_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">187500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
<nmus:StockIssuanceCosts contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">411661</nmus:StockIssuanceCosts>
<nmus:StockIssuanceCosts contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">0</nmus:StockIssuanceCosts>
<us-gaap:PreferredStockLiquidationPreferenceValue contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="-6">5000000</us-gaap:PreferredStockLiquidationPreferenceValue>
<us-gaap:PaymentsOfStockIssuanceCosts contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">3920</us-gaap:PaymentsOfStockIssuanceCosts>
<nmus:SeriesAPreferredStockIssuanceCosts contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">7700</nmus:SeriesAPreferredStockIssuanceCosts>
<nmus:SeriesBPreferredStockIssuanceCosts contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">411661</nmus:SeriesBPreferredStockIssuanceCosts>
<nmus:ConversionPrice contextRef="Context_Custom_01_Aug_2015T00_00_00_TO_31_Aug_2015T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.80</nmus:ConversionPrice>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_RangeAxis_MaximumMember_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="4">0.0185</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<xbrli:context id="Context_9ME_01-Jan-2015T00_00_00_TO_30-Sep-2015T00_00_00_RangeAxis_MinimumMember_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-09-30</xbrli:endDate></xbrli:period></xbrli:context>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_9ME_01-Jan-2015T00_00_00_TO_30-Sep-2015T00_00_00_RangeAxis_MinimumMember_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="4">0.0168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_9ME_01-Jan-2015T00_00_00_TO_30-Sep-2015T00_00_00_RangeAxis_MinimumMember_AwardTypeAxis_EmployeeStockOptionMember">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<xbrli:context id="Context_0ME_01-Oct-2015T00_00_00_TO_19-Oct-2015T00_00_00_TitleOfIndividualAxis_ManagementAndBoardOfDirectorsMember_AwardTypeAxis_RestrictedStockMember_PlanNameAxis_OmnibusIncentivePlan2014Member_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">nmus:ManagementAndBoardOfDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmus:OmnibusIncentivePlan2014Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-10-01</xbrli:startDate><xbrli:endDate>2015-10-19</xbrli:endDate></xbrli:period></xbrli:context>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_0ME_01-Oct-2015T00_00_00_TO_19-Oct-2015T00_00_00_TitleOfIndividualAxis_ManagementAndBoardOfDirectorsMember_AwardTypeAxis_RestrictedStockMember_PlanNameAxis_OmnibusIncentivePlan2014Member_SubsequentEventTypeAxis_SubsequentEventMember">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>nmus-20150930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.4.0.0 on Friday, November 13, 2015 12:10:53 AM -->
<schema targetNamespace="http://www.nemusbioscience.com/20150930" elementFormDefault="qualified" xmlns:nmus="http://www.nemusbioscience.com/20150930" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2015-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2015-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric">
<annotation><appinfo>
<link:roleType roleURI="http://www.nemusbioscience.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
<link:definition>001 - Document - Document and Entity Information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
<link:definition>002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/Consolidatedbalancesheetsparentheticals" id="Consolidatedbalancesheetsparentheticals">
<link:definition>003 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/ConsolidatedStatementsOfOperationsUnaudited" id="ConsolidatedStatementsOfOperationsUnaudited">
<link:definition>004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" id="ConsolidatedStatementsOfCashFlowsUnaudited">
<link:definition>005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/ConsolidatedStatementsOfCashFlowsUnauditedParentheticals" id="ConsolidatedStatementsOfCashFlowsUnauditedParentheticals">
<link:definition>006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (Parentheticals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPolicies" id="NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPolicies">
<link:definition>007 - Disclosure - Nature of Operations, Business Activities and Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/UniversityOfMississippiUmAgreements" id="UniversityOfMississippiUmAgreements">
<link:definition>008 - Disclosure - University of Mississippi ("UM") Agreements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/COMMITMENTSANDCONTINGENCIES" id="COMMITMENTSANDCONTINGENCIES">
<link:definition>009 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemption" id="StockholdersDeficitAndPreferredStockSubjectToRedemption">
<link:definition>010 - Disclosure - Stockholders' Deficit and Redeemable Convertible Series B Preferred Stock</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/ProvisionForConversionOfPreferredStock" id="ProvisionForConversionOfPreferredStock">
<link:definition>011 - Disclosure - Provision for Conversion of Preferred Stock</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/SeriesBWarrants" id="SeriesBWarrants">
<link:definition>012 - Disclosure - Series B Warrants</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>013 - Disclosure - Income Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>014 - Disclosure - Subsequent Events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesPolicies" id="NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>015 - Disclosure - Nature of Operations, Business Activities and Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/CommitmentsandContingenciesTables" id="CommitmentsandContingenciesTables">
<link:definition>016 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionTables" id="StockholdersDeficitAndPreferredStockSubjectToRedemptionTables">
<link:definition>017 - Disclosure - Stockholders'Deficit and Preferred Stock Subject to Redemption (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/SeriesBWarrantsTables" id="SeriesBWarrantsTables">
<link:definition>018 - Disclosure - Series B Warrants (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesDetailTextuals" id="NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesDetailTextuals">
<link:definition>019 - Disclosure - Nature of Operations, Business Activities and Summary of Significant Accounting Policies (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/UniversityOfMississippiUmAgreementsDetailTextuals" id="UniversityOfMississippiUmAgreementsDetailTextuals">
<link:definition>020 - Disclosure - University of Mississippi ("UM") Agreements (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsDetails" id="CommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsDetails">
<link:definition>021 - Disclosure - Commitments and Contingencies - Summary of Future minimum payments (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/CommitmentsAndContingenciesDetailTextuals" id="CommitmentsAndContingenciesDetailTextuals">
<link:definition>022 - Disclosure - Commitments and Contingencies (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionSummaryOfOptionActivityUnder2014PlanDetails" id="StockholdersDeficitAndPreferredStockSubjectToRedemptionSummaryOfOptionActivityUnder2014PlanDetails">
<link:definition>023 - Disclosure - Stockholders'Deficit and Preferred Stock Subject to Redemption - Summary of option activity under 2014 Plan (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionSummaryOfWeightedAverageAssumptionsForEmployeeOptionDetails1" id="StockholdersDeficitAndPreferredStockSubjectToRedemptionSummaryOfWeightedAverageAssumptionsForEmployeeOptionDetails1">
<link:definition>024 - Disclosure - Stockholders'Deficit and Preferred Stock Subject to Redemption - Summary of weighted average assumptions for employee option (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals" id="StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals">
<link:definition>025 - Disclosure - Stockholders'Deficit and Preferred Stock Subject to Redemption (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals1" id="StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals1">
<link:definition>026 - Disclosure - Stockholders'Deficit and Preferred Stock Subject to Redemption (Detail Textuals 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/ProvisionForConversionOfPreferredStockDetailTextuals" id="ProvisionForConversionOfPreferredStockDetailTextuals">
<link:definition>027 - Disclosure - Provision for Conversion of Preferred Stock (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/IncomeTaxesDetailTextuals" id="IncomeTaxesDetailTextuals">
<link:definition>030 - Disclosure - Income Taxes (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/SeriesBWarrantsDetails" id="SeriesBWarrantsDetails">
<link:definition>028 - Disclosure - Series B Warrants (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/SeriesBWarrantsDetailTextuals" id="SeriesBWarrantsDetailTextuals">
<link:definition>029 - Disclosure - Series B Warrants (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.nemusbioscience.com/role/SubsequentEventsDetailTextuals" id="SubsequentEventsDetailTextuals">
<link:definition>031 - Disclosure - Subsequent Events (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="nmus-20150930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="nmus-20150930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="nmus-20150930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="nmus-20150930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
</appinfo></annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<import namespace="http://fasb.org/us-gaap/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/exch/2015-01-31" schemaLocation="http://xbrl.sec.gov/exch/2015/exch-2015-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
<import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<import namespace="http://fasb.org/us-types/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-types-2015-01-31.xsd"/>
<element name="DocumentAndEntityInformationAbstract" id="nmus_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DepositsAndOtherAssets" id="nmus_DepositsAndOtherAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AccruedLicenseAndPatentReimbursementFees" id="nmus_AccruedLicenseAndPatentReimbursementFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockSubscriptionLiability" id="nmus_StockSubscriptionLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ProvisionForConversionOfPreferredStock" id="nmus_ProvisionForConversionOfPreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="GainLossOnConversionRightPreferredStock" id="nmus_GainLossOnConversionRightPreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IncreaseDecreaseInDepositsAndOtherAssets" id="nmus_IncreaseDecreaseInDepositsAndOtherAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees" id="nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IncreaseDecreaseInStockSubscriptionLiability" id="nmus_IncreaseDecreaseInStockSubscriptionLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ProceedsFromSeriesBPreferredStockIssuance" id="nmus_ProceedsFromSeriesBPreferredStockIssuance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CashPaidDuringPeriodForAbstract" id="nmus_CashPaidDuringPeriodForAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NoncashValueOfWarrantsIssued" id="nmus_NoncashValueOfWarrantsIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WarrantsIssuedInExchangeForExtinguishmentOfTradeAccountsPayable" id="nmus_WarrantsIssuedInExchangeForExtinguishmentOfTradeAccountsPayable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ExtinguishmentOfTradeAccountsPayableOwedToVendor" id="nmus_ExtinguishmentOfTradeAccountsPayableOwedToVendor" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="UniversityOfMississippiAgreementsAbstract" id="nmus_UniversityOfMississippiAgreementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="UniversityOfMississippiAgreementsTextBlock" id="nmus_UniversityOfMississippiAgreementsTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ProvisionForConversionOfPreferredStockAbstract" id="nmus_ProvisionForConversionOfPreferredStockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SeriesBWarrantsAbstract" id="nmus_SeriesBWarrantsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SeriesBWarrantsTextBlock" id="nmus_SeriesBWarrantsTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LiquidityAndGoingConcernPolicyTextBlock" id="nmus_LiquidityAndGoingConcernPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockBasedCompensationForNonEmployeesPolicyTextBlock" id="nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable" id="nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
<element name="NemusAcquisitionCorpMember" id="nmus_NemusAcquisitionCorpMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NemusBioscienceIncMember" id="nmus_NemusBioscienceIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems" id="nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NumberOfSharesExchanged" id="nmus_NumberOfSharesExchanged" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConversionRate" id="nmus_ConversionRate" type="xbrli:pureItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="UniversityOfMississippiAgreementsTable" id="nmus_UniversityOfMississippiAgreementsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
<element name="AgreementAxis" id="nmus_AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
<element name="AgreementDomain" id="nmus_AgreementDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="UniversityOfMississippiAgreementsMember" id="nmus_UniversityOfMississippiAgreementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OptionAgreementMember" id="nmus_OptionAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ResearchAgreementMember" id="nmus_ResearchAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AccruedLicenseAndPatentReimbursementFeesMember" id="nmus_AccruedLicenseAndPatentReimbursementFeesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MonthAndYearOfAgreementAxis" id="nmus_MonthAndYearOfAgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
<element name="MonthAndYearOfAgreementDomain" id="nmus_MonthAndYearOfAgreementDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="March2015Member" id="nmus_March2015Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="July2015Member" id="nmus_July2015Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="September2015Member" id="nmus_September2015Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="UniversityOfMississippiMember" id="nmus_UniversityOfMississippiMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="UniversityOfMississippiAgreementsLineItems" id="nmus_UniversityOfMississippiAgreementsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TermOfMemorandumOfUnderstandingAgreement" id="nmus_TermOfMemorandumOfUnderstandingAgreement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NumberOfLicenseAgreements" id="nmus_NumberOfLicenseAgreements" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NoticePeriodForTermination" id="nmus_NoticePeriodForTermination" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>

<element name="ReimbursementOfSunkPatentExpenses" id="nmus_ReimbursementOfSunkPatentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IndependentContractorAgreementsMember" id="nmus_IndependentContractorAgreementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ContractorAxis" id="nmus_ContractorAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
<element name="ContractorDomain" id="nmus_ContractorDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ContractorOneMember" id="nmus_ContractorOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ContractorTwoMember" id="nmus_ContractorTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PercentageOfContractorExpensesForTotalExpenditures" id="nmus_PercentageOfContractorExpensesForTotalExpenditures" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IndependentContractorExpense" id="nmus_IndependentContractorExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OmnibusIncentivePlan2014Member" id="nmus_OmnibusIncentivePlan2014Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SharesAvailableForGrantOfOptionsRollForward" id="nmus_SharesAvailableForGrantOfOptionsRollForward" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SharesAvailableForGrantOfOptionsOpeningBalance" id="nmus_SharesAvailableForGrantOfOptionsOpeningBalance" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>

<element name="SharesAvailableForGrantOptionsGranted" id="nmus_SharesAvailableForGrantOptionsGranted" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SharesAvailableForGrantOptionsExercised" id="nmus_SharesAvailableForGrantOptionsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SharesAvailableForGrantOptionsCancelled" id="nmus_SharesAvailableForGrantOptionsCancelled" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SharesAvailableForGrantOfOptionsEndingBalance" id="nmus_SharesAvailableForGrantOfOptionsEndingBalance" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OptionsOutstandingPricePerShareRollForward" id="nmus_OptionsOutstandingPricePerShareRollForward" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OptionsOutstandingPricePerShareOpeningBalance" id="nmus_OptionsOutstandingPricePerShareOpeningBalance" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OptionsOutstandingPricePerShareOptionsGranted" id="nmus_OptionsOutstandingPricePerShareOptionsGranted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OptionsOutstandingPricePerShareOptionsCancelled" id="nmus_OptionsOutstandingPricePerShareOptionsCancelled" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OptionsOutstandingPricePerShareEndingBalance" id="nmus_OptionsOutstandingPricePerShareEndingBalance" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="EquityTable" id="nmus_EquityTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
<element name="FoundersAndMemberOfBoardMember" id="nmus_FoundersAndMemberOfBoardMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockPurchaseAgreementJune2014Member" id="nmus_StockPurchaseAgreementJune2014Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="EquityLineItems" id="nmus_EquityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TermOfWarrant" id="nmus_TermOfWarrant" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NumberOfAdvisors" id="nmus_NumberOfAdvisors" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ValueOfCommonStockCalledByWarrants" id="nmus_ValueOfCommonStockCalledByWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AmortizationOfWarrantServiceCost" id="nmus_AmortizationOfWarrantServiceCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ValueOfShareExchangedForServices" id="nmus_ValueOfShareExchangedForServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ValueOfWarrantsIssued" id="nmus_ValueOfWarrantsIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NumberOfInvestor" id="nmus_NumberOfInvestor" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MinimumIssuanceOfSharesInEquityFinancing" id="nmus_MinimumIssuanceOfSharesInEquityFinancing" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MaximumIssuancePricePerShareInEquityFinancing" id="nmus_MaximumIssuancePricePerShareInEquityFinancing" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DownRoundProvisionsExpirationTerms" id="nmus_DownRoundProvisionsExpirationTerms" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConversionPrice" id="nmus_ConversionPrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>

<element name="PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants" id="nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommonStockVotingPercentage" id="nmus_CommonStockVotingPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PercentageOfFairValueOptionPriceAtDateOfGrants" id="nmus_PercentageOfFairValueOptionPriceAtDateOfGrants" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MaximumExercisablePeriodOfFairValueOfOption" id="nmus_MaximumExercisablePeriodOfFairValueOfOption" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SeriesBWarrantsMember" id="nmus_SeriesBWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NumberOfWarrantsIssued" id="nmus_NumberOfWarrantsIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ManagementAndBoardOfDirectorsMember" id="nmus_ManagementAndBoardOfDirectorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairMarketValueOfSharesGranted" id="nmus_FairMarketValueOfSharesGranted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" id="nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="false" nillable="true"/>
<element name="StockIssuanceCosts" id="nmus_StockIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" abstract="false" nillable="true" xbrli:balance="debit"/>
<element name="SeriesAPreferredStockIssuanceCosts" id="nmus_SeriesAPreferredStockIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="false" nillable="true" xbrli:balance="debit"/>
<element name="SeriesBPreferredStockIssuanceCosts" id="nmus_SeriesBPreferredStockIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="false" nillable="true" xbrli:balance="debit"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>nmus-20150930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.4.0.0 on Friday, November 13, 2015 12:10:53 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="nmus-20150930.xsd#ConsolidatedBalanceSheets" roleURI="http://www.nemusbioscience.com/role/ConsolidatedBalanceSheets"/>
<calculationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_OtherAssetsCurrent" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent"/><loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_DepositsAndOtherAssets" xlink:label="loc_nmus_DepositsAndOtherAssets"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="loc_nmus_DepositsAndOtherAssets" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" order="20" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedSalariesCurrent" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_AccruedLicenseAndPatentReimbursementFees" xlink:label="loc_nmus_AccruedLicenseAndPatentReimbursementFees"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_nmus_AccruedLicenseAndPatentReimbursementFees" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_StockSubscriptionLiability" xlink:label="loc_nmus_StockSubscriptionLiability"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_nmus_StockSubscriptionLiability" order="50" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ProvisionForConversionOfPreferredStock" xlink:label="loc_nmus_ProvisionForConversionOfPreferredStock"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_nmus_ProvisionForConversionOfPreferredStock" order="60" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent" order="70" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesNoncurrent" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_CommitmentsAndContingencies" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" order="30" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent" order="0" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent" order="1" use="optional" weight="1"/>
</calculationLink>






<roleRef xlink:type="simple" xlink:href="nmus-20150930.xsd#ConsolidatedStatementsOfOperationsUnaudited" roleURI="http://www.nemusbioscience.com/role/ConsolidatedStatementsOfOperationsUnaudited"/>
<calculationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/ConsolidatedStatementsOfOperationsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" order="10" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OperatingIncomeLoss" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_GainLossOnConversionRightPreferredStock" xlink:label="loc_nmus_GainLossOnConversionRightPreferredStock"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_nmus_GainLossOnConversionRightPreferredStock" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit" order="20" use="optional" weight="-1"/></calculationLink>



<roleRef xlink:type="simple" xlink:href="nmus-20150930.xsd#ConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.nemusbioscience.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"/>
<calculationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/ConsolidatedStatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_NetIncomeLoss" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_Depreciation" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ShareBasedCompensation" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_GainLossOnConversionRightPreferredStock" xlink:label="loc_nmus_GainLossOnConversionRightPreferredStock"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_nmus_GainLossOnConversionRightPreferredStock" order="50" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" order="60" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" order="70" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="80" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="loc_nmus_IncreaseDecreaseInDepositsAndOtherAssets"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_nmus_IncreaseDecreaseInDepositsAndOtherAssets" order="90" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable" order="100" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="110" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees" xlink:label="loc_nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees" order="120" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_IncreaseDecreaseInStockSubscriptionLiability" xlink:label="loc_nmus_IncreaseDecreaseInStockSubscriptionLiability"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_nmus_IncreaseDecreaseInStockSubscriptionLiability" order="130" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="140" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ProceedsFromSeriesBPreferredStockIssuance" xlink:label="loc_nmus_ProceedsFromSeriesBPreferredStockIssuance"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_nmus_ProceedsFromSeriesBPreferredStockIssuance" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="10" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="20" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="30" use="optional" weight="1"/></calculationLink>



<roleRef xlink:type="simple" xlink:href="nmus-20150930.xsd#CommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsDetails" roleURI="http://www.nemusbioscience.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="50" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="60" use="optional" weight="1"/>
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>nmus-20150930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.4.0.0 on Friday, November 13, 2015 12:10:53 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
<roleRef xlink:type="simple" xlink:href="nmus-20150930.xsd#NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesDetailTextuals" roleURI="http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="nmus-20150930.xsd#UniversityOfMississippiUmAgreementsDetailTextuals" roleURI="http://www.nemusbioscience.com/role/UniversityOfMississippiUmAgreementsDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="nmus-20150930.xsd#CommitmentsAndContingenciesDetailTextuals" roleURI="http://www.nemusbioscience.com/role/CommitmentsAndContingenciesDetailTextuals"/>
<roleRef xlink:type="simple" roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionSummaryOfOptionActivityUnder2014PlanDetails" xlink:href="nmus-20150930.xsd#StockholdersDeficitAndPreferredStockSubjectToRedemptionSummaryOfOptionActivityUnder2014PlanDetails"/>
<roleRef xlink:type="simple" roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionSummaryOfWeightedAverageAssumptionsForEmployeeOptionDetails1" xlink:href="nmus-20150930.xsd#StockholdersDeficitAndPreferredStockSubjectToRedemptionSummaryOfWeightedAverageAssumptionsForEmployeeOptionDetails1"/>
<roleRef xlink:type="simple" roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals" xlink:href="nmus-20150930.xsd#StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals"/>
<roleRef xlink:type="simple" roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals1" xlink:href="nmus-20150930.xsd#StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals1"/>
<roleRef xlink:type="simple" roleURI="http://www.nemusbioscience.com/role/ProvisionForConversionOfPreferredStockDetailTextuals" xlink:href="nmus-20150930.xsd#ProvisionForConversionOfPreferredStockDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="nmus-20150930.xsd#SeriesBWarrantsDetails" roleURI="http://www.nemusbioscience.com/role/SeriesBWarrantsDetails"/>
<roleRef xlink:type="simple" xlink:href="nmus-20150930.xsd#SeriesBWarrantsDetailTextuals" roleURI="http://www.nemusbioscience.com/role/SeriesBWarrantsDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="nmus-20150930.xsd#SubsequentEventsDetailTextuals" roleURI="http://www.nemusbioscience.com/role/SubsequentEventsDetailTextuals"/>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesDetailTextuals">
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" order="10" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>








<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_NemusAcquisitionCorpMember" xlink:label="loc_nmus_NemusAcquisitionCorpMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6" xlink:to="loc_nmus_NemusAcquisitionCorpMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_dei_LegalEntityAxis_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_8" xlink:to="loc_dei_EntityDomain_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_9_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_8" xlink:to="loc_dei_EntityDomain_9_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_NemusBioscienceIncMember" xlink:label="loc_nmus_NemusBioscienceIncMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_9" xlink:to="loc_nmus_NemusBioscienceIncMember_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_NumberOfSharesExchanged" xlink:label="loc_nmus_NumberOfSharesExchanged_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_nmus_NumberOfSharesExchanged_11" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_12" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_13" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_14" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ConversionRate" xlink:label="loc_nmus_ConversionRate_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_nmus_ConversionRate_15" order="100" use="optional"/>






<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_19" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDepreciationMethods_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDepreciationMethods_20" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_21" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_us-gaap_NumberOfReportableSegments_22" order="80" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/UniversityOfMississippiUmAgreementsDetailTextuals">
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_UniversityOfMississippiAgreementsLineItems" xlink:label="loc_nmus_UniversityOfMississippiAgreementsLineItems_0"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_UniversityOfMississippiAgreementsTable" xlink:label="loc_nmus_UniversityOfMississippiAgreementsTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nmus_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_nmus_UniversityOfMississippiAgreementsTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3" xlink:to="loc_us-gaap_IntellectualPropertyMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_AgreementAxis" xlink:label="loc_nmus_AgreementAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_nmus_AgreementAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_AgreementDomain" xlink:label="loc_nmus_AgreementDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nmus_AgreementAxis_5" xlink:to="loc_nmus_AgreementDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_AgreementDomain" xlink:label="loc_nmus_AgreementDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nmus_AgreementAxis_5" xlink:to="loc_nmus_AgreementDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_UniversityOfMississippiAgreementsMember" xlink:label="loc_nmus_UniversityOfMississippiAgreementsMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_AgreementDomain_6" xlink:to="loc_nmus_UniversityOfMississippiAgreementsMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_OptionAgreementMember" xlink:label="loc_nmus_OptionAgreementMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_AgreementDomain_6" xlink:to="loc_nmus_OptionAgreementMember_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ResearchAgreementMember" xlink:label="loc_nmus_ResearchAgreementMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_AgreementDomain_6" xlink:to="loc_nmus_ResearchAgreementMember_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_10" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_10" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_11_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_10" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_11_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_AccruedLicenseAndPatentReimbursementFeesMember" xlink:label="loc_nmus_AccruedLicenseAndPatentReimbursementFeesMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_11" xlink:to="loc_nmus_AccruedLicenseAndPatentReimbursementFeesMember_12" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_MonthAndYearOfAgreementAxis" xlink:label="loc_nmus_MonthAndYearOfAgreementAxis_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_nmus_MonthAndYearOfAgreementAxis_13" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_MonthAndYearOfAgreementDomain" xlink:label="loc_nmus_MonthAndYearOfAgreementDomain_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nmus_MonthAndYearOfAgreementAxis_13" xlink:to="loc_nmus_MonthAndYearOfAgreementDomain_14" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_MonthAndYearOfAgreementDomain" xlink:label="loc_nmus_MonthAndYearOfAgreementDomain_14_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nmus_MonthAndYearOfAgreementAxis_13" xlink:to="loc_nmus_MonthAndYearOfAgreementDomain_14_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_March2015Member" xlink:label="loc_nmus_March2015Member_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_MonthAndYearOfAgreementDomain_14" xlink:to="loc_nmus_March2015Member_15" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_July2015Member" xlink:label="loc_nmus_July2015Member_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_MonthAndYearOfAgreementDomain_14" xlink:to="loc_nmus_July2015Member_16" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_September2015Member" xlink:label="loc_nmus_September2015Member_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_MonthAndYearOfAgreementDomain_14" xlink:to="loc_nmus_September2015Member_17" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_dei_LegalEntityAxis_18" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_18" xlink:to="loc_dei_EntityDomain_19" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_19_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_18" xlink:to="loc_dei_EntityDomain_19_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_UniversityOfMississippiMember" xlink:label="loc_nmus_UniversityOfMississippiMember_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_19" xlink:to="loc_nmus_UniversityOfMississippiMember_20" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_TermOfMemorandumOfUnderstandingAgreement" xlink:label="loc_nmus_TermOfMemorandumOfUnderstandingAgreement_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_nmus_TermOfMemorandumOfUnderstandingAgreement_21" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_NumberOfLicenseAgreements" xlink:label="loc_nmus_NumberOfLicenseAgreements_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_nmus_NumberOfLicenseAgreements_22" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_NoticePeriodForTermination" xlink:label="loc_nmus_NoticePeriodForTermination_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_nmus_NoticePeriodForTermination_23" order="30" use="optional"/>


<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ReimbursementOfSunkPatentExpenses" xlink:label="loc_nmus_ReimbursementOfSunkPatentExpenses_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_nmus_ReimbursementOfSunkPatentExpenses_25" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_26" order="60" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/CommitmentsAndContingenciesDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_AgreementAxis" xlink:label="loc_nmus_AgreementAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" xlink:to="loc_nmus_AgreementAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_AgreementDomain" xlink:label="loc_nmus_AgreementDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nmus_AgreementAxis_2" xlink:to="loc_nmus_AgreementDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_AgreementDomain" xlink:label="loc_nmus_AgreementDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nmus_AgreementAxis_2" xlink:to="loc_nmus_AgreementDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_IndependentContractorAgreementsMember" xlink:label="loc_nmus_IndependentContractorAgreementsMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_AgreementDomain_3" xlink:to="loc_nmus_IndependentContractorAgreementsMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ContractorAxis" xlink:label="loc_nmus_ContractorAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" xlink:to="loc_nmus_ContractorAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ContractorDomain" xlink:label="loc_nmus_ContractorDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nmus_ContractorAxis_5" xlink:to="loc_nmus_ContractorDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ContractorDomain" xlink:label="loc_nmus_ContractorDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nmus_ContractorAxis_5" xlink:to="loc_nmus_ContractorDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ContractorOneMember" xlink:label="loc_nmus_ContractorOneMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_ContractorDomain_6" xlink:to="loc_nmus_ContractorOneMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ContractorTwoMember" xlink:label="loc_nmus_ContractorTwoMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_ContractorDomain_6" xlink:to="loc_nmus_ContractorTwoMember_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_PercentageOfContractorExpensesForTotalExpenditures" xlink:label="loc_nmus_PercentageOfContractorExpensesForTotalExpenditures_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_nmus_PercentageOfContractorExpensesForTotalExpenditures_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaap_AreaOfLand_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_us-gaap_AreaOfLand_10" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_11" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_IndependentContractorExpense" xlink:label="loc_nmus_IndependentContractorExpense_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_nmus_IndependentContractorExpense_12" order="40" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionSummaryOfOptionActivityUnder2014PlanDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_5" xlink:to="loc_us-gaap_PlanNameDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_5" xlink:to="loc_us-gaap_PlanNameDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_OmnibusIncentivePlan2014Member" xlink:label="loc_nmus_OmnibusIncentivePlan2014Member_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6" xlink:to="loc_nmus_OmnibusIncentivePlan2014Member_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RangeAxis_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_8" xlink:to="loc_us-gaap_RangeMember_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_8" xlink:to="loc_us-gaap_RangeMember_9_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_9" xlink:to="loc_us-gaap_MinimumMember_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_9" xlink:to="loc_us-gaap_MaximumMember_11" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_SharesAvailableForGrantOfOptionsRollForward" xlink:label="loc_nmus_SharesAvailableForGrantOfOptionsRollForward_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_nmus_SharesAvailableForGrantOfOptionsRollForward_12" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_SharesAvailableForGrantOfOptionsOpeningBalance" xlink:label="loc_nmus_SharesAvailableForGrantOfOptionsOpeningBalance_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_SharesAvailableForGrantOfOptionsRollForward_12" xlink:to="loc_nmus_SharesAvailableForGrantOfOptionsOpeningBalance_13" order="0" use="optional"/>


<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_SharesAvailableForGrantOptionsGranted" xlink:label="loc_nmus_SharesAvailableForGrantOptionsGranted_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_SharesAvailableForGrantOfOptionsRollForward_12" xlink:to="loc_nmus_SharesAvailableForGrantOptionsGranted_15" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_SharesAvailableForGrantOptionsExercised" xlink:label="loc_nmus_SharesAvailableForGrantOptionsExercised_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_SharesAvailableForGrantOfOptionsRollForward_12" xlink:to="loc_nmus_SharesAvailableForGrantOptionsExercised_16" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_SharesAvailableForGrantOptionsCancelled" xlink:label="loc_nmus_SharesAvailableForGrantOptionsCancelled_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_SharesAvailableForGrantOfOptionsRollForward_12" xlink:to="loc_nmus_SharesAvailableForGrantOptionsCancelled_17" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_SharesAvailableForGrantOfOptionsEndingBalance" xlink:label="loc_nmus_SharesAvailableForGrantOfOptionsEndingBalance_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_SharesAvailableForGrantOfOptionsRollForward_12" xlink:to="loc_nmus_SharesAvailableForGrantOfOptionsEndingBalance_18" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_19" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_20" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_21" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_19" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_22" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_23" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_OptionsOutstandingPricePerShareRollForward" xlink:label="loc_nmus_OptionsOutstandingPricePerShareRollForward_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_nmus_OptionsOutstandingPricePerShareRollForward_24" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_OptionsOutstandingPricePerShareOpeningBalance" xlink:label="loc_nmus_OptionsOutstandingPricePerShareOpeningBalance_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_OptionsOutstandingPricePerShareRollForward_24" xlink:to="loc_nmus_OptionsOutstandingPricePerShareOpeningBalance_25" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_OptionsOutstandingPricePerShareOptionsGranted" xlink:label="loc_nmus_OptionsOutstandingPricePerShareOptionsGranted_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_OptionsOutstandingPricePerShareRollForward_24" xlink:to="loc_nmus_OptionsOutstandingPricePerShareOptionsGranted_26" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_OptionsOutstandingPricePerShareOptionsCancelled" xlink:label="loc_nmus_OptionsOutstandingPricePerShareOptionsCancelled_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_OptionsOutstandingPricePerShareRollForward_24" xlink:to="loc_nmus_OptionsOutstandingPricePerShareOptionsCancelled_27" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_OptionsOutstandingPricePerShareEndingBalance" xlink:label="loc_nmus_OptionsOutstandingPricePerShareEndingBalance_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_OptionsOutstandingPricePerShareRollForward_24" xlink:to="loc_nmus_OptionsOutstandingPricePerShareEndingBalance_28" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_29" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_30" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_31" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_32" order="20" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionSummaryOfWeightedAverageAssumptionsForEmployeeOptionDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9" order="50" use="optional"/>




<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RangeAxis" order="1" use="optional"/>










<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis" xlink:to="loc_us-gaap_RangeMember" order="2" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember" xlink:to="loc_us-gaap_MaximumMember_1" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember" xlink:to="loc_us-gaap_MinimumMember_1" order="1" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis" xlink:to="loc_us-gaap_RangeMember_Default" order="3"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals">
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_EquityLineItems" xlink:label="loc_nmus_EquityLineItems_0"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_EquityTable" xlink:label="loc_nmus_EquityTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_EquityTable_1" order="10" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_CommonStockMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6" xlink:to="loc_us-gaap_RelatedPartyDomain_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_7_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6" xlink:to="loc_us-gaap_RelatedPartyDomain_7_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_FoundersAndMemberOfBoardMember" xlink:label="loc_nmus_FoundersAndMemberOfBoardMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_7" xlink:to="loc_nmus_FoundersAndMemberOfBoardMember_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_AgreementAxis" xlink:label="loc_nmus_AgreementAxis_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_nmus_AgreementAxis_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_AgreementDomain" xlink:label="loc_nmus_AgreementDomain_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nmus_AgreementAxis_9" xlink:to="loc_nmus_AgreementDomain_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_AgreementDomain" xlink:label="loc_nmus_AgreementDomain_10_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nmus_AgreementAxis_9" xlink:to="loc_nmus_AgreementDomain_10_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_StockPurchaseAgreementJune2014Member" xlink:label="loc_nmus_StockPurchaseAgreementJune2014Member_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_AgreementDomain_10" xlink:to="loc_nmus_StockPurchaseAgreementJune2014Member_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_12" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_12" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_13_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_12" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_13_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_13" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_14" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_15" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_15" xlink:to="loc_us-gaap_ClassOfStockDomain_16" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_16_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_15" xlink:to="loc_us-gaap_ClassOfStockDomain_16_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_16" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_17" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_16" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_18" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_19" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_20" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_TermOfWarrant" xlink:label="loc_nmus_TermOfWarrant_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_TermOfWarrant_21" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_NumberOfAdvisors" xlink:label="loc_nmus_NumberOfAdvisors_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_NumberOfAdvisors_22" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ValueOfCommonStockCalledByWarrants" xlink:label="loc_nmus_ValueOfCommonStockCalledByWarrants_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_ValueOfCommonStockCalledByWarrants_23" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_AmortizationOfWarrantServiceCost" xlink:label="loc_nmus_AmortizationOfWarrantServiceCost_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_AmortizationOfWarrantServiceCost_24" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_25" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ValueOfShareExchangedForServices" xlink:label="loc_nmus_ValueOfShareExchangedForServices_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_ValueOfShareExchangedForServices_26" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_27" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_28" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_29" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfServicesAmortization" xlink:label="loc_us-gaap_CostOfServicesAmortization_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_CostOfServicesAmortization_30" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_31" order="150" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ValueOfWarrantsIssued" xlink:label="loc_nmus_ValueOfWarrantsIssued_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_ValueOfWarrantsIssued_32" order="160" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_NumberOfInvestor" xlink:label="loc_nmus_NumberOfInvestor_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_NumberOfInvestor_33" order="170" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_34"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_34" order="180" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_35"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_35" order="190" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_36"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_36" order="200" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_MinimumIssuanceOfSharesInEquityFinancing" xlink:label="loc_nmus_MinimumIssuanceOfSharesInEquityFinancing_37"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_MinimumIssuanceOfSharesInEquityFinancing_37" order="210" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_MaximumIssuancePricePerShareInEquityFinancing" xlink:label="loc_nmus_MaximumIssuancePricePerShareInEquityFinancing_38"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_MaximumIssuancePricePerShareInEquityFinancing_38" order="220" use="optional"/>




<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ConversionPrice" xlink:label="loc_nmus_ConversionPrice_41"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_ConversionPrice_41" order="230" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_42"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_42" order="240" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_43"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_43" order="250" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_44"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_44" order="260" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockRedemptionTerms" xlink:label="loc_us-gaap_PreferredStockRedemptionTerms_45"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_PreferredStockRedemptionTerms_45" order="270" use="optional"/>


<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" xlink:label="loc_nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" order="110" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals1">
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_EquityLineItems" xlink:label="loc_nmus_EquityLineItems_0"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_EquityTable" xlink:label="loc_nmus_EquityTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_EquityTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_PlanNameAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_2" xlink:to="loc_us-gaap_PlanNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_2" xlink:to="loc_us-gaap_PlanNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_OmnibusIncentivePlan2014Member" xlink:label="loc_nmus_OmnibusIncentivePlan2014Member_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3" xlink:to="loc_nmus_OmnibusIncentivePlan2014Member_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_RangeAxis_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_8" xlink:to="loc_us-gaap_RangeMember_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_8" xlink:to="loc_us-gaap_RangeMember_9_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_9" xlink:to="loc_us-gaap_MaximumMember_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_11" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_11" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_12" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_12_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_11" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_12_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_12" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_14" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_15" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_16" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_17" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants" xlink:label="loc_nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants_18" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_CommonStockVotingPercentage" xlink:label="loc_nmus_CommonStockVotingPercentage_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_CommonStockVotingPercentage_19" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_PercentageOfFairValueOptionPriceAtDateOfGrants" xlink:label="loc_nmus_PercentageOfFairValueOptionPriceAtDateOfGrants_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_PercentageOfFairValueOptionPriceAtDateOfGrants_20" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_MaximumExercisablePeriodOfFairValueOfOption" xlink:label="loc_nmus_MaximumExercisablePeriodOfFairValueOfOption_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_nmus_MaximumExercisablePeriodOfFairValueOfOption_21" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_22" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_23" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_24" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_25" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_26" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_27" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_28" order="150" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmus_EquityLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_29" order="160" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/ProvisionForConversionOfPreferredStockDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockLineItems" xlink:label="loc_us-gaap_ConversionOfStockLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockTable" xlink:label="loc_us-gaap_ConversionOfStockTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConversionOfStockLineItems_0" xlink:to="loc_us-gaap_ConversionOfStockTable_1" order="10" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConversionOfStockTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_MinimumIssuanceOfSharesInEquityFinancing" xlink:label="loc_nmus_MinimumIssuanceOfSharesInEquityFinancing_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_0" xlink:to="loc_nmus_MinimumIssuanceOfSharesInEquityFinancing_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_MaximumIssuancePricePerShareInEquityFinancing" xlink:label="loc_nmus_MaximumIssuancePricePerShareInEquityFinancing_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_0" xlink:to="loc_nmus_MaximumIssuancePricePerShareInEquityFinancing_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_DownRoundProvisionsExpirationTerms" xlink:label="loc_nmus_DownRoundProvisionsExpirationTerms_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_0" xlink:to="loc_nmus_DownRoundProvisionsExpirationTerms_8" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ProvisionForConversionOfPreferredStock" xlink:label="loc_nmus_ProvisionForConversionOfPreferredStock_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_0" xlink:to="loc_nmus_ProvisionForConversionOfPreferredStock_9" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_0" xlink:to="loc_us-gaap_SharesIssued_10" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_11" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_GainLossOnConversionRightPreferredStock" xlink:label="loc_nmus_GainLossOnConversionRightPreferredStock_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_0" xlink:to="loc_nmus_GainLossOnConversionRightPreferredStock_12" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_0" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_13" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ConversionPrice" xlink:label="loc_nmus_ConversionPrice_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_0" xlink:to="loc_nmus_ConversionPrice_14" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockLineItems_0" xlink:to="loc_us-gaap_SharesIssuedPricePerShare" order="80" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/SeriesBWarrantsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_SeriesBWarrantsMember" xlink:label="loc_nmus_SeriesBWarrantsMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3" xlink:to="loc_nmus_SeriesBWarrantsMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_8" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9" order="50" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/SeriesBWarrantsDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_SeriesBWarrantsMember" xlink:label="loc_nmus_SeriesBWarrantsMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3" xlink:to="loc_nmus_SeriesBWarrantsMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_NumberOfWarrantsIssued" xlink:label="loc_nmus_NumberOfWarrantsIssued_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_nmus_NumberOfWarrantsIssued_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed_8" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_9" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_10" order="60" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/SubsequentEventsDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_PlanNameAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_5" xlink:to="loc_us-gaap_PlanNameDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_5" xlink:to="loc_us-gaap_PlanNameDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_OmnibusIncentivePlan2014Member" xlink:label="loc_nmus_OmnibusIncentivePlan2014Member_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6" xlink:to="loc_nmus_OmnibusIncentivePlan2014Member_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9" xlink:to="loc_us-gaap_RestrictedStockMember_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_11" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_11" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_12" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_12_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_11" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_12_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ManagementAndBoardOfDirectorsMember" xlink:label="loc_nmus_ManagementAndBoardOfDirectorsMember_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_12" xlink:to="loc_nmus_ManagementAndBoardOfDirectorsMember_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_14" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_FairMarketValueOfSharesGranted" xlink:label="loc_nmus_FairMarketValueOfSharesGranted_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_nmus_FairMarketValueOfSharesGranted_15" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_16" order="30" use="optional"/>
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>nmus-20150930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.4.0.0 on Friday, November 13, 2015 12:10:53 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_DocumentAndEntityInformationAbstract" xlink:label="loc_839743H4G541_nmus_DocumentAndEntityInformationAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_nmus_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_DocumentAndEntityInformationAbstract" xlink:to="lab_051965J6I763_nmus_DocumentAndEntityInformationAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_FG95812277699K094F4I_dei_EntityRegistrantName"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_dei_EntityRegistrantName" xlink:to="lab_HI17034499811M216H6K_dei_EntityRegistrantName"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_839743H4G541_dei_EntityCentralIndexKey"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_dei_EntityCentralIndexKey" xlink:to="lab_051965J6I763_dei_EntityCentralIndexKey"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_FG95812277699K094F4I_dei_TradingSymbol"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_dei_TradingSymbol" xlink:to="lab_HI17034499811M216H6K_dei_TradingSymbol"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_839743H4G541_dei_CurrentFiscalYearEndDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_dei_CurrentFiscalYearEndDate" xlink:to="lab_051965J6I763_dei_CurrentFiscalYearEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_FG95812277699K094F4I_dei_EntityFilerCategory"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_dei_EntityFilerCategory" xlink:to="lab_HI17034499811M216H6K_dei_EntityFilerCategory"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_839743H4G541_dei_EntityCommonStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_051965J6I763_dei_EntityCommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_FG95812277699K094F4I_dei_DocumentType"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_dei_DocumentType" xml:lang="en-US">Document Type</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_dei_DocumentType" xlink:to="lab_HI17034499811M216H6K_dei_DocumentType"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_839743H4G541_dei_DocumentPeriodEndDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_dei_DocumentPeriodEndDate" xlink:to="lab_051965J6I763_dei_DocumentPeriodEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_FG95812277699K094F4I_dei_AmendmentFlag"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_dei_AmendmentFlag" xlink:to="lab_HI17034499811M216H6K_dei_AmendmentFlag"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_839743H4G541_dei_DocumentFiscalYearFocus"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_dei_DocumentFiscalYearFocus" xlink:to="lab_051965J6I763_dei_DocumentFiscalYearFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_FG95812277699K094F4I_dei_DocumentFiscalPeriodFocus"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_dei_DocumentFiscalPeriodFocus" xlink:to="lab_HI17034499811M216H6K_dei_DocumentFiscalPeriodFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_839743H4G541_us-gaap_StatementOfFinancialPositionAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement Of Financial Position [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_051965J6I763_us-gaap_StatementOfFinancialPositionAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_FG95812277699K094F4I_us-gaap_AssetsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_AssetsAbstract" xlink:to="lab_HI17034499811M216H6K_us-gaap_AssetsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_839743H4G541_us-gaap_AssetsCurrentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_AssetsCurrentAbstract" xlink:to="lab_051965J6I763_us-gaap_AssetsCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_FG95812277699K094F4I_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, At Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents, beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents, end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_HI17034499811M216H6K_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_839743H4G541_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_051965J6I763_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_FG95812277699K094F4I_us-gaap_PrepaidExpenseCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid Expense, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_HI17034499811M216H6K_us-gaap_PrepaidExpenseCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_839743H4G541_us-gaap_OtherAssetsCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_OtherAssetsCurrent" xlink:to="lab_051965J6I763_us-gaap_OtherAssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_FG95812277699K094F4I_us-gaap_AssetsCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_AssetsCurrent" xlink:to="lab_HI17034499811M216H6K_us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_839743H4G541_us-gaap_PropertyPlantAndEquipmentNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Net equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_051965J6I763_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Net equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_051965J6I763_us-gaap_PropertyPlantAndEquipmentNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_FG95812277699K094F4I_us-gaap_OtherAssetsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_OtherAssetsAbstract" xml:lang="en-US">Other Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_OtherAssetsAbstract" xml:lang="en-US">Other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_OtherAssetsAbstract" xlink:to="lab_HI17034499811M216H6K_us-gaap_OtherAssetsAbstract"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_DepositsAndOtherAssets" xlink:label="loc_839743H4G541_nmus_DepositsAndOtherAssets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_DepositsAndOtherAssets" xml:lang="en-US">Deposits And Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_nmus_DepositsAndOtherAssets" xml:lang="en-US">Deposits and other assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_nmus_DepositsAndOtherAssets" xml:lang="en-US">Represents aggregate carrying amount, as of the balance sheet date, of deposits and other assets.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_DepositsAndOtherAssets" xlink:to="lab_051965J6I763_nmus_DepositsAndOtherAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_FG95812277699K094F4I_us-gaap_OtherAssetsNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other Assets, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Total other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_HI17034499811M216H6K_us-gaap_OtherAssetsNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="loc_839743H4G541_us-gaap_Assets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_Assets" xml:lang="en-US">Total Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_051965J6I763_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_Assets" xlink:to="lab_051965J6I763_us-gaap_Assets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_FG95812277699K094F4I_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_HI17034499811M216H6K_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_839743H4G541_us-gaap_LiabilitiesCurrentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_051965J6I763_us-gaap_LiabilitiesCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_FG95812277699K094F4I_us-gaap_AccountsPayableCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_AccountsPayableCurrent" xlink:to="lab_HI17034499811M216H6K_us-gaap_AccountsPayableCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_839743H4G541_us-gaap_AccruedSalariesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_AccruedSalariesCurrent" xml:lang="en-US">Accrued Salaries, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_AccruedSalariesCurrent" xml:lang="en-US">Accrued payroll and related expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_AccruedSalariesCurrent" xlink:to="lab_051965J6I763_us-gaap_AccruedSalariesCurrent"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_AccruedLicenseAndPatentReimbursementFees" xlink:label="loc_FG95812277699K094F4I_nmus_AccruedLicenseAndPatentReimbursementFees"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_AccruedLicenseAndPatentReimbursementFees" xml:lang="en-US">Accrued License And Patent Reimbursement Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_nmus_AccruedLicenseAndPatentReimbursementFees" xml:lang="en-US">Accrued license and patent reimbursement fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_AccruedLicenseAndPatentReimbursementFees" xml:lang="en-US">Represents carrying value as of the balance sheet date of obligations incurred through that date and payable for accrued license and patent reimbursement fees.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_AccruedLicenseAndPatentReimbursementFees" xlink:to="lab_HI17034499811M216H6K_nmus_AccruedLicenseAndPatentReimbursementFees"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_839743H4G541_us-gaap_AccruedLiabilitiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_051965J6I763_us-gaap_AccruedLiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_StockSubscriptionLiability" xlink:label="loc_FG95812277699K094F4I_nmus_StockSubscriptionLiability"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_StockSubscriptionLiability" xml:lang="en-US">Stock Subscription Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_nmus_StockSubscriptionLiability" xml:lang="en-US">Stock subscription liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_StockSubscriptionLiability" xml:lang="en-US">Represents carrying value as of the balance sheet date of stock subscription liability.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_StockSubscriptionLiability" xlink:to="lab_HI17034499811M216H6K_nmus_StockSubscriptionLiability"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ProvisionForConversionOfPreferredStock" xlink:label="loc_839743H4G541_nmus_ProvisionForConversionOfPreferredStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_ProvisionForConversionOfPreferredStock" xml:lang="en-US">Provision For Conversion Of Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_nmus_ProvisionForConversionOfPreferredStock" xml:lang="en-US">Fair value of the conversion feature</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_nmus_ProvisionForConversionOfPreferredStock" xml:lang="en-US">Provision for conversion of Series B preferred stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_nmus_ProvisionForConversionOfPreferredStock" xml:lang="en-US">Represents the amount related to provision for conversion of preferred stock as of balance sheet date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_ProvisionForConversionOfPreferredStock" xlink:to="lab_051965J6I763_nmus_ProvisionForConversionOfPreferredStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_FG95812277699K094F4I_us-gaap_AccruedIncomeTaxesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_AccruedIncomeTaxesCurrent" xml:lang="en-US">Accrued Income Taxes, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_AccruedIncomeTaxesCurrent" xml:lang="en-US">Income taxes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_HI17034499811M216H6K_us-gaap_AccruedIncomeTaxesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_839743H4G541_us-gaap_LiabilitiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_051965J6I763_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_LiabilitiesCurrent" xlink:to="lab_051965J6I763_us-gaap_LiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_FG95812277699K094F4I_us-gaap_LiabilitiesNoncurrentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_LiabilitiesNoncurrentAbstract" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_LiabilitiesNoncurrentAbstract" xml:lang="en-US">Noncurrent liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_HI17034499811M216H6K_us-gaap_LiabilitiesNoncurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_839743H4G541_us-gaap_DeferredRentCreditNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_DeferredRentCreditNoncurrent" xml:lang="en-US">Deferred Rent Credit, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_DeferredRentCreditNoncurrent" xml:lang="en-US">Deferred rent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_DeferredRentCreditNoncurrent" xlink:to="lab_051965J6I763_us-gaap_DeferredRentCreditNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_FG95812277699K094F4I_us-gaap_DerivativeLiabilitiesNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_DerivativeLiabilitiesNoncurrent" xml:lang="en-US">Derivative Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_DerivativeLiabilitiesNoncurrent" xml:lang="en-US">Series B warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_HI17034499811M216H6K_us-gaap_DerivativeLiabilitiesNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_839743H4G541_us-gaap_LiabilitiesNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_LiabilitiesNoncurrent" xml:lang="en-US">Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_LiabilitiesNoncurrent" xml:lang="en-US">Total noncurrent liabilities</label>
<label xlink:type="resource" xlink:label="lab_051965J6I763_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xml:lang="en-US">Total noncurrent liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_051965J6I763_us-gaap_LiabilitiesNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_FG95812277699K094F4I_us-gaap_Liabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_Liabilities" xlink:to="lab_HI17034499811M216H6K_us-gaap_Liabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_839743H4G541_us-gaap_CommitmentsAndContingencies"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies (Note 3)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_CommitmentsAndContingencies" xlink:to="lab_051965J6I763_us-gaap_CommitmentsAndContingencies"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_FG95812277699K094F4I_us-gaap_PreferredStockValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_PreferredStockValue" xml:lang="en-US">Redeemable Convertible Series B Preferred Stock, $0.001 par value, 20 million shares authorized; 5,000 issued and outstanding as of September 30, 2015 and none issued and outstanding as of December 31, 2014, net of $411,661 in issuance costs; $5.0 million liquidation preference as of September 30, 2015</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_PreferredStockValue" xml:lang="en-US">Series B preferred stock subject to redemption, $0.001 par value, 20 million shares authorized; 5,000 issued and outstanding as of September 30, 2015 and none issued and outstanding as of December 31, 2014. $5.0 million liquidation preference of Series B preferred stock as of September 30, 2014</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_PreferredStockValue" xlink:to="lab_HI17034499811M216H6K_us-gaap_PreferredStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_839743H4G541_us-gaap_StockholdersEquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_StockholdersEquityAbstract" xlink:to="lab_051965J6I763_us-gaap_StockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_FG95812277699K094F4I_us-gaap_CommonStockValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.001 par value; 236 million shares authorized; 18,078,163 issued and outstanding as of September 30, 2015 and 16 million issued and outstanding as of December 31, 2014</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_CommonStockValue" xlink:to="lab_HI17034499811M216H6K_us-gaap_CommonStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_839743H4G541_us-gaap_AdditionalPaidInCapitalCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional paid-in-capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_051965J6I763_us-gaap_AdditionalPaidInCapitalCommonStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_FG95812277699K094F4I_us-gaap_WarrantsAndRightsOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US">Warrants and Rights Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US">Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_HI17034499811M216H6K_us-gaap_WarrantsAndRightsOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_839743H4G541_us-gaap_RetainedEarningsAccumulatedDeficit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained earnings during the development stage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_051965J6I763_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_051965J6I763_us-gaap_RetainedEarningsAccumulatedDeficit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_FG95812277699K094F4I_us-gaap_StockholdersEquity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_StockholdersEquity" xml:lang="en-US">Total shareholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders' deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_StockholdersEquity" xlink:to="lab_HI17034499811M216H6K_us-gaap_StockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_839743H4G541_us-gaap_LiabilitiesAndStockholdersEquity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total Liabilities and Shareholders' Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_051965J6I763_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and stockholders' deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_051965J6I763_us-gaap_LiabilitiesAndStockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_FG95812277699K094F4I_us-gaap_PreferredStockParOrStatedValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_HI17034499811M216H6K_us-gaap_PreferredStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_839743H4G541_us-gaap_PreferredStockSharesAuthorized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_051965J6I763_us-gaap_PreferredStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_FG95812277699K094F4I_us-gaap_PreferredStockSharesIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_PreferredStockSharesIssued" xlink:to="lab_HI17034499811M216H6K_us-gaap_PreferredStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_839743H4G541_us-gaap_PreferredStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_051965J6I763_us-gaap_PreferredStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_FG95812277699K094F4I_us-gaap_CommonStockParOrStatedValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Par value of common stock issued (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_HI17034499811M216H6K_us-gaap_CommonStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_839743H4G541_us-gaap_CommonStockSharesAuthorized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_051965J6I763_us-gaap_CommonStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_FG95812277699K094F4I_us-gaap_CommonStockSharesIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_CommonStockSharesIssued" xlink:to="lab_HI17034499811M216H6K_us-gaap_CommonStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_839743H4G541_us-gaap_CommonStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_051965J6I763_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Balance (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_051965J6I763_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Balance (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_051965J6I763_us-gaap_CommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_FG95812277699K094F4I_us-gaap_IncomeStatementAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_IncomeStatementAbstract" xlink:to="lab_HI17034499811M216H6K_us-gaap_IncomeStatementAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_839743H4G541_us-gaap_OperatingExpensesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_OperatingExpensesAbstract" xlink:to="lab_051965J6I763_us-gaap_OperatingExpensesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_FG95812277699K094F4I_us-gaap_ResearchAndDevelopmentExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_HI17034499811M216H6K_us-gaap_ResearchAndDevelopmentExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_839743H4G541_us-gaap_GeneralAndAdministrativeExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<label xlink:type="resource" xlink:label="lab_051965J6I763_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US">General and administrative expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_051965J6I763_us-gaap_GeneralAndAdministrativeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_FG95812277699K094F4I_us-gaap_OperatingExpenses"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_OperatingExpenses" xlink:to="lab_HI17034499811M216H6K_us-gaap_OperatingExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_839743H4G541_us-gaap_OperatingIncomeLoss"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_051965J6I763_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_051965J6I763_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_OperatingIncomeLoss" xlink:to="lab_051965J6I763_us-gaap_OperatingIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_FG95812277699K094F4I_us-gaap_NonoperatingIncomeExpenseAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_HI17034499811M216H6K_us-gaap_NonoperatingIncomeExpenseAbstract"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_GainLossOnConversionRightPreferredStock" xlink:label="loc_839743H4G541_nmus_GainLossOnConversionRightPreferredStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_GainLossOnConversionRightPreferredStock" xml:lang="en-US">Gain Loss On Conversion Right Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_nmus_GainLossOnConversionRightPreferredStock" xml:lang="en-US">Loss on conversion right of Series A preferred stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_nmus_GainLossOnConversionRightPreferredStock" xml:lang="en-US">Represents the amount related to gain or loss on conversion right of preferred stock during the period.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_051965J6I763_nmus_GainLossOnConversionRightPreferredStock" xml:lang="en-US">Change in fair value of conversion rights of Series A preferred stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_GainLossOnConversionRightPreferredStock" xlink:to="lab_051965J6I763_nmus_GainLossOnConversionRightPreferredStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_FG95812277699K094F4I_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Net loss before income taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Net loss before income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_HI17034499811M216H6K_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_839743H4G541_us-gaap_IncomeTaxExpenseBenefit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Provision for income taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_051965J6I763_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax expense per books</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_051965J6I763_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Provision for income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_051965J6I763_us-gaap_IncomeTaxExpenseBenefit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_FG95812277699K094F4I_us-gaap_NetIncomeLoss"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss for the year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_NetIncomeLoss" xml:lang="en-US">Loss from operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_NetIncomeLoss" xml:lang="en-US">Net income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_NetIncomeLoss" xlink:to="lab_HI17034499811M216H6K_us-gaap_NetIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_839743H4G541_us-gaap_EarningsPerShareBasicAndDiluted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Net income (loss) per share (Basic) (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Basic and diluted loss per common share (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_051965J6I763_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Basic and diluted loss per common share (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_051965J6I763_us-gaap_EarningsPerShareBasicAndDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_FG95812277699K094F4I_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Number Of Shares Outstanding, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted average common shares outstanding (Basic)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Shares used in computing basic and diluted loss per share (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_HI17034499811M216H6K_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_839743H4G541_us-gaap_StatementOfCashFlowsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_051965J6I763_us-gaap_StatementOfCashFlowsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_FG95812277699K094F4I_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Operating Activities, Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Cash flows from operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_HI17034499811M216H6K_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_839743H4G541_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_051965J6I763_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_FG95812277699K094F4I_us-gaap_Depreciation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_Depreciation" xlink:to="lab_HI17034499811M216H6K_us-gaap_Depreciation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_839743H4G541_us-gaap_ShareBasedCompensation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation for employees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ShareBasedCompensation" xlink:to="lab_051965J6I763_us-gaap_ShareBasedCompensation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_FG95812277699K094F4I_us-gaap_AmortizationOfFinancingCosts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization of Financing Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization of warrants and stock issued for services</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_HI17034499811M216H6K_us-gaap_AmortizationOfFinancingCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_839743H4G541_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xml:lang="en-US">Increase (Decrease) In Operating Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xml:lang="en-US">Changes in assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="lab_051965J6I763_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" xlink:label="loc_FG95812277699K094F4I_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" xml:lang="en-US">Increase (Decrease) in Restricted Cash for Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" xml:lang="en-US">Restricted cash</label>
<label xlink:type="resource" xlink:label="lab_HI17034499811M216H6K_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US">Restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" xlink:to="lab_HI17034499811M216H6K_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_839743H4G541_us-gaap_IncreaseDecreaseInPrepaidExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_051965J6I763_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_051965J6I763_us-gaap_IncreaseDecreaseInPrepaidExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_FG95812277699K094F4I_us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xml:lang="en-US">Increase (Decrease) in Other Current Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xml:lang="en-US">Other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="lab_HI17034499811M216H6K_us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="loc_839743H4G541_nmus_IncreaseDecreaseInDepositsAndOtherAssets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_IncreaseDecreaseInDepositsAndOtherAssets" xml:lang="en-US">Increase Decrease In Deposits And Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_nmus_IncreaseDecreaseInDepositsAndOtherAssets" xml:lang="en-US">Represents amount of increase (decrease) in deposits and other assets.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_051965J6I763_nmus_IncreaseDecreaseInDepositsAndOtherAssets" xml:lang="en-US">Deposits and other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_IncreaseDecreaseInDepositsAndOtherAssets" xlink:to="lab_051965J6I763_nmus_IncreaseDecreaseInDepositsAndOtherAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_FG95812277699K094F4I_us-gaap_IncreaseDecreaseInAccountsPayable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_HI17034499811M216H6K_us-gaap_IncreaseDecreaseInAccountsPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_839743H4G541_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xml:lang="en-US">Accrued payroll and related expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_051965J6I763_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees" xlink:label="loc_FG95812277699K094F4I_nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees" xml:lang="en-US">Increase Decrease In Accrued License And Patent Reimbursement Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees" xml:lang="en-US">Accrued license and patent reimbursement fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees" xml:lang="en-US">Represents amount of increase (decrease) in accrued license and patent reimbursement fees.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_HI17034499811M216H6K_nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees" xml:lang="en-US">Accrued license and patent reimbursement fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees" xlink:to="lab_HI17034499811M216H6K_nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_IncreaseDecreaseInStockSubscriptionLiability" xlink:label="loc_839743H4G541_nmus_IncreaseDecreaseInStockSubscriptionLiability"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_IncreaseDecreaseInStockSubscriptionLiability" xml:lang="en-US">Increase Decrease In Stock Subscription Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_nmus_IncreaseDecreaseInStockSubscriptionLiability" xml:lang="en-US">Stock subscription liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_nmus_IncreaseDecreaseInStockSubscriptionLiability" xml:lang="en-US">Represents amount of increase (decrease) in Increase Decrease in stock subscription liability.</label>
<label xlink:type="resource" xlink:label="lab_051965J6I763_nmus_IncreaseDecreaseInStockSubscriptionLiability" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US">Stock subscription liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_IncreaseDecreaseInStockSubscriptionLiability" xlink:to="lab_051965J6I763_nmus_IncreaseDecreaseInStockSubscriptionLiability"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_FG95812277699K094F4I_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xml:lang="en-US">Accrued expenses and other liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_HI17034499811M216H6K_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_839743H4G541_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided By (Used In) Operating Activities, Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Cash flows provided from operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_051965J6I763_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net cash used in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_051965J6I763_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_FG95812277699K094F4I_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Investing Activities, Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Cash flows from investing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_HI17034499811M216H6K_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_839743H4G541_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments To Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchases of equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_051965J6I763_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchases of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_051965J6I763_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_FG95812277699K094F4I_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided By (Used In) Investing Activities, Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US">Net cash provided by (used in) financing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US">Net cash used in investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="lab_HI17034499811M216H6K_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_839743H4G541_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Financing Activities, Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Cash flows from financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_051965J6I763_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_FG95812277699K094F4I_us-gaap_ProceedsFromIssuanceOfCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Additional raise of funds for operations and development of lead products</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Additional fund raised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from common stock issuance, net of $3,920 issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_HI17034499811M216H6K_us-gaap_ProceedsFromIssuanceOfCommonStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_839743H4G541_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xml:lang="en-US">Proceeds from Issuance of Preferred Stock and Preference Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xml:lang="en-US">Proceeds from Series A preferred stock issuance, net of $7,700 issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="lab_051965J6I763_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ProceedsFromSeriesBPreferredStockIssuance" xlink:label="loc_FG95812277699K094F4I_nmus_ProceedsFromSeriesBPreferredStockIssuance"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_ProceedsFromSeriesBPreferredStockIssuance" xml:lang="en-US">Proceeds From Series B Preferred Stock Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_nmus_ProceedsFromSeriesBPreferredStockIssuance" xml:lang="en-US">Proceeds from Series B preferred stock issuance, net of $411,661 issuance costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_ProceedsFromSeriesBPreferredStockIssuance" xml:lang="en-US">It Represent amount of Proceeds from Series B preferred stock issuance.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_ProceedsFromSeriesBPreferredStockIssuance" xlink:to="lab_HI17034499811M216H6K_nmus_ProceedsFromSeriesBPreferredStockIssuance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_839743H4G541_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided By (Used In) Financing Activities, Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US">Net cash provided by financing activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_051965J6I763_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US">Net cash provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="lab_051965J6I763_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_FG95812277699K094F4I_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Net increase in cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_HI17034499811M216H6K_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_839743H4G541_us-gaap_SupplementalCashFlowElementsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_SupplementalCashFlowElementsAbstract" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_SupplementalCashFlowElementsAbstract" xml:lang="en-US">Supplemental disclosures of cash-flow information:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_051965J6I763_us-gaap_SupplementalCashFlowElementsAbstract"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_CashPaidDuringPeriodForAbstract" xlink:label="loc_FG95812277699K094F4I_nmus_CashPaidDuringPeriodForAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_CashPaidDuringPeriodForAbstract" xml:lang="en-US">Cash Paid During Period For Abstract</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_nmus_CashPaidDuringPeriodForAbstract" xml:lang="en-US">Cash paid during the period for:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_CashPaidDuringPeriodForAbstract" xlink:to="lab_HI17034499811M216H6K_nmus_CashPaidDuringPeriodForAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_839743H4G541_us-gaap_InterestPaid"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_InterestPaid" xml:lang="en-US">Interest Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_InterestPaid" xml:lang="en-US">Interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_InterestPaid" xlink:to="lab_051965J6I763_us-gaap_InterestPaid"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_FG95812277699K094F4I_us-gaap_IncomeTaxesPaid"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Income Taxes Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_IncomeTaxesPaid" xlink:to="lab_HI17034499811M216H6K_us-gaap_IncomeTaxesPaid"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_839743H4G541_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xml:lang="en-US">Warrants issued to purchase shares of common stock for consulting services (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="lab_051965J6I763_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_NoncashValueOfWarrantsIssued" xlink:label="loc_FG95812277699K094F4I_nmus_NoncashValueOfWarrantsIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_NoncashValueOfWarrantsIssued" xml:lang="en-US">Noncash Value Of Warrants Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_nmus_NoncashValueOfWarrantsIssued" xml:lang="en-US">Value of warrants issued to purchase shares of common stock for consulting services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_NoncashValueOfWarrantsIssued" xml:lang="en-US">Represents noncash value of warrants issued to purchase shares of common stock for consulting services.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_NoncashValueOfWarrantsIssued" xlink:to="lab_HI17034499811M216H6K_nmus_NoncashValueOfWarrantsIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_839743H4G541_us-gaap_StockIssued1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_StockIssued1" xml:lang="en-US">Stock Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_StockIssued1" xml:lang="en-US">Value of common stock issued for consulting services</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_StockIssued1" xlink:to="lab_051965J6I763_us-gaap_StockIssued1"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_WarrantsIssuedInExchangeForExtinguishmentOfTradeAccountsPayable" xlink:label="loc_FG95812277699K094F4I_nmus_WarrantsIssuedInExchangeForExtinguishmentOfTradeAccountsPayable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_WarrantsIssuedInExchangeForExtinguishmentOfTradeAccountsPayable" xml:lang="en-US">Warrants Issued In Exchange For Extinguishment Of Trade Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_nmus_WarrantsIssuedInExchangeForExtinguishmentOfTradeAccountsPayable" xml:lang="en-US">Warrants issued in exchange for extinguishment of trade accounts payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_WarrantsIssuedInExchangeForExtinguishmentOfTradeAccountsPayable" xml:lang="en-US">Represents the number of warrants issued in exchange for extinguishment of trade accounts payable owed to vendor.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_WarrantsIssuedInExchangeForExtinguishmentOfTradeAccountsPayable" xlink:to="lab_HI17034499811M216H6K_nmus_WarrantsIssuedInExchangeForExtinguishmentOfTradeAccountsPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_839743H4G541_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">common stock par value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Warrant exercise price (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_051965J6I763_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ExtinguishmentOfTradeAccountsPayableOwedToVendor" xlink:label="loc_FG95812277699K094F4I_nmus_ExtinguishmentOfTradeAccountsPayableOwedToVendor"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_ExtinguishmentOfTradeAccountsPayableOwedToVendor" xml:lang="en-US">Extinguishment Of Trade Accounts Payable Owed To Vendor</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_nmus_ExtinguishmentOfTradeAccountsPayableOwedToVendor" xml:lang="en-US">Extinguishment Of Trade Accounts Payable Owed To Vendor</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_ExtinguishmentOfTradeAccountsPayableOwedToVendor" xml:lang="en-US">Represents the amount related to extinguishment of trade accounts payable owed to vendor.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_ExtinguishmentOfTradeAccountsPayableOwedToVendor" xlink:to="lab_HI17034499811M216H6K_nmus_ExtinguishmentOfTradeAccountsPayableOwedToVendor"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_839743H4G541_us-gaap_AccountingPoliciesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_051965J6I763_us-gaap_AccountingPoliciesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_FG95812277699K094F4I_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Nature of Operations, Business Activities and Summary of Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_HI17034499811M216H6K_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_UniversityOfMississippiAgreementsAbstract" xlink:label="loc_839743H4G541_nmus_UniversityOfMississippiAgreementsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_UniversityOfMississippiAgreementsAbstract" xml:lang="en-US">University Of Mississippi Agreements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_UniversityOfMississippiAgreementsAbstract" xlink:to="lab_051965J6I763_nmus_UniversityOfMississippiAgreementsAbstract"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_UniversityOfMississippiAgreementsTextBlock" xlink:label="loc_FG95812277699K094F4I_nmus_UniversityOfMississippiAgreementsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_UniversityOfMississippiAgreementsTextBlock" xml:lang="en-US">University Of Mississippi Agreements [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_nmus_UniversityOfMississippiAgreementsTextBlock" xml:lang="en-US">University of Mississippi ("UM") Agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_UniversityOfMississippiAgreementsTextBlock" xml:lang="en-US">Represents entire disclosure for University of Mississippi ("UM") Agreements.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_UniversityOfMississippiAgreementsTextBlock" xlink:to="lab_HI17034499811M216H6K_nmus_UniversityOfMississippiAgreementsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_839743H4G541_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_051965J6I763_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_FG95812277699K094F4I_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_HI17034499811M216H6K_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_839743H4G541_us-gaap_EquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_EquityAbstract" xlink:to="lab_051965J6I763_us-gaap_EquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_FG95812277699K094F4I_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Deficit and Redeemable Convertible Series B Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_HI17034499811M216H6K_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ProvisionForConversionOfPreferredStockAbstract" xlink:label="loc_839743H4G541_nmus_ProvisionForConversionOfPreferredStockAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_ProvisionForConversionOfPreferredStockAbstract" xml:lang="en-US">Provision For Conversion Of Preferred Stock [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_ProvisionForConversionOfPreferredStockAbstract" xlink:to="lab_051965J6I763_nmus_ProvisionForConversionOfPreferredStockAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="loc_FG95812277699K094F4I_us-gaap_PreferredStockTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_PreferredStockTextBlock" xml:lang="en-US">Preferred Stock [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_PreferredStockTextBlock" xml:lang="en-US">Provision for Conversion of Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_PreferredStockTextBlock" xlink:to="lab_HI17034499811M216H6K_us-gaap_PreferredStockTextBlock"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_SeriesBWarrantsAbstract" xlink:label="loc_839743H4G541_nmus_SeriesBWarrantsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_SeriesBWarrantsAbstract" xml:lang="en-US">Series B Warrants [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_SeriesBWarrantsAbstract" xlink:to="lab_051965J6I763_nmus_SeriesBWarrantsAbstract"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_SeriesBWarrantsTextBlock" xlink:label="loc_FG95812277699K094F4I_nmus_SeriesBWarrantsTextBlock_1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_SeriesBWarrantsTextBlock" xml:lang="en-US">Series B Warrants [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_nmus_SeriesBWarrantsTextBlock" xml:lang="en-US">Series B Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_SeriesBWarrantsTextBlock_1" xlink:to="lab_HI17034499811M216H6K_nmus_SeriesBWarrantsTextBlock"/><label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_SeriesBWarrantsTextBlock" xml:lang="en-US">The entire disclosure for series B warrants.</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_839743H4G541_us-gaap_IncomeTaxDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_051965J6I763_us-gaap_IncomeTaxDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_FG95812277699K094F4I_us-gaap_IncomeTaxDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_HI17034499811M216H6K_us-gaap_IncomeTaxDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_839743H4G541_us-gaap_SubsequentEventsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_SubsequentEventsAbstract" xlink:to="lab_051965J6I763_us-gaap_SubsequentEventsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_FG95812277699K094F4I_us-gaap_SubsequentEventsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_HI17034499811M216H6K_us-gaap_SubsequentEventsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_839743H4G541_us-gaap_UseOfEstimates"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_UseOfEstimates" xml:lang="en-US">Use Of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_UseOfEstimates" xlink:to="lab_051965J6I763_us-gaap_UseOfEstimates"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_LiquidityAndGoingConcernPolicyTextBlock" xlink:label="loc_FG95812277699K094F4I_nmus_LiquidityAndGoingConcernPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_LiquidityAndGoingConcernPolicyTextBlock" xml:lang="en-US">Liquidity And Going Concern [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_nmus_LiquidityAndGoingConcernPolicyTextBlock" xml:lang="en-US">Liquidity and Going Concern</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_LiquidityAndGoingConcernPolicyTextBlock" xml:lang="en-US">Entire disclosure of policy for liquidity and going concern.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_LiquidityAndGoingConcernPolicyTextBlock" xlink:to="lab_HI17034499811M216H6K_nmus_LiquidityAndGoingConcernPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_839743H4G541_us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_051965J6I763_us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_FG95812277699K094F4I_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US">Restricted Cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_HI17034499811M216H6K_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_839743H4G541_us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value Measurements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_051965J6I763_us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_FG95812277699K094F4I_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property and Equipment, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_HI17034499811M216H6K_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_839743H4G541_us-gaap_IncomeTaxPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_051965J6I763_us-gaap_IncomeTaxPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_FG95812277699K094F4I_us-gaap_RevenueRecognitionPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_HI17034499811M216H6K_us-gaap_RevenueRecognitionPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_839743H4G541_us-gaap_ResearchAndDevelopmentExpensePolicy"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_051965J6I763_us-gaap_ResearchAndDevelopmentExpensePolicy"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_FG95812277699K094F4I_us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_CompensationRelatedCostsPolicyTextBlock" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_CompensationRelatedCostsPolicyTextBlock" xml:lang="en-US">Stock-Based Compensation Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_HI17034499811M216H6K_us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock" xlink:label="loc_839743H4G541_nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock" xml:lang="en-US">Stock Based Compensation For Non Employees [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock" xml:lang="en-US">Stock-Based Compensation for Non-Employees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock" xml:lang="en-US">Represents policy for stock based compensation for Non Employees.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock" xlink:to="lab_051965J6I763_nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_FG95812277699K094F4I_us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_HI17034499811M216H6K_us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_839743H4G541_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US">Comprehensive Income (Loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_051965J6I763_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_FG95812277699K094F4I_us-gaap_EarningsPerSharePolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_HI17034499811M216H6K_us-gaap_EarningsPerSharePolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_839743H4G541_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xml:lang="en-US">Schedule of future minimum payments under non-cancelable operating leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="lab_051965J6I763_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_FG95812277699K094F4I_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Schedule of summary of stock option activity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_HI17034499811M216H6K_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_839743H4G541_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of weighted average assumptions for employee options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_051965J6I763_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_FG95812277699K094F4I_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xml:lang="en-US">schedule of Series B Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_HI17034499811M216H6K_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_839743H4G541_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Nature Of Operations Business Activities And Summary Of Significant Accounting Policies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Represents Tabular disclosure of nature of operations, business activities and Summary of significant accounting policies.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_051965J6I763_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_FG95812277699K094F4I_us-gaap_SubsequentEventTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_HI17034499811M216H6K_us-gaap_SubsequentEventTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_839743H4G541_us-gaap_SubsequentEventTypeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_051965J6I763_us-gaap_SubsequentEventTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_FG95812277699K094F4I_us-gaap_SubsequentEventMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_SubsequentEventMember" xlink:to="lab_HI17034499811M216H6K_us-gaap_SubsequentEventMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_839743H4G541_us-gaap_BusinessAcquisitionAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_BusinessAcquisitionAxis" xml:lang="en-US">Business Acquisition [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_051965J6I763_us-gaap_BusinessAcquisitionAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_FG95812277699K094F4I_us-gaap_BusinessAcquisitionAcquireeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_BusinessAcquisitionAcquireeDomain" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_HI17034499811M216H6K_us-gaap_BusinessAcquisitionAcquireeDomain"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_NemusAcquisitionCorpMember" xlink:label="loc_839743H4G541_nmus_NemusAcquisitionCorpMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_NemusAcquisitionCorpMember" xml:lang="en-US">Nemus Acquisition Corp [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_nmus_NemusAcquisitionCorpMember" xml:lang="en-US">Nemus Acquisition Corp</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_nmus_NemusAcquisitionCorpMember" xml:lang="en-US">Represents information of Nemus Acquisition Corp.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_NemusAcquisitionCorpMember" xlink:to="lab_051965J6I763_nmus_NemusAcquisitionCorpMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_FG95812277699K094F4I_dei_LegalEntityAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_dei_LegalEntityAxis" xlink:to="lab_HI17034499811M216H6K_dei_LegalEntityAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_839743H4G541_dei_EntityDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_dei_EntityDomain" xlink:to="lab_051965J6I763_dei_EntityDomain"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_NemusBioscienceIncMember" xlink:label="loc_FG95812277699K094F4I_nmus_NemusBioscienceIncMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_NemusBioscienceIncMember" xml:lang="en-US">Nemus Bioscience Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_nmus_NemusBioscienceIncMember" xml:lang="en-US">Nemus Bioscience, Inc</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_NemusBioscienceIncMember" xml:lang="en-US">Represents information regarding Nemus Bioscience, Inc.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_NemusBioscienceIncMember" xlink:to="lab_HI17034499811M216H6K_nmus_NemusBioscienceIncMember"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_839743H4G541_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Nature Of Operations Business Activities And Summary Of Significant Accounting Policies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Nature of Operations, Business Activities and Summary of Significant Accounting Policies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_051965J6I763_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_NumberOfSharesExchanged" xlink:label="loc_FG95812277699K094F4I_nmus_NumberOfSharesExchanged"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_NumberOfSharesExchanged" xml:lang="en-US">Number Of Shares Exchanged</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_nmus_NumberOfSharesExchanged" xml:lang="en-US">Number of shares exchanged</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_NumberOfSharesExchanged" xml:lang="en-US">This element represents number of shares exchanged.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_NumberOfSharesExchanged" xlink:to="lab_HI17034499811M216H6K_nmus_NumberOfSharesExchanged"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ConversionRate" xlink:label="loc_839743H4G541_nmus_ConversionRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_ConversionRate" xml:lang="en-US">Conversion Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_nmus_ConversionRate" xml:lang="en-US">Conversion rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_nmus_ConversionRate" xml:lang="en-US">Represents information regarding conversion rate.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_ConversionRate" xlink:to="lab_051965J6I763_nmus_ConversionRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_FG95812277699K094F4I_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Warrants to purchase shares of common stock issued and outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Number of shares called by warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_HI17034499811M216H6K_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:label="loc_839743H4G541_us-gaap_PropertyPlantAndEquipmentDepreciationMethods"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xml:lang="en-US">Property, Plant and Equipment, Depreciation Methods</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xml:lang="en-US">Property, plant and equipment, depreciation methods</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:to="lab_051965J6I763_us-gaap_PropertyPlantAndEquipmentDepreciationMethods"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_FG95812277699K094F4I_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Property plant and equipment estimated useful life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="lab_HI17034499811M216H6K_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_839743H4G541_us-gaap_NumberOfReportableSegments"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_NumberOfReportableSegments" xml:lang="en-US">Number of Reportable Segments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_NumberOfReportableSegments" xml:lang="en-US">Number of reportable segment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_NumberOfReportableSegments" xlink:to="lab_051965J6I763_us-gaap_NumberOfReportableSegments"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_UniversityOfMississippiAgreementsTable" xlink:label="loc_FG95812277699K094F4I_nmus_UniversityOfMississippiAgreementsTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_UniversityOfMississippiAgreementsTable" xml:lang="en-US">University Of Mississippi Agreements [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_UniversityOfMississippiAgreementsTable" xml:lang="en-US">Tabular disclosure of information regarding University of Mississippi agreements.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_UniversityOfMississippiAgreementsTable" xlink:to="lab_HI17034499811M216H6K_nmus_UniversityOfMississippiAgreementsTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_839743H4G541_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_051965J6I763_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_FG95812277699K094F4I_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_HI17034499811M216H6K_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_839743H4G541_us-gaap_IntellectualPropertyMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_IntellectualPropertyMember" xml:lang="en-US">Intellectual Property [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_IntellectualPropertyMember" xml:lang="en-US">Intellectual Property</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_IntellectualPropertyMember" xlink:to="lab_051965J6I763_us-gaap_IntellectualPropertyMember"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_AgreementAxis" xlink:label="loc_FG95812277699K094F4I_nmus_AgreementAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_AgreementAxis" xml:lang="en-US">Agreement [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_AgreementAxis" xml:lang="en-US">Represents information regarding agreements of an entity.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_AgreementAxis" xlink:to="lab_HI17034499811M216H6K_nmus_AgreementAxis"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_AgreementDomain" xlink:label="loc_839743H4G541_nmus_AgreementDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_AgreementDomain" xml:lang="en-US">Agreement [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_nmus_AgreementDomain" xml:lang="en-US">Represents information regarding agreement of an entity.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_AgreementDomain" xlink:to="lab_051965J6I763_nmus_AgreementDomain"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_UniversityOfMississippiAgreementsMember" xlink:label="loc_FG95812277699K094F4I_nmus_UniversityOfMississippiAgreementsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_UniversityOfMississippiAgreementsMember" xml:lang="en-US">University Of Mississippi Agreements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_nmus_UniversityOfMississippiAgreementsMember" xml:lang="en-US">University of Mississippi ("UM") Agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_UniversityOfMississippiAgreementsMember" xml:lang="en-US">Represents information regarding University of Mississippi ("UM") Agreements.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_UniversityOfMississippiAgreementsMember" xlink:to="lab_HI17034499811M216H6K_nmus_UniversityOfMississippiAgreementsMember"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_OptionAgreementMember" xlink:label="loc_839743H4G541_nmus_OptionAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_OptionAgreementMember" xml:lang="en-US">Option Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_nmus_OptionAgreementMember" xml:lang="en-US">Option Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_nmus_OptionAgreementMember" xml:lang="en-US">Represents information regarding option agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_OptionAgreementMember" xlink:to="lab_051965J6I763_nmus_OptionAgreementMember"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ResearchAgreementMember" xlink:label="loc_FG95812277699K094F4I_nmus_ResearchAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_ResearchAgreementMember" xml:lang="en-US">Research Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_nmus_ResearchAgreementMember" xml:lang="en-US">Research Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_ResearchAgreementMember" xml:lang="en-US">Represents information about research agreement with UM.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_ResearchAgreementMember" xlink:to="lab_HI17034499811M216H6K_nmus_ResearchAgreementMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_839743H4G541_us-gaap_BalanceSheetLocationAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_BalanceSheetLocationAxis" xml:lang="en-US">Balance Sheet Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_051965J6I763_us-gaap_BalanceSheetLocationAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_FG95812277699K094F4I_us-gaap_BalanceSheetLocationDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_BalanceSheetLocationDomain" xml:lang="en-US">Balance Sheet Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_HI17034499811M216H6K_us-gaap_BalanceSheetLocationDomain"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_AccruedLicenseAndPatentReimbursementFeesMember" xlink:label="loc_839743H4G541_nmus_AccruedLicenseAndPatentReimbursementFeesMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_AccruedLicenseAndPatentReimbursementFeesMember" xml:lang="en-US">Accrued License And Patent Reimbursement Fees [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_nmus_AccruedLicenseAndPatentReimbursementFeesMember" xml:lang="en-US">Accrued license and patent reimbursement fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_nmus_AccruedLicenseAndPatentReimbursementFeesMember" xml:lang="en-US">Represents primary financial statement caption encompassing Accrued license and patent reimbursement fees.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_AccruedLicenseAndPatentReimbursementFeesMember" xlink:to="lab_051965J6I763_nmus_AccruedLicenseAndPatentReimbursementFeesMember"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_MonthAndYearOfAgreementAxis" xlink:label="loc_FG95812277699K094F4I_nmus_MonthAndYearOfAgreementAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_MonthAndYearOfAgreementAxis" xml:lang="en-US">Month And Year Of Agreement [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_MonthAndYearOfAgreementAxis" xml:lang="en-US">Information regarding month and year of agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_MonthAndYearOfAgreementAxis" xlink:to="lab_HI17034499811M216H6K_nmus_MonthAndYearOfAgreementAxis"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_MonthAndYearOfAgreementDomain" xlink:label="loc_839743H4G541_nmus_MonthAndYearOfAgreementDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_MonthAndYearOfAgreementDomain" xml:lang="en-US">Month And Year Of Agreement [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_nmus_MonthAndYearOfAgreementDomain" xml:lang="en-US">Represents month and year of agreement in which company entered into.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_MonthAndYearOfAgreementDomain" xlink:to="lab_051965J6I763_nmus_MonthAndYearOfAgreementDomain"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_March2015Member" xlink:label="loc_FG95812277699K094F4I_nmus_March2015Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_March2015Member" xml:lang="en-US">March 2015 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_nmus_March2015Member" xml:lang="en-US">March 2015</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_March2015Member" xml:lang="en-US">Represents march 2015 as agreement month and year.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_March2015Member" xlink:to="lab_HI17034499811M216H6K_nmus_March2015Member"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_July2015Member" xlink:label="loc_839743H4G541_nmus_July2015Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_July2015Member" xml:lang="en-US">July 2015 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_nmus_July2015Member" xml:lang="en-US">July 2015</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_nmus_July2015Member" xml:lang="en-US">Represents July 2015 as agreement month and year.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_July2015Member" xlink:to="lab_051965J6I763_nmus_July2015Member"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_September2015Member" xlink:label="loc_FG95812277699K094F4I_nmus_September2015Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_September2015Member" xml:lang="en-US">September 2015 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_nmus_September2015Member" xml:lang="en-US">September 2015</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_September2015Member" xml:lang="en-US">Represents September 2015 as agreement month and year.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_September2015Member" xlink:to="lab_HI17034499811M216H6K_nmus_September2015Member"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_UniversityOfMississippiMember" xlink:label="loc_839743H4G541_nmus_UniversityOfMississippiMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_UniversityOfMississippiMember" xml:lang="en-US">University Of Mississippi [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_nmus_UniversityOfMississippiMember" xml:lang="en-US">University of Mississippi</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_nmus_UniversityOfMississippiMember" xml:lang="en-US">Represents information regarding university of mississippi.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_UniversityOfMississippiMember" xlink:to="lab_051965J6I763_nmus_UniversityOfMississippiMember"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_UniversityOfMississippiAgreementsLineItems" xlink:label="loc_FG95812277699K094F4I_nmus_UniversityOfMississippiAgreementsLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_UniversityOfMississippiAgreementsLineItems" xml:lang="en-US">University Of Mississippi Agreements [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_UniversityOfMississippiAgreementsLineItems" xml:lang="en-US">Line item represents information regarding University of Mississippi agreements.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_UniversityOfMississippiAgreementsLineItems" xlink:to="lab_HI17034499811M216H6K_nmus_UniversityOfMississippiAgreementsLineItems"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_TermOfMemorandumOfUnderstandingAgreement" xlink:label="loc_839743H4G541_nmus_TermOfMemorandumOfUnderstandingAgreement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_TermOfMemorandumOfUnderstandingAgreement" xml:lang="en-US">Term Of Memorandum Of Understanding Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_nmus_TermOfMemorandumOfUnderstandingAgreement" xml:lang="en-US">Term of memorandum of understanding agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_nmus_TermOfMemorandumOfUnderstandingAgreement" xml:lang="en-US">This element represents duration of an agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but not limited to, weeks in a year or quarter.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_TermOfMemorandumOfUnderstandingAgreement" xlink:to="lab_051965J6I763_nmus_TermOfMemorandumOfUnderstandingAgreement"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_NumberOfLicenseAgreements" xlink:label="loc_FG95812277699K094F4I_nmus_NumberOfLicenseAgreements"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_NumberOfLicenseAgreements" xml:lang="en-US">Number Of License Agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_nmus_NumberOfLicenseAgreements" xml:lang="en-US">Number of license agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_NumberOfLicenseAgreements" xml:lang="en-US">Represents number of license agreements.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_NumberOfLicenseAgreements" xlink:to="lab_HI17034499811M216H6K_nmus_NumberOfLicenseAgreements"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_NoticePeriodForTermination" xlink:label="loc_839743H4G541_nmus_NoticePeriodForTermination"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_NoticePeriodForTermination" xml:lang="en-US">Notice Period For Termination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_nmus_NoticePeriodForTermination" xml:lang="en-US">Notice period for termination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_nmus_NoticePeriodForTermination" xml:lang="en-US">This element represents written notice period for termination under agreement by either party.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_NoticePeriodForTermination" xlink:to="lab_051965J6I763_nmus_NoticePeriodForTermination"/>





<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ReimbursementOfSunkPatentExpenses" xlink:label="loc_839743H4G541_nmus_ReimbursementOfSunkPatentExpenses"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_ReimbursementOfSunkPatentExpenses" xml:lang="en-US">Reimbursement Of Sunk Patent Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_nmus_ReimbursementOfSunkPatentExpenses" xml:lang="en-US">Reimbursement of sunk patent expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_nmus_ReimbursementOfSunkPatentExpenses" xml:lang="en-US">This element represents amount of reimbursement of sunk patent expenses.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_ReimbursementOfSunkPatentExpenses" xlink:to="lab_051965J6I763_nmus_ReimbursementOfSunkPatentExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_FG95812277699K094F4I_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xml:lang="en-US">2015</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="lab_HI17034499811M216H6K_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_839743H4G541_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xml:lang="en-US">2016</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="lab_051965J6I763_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_FG95812277699K094F4I_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xml:lang="en-US">2017</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="lab_HI17034499811M216H6K_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_839743H4G541_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xml:lang="en-US">2018</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="lab_051965J6I763_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_FG95812277699K094F4I_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xml:lang="en-US">2019</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="lab_HI17034499811M216H6K_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_839743H4G541_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xml:lang="en-US">Thereafter</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="lab_051965J6I763_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_FG95812277699K094F4I_us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="lab_HI17034499811M216H6K_us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_839743H4G541_us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_051965J6I763_us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_IndependentContractorAgreementsMember" xlink:label="loc_FG95812277699K094F4I_nmus_IndependentContractorAgreementsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_IndependentContractorAgreementsMember" xml:lang="en-US">Independent Contractor Agreements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_nmus_IndependentContractorAgreementsMember" xml:lang="en-US">Independent Contractor Agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_IndependentContractorAgreementsMember" xml:lang="en-US">Represents information of independent contractor agreements of the entity.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_IndependentContractorAgreementsMember" xlink:to="lab_HI17034499811M216H6K_nmus_IndependentContractorAgreementsMember"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ContractorAxis" xlink:label="loc_839743H4G541_nmus_ContractorAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_ContractorAxis" xml:lang="en-US">Contractor [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_nmus_ContractorAxis" xml:lang="en-US">Represents information regarding contractor.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_ContractorAxis" xlink:to="lab_051965J6I763_nmus_ContractorAxis"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ContractorDomain" xlink:label="loc_FG95812277699K094F4I_nmus_ContractorDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_ContractorDomain" xml:lang="en-US">Contractor [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_ContractorDomain" xml:lang="en-US">Represents information regarding contractor.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_ContractorDomain" xlink:to="lab_HI17034499811M216H6K_nmus_ContractorDomain"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ContractorOneMember" xlink:label="loc_839743H4G541_nmus_ContractorOneMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_ContractorOneMember" xml:lang="en-US">Contractor One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_nmus_ContractorOneMember" xml:lang="en-US">Contractor One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_nmus_ContractorOneMember" xml:lang="en-US">Represents information of contractor one.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_ContractorOneMember" xlink:to="lab_051965J6I763_nmus_ContractorOneMember"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ContractorTwoMember" xlink:label="loc_FG95812277699K094F4I_nmus_ContractorTwoMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_ContractorTwoMember" xml:lang="en-US">Contractor Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_nmus_ContractorTwoMember" xml:lang="en-US">Contractor Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_ContractorTwoMember" xml:lang="en-US">Represents information of contractor two.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_ContractorTwoMember" xlink:to="lab_HI17034499811M216H6K_nmus_ContractorTwoMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_839743H4G541_us-gaap_OperatingLeasedAssetsLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_OperatingLeasedAssetsLineItems" xml:lang="en-US">Operating Leased Assets [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_051965J6I763_us-gaap_OperatingLeasedAssetsLineItems"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_PercentageOfContractorExpensesForTotalExpenditures" xlink:label="loc_FG95812277699K094F4I_nmus_PercentageOfContractorExpensesForTotalExpenditures"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_PercentageOfContractorExpensesForTotalExpenditures" xml:lang="en-US">Percentage Of Contractor Expenses For Total Expenditures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_nmus_PercentageOfContractorExpensesForTotalExpenditures" xml:lang="en-US">Percentage of contractor expenses for total expenditures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_PercentageOfContractorExpensesForTotalExpenditures" xml:lang="en-US">This element represents percentage of contract expenses of total expenditures.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_PercentageOfContractorExpensesForTotalExpenditures" xlink:to="lab_HI17034499811M216H6K_nmus_PercentageOfContractorExpensesForTotalExpenditures"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AreaOfLand" xlink:label="loc_839743H4G541_us-gaap_AreaOfLand"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_AreaOfLand" xml:lang="en-US">Area of Land</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_AreaOfLand" xml:lang="en-US">Area of corporate office headquarters</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_AreaOfLand" xml:lang="en-US">Area of land</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_AreaOfLand" xlink:to="lab_051965J6I763_us-gaap_AreaOfLand"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_FG95812277699K094F4I_us-gaap_OperatingLeasesRentExpenseNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_OperatingLeasesRentExpenseNet" xml:lang="en-US">Operating Leases, Rent Expense, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_OperatingLeasesRentExpenseNet" xml:lang="en-US">Rent expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_OperatingLeasesRentExpenseNet" xlink:to="lab_HI17034499811M216H6K_us-gaap_OperatingLeasesRentExpenseNet"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_IndependentContractorExpense" xlink:label="loc_839743H4G541_nmus_IndependentContractorExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_IndependentContractorExpense" xml:lang="en-US">Independent Contractor Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_nmus_IndependentContractorExpense" xml:lang="en-US">Independent contractor expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_nmus_IndependentContractorExpense" xml:lang="en-US">Represents independent contractor expense.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_IndependentContractorExpense" xlink:to="lab_051965J6I763_nmus_IndependentContractorExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_FG95812277699K094F4I_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_HI17034499811M216H6K_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_839743H4G541_us-gaap_AwardTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_AwardTypeAxis" xlink:to="lab_051965J6I763_us-gaap_AwardTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Equity Award [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_839743H4G541_us-gaap_EmployeeStockOptionMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock Option</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_EmployeeStockOptionMember" xlink:to="lab_051965J6I763_us-gaap_EmployeeStockOptionMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_FG95812277699K094F4I_us-gaap_PlanNameAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_PlanNameAxis" xlink:to="lab_HI17034499811M216H6K_us-gaap_PlanNameAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_839743H4G541_us-gaap_PlanNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_PlanNameDomain" xlink:to="lab_051965J6I763_us-gaap_PlanNameDomain"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_OmnibusIncentivePlan2014Member" xlink:label="loc_FG95812277699K094F4I_nmus_OmnibusIncentivePlan2014Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_OmnibusIncentivePlan2014Member" xml:lang="en-US">Omnibus Incentive Plan 2014 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_nmus_OmnibusIncentivePlan2014Member" xml:lang="en-US">Omnibus Incentive Plan 2014</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_OmnibusIncentivePlan2014Member" xml:lang="en-US">Represents information of Omnibus Incentive Plan 2014.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_OmnibusIncentivePlan2014Member" xlink:to="lab_HI17034499811M216H6K_nmus_OmnibusIncentivePlan2014Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_839743H4G541_us-gaap_RangeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_RangeAxis" xlink:to="lab_051965J6I763_us-gaap_RangeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_FG95812277699K094F4I_us-gaap_RangeMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_RangeMember" xml:lang="en-US">Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_RangeMember" xlink:to="lab_HI17034499811M216H6K_us-gaap_RangeMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_839743H4G541_us-gaap_MinimumMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_MinimumMember" xml:lang="en-US">Minimum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_MinimumMember" xlink:to="lab_051965J6I763_us-gaap_MinimumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_FG95812277699K094F4I_us-gaap_MaximumMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_MaximumMember" xml:lang="en-US">Maximum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_MaximumMember" xlink:to="lab_HI17034499811M216H6K_us-gaap_MaximumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_SharesAvailableForGrantOfOptionsRollForward" xlink:label="loc_FG95812277699K094F4I_nmus_SharesAvailableForGrantOfOptionsRollForward"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_SharesAvailableForGrantOfOptionsRollForward" xml:lang="en-US">Shares Available For Grant Of Options [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_nmus_SharesAvailableForGrantOfOptionsRollForward" xml:lang="en-US">Shares Available For Grant Of Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_SharesAvailableForGrantOfOptionsRollForward" xml:lang="en-US">A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_SharesAvailableForGrantOfOptionsRollForward" xlink:to="lab_HI17034499811M216H6K_nmus_SharesAvailableForGrantOfOptionsRollForward"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_SharesAvailableForGrantOfOptionsOpeningBalance" xlink:label="loc_839743H4G541_nmus_SharesAvailableForGrantOfOptionsOpeningBalance"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_SharesAvailableForGrantOfOptionsOpeningBalance" xml:lang="en-US">Shares Available For Grant Of Options Opening Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_nmus_SharesAvailableForGrantOfOptionsOpeningBalance" xml:lang="en-US">Balance at the beginning</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_nmus_SharesAvailableForGrantOfOptionsOpeningBalance" xml:lang="en-US">This element represents shares available for grant of options.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_SharesAvailableForGrantOfOptionsOpeningBalance" xlink:to="lab_051965J6I763_nmus_SharesAvailableForGrantOfOptionsOpeningBalance"/>





<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_SharesAvailableForGrantOptionsGranted" xlink:label="loc_839743H4G541_nmus_SharesAvailableForGrantOptionsGranted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_SharesAvailableForGrantOptionsGranted" xml:lang="en-US">Shares Available For Grant Options Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_nmus_SharesAvailableForGrantOptionsGranted" xml:lang="en-US">Options granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_nmus_SharesAvailableForGrantOptionsGranted" xml:lang="en-US">This element represents number of Options granted.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_051965J6I763_nmus_SharesAvailableForGrantOptionsGranted" xml:lang="en-US">Options granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_SharesAvailableForGrantOptionsGranted" xlink:to="lab_051965J6I763_nmus_SharesAvailableForGrantOptionsGranted"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_SharesAvailableForGrantOptionsExercised" xlink:label="loc_FG95812277699K094F4I_nmus_SharesAvailableForGrantOptionsExercised"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_SharesAvailableForGrantOptionsExercised" xml:lang="en-US">Shares Available For Grant Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_nmus_SharesAvailableForGrantOptionsExercised" xml:lang="en-US">Options exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_SharesAvailableForGrantOptionsExercised" xml:lang="en-US">This element represents number of Options exercised.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_SharesAvailableForGrantOptionsExercised" xlink:to="lab_HI17034499811M216H6K_nmus_SharesAvailableForGrantOptionsExercised"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_SharesAvailableForGrantOptionsCancelled" xlink:label="loc_839743H4G541_nmus_SharesAvailableForGrantOptionsCancelled"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_SharesAvailableForGrantOptionsCancelled" xml:lang="en-US">Shares Available For Grant Options Cancelled</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_nmus_SharesAvailableForGrantOptionsCancelled" xml:lang="en-US">Options cancelled</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_nmus_SharesAvailableForGrantOptionsCancelled" xml:lang="en-US">This element represents number of options cancelled.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_SharesAvailableForGrantOptionsCancelled" xlink:to="lab_051965J6I763_nmus_SharesAvailableForGrantOptionsCancelled"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_SharesAvailableForGrantOfOptionsEndingBalance" xlink:label="loc_FG95812277699K094F4I_nmus_SharesAvailableForGrantOfOptionsEndingBalance"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_SharesAvailableForGrantOfOptionsEndingBalance" xml:lang="en-US">Shares Available For Grant Of Options Ending Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_nmus_SharesAvailableForGrantOfOptionsEndingBalance" xml:lang="en-US">Balance at the ending</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_SharesAvailableForGrantOfOptionsEndingBalance" xml:lang="en-US">This element represents shares available for grant of options.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_SharesAvailableForGrantOfOptionsEndingBalance" xlink:to="lab_HI17034499811M216H6K_nmus_SharesAvailableForGrantOfOptionsEndingBalance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Number of Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Balance at the beginning</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Balance at the ending</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Options granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Aggregate number of shares granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Options to purchase shares common stock granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_FG95812277699K094F4I_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Options exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_HI17034499811M216H6K_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Options cancelled</label>
<label xlink:type="resource" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US">Options cancelled</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_OptionsOutstandingPricePerShareRollForward" xlink:label="loc_FG95812277699K094F4I_nmus_OptionsOutstandingPricePerShareRollForward"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_OptionsOutstandingPricePerShareRollForward" xml:lang="en-US">Options Outstanding Price Per Share [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_nmus_OptionsOutstandingPricePerShareRollForward" xml:lang="en-US">Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_OptionsOutstandingPricePerShareRollForward" xml:lang="en-US">A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_OptionsOutstandingPricePerShareRollForward" xlink:to="lab_HI17034499811M216H6K_nmus_OptionsOutstandingPricePerShareRollForward"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_OptionsOutstandingPricePerShareOpeningBalance" xlink:label="loc_839743H4G541_nmus_OptionsOutstandingPricePerShareOpeningBalance"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_OptionsOutstandingPricePerShareOpeningBalance" xml:lang="en-US">Options Outstanding Price Per Share Opening Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_nmus_OptionsOutstandingPricePerShareOpeningBalance" xml:lang="en-US">Balance at the beginning</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_nmus_OptionsOutstandingPricePerShareOpeningBalance" xml:lang="en-US">This element represents options outstanding price per share.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_OptionsOutstandingPricePerShareOpeningBalance" xlink:to="lab_051965J6I763_nmus_OptionsOutstandingPricePerShareOpeningBalance"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_OptionsOutstandingPricePerShareOptionsGranted" xlink:label="loc_FG95812277699K094F4I_nmus_OptionsOutstandingPricePerShareOptionsGranted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_OptionsOutstandingPricePerShareOptionsGranted" xml:lang="en-US">Options Outstanding Price Per Share Options Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_nmus_OptionsOutstandingPricePerShareOptionsGranted" xml:lang="en-US">Options granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_OptionsOutstandingPricePerShareOptionsGranted" xml:lang="en-US">This element represents options outstanding price per share.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_OptionsOutstandingPricePerShareOptionsGranted" xlink:to="lab_HI17034499811M216H6K_nmus_OptionsOutstandingPricePerShareOptionsGranted"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_OptionsOutstandingPricePerShareOptionsCancelled" xlink:label="loc_839743H4G541_nmus_OptionsOutstandingPricePerShareOptionsCancelled"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_OptionsOutstandingPricePerShareOptionsCancelled" xml:lang="en-US">Options Outstanding Price Per Share Options Cancelled</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_nmus_OptionsOutstandingPricePerShareOptionsCancelled" xml:lang="en-US">Options cancelled</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_nmus_OptionsOutstandingPricePerShareOptionsCancelled" xml:lang="en-US">This element represents options outstanding price per share.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_OptionsOutstandingPricePerShareOptionsCancelled" xlink:to="lab_051965J6I763_nmus_OptionsOutstandingPricePerShareOptionsCancelled"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_OptionsOutstandingPricePerShareEndingBalance" xlink:label="loc_FG95812277699K094F4I_nmus_OptionsOutstandingPricePerShareEndingBalance"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_OptionsOutstandingPricePerShareEndingBalance" xml:lang="en-US">Options Outstanding Price Per Share Ending Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_nmus_OptionsOutstandingPricePerShareEndingBalance" xml:lang="en-US">Balance at the ending</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_OptionsOutstandingPricePerShareEndingBalance" xml:lang="en-US">This element represents options outstanding price per share.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_OptionsOutstandingPricePerShareEndingBalance" xlink:to="lab_HI17034499811M216H6K_nmus_OptionsOutstandingPricePerShareEndingBalance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US">Weighted Average Exercise Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Balance at the beginning</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Balance at the ending</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Options granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Options cancelled</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Dividend yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Volatility factor</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk-free interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_FG95812277699K094F4I_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Contractual term of option outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected term (years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_HI17034499811M216H6K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted-average fair value of options granted during the periods</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_EquityTable" xlink:label="loc_FG95812277699K094F4I_nmus_EquityTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_EquityTable" xml:lang="en-US">Equity [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_EquityTable" xml:lang="en-US">Represents tabular disclosure of Equity.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_EquityTable" xlink:to="lab_HI17034499811M216H6K_nmus_EquityTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_839743H4G541_us-gaap_StatementEquityComponentsAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_051965J6I763_us-gaap_StatementEquityComponentsAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_FG95812277699K094F4I_us-gaap_EquityComponentDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_EquityComponentDomain" xlink:to="lab_HI17034499811M216H6K_us-gaap_EquityComponentDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_839743H4G541_us-gaap_WarrantMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_WarrantMember" xml:lang="en-US">Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_WarrantMember" xlink:to="lab_051965J6I763_us-gaap_WarrantMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_FG95812277699K094F4I_us-gaap_CommonStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_CommonStockMember" xlink:to="lab_HI17034499811M216H6K_us-gaap_CommonStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_839743H4G541_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_051965J6I763_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_FG95812277699K094F4I_us-gaap_RelatedPartyDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_RelatedPartyDomain" xlink:to="lab_HI17034499811M216H6K_us-gaap_RelatedPartyDomain"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_FoundersAndMemberOfBoardMember" xlink:label="loc_839743H4G541_nmus_FoundersAndMemberOfBoardMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_FoundersAndMemberOfBoardMember" xml:lang="en-US">Founders And Member Of Board [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_nmus_FoundersAndMemberOfBoardMember" xml:lang="en-US">Founders and Board member</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_nmus_FoundersAndMemberOfBoardMember" xml:lang="en-US">Represents information pertaining to founders and Member of board.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_FoundersAndMemberOfBoardMember" xlink:to="lab_051965J6I763_nmus_FoundersAndMemberOfBoardMember"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_StockPurchaseAgreementJune2014Member" xlink:label="loc_FG95812277699K094F4I_nmus_StockPurchaseAgreementJune2014Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_StockPurchaseAgreementJune2014Member" xml:lang="en-US">Stock Purchase Agreement June 2014 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_nmus_StockPurchaseAgreementJune2014Member" xml:lang="en-US">Stock Purchase Agreement June 2014</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_StockPurchaseAgreementJune2014Member" xml:lang="en-US">Represents information of Stock Purchase Agreement June 2014.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_StockPurchaseAgreementJune2014Member" xlink:to="lab_HI17034499811M216H6K_nmus_StockPurchaseAgreementJune2014Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_839743H4G541_us-gaap_IncomeStatementLocationAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_051965J6I763_us-gaap_IncomeStatementLocationAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_FG95812277699K094F4I_us-gaap_IncomeStatementLocationDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_HI17034499811M216H6K_us-gaap_IncomeStatementLocationDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_839743H4G541_us-gaap_GeneralAndAdministrativeExpenseMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and administrative expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_051965J6I763_us-gaap_GeneralAndAdministrativeExpenseMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_FG95812277699K094F4I_us-gaap_StatementClassOfStockAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_StatementClassOfStockAxis" xlink:to="lab_HI17034499811M216H6K_us-gaap_StatementClassOfStockAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_839743H4G541_us-gaap_ClassOfStockDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ClassOfStockDomain" xlink:to="lab_051965J6I763_us-gaap_ClassOfStockDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_FG95812277699K094F4I_us-gaap_SeriesAPreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series A Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series A preferred stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_HI17034499811M216H6K_us-gaap_SeriesAPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_839743H4G541_us-gaap_SeriesBPreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_SeriesBPreferredStockMember" xml:lang="en-US">Series B Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_SeriesBPreferredStockMember" xml:lang="en-US">Series B Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_SeriesBPreferredStockMember" xlink:to="lab_051965J6I763_us-gaap_SeriesBPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_EquityLineItems" xlink:label="loc_FG95812277699K094F4I_nmus_EquityLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_EquityLineItems" xml:lang="en-US">Equity [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_EquityLineItems" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_EquityLineItems" xlink:to="lab_HI17034499811M216H6K_nmus_EquityLineItems"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_TermOfWarrant" xlink:label="loc_839743H4G541_nmus_TermOfWarrant"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_TermOfWarrant" xml:lang="en-US">Term Of Warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_nmus_TermOfWarrant" xml:lang="en-US">Term of warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_nmus_TermOfWarrant" xml:lang="en-US">Represents term of warrant.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_TermOfWarrant" xlink:to="lab_051965J6I763_nmus_TermOfWarrant"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_NumberOfAdvisors" xlink:label="loc_FG95812277699K094F4I_nmus_NumberOfAdvisors"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_NumberOfAdvisors" xml:lang="en-US">Number Of Advisors</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_nmus_NumberOfAdvisors" xml:lang="en-US">Number of advisors</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_NumberOfAdvisors" xml:lang="en-US">Represents number of advisors.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_NumberOfAdvisors" xlink:to="lab_HI17034499811M216H6K_nmus_NumberOfAdvisors"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ValueOfCommonStockCalledByWarrants" xlink:label="loc_839743H4G541_nmus_ValueOfCommonStockCalledByWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_ValueOfCommonStockCalledByWarrants" xml:lang="en-US">Value Of Common Stock Called By Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_nmus_ValueOfCommonStockCalledByWarrants" xml:lang="en-US">Value of common stock called by warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_nmus_ValueOfCommonStockCalledByWarrants" xml:lang="en-US">Represents amount of common stock called by warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_ValueOfCommonStockCalledByWarrants" xlink:to="lab_051965J6I763_nmus_ValueOfCommonStockCalledByWarrants"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_AmortizationOfWarrantServiceCost" xlink:label="loc_FG95812277699K094F4I_nmus_AmortizationOfWarrantServiceCost"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_AmortizationOfWarrantServiceCost" xml:lang="en-US">Amortization Of Warrant Service Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_nmus_AmortizationOfWarrantServiceCost" xml:lang="en-US">Amortization of warrant service cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_AmortizationOfWarrantServiceCost" xml:lang="en-US">Represents amortization of warrant service cost.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_AmortizationOfWarrantServiceCost" xlink:to="lab_HI17034499811M216H6K_nmus_AmortizationOfWarrantServiceCost"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_839743H4G541_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Number of shares issued for services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Number of common shares issued to founders and one board member</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_051965J6I763_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ValueOfShareExchangedForServices" xlink:label="loc_FG95812277699K094F4I_nmus_ValueOfShareExchangedForServices"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_ValueOfShareExchangedForServices" xml:lang="en-US">Value Of Share Exchanged For Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_nmus_ValueOfShareExchangedForServices" xml:lang="en-US">Value of shares exchanged for services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_ValueOfShareExchangedForServices" xml:lang="en-US">Represents value of share exchanged for services.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_ValueOfShareExchangedForServices" xlink:to="lab_HI17034499811M216H6K_nmus_ValueOfShareExchangedForServices"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_839743H4G541_us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Fair market value of common stock issued recorded as prepaid expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Value of common shares issued to founders and one board member</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_051965J6I763_us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_FG95812277699K094F4I_us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Number of shares issued to group of private investors</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of common stock to investors in prior entity (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Number of common shares issued to individual investors</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_HI17034499811M216H6K_us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_839743H4G541_us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Value of shares issued to group of private investors</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Issuance of common stock to investors in prior entity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_051965J6I763_us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfServicesAmortization" xlink:label="loc_FG95812277699K094F4I_us-gaap_CostOfServicesAmortization"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_CostOfServicesAmortization" xml:lang="en-US">Cost of Services, Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_CostOfServicesAmortization" xml:lang="en-US">Amortization of cost of service</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_CostOfServicesAmortization" xlink:to="lab_HI17034499811M216H6K_us-gaap_CostOfServicesAmortization"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ValueOfWarrantsIssued" xlink:label="loc_839743H4G541_nmus_ValueOfWarrantsIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_ValueOfWarrantsIssued" xml:lang="en-US">Value of warrants issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_nmus_ValueOfWarrantsIssued" xml:lang="en-US">Additional fund raised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_nmus_ValueOfWarrantsIssued" xml:lang="en-US">Value of warrants issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_nmus_ValueOfWarrantsIssued" xml:lang="en-US">This element represents value of warrants issued.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_ValueOfWarrantsIssued" xlink:to="lab_051965J6I763_nmus_ValueOfWarrantsIssued"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_NumberOfInvestor" xlink:label="loc_FG95812277699K094F4I_nmus_NumberOfInvestor"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_NumberOfInvestor" xml:lang="en-US">Number Of Investor</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_nmus_NumberOfInvestor" xml:lang="en-US">Number of individual investor</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_NumberOfInvestor" xml:lang="en-US">This element represents number of individual investors.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_NumberOfInvestor" xlink:to="lab_HI17034499811M216H6K_nmus_NumberOfInvestor"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_MinimumIssuanceOfSharesInEquityFinancing" xlink:label="loc_839743H4G541_nmus_MinimumIssuanceOfSharesInEquityFinancing"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_MinimumIssuanceOfSharesInEquityFinancing" xml:lang="en-US">Minimum Issuance Of Shares In Equity Financing</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_nmus_MinimumIssuanceOfSharesInEquityFinancing" xml:lang="en-US">Minimum equity financing under down-round protection feature</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_nmus_MinimumIssuanceOfSharesInEquityFinancing" xml:lang="en-US">Represents value of minimum issuance of shares under equity financing.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_MinimumIssuanceOfSharesInEquityFinancing" xlink:to="lab_051965J6I763_nmus_MinimumIssuanceOfSharesInEquityFinancing"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_MaximumIssuancePricePerShareInEquityFinancing" xlink:label="loc_FG95812277699K094F4I_nmus_MaximumIssuancePricePerShareInEquityFinancing"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_MaximumIssuancePricePerShareInEquityFinancing" xml:lang="en-US">Maximum Issuance Price Per Share In Equity Financing</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_nmus_MaximumIssuancePricePerShareInEquityFinancing" xml:lang="en-US">Maximum common stock issuance price per share (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_MaximumIssuancePricePerShareInEquityFinancing" xml:lang="en-US">Represents maximum issuance price per share under equity financing.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_MaximumIssuancePricePerShareInEquityFinancing" xlink:to="lab_HI17034499811M216H6K_nmus_MaximumIssuancePricePerShareInEquityFinancing"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_DownRoundProvisionsExpirationTerms" xlink:label="loc_839743H4G541_nmus_DownRoundProvisionsExpirationTerms"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_DownRoundProvisionsExpirationTerms" xml:lang="en-US">Down Round Provisions Expiration Terms</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_nmus_DownRoundProvisionsExpirationTerms" xml:lang="en-US">Down round provisions expiration terms</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_nmus_DownRoundProvisionsExpirationTerms" xml:lang="en-US">Description of down round provisions expiration terms.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_DownRoundProvisionsExpirationTerms" xlink:to="lab_051965J6I763_nmus_DownRoundProvisionsExpirationTerms"/>




<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ConversionPrice" xlink:label="loc_839743H4G541_nmus_ConversionPrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_ConversionPrice" xml:lang="en-US">Conversion Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_nmus_ConversionPrice" xml:lang="en-US">Conversion price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_nmus_ConversionPrice" xml:lang="en-US">Represents conversion price per share.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_ConversionPrice" xlink:to="lab_051965J6I763_nmus_ConversionPrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_FG95812277699K094F4I_us-gaap_ConversionOfStockSharesConverted1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ConversionOfStockSharesConverted1" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ConversionOfStockSharesConverted1" xml:lang="en-US">Number of shares converted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ConversionOfStockSharesConverted1" xlink:to="lab_HI17034499811M216H6K_us-gaap_ConversionOfStockSharesConverted1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_839743H4G541_us-gaap_ConversionOfStockSharesIssued1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ConversionOfStockSharesIssued1" xml:lang="en-US">Conversion of Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_ConversionOfStockSharesIssued1" xml:lang="en-US">Number of shares issued in conversion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ConversionOfStockSharesIssued1" xlink:to="lab_051965J6I763_us-gaap_ConversionOfStockSharesIssued1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_FG95812277699K094F4I_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xml:lang="en-US">Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xml:lang="en-US">Proceeds received from the Series B financing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:to="lab_HI17034499811M216H6K_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockRedemptionTerms" xlink:label="loc_839743H4G541_us-gaap_PreferredStockRedemptionTerms"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_PreferredStockRedemptionTerms" xml:lang="en-US">Preferred Stock, Redemption Terms</label>
<label xlink:type="resource" xlink:label="lab_051965J6I763_us-gaap_PreferredStockRedemptionTerms" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Preferred stock, redemption terms</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_PreferredStockRedemptionTerms" xlink:to="lab_051965J6I763_us-gaap_PreferredStockRedemptionTerms"/>





<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_839743H4G541_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Number of shares reserved for future grants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_051965J6I763_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Number of shares available for future grant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_839743H4G541_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Expiry period of options granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_051965J6I763_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants" xlink:label="loc_FG95812277699K094F4I_nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants" xml:lang="en-US">Percentage Of Option Price At Least Of Fair Value On Date Of Grants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants" xml:lang="en-US">Percentage of option price at least of fair value on date of grants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants" xml:lang="en-US">This element represents percentage of option price least of fair value on the date of grants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants" xlink:to="lab_HI17034499811M216H6K_nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_CommonStockVotingPercentage" xlink:label="loc_839743H4G541_nmus_CommonStockVotingPercentage"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_CommonStockVotingPercentage" xml:lang="en-US">Common Stock Voting Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_nmus_CommonStockVotingPercentage" xml:lang="en-US">Voting percentage of common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_nmus_CommonStockVotingPercentage" xml:lang="en-US">Percentage of vesting of share-based compensation awards.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_CommonStockVotingPercentage" xlink:to="lab_051965J6I763_nmus_CommonStockVotingPercentage"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_PercentageOfFairValueOptionPriceAtDateOfGrants" xlink:label="loc_FG95812277699K094F4I_nmus_PercentageOfFairValueOptionPriceAtDateOfGrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_PercentageOfFairValueOptionPriceAtDateOfGrants" xml:lang="en-US">Percentage Of Fair Value Option Price At Date Of Grants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_nmus_PercentageOfFairValueOptionPriceAtDateOfGrants" xml:lang="en-US">Percentage of fair value option price at date of grants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_PercentageOfFairValueOptionPriceAtDateOfGrants" xml:lang="en-US">This element represents percentage of option price least of fair value on the date of grants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_PercentageOfFairValueOptionPriceAtDateOfGrants" xlink:to="lab_HI17034499811M216H6K_nmus_PercentageOfFairValueOptionPriceAtDateOfGrants"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_MaximumExercisablePeriodOfFairValueOfOption" xlink:label="loc_839743H4G541_nmus_MaximumExercisablePeriodOfFairValueOfOption"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_MaximumExercisablePeriodOfFairValueOfOption" xml:lang="en-US">Maximum Exercisable Period Of Fair Value Of Option</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_nmus_MaximumExercisablePeriodOfFairValueOfOption" xml:lang="en-US">Maximum exercisable period of fair value of option</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_nmus_MaximumExercisablePeriodOfFairValueOfOption" xml:lang="en-US">This element represents maximum exercisable period of fair value of option.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_MaximumExercisablePeriodOfFairValueOfOption" xlink:to="lab_051965J6I763_nmus_MaximumExercisablePeriodOfFairValueOfOption"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Vested period of shares granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Vested period of shares acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_839743H4G541_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Remaining contractual life of options outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_051965J6I763_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xml:lang="en-US">Aggregate intrinsic value of options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_839743H4G541_us-gaap_AllocatedShareBasedCompensationExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_051965J6I763_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Recognized stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_051965J6I763_us-gaap_AllocatedShareBasedCompensationExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_FG95812277699K094F4I_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Total amount of unrecognized compensation cost related to non-vested stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_HI17034499811M216H6K_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_839743H4G541_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Recognized period of non-vested stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_051965J6I763_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockTable" xlink:label="loc_FG95812277699K094F4I_us-gaap_ConversionOfStockTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ConversionOfStockTable" xml:lang="en-US">Conversion of Stock [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ConversionOfStockTable" xlink:to="lab_HI17034499811M216H6K_us-gaap_ConversionOfStockTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockLineItems" xlink:label="loc_839743H4G541_us-gaap_ConversionOfStockLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ConversionOfStockLineItems" xml:lang="en-US">Conversion of Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ConversionOfStockLineItems" xlink:to="lab_051965J6I763_us-gaap_ConversionOfStockLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_FG95812277699K094F4I_us-gaap_SharesIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_SharesIssued" xml:lang="en-US">Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_SharesIssued" xml:lang="en-US">Number of additional shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_SharesIssued" xlink:to="lab_HI17034499811M216H6K_us-gaap_SharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_839743H4G541_us-gaap_OperatingLossCarryforwards"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Net operating loss carry forwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_OperatingLossCarryforwards" xlink:to="lab_051965J6I763_us-gaap_OperatingLossCarryforwards"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_FG95812277699K094F4I_us-gaap_ClassOfWarrantOrRightTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ClassOfWarrantOrRightTable" xml:lang="en-US">Class of Warrant or Right [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_HI17034499811M216H6K_us-gaap_ClassOfWarrantOrRightTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_839743H4G541_us-gaap_ClassOfWarrantOrRightAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_051965J6I763_us-gaap_ClassOfWarrantOrRightAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_FG95812277699K094F4I_us-gaap_ClassOfWarrantOrRightDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_HI17034499811M216H6K_us-gaap_ClassOfWarrantOrRightDomain"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_SeriesBWarrantsMember" xlink:label="loc_839743H4G541_nmus_SeriesBWarrantsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_SeriesBWarrantsMember" xml:lang="en-US">Series B Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_nmus_SeriesBWarrantsMember" xml:lang="en-US">Series B Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_nmus_SeriesBWarrantsMember" xml:lang="en-US">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_SeriesBWarrantsMember" xlink:to="lab_051965J6I763_nmus_SeriesBWarrantsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_FG95812277699K094F4I_us-gaap_ClassOfWarrantOrRightLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ClassOfWarrantOrRightLineItems" xml:lang="en-US">Class of Warrant or Right [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_HI17034499811M216H6K_us-gaap_ClassOfWarrantOrRightLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_839743H4G541_us-gaap_FairValueAssumptionsExpectedDividendRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_FairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_FairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Dividend yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:to="lab_051965J6I763_us-gaap_FairValueAssumptionsExpectedDividendRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_FG95812277699K094F4I_us-gaap_FairValueAssumptionsExpectedVolatilityRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Volatility factor</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_HI17034499811M216H6K_us-gaap_FairValueAssumptionsExpectedVolatilityRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_839743H4G541_us-gaap_FairValueAssumptionsRiskFreeInterestRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk-free interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_051965J6I763_us-gaap_FairValueAssumptionsRiskFreeInterestRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_FG95812277699K094F4I_us-gaap_FairValueAssumptionsExpectedTerm"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Expected term (years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="lab_HI17034499811M216H6K_us-gaap_FairValueAssumptionsExpectedTerm"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted-average fair value of warrants granted during the periods</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_NumberOfWarrantsIssued" xlink:label="loc_FG95812277699K094F4I_nmus_NumberOfWarrantsIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_NumberOfWarrantsIssued" xml:lang="en-US">Number Of Warrants Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_nmus_NumberOfWarrantsIssued" xml:lang="en-US">Number of warrants issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_NumberOfWarrantsIssued" xml:lang="en-US">Represents number of warrants issued during period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_NumberOfWarrantsIssued" xlink:to="lab_HI17034499811M216H6K_nmus_NumberOfWarrantsIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed" xlink:label="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Method Used</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed" xml:lang="en-US">Method used for valuation of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed" xlink:to="lab_051965J6I763_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_FG95812277699K094F4I_us-gaap_SubsequentEventTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_SubsequentEventTable" xlink:to="lab_HI17034499811M216H6K_us-gaap_SubsequentEventTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_839743H4G541_us-gaap_RestrictedStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted stock awards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_RestrictedStockMember" xlink:to="lab_051965J6I763_us-gaap_RestrictedStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_FG95812277699K094F4I_us-gaap_TitleOfIndividualAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_TitleOfIndividualAxis" xlink:to="lab_HI17034499811M216H6K_us-gaap_TitleOfIndividualAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_839743H4G541_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Relationship to Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_051965J6I763_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ManagementAndBoardOfDirectorsMember" xlink:label="loc_FG95812277699K094F4I_nmus_ManagementAndBoardOfDirectorsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_nmus_ManagementAndBoardOfDirectorsMember" xml:lang="en-US">Management And Board Of Directors [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_nmus_ManagementAndBoardOfDirectorsMember" xml:lang="en-US">Senior management and board of directors</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HI17034499811M216H6K_nmus_ManagementAndBoardOfDirectorsMember" xml:lang="en-US">Person or persons controlling and directing the affairs of an entity and person serving on the board of directors.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_nmus_ManagementAndBoardOfDirectorsMember" xlink:to="lab_HI17034499811M216H6K_nmus_ManagementAndBoardOfDirectorsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_839743H4G541_us-gaap_SubsequentEventLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_us-gaap_SubsequentEventLineItems" xlink:to="lab_051965J6I763_us-gaap_SubsequentEventLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Number of shares granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FG95812277699K094F4I_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_HI17034499811M216H6K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_FairMarketValueOfSharesGranted" xlink:label="loc_839743H4G541_nmus_FairMarketValueOfSharesGranted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_051965J6I763_nmus_FairMarketValueOfSharesGranted" xml:lang="en-US">Fair Market Value Of Shares Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_051965J6I763_nmus_FairMarketValueOfSharesGranted" xml:lang="en-US">Fair market value of shares granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_051965J6I763_nmus_FairMarketValueOfSharesGranted" xml:lang="en-US">Fair value of shares granted.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_839743H4G541_nmus_FairMarketValueOfSharesGranted" xlink:to="lab_051965J6I763_nmus_FairMarketValueOfSharesGranted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare"/>
<label xlink:type="resource" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Shares Issued, Price Per Share</label>
<label xlink:type="resource" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Shares issued, price per share (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare"/>





<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" xlink:label="loc_nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants_1"/>
<label xlink:type="resource" xlink:label="lab_nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Stock And Warrants Issued During Period Shares Preferred Stock And Warrants</label>
<label xlink:type="resource" xlink:label="lab_nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Number of preferred stock and warrants sold</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants_1" xlink:to="lab_nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants"/><label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" xml:lang="en-US">Number of preferred stock and warrants for common stock issued.</label>

<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_StockIssuanceCosts" xlink:label="loc_nmus_StockIssuanceCosts_1"/>
<label xlink:type="resource" xlink:label="lab_nmus_StockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Stock Issuance Costs</label>
<label xlink:type="resource" xlink:label="lab_nmus_StockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US">Issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nmus_StockIssuanceCosts_1" xlink:to="lab_nmus_StockIssuanceCosts"/><label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nmus_StockIssuanceCosts" xml:lang="en-US">Represents amount of stock issuance costs.</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue"/>
<label xlink:type="resource" xlink:label="lab_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Preferred Stock, Liquidation Preference, Value</label>
<label xlink:type="resource" xlink:label="lab_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US">Liquidation preference value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:to="lab_us-gaap_PreferredStockLiquidationPreferenceValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts"/>
<label xlink:type="resource" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Payments of Stock Issuance Costs</label>
<label xlink:type="resource" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US">Proceeds from common stock issuance, net of $3,920 issuance costs</label>
<label xlink:type="resource" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Common stock issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_SeriesAPreferredStockIssuanceCosts" xlink:label="loc_nmus_SeriesAPreferredStockIssuanceCosts_1"/>
<label xlink:type="resource" xlink:label="lab_nmus_SeriesAPreferredStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Series A Preferred Stock Issuance Costs</label>
<label xlink:type="resource" xlink:label="lab_nmus_SeriesAPreferredStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US">Series A preferred stock issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nmus_SeriesAPreferredStockIssuanceCosts_1" xlink:to="lab_nmus_SeriesAPreferredStockIssuanceCosts"/><label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nmus_SeriesAPreferredStockIssuanceCosts" xml:lang="en-US">This element represents amount of Series A preferred stock issuance costs.</label>

<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_SeriesBPreferredStockIssuanceCosts" xlink:label="loc_nmus_SeriesBPreferredStockIssuanceCosts_1"/>
<label xlink:type="resource" xlink:label="lab_nmus_SeriesBPreferredStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Series B Preferred Stock Issuance Costs</label>
<label xlink:type="resource" xlink:label="lab_nmus_SeriesBPreferredStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US">Series B preferred stock issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nmus_SeriesBPreferredStockIssuanceCosts_1" xlink:to="lab_nmus_SeriesBPreferredStockIssuanceCosts"/><label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_nmus_SeriesBPreferredStockIssuanceCosts" xml:lang="en-US">This element represents amount of Series B preferred stock issuance costs.</label>




<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
<label xlink:type="resource" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
</labelLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>nmus-20150930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.4.0.0 on Friday, November 13, 2015 12:10:53 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="nmus-20150930.xsd#DocumentAndEntityInformation" roleURI="http://www.nemusbioscience.com/role/DocumentAndEntityInformation"/>
<roleRef xlink:type="simple" xlink:href="nmus-20150930.xsd#ConsolidatedBalanceSheets" roleURI="http://www.nemusbioscience.com/role/ConsolidatedBalanceSheets"/>
<roleRef xlink:type="simple" xlink:href="nmus-20150930.xsd#Consolidatedbalancesheetsparentheticals" roleURI="http://www.nemusbioscience.com/role/Consolidatedbalancesheetsparentheticals"/>
<roleRef xlink:type="simple" xlink:href="nmus-20150930.xsd#ConsolidatedStatementsOfOperationsUnaudited" roleURI="http://www.nemusbioscience.com/role/ConsolidatedStatementsOfOperationsUnaudited"/>
<roleRef xlink:type="simple" xlink:href="nmus-20150930.xsd#ConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.nemusbioscience.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"/>
<roleRef xlink:type="simple" xlink:href="nmus-20150930.xsd#ConsolidatedStatementsOfCashFlowsUnauditedParentheticals" roleURI="http://www.nemusbioscience.com/role/ConsolidatedStatementsOfCashFlowsUnauditedParentheticals"/>
<roleRef xlink:type="simple" xlink:href="nmus-20150930.xsd#NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPolicies"/>
<roleRef xlink:type="simple" xlink:href="nmus-20150930.xsd#UniversityOfMississippiUmAgreements" roleURI="http://www.nemusbioscience.com/role/UniversityOfMississippiUmAgreements"/>
<roleRef xlink:type="simple" xlink:href="nmus-20150930.xsd#COMMITMENTSANDCONTINGENCIES" roleURI="http://www.nemusbioscience.com/role/COMMITMENTSANDCONTINGENCIES"/>
<roleRef xlink:type="simple" roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemption" xlink:href="nmus-20150930.xsd#StockholdersDeficitAndPreferredStockSubjectToRedemption"/>
<roleRef xlink:type="simple" roleURI="http://www.nemusbioscience.com/role/ProvisionForConversionOfPreferredStock" xlink:href="nmus-20150930.xsd#ProvisionForConversionOfPreferredStock"/>
<roleRef xlink:type="simple" xlink:href="nmus-20150930.xsd#SeriesBWarrants" roleURI="http://www.nemusbioscience.com/role/SeriesBWarrants"/>
<roleRef xlink:type="simple" xlink:href="nmus-20150930.xsd#IncomeTaxes" roleURI="http://www.nemusbioscience.com/role/IncomeTaxes"/>
<roleRef xlink:type="simple" xlink:href="nmus-20150930.xsd#SubsequentEvents" roleURI="http://www.nemusbioscience.com/role/SubsequentEvents"/>
<roleRef xlink:type="simple" xlink:href="nmus-20150930.xsd#NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesPolicies"/>
<roleRef xlink:type="simple" xlink:href="nmus-20150930.xsd#CommitmentsandContingenciesTables" roleURI="http://www.nemusbioscience.com/role/CommitmentsandContingenciesTables"/>
<roleRef xlink:type="simple" roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionTables" xlink:href="nmus-20150930.xsd#StockholdersDeficitAndPreferredStockSubjectToRedemptionTables"/>
<roleRef xlink:type="simple" xlink:href="nmus-20150930.xsd#SeriesBWarrantsTables" roleURI="http://www.nemusbioscience.com/role/SeriesBWarrantsTables"/>
<roleRef xlink:type="simple" xlink:href="nmus-20150930.xsd#NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesDetailTextuals" roleURI="http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="nmus-20150930.xsd#UniversityOfMississippiUmAgreementsDetailTextuals" roleURI="http://www.nemusbioscience.com/role/UniversityOfMississippiUmAgreementsDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="nmus-20150930.xsd#CommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsDetails" roleURI="http://www.nemusbioscience.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsDetails"/>
<roleRef xlink:type="simple" xlink:href="nmus-20150930.xsd#CommitmentsAndContingenciesDetailTextuals" roleURI="http://www.nemusbioscience.com/role/CommitmentsAndContingenciesDetailTextuals"/>
<roleRef xlink:type="simple" roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionSummaryOfOptionActivityUnder2014PlanDetails" xlink:href="nmus-20150930.xsd#StockholdersDeficitAndPreferredStockSubjectToRedemptionSummaryOfOptionActivityUnder2014PlanDetails"/>
<roleRef xlink:type="simple" roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionSummaryOfWeightedAverageAssumptionsForEmployeeOptionDetails1" xlink:href="nmus-20150930.xsd#StockholdersDeficitAndPreferredStockSubjectToRedemptionSummaryOfWeightedAverageAssumptionsForEmployeeOptionDetails1"/>
<roleRef xlink:type="simple" roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals" xlink:href="nmus-20150930.xsd#StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals"/>
<roleRef xlink:type="simple" roleURI="http://www.nemusbioscience.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals1" xlink:href="nmus-20150930.xsd#StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals1"/>
<roleRef xlink:type="simple" roleURI="http://www.nemusbioscience.com/role/ProvisionForConversionOfPreferredStockDetailTextuals" xlink:href="nmus-20150930.xsd#ProvisionForConversionOfPreferredStockDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="nmus-20150930.xsd#IncomeTaxesDetailTextuals" roleURI="http://www.nemusbioscience.com/role/IncomeTaxesDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="nmus-20150930.xsd#SeriesBWarrantsDetails" roleURI="http://www.nemusbioscience.com/role/SeriesBWarrantsDetails"/>
<roleRef xlink:type="simple" xlink:href="nmus-20150930.xsd#SeriesBWarrantsDetailTextuals" roleURI="http://www.nemusbioscience.com/role/SeriesBWarrantsDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="nmus-20150930.xsd#SubsequentEventsDetailTextuals" roleURI="http://www.nemusbioscience.com/role/SubsequentEventsDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/DocumentAndEntityInformation">
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_DocumentAndEntityInformationAbstract" xlink:label="loc_nmus_DocumentAndEntityInformationAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityRegistrantName_1" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCentralIndexKey_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_TradingSymbol_3" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_4" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityFilerCategory_5" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_6" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentType_7" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentPeriodEndDate_8" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_AmendmentFlag_9" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalYearFocus_10" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_11" order="100" use="optional"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_AssetsAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_OtherAssetsCurrent_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_AssetsCurrent_7" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaap_OtherAssetsAbstract_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_OtherAssetsAbstract_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_DepositsAndOtherAssets" xlink:label="loc_nmus_DepositsAndOtherAssets_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_9" xlink:to="loc_nmus_DepositsAndOtherAssets_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_9" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_Assets_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14" xlink:to="loc_us-gaap_AccountsPayableCurrent_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14" xlink:to="loc_us-gaap_AccruedSalariesCurrent_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_AccruedLicenseAndPatentReimbursementFees" xlink:label="loc_nmus_AccruedLicenseAndPatentReimbursementFees_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14" xlink:to="loc_nmus_AccruedLicenseAndPatentReimbursementFees_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_18" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_StockSubscriptionLiability" xlink:label="loc_nmus_StockSubscriptionLiability_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14" xlink:to="loc_nmus_StockSubscriptionLiability_19" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ProvisionForConversionOfPreferredStock" xlink:label="loc_nmus_ProvisionForConversionOfPreferredStock_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14" xlink:to="loc_nmus_ProvisionForConversionOfPreferredStock_20" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_21" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14" xlink:to="loc_us-gaap_LiabilitiesCurrent_22" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_23" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_23" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_24" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_23" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_25" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_23" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_26" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_Liabilities_27" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_CommitmentsAndContingencies_28" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_PreferredStockValue_29" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_StockholdersEquityAbstract_30" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_30" xlink:to="loc_us-gaap_CommonStockValue_31" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_30" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_32" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_30" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_33" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_30" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_34" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_30" xlink:to="loc_us-gaap_StockholdersEquity_35" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_36" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/Consolidatedbalancesheetsparentheticals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_3" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_4" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_7" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_StockIssuanceCosts" xlink:label="loc_nmus_StockIssuanceCosts"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_nmus_StockIssuanceCosts" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockLiquidationPreferenceValue" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/ConsolidatedStatementsOfOperationsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_OperatingExpenses_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingIncomeLoss_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_GainLossOnConversionRightPreferredStock" xlink:label="loc_nmus_GainLossOnConversionRightPreferredStock_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6" xlink:to="loc_nmus_GainLossOnConversionRightPreferredStock_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_10" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_11" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_12" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/ConsolidatedStatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_Depreciation_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_ShareBasedCompensation_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_GainLossOnConversionRightPreferredStock" xlink:label="loc_nmus_GainLossOnConversionRightPreferredStock_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_nmus_GainLossOnConversionRightPreferredStock_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_8" xlink:to="loc_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_8" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_8" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="loc_nmus_IncreaseDecreaseInDepositsAndOtherAssets_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_8" xlink:to="loc_nmus_IncreaseDecreaseInDepositsAndOtherAssets_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_13" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_8" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_14" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees" xlink:label="loc_nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_8" xlink:to="loc_nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees_15" order="60" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_IncreaseDecreaseInStockSubscriptionLiability" xlink:label="loc_nmus_IncreaseDecreaseInStockSubscriptionLiability_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_8" xlink:to="loc_nmus_IncreaseDecreaseInStockSubscriptionLiability_16" order="70" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_17" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_18" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_19" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_19" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_21" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_22" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_22" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_23" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_22" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_24" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ProceedsFromSeriesBPreferredStockIssuance" xlink:label="loc_nmus_ProceedsFromSeriesBPreferredStockIssuance_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_22" xlink:to="loc_nmus_ProceedsFromSeriesBPreferredStockIssuance_25" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_22" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_26" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_27" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_28" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_29" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_30" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_CashPaidDuringPeriodForAbstract" xlink:label="loc_nmus_CashPaidDuringPeriodForAbstract_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_30" xlink:to="loc_nmus_CashPaidDuringPeriodForAbstract_31" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_CashPaidDuringPeriodForAbstract_31" xlink:to="loc_us-gaap_InterestPaid_32" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_CashPaidDuringPeriodForAbstract_31" xlink:to="loc_us-gaap_IncomeTaxesPaid_33" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/ConsolidatedStatementsOfCashFlowsUnauditedParentheticals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_NoncashValueOfWarrantsIssued" xlink:label="loc_nmus_NoncashValueOfWarrantsIssued_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_nmus_NoncashValueOfWarrantsIssued_2" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_StockIssued1_3" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_WarrantsIssuedInExchangeForExtinguishmentOfTradeAccountsPayable" xlink:label="loc_nmus_WarrantsIssuedInExchangeForExtinguishmentOfTradeAccountsPayable_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_nmus_WarrantsIssuedInExchangeForExtinguishmentOfTradeAccountsPayable_4" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ExtinguishmentOfTradeAccountsPayableOwedToVendor" xlink:label="loc_nmus_ExtinguishmentOfTradeAccountsPayableOwedToVendor_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_nmus_ExtinguishmentOfTradeAccountsPayableOwedToVendor_6" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_SeriesAPreferredStockIssuanceCosts" xlink:label="loc_nmus_SeriesAPreferredStockIssuanceCosts"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_nmus_SeriesAPreferredStockIssuanceCosts" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_SeriesBPreferredStockIssuanceCosts" xlink:label="loc_nmus_SeriesBPreferredStockIssuanceCosts"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_nmus_SeriesBPreferredStockIssuanceCosts" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/UniversityOfMississippiUmAgreements">
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_UniversityOfMississippiAgreementsAbstract" xlink:label="loc_nmus_UniversityOfMississippiAgreementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_UniversityOfMississippiAgreementsTextBlock" xlink:label="loc_nmus_UniversityOfMississippiAgreementsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_UniversityOfMississippiAgreementsAbstract_0" xlink:to="loc_nmus_UniversityOfMississippiAgreementsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/COMMITMENTSANDCONTINGENCIES">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemption">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/ProvisionForConversionOfPreferredStock">
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ProvisionForConversionOfPreferredStockAbstract" xlink:label="loc_nmus_ProvisionForConversionOfPreferredStockAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="loc_us-gaap_PreferredStockTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_ProvisionForConversionOfPreferredStockAbstract_0" xlink:to="loc_us-gaap_PreferredStockTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/SeriesBWarrants">
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_SeriesBWarrantsAbstract" xlink:label="loc_nmus_SeriesBWarrantsAbstract_0"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_SeriesBWarrantsTextBlock" xlink:label="loc_nmus_SeriesBWarrantsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_SeriesBWarrantsAbstract_0" xlink:to="loc_nmus_SeriesBWarrantsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_UseOfEstimates_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_LiquidityAndGoingConcernPolicyTextBlock" xlink:label="loc_nmus_LiquidityAndGoingConcernPolicyTextBlock_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_nmus_LiquidityAndGoingConcernPolicyTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock" xlink:label="loc_nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_13" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_14" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/CommitmentsandContingenciesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/SeriesBWarrantsTables">
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_SeriesBWarrantsAbstract" xlink:label="loc_nmus_SeriesBWarrantsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_SeriesBWarrantsAbstract_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>






<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_NemusAcquisitionCorpMember" xlink:label="loc_nmus_NemusAcquisitionCorpMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6" xlink:to="loc_nmus_NemusAcquisitionCorpMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_dei_LegalEntityAxis_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_8" xlink:to="loc_dei_EntityDomain_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_NemusBioscienceIncMember" xlink:label="loc_nmus_NemusBioscienceIncMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_9" xlink:to="loc_nmus_NemusBioscienceIncMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_NumberOfSharesExchanged" xlink:label="loc_nmus_NumberOfSharesExchanged_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_11" xlink:to="loc_nmus_NumberOfSharesExchanged_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_11" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_11" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_11" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_15" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ConversionRate" xlink:label="loc_nmus_ConversionRate_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_11" xlink:to="loc_nmus_ConversionRate_16" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>






<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_20" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDepreciationMethods_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDepreciationMethods_21" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_22" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_11" xlink:to="loc_us-gaap_NumberOfReportableSegments_23" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/UniversityOfMississippiUmAgreementsDetailTextuals">
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_UniversityOfMississippiAgreementsAbstract" xlink:label="loc_nmus_UniversityOfMississippiAgreementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_UniversityOfMississippiAgreementsTable" xlink:label="loc_nmus_UniversityOfMississippiAgreementsTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_UniversityOfMississippiAgreementsAbstract_0" xlink:to="loc_nmus_UniversityOfMississippiAgreementsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3" xlink:to="loc_us-gaap_IntellectualPropertyMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_AgreementAxis" xlink:label="loc_nmus_AgreementAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_nmus_AgreementAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_AgreementDomain" xlink:label="loc_nmus_AgreementDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_AgreementAxis_5" xlink:to="loc_nmus_AgreementDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_UniversityOfMississippiAgreementsMember" xlink:label="loc_nmus_UniversityOfMississippiAgreementsMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_AgreementDomain_6" xlink:to="loc_nmus_UniversityOfMississippiAgreementsMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_OptionAgreementMember" xlink:label="loc_nmus_OptionAgreementMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_AgreementDomain_6" xlink:to="loc_nmus_OptionAgreementMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ResearchAgreementMember" xlink:label="loc_nmus_ResearchAgreementMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_AgreementDomain_6" xlink:to="loc_nmus_ResearchAgreementMember_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_10" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_AccruedLicenseAndPatentReimbursementFeesMember" xlink:label="loc_nmus_AccruedLicenseAndPatentReimbursementFeesMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_11" xlink:to="loc_nmus_AccruedLicenseAndPatentReimbursementFeesMember_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_MonthAndYearOfAgreementAxis" xlink:label="loc_nmus_MonthAndYearOfAgreementAxis_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_nmus_MonthAndYearOfAgreementAxis_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_MonthAndYearOfAgreementDomain" xlink:label="loc_nmus_MonthAndYearOfAgreementDomain_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_MonthAndYearOfAgreementAxis_13" xlink:to="loc_nmus_MonthAndYearOfAgreementDomain_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_March2015Member" xlink:label="loc_nmus_March2015Member_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_MonthAndYearOfAgreementDomain_14" xlink:to="loc_nmus_March2015Member_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_July2015Member" xlink:label="loc_nmus_July2015Member_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_MonthAndYearOfAgreementDomain_14" xlink:to="loc_nmus_July2015Member_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_September2015Member" xlink:label="loc_nmus_September2015Member_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_MonthAndYearOfAgreementDomain_14" xlink:to="loc_nmus_September2015Member_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_dei_LegalEntityAxis_18" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_18" xlink:to="loc_dei_EntityDomain_19" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_UniversityOfMississippiMember" xlink:label="loc_nmus_UniversityOfMississippiMember_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_19" xlink:to="loc_nmus_UniversityOfMississippiMember_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_UniversityOfMississippiAgreementsLineItems" xlink:label="loc_nmus_UniversityOfMississippiAgreementsLineItems_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_nmus_UniversityOfMississippiAgreementsLineItems_21" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_TermOfMemorandumOfUnderstandingAgreement" xlink:label="loc_nmus_TermOfMemorandumOfUnderstandingAgreement_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_UniversityOfMississippiAgreementsLineItems_21" xlink:to="loc_nmus_TermOfMemorandumOfUnderstandingAgreement_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_NumberOfLicenseAgreements" xlink:label="loc_nmus_NumberOfLicenseAgreements_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_UniversityOfMississippiAgreementsLineItems_21" xlink:to="loc_nmus_NumberOfLicenseAgreements_23" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_NoticePeriodForTermination" xlink:label="loc_nmus_NoticePeriodForTermination_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_UniversityOfMississippiAgreementsLineItems_21" xlink:to="loc_nmus_NoticePeriodForTermination_24" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>


<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ReimbursementOfSunkPatentExpenses" xlink:label="loc_nmus_ReimbursementOfSunkPatentExpenses_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_UniversityOfMississippiAgreementsLineItems_21" xlink:to="loc_nmus_ReimbursementOfSunkPatentExpenses_26" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_UniversityOfMississippiAgreementsLineItems_21" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_27" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/CommitmentsAndContingenciesDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_AgreementAxis" xlink:label="loc_nmus_AgreementAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" xlink:to="loc_nmus_AgreementAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_AgreementDomain" xlink:label="loc_nmus_AgreementDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_AgreementAxis_2" xlink:to="loc_nmus_AgreementDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_IndependentContractorAgreementsMember" xlink:label="loc_nmus_IndependentContractorAgreementsMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_AgreementDomain_3" xlink:to="loc_nmus_IndependentContractorAgreementsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ContractorAxis" xlink:label="loc_nmus_ContractorAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" xlink:to="loc_nmus_ContractorAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ContractorDomain" xlink:label="loc_nmus_ContractorDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_ContractorAxis_5" xlink:to="loc_nmus_ContractorDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ContractorOneMember" xlink:label="loc_nmus_ContractorOneMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_ContractorDomain_6" xlink:to="loc_nmus_ContractorOneMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ContractorTwoMember" xlink:label="loc_nmus_ContractorTwoMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_ContractorDomain_6" xlink:to="loc_nmus_ContractorTwoMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_PercentageOfContractorExpensesForTotalExpenditures" xlink:label="loc_nmus_PercentageOfContractorExpensesForTotalExpenditures_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_9" xlink:to="loc_nmus_PercentageOfContractorExpensesForTotalExpenditures_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaap_AreaOfLand_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_9" xlink:to="loc_us-gaap_AreaOfLand_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_9" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_IndependentContractorExpense" xlink:label="loc_nmus_IndependentContractorExpense_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_9" xlink:to="loc_nmus_IndependentContractorExpense_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionSummaryOfOptionActivityUnder2014PlanDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_5" xlink:to="loc_us-gaap_PlanNameDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_OmnibusIncentivePlan2014Member" xlink:label="loc_nmus_OmnibusIncentivePlan2014Member_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6" xlink:to="loc_nmus_OmnibusIncentivePlan2014Member_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RangeAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_8" xlink:to="loc_us-gaap_RangeMember_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_9" xlink:to="loc_us-gaap_MinimumMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_9" xlink:to="loc_us-gaap_MaximumMember_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_SharesAvailableForGrantOfOptionsRollForward" xlink:label="loc_nmus_SharesAvailableForGrantOfOptionsRollForward_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12" xlink:to="loc_nmus_SharesAvailableForGrantOfOptionsRollForward_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_SharesAvailableForGrantOfOptionsOpeningBalance" xlink:label="loc_nmus_SharesAvailableForGrantOfOptionsOpeningBalance_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_SharesAvailableForGrantOfOptionsRollForward_13" xlink:to="loc_nmus_SharesAvailableForGrantOfOptionsOpeningBalance_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>


<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_SharesAvailableForGrantOptionsGranted" xlink:label="loc_nmus_SharesAvailableForGrantOptionsGranted_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_SharesAvailableForGrantOfOptionsRollForward_13" xlink:to="loc_nmus_SharesAvailableForGrantOptionsGranted_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_SharesAvailableForGrantOptionsExercised" xlink:label="loc_nmus_SharesAvailableForGrantOptionsExercised_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_SharesAvailableForGrantOfOptionsRollForward_13" xlink:to="loc_nmus_SharesAvailableForGrantOptionsExercised_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_SharesAvailableForGrantOptionsCancelled" xlink:label="loc_nmus_SharesAvailableForGrantOptionsCancelled_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_SharesAvailableForGrantOfOptionsRollForward_13" xlink:to="loc_nmus_SharesAvailableForGrantOptionsCancelled_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_SharesAvailableForGrantOfOptionsEndingBalance" xlink:label="loc_nmus_SharesAvailableForGrantOfOptionsEndingBalance_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_SharesAvailableForGrantOfOptionsRollForward_13" xlink:to="loc_nmus_SharesAvailableForGrantOfOptionsEndingBalance_19" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_22" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_20" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_23" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_24" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_20" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_25" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_OptionsOutstandingPricePerShareRollForward" xlink:label="loc_nmus_OptionsOutstandingPricePerShareRollForward_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12" xlink:to="loc_nmus_OptionsOutstandingPricePerShareRollForward_26" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_OptionsOutstandingPricePerShareOpeningBalance" xlink:label="loc_nmus_OptionsOutstandingPricePerShareOpeningBalance_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_OptionsOutstandingPricePerShareRollForward_26" xlink:to="loc_nmus_OptionsOutstandingPricePerShareOpeningBalance_27" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_OptionsOutstandingPricePerShareOptionsGranted" xlink:label="loc_nmus_OptionsOutstandingPricePerShareOptionsGranted_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_OptionsOutstandingPricePerShareRollForward_26" xlink:to="loc_nmus_OptionsOutstandingPricePerShareOptionsGranted_28" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_OptionsOutstandingPricePerShareOptionsCancelled" xlink:label="loc_nmus_OptionsOutstandingPricePerShareOptionsCancelled_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_OptionsOutstandingPricePerShareRollForward_26" xlink:to="loc_nmus_OptionsOutstandingPricePerShareOptionsCancelled_29" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_OptionsOutstandingPricePerShareEndingBalance" xlink:label="loc_nmus_OptionsOutstandingPricePerShareEndingBalance_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_OptionsOutstandingPricePerShareRollForward_26" xlink:to="loc_nmus_OptionsOutstandingPricePerShareEndingBalance_30" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_31" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_32" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_33" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_34" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_35" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionSummaryOfWeightedAverageAssumptionsForEmployeeOptionDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_8" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_10" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>




<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RangeAxis" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis" xlink:to="loc_us-gaap_RangeMember" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember" xlink:to="loc_us-gaap_MaximumMember" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember" xlink:to="loc_us-gaap_MinimumMember" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_EquityTable" xlink:label="loc_nmus_EquityTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_nmus_EquityTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_CommonStockMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6" xlink:to="loc_us-gaap_RelatedPartyDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_FoundersAndMemberOfBoardMember" xlink:label="loc_nmus_FoundersAndMemberOfBoardMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_7" xlink:to="loc_nmus_FoundersAndMemberOfBoardMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_AgreementAxis" xlink:label="loc_nmus_AgreementAxis_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_nmus_AgreementAxis_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_AgreementDomain" xlink:label="loc_nmus_AgreementDomain_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_AgreementAxis_9" xlink:to="loc_nmus_AgreementDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_StockPurchaseAgreementJune2014Member" xlink:label="loc_nmus_StockPurchaseAgreementJune2014Member_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_AgreementDomain_10" xlink:to="loc_nmus_StockPurchaseAgreementJune2014Member_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_12" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_13" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_15" xlink:to="loc_us-gaap_ClassOfStockDomain_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_16" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_16" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_EquityLineItems" xlink:label="loc_nmus_EquityLineItems_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_nmus_EquityLineItems_19" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_21" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_TermOfWarrant" xlink:label="loc_nmus_TermOfWarrant_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_nmus_TermOfWarrant_22" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_NumberOfAdvisors" xlink:label="loc_nmus_NumberOfAdvisors_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_nmus_NumberOfAdvisors_23" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ValueOfCommonStockCalledByWarrants" xlink:label="loc_nmus_ValueOfCommonStockCalledByWarrants_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_nmus_ValueOfCommonStockCalledByWarrants_24" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_AmortizationOfWarrantServiceCost" xlink:label="loc_nmus_AmortizationOfWarrantServiceCost_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_nmus_AmortizationOfWarrantServiceCost_25" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_26" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ValueOfShareExchangedForServices" xlink:label="loc_nmus_ValueOfShareExchangedForServices_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_nmus_ValueOfShareExchangedForServices_27" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_28" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_29" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_30" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfServicesAmortization" xlink:label="loc_us-gaap_CostOfServicesAmortization_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_us-gaap_CostOfServicesAmortization_31" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_32" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ValueOfWarrantsIssued" xlink:label="loc_nmus_ValueOfWarrantsIssued_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_nmus_ValueOfWarrantsIssued_33" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_NumberOfInvestor" xlink:label="loc_nmus_NumberOfInvestor_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_nmus_NumberOfInvestor_34" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_35" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_36" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_37"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_37" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_MinimumIssuanceOfSharesInEquityFinancing" xlink:label="loc_nmus_MinimumIssuanceOfSharesInEquityFinancing_38"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_nmus_MinimumIssuanceOfSharesInEquityFinancing_38" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_MaximumIssuancePricePerShareInEquityFinancing" xlink:label="loc_nmus_MaximumIssuancePricePerShareInEquityFinancing_39"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_nmus_MaximumIssuancePricePerShareInEquityFinancing_39" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>




<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ConversionPrice" xlink:label="loc_nmus_ConversionPrice_42"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_nmus_ConversionPrice_42" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_43"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_43" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_44"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_44" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_45"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_45" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockRedemptionTerms" xlink:label="loc_us-gaap_PreferredStockRedemptionTerms_46"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_us-gaap_PreferredStockRedemptionTerms_46" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>


<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" xlink:label="loc_nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_19" xlink:to="loc_nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_EquityTable" xlink:label="loc_nmus_EquityTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0" xlink:to="loc_nmus_EquityTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_PlanNameAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_2" xlink:to="loc_us-gaap_PlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_OmnibusIncentivePlan2014Member" xlink:label="loc_nmus_OmnibusIncentivePlan2014Member_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3" xlink:to="loc_nmus_OmnibusIncentivePlan2014Member_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_RangeAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_8" xlink:to="loc_us-gaap_RangeMember_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_9" xlink:to="loc_us-gaap_MaximumMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_11" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_12" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_EquityLineItems" xlink:label="loc_nmus_EquityLineItems_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityTable_1" xlink:to="loc_nmus_EquityLineItems_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_14" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_14" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_18" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants" xlink:label="loc_nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_14" xlink:to="loc_nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants_19" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_CommonStockVotingPercentage" xlink:label="loc_nmus_CommonStockVotingPercentage_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_14" xlink:to="loc_nmus_CommonStockVotingPercentage_20" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_PercentageOfFairValueOptionPriceAtDateOfGrants" xlink:label="loc_nmus_PercentageOfFairValueOptionPriceAtDateOfGrants_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_14" xlink:to="loc_nmus_PercentageOfFairValueOptionPriceAtDateOfGrants_21" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_MaximumExercisablePeriodOfFairValueOfOption" xlink:label="loc_nmus_MaximumExercisablePeriodOfFairValueOfOption_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_14" xlink:to="loc_nmus_MaximumExercisablePeriodOfFairValueOfOption_22" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_23" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_14" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_24" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_25" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_14" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_26" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_14" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_27" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_14" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_28" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_14" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_29" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_EquityLineItems_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/ProvisionForConversionOfPreferredStockDetailTextuals">
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ProvisionForConversionOfPreferredStockAbstract" xlink:label="loc_nmus_ProvisionForConversionOfPreferredStockAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockTable" xlink:label="loc_us-gaap_ConversionOfStockTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_ProvisionForConversionOfPreferredStockAbstract_0" xlink:to="loc_us-gaap_ConversionOfStockTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockLineItems" xlink:label="loc_us-gaap_ConversionOfStockLineItems_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockTable_1" xlink:to="loc_us-gaap_ConversionOfStockLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_MinimumIssuanceOfSharesInEquityFinancing" xlink:label="loc_nmus_MinimumIssuanceOfSharesInEquityFinancing_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_6" xlink:to="loc_nmus_MinimumIssuanceOfSharesInEquityFinancing_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_MaximumIssuancePricePerShareInEquityFinancing" xlink:label="loc_nmus_MaximumIssuancePricePerShareInEquityFinancing_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_6" xlink:to="loc_nmus_MaximumIssuancePricePerShareInEquityFinancing_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_DownRoundProvisionsExpirationTerms" xlink:label="loc_nmus_DownRoundProvisionsExpirationTerms_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_6" xlink:to="loc_nmus_DownRoundProvisionsExpirationTerms_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ProvisionForConversionOfPreferredStock" xlink:label="loc_nmus_ProvisionForConversionOfPreferredStock_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_6" xlink:to="loc_nmus_ProvisionForConversionOfPreferredStock_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_6" xlink:to="loc_us-gaap_SharesIssued_11" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_GainLossOnConversionRightPreferredStock" xlink:label="loc_nmus_GainLossOnConversionRightPreferredStock_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_6" xlink:to="loc_nmus_GainLossOnConversionRightPreferredStock_13" order="80" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_6" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_14" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ConversionPrice" xlink:label="loc_nmus_ConversionPrice_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_6" xlink:to="loc_nmus_ConversionPrice_15" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>


<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockLineItems_6" xlink:to="loc_us-gaap_SharesIssuedPricePerShare" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/IncomeTaxesDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLossCarryforwards_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/SeriesBWarrantsDetails">
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_SeriesBWarrantsAbstract" xlink:label="loc_nmus_SeriesBWarrantsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_SeriesBWarrantsAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_SeriesBWarrantsMember" xlink:label="loc_nmus_SeriesBWarrantsMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3" xlink:to="loc_nmus_SeriesBWarrantsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/SeriesBWarrantsDetailTextuals">
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_SeriesBWarrantsAbstract" xlink:label="loc_nmus_SeriesBWarrantsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmus_SeriesBWarrantsAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_SeriesBWarrantsMember" xlink:label="loc_nmus_SeriesBWarrantsMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3" xlink:to="loc_nmus_SeriesBWarrantsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_NumberOfWarrantsIssued" xlink:label="loc_nmus_NumberOfWarrantsIssued_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5" xlink:to="loc_nmus_NumberOfWarrantsIssued_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_11" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.nemusbioscience.com/role/SubsequentEventsDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_PlanNameAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_5" xlink:to="loc_us-gaap_PlanNameDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_OmnibusIncentivePlan2014Member" xlink:label="loc_nmus_OmnibusIncentivePlan2014Member_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6" xlink:to="loc_nmus_OmnibusIncentivePlan2014Member_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9" xlink:to="loc_us-gaap_RestrictedStockMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_11" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_ManagementAndBoardOfDirectorsMember" xlink:label="loc_nmus_ManagementAndBoardOfDirectorsMember_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_12" xlink:to="loc_nmus_ManagementAndBoardOfDirectorsMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventLineItems_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="nmus-20150930.xsd#nmus_FairMarketValueOfSharesGranted" xlink:label="loc_nmus_FairMarketValueOfSharesGranted_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_14" xlink:to="loc_nmus_FairMarketValueOfSharesGranted_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0````(`&24;$=V;+^IJ@$``/`4```3````6T-O;G1E;G1?5'EP97-=
M+GAM;,V8RV[",!!%?P5E6Q%CT]*'@$WIMD5J?\!-)L0B?L@V`?Z^=H"JC6@%
M+9%FDP=W//<FXYP%X[>M`=?;R$JY25)Z;QX(<5D)DKM4&U!!*;25W(=;NR"&
M9TN^`,(&@Q')M/*@?-_''LET_%*#M2*'WN-.B+TG"3>F$AGW0BM2J[S5M:^+
M0F20ZVPEPY+4!VNX"GK2FW/KG[D,+<BF(HVP.](TZN0RALY8X+DK`;RL4N>W
M%;AC_COEX#R#@J\J?Y;Q_MVE%JJFQI7"[*V>-J&+"[]-DJ"ZDQS:"W]+)F0<
MFE&+;ROB_1^?I?42:UG-+%^+ED'=V9CB.95<J&.C6FN[?-=Z><EM`O&I<LC[
MQH9"Z\6171**YT%U)+3^E_=AIV3:PDF&L;##CZ+D%O)7;\-\CW\;7PNZRQ'G
MVES_-/1&=*0Y=0B)LW(P)#F&2')<(\EQ@R3'"$F.6R0Y[I#DN$>2@PZP!,%"
M5(H%J10+4RD6J%(L5*58L$JQ<)5B`2O%0E:&A:P,"UD9%K(R+&1E6,C*L)"5
M82$KPT)6AH6L#`M9AUC(.OPD*VG^Z)Q^`%!+`P04````"`!DE&Q'2'4%[L4`
M```K`@``"P```%]R96QS+RYR96QSK9++;L)`#$5_)9I]<4HE%A%AQ88=0OR`
M.^,\E,QXY#$B_?N.V(#"0ZW$TJ][CZZ\#JFL#C2B]AQ2U\=43'X,J<K]VG2J
ML0)(MB./:<&10IXV+!XUE])"1#M@2[`LRQ7(K8[9K.?:Q<[51G;NTQ1'E):T
M-M,(9Y;AFWE89.D\^(GT%V-NFM[2ENW)4]`'_K,-`\]YEE<>QW8OG*\M"_V/
MZ'D4X$G1H>)%]2-F`Q+M*;V"^GH`A3&^.R6:E((C-Z."N[_8_`)02P,$%```
M``@`9)1L1V2&T#=T`0``RA,``!H```!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<\782VK#,!#&\:L$'Z#RC/(FR:J;;-M>0#@3VR1^(*FTN7U=+XK[T-!%
MX-O8V(+1'PP_A'=MR+=/<G6Q[MI0U7V8O3?7-FR']_NLBK'?&A.*2AH7'KI>
MVF'UW/G&Q>'1EZ9WQ<658CC/E\9/YV2'W<_9L^-IG_GCB;+9B_.EQ'WVUOE+
MJ$1B,..-'H8-AN5;+__9OCN?ZT(>N^*UD3;^46&^-LA,.HC300P)LND@"PF:
MIX/FD*!%.F@!"5JF@Y:0H%4Z:`4)6J>#UI"@33IH`PFB7)$QQR1I6&.T)H5K
MPGA-"MB$$9L4L@EC-BEH$T9M4M@FC-NDP$T8N4FAFS!VDX(W8?1F16_&Z,V*
MW@PZ:VN';8S>K.C-&+U9T9LQ>K.B-V/T9D5OQNC-BMZ,T9L5O1FC-RMZ,T9O
MJ^AM,7I;16^+T=M.]`Z5\W)ZCKYNRW#OFF_#U:()WB'>KG+_E'&JVC#1.@X[
MB1FO=_]$X]3/$//KM]WA`U!+`P04````"`!DE&Q'NVE4M9T"``!K"0``$```
M`&1O8U!R;W!S+V%P<"YX;6R]5FU/VS`0_BM6OJR3!FD#8UI5(I4T$TCT123`
M9^-<J$5B9[83E?WZG1/:I9`"[8=5D6I?GN?.]]Q=DI'0_>%"R0*4X:#)*L^$
M'J+QW%D:4PQ=5[,EY%0?(T3@W52JG!K<JD=7IBEG,)&LS$$8U^OWSUQ8&1`)
M)$?%QJGCCVR4<5%DG%'#I?"GG"FI96I(N&*0C=S7@)J!GB-@I>+FV>\WF+:I
MQD2,9A!@+#^EF88&]<]88P*9%U0\N\WNFHLG?5O$<D(-M%G;-QKO2ZH@P:!;
MWC?&&G/YC'EFEALLJ7B$I(U]>W.MQ1TH;3,=>,=]_&TD6-L;WT`3+AX7E"OM
MCRHSK(`9J5[*5)E#JY1(9HNN[V(\GW;(`]5@E^=.116GPCA$\S^X]9PF;&.M
MUUFAC?+OI7K22P"C1^[&6"_;V/::G_HG@QJ!JVVDN\G,?Y%M*V]KB;G)0,_3
M!57F/TE1Y[06XF3@M+)?NR!4)"04!MN17(DF%!:O+<EF%<QGT?SZ:C*.PPFY
M&%^/9T%(HLLPC*-]\:2WH!]SHAC_IN$,\?-?9+X(;_;E!./H\@#.62=G1DVI
M@,B4S'$F:IWT-W)1:BY`:]+)N16\LO.`\B)ORK6V5U%PTG-NIT[WV62><V.K
MH^OR!!+K@Z,G&#Z+.AF1D>QI*;,$0WTA$\`FX4UI;R`!Z.1@SU3<#BK!JML8
M53.W]IP+U<V)0-EG[`6YITIAXW>?YDHPF0.)Z6K7<<L'#;]+VWYA!;O<O"OW
MX/O^TI'>Q^*UM4,54E"?$X+T8OJ`\_WU@%1^[M\Y7O^`](_VYWC>_I)Y)P=P
M3@_@=+?`^YSNR7YW%KP?GVV!"1C*LQT]L!-/8OSD*#^<I&TXW1GF]6SM#O/F
MI?7J%>5N?UKY?P%02P,$%`````@`9)1L1T'7..(^`0``:0,``!$```!D;V-0
M<F]P<R]C;W)E+GAM;,V334_#,`R&_PKJO4NS:0A%70^`.#$)B2$0MY!X6UCS
MH<13UW]/EG4M`RZ]<:MKOX]?QTDI'!/6PY.W#CPJ"%<'79O`A%MD6T3'"`EB
M"YJ'2:PP,;FV7G.,H=\0Q\6.;X!,B^*::$`N.7)R!.:N)V95*043'CA:W^&E
MZ/%N[^L$DX)`#1H,!D(GE&35B]D9VYB2#/JJC(YK'G!II5HKD+?M4/8[%3LC
M>!U.<I!]^_3W3P\I0[*N\A!47]4TS:29I;HX,"5OR\?G=#:Y,@&Y$1!503%L
M'2RR<^?7V=W]ZB&KI@6=YY3F=+JB-VPV9\7\_3C9A;_!L.Z&^+>.SP;3=E%A
M#2-WFS0R+3=])I"$(+QRJ*P9A4N8;^($"_N/3Q`X'M0)TV7;0=M8+T.5[M<0
M'5].7-G&^O:4^A%=O*KJ"U!+`P04````"`!DE&Q'F5R<(Q`&``"<)P``$P``
M`'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEV
MV[29A.U.'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYB
MZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#`"J5,7K5::0##.'W)$Q+#W(*+
M"$MX%,O67.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+
M5(UEHP$35T$FN8BT\OELQ?S:WCYES^DZ'3*!;C`;6"!_SF^GY$Y:B.%4PL3`
M:F<_5FO'T=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q
M>#BVR]*+<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*
MC5M/TVMWW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6U
MY4#3(`!8<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0
M!0X`-\313%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=
M?3K.:Y1_::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="
M?,_V]I&E)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>4
M1B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I`DQEJ&&^+3&K!'@$WVWO@C(WXV(
M]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76
M>)7`\:V</!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,C
MIW0FS>@S&L%&KQMUAVC2/'K^!?F<-0H<D1L=`F<;LT8AA&F[\!ZO)(Z:K<(1
M*T(^8ADV&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW
M0CYBSHN0$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y`\F
MIS_I,C0'HYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z>`HWEL:\4*Z">P'_T=HW
MPJOX@L`Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'
M5*^3*=@YG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+
M5--E-XH2GD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JV
ME+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^`VVZG=PZ
M.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'N
MH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+:`'@Z]1`O)256`Q
M6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5
M'<]56_*POFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V
M$I<8O./FQW%.4[@2=K8/`C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN
M>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41`71%`B.5'`86
M%S+D4.Z2D`83`<V4R43P`H)DIAR`F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4
MBK`,!2$7<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4
MS;L:OB9@2\-Z;ITM)__;7M0]M!<]1O.CF>`>LX=SFWJXPD6L_UC6'ODRWSEP
MVSK>`U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X`Q\U*M:
MI60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F`6/,,H68XWX=%FAHSU8NL
M.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#
M!!0````(`&24;$=S-N`83`(``'H*```-````>&PO<W1Y;&5S+GAM;,U66VO;
M,!3^*T(9HX41VRE-:6L;1B$PV,J@>>A;D6W9%NCBR7+F]-=/%U^20)8V34OS
MHJ-/1]_Y='2<H[!6:XH?2HP5:!GE=01+I:H;SZO3$C-43T6%N5[)A61(Z:DL
MO+J2&&6UV<2H-_/]N<<0X3`.><,63-4@%0U7$;P8(.#VWXD,1_#I[.N?1JC;
M+\"-DV^3B?]T?KN+G]F%<P@<QX\L@L'\$GHO)YWZ_GYBL[A#/G\E^?^X=ZBO
M#+77)2@.<\''/,V@`^*P?@8K1+5_8-Q3084$2E^$UF`1CAAV'G>(DD02`^:(
M$;IV\,P`]NXZ/T:XD#:VB[`;9^J/D6211-#O?B\/EXSL=C#'(Y1N'T\#<5@A
MI;#D"ST!G;U<5_IP7'#L1%J_`]Z%1.M@=KFQP0XZ;B)DAN40.8`]%(<4YTIO
MD*0HS:A$9:0+I0331D90(3BBAK+?T1F:-L64/I@OY3'?XFYSX'S,'?L0&!6]
MJ1/1F6,9V*1ZFVR.>Y/V.%[0YD,`O1M5%5U_IZ3@##NQ#EJ(;G:(/MA#'X>H
M9P6ED.19^YM"2#6`)00K+!5)-Y&_$E5+W*JN@KTVWZ?PV"._IZ;39VU4HTOP
MH]-S='`+W3<LP7)A_QA?+^GBZO"5V:\3[LC\V*HY0L()DF,:VZ>5-O^\TMZG
MIDY1[==O5.9UC6&C^VSUG@$%24.H(KR7@,QKX=[(IEMM8>P[FC-KQY9C5Q5*
M]$-P*XHFRW".&JI^DY50=C&"H_W3R`_F@]=RH(C@:/_"&6G8M54POC;C?U!+
M`P04````"`!DE&Q'M-0&;W0#``!+"P``#P```'AL+W=O<FMB;V]K+GAM;)66
M;6_3.A2`_XJ5#[`K<6GCOHSU4J2M+:S2UE9+@<]N<DJM.7&PG6WPZSE.MLL)
M-8%)D1([R>.7\_CHO+63>VUN=UK?LH=<%79BIM'!N7+2Z]GT`+FPKW4)!;[;
M:Y,+ATWSI:?W>YG"7*=5#H7K\7Y_W#.@A).ZL`=9VNB19O^&9DL#(K,'`)>K
M!I8+643OWMK)7BKX!,8BF(FR7(D<IM&#BI@2UBTRZ2";1D-LZGMH=9BJO*BD
M\HU1?Q3U/.QIJ1O#4IU!`]L>I/W\^")B&>Q%I=P6)_LT[C2*^9#S<</PGWV2
M<&\IT'<PD3IY!UNQFT;]B(G*Z?=2.3!SX>"#T54IBR_(BMA>&NL2O]SZRUP6
M,I??_;RQ90_Z_E(;^5T73J@D-5JI^B__HOX)1[#_]^`<G4Q;'SJQN_&1F$;C
M/@+OI)4[J:3[-HWJ9P5^);U?EE)O_\\G5M2;\Q1B)HJ,+0J'%+8LFN#AUO@Y
MX,?+K![83"0^F&46-UM%0;/U*EE?+>?GV\6<79Q?G:]F"Y9<+A;;A$`X@?!G
M0=C)1A#0@(`&?P`E6[Q=+U8(6;]GZ\WBAH"&!#1\%FAVGEP2T(B`1L\%C0EH
M3$#C8]!*N,H`TWNV+L$T)_(5NZBL+,!:1D"G!'1Z#/I8H,UX`##B"+N6UOJK
M+"4[>?&UTNZ_C]?-G2#?$.2;P")UGDOG?;*U4#-T'`\%%*D$2S!G!'-VC$F<
M3F\/6F4XO9=L#IB+9&/H#60`5,H^M;)_C-H8[<\$)A=TVL_G[C'7X)(WIH5J
M"1XP/`&#JV`7[+,P1N`2Z<]4[#A@]K)(=0YL*QY:&Q%3C^.`R$FUL_"U\B=T
M<0>_#$K=C0/R=JH2CRB*VAN'].V*+#NA*.IO'!"X%5T:7(S''@Q%48/C@,)'
M(6$GF#P5V'\HA4H;!ZSMWJ8SBJ+BQ@%S_WRF>)^F0ZHO#^C;O>W_4A35EX<2
M=!>*<XIJ9>F`S)T1Y`.*HG[SD-^=J"%%4=MYP/9N%+6=4]MYP/9N%$W6G-K.
M`[9W)B!^2E'4=OYWML_!":E:NG.J.P_H_EL,V\*#JRB*ZLX#NM.LUJ:(]J0&
M5/1!0/2C//?;20VHZ(/XL=3Y6=U@@8?G-O.UGZV'P>(I]04AWII4/1SY<^S;
MUU@D3B-?R6'15BDUP[YU<:5%7>\TY*<2\-T/4$L#!!0````(`&24;$>#>:KW
M3@(``/0'```8````>&PO=V]R:W-H965T<R]S:&5E=#$N>&ULC97+CILP%(9?
MQ>(!!FQN2420DE15NZ@TFD6[=A(GH,&8VDZ8OGU]@TE&#F$#V/S_^<[QM>@9
M?Q<5(1)\T*85ZZ"2LEN%H3A4A&+QPCK2JC\GQBF6JLG/H>@XP4=CHDV(HB@+
M*:[;H"Q,WRLO"W:13=V25P[$A5+,_VU)P_IU`(.AXZT^5U)WA&41CKYC34DK
M:M8"3D[K8`-7.YAHB5'\KDDO;KZ!3G[/V+MN_#RN@TCG0!IRD#H$5J\KV9&F
MT9$4^:\+^LG4QMOO(?IW4ZY*?X\%V;'F3WV4E<HV"L"1G/"ED6^L_T%<#:D.
M>&"-,$]PN`C)Z&`)`,4?]EVWYMW;/TGL;'X#<@8T&E`V:8B=(1X-=NA"FYFI
MZQN6N"PXZX'HL)YMN%)RKH.HR$`5(]0XF9C<C%197,NH"*\ZS)T"&<76*N"H
M"%5L+P`%/CLR=O08L+.*^#D@O@?8SDUL[,ES>W)O3ZP],?;4EY]5;*TB>PY(
MO8#4V/-[0&L4J058!4QAEJ8SQCGS8C(39#%1AU4LGP-R+R"W67J7BB,XR8P:
M%E[$POJ]B\4AG&3&:EEZ$4OK3QY/Q\Y)EBA?P&P&"$9>DNG6TSI1S:"9L;@@
M]%/<]LRG*$ZSF$%!?@IR8S)%<3L]FD&)_12[E1&<V"N#)KH9U\<<_Y:'=D<C
M[SK+',=IOLY_>'/(4L+/YO(1X,`NK;1G[-@[7G`;9`[I3WE9=/A,?F%^KEL!
M]DRJH]Z<R"?&)%'XZ$656ZDK>&PTY"3U9Z['P5Y*MB%9-]RQXT5?_@=02P,$
M%`````@`9)1L1UBIBL8>!```FQ,``!@```!X;"]W;W)K<VAE971S+W-H965T
M,BYX;6R-F%%SHS80Q[^*Q^]W2"L)H8SCF0N=3OO0F9M[:)])+,>>`^,"B:_?
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M+V_]T#9SR'K55#_BY_$T?5[B+X7`,#H`,`"N`5*S`0H#U$\!650VU?5+-53;
M3==>5OVY&J^V?`AX-R8)F5>AF#[,TY2SFV9JNWG?@MYD[V.>#PA,R!,BRT2)
MA+DB61B?%`$?1<237R#&Y_?CU<=X'>-5C+<?)9XFQ,8B(J*5!@NPS)682EBE
MQ'TYFI2C8XZ"&L9$.1%1UHB$40PYBHFC.&:4B#AC-*.EC%2N=>'N:\E)+7DL
M1S!:$)%2,E2)5&Z*A'FQI!:+`S%:(J*-R(N"4X.I1*%<PM04I)PBYB#7',J)
MB,R%SADQD0*IC+ZOQ9'WF8M:U/UX*<ABIM,A@V:J0486QC%826++>B2M)SJ/
M,IP>F::'PI;U`*T'</UR>@!7GY8&N-4W)].%TC9!DB*ON51H-0D9:#N3:%:<
MGR$C%0"W.$KDM'#:I2BBK4]&RU*<]R$CM;:@.$4&+X?)$_8?2?N?S+$L3E!D
MG`#)W>:(2>GTS0ZR+(@V08D6Q[D@,M):43!<.7-@;(H-2MH'9?0OS1AAB8P4
MXU_"2(X>R>%>S]4>&1MVQH1)!MH-(5J8YA8\,D5*/4";'$A<H4P]R.3267:&
MD2N$%"Y%T4*_AA:6<,,`W;$!]F-DRS;7A,X%P*U.I`J1TGW2!@=H2IS!P=S4
M.5`.$H:BG0O0;3CG0B8,97+)61>"::73Q@71;0QI7-@Z(Z.,-,J0BQ![9P3#
MX@K2$R31U@71;LQ/%_V6>9H9\J%$HYK_,<M*:,N":$>&O`;SY,S-&PAM$MP1
MZ,X,HA^EM':*-B,5C8:^0+BRU-QS"4NN]?D92,P-:8IK*=JU5'0:P[5",Q-V
MZ*+@'E$0A+`%62L3--'MF0(<C],4&:NDX-JX$CGITO8JM?#D&MW+<-:#S"<K
M<@N.U80D.!GT)ZQ&11NBBF9G.)="YE-HEX%MK&=0!_?0"9NMHIU3X6,JYU1J
M[N466^MYA9OEUCJ[>8URKE[]'U7W>CSUJ^=V&-IF>G&R;]O!ASSB<ZCQX*O=
M]:#V^V'\:L?BX[NC>#"TY_E5V/5]W/9?4$L#!!0````(`&24;$<GN2JI2`(`
M`)((```8````>&PO=V]R:W-H965T<R]S:&5E=#,N>&ULC9;+CILP%(9?!?$`
M`S;71`1IPJAJ%Y5&LVC73N($-("I[83IV]?V`9J,#$,6\87_/^>S+5^RGO%W
M45(JG8^F;L7.+:7LMIXGCB5MB'AB'6W5ES/C#9&JR2^>Z#@E)V-J:@_[?NPU
MI&K=/#-]KSS/V%7654M?N2.N34/XWSVM6;]SD3MVO%674NH.+\^\R7>J&MJ*
MBK4.I^>=^XRV!<):8A2_*MJ+N[JCX0^,O>O&C]/.]34#K>E1ZA!$%3=:T+K6
MD53F/T/0_SFU\;X^1O]FAJOP#T30@M6_JY,L%:WO.B=Z)M=:OK'^.QW&$.F`
M1U8+\^\<KT*R9K2X3D,^H*Q:4_;P)1IM=@,>#'@RH'#1$`R&X)/!`S(SKA<B
M29YQUCNB(WJUT5;)N0ZB(CMJ,$+-DXG)S4SEV2V/4>;==)P'"3:2/4CPO*(8
M%-$D\51^*P1^A(#.9PP0^&M_\.@/P1^`/WA$;(TDA4&`Q'_R?32O*FRJ69;0
MRA("2VC+$@$+2-2N,K]Y83$CG"6*K$01$$4+1"")EFE`M`(CMF+$@!$O8,1K
M,.*U&(D5(P&,Q)8A`0R0A`C%G_?%O:Q(UH*D5I`40-(%D'2:CU7+O['FV4">
MS<+FV*S:'#;5+`ORK3"F^Y8G"PN\'S0XB+_<(+/2>2YDYX(C++&.?^0"#4K]
M)$7VPV;$&I3KJ;"="@[&!"]1X=54>(G*N[L].G*A/PF_5*UP#DRJB\C<%V?&
M)%61_"<5L50/A*E1T[/4U42G@BL3&I)UXPM@>H;D_P!02P,$%`````@`9)1L
M1[-CB'-6`P``7PT``!@```!X;"]W;W)K<VAE971S+W-H965T-"YX;6R-E\UR
MFS`4A5^%89\@"03(8S,38W?:16<R7;1K8LLV$T`NX#A]^TJZ`L>)D)U%`/D[
M5_?HAROF9]&^=@?.>^^]KIINX1_Z_C@+@FYSX'71/8HC;^0O.]'612\?VWW0
M'5M>;+6HK@*"4!S41=GXV5RW/;?97)SZJFSX<^MUI[HNVG]+7HGSPL?^T/"K
MW!]ZU1!D\V#4;<N:-UTI&J_ENX7_A&=K'"E$$[]+?NX^W'LJ^1<A7M7#C^W"
M1RH'7O%-KT(4\O+&<UY5*I+L^:\)>NE3"3_>#]&_:;LR_9>BX[FH_I3;_B"S
M1;ZWY;OB5/6_Q/D[-QZH"K@15:?_>YM3UXMZD/A>7;S#M6ST]0R_),C([`)B
M!&04C/W8!:$1A!=!Y!1$1A#=VP,U`OJIAP"\ZY%;%7V1S5MQ]KICH=83GDF\
M54%D9$\.5R=G0L=L]5QD\[<L">?!FXISA1"-+`T232,K0/!(!+)_:Q+$M_5`
MM)Q,=Y`#D5!'#C>#K+\$F4PSO$XSA+$*01_?UD?7^@CT$>B3ZQ0;C20P$H!@
M2DB:3F.YP1A%"$UC*\!(2-*83&-K:[1);]3JC8(W:]*@6QHDBA"*IK$<L#@F
M,0ZGL15@A!&6,#;-K8%+0QJ'T6USL=5<#)D[NED"DK)89N0P9S":N,T!%F(Y
M"#%VF`,.HQ#=Y2ZQNDL@)^M",NX`>;AI;^!N^3/<;8,&O-MA:MVX*3B\X_W$
MK"/$0.]PO@1$;K2)'6F,`\:NL<EL,+*FHYO5FG;D8Y@'C%/BGK.!O#EI`QCA
M*'7/VMCYO=.&L=THU)74\;I8&H:ZACTW$$/4Y<]4,;DJ7=Z^AIJV1>RVB'D+
M.`J!8?3\)?;Y,[5@(%.:4NPH&JL!E//'F*L*K<?.48AIR.XP&MJ-0L5,K>/)
MC%%@'M`C2M#5GW6%,6/ZHK):9L;RB!'K8#/C=\0PN<.LO;IC**.I=6"'Q6I*
M;8)B$L:.998/)**(Q,A1>58#&5/,4NK8*NLAPQ3)K?[Y%!-\.#W6O-WK<WOG
M;<2IZ>%`-+:.WP9/1)T^/[4O\2S'EO:5^I;0I]5+^&Q^+/;\9]'NRZ;S7D0O
MS[SZ:+H3HN<R9_0H<S_(KYWQH>*[7MTFRA2<_^&A%\?A<V;\ILK^`U!+`P04
M````"`!DE&Q'K@X4"#P$``"K$P``&````'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;)5836_C-A#]*X+O68DSI"@9CH&-A:(]%%CLH3TK-OV!U8<K*?'VWY<2
M1TZ<G=#LQ;+(-S-OAN03R=6E[7[T1V.&Z&==-?WCXC@,YV4<]]NCJ<O^2WLV
MC>W9MUU=#O:U.\3]N3/E;C*JJQB2)(WK\M0LUJNI[5NW7K4O0W5JS+<NZE_J
MNNS^?3)5>WE<B,7<\/UT.`YC0[Q>Q5>[W:DV37]JFZ@S^\?%5[$L4(^0"?'7
MR5SZ=_^CD?QSV_X87_[8/2Z2D8.IS'88793V\6HVIJI&3S;R/^3T+>9H^/[_
M[/VW*5U+_[GLS::M_C[MAJ-EFRRBG=F7+]7PO;W\;B@'-3K<ME4__4;;EWYH
MZ]ED$=7E3_<\-=/SXGJRA,QX`R`#"#5`,L"KP948;R#)0+X9R*DT+I6I$$4Y
ME.M5UUZB_ER.TT,L+;P;G5C/D<V^MX6=?'93:=>KUW66K>+7T<\-!";(QD'$
M%1%;YVP$6'#F,)G#YP$*A]#J?@2\C8`N!W0YY/?MY:V]:_PJG;VZI=A,$.V2
M<)`'*62>:_TYL""@2%`H#&"DV(S4Y"5/[MNG;$:ILQ<<4>4R<A`-[X+\`BH<
M"*6\3T2S1+0C`AXB#@(IYEG`#,C8,)D+@]PD<Y`G@D@/$P=1MB0BO<\D9YGD
M;B[Y$G:0/$N3)&"`1<+.D*G9>@DHF1`L4^'6-60>JH1Y0*V"N`(?B20@]PP/
M8?+4QX;\J"SQ35J"/8!EG0601IZT4Q7T1-H01DD=4AQ>?(2D->;+B%0EE7E0
M),5'<JJ"K-;/PT#*PTK<G+6B^J8:T@!E$+Q&"1*7W!>*A"P72@<$XC5(.(61
MWI'4E%,.`@(B\3(DG()(W^HGC/U")&'KG]<9,:N(+U1.@I;EGB(7!!.I1A4@
M)Y"PA(`$R3><A+$S1TA$SU(O9F2N0*4!BQ@^:!RI)-#>):30P(L7`+GP?4P)
M]"!RG_(75QA@R&X%>&4")$:^:4:@NXSP_S&2?)DE,<(`%[PX@2(7O@\T@32(
M)/7-Z-E9;B=^%C+TO$)!2IS8G>',B4!2`B8!T@&\2(&F6+X/((&DRC(,V5P"
M+U.042R?RA,HU4IHX?O<SMZ"B\T+&I`*)3Y%(Y`4:#?7WGD]>P.50,"L1%[4
M,"$W/E4C$"0:,2!_Y+=C2%+%UYJ.(022*$$#FS\=0V9OP?D#N["1Q$\$G/Z0
M5RLDM1+L"5!27K21\F"*7S&?4^&W6D@R)=!7XAG$+L2YO)(.:"%GUJO@-41C
M;/";\'J$*;M'OMG`$4:(@(T9\E*$FMT#WH8AN1(?"Q"_NX2H37>8;G/Z:-N^
M-(,[[5Y;KS=&3S!>8GQHWXAE(9AV6[[E!A738W.W/2G;HVW/="T5OY%:K\[E
MP?Q9=H=3TT?/[3"T]70OLF_;P=@LDR]VA1]-N;N^5&8_C'_UN/3=79)[&=KS
M?#5VO9];_P=02P,$%`````@`9)1L1[])S-DM`@``]@8``!@```!X;"]W;W)K
M<VAE971S+W-H965T-BYX;6R-E=^.HR`4QE^%^`!%L8IMK,ET-IO=BTTF<[%[
M35M:S:"X0.OLVR__ZMB$6&\JX'>^WSE0CN7`Q8>L*57@LV6=W$6U4OT60GFL
M:4ODBO>TTV_.7+1$Z:FX0-D+2DXVJ&40Q7$.6])T457:M3=1E?RJ6-/1-P'D
MM6V)^+>GC`^[*(GN"^_-I59F`58E'.-.34L[V?`."'K>12_)=I\@([&*WPT=
MY&0,3/('SC_,Y.=I%\4F!\KH41D+HA\W^DH9,TZ:_->;?C%-X'1\=_]NR]7I
M'XBDKYS]:4ZJUMG&$3C1,[DR]<Z'']37D!G#(V?2_H+C52K>WD,BT))/]VPZ
M^QS<FR+V8>$`Y`/0&)!BF[@#V32_$46J4O`!R)Z8PTNV6BZ,B78&.C>IR[:>
MPA9>E;<J2?(2WHS1@\8%[KUF5$#M'D2@*!2./`(_-T@?#5*78^H-BN<&ZT>#
MM3-8>X/-8Y&=U6"7I=.D&Q0_IV1!2N8H$X,))7,4I\$X7D#)@Y3<4Y*96IQF
MK4\U7W!J.,C!GH-FJG$:?=OC)?4404[A.>E,/86O!Q<X>\[9!#D;SUG/<+PF
M+Q;5D\1!D%TVI&QFY[PH7P9*PB!_+U$>`FT\R(G0:L'&)2C,\1<8X9FMNXL"
M?P4XZ4LM%1?;?B4X\FNG7%L:5\<6_V([//R25V5/+O07$9>FD^#`E>Z.MHF=
M.5=49Q"O]-;6^B,T3A@]*S/$9L]=6W83Q?O[5V;\U%7_`5!+`P04````"`!D
ME&Q'DHQCCJ(!``"Q`P``&````'AL+W=O<FMS:&5E=',O<VAE970W+GAM;(53
MRV[;,!#\%8(?$,JRW2:&+"!V$;2'`$$.S9F65A(1DJN0E)7\??F0%3LPFHNX
MNYJ9G>6C&-&\V@[`D7<EM=W2SKE^PYBM.E#<WF`/VO]IT"CN?&I:9GL#O(XD
M)5F>93^8XD+3LHBU)U,6.#@I-#P98@>EN/G8@<1Q2Q?T5'@6;>="@94%FWFU
M4*"M0$T,-%MZO]CL5@$1`7\%C/8L)L'[`?$U)'_J+<V"!9!0N:#`_7*$/4@9
MA'SCMTGSLV4@GL<G]8<XK7=_X!;V*%]$[3IO-J.DAH8/TCWC^!NF$=9!L$)I
MXY=4@W6H3A1*%']/J]!Q'=.?VVRB72?D$R'_0F"I4;3YBSM>%@9'8GL>SFZQ
M\7`31+PR\=ZL'SMJFCAX61S+17Y;L&,0NL`DXF["S`CFU:^VR.DU>A[I^??T
MY25]F1PN)X=WWPNL+@5626#UOQ$39C=AEMF7)NQL3Q68-EX=2RH<M$M;.E?G
MVWF?QS/YA)=%SUMXY*85VI(#.G^R\0`:1`>^?7:SIJ3S[V=.)#0NA#]];-*5
M2HG#_O1`YE=:_@-02P,$%`````@`9)1L1^XVN;FB`0``L0,``!@```!X;"]W
M;W)K<VAE971S+W-H965T."YX;6R-4]MNG#`0_17+'Q!S2QJM6*1LJBAYJ!3E
MH7WVP@!6;(;:9DG_OKX`V:U6;5_PS'#.F3.^E#/J=],#6/*AY&#VM+=VW#%F
MZAX4-S<XPN#^M*@5MR[5'3.C!MX$DI(L2Y([IK@8:%6&VJNN2IRL%`.\:F(F
MI;C^=0")\YZF="V\B:ZWOL"JDFV\1B@8C,"!:&CW]"'='0J/"(#O`F9S%A/O
M_8CX[I.79D\3;P$DU-8K<+><X!&D]$*N\<]%\[.E)Y['J_I3F-:Y/W(#CRA_
MB,;VSFQ"20,MGZ1]P_D9EA%NO6"-TH0OJ2=C4:T42A3_B*L8PCK'/\7]0KM.
MR!9"MA'NDV`\-@HVOW++JU+C3,S(_=FE.P?77L0I$^?-N+&#I@Z#5^6I2O.T
M9"<O=(&)Q,."V1#,J5]MD=%K]"S0LW_3\TMZ'AWFB\/_$"@N!8HH4/QMQ(@Y
MK)C\CR;L;$\5Z"Y<'4-JG`8;MW2K;K?S(0MG\@FORI%W\(WK3@R&'-&ZDPT'
MT"):<.V3FUM*>O=^MD1":WWXQ<4Z7JF86!S7![*]TNHW4$L#!!0````(`&24
M;$<#"0[]HP$``+$#```8````>&PO=V]R:W-H965T<R]S:&5E=#DN>&ULA5/+
M;MLP$/P5@A\0RK*<%H8L($Y0M(<"00[MF996$A&2JY"4E?Y]^9`4NS":B[B[
MFIF=Y:.<T+S:'L"1=R6U/=#>N6'/F*U[4-S>X0#:_VG1*.Y\:CIF!P.\B20E
M69YE]TQQH6E5QMJSJ4H<G10:G@VQHU+<_#F"Q.E`-W0IO(BN=Z'`JI*MO$8H
MT%:@)@;:`WW8[(]%0$3`+P&3O8A)\'Y"?`W)C^9`LV`!)-0N*'"_G.$1I`Q"
MOO';K/G1,A`OXT7]6YS6NS]Q"X\H?XO&]=YL1DD#+1^E>\'I.\PC[()@C=+&
M+ZE'ZU`M%$H4?T^KT'&=TI]=/M-N$_*9D*^$KUDTGAI%FT_<\:HT.!$[\'!V
MF[V'FR#BE8GW9OW84=/$P:OR7&VV1<G.0>@*DXC'&;,BF%>_V2*GM^AYI.>?
MT[?7]&URN)T=[CX7**X%BB10_&_$A#DNF/M_FK"+/55@NGAU+*EQU"YMZ5I=
M;^=#/$3V`:_*@7?PDYM.:$M.Z/S)Q@-H$1WX]MG=CI+>OY\UD="Z$'[QL4E7
M*B4.A^6!K*^T^@M02P,$%`````@`9)1L1SF!->2D`0``L0,``!D```!X;"]W
M;W)K<VAE971S+W-H965T,3`N>&ULA5/+;MLP$/P5@A\0RK)2IX8L($Y1M(<"
M00[MF996$A&2JY*4E?Y]^9`4NS":B[B[FIF=Y:.<T+S:'L"1-R6U/=#>N6'/
MF*U[4-S>X0#:_VG1*.Y\:CIF!P.\B20E69YEGYCB0M.JC+5G4Y4X.BDT/!MB
M1Z6X^7,$B=.!;NA2>!%=[T*!525;>8U0H*U`30RT!_JXV1^+@(B`GP(F>Q&3
MX/V$^!J2[\V!9L$"2*A=4.!^.<,32!F$?./?L^9[RT"\C!?UKW%:[_[$+3RA
M_"4:UWNS&24-M'R4[@6G;S"/<!\$:Y0V?DD]6H=JH5"B^%M:A8[KE/[LBIEV
MFY#/A'PE/&31>&H4;7[ACE>EP8G8@8>SV^P]W`01KTR\-^O'CIHF#EZ5YVJS
MW97L'(2N,(EXG#$K@GGUFRUR>HN>1WK^,7U[3=\FA]O9X</'`L6U0)$$BO^-
MF##'!?/YGR;L8D\5F"Y>'4MJ'+5+6[I6U]OYF,<S>8=7Y<`[^,%-)[0E)W3^
M9.,!M(@.?/OL[IZ2WK^?-9'0NA#N?&S2E4J)PV%Y(.LKK?X"4$L#!!0````(
M`&24;$=\VO7]H0$``+$#```9````>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM
M;(U3RV[;,!#\%8(?$,JRW!:&+"!.$;2'`D$.[9F65A(1DJN0E)7^??F0%#LP
MVE[$W=7,["P?Y83FQ?8`CKPIJ>V!]LX->\9LW8/B]@X'T/Y/BT9QYU/3,3L8
MX$TD*<GR+/O$%!>:5F6L/9FJQ-%)H>')$#LJQ<WO(TB<#G1#E\*SZ'H7"JPJ
MV<IKA`)M!6IBH#W0^\W^6`1$!/P4,-F+F`3O)\27D'QO#C0+%D!"[8("]\L9
M'D#*(.0;O\Z:[RT#\3)>U!_CM-[]B5MX0/E+-*[W9C-*&FCY*-TS3M]@'F$7
M!&N4-GY)/5J':J%0HOA;6H6.ZY3^[!;:;4(^$_*5\"6+QE.C:/,K=[PJ#4[$
M#CR<W6;OX2:(>&7BO5D_=M0T<?"J/%>;(BO9.0A=81+Q.&-6!//J-UOD]!8]
MC_3\W_3M-7V;'&YGA__1O[@6*))`\;<1$^:X8#ZZ9!=[JL!T\>I84N.H7=K2
MM;K>SOL\GLD[O"H'WL$/;CJA+3FA\R<;#Z!%=.#;9W<[2GK_?M9$0NM"^-G'
M)EVIE#@<E@>ROM+J#U!+`P04````"`!DE&Q'KS3AV*,!``"Q`P``&0```'AL
M+W=O<FMS:&5E=',O<VAE970Q,BYX;6R%4\MNVS`0_!6"'Q#*LMR'(0N($Q3M
MH4"00WNFI95$A.0J)&6E?U\^),4NC.8B[JYF9F?Y*"<T+[8'<.1-26T/M'=N
MV#-FZQX4MW<X@/9_6C2*.Y^:CMG!`&\B24F69]DGIKC0M"IC[<E4)8Y."@U/
MAMA1*6[^'$'B=*`;NA2>1=>[4&!5R59>(Q1H*U`3`^V!WF_VQR(@(N"7@,E>
MQ"1X/R&^A.1'<Z!9L``2:A<4N%_.\`!2!B'?^'76?&\9B)?QHOXM3NO=G[B%
M!Y2_1>-Z;S:CI(&6C](]X_0=YA%V0;!&:>.7U*-UJ!8*)8J_I57HN$[I3_YU
MIMTFY#,A7PE?LF@\-8HV'[GC56EP(G;@X>PV>P\W0<0K$^_-^K&CIHF#5^6Y
MVA3;DIV#T!4F$8\S9D4PKWZS14YOT?-(SS^F;Z_IV^1P.SLL/A8HK@6*)%#\
M;\2$.2Z8W3]-V,6>*C!=O#J6U#AJE[9TK:ZW\SZ/9_(.K\J!=_"3FTYH2T[H
M_,G&`V@1'?CVV=V.DMZ_GS61T+H0?O:Q25<J)0Z'Y8&LK[3Z"U!+`P04````
M"`!DE&Q'IO!@GJ4!``"Q`P``&0```'AL+W=O<FMS:&5E=',O<VAE970Q,RYX
M;6R%4]M.XS`0_17+'X!SXZ(JC41!"!Z0$`^[SVXR22SL3+"=AOW[]24-+:K$
M2SPS.>?,&5_*&?6'Z0$L^5)R,%O:6SMN&#-U#XJ;*QQA<']:U(I;E^J.F5$#
M;P))298ER0U37`RT*D/M35<E3E:*`=XT,9-27/_;@<1Y2U-Z++R+KK>^P*J2
MK;Q&*!B,P(%H:+?T/MWL"H\(@#\"9G,2$^]]C_CADY=F2Q-O`234UBMPMQS@
M`:3T0J[QYZ+YW=(33^.C^E.8UKG?<P,/*/^*QO;.;$))`RV?I'W'^1F6$:Z]
M8(W2A"^I)V-1'2F4*/X55S&$=8Y_\GRA729D"R%;"7=),!X;!9N/W/*JU#@3
M,W)_=NG&P;47<<K$>3-N[*"IP^!5>:C2XJ9D!R]TAHG$W8)9$<RI7VR1T4OT
M+-"SW^GY.3V/#O/%X>WO`L6Y0!$%BBB0YI=&C)C=@BGN?C1A)WNJ0'?AZAA2
MXS38N*5K=;V=]UDXDV]X58Z\@U>N.S$8LD?K3C8<0(MHP;5/KJXIZ=W[61,)
MK?7AK8MUO%(QL3@>'\CZ2JO_4$L#!!0````(`&24;$?SJ'L`I`$``+$#```9
M````>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;(53RV[;,!#\%8(?$,JRG":&
M+"!.4:2'`D$.[9F65A(1DJN2E)7^??B0%3LPFHNXNYJ9G>6CG-"\VA[`D3<E
MM=W1WKEARYBM>U#<WN``VO]IT2CN?&HZ9@<#O(DD)5F>9;=,<:%I5<;:LZE*
M')T4&IX-L:-2W/S;@\1I1U?T5'@17>]"@54E6WB-4*"M0$T,M#OZL-KNBX"(
M@-\")GL6D^#]@/@:DI_-CF;!`DBH75#@?CG"(T@9A'SCO[/F1\M`/(]/ZC_B
MM-[]@5MX1/E'-*[W9C-*&FCY*-T+3D\PC[`)@C5*&[^D'JU#=:)0HOA;6H6.
MZY3^Y/<S[3HAGPGY0KC+HO'4*-K\SAVO2H,3L0,/9[?:>K@)(EZ9>&_6CQTU
M31R\*H_5JK@OV3$(76`2<3]C%@3SZE=;Y/0:/8_T_&OZ^I*^3@[7J?LF^UJ@
MN!0HDD#QOQ$39C]C-I^'9&=[JL!T\>I84N.H7=K2I;K<SH<\GLD'O"H'WL$O
M;CJA+3F@\R<;#Z!%=.#;9S<;2GK_?I9$0NM"^,W')EVIE#@<3@]D>:75.U!+
M`P04````"`!DE&Q'\H`,1U<"``#K"```&0```'AL+W=O<FMS:&5E=',O<VAE
M970Q-2YX;6R-EM&.HR`4AE^%^`"#:-6VL2;3V6QV+S:9S,7N-6UI-8/B`JVS
M;[^`X+03@MY4H/_YOT/D<"P'QM]%38@$'RWMQ"ZJI>RW$(IC35HLGEA/.O7/
MF?$62S7E%RAZ3O#)!+44)G&<PQ8W75259NV55R6[2MITY)4#<6U;S/_M"67#
M+D*16WAK+K74"[`JX11W:EK2B89U@)/S+GI&VSTJM,0H?C=D$'=CH),_,/:N
M)S]/NRC6.1!*CE);8/6XD1="J792Y+_6]).I`^_'SOV[V:Y*_X`%>6'T3W.2
MM<HVCL")G/&5RC<V_"!V#YDV/#(JS"\X7H5DK0N)0(L_QF?3F><P_K..;9@_
M(+$!R9<`.(),FM^PQ%7)V0!$C_7+0ULEY]I$.0.5FU#;-I[<;+PJ;Q7*DA+>
MM-&#9@S<6\VD@,K=BT@B7WABPI/Y\/0Q/!TS3$=ZLIDW6#T:K$:#E=UBZMOB
MJ-D[S6H>DGDAF37(`A"GR><AN1>26X,B`'&:]3RD\$(*:[`)0*PFC^<A:R]D
M;0U0`.(T"T[.Q@O96(/0BW>:!2\>Q5Z*6586*(1QHCQ;P$%^CBW#/`]QG*A8
MP$G\G,1:K$,<)UI0E2CU<VQA%W&(XT0+;A_D+W]D:[OP7G&.XT3I`H[_!D"V
MO(M5B.-$2\Z!_Q)`ML*+X#EPHB7GP'\/(%OD1?`<.-'7<P#OFE%+^,7T7`&.
M[-K)L1=-JU-??TY,,_N45V6/+^07YI>F$^#`I&J)IG.=&9-$\>.G+`*U^O*8
M)I2<I1X6:LS'7CQ.).O=I\7T?5/]!U!+`P04````"`!DE&Q'+N`Y&Z4!``"Q
M`P``&0```'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6R%4]MNHS`0_17+'U`#
M(=LJ(DA-5]7NPTI5']IG!P:P:C/4-J']^_H"-%E%Z@N>&<XY<\:78D+]9CH`
M2SZ4[,V>=M8..\9,U8'BY@8'Z-V?!K7BUJ6Z96;0P.M`4I)E2?*+*2YZ6A:A
M]J3+`D<K10]/FIA1*:X_#R!QVM.4+H5GT7;6%UA9L)57"P6]$=@3#<V>WJ>[
M0^X1`?`B8#)G,?'>CXAO/OE;[VGB+8"$RGH%[I83/("47L@U?I\UOUMZXGF\
MJ#^&:9W[(S?P@/)5U+9S9A-*:FCX*.TS3G]@'F'K!2N4)GQ)-1J+:J%0HOA'
M7$4?UBG^N<UGVG5"-A.RE7"7!..Q4;#YFUM>%AHG8@;NSR[=.;CV(DZ9.&_&
MC1TT=1B\+$YE>I<4[.2%+C"1>)@Q*X(Y]:LM,GJ-G@5Z]C-]<TG?1(>;V'VS
M_5D@OQ3(HT`^CYA>&S%B#@OF?Y?L;$\5Z#9<'4,J''L;MW2MKK?S/@MG\@TO
MBX&W\(_K5O2&'-&ZDPT'T"!:<.V3FRTEG7L_:R*AL3Z\=;&.5RHF%H?E@:RO
MM/P"4$L#!!0````(`&24;$=YC&=UL@$``!8$```9````>&PO=V]R:W-H965T
M<R]S:&5E=#$W+GAM;(54VVZ;,!A^%<L/4!,(3101I*;5M%U,JGJQ73OP`U9]
MH+8)W=O/!Z#)A)8;[-_^3K]L4XQ*OYL.P*)/P:4YXL[:_D"(J3H0U#RH'J3;
M:906U+I2M\3T&F@=2(*3-$D>B:!,XK((:Z^Z+-1@.9/PJI$9A*#ZSPFX&H]X
M@^>%-]9VUB^0LB`+KV8"I&%*(@W-$3]M#J?<(P+@%X/17,V1SWY6ZMT7/^HC
M3GP$X%!9KT#=<(%GX-P+.>./2?/+TA.OY[/ZM]"M2W^F!IX5_\UJV[FP"48U
M-'3@]DV-WV%J(22L%#?ABZK!6"5F"D:"?L:1R3".<6>73K1U0CH1TH6P3T+P
M:!1BOE!+RT*K$9F>^K/;'!Q<>Q&GC%PVX]H.FCHT7A:7<K//"G+Q0C>82#Q-
MF`5!G/JJ18K7Z&F@I_?IV2T]BPFSZ)[M[PML;P6V46`[M;A=:S%B3C,FOV^2
MKYKDD\#C?TQFS.X?$W)U<`)T&^ZG094:I(WGMJPN3^`IW!3R!2^+GK;PD^J6
M28/.RKKK$TZY4<J"LT\><HPZ]TB7@D-C_73GYCK>VUA8U<^O</D5E'\!4$L#
M!!0````(`&24;$>0YZZ)IP$``+$#```9````>&PO=V]R:W-H965T<R]S:&5E
M=#$X+GAM;(53VV[C(!#]%<0'%,=Q=]/(L=1TM6H?5JKZL/M,[+&-"HP7<-S^
M?;DX;E)%Z@O,#.><F6&@G-"\VA[`D3<EM=W1WKEARYBM>U#<WN``VI^T:!1W
MWC4=LX,!WD22DBS/LA],<:%I5<;8LZE*')T4&IX-L:-2W+SO0>*THRMZ"KR(
MKG<AP*J2+;Q&*-!6H"8&VAV]7VWW14!$P%\!DSVS2:C]@/@:G*=F1[-0`DBH
M75#@?CO"`T@9A'SB_[/F9\I`/+=/ZK]CM[[Z`[?P@/*?:%SOB\TH::#EHW0O
M.#W"W,)M$*Q1VKB2>K0.U8E"B>)O:1<Z[E,Z66<S[3HAGPGY0MA$`DN)8IF_
MN.-5:7`B=N!A=JNMAYL@XI6)K\WZMJ.FB8U7Y;%:;38E.P:A"TPB[F?,@F!>
M_6J*G%ZCYY&>?T]?7]+7J<)UREX4WPL4EP)%$BCF%N^NM9@P^QESEWU)PL[N
M5('IXM.QI,91NW2E2W1YG?=YG,DGO"H'WL$?;CJA+3F@\Y.-`V@1'?CTV<TM
M);W_/XLCH77!_.EMDYY4<AP.IP^R_-+J`U!+`P04````"`!DE&Q'_@J]VK@"
M``":"@``&0```'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6R55MMNFS`8?A7$
M`PP?.*4B2$W2:;N85/5BNW83)T$%G&&GZ=Y^/OR01G*`YB*`^4ZV^6T7%]&]
MR2/G*OAHZE8NPZ-2IX<HDMLC;YC\)DZ\U6_VHFN8TH_=(9*GCK.=)35U1!!*
MHX95;5@6MNVY*PMQ5G75\N<ND.>F8=V_%:_%91GBL&]XJ0Y'91JBLH@&WJYJ
M>"LKT08=WR_#1_SPA',#L8C?%;_(3_>!"?\JQ)MY^+E;ALADX#7?*B/!].6=
MKWE=&R7M_!=$KYZ&^/F^5_]NNZOCOS+)UZ+^4^W44:=%8;#C>W:NU8NX_.#0
MA\0(;D4M[7^P/4LEFIX2!@W[<->JM=>+>Y,CH/D)!`AD()!Q`@4"'0@T'B7$
M0(BO#MDH(0%"<B6XL71]MR.W88J512<N@3PQ\SWA!PWOC(A6#O1P23T35K.S
M<U$6[R5>X")Z-T(W&&(QJQY#[F/6@!D0D4[@C4%"GP4!"SIBT6/B^YA-CTGN
M8YYZ3#H=EMZ&I6[,*`ADTP+QK4#L!&(0R&]3MA:3N=XZ3$QCDA%R'[=Q.((R
M2M%]V!-8(I(@0J=S)][<">1>^(P<<>TP-$L0FK9)O38I=&FD/VN'P2F*TY'!
M`25,DW@Z3.8-DT$8;X$XS+K'D&F3W&N2@X#W\P>3'C.C)PNOR0($DI'96\PM
M8XR\'K;9F'AG!4P`A'.4Y3BE]Y&;'IDB^YL1"_MCX;Y*9D@0;]%C,K_J,?6G
MH)#"6_<)++:PNI`\G]EE_QJ#X^F96`'H"^/K7QAP`F8C*\,*0',^+O^Z@/MR
MGA,T\\]B]H59]-<JSN<,K`-13#SC&GW:J!O>'>P1209;<6Z5VZ>'UN$8]DCL
M1G^%E\6)'?@OUAVJ5@:O0NGC@MW5]T(HKC.@;SK+41\4AX>:[Y6YS4Q(=W1R
M#TJ<^I/@<!PM_P-02P,$%`````@`9)1L1Y6<+&-5`P``VP\``!D```!X;"]W
M;W)K<VAE971S+W-H965T,C`N>&ULE5?1<J(P%/T5A@\HY`8(.NI,U6KW86<Z
M?=A]IAJ5*1`7L';_?H%<:'4O&%\$XCGGWAQR0^[DK/+WXB!E:7VF259,[4-9
M'L>.4VP.,HV*!W646?7/3N5I5%:/^=XICKF,M@TI31QPW<!)HSBS9Y-F["6?
M3=2I3.),ON16<4K3*/\[EXDZ3VUFMP.O\?Y0U@/.;.)TO&V<RJR(56;E<C>U
M']GXF;LUI$'\BN6Y^'9OU<F_*?5>/_S83FVWSD$F<E/6$E%U^9`+F22U4A7Y
M#XI^Q:R)W^];]54SW2K]MZB0"Y7\CK?EH<K6M:VMW$6GI'Q5YV>)<_!KP8U*
MBN;7VIR*4J4MQ;;2Z%-?XZRYGO4_H8LTF@!(@(X`;)#`D<`[`A\F>$CP.@+S
M!@D^$GS3E`(D!*8$@01A2@B1$%X1'/TZFI>YC,IH-LG5V2J.4;W$V;B"Y[5(
MI6Q5;["H%D>CF3?+8S;YF`%C$^>C%KK`0(.9:PP;03_F26.$UP]9HTR'<*HD
MR4S!IK(`S'0@BT6+X?V898L92/6IQ?C]F!6@*\'`E`UTGO_7Z36&7QK#]2OD
M&,1`P+L4\+2`AP+B,LNLP0CMB,8P'R`,^V$KA(U\UW7[86N,R"$,H!_V3*KU
M3LXG)^?CY,+;`@%I;V!NKR`S$"@PHA:!QBP1`P;3#,D@(0J0=8Q!6@S<#C(B
M@XQ0@-\68"YI9C-LZ"9C9!(,MRSPJ)7CZXT`02:)`AT%;ANZZ$"^01Q.Q\'J
M!1-#/-I3[PY/Z2)A6"4PL`7,$23<0!@4$POH2%A.8"(AZ/F*.^9+5PL+A[8\
M'S]I&L3"0/"!O0QA02`\89`075FL+:W1;0F@2PON*"V@2PO8[46_;D'<8*\"
MNK@`#.Q'T"W[$69H/]!5"%B%W.1T0E<AW%&%0%<A^";V^W?83]<@!";V:Q`7
M[/K#=6D_!>M/B/Y"@FC/`P82(6U_>(?]=`W"R,3^D;G]W"7C<'?(?CQO=2#O
M^H!Y83\)TPDYW]J!5.;[IC<LK(TZ9:4^"7:C7?_Y"'4[<34^9^,E(\:?V'A%
MC:^K/E:W)5]A9Y-CM)<_HWP?9X7UILJJN6EZD)U2I:QFXCY4Z^Y0==K=0R)W
M97TKZ@6I>T_]4*ICVTIW_?SL'U!+`P04````"`!DE&Q'$V"JDND!``"C!0``
M&0```'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6R-E-ENW"`4AE\%^0&"-[R,
M/)8RJ:+VHE*4B_::&>.Q%3`.,./T[<MB3QT537QCMO_\WSE@J"8NWF1'B`(?
MC`YR'W1*C3L(Y:DC#,L'/I)!K[1<,*ST4)RA'`7!C0UB%,9AF$&&^R&H*SOW
M(NJ*7Q3M!_(B@+PPAL6?`Z%\V@=1L$R\]N=.F0E85_`6U_2,#++G`Q"DW0>/
MT>Y0&H45_.K))%=]8'(_<OYF!C^:?1":%`@E)V4<L&ZNY(E0:HPT^'WV_(<T
M@>O^XOYLJ]79'[$D3YS^[AO5Z63#`#2DQ1>J7OGTG<PE(&-XXE3:+SA=I.)L
M"0D`PQ^N[0?;3FXES^<P?T`\!\2W@-@E[D`VS6]8X;H2?`)RQ.;LHIV6"V.B
MG8'.3>JRK:>PA=?5M8Z3I()78_1)XP(/LR9"-PW4_EY(_!F2.$AL#:)D@T&R
M&`S6`#F#Q&40KE)8B7*7IA.E21F&7W-2+R==.)F/XT0')XHRE&\!(2\(+:#\
M3D%.5*!-!65>3K9P"M_YIH[C1"C^&I)[(?D"*>]`\LV0(O#$/Q;SCYK>812;
M&:674<Z,>W_9K"D1^N]4X.H"COA,?F)Q[@<)CESINVRO7,NY(MHF?-![U^D7
M\S:@I%6FFYM-=8^(&R@^+D_B[5VN_P)02P,$%`````@`9)1L1Q3B^O"[`@``
MEPH``!D```!X;"]W;W)K<VAE971S+W-H965T,C(N>&ULE59=<Z(P%/TK##^@
MD!"^'&2FU:K[L#.=/NP^IQJ5*1"7Q-K]]YLOJ'4"9E^$7,\Y]RO<I+C0[IT=
M">'>9U.W;.X?.3_-@H!MCZ3![(&>2"O^V=.NP5PLNT/`3AW!.T5JZ@"&81(T
MN&K]LE"VEZXLZ)G754M>.H^=FP9W?Y](32]S'_B]X;4Z'+DT!&41#+Q=U9"6
M5;3U.K*?^X]@M@%(0A3B5T4N[.K=D\&_4?HN%S]V<S^4,9":;+F4P.+Q01:D
MKJ62\/S'B'[YE,3K]UY]I=(5X;]A1A:T_EWM^%%$&_K>CNSQN>:O]+(A)H=8
M"FYIS=2OMSTS3IN>XGL-_M3/JE7/B_XG3@W-3H"&``<"1).$R!"B+P*8)"!#
M0*Z$V!!B5T)B"(DK(36$U)60&4)V0PAT.U0SEYCCLNCHQ6,G++<XF`EX)T6$
MLB<ZR,3F4)J=VAYE\5'"*"F"#RGT#0,5YDEC0`[',4N-2=$X9&5DQA&;/IAT
MP`0B$6LVT+=%"HU`-NYD`4TV$QDOC0Z(QS'/#CHK!YVU@\ZFSRN_7YCH>V$B
MW>9("Z#PO@#Z+H"T`#("-^UK%2;6U=<8%&8._8NM7F+C!=J\I-J+QL11&HV#
M%AJ4AV$X#EH:I23))E#/&I7`'(V#5AH$TC"/K!72L+71RM"$UL84(4P<FI58
MRYB8,D;W!5+K=DG=MTMFC2`S`E,URX8>391_K5%1'%W#1J/)K='D)IKXO@`(
MK0519L>*`&`-`ICIAJP?N@:M!Y##)P2@W8\9%BASD+!/"_`?XP+8YP5`+MGV
MH-NY%EP=90WI#NI>P[PM/;=<3ZC!.MR='J$\"F_L3V"V`!;[$LR>;?85F*WU
MD?KEMBQ.^$!^XNY0M<Q[HUP<S.K\W%/*B<@C?!`#\"ANB<.B)GLN7U,Y&?6]
M22\X/?77P.$N6OX#4$L#!!0````(`&24;$>7"T<L'0,``#X/```9````>&PO
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M/>FGI@D\/Q_9O]MR=?JOU2">9/.GWJB]SC8.@XW85L=&O<C3#^%K2`WA6C:#
M_0[6QT')=@P)@[;Z<,>ZL\>3^R6/?1@<0'T`G0)89A-W0C;-;Y6JRJ*7IV`X
M5.;AD7L-[PV)9@YT;H,NVW+VMO"R>"]I&A?1NR&ZP+C`1X<A$R+2[*`$#:%P
MZL))=IV`71(PER/S.2(R2"X)$D>0>`)Z661G,:G+,O%9YK'^7!=*0:'4"['K
M!!PLE>-+S<`,,D2IV6VEYJ!0[H62ZP1+L-2E)TBO$Y`83,'>-A1\IE@/(DF&
MJY806(L@%M:#[@A#:E%8BWJM##)EXK4<Z"R?KV48+#/Z*I\KR8$XLE<(;$`R
M.G`Y)^5!,45JI6!?D13O(<+A=#FFL1R(9-B'#1N68!SK0>B^@BU+<DQ?Y?B^
M6L(R2TQ?.=`=MK$H_`J@,:*Q/`C]PJ,$;"SJ7P$<0P$[FWIG<P*EN_3I.E"\
M2!#/@,+>IM[;'.PJ\Y_%*K%;E!)X5;QK.6+/H_"N2=.Y59F236])%C8V]<;F
MR:R21RWH$J$$VYIFJ`>0W5(3[&KJ7<W3N9[*O1#J,<&^IM[7G%^G8#'8+"S&
M6XC!&S$;79C-E.M!9$$0_RX8[%5&$>O*;O$J@[W*1J_F"`K8A"RY85UA$[)T
M;ETS7ZX#(7J(P09D?&Y11Q4.JD1G\TTK^IT=XX9@+8^=<N/-='<:%1^HG8\^
MX65QJ';B5]7OZFX(7J724Y8=AK92*J'5XX7>-?9ZF)TN&K%5YC0SVXD;[]R%
MDH=Q6IU&YO(_4$L#!!0````(`&24;$>YZ%'\7`(``,4(```9````>&PO=V]R
M:W-H965T<R]S:&5E=#(T+GAM;)56VXZ;,!3\%8L/"-A<$Q&D)*NJ?:BTVH?V
MV4F<@!8P:SMA^_?U#9*LW$!?P#[,F9EC8PYY3]D[+PD1X+.I6[[V2B&ZE>_S
M0TD:S!>T(ZU\<J*LP4).V=GG'2/XJ).:VD=!D/@-KEJOR'7LE14YO8BZ:LDK
M`_S2-)C]V9*:]FL/>D/@K3J70@7\(O?'O&/5D)97M`6,G-;>!JYV,%$0C?A5
MD9[?C8$ROZ?T74U^'-=>H#R0FAR$HL#R=B4[4M>*22I_6-*;IDJ\'P_LWW2Y
MTOX><[*C]>_J*$KI-O#`D9SPI19OM/].;`VQ(CS0FNLK.%RXH,V0XH$&?YI[
MU>I[;YYD@4US)R";@,8$F#Y-"&U">$N(=*7&F:[K!0M<Y(SV@'=8[39<23A3
M))(9R&*X7"?-R?1*%?FU0,DR]Z^*Z`&#-&9K,'!$^)+=*8$\5SHR$O\6V!E$
M&D\KA(\*)K@)C4(:3!-$CP21(8@L`729-)CM@'$68C`[@XG1M(_8Z2.V&N$3
M'P,F>N(CGNTC<?I(K$;\1".9K9$Z-5*KD3RI=<"DTR*94R2S!-FC2*LQ2R-B
M,0OW&;#59K.K73J-+*V1Y30!#)PON0[/?,LA=)J`<'I?MP,HFZ.#W#IHQMZ.
MH!F;"T.WCCWX<3B#(G*O:O0?J^H^M#">LZH6E,WXC$+WH83)G%6UH.SKF^K?
M=8>&L+/NFAP<Z*45YLL]1L?.O$&JNWR);U7'UEWG1E/D'3Z3GYB=JY:#/16R
M=^D6<Z)4$.DK6,0>*.4_Q3BIR4FH82K'S'19,Q&T&WX:QC^7XB]02P,$%```
M``@`9)1L1W;`(&"@!@``+B<``!D```!X;"]W;W)K<VAE971S+W-H965T,C4N
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MH=`OG?7`S=^]]/-FNI7YO](B.\WG_\Z>RM?*VJ#;><J>T_=Y>9]_CC.<@ZT%
M/N;SHOF_\_A>E/G"#^EV%ND?]W.V;'Y^NK_$`0ZC!R@<H*0#-`[0ZP$Z8@<8
M'&#6`Q0_P.(`*]40XH#P2P,_AP@'1%(-,0Z(I0,2')!(!]0^=YX+OF81\T/6
MS@:Q%N]N^/*W,?P0[W`0>QR\R\&(AWBG@]CKX-T.&WX'?HAW/(@]#][U$(NU
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MF2"D@N![K=LA;\7DM(UD9D"7"\!Z`6Q81++]+L*F),883E<6P-("2B)CJVQ@
MHP/)`9V.HC.]\IF>R;YG"$',N_7<<Y;G1L@I*W2^HBN'@OW.'R$D=9>B"X?"
MPL&%[YE:GVM:IH\='7(@WOR*KC`**PR0.2I!9?J`SD_1R5EA<@9FDPP1LGLV
MR2G-,3;1B5QA(@?)04&%9`"I\)``HC.0\AF(+/-^;1QDA3.F4X:*][M[B%!P
M)*F1BFY'%?:C0-9BKR@Y0)&FDX_&Y`-,K1LB9-N+B@-/6T#&*CJM:$PKBCPV
M&[3*0Y*DHNFDHGTW*NDR=<MA]Y#3KJ;#6_O>BSETC3RD0N'BTF&K,6P5=Z1"
M"$#'@>@>@&YO-+8W2G)BT!&]OM$AZTL'KO;'2.9\=XU0%$72W4L'K\;@54SC
M>HT0R#09.GH-QIOHG@7(U35PR%T-'47&WQ@Q)X<A0J':TYK\-!NUF;O]07DL
M-48JX85=^1FH/6WSM?$)8P]X0RIF5I;N+XS++2W74U@'/'1$-P<1+JNCF!NJ
MD=EM5':@,0_A[O8FM<NY(>0PR]-R2^BO"9D;L9\>XHK)2`*-"8@QF<Z^QF=?
MII&[1DAR,#%TXC7^'I`I*$.$XCHFN9WC,#`1VU-[C.\1QHCMN3N\\M)@3\]Q
M0\ICUHON(8V_]>3Z:X0@CBP7^V=>&)^;SM<Z]R2ZK\Y5-$&Z`IK8-P_<AHAW
MBQ+AZ'@CDTLLHLND\6524GGL5@'$ZF6#`ZJ7I9M-"UR.]5\!P%;V9-301=)B
MY5"2;MW2K:8]I-6T=,ZT@J]6KA"R>VKU!#FSAYL*N0?KKQ?%7^JT?*LC^%KG
MRD/,->1^9+J#,,;2N=H*<O4#0HEX8>@\9Z/]:>`*(0A,2Y[S4W=<;*W,)#HS
M69^9)&<P2]_#V4/NX4*ZF0[]49@,#,R0"+5E2*?@%"G9R3RDTU*(QUO-Q,LP
M]+F+KJ5XW^.IN.:V/=7;>&5BD:U>FM>MBLYC_KXLW;>SZZ?K5[I^J/J5BZWG
M0SB^!N+Y!([OJ.=3.+YW+W)]J1WTW]*7;)*N7F;+HO,K+\M\T;RF\9SG95;-
M)3BJYO2:I4_K#_/LN:Q_C>K)NM>YW(<R?_-OIZU?D1O\!5!+`P04````"`!D
ME&Q'"C@=V"(#```@#@``&0```'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6R5
M5]MRFS`0_16&#RAH)2[.8,_$[G3:A\YD\M`^$UNVF0!R08[3OZ^0%G+I!BM^
M,"#.[EGM<B1M<5'=8W^44@?/3=WVR_"H]>DFBOKM439E_T6=9&O>[%77E-H\
M=H>H/W6RW%FCIHX@CM.H*:LV7!5V[*Y;%>JLZZJ5=UW0GYNF[/ZN9:TNRY"%
MX\!]=3CJ82!:%=%DMZL:V?:5:H-.[I?A+;O9<`NQB%^5O/2O[H,A^`>E'H>'
M'[ME&`\QR%IN]>"B-)<GN9%U/7@RS'_0Z0OG8/CZ?O3^S4[7A/]0]G*CZM_5
M3A]-M'$8[.2^/-?Z7EV^2YQ#,CC<JKJW_\'VW&O5C"9AT)3/[EJU]GIQ;_(8
MS6@#0`.8#$#,&G`TX),!LP:1B\S.ZVNIRU71J4O0G\JAVNS&P+O!B?$<F,GT
M)D_69V<SM2J>5IRS(GH:'+W!@,6L'>8%$1GO)`6$E#E8<_B88.,067*=@;]E
M<(.WW#$LLNL.Q%L'PCD0F(5W0;86D[D@'2:^3I&0%`E2\(\IU@[#1)8QP:\3
MI211BD2"2KC#K$>,1\8SDB1S#N+%=0<Y6;+<OV0+,H+%]9*M'092OL@]9LIB
MDL@.#TRIAPM&3I8Q_]DRH*,`C"*CYIN@4!V(L3PV/P\N3G-QY,IG/B$$0>8S
M)UIU3*`+<O$9>480N8`XT`9!"7C$0LN3C?KT^*)92E<Y_425:5FQS*?*V2>K
MG--<N4^54:>Y3V9IH3)4JO`(%6(RLQ#[9Q88&07@1B?83&9'$,1^F05:J^"C
M500Q[DE%2Q50JH)<!D<JE&H,GERT7`%W2<%G/I@1Y,5#2Q%0BF)N!YM`'@L[
MT!LEX"XHTCF>$>3SZ=&B!A2UF!/:!/)8?X`6-*"@DWB.!P4-/O6A!0THZ&1N
MV4:0%P^G-UZ.&V\RL_*O)Y#'>8G32P-'U2>"TA`>)1!DSF;_2RAZ=?!N9'>P
M#4D?;-6YU>Y0/(U.3<\M#`?W=^-KTPRYUN7%S:HXE0?YL^P.5=L'#TJ;ML">
MWO=*:6E"B[\8F1]-NS8]U'*OA]MLT+]K8-R#5J>Q'YN:PM4_4$L#!!0````(
M`&24;$=!=5<-`@,``,H,```9````>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM
M;(U777.B,!3]*PP_0)+P[2`SU=JZ#SO3V8?=9ZI1F0)Q2:S=?[_Y@E:;2'P0
MB.?<<W)O<@W%A?1O](@Q\S[:IJ,+_\C8:1X$='O$;45GY(0[_LN>]&W%^&-_
M".BIQ]5.DMHF0``D05O5G5\6<NRE+PMR9DW=X9?>H^>VK?I_2]R0R\*'_C#P
MJSX<F1@(RB(8>;NZQ1VM2>?U>+_P'^!\@X"`2,3O&E_HEWM/F'\EY$T\_-@M
M?"`\X`9OF0A1\<L[7N&F$9&X\E\=]%-3$+_>#]&?Y'2Y_=>*XA5I_M0[=N1N
M@>_M\+XZ-^P7N6RPGD,L`FY)0^6WMSU31MJ!XGMM]:&N=2>O%_5+BC3-3$":
M@$;"J&,FA)H0?A*BNX1($R)70JP)\4C(P%U"H@F)ZQQ234A="9DF9#=S"%0Y
M9#$?*U:514\N'CU58HG#.8?W(@B/[/$*4KXX9,Q>+H^R>"_#."Z"=Q'H"H,D
M9JDP,$=VS)/"I)$=\JS#C(B`FS0Z1;[)!=).$[O$:L"D=LSC@,GLF/6`R>_,
M6&'NY.1Y$K'1.@F83DIXG910E2_4`1RR&ET'B%2`2`>X<=E)3*IFJC!I'&69
M'?5L0EG-Q$8SL0R1W?.B("A+``!WS"A8?@VSNDF,;A*5&HBF`Z3&XJ3NQ<F,
M#C+M(+3/]#%S2LA:P2"0GVD_N=%/KB=D]),K(85!LWA:!`*CBAP6,L9FHD#K
M$>2B`\TZ<'KM;S0H=<P;1&:I8:,G)JE855*#8.8H%9JEAI:0VJ66&A1?2WW#
MK<PXNR5SCX&ZR<#$(41LW$HP=M]+T+R=83*]>I<:!&8./0RF9AV][6%N7U9+
M#8IO]N,WX,H"M)LR=Q*832_`E09!%"(W+7.7@$.;,/Y;Y%HK=T\T,O<)-+0`
M8Z)U037HNT[PY;34XOX@C\[4VY)SQ]019!P=C^</\A![,[Z$\[4Z9'^&*8M3
M=<`_J_Y0=]1[)8R?Y>21:T\(P]P7F/&<'_F+Q?C0X#T3MZDHACIJJP=&3L.;
MP_CZ4OX'4$L#!!0````(`&24;$>;4TX2#P(``#X&```9````>&PO=V]R:W-H
M965T<R]S:&5E=#(X+GAM;(V5W8[:,!"%7\7*`Y"07XI")$BU:B\JK?:BO38P
M)-':<=9VR/;MZS^RL)L&;HAMSCGS39"'?&#\5=0`$KU3THJ-5TO9K7U?'&J@
M6"Q8!ZWZYL0XQ5)M>>6+C@,^&A,E?A@$J4]QTWI%;LZ>>9&S7I*FA6>.1$\I
MYG]W0-BP\9;>Y>"EJ6JI#_PB]T??L:'0BH:UB,-IXVV7ZW*E%4;PNX%!7*V1
M9M\S]JHW/X\;+]`(0.`@=0)6CS.40(@.4H7?7.9'26V\7E_2GTRWBGZ/!92,
M_&F.LE:P@8>.<,(]D2]L^`&NA40''A@1YA,=>B$9O5@\1/&[?3:M>0[VFS1S
MMFE#Z`SA:`B364/D#-%H6,:F4TMF^OJ.)2YRS@8D.JQ_[.5:R;D.4<E(-2/4
M>S*9W+RI(C\741;D_ED'W6A"H]E9S7)4^"I]LD3H3=E#8P__7Z"TBBRY7R&Z
MK6`/MY%KX@'$^#8@M@&Q1;P*^*+97323C5A-:35)>)\CF>1(7(UHAB-QS<YQ
M)`]SI),<J>-(9CA2QS'#6J8/<V23')GC2&<X,L<1WR^RFBRR<@&?FFV-YILM
M8C7!(IXA*5?3W?I7]Y("K\R\$NC`^E;:.S.>CB-Q&^I[_>E\IT:EG6P?,47>
MX0I^85XUK4![)M74,)?[Q)@$114L$@_5:IB/&P(GJ9>96G,[W^Q&LNXRK<>_
MC.(?4$L#!!0````(`&24;$>=3GU::0(``'$(```9````>&PO=V]R:W-H965T
M<R]S:&5E=#(Y+GAM;(U6VXZ;,!3\%<0'!&QSC0A2+JK:ATJK?6B?G<0):`%3
MVPG;OZ]O89/*">0A8&=FSHPYV"D&RCYX18CP/MNFXRN_$J)?!@$_5*3%?$%[
MTLE?3I2U6,@A.P>\9P0?-:EM`AB&2=#BNO/+0L^]L;*@%]'4'7EC'K^T+69_
M-Z2AP\H'_FWBO3Y70DT$91&,O&/=DH[7M/,8.:W\-5CN0*0@&O&K)@._N_>4
M^3VE'VKPX[CR0^6!-.0@E`26ERO9DJ912K+R'ROZ55,1[^]OZM]T7&E_CSG9
MTN9W?125=!OZWI&<\*41[W3X3FR&6`D>:,/UMW>X<$';&\7W6OQIKG6GKX/Y
M)4HLS4V`E@!'`LQ>$I`EH)%@ENXI(;*$Z#]"8*+HA=AA@<N"T<'C/5;M`982
MSI2(5/9D>BX75FLRO;1E<2U1FA3!50D]8*#&;`P&C(A`JCM+0-]%AYH.GQ?8
M&@2*\^>8G56)IUV@1Q?(!$4VZ(P8T:.`F5Q'5B!]--EI3&ZB&@Q<Q"Y,:L(:
MS(P<L=-&;.A.%Z;"QD!2!$*4/(?M#`SDH?Q,NTF<;A*M$64OW!@(S'*(<CA=
M)W7628W7"$T+9,['G\U__+G306X%G%%C$]5@D@BE\9PE!:&SDIZ>ZC0+`@LP
MHY,`<!<"T[UD,3!'<38K$W27LJ]XZGS%(UO+@K(Y=9"[CGW-0?XJDP'%83BO
M]8%[0P#1=/-;C+O[@[L-NR7LK$\^[AWHI1-FOQYGQ]-U#?6&_P4OBQZ?R4_,
MSG7'O3T5\MC0N_N)4D&DAW`AN[.2Y_\X:,A)J-M4M:TY$<U`T/YVP(__,LI_
M4$L#!!0````(`&24;$>YGKZZCP$``#T#```9````>&PO=V]R:W-H965T<R]S
M:&5E=#,P+GAM;(53VX[;(!#]%<0'+!@G314YEIJM5NU#I=4^M,\D'L=H@?$"
MB;=_7RZ.FU0K]<4S`^><.0.XF="]^@$@D'>CK=_1(81QRY@_#F"D?\`1;-SI
MT1D98NE.S(\.9)=)1C/!^2=FI+*T;?+:LVL;/`>M+#P[XL_&2/=[#QJG':WH
M=>%%G8:0%EC;L(77*0/6*[3$0;^C7ZKMODZ(#/BI8/(W.4G>#XBOJ?C>[2A/
M%D##,20%&<,%'D'K)!0;O\V:?ULFXFU^57_*TT;W!^GA$?4OU84AFN64=-#+
MLPXO.'V#>81U$CRB]OE+CF<?T%PIE!CY7J*R.4YEIU[-M(\)8B:(A2"*\=(H
MV_PJ@VP;AQ/QHTQW5VTCW"61J$RB-Q_'SIHN#]XVE[;^7#7LDH3N,(6X+QA1
MK1<,B_H?-A'W3>K21&2!:K7YOT!]+[`J`O7L4MR[M!FS*2X+9L5%S3G_IQ&[
M.9I1GN"'="=E/3E@B*><#Z-'#!!U^,.:DB&^Y:70T(>4;F+NRO66(N!X?:S+
M']/^`5!+`P04````"`!DE&Q'D3Y;Z^P!```7!0``&0```'AL+W=O<FMS:&5E
M=',O<VAE970S,2YX;6R-5,ENVS`0_15"'Q"MEA?(`FP707HH$.30GFEIM""D
MJ)*4E?Y]N4FV`P6.#R8Y>LL,R6$V,OXN&@")/BCIQ-YKI.QWOB^*!B@63ZR'
M3GVI&*=8JB6O?=%SP*4A4>)'09#Z%+>=EV<F]LKSC`V2M!V\<B0&2C'_=P3"
MQKT7>E/@K:T;J0-^GODSKVPI=*)E'>)0[;U#N#NE&F$`OUL8Q<T<Z=S/C+WK
MQ<]R[P4Z!2!02*V`U7"!$Q"BA93Q7Z=YM=3$V_FD_FRJ5=F?L8`3(W_:4C8J
MV<!#)51X(/*-C2_@2EAIP8(18?Y1,0C)Z$3Q$,4?=FP[,X[VRR9PM&5"Y`C1
M3)A]E@FQ(\170F(JM9F9NGY@B?.,LQ&)'NO##G<*SK6(4D:J&*'VR6ARLU-Y
M=LGC39SY%RUTAXD,YF@QX3::,;[27S2)O"6!R)DD7YN<)LSJL4E\;V*#A]@)
MI(\%DGN!Q`HD3F!]GV5G,"M;B<6$JB'4[['1:M%HY8PV2T9K:V0QVV_ZI(L^
MJ?/9+FV[Q1P=9AM\C3E-F/!3(O[-A:/`:].(`A5LZ*2]"G-T[O5#I"_LI_A1
MO0&V9:\R>=;C&GYA7K>=0&<F53N86ULQ)D&E%3RI,VG4*S4O"%123]?ZL&SC
MVH5D_?0,S6]A_A]02P,$%`````@`9)1L1V3Z"S7H4P``*#8!`!0```!X;"]S
M:&%R9613=')I;F=S+GAM;.U]V6X<V97@\_`K`H3<)H%@%C.YJVP#%"55R2.)
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ME_:7\O(GLTCQ#1CB8[(TG<G-LJFB5VE135.33TT,HT]'`V-=P4+*)(-79N9K
M]-_-4_N]SV4R2_-%=/NTO"NR]M,<IFK_[:HI2]S>V[2:PLC_PR0E@C!ZG=2=
MM1X<C"<'1^.!Q;U-,U-&5_#=HB@[*[M=)AD^_V1615GC&J^*Y2K).R_J5HOE
M$L![6Q?3+W%T2V<>73=U5<-!P.>#Y_3Y:=59^/CPX)\'/[@Q95K,!C>MJ+/S
MW_Y;'WY<PA@S&N=MEG16-4^RJC.BG=F'^5OX8^=PVF_*4GO?_>>CSM%>?[R]
M?O_N]>7G-Z^C5Y?O+S]>O8ENOW_SYO,M7*,?;E]'>R_V.U.:*6QW3)?A>`A9
MDJHR=1>5DNJ>KLD4?S!_;M*')(/7.R]^,G`ATFEM^-7VXYO2K))T%IFO0%"J
M[E6_KN\!D:9KU_*YJ`%>Z]^Y*8%BE8!KN&9<[@IA'4>YJ?NG[!_F-6!TE=85
M#5.L>9'7M/F-`>C*7K(TN4NSM$Z[@+F<3I&@5M$J>4KNL@[BP?.R`:##X[+(
M,EIP:;($#V((V/I-ED[Q.7VS@B]@):5)EW=-61E"T;D9_GAH<+K=4=7<5=,R
M71$]U>UUZ`*<UD-:X2M`?*-ID3^8DGXMYM$MW`L@#Z\B8#=S`W":114.W1X#
M2&NQ-%&=?#6#0`HQ9PVT/Q;Y%F^]U@7ABUW:(NM^3$KD$`,(D6\U$[^[Y@4D
MJ6F-A\6X"C!$0@Q<!Q>Q][&H3734)@C(ZU]6JV1J?KL+T*U,^6!V?Q=UK_3,
M@!``\`3*C4=3I_BSW>"-/1BAZ"\.1X>'8SB$,@(JT1@D.-$RS3(\4F;Q4=+4
M]T69_L7,OHU.XL/#PRBM*L0GNFF.%\"-82Q8U69Y![=+.3V]"-`SZS\$FB??
M"=TC&H!/7AR/Q_'IZ3A*<QHB`0X-<*OJZMOHQ<G(K3@#<2:=L4C`2(C,?'!A
MO1?AOLAF@-._CF9FGD[3#K8(2ZSZ`?AM-#DZ70?!\7E\>'8>CT^/?A(8QV[P
MYP&S0Q1FLQ3A!,B*9/X@S0^FR2H%Y&V_^>/`K0"RTBP;IEL#L.++4&T#ULZ]
MH8UM]>DZ#KMWD^"-O3=U"JR[VA]FN;<U[(1HZ/4<.'T.2)8BLT>NLE[$O`G)
M7>RP(=H#C)T!D4]*H'1P&H00G:D[`W3P9MLO&">V?;L8%N3>!=>L_?1]_SVC
M/:^_+\\%3?CU1KCTOMX/E-Y7UT`DP++;S_#/AS<?`<.NWT;7-V\^77Y^!R]$
M>TV>-'"SS&P-JAUMK25UKNTU@"HAP7V(FX-8!Y+LE&7`F7DP64$25?N][TQN
M4(O!UY+9,LU)/ZK3AP%>7&R<V:TM*ZH!>5&^[0#W/@$6B/1]GJ2*(4#&/`&C
M3!?W=>7)&9>;Y(R/P#UP)=&=`6$%1W=RQWJY9MV;.FK[[Z^2*ITRT-.L0:)(
M<R-J3P75$,>VQ'M1M9H*QH$/8(150Z"]&Y[&C<_8W+U,PRA\=7G[??3V_?6/
M6Z(P:1GSK'BLHGE9+#WL``J9/A`%?]GE.7]J*A%]Z@)D,3C>*>BKQ.=I&_!7
M_)E4%]W[5D.#^`_#I422>MGZ`0`.-1T`)"`@DRX\:K-<9<53G]2\1`WY+_PF
M8)T*AXXO*0?&85`B`]F\,\H?Q_\2_W'281F,[Q5NC_4,&M7C?IT-PD"=/W7'
M;8OZGC:T3H;>!N2;,""%FUIM.J:;!BA3@@L#B*YZ-;^-B^N;:-/BYLS/-RRN
M+*;&S.23J<<?K-3I1-*C^&)RV))&UP\X1+9Z!C^+SPY_TN`=W:MG<"M,KQW>
M@GV%E!'85'3WU`O&O@^!?I8&CIE(U[;VB$'#10P$?)'F.<Z+:$/FEV=\;?`.
MK/V.#!VSIL09X++(JWBQ.TCR+J]!VJDZ:/IN#<MX[4:&39AHR=S?(/?O$?1C
M>E,,<TID)H>'I'M9,@2D<B6WR4HO<Q!@RA!S14VOFHRNC-*I4?09YK"#/<*>
MF.N",%`CCIS%YV<G_):N!.3G0I?C9MQF-G_H\>DY;F04W38HI"S95D(+0(90
M(DQ`ATDB-4"]85K&@@J\=6<(`9D\P\L%2`@$,9E-3J]CO?W<!>II"-($[<M`
M.TTY36'"58FCX969C$X.$>")FX-O!8H*\,&4Q1?B)U]QYTU:W9,N@5^/^>3@
M1Q"P9K"1EH$H*AYA+3!\?9\"J``MBK*S^N?S[K;JL]8:+VS^1?2-'&V_?=\I
M2;`;NCIOB<@.*T=7?62TG^1L))!K/QLF??V?J5JKN-!_G[;";D_DBOXZX!GY
M@XJTC[_8O(-3=%B7""E;C-&&RF;T'L#I(3C(!.U;UB\5PR@.(SLNBG`IH+5_
MIJ58^^N-+.4:K]?G(OH#W:P.OTKJIB2PB?X"0(JC5TT%E!HDTDO+Z(@`W3;+
M95(^D1J2+O)T#G<+)I<Y$;(W199.A\W"_BMKKLUX%/VM%M8[,(V!*@QAWPV:
M&/.:9=]^WQ@@")##N[18P>$LDZEIB,R0@(T4MKX':KK*DIPXE>BA8O!<+O'L
MDPS(-Q+N,EG1URIX)7D.HFI>I"#<U/=ET2R`3Z#EH`:-M;I/5]%C6M\3R?\A
M3TD_K&GC'P!I\?^K5<J<:_!QM+?[PX?=?=S$W,Q0#\Z>$.^6:5V+34U,[71!
MIWAK'H#TZ>(JN@REKVJ[;>%]7A45,MD?\@S/BB3P1\3V:@5:RCPULSBR=A-2
M`^`->(S6WXI9`:Y>:#D:<RLXO1G9VIQMRE)C^\FN,+AX-]I]-+L1+'(71()=
MG@S?ZC_-&`#\T3PDLP3V`8LOK8($>P+0?,F+1U15HO=%,HN^:Y)R!C^B2Q6.
M31!B;_?]=^]W]T%Z*1:&5`XZ)O3)/-[#U7XZ@#&0.#=W53I+`5EC7@U.?@78
M`+/E:;B`O5UZ8W=_)`N_,]-D25@C@T;M0?&D!U!6D0F__F#*!2QQ#_:$9D4<
MXPY0]-'.U/EZST(#]KD/=+PB.P$OEDFE@!`6_H'P8GQ*W'6L8_9]X^T<OOM]
M`^.#\(6?34;1-8AS]R:9_1D@#G)G10)05DSMQ\#9$MA+E<3>0*/H<L"&'(J6
M][3YAZ(6`-9`,5*Z"O`?'`#/SLQA4,:PRDQ9D@7I9]9,:[TC<()EDE;X1&S(
M,5V)NR;-R":=YO,R`4H'WP#EX8<X>5Z@_XH(`;IF0/0!!L;:)+(2H!YX+L`A
M`-]7S@8%MV'42PBO\^AZ6A>A$P%N(\H!-0EP>72Y*(VQL00W,`?1!D*'..(K
MIH/(01Q'>W2Y!&?L"(CL@`N"QK`0T#K$6GP%9XQ7PO_;;7.'7PRAURX&)D1B
M"9.IY!-<J5R5UH#1$E^<\57#U]+<7G+[%1PN</L'%:P';B."`783[!4OWCN@
M:_!";1`OYK4(VPHP_(+E@QD=6D[7LXAV^[>YBVHDKAG1@A;=O^M1=.,=FW=A
M+?!!KTO@BK'1R][Y0/3QW2(U&C'QA_$D/C]GB5S$+;R5*N20CI)$XY?CP/:(
MI!_6@9M5&S0`]_'>D&GNCLB'94I'\7@23""`'5I;+%H0\YHQ*27T><WNDXYI
M.FI6!=L$,Z/F*9R8<*%DUB?@2BO5EU@0$$F0\``O7%F9`_Y,_-!R@<7PI80K
MK6B"!)&OA'=QC+GE0Z6-)E'.1X/AGL,/9RH>C(BE@98.!YD],57J-X31[_C8
MW7V6+1Y3H%%WJ#3.,S,5>H@O@A)5%Z4((Q[?=.NM'-\$VE*4+133D>M[V(I#
M+3IQ.ZEJJG5WSJHF*VUE/XWM)C8OB&]8]VS]M0$YS)J960<U03F/<+26Z8$S
MV&$+U#([/R?*3&JX)0/3K""ZCSL*EPK"#T/O#0@)RP3E&L3+%6KUI;6J;@8(
M6;\IU`O%.+ID/XQN1]&"_1=(E*939'0SQ7'F4,0S,M3.=NG][RXO;T#B*PUA
M8A4MDSQ9,".`XU\F7TQD[$IIDZ`!+5<>QB7S.2`:;9$Q'J<4^P5L90W^SM(*
M`252M_7XUX/?\"P^4+?`'#F]OK4I;R5+J]A3/'N7=X'9=H),M:&;C0HCDM4F
MPVW,48HD-.#+82$VBM@GF(HY][N"@\N`\)=Y8$6Z9QFH(46]"%Q&`JW<+,@/
MQ::\KI,!#P20#FTS#?EJS(IIU;#4\PBXG\R&;9%L&(V/CB?QV632,GO!::'X
M09(YXD$JQ(?/L2'.0#NR?@P2Z86HH.NI,H8TT7E#FA="H+:?DVB5S![(5.$Y
M[8!"YPWM`XV7!0;[X(G/R@;%+&`$,UH2383.#^!N=+,]GY]GIM6CAW\J8M16
M"FU)9\#54N"K0F,J0;X*$:RJ"G2Q**\3Q@)$_PX$04?:?X2'P*U@3S;$8-X(
MI_-N'8C;*2Q5@.K+I01=E`WO$\""JIFCVY^BFQI</5Y7@U9F/#>8>B$X@8M"
MYT5NHB<,YG-4BB[2EK>HU#`5PH**ON%]5-$"L;)$/0ZE82<Q1[.BN</;K)Q$
M=O)K&(_CJ$B+5'PA[KN@&S+E&\(8A_2+OI,G&Y8Z*PA(R@T(5WT/&X)UB5Y3
MN<9Z<?'>U&2M)MH"C*K!1=0)H-)3B/M6@?=Q'4^!@"^HWKZ;?,%(C-"#AYMA
M/&U>,`8X+]!ITJOQ+J*67@+Z`B2MHP$8%[FES8(P+,N2N\+:0EC]("1$HQ+C
M%7);I*I1!5<;?EF@?3@GC%NP:0LFD?`_[ZM1]'WQB`)1J"*AOE\@KD9$O0FF
M%1FN0^2NK&B0/"1IQF;=')6;"M[!WP`7E[`<%+YJU*]`L)X'4Z$*A?>T/?`=
MFZO)\\Y08CT,;W4<8B%ZA)&QPB&9KRD[R?P0FNB1Z#BC0V<!A`B\5M'U8#<S
MF!,/J.\R^Q\ODR?</5"[*<NQQ%%1R$1-D>*5<K1^R*?F:VTHAO&).3`"AZE*
MU:Q60!A*.E\.,[%2#@C<L":0,"N,:R.QZAMTOC8T,,(6%@UXG'FZ8P&GOH3C
MM0XB^N&-1_M]A,=;EQ*H4`6^A]L#`@:O0QR/(C>*R=9J7C!Y"DH-@&>)YC4Q
M.0'"&^OO@>61-0B`<V<Z+(@OWA1PDJZ_#8%@1NO/G:Q@5U]%4H$S2$N.FE@F
MY1?`>_YRQG>5'U?WP-[=PEC<$';M0:;#%96TT`,XPGN2BW)/M,CAOE+@+</!
MT:DT!_2K&[FIS%/T*\05)/GITI#F99#"63,<?-F4%.L*$E\UZ@@/>!]1ABE)
MK9P1W1-*A-H574XU`1,[+0Q_)`P'>6^*\Z*F,F.K`-PISV@ZA>GA)2#T7T:1
M%R9-@+JT.R8W\%E\`IK:8,P>ZI:E&X%()4)J5B:/$GQS;S)RKB:@->1?5(M!
M@9>DR@A),ZV,A4&9'>$"N_`?4E0HZ?A$*&L*[T%-36]9,6\Q)]DH(-VL"G;*
M@E)_)"'MZ<7A*'J+2,=.AP]`Y^#0&#^OF)<,"K<EHWG*ZI,7\`-T!>:QTKK,
MP,]29Z=+6"BQ?@GV(+!22/2-%31#%@_2=F4MQ'#0I8@7`TA_A=)LXH*=HSUR
M_P%$:,A]/0O/``6W#/4[$M=JD&2*IM)[AS-9C8PNNQT7@8$48D;F0YHZ8:)X
M9^I'8W(=`XW<)&S*Y6*MWL*6!)D1P9PUJ-I,[RF'1T*%2#2BUWVX@NZ&MQ](
MAEC<\67R%M\ASA#)3_-5(X>%L6#M-YN\\R[(V_XD]T"ST>CY%'&D#:T>J5^&
M\BBA$G\7DQ>,"`(A>EK"ZNK'@A%#Z"\.X"94U28#,14QP7O+7UA,+&P0#B]W
MWN-2HO'+'0O!2LPAO9A*KBVR*Y`<;>241.+!G*H4U4_+\!%KB.6"7H)F?:9%
M5?3GADRLA%15WW`8<C9#^7YJ$P]\!(*UC&3MDY<[UYU#VV-Q!FY`'LD6PSGW
MG[64"DX_2\K^A<3=(?1;5I(!Y$AL9=QP:YL'M[*9;,V.Z6$#LODD)QY:E&5Q
M)[9T(*'>2W*AX,(D"KNCE]$/731V4Z#DP9KS'?+\NN:Y\D('$VWJ2?!1/_,X
M![FZ4)A)<]6MPX!&SV33WCHS6S%>$!XMBQG<G)C,!V*\LRHQX#=(!K,B*Q8V
M6%I`ZXA"GTQAPT1"7ETV(CS;9<3#ZG+,9APO.RCN>(#9Z)5T`M*<\.+++FVA
M)119Q*+%/K+>=8^B((_HC<LCPGBD8<-`?PP:!4O%S.C0'GM\&C/-J=2X!!B!
M=Y^=[8!&)#'Z0[3EEEGT8C*.CTZ.AR/?9-8!MCOB0!C@UPV:KXALB4R._A>3
M&Q`H>!'I$L-3A!NK7F(-N\QV4:4?17[8)+_IS&ITOVAO1,P34L10G3S(*(B)
M\,\G]LX<-$,J/&\PGG]NT5YSG`3])9<F0\4G)W<`JZ?`"`@%D'6@&@]'^P$U
M4Y-;`PGA7BDW5[1@42B(2\BD2M61K=PGY"8AQ8C-7V2\5T/4*/H1?Y5S42D%
M[AW+B,4\#K8@]A#&;R\)P@-F0O%,R^)!I;[ZWH1R*>+%`N4D)`08_)I6SG:G
MD@<'HN&/OM10@VY%_K&I:2&^1299P$-J'D4*`JP`J-$SW#OJNA&:!9D435U$
MZC0M85.H53*!G[%X6?NDA$5Y@K(*5RC5BZZ,YG$8'LD`BI7R"\M"[F!8#R+Q
M%Y?.\9V5,FZ1B<DB`I*XLX2O6P.>K\/!O(]PDN3/#@->`&.\D'U+GZUVW)Z.
M]16VH;FYQ+(W,"720A_^C(Y\X-,"V,=?O-EY&OC-R4A#:UC#7X3T$Z):<ZN*
MJ!)+#_M'\<Y%.B#C4(XB&%@.I!/@70'T"/B6L\=@&J+(DJ#RUFB2$R4$E4&E
M2.Y2#LZBM]4W&J,A`:B@6OW()M!V:Y-AC.2..>D9@"`9$.F<#<MZ6I5Q4KMZ
MJ!@VL0TW].GFP,QD,J0C]F;LG6X4?2S80]0VIGJR=O]YX*[N4%7P%X3R!JD$
M$G[ZF7(J`^NUDAS<*++]F0;)N22'(?G7TG8V_'.LBFHL++MW78`D&\&8=QKF
MW3]X+*;^NN4#8%S'U3ZB5BK>Z(_7[ZO=?2^:'6=PVJOW@5IM4V#U3,4M/6DJ
ME<F`ES`!@%%*Z_#)DL>6;Q&CW]CI0]R"3,D>*'!TGYB(0Y6OGGS(*KQ-;W$S
MDNE$CF+-&80THLT6$FO^K=S&/$WQ$LUZ$K%,VB^\D-&XOJ;,KDP9VUD'*C_8
MT[/OAHMP+-1'.QX5[=P/5ED%J:)X)"9.L)HU4[ZW:S!2A$$A>[Q?X!"8S9.E
M7S`B@90>O.U,S#6:!&\$FB!)'4/=1\5RM1U[CHC0YN>I<Y3Z]V!"IY3!N%^*
M9W"$#VMOS)I,@EC**F%]-SC?`/>!>/Z)T49H`[PA.@F"(*8OR(;))ERV@`N>
MHFTCK[W+YX?%7+)GG^S]3)I8(_.!>P<<;X[\J^,['SIR`&XQGR.'!1'G@+9#
M%K?NH1.BXAJ\B5@`LDX&WISD558BB*TY6'4/Z2?V>E9-A>/AU<:`"/,UT0/V
M#P>`4;!=G,D1+51$T=7*T%FA*E:+(TDY&YY3(-VR7H5Z[!)0O[;.<5T7BCKL
M9OW$@*#1^LR7=V;1Y&OCFX(0*2>A\.)Y$G:!>N[/(//OM<=$WZCR-90;&.WM
M?OJG9+GZ]C4061%NA;81(VK)RNH7J\26*ZH1P@/%\#)GS_%:CN[Q<S;[)1K8
M4RE#3,O9`1K$:`(*DW6C%N4BR25(190>3@N26PHG8BCHP0T"-[Z9)^CCI$22
MS@`2'8VFMV]M6MA!NS)#'/I'T<N4E'2G[:VR"6)#.6="/4&FS0UJL0]%]L!W
M$!FT[\NE=5G'+GI^^[V[W]*;L#ME&[+<N*64N-H8F481ZL:^;>L/Q!')N%(`
M?Q6W#-QX3J=[15N[\K=FT6PPX8XDG]27F^5JDV>.W;3!E>L1;I'+^P$U/*+'
M(Q.[>^2T0%6?7(J(9HYIF,./+'3AHU>@37TYN)W>%Q@T4JR$%'B6&`Z`YZ6K
M).$M/%RK1'FM''[9P'\GA\P+9(F<M6^#35[N_/O_`5@&X?$'N%)E868F]N_@
M%0NW!V?;=#/=H0"0>A63')LC7YUEAG(@Z)M1D+L!1[BT/Q1P(UB7^X]__3=<
MF!ZGL!#<.*_IP;UJEP?Z))#M$L.MR2-YSX9?3BX2,T*"9G(?TRNTM9/[/1<5
M?TF!T9Z5S]N1"BCL9<8LF&3$0%59#>`(,"4Q+?A;Z@F]"1K4`.=)G!=K!]]]
M=D14SM@@'HD$U=R%'[)#5`L#:6AT^7LO4BA"/QK4/\SL0`<+49;M/AFQBIPO
M`Y_*I[3Z<C!'HPG%=/#F2OM'*P324R5"X>:#Y2%/E,4%4/'W*="G(>$1.6[J
MDL1MWTGMB=%>S)&$-.-#I^CRAC@;C*X6L!O<W>N4I"YXA"CWF>1P_DOTE)(!
MP=Z?8+5(3SGH[<G&/DUK&WT&.BD%)Q1VN'7T#:'VL<@/WFC*\+"B%1RKGK=+
M^,EA%)MX+/SO\O8J.CD\.3@YC,E\*==+?N3EW(@.38'\_DKBZ-8LZ*;X5=%P
M>2Y;P$L%N<5`4H+TJP)#^?=VWU[>O@+>W_O.53%C%R-'Y,-"X<V/Q2B:G,-:
M=W5F6U-L%PD"7,2TNC>D1<@XG#*A>F)`C.XP7HB?T0VN>$PX#5=40/_&ICGG
M"T0.4^0:Q84>/,3U%87I\,",7Q4''H8&9+<&U.`=311-PS#M(\%^T61$E\1.
M,[U/S=Q37F?`92E8&`,?RIA#6?A/!Z*(+,JB60$$KZY??\"P;LQY@E=(2KTO
M'LD5+7R9I%;V(K%P0QI150DEH&7G4U$U<3R[U$H%1/X2YL3R`&5!HHF]&"Z"
M/U>M`B#%L6A\K4>"<\5ZFBS.!"NY4JP=_T:$&*EHOLA,S^F.Z.Z4YAZ-1B"S
MB0UC[SVL>+_U3+27O8R>=9W!3L.6&!FA-(FEFV2#=394/S5>K*`D;`6V3_H(
M+RO&RI?JUPN5'A(^Q'8D10W*&9'H$#&GP7[8X)MO&936UK@=Q7P2.Z]*/Z-(
M\J\]:+F-=M=@T\+9%Z/2+FIH3+)CC)+BW(%:S+'A"*/HK7`3MMF3LKQ%EC.]
MR!D:#(0.>"@N_\_$/=D,H.&5H^A-4J)F[->]"&@QRZH14C4BK)-3I%3!5U1A
M8[0;<=T.HX\$9F[<M')N$+CZQ"@H%JOU12!0^:'^&GLE=*/#X%V0IU\G)`CX
M'P$#Y&(?=E9U&KB%LD7'CPWG>+"'P!;%#%9X*]G+6WQH4'.A6$`@6J1"TQW`
M20U;%^Q4,D%0D:KN.?Y.@O/&7#V;^=%)K?0^O0X_==^LR;6<C#8G"GH#O9,L
M+=C%41@#1XS'2`X.IF4M07L"<9=$JQ\0NA8F>Q^N?]CW\A@_T%'DBX2)V)^*
M-/>U75*L<?$:1)NNT.G$R2.D;C8SCAK5_$3TXXBY!9E%D(6)PF"&AA^\6]87
MN??NQEL1>=PTF!"K.=1F??9FA%E"4V0G-ML-S324-PC_OKO1Z0%`0.X,<U+R
MHE@,M"D6M'].[NM^K0_5$NV2%P",=C"FTKY@"R!W5@9*_42$)1^C%;\I``=7
M@N]Q.9I%4:<<7B7R@[.B.*0@`Q3!35P`4T_(1$A*#*AGT$]0SD6#8T5F':S<
M9WU2B:15@Q!=JB_'+5UB+=6@R83)I$3BV=8AQ^@%'SZ6F-I*%K5T:KWLA?MF
MA-ES'V!D=(L[NMR/VSG(9;0_ETUGN1(<@I*7A@R!N(P#6H;J%I*,3I&A*#HU
M1*O2A1'CL/D*1`P9`05?2LE+CL^`.XK"_*RHDH5$R:&>E7#`Q>NRX-SA+/K>
M+%,T_4X)1#ZWK\A;O[?[\>8J.CX;GV.2FV\V%9$F6%6,<I"C8I.+7AA]!9V'
MR"H'/NG*6Y8M`)"?D]@'-0N`&`G\RN!-!<FJ*+/9(V"8EWCI[)S6L2?!Z?).
MS.D)?3?><OL"I@?=XQ`S<>'I`5F:$+9$9,3U:@`E[Y]F96$3M#.2<C]_?\51
MABQ25K::&.&+AGQ3LAY"=HIB-'[(\4`EZF.8M)`A!9;P\P[DK,8Z)VT/QRF]
MK]1Z()X0Y]X$J(XGO*^[M#A(9J"1X*6_+^`6F8S"!LIF1G)7MN19BI4UO2V;
M*>`9_$S?H:*"@L74&=/$)+=V[94BJ"7(SBG*@O=3DL%I.`>IEY-,)OPT5YNK
MGCMO6.3.``=)!)6*L+A]CO^LV<\1.(.]T^?`&GN`+`C(7.1)82=T94T;?(IV
MK_X"..+5%XAU-563?]&U6"LPE3LZC$_/SI&"O#5W98.YJ"@B?!M1<H(X?WA<
MSU^1/*<F[G!430#8\*YFF:.QZF)8I2YYC1E&+36*2D9Q\K`F0D?J7H2@:T/C
MG1Y&L^2I0YU%5/3.](</(S^[V='H1PY`0_E<@H`H1([I;/?^N*L!6\G0W<)$
M4;0_<EK)G4*9A:@"^2">,/X-AQ-GBX3>IYH`JR%$2.19U_#+.-BP/@KGX*JT
MI!XUN;AL49:DO!BX%@=D?6Q6!Z!_H2M*;+$2Q>RR%/G/K!3AQQR\^-5J'GA8
M9.O7?'PY]1."98>:GW2H.=E7.=?%4E8"L@TK=ED1WL1\?\@8BLG-3J7C-`=Q
M-DCLUFCG6M/^-_)=T;#<I&TN7,7K60N+2CY'MIS&FJG6,F>URUO#-2_).VR5
M5*LA1@[?+YT;1!.&*1I9V?C;UY<<*/B@/A!/ZK1.?)GGY<YXGPC]\<4AF<Q(
MRU?2[:.SCY([$_KHY/!,/P(1UUX5-/>",)ME:7X`4D%**39H$EO=/V7%M)A.
M4;1I2M-4.T<TT/F9S"ZD<6A>I*8?5*AGI$NQ<+%I.%2@0RW6JAAE1Q2U(@8)
MD@N,6`'=`.5-2353\)&X#@!J:AN7%:R3Q-(Z/4ASU!T10>J@5`M`Z<.GVTMF
M>D!B;>4?9KON#@0B=VA'1AO:@_4W=]BC,WRPNWS`VSR+7HS/@8,<$:J\.#V-
MSX[/..MU0U31?)/E@@RA/5D==*]*L^(Z.1A-47[1I&T7EF.!P"'KA*YM69X8
M^4*-Q9WKB$/Y7-9J$$\NJM!37B4%<GPN?,6^0Q<(SM_/`[&+&$5O?.4!U0O'
M]\(C).PZZN5:(ZL96\S^Y3%W\$@=^LY2D/[WKEZ]WO=%V&H(4?]V2'ET%H_'
M%ULCXETAJO<_L/&7PD8'K)^/DIJA_?'-AQ]N?QUE)J'LPE69FAHE5H]XBO6,
MZ>53M,=BU+YGPK"$QW(=4C><&Q;6N\@2X&'+Q*K<>`9++GD("SF8)2DE$WE\
M2Y'][X_KDW%\?''Z#US_S\'U33TFKOP>$\]Z.7KM2E<,6U"/R)6S9I3W5`W6
M?\='I,SP?3%+K$@`=RDH>>5%M4BD$*/)05U8JY*-(*5Y//!2DB3_%34$SV3&
M-G$\[QZED.JS8VJ"C[@>3KD17TSBP]/#ED+1*\FKFI9WUHLWP@NU(5,5UCS`
M<G$)YCQP3,:[/`>!F'#S^^8.ZRE5I)3<)'`%-)Q';O:P07N:+%>-<$.>GFRD
MBJ8T@E4S)>-37.=4-P4>MP%VIAH<!7+D.1J9#+9*XDV6$B[.!=;%UOI8V+3H
M><1Q"V)%;%T0LN)R-Q@NU2LN<!O3X^>8R/F7&A]@H^IY!.=JD;EE.OY,-$G5
M+]4_4_+MZ\2L*UJ0VL^(Z(4W^$/R)I:"4V+/"*+?/2P#['IQP15RW[F38/[5
MTO=;V&Y#O%UI#T&CX#Z1;UM"]MAE[E*R8'G'\>'Y653AZ\1":HM:\-GIR6'T
M&8WR5\0[H]<EV2AOFQ0F&Y^=`9D.2M)=1A>3T\FICVT>'K5JM9TRYC>E!54I
M6L.+D_CH["BVW(S=O!B(*2]B)EB299Z1M86&+``R$F#(B@]QSQ#FN;+U=E:6
M63_+JRG)8P"1BZ,QZR7Q^?$Q9FIA#<B:=.*V[_09+M/^K="D)Z?Q*;`AF71R
M`?3L+4<94V9OLW27R&EIZ.6>HH"CL<^E6KEZ83+<I(;KV["!`'1SW2!59!&^
M[M./'?QJY\7.\5%\<7B(OYWNC$]/L``Z_G*V<WZB#\YW#O"?"_B'R`W5=\%?
M$!8PQ.3BA)+QL2\?9LHA8*Z$^1>E[\+SF0\&V0:"8.I]/G6?MZWXF!<%)*;!
M^&&7I6KAI+[]!"BX4&'";*_JE$F69`ETF:18E)>_)=L2$$SD!V6!:50VJ]ZM
M@Z\2BX/BM'-KDDJ9\R;+V)[F><;>]6^QK19OA?"$<A=<L(Z"4+?_6"[)T<D1
MT[O/CX5+\W3KJEK%ZXX.?T4SC4]^%=PFA3'?#=/.EMQV4;XY,B^"]-X!U/"2
ME"C>9*H!]#][,2<C$)T6,,"'I";BK5U;WKMP=8KV3JL5&7#?DMB9<@U&_#=6
M3,PQ9`B#4L@6WP[;J8BSB&,Q$7&4).!@'C;BSG@VS,ZUB:_3+$FIS(I-Z[25
M`]%\;`<D><\.&G?&0N.C#.7M4?*]&=":D@&?ELV*35.%[N].RX+Z21$?BM(4
MMK:/%C63H)S,?`6JMF#'&.;547P%RQ#(/BF3@DILS=)I;7D49E8Z;-7E4SB\
MR_:Y]VM^L;`2P%,BCRP'0L3#K+P<Z"=68<OQQ^2A*-FJ+V6;%(RT:)Z9XC*0
M@Y<I>@JY7AN5STKLGU'VF%&&D@T(R5M8$(D$X4S6FMR@U7BD2I,'0Q_0W[EB
M2S<>,-^G7XSO`,B]!,-6_6@-#R9\Y*S\NS]1V;V"<WSI^#D:CRMH/$7L?,!]
M4\P4AZX7.)I7_"E1722U$C*"G&HHAWDS,4?+2JXM$?N^<=`(7%9;7B^@N23)
M:.TBD<+*=$DU@U@8E-0!KZ+37,/ST-<R!=J>>2E<Z&I*ELG":'T^O\P791>[
M57O9$1S;ZW!]^VK!V,7/]F3T+PLY@M#E1PD"KID3<=\B@Z%1ED8N1?5VW[4<
M?7S6LX*+.'KW9RK?5_9[#$**7:P!`ADKSL[$]T[J.\F\6$=>BZG4Z`2G>N3<
MM<&18*\RCIO#)G*D<W$TR-"8$R?]'])`EQ3EOWXTV8,EZ5YP?W=+L<9K2,F#
MQ`ZG.(>!J].$4D+%64CX"=S(12,OBF(F-<:HDC6I(AK(KBYDO6<`N7W2*61F
M2HLC`L0Q1+;12[!G8B*9C6UHE50JS4-!9;ZD;`!2,B-^8B;C<%\2E,Y]5(JC
M>]I5A>%PHEAAU$R=V1A*+-[S,MI+]U'-:98K6.TR4`!=9""<*\Y9^QZXHGMR
MJBKX,6V@4604.N3[U%B5HUP/!"<*4"R]$I+P\9/RB?-1]%`,"TWW=7<'5!@#
MV,4R;9;6G4;5\[#8$US>>ZYQ1<A&CD15/>V>,I,OZGN7\5[=^W>`7RZ8Z&-@
M;HH,@)*TW+F!_%<LB30\&"_+BL@+%]Y5B;`$Z/"ZIDAP^8KA,<.N8%L$`,U"
M0'41W>(PUT%0D9CHBYGUY+UXY:_XH60MK.^^^9I[/=((SVQKVFD4P1'!P^:K
M8PGZ_R4F#UIF1]>MBNZ]K7W.8E2<PWK10:UH8D%`>EWSQ"!U9*\R6D8)(]06
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MB\%>H%:WI0+)IZ>(H*Y$85/"L6DBER``,W"*T^*W.J4I;7I<MTM1'S0Z`!#O
MUG/&?:20.IL^^9`F5*[#4^?]3&%7LD#B8#C/!,9O=Y=@DI;DC?1/Z$K-?*^/
ML>7>T5KL=ZB/H.:VTH/W^6QR'%^<7VR^S=UHDY[K"8-MNIM]JV.Q%>$FZGW[
M]"S3X*!FR5L*0P^U<8A'<J3`R2"VMFJ/,8'CKG(6-8D;*F;^'(RD[*M*V\VQ
M=3]U&<;6"V%3U,,N=)HM7MFRU$/8VT)1"LNQL4Y>R4XIN.^GV2:5OP/K;&R5
MC^];GC-`/[\QH>O`]V(\/@*^?8J`WDQ*?%9H`Z!@?7]J<D_CQID&92PL[1SM
M"6LRVKDG7!Z54YZ%_>&I_R#AB4N;8:79,]DF35U@3N#4[P`B8+0MZMHK:N7\
MB..1QW8Z6#C@R7F;)PX.CPNG)H1NW1+![ZKRX0`@/H&0>3)XF4>=D=NF<-=;
M.^(F)JTEMIOLL;.EES[8M8X&-_:2YE_;^`_O('KJ:7'1[JQXS`]*Y.F[*(O6
MAG%F;KBIF2^>,F-6>2$-BUT[-2@3.DAFC,ID&>=C:/-PTKMQ/LK"857"]4%%
M%JWZ)Z,6HY>V%0D]J2=AMO,`P944$"U(11Z5FL6:J9$2TE@<I841:],2:8=!
MN.K@W"VPL2^"?99D,K#U6!"$TS)UE1(,5=<5372#`S;HS<Y6`#%?R8R:JZ##
M>JC?7K15FVE]0`I,R1]JD63OVDTE^AVIK:4?R5WQ8)Y/AAP:V.Y"(;G)9[\H
M"<#N0!LO^'/UU9<:WT^F(*V0HZ77U4:O)72H+$"J78B4+%HI5$Q+#_!V3E%1
M9!FTO\:#?8HU25),/Q[.N6,/<D$].#JQZ'"$&>F>Q=A1"Z\U0APMD>)CBJA7
M\^\@U7;S9*F@&5V%01!\3_BH@B3-N/_DJ7B@30D+8,F3V<*4:`BR[2W0RT`]
M")V#5G9KP29PBKE4%8]#?H"@$+$:U6;(?-.[QM.,"BJ*(@V*8'\B8+0GP-<Q
MNDW<P-K+!$U!6L6]QNQC3CIU_0W[+7E<B*P$M.3X;@\`_A+MZMRZ>A)I45&S
M!VQ+2I7I8N$5M*1K;IL4#+:(U=V2IX24#0WSIT8&`<?@HF5PMUJTNSVF1ZM7
M1(CLXRX6+RBQD@CBWN5^-$:7II/8%,$%#<DD]VI?`_(H?Q\_'.^W/]#D>W'S
M:,\*\@O2*)-];WI@75:J3#)/S9#=.W-6MT6VUYE;ZN/1U%[+."P_9&:V#IL<
M%&506[5:X@+\(>AE/AZ-I:_$T5++\O`TEE+[ZK9O;-O`X.7.`=:2SZ0!4X`2
MG\Q"1%3:IM8_8R8\,Z!RED&TF!",VS=7D7I2O!9BTFF&JT>@3(VE"#!BSS6C
M>:-#D9ORM4EF6(3A6UCB+?6Q\.5-P;W_^-?_U6IMI^4,"&Z!#1DQ8K)/`3[6
MA"_OX4*^[8+"0W"!M-IX/2SOZ$>8)8$M/HB@K3@2ECND^E%:1'7$A;#$<F>E
M-J\;$*T]!H5+O:3,6)M/A1K['9`*!)T^GJ>92&)#;(<:*Z"K>/K42JVB,8B/
M9]&?FME",UFQP&K%R6EJ."M1*R+)H6M^P6%>E9KB:*-3O>)B8CCS_(]#AD?_
M@%BK6&5//<+(5=@6XK7G&H+=?VK@(H^/CU4(E&HJEY6EF-88U;TUK4+\?!70
MVI_.;!LE\LNUV?]:6AO6[9<F*+85&D5[6<EEZDDNI$GZWEE7"34#1B+E5K%N
M\%_^DI`:*U)Z6-"2[M!=DI$EKKHW7,O0'M-HQ[:^WLIH;RVAM=>_&R0B^/6H
M1VWBL+Q0T.Y8XJD)`D?]:-\[`I=S^'7-\*YP8UD?L$3F>YU1)7#%B$I;-8S;
M*CA.19@^"A1C%_3)C6G)8HX0F1R%JH98_1F;7)6SP(`15E=S!C8NK";6RB<N
M)^'7.6/4FP/59T<YZYBN$)C==VZ;6H?V$K^D8EC:C$*_R1C1*_5O=A$\%R^.
M3];:P#?:\G[9LT2\AK,\W.8LT?QP3L%UHE$%.;EJF*O"LE?RT-U1&Q(OX;P!
M=@<-6VQZ0`"@P-5A&S"US$G'N`XT1RHJ_/+G>++^'+4A5*L^7\^ID)P@QY)Z
MF]C^4,:'Q_^%3X4MSYOR;O)VDD/BA1_9($B*4.""?F0]IALM)3M)!DK+95B:
MDQT@OO-ES9E>_-0C;5GE9`-:=L15&-%$<[L&(G6#%G-G*W<2=J]MF\!O.$ZJ
M9=`BYG`)2\TDE-#'*5>"LW9DQ?G>@.J^.#V++V!S/80\6ELFDQBV,PY?Q)/)
MR0#WTNH0?8&/[_S%/PN!"G8Q4PB/\Q<6.JU#*KN@@LO,:!2?*ZIA33Q#C"*M
MAE)U.X0$;_L#U>'TU",?%<=;.'_[L?`D)"PM+,1,(8>$ST&!HPEUH_YI.&!I
MD%_&82L7@?7]*99[C6$L\#0F92VFN)J+B?I"K0>$L:$;[[#-@,(">BE*RV$3
M.)5Z<`C1=-#JY^'?<]C_R2#[]VH>6<IO::3V$J`Z0(-[/VKM70H4:E$L^.CH
M-'RC51"AMPR"#0Y9?X@;3\_C"5U/4\^HSK+7>YC/.;XU%F*.JYBCPYP#J#6H
M`H;\6``RGW;C1`:7/#[GKH.;%RQ:ANL>2:IP#]0L);1J[D^WAK=0M4/RN+0Y
M&WE[A:3QR9!7(R19@?/6!P:2KG,ZV%^6<A78^X'*K$E#9,KFX\+X\/C2N5=N
MDG1VD.8'5^++WOD<$`6.MX*5SU(L@(3\R=.-'Y(RQ<:"!9DY-=Q=S-K44(3S
M(M`*C(92R4=9-1+[ZY),8C;JB#[EO-^]D/.*25$-:HS>Y93,G/H<.JV-F[BS
M]7RK.`I,TL#B'8`)SI+&;FNZ\YI[$7<B+#B4A:GQ6-W0]">])/)'7/&[6GVN
MK<CTN">BW<;(8-!X(VW2AW*7YW!);,NG(&G:N&JS+F^:5O/Y7HK<R'S818J(
MGK1:JHNXQ2M:V4'T=A=5[."$S,7<C\R?2V]O7T!'VTEN'M$6&W3JMN.X!=B:
MKM[F8Y=3(8THGBSH-+6`*DU7?EP'59O5[YA#2&"_SNJP`]5=6EGV="`]%SMI
M`G=IX65@5QXDWFC+`0FG\/IU)XQK6@,]&,+6(:_:4,7^$^E]P;94/FV.XG9P
M9M.U2BGJ1>B!?FP[+](]22FJ7]M?"S6A)+!W-]?<')IM\&W+&EL\X-ZACX>(
M57NSA%NZ!\Z#D$%@:+]'J;0)S)ZDEQ%>XP`R%O8QE]Y67E5QKR[N_4YL!,L-
MV<;T5M36<'*3479#R3GM;'.KG$KIZ>D.[U%@DM;A%,"A-\_/,/8SLM1H*]WW
MA#T@UN#K+J$X:/^B@.F20G<3E"BJWC8\D:=L>E7\,44%+B[I;6CGXRP@%SOH
M%7&.G5E*#;Y&6BG1V=GB66W\TUO8NSG?)N_9VZB.?=7I_8V!E$NL.*G]C6I_
M,QQ>Z&L(&AYGTXS((.N=#!:+UJ%&&@W-_!9S0*J7;).Y7N8ID`FL_8QH]"`9
M(HC#ZYYS%"^]@;_O[G/Q,$DA\54];/^45ZZ=FF:'Q$$1=H^X\OG:DJ3D#P^:
M@Z@B8N.@<JX0!L0&KB8AQ52;*_&UI91_=*4V>2I9<!S<01*0&JNE0']HM1Y%
MEUA$]9=?-.H/6;I(I3B(%T2K*[#0#2K/>7S9>K34>RB8]\&4"ZJ`WI127Q[]
M$U;0X<)><F.\23[[OQ(KIG;61^V8:*1A<IT6<D6'$Y@T$6%/REQSBK.A7O$V
M?9;?V>=4";EXR6*!-YBIZ#@>=P(UUFAY>)GH/MB*GE;_L1MT(;K^%703Z<*#
M0LJ8_AT?3H*E.*]_!S!]\XYVKF7D-8M393$O(NHC'E&\T?BPK3AJA*&8TK<9
M65),)5`DM=>:&NWF!^@<9[MDD$C"<8KN;8[%'GI=ML]TM?#CDP!F'!EA@[;&
MAX>_ZN,'>7>#6IG3>B="7^*OJQYL)T*+RCGZ5XG">R?NBL_P(AU.\._VBF?D
MT41AN^9@":+SCWFE8:"%;0Y`+;3DN.S&U+2+A1I1ORB8!5&@E&3TD$68,5M`
MV>/;VP3+<2\L27FAEZ4]J&^X<.OUJS%;TO+3,<S7./T)T[D$V?AMSU`]`1(K
M[7PLA9(#[B-B^8RSKVR12&Z0()-[(4B@*KGX;:V!PM1.;[!&^KG>NZ0S4VRQ
M[]?OL]VT`/2YC5Z.OH6FQC9%&[;$QKUDA*.8;8HCJLF8H[>40'C;*KOOA%K%
M(WB:EY8P73N2MW/+J[M4(K?SHY3/AS]1>98=I'K?T;$5\YV/&E^XHPV4=%09
M:>?&!N;0'_CWG5?B%P94[E0#VAG'QYR?!3^=L?%KY\7.X>AXHO^TT')G;RRO
M[>^,[0=DUSB(7AR-Z-?):')A/[1HM',`_]._,K,";K5SRH>ULZ<_[+=6X&V@
M>X([EFGLV'.7#[T%'8Y.C]ARHR!V%7`T<,MO:41U=U*Q+.NU[V5;0[5"4&:[
M&(W/U3A]:7DN2$/`B+$Q`Y.0E&-_JL86<]<HM*!/KK2F%V6G'<=D=5R*&:46
MNJ:WE99\TDIE[(.LJ(!%U7Z;F@"M79=+_I%(DYZ%[.VF^0'\'>M<F2<=7.J5
M#T@\!)Q!0))5I'M$7*SF^(S3](8'!X&@CYH,.2Q,:*56/6"X=]Q0.\G!IA3J
M,%C;-0XSOUT]F_"@;/$5M!DOE5VXGJY$B3MQ;]HE:LV*NEU;@SXOP\U5I8AY
M[Z"DOWLS2[>-@2;L`\WI-&6%0H.P4>(OF!3B[7KCF9'[]/0HOCC7NGYMS_56
MF6G/@.ZS=G8<;]X"W9M#OTB9"QEN<@\8P=?4M-"SE:$DVYL^S=<2V,]9/#X^
M&B2D+?>_!/]ZLXLDT2'L3K0X'@%S%C+\!ZO?7WKVC,^=B^6OLM/1,9!+O$:$
MF]LLCER?/J]_8+MT)7=UHY(AWEOK]3+/^L4^J%%/"\!P-V[AW6:`2>5)DBSG
MW%Z^HLYHF.[JI8?Z"39YH0U\+;%'O:THYX;J`]E^=1I%ZH<3/@2`5P'/(T\N
MPRS<E5<Q,Z01#@5$/<%@X9#QM;I<2RR@L([89;BYS!2YCV'W0_N>$W-;CNFA
M=H7MLZ=&@Y^UT2`U`&SMN=4=$`;XBRF+6*OPZ'G8.A88FBG6#^D):!L"V@(O
M6`*"U>M1OYCD6_^H?(3::7Q(]M5&^XC$Z`,3HS==8L0ETD@4?1WL:P?SK'ZU
M\_%RQ^O)R;ZAG;,3??:I'ZH@CYZ>'XQ'YR?T5M@;<X].97_G=#0Y.3@=G1SB
M*S^V.U?UDX,>K&0DJW9>3$:G%S!4NP##C2I&!+>K(#9X0W$']^G;\-/KSJ=K
M*D"<8&+<UFL8=M=[G[V7?M]/$CB2FWY':C?KS3I2NZQ5,F`S.[;'1;Q<%R\Q
MKIT0%V3;I'[FC\WK"FY'DK/MV;H^VT*>IC!P2II+@?,B$LBSW9^N%BY:#D!+
M1,IZ//-B4+[$I5])?E[92;<CFH.%4ZB9(U=*&44_ZA%@$!SW^N/!-SDOPP-Q
M87E^.+L[&[\3`\WFFFLN,"%(IL7^=.>3PP-D&6_Q1OV!;M0'(F]2Z>^RXRKM
MR%T'KE=E'7JQ4'8*G&V)Y[7Q#D"C:I/:=T3::.M$R^S1OKC9F//44/BX^FHD
MHRR!HU+8<AP_><`>!KL;`#?'[@FZAZY_QH.S9GR*N_],T`Y;](F%3JG//9`M
MI'J`8'=Z-@P%&R##>&HI_5>?(\Q<^J=W,]E$I4Y[4G,SOUI&]3/]9-V0SKNB
M^*)BL5:O<,C6=::?V'A/+37+GF!L9VG=4.V`*]4`UI;R![FFY)+-Z/?HO<)P
M#"\FYQP&%/!N_S('99<LD-4P9>FC:)=\!]3M;V,!;)I=RPNQ/GF<BQIP";.J
M/XEOH)+)Y&C"]&UC+BT&Z&)&8A#Q"PP8F[7QD=>VGH`[2-2*+@1R4@FZ,C4G
MJ&^*,NG@C'>A>BZ&.N@8]</;@.]H@[V`6PTGP?:$PZH]>_`PW@9?MZ#53=/4
M?%G6M6R*MKA@T]92E6>-=M94:^IAV"&F67J;KN7CW827_Y)\G*,+RB`NNA6P
M$$C_'%%GDW&\KMZ/Y)"OU8ZM-+12=A\>YO^+7/>UH20,8%CL]?_>S!8PSC=:
M5)@`_X9*ZX"J>?V82[?N3F4SQ1!-,=KXPAI1]704=5\?2F+9'*PW$!-Y?-0.
M,50[V=JD$S]R[YE1IZ12!<'QKIK8BTE\<72"I<'6IA5U`_GJP$GA*6A_8^7K
M<+/R=;9.[SH>G8ZW4+DLO-;I7(>CXU,8:WW\,-(V3-PDH+`G**&_D%+OF:6%
MP8_\PAVOO'&Y5`?5G?U[U.KP2W6LIV3Q&E+66UZCWS'@D)S2/67C(PGV:]4D
M2"M734;J[V(1`CPH+*(O^PZ<#IA:6C8<JFO8LX97LET,":L/*Q647)YI$/[C
M3L0)%U(T5B).G&>N31>/SYDNODXIP+Y)JWM<R7MO&+K%_=1.VKA_3KYV>XVX
M9]LU%CD;1?YPT66?$Z:G3*WQR[11G^PIP`.+P95L,=_;_7C]OMK=MZX2H@]A
MT<+C^'!RQ)'AJ$:2OQ>-10V(L[&7MS4Y/)+D&B9._CD`ZN!$XA>FG7B^890"
M-4O82LDK=*53)76.Y=!PT91<_H!?]VF[\$;`]-[E$@_Y">6!!E^:X57ERW=T
M/NDKK(6:@>.]"5),]B=*LO-,V0=VAI?R#5J!Z&MMQ8Z4+);DTR<%](FO$D*-
M+8L(`/'%<+@C13?Q"?;-0<9L"1L`G2/C'O>O73J(7RUY5C1W@6$]M`6KA(`%
MMNF@#.LOW6GC`6C8+K2N#H:>1-_BK>IL"V4R.^NSX+<:$)-2T+>$VH9!YM3Q
MENJ!PY2V:''0(U4%(`(!EPWK=SMQ<'O%2=$'.&!&,24AKHC]NLEMV0UX4>.;
MAYM"=$N].B/.&THYW_C"&AIQ3@5!6J]_<D5G6>"YY'OO_=TO1@OTX-/M)=$#
MC9XRMB%(3[`^=>NB37+$C,G3(FCN0/ZJTJA`U19*'5*NB7(,XNZ<&I*(]D-Q
M:1H;AZMGJ<E;O+?"E@N\=[T]^]1\S+Z*>2UJ*056-5Z6%D3.4V(5F))7:P/3
MEB#HW)0=1/EHL[JOO5C^5QI7?LE1)JG(Y[<N_N36BQ&^=!K`39&E5+Q]3W_:
M;T_Y`WLFWVB$[Z;G=$$X(<(2_L`7Z3(/[.73['Z,`-;F8>S5<+X1N+:&"Z*[
MY8.D`".M4-;=VZ7WO[N\O`&LE2H/809!P04Z7*PR5U)P3@J6Z;E&##N$D32;
MF0VNP%.64CU84M_C_])_03DX[UE*.0Q^$WH&.T[;7D"I%-^WME(8G"@:9,CR
M)&#^1(*MR:IUR>XH31'A,%VV@B@Z8BB'A5@'']_;"&R<\[L"![_B[I3/>+5#
M4VU/[E!H$3CG))\\2&F5.?J.Y%(Y^LV^1J16MA3MNCB.1T-R$@U(D<+X@RLE
MR)5/CN.CXTE\-FD)#,XR6EFF3VQ:JYQ3^@?NB.0PV8CT+R8>"O3!<,2J[8V1
MUO9S8D;:;=%+Q$';I2T?YQFPL07[%)V1,PG(YV8=TRS-R3WLY_$D(<$`I$G(
MQ4?(H$VSTGQ>)BB%3VEU05)Y)6C+Z5]5,4UM`P"1UY-6E@T;/K":OV<QG#?B
M//7NZYW),*^HZAIPK!!$BI57,`R'J9C2FYIV4<#4"\$)Z4J@A4?;495;WC_+
MQ)2R>_DU"^K%@?H1%=]K2V)).^P\%,(LOG"D1R$!9GA#I%>C+[EL7NJL("#)
M29%FZ(J^"5B75-_+;Y2!R]/&*BIX60&G73,9:^-7P=JQ5%@C&0""ZNV[R1>,
M725R\'`SR.XLJK8F!)6V[(?H:-1-_LYS=56Q)F$1AF72-I#Y(K>K)"1$Y6^A
M+<&)'I/E#W[QFH)(_+'-+_&_&D7?%X_&]LQQ'II<I'&B^RS44X93B-R5#4-Q
M\>E43P)[57!'4@S`8!T`>W%FG904RO^IN@/?L0V`O!<,):?)QR$6IE*TD'K'
ML#(;&DX?O;XIG040(FCW5)H#2P=@_;;:]%YF_V,)!*8R<C/+BU'$I\;JG/E;
MK8Q\2DK4S#:WX`QIHBI5LT(3>%G%MI"@K2#()ECM*1-KHYB*ZHB10Q06#7B<
M$>)BZ#>(;'#JRRYGNU)60#^\<:Q@ZQ>#BZ*.L8HT//3`95I4TLM&]@J&V.H&
M19DN4D[GJ_%4):C':X^'W3+)2L,EI%JL2TPQJ.[C<7ONPZ(RP=R>`$MD'63<
MKJ#K*@^D:-<$@<(MC`4<8?.CZ&J0FRI)8A-;#G0\GVF9#!9F<KCGI$@Q'!Q]
M0^T[K1NYX<R+]"O$,605*?;YX(#6:&YF(D!2CQ$S8R-#KR+'?0/+E/M^4ME/
MIF!H0J-+S:)GJ^F+,"I1]F&(HF(4URZG*GA/L65636$]'7SS%#&$VX;'T:6%
M#THF8IQ>&UCLM1TA@HQPG96@[K%EF%(9,:."7+2NI#U7S$BH3)I77DUFUX*R
MWD-)4T)G&Y+CFL(5T5#@]19JQ:0Q6*;4!<772%D<HTUUHM`UU+`-J`'?Q9:O
MN:Z"`R)[R5<I9<.%9WUFZZ'504;L1+'1VMI\2`*N;*T!MG42VWC4)+F@R%`B
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MO=`T;0G5)Z2J^H9#WRE6.B#=0A;C(1!V0).U3U[N7'<.;8]%+3*+RA;#.?>?
MM10-9^U=2-P=0K^U[CR*?I2J$L'6-@]NY4;9FNN"ZG:-(@CW;@3]JBQ(6&5W
MOO>27"BX,(G"[NAE]$,7C=T4*!6Q/>".^DG6F:00ZF`V`8GQ43_SN)-7&4,M
M!MV`HX&MNP)1@<^QHEK9VJO4JNL2,(S9]:IYNC!D)0I]<HLM'1G*`^P?\I<1
M#ZOR<;M?!BH$RM>EH7(LA2VF)1HK]3U?0/+EH[9@%(I%J4V/Q;"BOG5W>-A-
MB=J2G!5*E%)WXJ.IG_'J&G/'RO_*N*]R`__A(/O3^/#X-(ZD+[:<+.!2RD%0
MJ(@VMMFI':(M5<VB%Y-Q?'1R3#:*=;,.L'D.?@]:Q:JF46'OZ-P\)ID4U%A2
MEJ*V));^Y*QG4M0_M?FN8(VO,?@;+14<&P!O.C/CG=&]$1M(2+U$)?D@HQ0)
M#G4?2#`!^CUOLJ`#NWI?Y.),;3M85"VIHAHIW<!"0G/P*/J`^K;)K=F'L%8;
M/8EN+VH2!SCRI%XM\9[F[-2*0,UKH^C'>Y/KN:A\@QUH28)5/Y1N0:P\?#.:
MI<11S7Q@<@.1)26+6FM"(#53(B;5VRW9$<D1_4R[5&;A&'S\T9<W:M`8*]3<
ML)'!32\RR0+$&TP$?(E0XUIXL%F*?=6BZ*7O2YRF)6R*XW#P#S,69VN?"#D7
MEQ7+4.>P_CA*F.?,KD_ZBXNOM%[".\/B-BZ=6#[Z")GEBPQ.=A[0$YS_>MT:
MN/6<XF#>1W*K=LH"8WQMO(K_,)35^=O3L3;%ED$WE]@K!Z:,J<:+@S^C(Q^X
M3<71V7F:('MQ:`UK.)/&'52U9T2VC;/P&M,!H&#(QB$*-)%*+UYUG<'"1Q0B
M604<SUF9YL:H%"J%CVSA[]A1)'<IA\LKN0;:=A=H'J'Z-&S+M,%F;166)18N
M`HV.4G)^LSPCI^6%M]I4:X9-;/UT/MT<F+GD>(X\F+%WNE'TL>`DK[:)V)/2
M^\_#U;;V%H222I]W+`B-"$ST2H'FTL_9>J<]C_&`(&U)O8L.K8)(4,?3G8.%
MA"ST0B=20Z!_\%C\&1NC,W`>&Z&1:]]QG,$IS]X':II.@?,S4;?DQ25P`6MA
M>@"CE-8?EB6/PF(485W?!&(>=1`HVTV'0B=464D`F_;5G@<]?]V,9.?I!@JT
MSR`D&6TND5@;=^4VYJF<E[E73@;5:-LQVE>Y.08UK#;#%<`&\E+]13B.NGTH
M"??/:"0E;@U&:N"FE-V3-+C^H)(B#`QYAQK.%]ML(BB,5`7>EM!`Z>F%%,V@
M)4;4\V8H\@]+-3DZ6$WO83M82X91(&'%.3C?`/>!EOZ)T49(!;PAR@V"(.9H
M"C34LIV:S?Q&N^A.O9P7U,^\K%8_>.3Y`2(_+R;$R])._(E8'AH*%6&Y;$.T
M$"&<5L_3ZUDU%8Z'5WM%N4*)'K!_.``,Z5A4:?J)E4Q7*T-GA3J=;8DNC`[/
M*1!V64%#A7@)J%_;8`I=5X]ADYW2GQ@N^,X6K_1:9^_,HLD]T[VU;(6^)7W=
MB3@2(TB3L&?8>85[+*V.*;_VF+*DY'=,B1L_B#X-\?F]W4__E"Q7W[[>W5?I
MNK2)W+.VL*[NQDI,W:*;X0D8K?FW2:3P!`II@*V91Y6MX&R#SVV31#MJ42Z2
M7"+ZM(PAE1T6NH#9\U1GR`T"-*;!,&".0^@.X!7E^M:FB!XH<CH=/7`[H_,N
M*8F*V'M,9H2A!'4OGZ?"G`5*.\)&MG3K423P7>2T+NLO1X=ZO]/\6XY+3*;*
MJ&2Y<4LKLAP;J?\TV-BW;06&>##9A:@B-WN[!KJ#'PQ7CNB&D&WZ8+B$`XEN
M:4]2NU=086W!"<-A9:Z>DX[H<?7$-1'%GE=W:&?0R@S:;5WC5GYDJ;'N1+SW
M5K"EW&->NLH^`Y4@VL4P@EK^3G(:B*"GVIM!?/0!KM1OW]$-H;9P>W!F73?3
M'5?`H\J(C$J6,9,+U<6KA;T\"&AVP!$NS8O*_X]__3=<F!ZG,#W7/]4K(&"7
M9\N#K@PYBN_9YDWQ[9IN0Q6?_)O"Y5-==Q)RO9F9;^#T=J0B%3O_8?0\&3%0
M_92`@YYL?C\A/NFI3,"T@WTPE;.6B#-&<PE<#%:8J-\JY1,@A2+T8SLQ(419
M-EQEQ*IRB;&DO;E\"`JU.5B;]Z]$+-Q\L#SJ1RAU*=ME`G1I`GT:$AZ1SZK6
MZ@%>%H`3_+T@,JU`'S3NE*!1/]YRQ+52M6@`HMQGTAR"0@3N_@2K17JL91\T
MF&U:N^*X7)(`Y#E;E6![^HA`_%CD!V^T.N1/_W)8QPSP0Q''E6WWJU9J54),
M-#@Y/#DX.8PED8"`)C_R<FZ\-HC!2N)N!A7W[GKG:,<6K]"&WEJ1V@L4O<7R
M%G3(7/QM;_?MY>TK$%MZW[DJ9BX!8V\7M@9O8AV0"?:CW-69/ZF^O.M%A)/*
M)>,@*)U2'=#!.XP@XV<)9Z\L)$[GVO6C-UJBEKHH60\L%:'.-:X/_::N9C4/
MS*A=<1!K:+9W:TC]8I.JEKFL\Q*D5:XK+#8NK)P\]S3]&0@(E!R#H3!ES,%-
M_*<#T=JX_='>[M7UZP^[^Y1RB:^02']?/%*0@8@4).*S[TX:$"2V"*)77%>4
M%1C/+K52V9B_A#DK:DE"4I5+PY`.BQG14%+!`%(<G<@492186JQG!^+"L4([
M15_R;\0#D(#GB\STG&XW2@=.LC3W:'\#Z5/L/WOO80.=..8UKT;A,U$2]S)Z
MUG7>.T.&Q%L)>;2E";49H5JN*T\"U)9R*&$&%F?ZB)+1,:E%_;!KFQBS?8'+
M508H/0WVPV;VGJI00Y'8@6'#D?DGL:ZKR#8B+U,(+;?1[AKB2(K.LN_,YJ6`
M(LQ\)L:(.ZZ%78L1/!S!U:MB3PG9)+:HR<658JF$%0.A`QZJ<N1W(M50W0[*
MO4E*M$=4+K%S\QLAHV")/D("2E1_<HI$,?B*:C&.=O%"@2AD])$`V8V;5LY;
MA0GMR`XI$+#U12`V3KL]9)5$=<08%V$\]?O\^A6/1L#F,UJ!G55].UX''K*T
MJ?;&-L2,NW%Z-D(6([R,C3:3'-3O*!"5,M(HQ/@S&7U('B$I0::2"8)BC+WI
M1SW$`R17%X%_I<']G#SQ&4';)3FW8A&C4AELXJ+XE&;I&H+ROO#><W5+CA)P
MUF"L*]$64:*OR^QEM4JFYK>[*RD,O?L[O1H4VRP=9'U_*F?NOM@Y/HHO#@_Q
MM].=\>E)?,:_G.V<G^B#\YT#_.<"_B%(4J0T_H*)-EBK\X*:WT6]HI.@U*]?
M&PS+9HVV4S#(Y?Q]LEUKMX*C5U,U*'&L\0U;@>H?E57_\RNKKCOD9Y<2ZX3W
M_:.2V%`EA:%+5GGPWUB@X?^W8@%_OSR\UX;BTS^;KVB`Z![3.`!W^^GU%*1P
M)2?,JKL8L1K9^_K#[>MH[\6^*&3]'P"9<F/*!YN'UC?_;I#[XWO$Q7?H\>RD
MQ`Y'HO\U>K$FU)I>[WFE/_B$Y=LUK\<DIM3MKP);L30DZ7+6;A32X*IZ9ND/
M4FJ/T`U#ZAR?E0>[VAEL71"I3WRR9:`\Z:LSNEDVB`-<AQ?!<564J^$UB#"J
MT=0=B'C5C)!P;#<=;(,?O$J+:IJRFQ/TQ4[B:Y[2X!S=\R'%*CY5NEJEF(OZ
M`4TCSK6R\5J_-7=H'0EN9>_UFESP]7K/X1+_T_IOVF__OLGLM3W:A@BLV=]U
MN#]O8^MNW:#;2^S\/P>@?Z6R#ADZ;E%I4]1O#_E9#*1+L\2V;3.NE\XMQJT&
M,`3!DX$K4-2N-C3;9)U3O?WRD:BF'4+-4JO=T;8;<K@O\3*^`^^OT4:L.#V,
M9LG33UX._/U2HF+M_)2F124O2I,N[YJRXB'F/;;53\$;),[G7_1SL\G!>CFT
MJ^X;L-!A=!K>G.O0W#G(?L#]8C/;;J%_LQF<9-8WS7H-]\#GQ&\'5%DA<EWB
MYG3(SA-4*)^I;&^4D";;BTA"^N;UO__O;<2>[K51/?T]UW^\Y(B==53Q$D#!
M]A3-K^9N5M&]26;B7<&KW+>F3VNHYSNOZ:069`/:Y&CFN@^F[H.?.CPLV?O[
M==X9X0843Y.K";@[(VMV7,O#>$'?W9N(^L'/7-_GQZ*#-R=]X_Y,DT9P<5JF
M"K']N#XP]@+A9UZ'N&$F<-LKA[>,!.W''S";JEEVONIO+8?+ZP"E92LALRR;
M1J[GVI2H_9%G.&#7MO1Q'UJ]M50,O6"-%AMF,KVR)IMG;M0\L^UJ4;Z/OHGZ
M%:#.RM:^W38PN>@!6MN&4UT[="\$UB]]^/21+S*MWV))SQRW'Q5_R4OW7%N2
MO871N'T/T80U"$#"(C%-!V[C2U=%`,WL_GOBS^5B3&NY1F@^:3_MI8@=RTJG
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M\?H"D$K+/[:_^VYC-ZRNU!?4)(]MS\FFOB]*"D0=`E[GTY6%Q$_8\E"WDP&.
MIJ$FKKH\*P_]Q=&EHO"`X-\]-9(55]9?R2[[GW6.2AVXOO`:J`Y5Y!X>NEU6
M/HC'K(`U#\YUU:Y'O&XO-]H,P97CT(16NV9[&AMQI70R`-4R:G^P=[D?C<<G
MMEVL5SI9\GYPFWNO]J6H!\=BP<M[X_WV!QI()8$56I&*8H-IE,F^!$%CIQJ0
M[[13!-7";W>)1$QAD:8C?GE:4>'U!_8[S:)GP\QL`E)=IHL%MP=Q+=M%._&'
MH)=9S(IF)B-C%X?EL/&5_`\*T4ZT1IOR4[0YE24E"MZAVP4;A&DQ'-[(E4(W
MD4_K=PCXPS#F)LSDD3X+OQ^<P2(T$]6.X.QX[;:$Q/^$CO-&NU4ZPR*U2^E3
M^'T\V)9%<4E/1<K!^__+"M2LM`V8ZSYMWXRQUU#YBS8S7+,XUX-NVX^E5V$T
M9K4%SK#76KW.J.2:S>;M`QVP(UWU!,IK%/JPCR]0J`<M`.O-!ML9QV3U$O4S
MZ_:#W_CI<"_Y'G4XI>0(/;EBO0TN-(8&?<1M^W",&@LZL(?=U[OR\X`90/,0
M`NNKDP"ZX_0-$R[87U=K[1L6V3^Z2B9^"P:OSW>/5:"S3;XE[J-6,_'N=1OL
MX5ST]@1N#W`A5VZBP:<GO5=NN(>SFZ9']-BZ]5['HC!,_@+;PEHCPEIKP5I-
M?JWU8(T\AK9L[DFX1OE\NT7_L[^%S-O1PK%91:O#5\4-$))A$<^DG`)8PRS[
M8>>^CG"/PH*2`:^'(&##7@H?M]KZK9,XVDVY^N6)8<%]P/3/P\0_$8!M07Q0
M*7!1:[YKI/-TG5WV"MN!X,[D;03B)ZIZNP[5SGK)%`6>#?'>,R4$XW[F^_/#
MT;8&TS;40,'1;K&^U0$Z?-D@J'[@!#RJ<H/$+.B[.&2Y6=/%J/UJ4/)CHW7U
MXZ9*&QT(=QHI]$&X_1;\:9W\<C#8=0%Q>\M.!(/G2L;+R0#%I8?CB_Z'G6T\
MRQ`X(.CT&L76?S+$R@=>/^HW&X[IS^ZOWU15_;O_"U!+`0(4`Q0````(`&24
M;$=V;+^IJ@$``/`4```3``````````````"``0````!;0V]N=&5N=%]4>7!E
M<UTN>&UL4$L!`A0#%`````@`9)1L1TAU!>[%````*P(```L`````````````
M`(`!VP$``%]R96QS+RYR96QS4$L!`A0#%`````@`9)1L1V2&T#=T`0``RA,`
M`!H``````````````(`!R0(``'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L!`A0#%`````@`9)1L1[MI5+6=`@``:PD``!```````````````(`!=00`
M`&1O8U!R;W!S+V%P<"YX;6Q02P$"%`,4````"`!DE&Q'0=<XXCX!``!I`P``
M$0``````````````@`%`!P``9&]C4')O<',O8V]R92YX;6Q02P$"%`,4````
M"`!DE&Q'F5R<(Q`&``"<)P``$P``````````````@`&M"```>&PO=&AE;64O
M=&AE;64Q+GAM;%!+`0(4`Q0````(`&24;$=S-N`83`(``'H*```-````````
M``````"``>X.``!X;"]S='EL97,N>&UL4$L!`A0#%`````@`9)1L1[34!F]T
M`P``2PL```\``````````````(`!91$``'AL+W=O<FMB;V]K+GAM;%!+`0(4
M`Q0````(`&24;$>#>:KW3@(``/0'```8``````````````"``085``!X;"]W
M;W)K<VAE971S+W-H965T,2YX;6Q02P$"%`,4````"`!DE&Q'6*F*QAX$``";
M$P``&```````````````@`&*%P``>&PO=V]R:W-H965T<R]S:&5E=#(N>&UL
M4$L!`A0#%`````@`9)1L1R>Y*JE(`@``D@@``!@``````````````(`!WAL`
M`'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+`0(4`Q0````(`&24;$>S8XAS
M5@,``%\-```8``````````````"``5P>``!X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"%`,4````"`!DE&Q'K@X4"#P$``"K$P``&```````````````
M@`'H(0``>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!`A0#%`````@`9)1L
M1[])S-DM`@``]@8``!@``````````````(`!6B8``'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;%!+`0(4`Q0````(`&24;$>2C&..H@$``+$#```8````````
M``````"``;TH``!X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"%`,4````
M"`!DE&Q'[C:YN:(!``"Q`P``&```````````````@`&5*@``>&PO=V]R:W-H
M965T<R]S:&5E=#@N>&UL4$L!`A0#%`````@`9)1L1P,)#OVC`0``L0,``!@`
M`````````````(`!;2P``'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+`0(4
M`Q0````(`&24;$<Y@37DI`$``+$#```9``````````````"``48N``!X;"]W
M;W)K<VAE971S+W-H965T,3`N>&UL4$L!`A0#%`````@`9)1L1WS:]?VA`0``
ML0,``!D``````````````(`!(3```'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6Q02P$"%`,4````"`!DE&Q'KS3AV*,!``"Q`P``&0``````````````@`'Y
M,0``>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+`0(4`Q0````(`&24;$>F
M\&">I0$``+$#```9``````````````"``=,S``!X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL4$L!`A0#%`````@`9)1L1_.H>P"D`0``L0,``!D`````````
M`````(`!KS4``'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"%`,4````
M"`!DE&Q'\H`,1U<"``#K"```&0``````````````@`&*-P``>&PO=V]R:W-H
M965T<R]S:&5E=#$U+GAM;%!+`0(4`Q0````(`&24;$<NX#D;I0$``+$#```9
M``````````````"``1@Z``!X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L!
M`A0#%`````@`9)1L1WF,9W6R`0``%@0``!D``````````````(`!]#L``'AL
M+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"%`,4````"`!DE&Q'D.>NB:<!
M``"Q`P``&0``````````````@`'=/0``>&PO=V]R:W-H965T<R]S:&5E=#$X
M+GAM;%!+`0(4`Q0````(`&24;$?^"KW:N`(``)H*```9``````````````"`
M`;L_``!X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L!`A0#%`````@`9)1L
M1Y6<+&-5`P``VP\``!D``````````````(`!JD(``'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6Q02P$"%`,4````"`!DE&Q'$V"JDND!``"C!0``&0``````
M````````@`$V1@``>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+`0(4`Q0`
M```(`&24;$<4XOKPNP(``)<*```9``````````````"``59(``!X;"]W;W)K
M<VAE971S+W-H965T,C(N>&UL4$L!`A0#%`````@`9)1L1Y<+1RP=`P``/@\`
M`!D``````````````(`!2$L``'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q0
M2P$"%`,4````"`!DE&Q'N>A1_%P"``#%"```&0``````````````@`&<3@``
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+`0(4`Q0````(`&24;$=VP"!@
MH`8``"XG```9``````````````"``2]1``!X;"]W;W)K<VAE971S+W-H965T
M,C4N>&UL4$L!`A0#%`````@`9)1L1PHX'=@B`P``(`X``!D`````````````
M`(`!!E@``'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"%`,4````"`!D
ME&Q'0757#0(#``#*#```&0``````````````@`%?6P``>&PO=V]R:W-H965T
M<R]S:&5E=#(W+GAM;%!+`0(4`Q0````(`&24;$>;4TX2#P(``#X&```9````
M``````````"``9A>``!X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L!`A0#
M%`````@`9)1L1YU.?5II`@``<0@``!D``````````````(`!WF```'AL+W=O
M<FMS:&5E=',O<VAE970R.2YX;6Q02P$"%`,4````"`!DE&Q'N9Z^NH\!```]
M`P``&0``````````````@`%^8P``>&PO=V]R:W-H965T<R]S:&5E=#,P+GAM
M;%!+`0(4`Q0````(`&24;$>1/EOK[`$``!<%```9``````````````"``41E
M``!X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L!`A0#%`````@`9)1L1V3Z
M"S7H4P``*#8!`!0``````````````(`!9V<``'AL+W-H87)E9%-T<FEN9W,N
9>&UL4$L%!@`````H`"@`R@H``(&[````````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139753841546320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders'Deficit and Preferred Stock Subject to Redemption (Detail Textuals)<br></strong></div></th>
<th class="th" colspan="11">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 21, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May. 31, 2015 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2014 </div>
<div>Investor </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2014 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 17, 2012 </div>
<div>USD ($) </div>
<div>Advisor </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2014 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_TermOfWarrant', window );">Term of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ValueOfCommonStockCalledByWarrants', window );">Value of common stock called by warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_AmortizationOfWarrantServiceCost', window );">Amortization of warrant service cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Number of shares issued for services | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Fair market value of common stock issued recorded as prepaid expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 168,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued to group of private investors | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Value of shares issued to group of private investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 724,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value of common stock issued (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NumberOfInvestor', window );">Number of individual investor | Investor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 744,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 466,200<span></span>
</td>
<td class="nump">$ 662,613<span></span>
</td>
<td class="nump">$ 2,929,799<span></span>
</td>
<td class="nump">$ 835,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued to group of private investors | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_MinimumIssuanceOfSharesInEquityFinancing', window );">Minimum equity financing under down-round protection feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 286,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_MaximumIssuancePricePerShareInEquityFinancing', window );">Maximum common stock issuance price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted | shares</a></td>
<td class="nump">580,000<span></span>
</td>
<td class="nump">580,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants', window );">Number of preferred stock and warrants sold | shares</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_MaximumIssuancePricePerShareInEquityFinancing', window );">Maximum common stock issuance price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ConversionPrice', window );">Conversion price | $ / shares</a></td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants', window );">Proceeds received from the Series B financing</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionTerms', window );">Preferred stock, redemption terms</a></td>
<td class="text">(A) 115% of the conversion amount and (B) the product of (1) the conversion rate in effect at such time and (2) the greatest closing sale price of the Common Stock during the period beginning on the date immediately preceding such triggering event and ending on the date such holder delivers the notice of redemption.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ValueOfCommonStockCalledByWarrants', window );">Value of common stock called by warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 326,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfServicesAmortization', window );">Amortization of cost of service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nmus_FoundersAndMemberOfBoardMember', window );">Founders and Board member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Number of shares issued for services | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,770,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ValueOfShareExchangedForServices', window );">Value of shares exchanged for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants | shares</a></td>
<td class="nump">6,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_TermOfWarrant', window );">Term of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NumberOfAdvisors', window );">Number of advisors | Advisor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ValueOfCommonStockCalledByWarrants', window );">Value of common stock called by warrants</a></td>
<td class="nump">$ 86,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 67,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued to group of private investors | shares</a></td>
<td class="nump">187,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ValueOfWarrantsIssued', window );">Value of warrants issued</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants | Series A preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants | Stock Purchase Agreement June 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ValueOfCommonStockCalledByWarrants', window );">Value of common stock called by warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ValueOfWarrantsIssued', window );">Value of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ConversionPrice', window );">Conversion price | $ / shares</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of shares issued in conversion | shares</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">1,812,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_AmortizationOfWarrantServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amortization of warrant service cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_AmortizationOfWarrantServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents conversion price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_EquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_EquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_MaximumIssuancePricePerShareInEquityFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents maximum issuance price per share under equity financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_MaximumIssuancePricePerShareInEquityFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_MinimumIssuanceOfSharesInEquityFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents value of minimum issuance of shares under equity financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_MinimumIssuanceOfSharesInEquityFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_NumberOfAdvisors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of advisors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_NumberOfAdvisors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_NumberOfInvestor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents number of individual investors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_NumberOfInvestor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_StockAndWarrantsIssuedDuringPeriodSharesPreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_TermOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents term of warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_TermOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ValueOfCommonStockCalledByWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of common stock called by warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ValueOfCommonStockCalledByWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ValueOfShareExchangedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents value of share exchanged for services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ValueOfShareExchangedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ValueOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents value of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ValueOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i)(2))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfServicesAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the costs of intangible assets over the expected benefit period of such assets. This element applies only to intangible assets used in the delivery of services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.2(d))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfServicesAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The redemption terms of preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity. The redemption features of this capital stock are solely within the control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nmus_FoundersAndMemberOfBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nmus_FoundersAndMemberOfBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_AgreementAxis=nmus_StockPurchaseAgreementJune2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_AgreementAxis=nmus_StockPurchaseAgreementJune2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139753863659040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="font: bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">3. Commitments and Contingencies</div>
<div style="font: bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Lease Commitments</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company leased temporary headquarters facilities under a month-to-month operating lease agreement. This lease was terminated effective December 31, 2014. Monthly rent expense under this lease was $2,060.</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">On September 1, 2014, the Company signed an operating lease for laboratory and office space at the Innovation Hub, Insight Park located on the University of Mississippi campus. The lease term commenced on October 1, 2014 and expires on December 31, 2017. There are annual escalating rent provisions and two months of free rent in the agreement. The total cash payments over the life of the lease are divided by the total number of months in the lease period and the average rent will be charged to expense each month during the lease period. The monthly amount charged to rent expense is $9,000.</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">In October of&#160;2014, we signed a lease agreement for our corporate office headquarters that consists of approximately 4,087 square feet located at 650 Town Center Drive, Suite 1770, Costa Mesa, CA 92626. &#160; The lease expires on October 31, 2016 and our monthly rent is $5,373, payable in equal monthly installments with annual escalations.</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Total net rent expense related to our operating leases for the nine months ended September 30, 2015 and 2014 was $170,931and $6,844, respectively. For the three months ended September 30, 2015 and 2014, total net rent expense was $56,680 and $6,294.</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 35.9pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.2pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Future minimum payments under the non-cancelable portion of our operating leases as of September 30, 2015 are as follows:</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 35.9pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.2pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<table align="center" style="widows: 1; text-transform: none; text-indent: 0px; width: 100%; font-family: 'times new roman', times, serif; letter-spacing: normal; font-size: 10pt; word-spacing: 0px; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="vertical-align: bottom;" valign="bottom">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">For the year ending December 31,</div>
</td>
<td style="vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="vertical-align: bottom;" valign="bottom" colspan="2"></td>
<td style="text-align: left; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="width: 1337px; vertical-align: bottom; background-color: #cceeff;" valign="bottom">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">2015</div>
</td>
<td style="width: 16px; vertical-align: bottom; background-color: #cceeff;" valign="bottom">&#160;</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div>
</td>
<td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #cceeff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">43,900</div>
</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="width: 1337px; vertical-align: bottom; background-color: #ffffff;" valign="bottom">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">2016</div>
</td>
<td style="width: 16px; vertical-align: bottom; background-color: #ffffff;" valign="bottom">&#160;</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;" valign="bottom">&#160;</td>
<td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #ffffff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">165,700</div>
</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="width: 1337px; vertical-align: bottom; background-color: #cceeff;" valign="bottom">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">2017</div>
</td>
<td style="width: 16px; vertical-align: bottom; background-color: #cceeff;" valign="bottom">&#160;</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom">&#160;</td>
<td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #cceeff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">85,900</div>
</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="width: 1337px; vertical-align: bottom; background-color: #ffffff;" valign="bottom">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">2018</div>
</td>
<td style="width: 16px; vertical-align: bottom; background-color: #ffffff;" valign="bottom">&#160;</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;" valign="bottom">&#160;</td>
<td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #ffffff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div>
</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="width: 1337px; vertical-align: bottom; background-color: #cceeff;" valign="bottom">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">2019</div>
</td>
<td style="width: 16px; vertical-align: bottom; background-color: #cceeff;" valign="bottom">&#160;</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom">&#160;</td>
<td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #cceeff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div>
</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="width: 1337px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;" valign="bottom">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Thereafter</div>
</td>
<td style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;" valign="bottom">&#160;</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;" valign="bottom">&#160;</td>
<td style="width: 136px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div>
</td>
<td style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="width: 1337px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;" valign="bottom">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Total</div>
</td>
<td style="width: 16px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;" valign="bottom">&#160;</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div>
</td>
<td style="width: 136px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">295,500</div>
</td>
<td style="width: 15px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Independent Contractor Agreements</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company has entered into independent contractor agreements with individuals that are operating in the capacity of our management team, or that are serving in an advisory role. Certain agreements expired once the individuals became full-time employees. Independent contractor expense for the nine months ended September 30, 2015 was $90,000 and for the nine months ended September 30, 2014 was $353,000. Two of these contractors accounted for 30% and 15% respectively of our total expenditures for the nine months ended September 30, 2014. There was no significant independent contractor expense as a percent of our total expenditures&#160;for the nine months ended September 30, 2015.</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Legal Matters</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: italic 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">General Litigation and Disputes</div>
<div style="font: italic 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">From time to time, in the normal course of our operations, we may be a party to litigation and other dispute matters and claims. Currently Nemus is not party to any litigation, dispute matters or claims. Litigation can be expensive and disruptive to normal business operations. Moreover, the results of complex legal proceedings are difficult to predict and our view of these matters may change in the future as the litigation and events related thereto unfold. An unfavorable outcome to any legal matter, if material, could have a materially adverse effect on our operations or our financial position, liquidity or results of operations.</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: italic 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Government Proceedings</div>
<div style="font: italic 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Like other companies in the pharmaceutical industry, we are subject to extensive regulation by national, state and local government agencies in the United States. As a result, interaction with government agencies occurs in the normal course of our operations. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from any government investigation or proceeding. As of September 30, 2015, the Company had no current proceedings or inquiries.</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Change in Control Severance Plan</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">In February 2015, we adopted a change in control severance plan, in which our named executive officers participate, that provides for the payment of severance benefits if the executive's service is terminated within twelve months following a change in control, either due to a termination without cause or upon a resignation for good reason (as each term is defined in the plan).</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">In either such event, and provided the executive timely executes and does not revoke a general release of claims against the Company, he or she will be entitled to receive: (i) a lump sum cash payment equal to at least six months of the executive's monthly compensation, plus an additional month for each full year of service over six years, (ii) Company-paid premiums for continued health insurance for a period equal to length of the cash severance period or, if earlier, when executive becomes covered under a subsequent employer's healthcare plan, and (iii) full vesting of all then-outstanding unvested stock options and restricted stock awards.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 460<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51674963&amp;loc=d3e12565-110249<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 440<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139753851392672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Series B Warrants (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Apr. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants</a></td>
<td class="nump">$ 731,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Series B warrants</a></td>
<td class="nump">$ 2,892,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_SeriesBWarrantsMember', window );">Series B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NumberOfWarrantsIssued', window );">Number of warrants issued</a></td>
<td class="nump">6,437,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants</a></td>
<td class="nump">$ 2,935,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed', window );">Method used for valuation of warrants</a></td>
<td class="text">Black-Scholes pricing model<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants', window );">Proceeds received from the Series B financing</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Series B warrants</a></td>
<td class="nump">$ 2,892,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_NumberOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of warrants issued during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_NumberOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 10<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13433-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13495-108611<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For each plan, identification of the award pricing model or other valuation method used in calculating the weighted average fair values disclosed. The model is also used to calculate the compensation expense that is shown within the balance sheet, income statement, and cash flow. Examples of valuation techniques are lattice models (binomial model), closed-form models (Black-Scholes-Merton formula), and a Monte Carlo simulation technique. Fair value is the amount at which an asset or liability could be bought or incurred or sold or settled in a current transaction between willing parties, that is, other than in a forced or liquidation sale. May include disclosures about the assumptions underlying application of the method selected.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nmus_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139754048723344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Series B Warrants (Details) - Series B Warrants - $ / shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility factor</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">4 years 7 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of warrants granted during the periods</a></td>
<td class="nump">$ 0.46<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(2)(iii)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nmus_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nmus_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139753857256688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Detail Textuals)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">$ 4,023,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139753860375312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Detail Textuals) - Subsequent Event - Omnibus Incentive Plan 2014 - Restricted stock awards - Senior management and board of directors - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 20, 2015</div></th>
<th class="th"><div>Oct. 19, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_FairMarketValueOfSharesGranted', window );">Fair market value of shares granted</a></td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vested period of shares granted</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_FairMarketValueOfSharesGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of shares granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_FairMarketValueOfSharesGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(2)(iii)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nmus_OmnibusIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nmus_OmnibusIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=nmus_ManagementAndBoardOfDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=nmus_ManagementAndBoardOfDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139753857250384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>University of Mississippi ("UM") Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_UniversityOfMississippiAgreementsAbstract', window );"><strong>University Of Mississippi Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_UniversityOfMississippiAgreementsTextBlock', window );">University of Mississippi ("UM") Agreements</a></td>
<td class="text"><div style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">2. University of Mississippi ("UM") Agreements</div>
<div style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">In July 2013, the Company entered into a Memorandum of Understanding (MOU) with the UM to engage in joint research of extracting, manipulating, and studying cannabis in certain forms to develop intellectual property (IP) with the intention to create and commercialize therapeutic medicines. Nemus will own all IP developed solely by its employees and will jointly own all IP developed jointly between Nemus and UM employees. The term of the MOU agreement is five years and the parties agree to negotiate separate Research agreements upon the identification of patentable technologies as well as any deemed to be a trade secret. The agreement may be terminated by either party with three months written notice to the other party.</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">On May 15, 2014, the Company entered into an Option Agreement in which UM granted us a three-month option for conducting due diligence to exclusively license a suppository dosage form containing Dronabinol Hemi succinate and other esters ("NPC 4718").</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">As a result of our due diligence, on September 29, 2014, the Company executed three license agreements with UM pursuant to which UM granted us exclusive, perpetual, worldwide licenses, including the right to sublicense, to intellectual property related to UM5050, a pro-drug formulation of tetrahydrocannabinol, or THC for products administered through each of ocular, oral or rectal delivery. The license agreement for the field of oral delivery also includes rights to UM 1250, a bio-adhesive hot melt extruded film for topical and mucosal adhesion application and drug delivery.&#160; The license agreements contain certain milestone and royalty payments, as defined therein. These licenses also require the Company to reimburse UM for patent costs incurred related to these products under license. In the case of the ocular license the Company was required to reimburse sunk patent expenses of $70,678 in February 2015; this amount was reflected in accrued license and patent reimbursement fees as of December 31, 2014. These license agreements will terminate upon expiration of the patents, breach or default of the license agreements, or upon 60 days written notice by the Company to UM.</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">On October 15, 2014, we signed a renewable option agreement for the rights to explore other routes of delivery of UM5050 not yet agreed upon and/or in combination with other cannabinoids or other compatible compounds. There was a one-time up-front option payment and the option period was for six months expiring on March 31, 2015. On September 29, 2015, the Company exercised its right to renew for an additional six months under the same financial terms and conditions.</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 3pt; margin-bottom: 3pt;">&#160;</div>
</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 20pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.1pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">On July 1, 2014, the Company entered into three additional Option Agreements, pursuant to which UM granted Nemus three-month exclusive options for conducting due diligence on the following three cannabinoid extracts to exclusively license them for the purposes of obtaining FDA approval and commercializing the extracts:</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 20pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.1pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">
<table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="width: 20pt;"></td>
<td style="width: 27.35pt; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">1)</td>
<td style="width: auto; text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">UM 1490 &#8211; transmucosal delivery of cannabinoids</td>
</tr>
</table>
</div>
<div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">
<table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="width: 20pt;"></td>
<td style="width: 27.35pt; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">2)</td>
<td style="width: auto; text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">UM 5070 &#8211; treatment for methicillin-resistant&#160;<font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;">Staphylococcus aureus&#160;</font>(MRSA) infections</td>
</tr>
</table>
</div>
<div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">
<table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="width: 20pt;"></td>
<td style="width: 27.35pt; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">3)</td>
<td style="width: auto; text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">UM 8790 &#8211; ocular delivery of cannabinoids</td>
</tr>
</table>
</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-right: 0.1pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-right: 0.1pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">In March of 2015, in lieu of a license agreement, the Company entered into a research agreement with UM to begin studies concerning the medical utility of cannabinoids as anti-infective therapeutics for MRSA.&#160; The fee payable to UM under the agreement is based on the achievement of certain milestones in the project. The Company recognized $18,673 and $66,747 of research and development expense for the three and nine months ending September 30, 2015 which represents work completed to date under this contract.&#160; The agreement also grants an exclusive option to license the technology from the University within 180 days from the commencement of the agreement. Either party may terminate the agreement with 30 days written notice.</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-right: 0.1pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 35.9pt; letter-spacing: normal; margin-right: 3.8pt; margin-left: 0.6pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">In July of 2015, the Company entered into a research agreement with UM to begin studies concerning research and development of cannabidiol (CBD) formulations.&#160; The fee payable to UM is based on the achievement of certain milestones in the project. The Company recognized $37,119 of research and development expense for both the three and nine months ending September 30, 2015 which represents work completed to date under this contract. The agreement also grants an exclusive option to license the technology from the University within 180 days from the commencement of the agreement. Either party may terminate the agreement with 30 days written notice.</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 35.9pt; letter-spacing: normal; margin-right: 3.8pt; margin-left: 0.6pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 35.8pt; letter-spacing: normal; margin-right: 0.2pt; margin-left: 0.3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">In September of 2015, the Company entered into a research agreement with UM to advance NEMUS' lead proprietary cannabinoid-based therapy (UM5050) developed for the treatment and management of glaucoma into an optimized once-daily treatment formulation. The fee payable to UM is based on the achievement of certain milestones in the project. The Company recognized $21,496 of research and development expense for both the three and nine months ending September 30, 2015 which represents work completed to date under this contract. The agreement also grants an exclusive option to license the technology from the University within 180 days from the commencement of the agreement. Either party may terminate the agreement with 30 days written notice.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_UniversityOfMississippiAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_UniversityOfMississippiAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_UniversityOfMississippiAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents entire disclosure for University of Mississippi ("UM") Agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_UniversityOfMississippiAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139753851430528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 4,342,722<span></span>
</td>
<td class="nump">$ 207,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">95,548<span></span>
</td>
<td class="nump">64,489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">31,110<span></span>
</td>
<td class="nump">36,580<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">4,506,880<span></span>
</td>
<td class="nump">308,399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">16,046<span></span>
</td>
<td class="nump">21,354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_DepositsAndOtherAssets', window );">Deposits and other assets</a></td>
<td class="nump">18,594<span></span>
</td>
<td class="nump">18,594<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total other assets</a></td>
<td class="nump">18,594<span></span>
</td>
<td class="nump">18,594<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">4,541,520<span></span>
</td>
<td class="nump">348,347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">132,234<span></span>
</td>
<td class="nump">409,497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll and related expenses</a></td>
<td class="nump">144,723<span></span>
</td>
<td class="nump">45,566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_AccruedLicenseAndPatentReimbursementFees', window );">Accrued license and patent reimbursement fees</a></td>
<td class="nump">90,216<span></span>
</td>
<td class="nump">119,428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">177,081<span></span>
</td>
<td class="nump">125,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_StockSubscriptionLiability', window );">Stock subscription liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ProvisionForConversionOfPreferredStock', window );">Provision for conversion of Series B preferred stock</a></td>
<td class="nump">75,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">619,742<span></span>
</td>
<td class="nump">801,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
<td class="nump">3,221<span></span>
</td>
<td class="nump">805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Series B warrants</a></td>
<td class="nump">2,892,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total noncurrent liabilities</a></td>
<td class="nump">2,895,613<span></span>
</td>
<td class="nump">805<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">$ 3,515,355<span></span>
</td>
<td class="nump">$ 801,895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 3)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Redeemable Convertible Series B Preferred Stock, $0.001 par value, 20 million shares authorized; 5,000 issued and outstanding as of September 30, 2015 and none issued and outstanding as of December 31, 2014, net of $411,661 in issuance costs; $5.0 million liquidation preference as of September 30, 2015</a></td>
<td class="nump">$ 1,620,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 236 million shares authorized; 18,078,163 issued and outstanding as of September 30, 2015 and 16 million issued and outstanding as of December 31, 2014</a></td>
<td class="nump">18,078<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in-capital</a></td>
<td class="nump">5,723,888<span></span>
</td>
<td class="nump">2,257,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants</a></td>
<td class="nump">731,036<span></span>
</td>
<td class="nump">190,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(7,067,296)<span></span>
</td>
<td class="num">(2,917,319)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
<td class="num">(594,294)<span></span>
</td>
<td class="num">(453,548)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' deficit</a></td>
<td class="nump">$ 4,541,520<span></span>
</td>
<td class="nump">$ 348,347<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_AccruedLicenseAndPatentReimbursementFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents carrying value as of the balance sheet date of obligations incurred through that date and payable for accrued license and patent reimbursement fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_AccruedLicenseAndPatentReimbursementFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_DepositsAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents aggregate carrying amount, as of the balance sheet date, of deposits and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_DepositsAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ProvisionForConversionOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount related to provision for conversion of preferred stock as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ProvisionForConversionOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_StockSubscriptionLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents carrying value as of the balance sheet date of stock subscription liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_StockSubscriptionLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 15<br><br><br><br> -Article 9<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 15<br><br><br><br> -Subparagraph b(1)<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.26(c))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39927-112707<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 10<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13433-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13495-108611<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22, 23, 24, 25, 26, 27<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 340<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51662447&amp;loc=d3e5879-108316<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Assets<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (g)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139753860313120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (Parentheticals)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Common stock issuance costs</a></td>
<td class="nump">$ 3,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_SeriesAPreferredStockIssuanceCosts', window );">Series A preferred stock issuance costs</a></td>
<td class="nump">7,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_SeriesBPreferredStockIssuanceCosts', window );">Series B preferred stock issuance costs</a></td>
<td class="nump">$ 411,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants issued to purchase shares of common stock for consulting services (in shares) | shares</a></td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NoncashValueOfWarrantsIssued', window );">Value of warrants issued to purchase shares of common stock for consulting services</a></td>
<td class="nump">$ 417,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Value of common stock issued for consulting services</a></td>
<td class="nump">$ 168,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_WarrantsIssuedInExchangeForExtinguishmentOfTradeAccountsPayable', window );">Warrants issued in exchange for extinguishment of trade accounts payable | shares</a></td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ExtinguishmentOfTradeAccountsPayableOwedToVendor', window );">Extinguishment Of Trade Accounts Payable Owed To Vendor</a></td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ExtinguishmentOfTradeAccountsPayableOwedToVendor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount related to extinguishment of trade accounts payable owed to vendor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ExtinguishmentOfTradeAccountsPayableOwedToVendor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_NoncashValueOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents noncash value of warrants issued to purchase shares of common stock for consulting services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_NoncashValueOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_SeriesAPreferredStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents amount of Series A preferred stock issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_SeriesAPreferredStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_SeriesBPreferredStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents amount of Series B preferred stock issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_SeriesBPreferredStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_WarrantsIssuedInExchangeForExtinguishmentOfTradeAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of warrants issued in exchange for extinguishment of trade accounts payable owed to vendor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_WarrantsIssuedInExchangeForExtinguishmentOfTradeAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139753851300880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Detail Textuals)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2014 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of corporate office headquarters | ft&#178;</a></td>
<td class="nump">4,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
<td class="nump">$ 5,373<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="nump">$ 56,680<span></span>
</td>
<td class="nump">$ 6,294<span></span>
</td>
<td class="nump">$ 170,931<span></span>
</td>
<td class="nump">$ 6,844<span></span>
</td>
<td class="nump">$ 2,060<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_AgreementAxis=nmus_IndependentContractorAgreementsMember', window );">Independent Contractor Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_IndependentContractorExpense', window );">Independent contractor expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000<span></span>
</td>
<td class="nump">$ 353,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_AgreementAxis=nmus_IndependentContractorAgreementsMember', window );">Independent Contractor Agreements | Contractor One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_PercentageOfContractorExpensesForTotalExpenditures', window );">Percentage of contractor expenses for total expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_AgreementAxis=nmus_IndependentContractorAgreementsMember', window );">Independent Contractor Agreements | Contractor Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_PercentageOfContractorExpensesForTotalExpenditures', window );">Percentage of contractor expenses for total expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_IndependentContractorExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents independent contractor expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_IndependentContractorExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_PercentageOfContractorExpensesForTotalExpenditures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents percentage of contract expenses of total expenditures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_PercentageOfContractorExpensesForTotalExpenditures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_AgreementAxis=nmus_IndependentContractorAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_AgreementAxis=nmus_IndependentContractorAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ContractorAxis=nmus_ContractorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ContractorAxis=nmus_ContractorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ContractorAxis=nmus_ContractorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ContractorAxis=nmus_ContractorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139753860070192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders'Deficit and Preferred Stock Subject to Redemption - Summary of weighted average assumptions for employee option (Details 1) - Stock Option - $ / shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility factor</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of options granted during the periods</a></td>
<td class="nump">$ 2.69<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.68%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)(iii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)(ii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)(iv)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (d)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br> -Section D<br><br><br><br> -Subsection 2<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139753851424784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations, Business Activities and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Nature of Operations, Business Activities and Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 5pt; margin-bottom: 5pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">1. Nature of Operations, Business Activities and Summary of Significant Accounting Policies</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Nature of Operations and Basis of Presentation</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Nemus Bioscience, Inc. is a biopharmaceutical company that plans to develop and commercialize therapeutics from cannabinoids through a partnership with the University of Mississippi. The University of Mississippi ("UM") is federally permitted and licensed to cultivate cannabis for research and commercial purposes. Unless otherwise specified, references in these Notes to the Unaudited Consolidated Financial Statements to the "Company," "we" or "our" refer to Nemus Bioscience, Inc., a Nevada corporation formerly known as Load Guard Logistics, Inc. ("LGL"), together with its wholly-owned subsidiary, Nemus, a California corporation ("Nemus"). Nemus became the wholly owned subsidiary of Nemus Bioscience, Inc. through the Merger (as defined below).</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Nemus Bioscience, Inc. (formerly LGL) was incorporated in Nevada on March 16, 2011. Nemus was incorporated in California on July 17, 2012. Our headquarters are located in Costa Mesa, California.</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">As of September 30, 2015, the Company has devoted substantially all of its efforts to securing product licenses, raising capital, and building infrastructure, and has not realized revenue from its planned principal operations.</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Business Activities</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">On October 31, 2014, pursuant to an Agreement and Plan of Merger, dated October 17, 2014 (the "Merger Agreement"), LGL,&#160; Nemus Acquisition Corp. ("Acquisition Sub"), Nemus Bioscience, Inc. ("Name Change Merger Sub"), and Nemus, Acquisition Sub merged with and into Nemus and Nemus survived as a wholly-owned subsidiary of LGL (the "Merger"). Immediately after the Merger, LGL changed its name to "Nemus Bioscience, Inc." by merging with Name Change Merger Sub.&#160;Pursuant to the Merger Agreement, each share of Nemus common stock outstanding totaling 12,880,000 shares was exchanged at a 1:1 conversion rate to LGL shares and when combined with the 3,120,000 shares of LGL common stock outstanding, amounted to 16,000,000 total shares outstanding upon completion of the merger.</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">The Merger is being accounted for as a reverse-merger and recapitalization. Nemus is the acquirer for financial reporting purposes and LGL is the acquired company. Consequently, the assets and liabilities and the operations that will be reflected in the historical consolidated&#160;financial statements prior to the Merger will be those of Nemus and will be recorded at the historical cost basis of Nemus, and the consolidated financial statements after completion of the Merger will include the assets and liabilities of LGL and Nemus, the historical operations of Nemus and the operations of the Nemus from and after the closing date of the Merger.</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Use of Estimates</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles ("U.S. GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates.</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Liquidity and Going Concern</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">The Company has incurred operating losses and negative cash flows from operations since our inception. As of September 30, 2015, we had cash and cash equivalents of $4,342,722.&#160; The Company anticipates that it will continue to incur net losses into the foreseeable future as it continues to advance and develop a number of potential drug candidates into preclinical development activities and expands its corporate infrastructure which includes the costs associated with being a public company. Without additional funding, management believes that the Company will not have sufficient funds to meet its obligations within one year after the date the consolidated financial statements are issued. These conditions give rise to substantial doubt as to the Company's ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">The Company plans to continue to fund its losses from operations and capital funding needs through public or private equity or debt financings, strategic collaborations, licensing arrangements, asset sales, government grants or other arrangements. However, the Company cannot be sure that such additional funds will be available on reasonable terms, or at all. If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result. If the Company is unable to secure adequate additional funding, the Company may be forced to make a reduction in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs.</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Cash and Cash Equivalents</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The carrying value of those investments approximates their fair market value due to their short maturity and liquidity. Cash and cash equivalents include cash on hand and amounts on deposit with financial institutions, which amounts may at times exceed federally insured limits. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk.</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Restricted Cash</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"><font style="font-size: 5.14pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">A deposit of $37,500 as of September 30, 2015 was restricted from withdrawal and held by a bank in the form of a certificate of deposit. This certificate served as collateral for payment of the Company's credit cards.&#160; Restricted cash as of December 31, 2014 was $0.</font></div>
<div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Fair Value Measurements</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last is considered unobservable, is used to measure fair value:</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">
<table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="width: 20.45pt;"></td>
<td style="width: 51.55pt; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">Level 1:</td>
<td style="width: auto; text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">
<div>Valuations for assets and liabilities traded in active markets from readily available pricing sources such as quoted prices in active markets for identical assets or liabilities.</div>
<div>&#160;</div>
</td>
</tr>
</table>
</div>
<div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">
<table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="width: 20.45pt;"></td>
<td style="width: 51.55pt; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">Level 2:</td>
<td style="width: auto; text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">
<div>Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</div>
<div>&#160;</div>
</td>
</tr>
</table>
</div>
<div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">
<table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="width: 20.45pt;"></td>
<td style="width: 51.55pt; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">Level 3:</td>
<td style="width: auto; text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</td>
</tr>
</table>
</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 35.9pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.1pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 35.9pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.1pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">The carrying values of our financial instruments, including, cash and cash equivalents, prepaid expenses, accounts payable, and accrued expenses approximate their fair value due to the short maturities of these financial instruments.</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Property and Equipment, Net</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">As of September 30, 2015, property and equipment, net, was $16,046, consisting primarily of computers and equipment. The Company had $21,354 of property and equipment, net, as of December 31, 2014. Expenditures for additions, renewals and improvements will be capitalized at cost. Depreciation will generally be computed on a straight-line method based on the estimated useful life of the related assets currently ranging from two to three years. Maintenance and repairs that do not extend the life of assets are charged to expense when incurred. When properties are disposed of, the related costs and accumulated depreciation are removed from the accounts and any gain or loss is reported in the period the transaction takes place.</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount exceeds its estimated future undiscounted cash flows, an impairment charge is recognized by the amount by which the carrying amount exceeds the fair value of the asset.</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">The costs incurred for the rights to use licensed technologies in the research and development process, including licensing fees and milestone payments, will be charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where there is an identified alternative future use. No cost associated with the use of licensed technologies has been capitalized to date.</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Income Taxes</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">The Company accounts for our deferred income tax assets and liabilities based on differences between the financial reporting and tax bases of assets and liabilities, and net operating loss carry forwards (the "NOLs") and other tax credit carry forwards. These items are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the period that includes the enactment date. Any interest or penalties would be recorded in the Company's statement of operations in the period incurred.</div>
<div style="font: 10pt/normal 'times new roman', times,;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">The Company records a valuation allowance to reduce the deferred income tax assets to the amount that is more likely than not to be realized. In making such determinations, management considers all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. As a result there are no income tax benefits reflected in the statement of operations to offset pre-tax losses.</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">The Company recognizes a tax benefit from uncertain tax positions when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position.</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Revenue Recognition</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">The Company has not begun planned principal operations and has not generated any revenue since inception.</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Research and Development Expenses</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Research and development ("R&amp;D") costs are expensed when incurred. These costs may consist of external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, third-party manufacturing organizations and consultants; employee-related expenses, which include salaries, benefits and stock-based compensation for the personnel involved in our preclinical and clinical drug development activities; and facilities expense, depreciation and other allocated expenses; and equipment and laboratory supplies.</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Stock-Based Compensation Expenses</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Stock-based compensation cost is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period. We use the Black-Scholes option pricing model for estimating the grant date fair value of stock options and warrants using the following assumptions:</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">
<table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="width: 20.25pt;"></td>
<td style="width: 27pt; font-family: symbol, serif; font-size: 10pt; vertical-align: top;">&#183;</td>
<td style="width: auto; text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">Exercise price - We determined the exercise price based on valuations using the best information available to management at the time of the valuations.</td>
</tr>
</table>
</div>
<div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">
<table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="width: 20.25pt;"></td>
<td style="width: 27pt; font-family: symbol, serif; font-size: 10pt; vertical-align: top;">&#183;</td>
<td style="width: auto; text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">Volatility &#8211; We estimate the stock price volatility based on industry peers who are also in the early development stage given the limited market data available in the public arena.</td>
</tr>
</table>
</div>
<div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">
<table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="width: 20.25pt;"></td>
<td style="width: 27pt; font-family: symbol, serif; font-size: 10pt; vertical-align: top;">&#183;</td>
<td style="width: auto; text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">Expected term - The expected term is based on a simplified method which defines the life as the average of the contractual term of the options and warrants and the weighted-average vesting period for all open awards.</td>
</tr>
</table>
</div>
<div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">
<table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="width: 20.25pt;"></td>
<td style="width: 27pt; font-family: symbol, serif; font-size: 10pt; vertical-align: top;">&#183;</td>
<td style="width: auto; text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">Risk-free rate - The risk-free interest rate for the expected term of the option or warrant is based on the average market rate on U.S. treasury securities in effect during the quarter in which the awards were granted.</td>
</tr>
</table>
</div>
<div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">
<table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="width: 20.35pt;"></td>
<td style="width: 27pt; font-family: symbol, serif; font-size: 10pt; vertical-align: top;">&#183;</td>
<td style="width: auto; text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">Dividends &#8211; The dividend yield assumption is based on our history and expectation of paying no dividends.</td>
</tr>
</table>
</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Stock-Based Compensation for Non-Employees</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">The Company accounts for warrants and options issued to non-employees under ASC 505-50,&#160;<font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;">Equity &#8211; Equity Based Payments to Non-Employees,</font>&#160;using the Black-Scholes option-pricing model. The value of such non-employee awards are periodically re-measured over the vesting terms and at each quarter end.</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Segment Information</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">The Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") No. 280, "Segment Reporting" establishes standards for reporting information about reportable segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group ("CODM"), in deciding how to allocate resources and in assessing performance. The CODM evaluates revenues and gross profits based on product lines and routes to market. Based on the early development stage of our operation, we operate in a single reportable segment.</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Comprehensive Income (Loss)</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company is required to record all components of comprehensive loss in the consolidated&#160;financial statements in the period in which they are recognized. Net income (loss) and other comprehensive loss, net of their related tax effect, arrived at a comprehensive loss. For the three and nine months ended September 30, 2015 and 2014, the comprehensive loss was equal to the net loss.</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Earnings per share</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">The Company applies FASB ASC 260, "Earnings per Share." Basic earnings (loss) per share is computed by dividing earnings (loss) available to common stockholders by the weighted-average number of common shares outstanding. Diluted earnings or loss per share would include the dilutive effect of awards granted to employees under stock-based compensation plans, if any. There were no dilutive awards outstanding at September 30, 2015.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139753848725696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_StockIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 411,661<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Liquidation preference value</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">236,000,000<span></span>
</td>
<td class="nump">236,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">18,078,163<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">18,078,163<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_StockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of stock issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_StockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreferenceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of the difference between preference in liquidation and the par or stated values of the preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreferenceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139753848717344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders'Deficit and Preferred Stock Subject to Redemption (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of summary of stock option activity</a></td>
<td class="text"><table align="center" style="width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; widows: 1; -webkit-text-stroke-width: 0px;"  border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="padding-bottom: 2px; vertical-align: middle;" valign="bottom">&#160;</td>
<td style="padding-bottom: 2px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="padding-bottom: 2px; vertical-align: middle;" valign="bottom" colspan="2"></td>
<td style="text-align: left; padding-bottom: 2px; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 2px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="vertical-align: middle; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" valign="bottom" colspan="10">
<div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Options Outstanding</div>
</td>
<td style="text-align: left; padding-bottom: 2px; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="vertical-align: middle;" valign="bottom">&#160;</td>
<td style="vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="vertical-align: middle;" valign="bottom" colspan="2">
<div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Shares Available</div>
</td>
<td style="text-align: left; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="vertical-align: middle;" valign="bottom" colspan="2"></td>
<td style="text-align: left; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="vertical-align: middle;" valign="bottom" colspan="3"></td>
<td style="text-align: left; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="vertical-align: middle;" valign="bottom" colspan="2">
<div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Weighted Average</div>
</td>
<td style="text-align: left; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="vertical-align: middle;" valign="bottom">&#160;</td>
<td style="vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="vertical-align: middle;" valign="bottom" colspan="2">
<div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">for Grant of</div>
</td>
<td style="text-align: left; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="vertical-align: middle;" valign="bottom" colspan="2">
<div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Number of</div>
</td>
<td style="text-align: left; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="vertical-align: middle;" valign="bottom" colspan="3"></td>
<td style="text-align: left; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="vertical-align: middle;" valign="bottom" colspan="2">
<div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Exercise</div>
</td>
<td style="text-align: left; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="padding-bottom: 2px; vertical-align: middle;" valign="bottom">&#160;</td>
<td style="padding-bottom: 2px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="vertical-align: middle; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" valign="bottom" colspan="2">
<div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Options</div>
</td>
<td style="text-align: left; padding-bottom: 2px; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 2px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="vertical-align: middle; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" valign="bottom" colspan="2">
<div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Shares</div>
</td>
<td style="text-align: left; padding-bottom: 2px; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="vertical-align: middle; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" valign="bottom" colspan="3">
<div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Price per Share</div>
</td>
<td style="text-align: left; padding-bottom: 2px; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 2px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="vertical-align: middle; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" valign="bottom" colspan="2">
<div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Price</div>
</td>
<td style="text-align: left; padding-bottom: 2px; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="width: 790px; vertical-align: middle; background-color: #cceeff;" valign="bottom">
<div style="text-align: left; text-indent: 10.05pt; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Balance at December&#160;31, 2014</div>
</td>
<td style="width: 16px; vertical-align: bottom; background-color: #cceeff;" valign="bottom">&#160;</td>
<td style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom">&#160;</td>
<td style="width: 137px; text-align: right; vertical-align: bottom; background-color: #cceeff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1,470,000</div>
</td>
<td style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="width: 16px; vertical-align: bottom; background-color: #cceeff;" valign="bottom">&#160;</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom">&#160;</td>
<td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #cceeff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size:
 10pt;">1,730,000</div>
</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="width: 15px; vertical-align: bottom; background-color: #cceeff;" valign="bottom">&#160;</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div>
</td>
<td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #cceeff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">0.42</div>
</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="width: 15px; vertical-align: bottom; background-color: #cceeff;" valign="bottom">&#160;</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div>
</td>
<td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #cceeff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">0.42</div>
</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="width: 729.25px; padding-left: 60.75px; vertical-align: middle; background-color: #ffffff;" valign="bottom">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Options granted</div>
</td>
<td style="width: 16px; vertical-align: bottom; background-color: #ffffff;" valign="bottom">&#160;</td>
<td style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;" valign="bottom">&#160;</td>
<td style="width: 137px; text-align: right; vertical-align: bottom; background-color: #ffffff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(130,000</div>
</td>
<td style="width: 16px; text-align: left; vertical-align: bottom; background-color: #ffffff;" valign="bottom" nowrap="nowrap">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div>
</td>
<td style="width: 16px; vertical-align: bottom; background-color: #ffffff;" valign="bottom">&#160;</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;" valign="bottom">&#160;</td>
<td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #ffffff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">130,000</div>
</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="width: 15px; vertical-align: bottom; background-color: #ffffff;" valign="bottom">&#160;</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;" valign="bottom">
<div>$&#160;</div>
</td>
<td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #ffffff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1.15 - $3.00</div>
</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="width: 15px; vertical-align: bottom; background-color: #ffffff;" valign="bottom">&#160;</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div>
</td>
<td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #ffffff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">2.29</div>
</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="width: 729.25px; padding-left: 60.75px; vertical-align: middle; background-color: #cceeff;" valign="bottom">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Options exercised</div>
</td>
<td style="width: 16px; vertical-align: bottom; background-color: #cceeff;" valign="bottom">&#160;</td>
<td style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom">&#160;</td>
<td style="width: 137px; text-align: right; vertical-align: bottom; background-color: #cceeff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div>
</td>
<td style="width: 16px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="width: 16px; vertical-align: bottom; background-color: #cceeff;" valign="bottom">&#160;</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom">&#160;</td>
<td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #cceeff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div>
</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="width: 15px; vertical-align: bottom; background-color: #cceeff;" valign="bottom">&#160;</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom">&#160;</td>
<td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #cceeff;" valign="bottom">&#160;</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="width: 15px; vertical-align: bottom; background-color: #cceeff;" valign="bottom">&#160;</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom">&#160;</td>
<td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #cceeff;" valign="bottom">&#160;</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="width: 729.25px; padding-bottom: 2px; padding-left: 60.75px; vertical-align: middle; background-color: #ffffff;" valign="bottom">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Options cancelled</div>
</td>
<td style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;" valign="bottom">&#160;</td>
<td style="width: 16px; text-align: left;
 vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;" valign="bottom">&#160;</td>
<td style="width: 137px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">680,000</div>
</td>
<td style="width: 16px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;" valign="bottom">&#160;</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;" valign="bottom">&#160;</td>
<td style="width: 136px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(680,000</div>
</td>
<td style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;" valign="bottom" nowrap="nowrap">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div>
</td>
<td style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;" valign="bottom">&#160;</td>
<td style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div>
</td>
<td style="width: 136px; text-align: right; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">0.42</div>
</td>
<td style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="width: 15px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;" valign="bottom">&#160;</td>
<td style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div>
</td>
<td style="width: 136px; text-align: right; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">0.42</div>
</td>
<td style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="width: 790px; padding-bottom: 4px; vertical-align: middle; background-color: #cceeff;" valign="bottom">
<div style="text-align: left; text-indent: 10.05pt; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Balance at September&#160;30, 2015</div>
</td>
<td style="width: 16px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;" valign="bottom">&#160;</td>
<td style="width: 16px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;" valign="bottom">&#160;</td>
<td style="width: 137px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">2,020,000</div>
</td>
<td style="width: 16px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="width: 16px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;" valign="bottom">&#160;</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;" valign="bottom">&#160;</td>
<td style="width: 136px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1,180,000</div>
</td>
<td style="width: 15px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="width: 15px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;" valign="bottom">&#160;</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div>
</td>
<td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #cceeff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">0.42 - $3.00</div>
</td>
<td style="width: 15px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="width: 15px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;" valign="bottom">&#160;</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div>
</td>
<td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #cceeff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">0.63</div>
</td>
<td style="width: 15px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted average assumptions for employee options</a></td>
<td class="text"><div style="text-align: left; widows: 1; text-transform: none; text-indent: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"><br class="apple-interchange-newline"  />
<table style="width: 100%; border-collapse: collapse; font-family: 'times new roman', times, serif; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="width: 1141px; vertical-align: middle;">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div>
</td>
<td style="border-bottom: #000000 2px solid; width: 378px; vertical-align: middle;" colspan="3">
<div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">For the Nine Months Ended&#160;&#160; September 30,</div>
</td>
</tr>
<tr>
<td style="width: 1141px; vertical-align: middle;">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div>
</td>
<td style="border-bottom: #000000 2px solid; width: 196px; vertical-align: middle;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">2015</div>
</td>
<td style="width: 30px; vertical-align: middle;">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div>
</td>
<td style="border-bottom: #000000 2px solid; width: 152px; vertical-align: middle;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">2014</div>
</td>
</tr>
<tr>
<td style="background-color: #cceeff; width: 1141px; vertical-align: middle;">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Dividend yield</div>
</td>
<td style="background-color: #cceeff; width: 196px; vertical-align: middle;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">0.00%</div>
</td>
<td style="background-color: #cceeff; width: 30px; vertical-align: middle;">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div>
</td>
<td style="background-color: #cceeff; width: 152px; vertical-align: middle;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">NA</div>
</td>
</tr>
<tr>
<td style="background-color: #ffffff; width: 1141px; vertical-align: middle;">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Volatility factor</div>
</td>
<td style="background-color: #ffffff; width: 196px; vertical-align: middle;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">75.00%</div>
</td>
<td style="background-color: #ffffff; width: 30px; vertical-align: middle;">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div>
</td>
<td style="background-color: #ffffff; width: 152px; vertical-align: middle;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">NA</div>
</td>
</tr>
<tr>
<td style="background-color: #cceeff; width: 1141px; vertical-align: middle;">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Risk-free interest rate</div>
</td>
<td style="background-color: #cceeff; width: 196px; vertical-align: middle;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">1.68-1.85%</div>
</td>
<td style="background-color: #cceeff; width: 30px; vertical-align: middle;">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div>
</td>
<td style="background-color: #cceeff; width: 152px; vertical-align: middle;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">NA</div>
</td>
</tr>
<tr>
<td style="background-color: #ffffff; width: 1141px; vertical-align: middle;">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Expected term (years)</div>
</td>
<td style="background-color: #ffffff; width: 196px; vertical-align: middle;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">6.25-6.50</div>
</td>
<td style="background-color: #ffffff; width: 30px; vertical-align: middle;">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div>
</td>
<td style="background-color: #ffffff; width: 152px; vertical-align: middle;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">NA</div>
</td>
</tr>
<tr>
<td style="background-color: #cceeff; width: 1141px; vertical-align: middle;">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Weighted-average fair value of options granted during the periods</div>
</td>
<td style="background-color: #cceeff; width: 196px; vertical-align: middle;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">$2.69</div>
</td>
<td style="background-color: #cceeff; width: 30px; vertical-align: middle;">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div>
</td>
<td style="background-color: #cceeff; width: 152px; vertical-align: middle;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">NA</div>
</td>
</tr>
</table>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139753852141488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Nov. 12, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Nemus Bioscience, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001516551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">nmus<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,278,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation 12B<br><br><br><br> -Number 240<br><br><br><br> -Section 12b<br><br><br><br> -Subsection 1<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation 12B<br><br><br><br> -Number 240<br><br><br><br> -Section 12b<br><br><br><br> -Subsection 1<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139753851456544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Series B Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_SeriesBWarrantsAbstract', window );"><strong>Series B Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">schedule of Series B Warrants</a></td>
<td class="text"><table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;"  border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="width: 1123px; vertical-align: middle;">&#160;</td>
<td style="width: 396px; vertical-align: middle; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="3">
<div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">For the Nine Months Ended&#160;&#160; September 30,</div>
</td>
</tr>
<tr>
<td style="width: 1123px; vertical-align: middle;">&#160;</td>
<td style="width: 195px; vertical-align: middle; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">2015</div>
</td>
<td style="width: 51px; vertical-align: middle;">&#160;</td>
<td style="width: 150px; vertical-align: middle; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">2014</div>
</td>
</tr>
<tr>
<td style="width: 1123px; vertical-align: middle; background-color: #cceeff;">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Dividend yield</div>
</td>
<td style="width: 195px; vertical-align: middle; background-color: #cceeff;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">0.00%</div>
</td>
<td style="width: 51px; vertical-align: middle; background-color: #cceeff;">&#160;</td>
<td style="width: 150px; vertical-align: middle; background-color: #cceeff;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">NA</div>
</td>
</tr>
<tr>
<td style="width: 1123px; vertical-align: middle; background-color: #ffffff;">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Volatility factor</div>
</td>
<td style="width: 195px; vertical-align: middle; background-color: #ffffff;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">70.00%</div>
</td>
<td style="width: 51px; vertical-align: middle; background-color: #ffffff;">&#160;</td>
<td style="width: 150px; vertical-align: middle; background-color: #ffffff;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">NA</div>
</td>
</tr>
<tr>
<td style="width: 1123px; vertical-align: middle; background-color: #cceeff;">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Risk-free interest rate</div>
</td>
<td style="width: 195px; vertical-align: middle; background-color: #cceeff;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">1.75%</div>
</td>
<td style="width: 51px; vertical-align: middle; background-color: #cceeff;">&#160;</td>
<td style="width: 150px; vertical-align: middle; background-color: #cceeff;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">NA</div>
</td>
</tr>
<tr>
<td style="width: 1123px; vertical-align: middle; background-color: #ffffff;">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Expected term (years)</div>
</td>
<td style="width: 195px; vertical-align: middle; background-color: #ffffff;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">4.61</div>
</td>
<td style="width: 51px; vertical-align: middle; background-color: #ffffff;">&#160;</td>
<td style="width: 150px; vertical-align: middle; background-color: #ffffff;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">NA</div>
</td>
</tr>
<tr>
<td style="width: 1123px; vertical-align: middle; background-color: #cceeff;">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Weighted-average fair value of warrants granted during the periods</div>
</td>
<td style="width: 195px; vertical-align: middle; background-color: #cceeff;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">$0.46</div>
</td>
<td style="width: 51px; vertical-align: middle; background-color: #cceeff;">&#160;</td>
<td style="width: 150px; vertical-align: middle; background-color: #cceeff;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">NA</div>
</td>
</tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_SeriesBWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_SeriesBWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the inputs and valuation techniques used to measure fair value, and a discussion of changes in valuation techniques and related inputs, if any, applied during the period to each separate class of assets, liabilities, and financial instruments classified in shareholders' equity that are measured on a recurring and/or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (bbb)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139753849449296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 152,288<span></span>
</td>
<td class="nump">$ 195,000<span></span>
</td>
<td class="nump">$ 232,862<span></span>
</td>
<td class="nump">$ 195,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">744,004<span></span>
</td>
<td class="nump">662,613<span></span>
</td>
<td class="nump">2,929,799<span></span>
</td>
<td class="nump">835,634<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">896,292<span></span>
</td>
<td class="nump">857,613<span></span>
</td>
<td class="nump">3,162,661<span></span>
</td>
<td class="nump">1,030,634<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(896,292)<span></span>
</td>
<td class="num">(857,613)<span></span>
</td>
<td class="num">(3,162,661)<span></span>
</td>
<td class="num">(1,030,634)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_GainLossOnConversionRightPreferredStock', window );">Change in fair value of conversion rights of Series A preferred stock</a></td>
<td class="nump">286,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">986,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income taxes</a></td>
<td class="num">(1,182,292)<span></span>
</td>
<td class="num">(857,613)<span></span>
</td>
<td class="num">(4,148,661)<span></span>
</td>
<td class="num">(1,030,634)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">905<span></span>
</td>
<td class="nump">1,316<span></span>
</td>
<td class="nump">905<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (1,182,792)<span></span>
</td>
<td class="num">$ (858,518)<span></span>
</td>
<td class="num">$ (4,149,977)<span></span>
</td>
<td class="num">$ (1,031,539)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted loss per common share (in dollars per share)</a></td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Shares used in computing basic and diluted loss per share (in shares)</a></td>
<td class="nump">17,062,366<span></span>
</td>
<td class="nump">10,502,609<span></span>
</td>
<td class="nump">16,519,854<span></span>
</td>
<td class="nump">8,805,766<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_GainLossOnConversionRightPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount related to gain or loss on conversion right of preferred stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_GainLossOnConversionRightPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 940<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51673353&amp;loc=d3e41242-110953<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 10<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -Subparagraph (a),(b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(h))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Income Tax Expense (or Benefit)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 985<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139753860305120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Series B Warrants<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_SeriesBWarrantsAbstract', window );"><strong>Series B Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_SeriesBWarrantsTextBlock', window );">Series B Warrants</a></td>
<td class="text"><div style="font: bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">6. Series B Warrants</div>
<div style="font: bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">In conjunction with the Series B Preferred Stock financing, the Company issued 6,437,500 warrants that are exercisable at a price of $1.15 per share and expire five years from the issuance date. The warrants were valued at $2,935,800 utilizing the Black-Scholes pricing model and the following assumptions:</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 35.9pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.1pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">
<table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="width: 1123px; vertical-align: middle;">&#160;</td>
<td style="width: 396px; vertical-align: middle; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;" colspan="3">
<div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">For the Nine Months Ended&#160;&#160; September 30,</div>
</td>
</tr>
<tr>
<td style="width: 1123px; vertical-align: middle;">&#160;</td>
<td style="width: 195px; vertical-align: middle; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">2015</div>
</td>
<td style="width: 51px; vertical-align: middle;">&#160;</td>
<td style="width: 150px; vertical-align: middle; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">2014</div>
</td>
</tr>
<tr>
<td style="width: 1123px; vertical-align: middle; background-color: #cceeff;">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Dividend yield</div>
</td>
<td style="width: 195px; vertical-align: middle; background-color: #cceeff;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">0.00%</div>
</td>
<td style="width: 51px; vertical-align: middle; background-color: #cceeff;">&#160;</td>
<td style="width: 150px; vertical-align: middle; background-color: #cceeff;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">NA</div>
</td>
</tr>
<tr>
<td style="width: 1123px; vertical-align: middle; background-color: #ffffff;">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Volatility factor</div>
</td>
<td style="width: 195px; vertical-align: middle; background-color: #ffffff;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">70.00%</div>
</td>
<td style="width: 51px; vertical-align: middle; background-color: #ffffff;">&#160;</td>
<td style="width: 150px; vertical-align: middle; background-color: #ffffff;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">NA</div>
</td>
</tr>
<tr>
<td style="width: 1123px; vertical-align: middle; background-color: #cceeff;">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Risk-free interest rate</div>
</td>
<td style="width: 195px; vertical-align: middle; background-color: #cceeff;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">1.75%</div>
</td>
<td style="width: 51px; vertical-align: middle; background-color: #cceeff;">&#160;</td>
<td style="width: 150px; vertical-align: middle; background-color: #cceeff;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">NA</div>
</td>
</tr>
<tr>
<td style="width: 1123px; vertical-align: middle; background-color: #ffffff;">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Expected term (years)</div>
</td>
<td style="width: 195px; vertical-align: middle; background-color: #ffffff;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">4.61</div>
</td>
<td style="width: 51px; vertical-align: middle; background-color: #ffffff;">&#160;</td>
<td style="width: 150px; vertical-align: middle; background-color: #ffffff;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">NA</div>
</td>
</tr>
<tr>
<td style="width: 1123px; vertical-align: middle; background-color: #cceeff;">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Weighted-average fair value of warrants granted during the periods</div>
</td>
<td style="width: 195px; vertical-align: middle; background-color: #cceeff;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">$0.46</div>
</td>
<td style="width: 51px; vertical-align: middle; background-color: #cceeff;">&#160;</td>
<td style="width: 150px; vertical-align: middle; background-color: #cceeff;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">NA</div>
</td>
</tr>
</table>
</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 35.9pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.1pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 35.9pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.1pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">The warrants are exercisable in cash or through a cashless exercise provision. The Series B warrants also have a "down-round" protection feature provided to the investors if the Company subsequently issues or sell any shares of common stock, stock options, or convertible securities at a price less than the exercise price of $1.15 per each warrant. The conversion price is automatically adjusted down to the price of the instrument being issued.&#160;The Company reviewed the classification of the warrants as liabilities or equity under the guidance of ASC 480-10,&#160;<font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;">Distinguishing Liabilities from Equity</font>, and concluded that the Series B warrants should be classified as a liability. The Company then applied the relative fair value allocation methodology for allocating the proceeds of $5.0 million received from the Series B financing between the conversion liability and the warrants with the residual amount being allocated to the Preferred Stock. As such, the warrant value as of September 30, 2015 was $2,892,392 and will be subject to fair value re-measurement at the end of each reporting period.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_SeriesBWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_SeriesBWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_SeriesBWarrantsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for series B warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_SeriesBWarrantsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139753860371936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision for Conversion of Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ProvisionForConversionOfPreferredStockAbstract', window );"><strong>Provision For Conversion Of Preferred Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Provision for Conversion of Preferred Stock</a></td>
<td class="text"><div style="font: bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">5. Provision for Conversion of Preferred Stock</div>
<div style="font: bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Series A Preferred Stock Conversion Liability</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 35.8pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.2pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">In connection with the Series A preferred stock financing, the Company recorded a liability related to down-round protection provided to the stockholders in the event that the Company does another offering of common stock greater than $1,000,000 at a price below $2.50 per share. The down-round provision expires at the closing of a subsequent financing round or October 1, 2015 whichever is earlier. With the assistance of a third-party valuation specialist, the Company valued the conversion liability pursuant to the accounting guidance of ASC 820-10,&#160;<font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;">Fair Value Measurements</font>, as of the closing date of the first round of financing which was April 1, 2015.</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 35.8pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.2pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 35.9pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.1pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">As of June 30, 2015, the Company re-evaluated the likelihood and valuation of a potential down-round given that management has been actively pursuing capital raising efforts. In the absence of any definitive agreement, the Company calculated the fair value of the conversion feature to be $700,000 by determining the highest probability of a per share price in the next anticipated round of financing, after considering all discussions with bankers, potential investors, and preliminary term sheets. This amount was booked as a current liability as of June 30, 2015 and was charged as a non-operating expense for the period.</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 35.9pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.1pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 35.9pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.1pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">In July of 2015, the Company increased its down-round provision by $286,000 based on the closing of an additional round of 180,000 Series A shares<font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">&#160;</font>by determining the highest probability of a per share price in the next anticipated round of financing, after considering all discussions with bankers, potential investors, and preliminary term sheets. This amount was charged to non-operating expense for the three months ended September 30, 2015.</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 35.9pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.1pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 35.8pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.2pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">As of August 21, 2015, upon the closing of the Series B Preferred Stock sale with proceeds totaling $5.0 million, the Company issued 1,232,000 additional shares of common stock at $0.80 per share thereby eliminating this liability of $986,000 and offsetting it to Additional Paid-in-Capital. This amount was calculated by determining the difference in per share pricing between the Series A Preferred Stock financing of $2.50 per share and the Series B Preferred Stock Financing of $0.80 per share multiplied by the 580,000 total shares included in the Series A offering.</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 35.8pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.2pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 35.8pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.2pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 3pt; margin-bottom: 3pt;">Series B Preferred Stock Conversion Liability</div>
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 3pt; margin-bottom: 3pt;">&#160;</div>
<div style="text-align: justify; text-indent: 35.9pt; font-family: 'times new roman', times, serif; font-size: 10pt; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.2pt;">As of August 20, 2015, in connection with the Series B preferred stock financing, the Company recorded a liability related to down-round protection provided to the stockholders in the event that the Company does another sale or issuance of common stock, stock options or convertible securities where the share price is below $0.80 per share. With the assistance of a third-party valuation specialist, the Company valued the conversion liability pursuant to the accounting guidance of ASC 820-10,&#160;<font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;">Fair Value Measurements</font>, as of the closing date of the financing. The Company also performed a review of the conversion liability in conjunction with ASC 815,&#160;<font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;">Derivatives and Hedging/Contracts in Entity's Own Equity</font>, and determined that the liability requires bifurcation and re-measurement to fair market value at the end of each reporting period. The derivative was valued at $75,488 and was booked as a current liability as of September 30, 2015. The value of this embedded derivative was determined utilizing a with and without method by valuing the preferred stock with and without the down round protection.</div>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ProvisionForConversionOfPreferredStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ProvisionForConversionOfPreferredStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139753854661600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders'Deficit and Preferred Stock Subject to Redemption - Summary of option activity under 2014 Plan (Details) - Stock Option<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="nump">1,180,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="nump">1,180,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Omnibus Incentive Plan 2014</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_SharesAvailableForGrantOfOptionsRollForward', window );"><strong>Shares Available For Grant Of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_SharesAvailableForGrantOfOptionsOpeningBalance', window );">Balance at the beginning</a></td>
<td class="nump">1,470,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_SharesAvailableForGrantOptionsGranted', window );">Options granted</a></td>
<td class="num">(130,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_SharesAvailableForGrantOptionsExercised', window );">Options exercised</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_SharesAvailableForGrantOptionsCancelled', window );">Options cancelled</a></td>
<td class="nump">680,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_SharesAvailableForGrantOfOptionsEndingBalance', window );">Balance at the ending</a></td>
<td class="nump">2,020,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the beginning</a></td>
<td class="nump">1,730,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="nump">130,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options cancelled</a></td>
<td class="num">(680,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the ending</a></td>
<td class="nump">1,180,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_OptionsOutstandingPricePerShareRollForward', window );"><strong>Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_OptionsOutstandingPricePerShareOpeningBalance', window );">Balance at the beginning | $ / shares</a></td>
<td class="nump">$ 0.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_OptionsOutstandingPricePerShareOptionsCancelled', window );">Options cancelled | $ / shares</a></td>
<td class="nump">0.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the beginning | $ / shares</a></td>
<td class="nump">0.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted | $ / shares</a></td>
<td class="nump">2.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options cancelled | $ / shares</a></td>
<td class="nump">0.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the ending | $ / shares</a></td>
<td class="nump">$ 0.63<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Omnibus Incentive Plan 2014 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_OptionsOutstandingPricePerShareRollForward', window );"><strong>Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_OptionsOutstandingPricePerShareOptionsGranted', window );">Options granted | $</a></td>
<td class="nump">$ 1.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_OptionsOutstandingPricePerShareEndingBalance', window );">Balance at the ending | $ / shares</a></td>
<td class="nump">$ 0.42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Omnibus Incentive Plan 2014 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_OptionsOutstandingPricePerShareRollForward', window );"><strong>Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_OptionsOutstandingPricePerShareOptionsGranted', window );">Options granted | $</a></td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_OptionsOutstandingPricePerShareEndingBalance', window );">Balance at the ending | $ / shares</a></td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_OptionsOutstandingPricePerShareEndingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents options outstanding price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_OptionsOutstandingPricePerShareEndingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_OptionsOutstandingPricePerShareOpeningBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents options outstanding price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_OptionsOutstandingPricePerShareOpeningBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_OptionsOutstandingPricePerShareOptionsCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents options outstanding price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_OptionsOutstandingPricePerShareOptionsCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_OptionsOutstandingPricePerShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents options outstanding price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_OptionsOutstandingPricePerShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_OptionsOutstandingPricePerShareRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_OptionsOutstandingPricePerShareRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_SharesAvailableForGrantOfOptionsEndingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents shares available for grant of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_SharesAvailableForGrantOfOptionsEndingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_SharesAvailableForGrantOfOptionsOpeningBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents shares available for grant of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_SharesAvailableForGrantOfOptionsOpeningBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_SharesAvailableForGrantOfOptionsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_SharesAvailableForGrantOfOptionsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_SharesAvailableForGrantOptionsCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents number of options cancelled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_SharesAvailableForGrantOptionsCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_SharesAvailableForGrantOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents number of Options exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_SharesAvailableForGrantOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_SharesAvailableForGrantOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents number of Options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_SharesAvailableForGrantOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(i)-(ii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28,29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nmus_OmnibusIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nmus_OmnibusIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139753854767456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations, Business Activities and Summary of Significant Accounting Policies (Detail Textuals)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2014 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($) </div>
<div>Segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Nature of Operations, Business Activities and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,342,722<span></span>
</td>
<td class="nump">$ 207,330<span></span>
</td>
<td class="nump">$ 1,025,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,046<span></span>
</td>
<td class="nump">$ 21,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDepreciationMethods', window );">Property, plant and equipment, depreciation methods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Straight-line method<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property plant and equipment estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">two to three years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segment | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,078,163<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=nmus_NemusAcquisitionCorpMember', window );">Nemus Acquisition Corp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Nature of Operations, Business Activities and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NumberOfSharesExchanged', window );">Number of shares exchanged</a></td>
<td class="nump">12,880,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding</a></td>
<td class="nump">16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ConversionRate', window );">Conversion rate</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=nmus_NemusAcquisitionCorpMember', window );">Nemus Acquisition Corp | Nemus Bioscience, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Nature of Operations, Business Activities and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding</a></td>
<td class="nump">3,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ConversionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information regarding conversion rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ConversionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_NumberOfSharesExchanged">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents number of shares exchanged.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_NumberOfSharesExchanged</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDepreciationMethods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the methodology for computing depreciation for classes of depreciable assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (d)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDepreciationMethods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51661791&amp;loc=d3e1205-110223<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=nmus_NemusAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=nmus_NemusAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nmus_NemusBioscienceIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nmus_NemusBioscienceIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139753865496384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations, Business Activities and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Use of Estimates</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles ("U.S. GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates.</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_LiquidityAndGoingConcernPolicyTextBlock', window );">Liquidity and Going Concern</a></td>
<td class="text"><div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Liquidity and Going Concern</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">The Company has incurred operating losses and negative cash flows from operations since our inception. As of September 30, 2015, we had cash and cash equivalents of $4,342,722.&#160; The Company anticipates that it will continue to incur net losses into the foreseeable future as it continues to advance and develop a number of potential drug candidates into preclinical development activities and expands its corporate infrastructure which includes the costs associated with being a public company. Without additional funding, management believes that the Company will not have sufficient funds to meet its obligations within one year after the date the consolidated financial statements are issued. These conditions give rise to substantial doubt as to the Company's ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">The Company plans to continue to fund its losses from operations and capital funding needs through public or private equity or debt financings, strategic collaborations, licensing arrangements, asset sales, government grants or other arrangements. However, the Company cannot be sure that such additional funds will be available on reasonable terms, or at all. If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result. If the Company is unable to secure adequate additional funding, the Company may be forced to make a reduction in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs.</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Cash and Cash Equivalents</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The carrying value of those investments approximates their fair market value due to their short maturity and liquidity. Cash and cash equivalents include cash on hand and amounts on deposit with financial institutions, which amounts may at times exceed federally insured limits. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk.</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Restricted Cash</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"><font style="font-size: 5.14pt;" >&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">A deposit of $37,500 as of September 30, 2015 was restricted from withdrawal and held by a bank in the form of a certificate of deposit. This certificate served as collateral for payment of the Company's credit cards.&#160; Restricted cash as of December 31, 2014 was $0.</font></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Fair Value Measurements</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last is considered unobservable, is used to measure fair value:</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">
<table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="width: 20.45pt;"></td>
<td style="width: 51.55pt; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">Level 1:</td>
<td style="width: auto; text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">
<div>Valuations for assets and liabilities traded in active markets from readily available pricing sources such as quoted prices in active markets for identical assets or liabilities.</div>
<div>&#160;</div>
</td>
</tr>
</table>
</div>
<div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">
<table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="width: 20.45pt;"></td>
<td style="width: 51.55pt; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">Level 2:</td>
<td style="width: auto; text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">
<div>Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</div>
<div>&#160;</div>
</td>
</tr>
</table>
</div>
<div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">
<table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="width: 20.45pt;"></td>
<td style="width: 51.55pt; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">Level 3:</td>
<td style="width: auto; text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</td>
</tr>
</table>
</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 35.9pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.1pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 35.9pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; margin-left: 0.1pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">The carrying values of our financial instruments, including, cash and cash equivalents, prepaid expenses, accounts payable, and accrued expenses approximate their fair value due to the short maturities of these financial instruments.</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Property and Equipment, Net</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">As of September 30, 2015, property and equipment, net, was $16,046, consisting primarily of computers and equipment. The Company had $21,354 of property and equipment, net, as of December 31, 2014. Expenditures for additions, renewals and improvements will be capitalized at cost. Depreciation will generally be computed on a straight-line method based on the estimated useful life of the related assets currently ranging from two to three years. Maintenance and repairs that do not extend the life of assets are charged to expense when incurred. When properties are disposed of, the related costs and accumulated depreciation are removed from the accounts and any gain or loss is reported in the period the transaction takes place.</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount exceeds its estimated future undiscounted cash flows, an impairment charge is recognized by the amount by which the carrying amount exceeds the fair value of the asset.</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">The costs incurred for the rights to use licensed technologies in the research and development process, including licensing fees and milestone payments, will be charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where there is an identified alternative future use. No cost associated with the use of licensed technologies has been capitalized to date.</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Income Taxes</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">The Company accounts for our deferred income tax assets and liabilities based on differences between the financial reporting and tax bases of assets and liabilities, and net operating loss carry forwards (the "NOLs") and other tax credit carry forwards. These items are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the period that includes the enactment date. Any interest or penalties would be recorded in the Company's statement of operations in the period incurred.</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">The Company records a valuation allowance to reduce the deferred income tax assets to the amount that is more likely than not to be realized. In making such determinations, management considers all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. As a result there are no income tax benefits reflected in the statement of operations to offset pre-tax losses.</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">The Company recognizes a tax benefit from uncertain tax positions when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position.</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Revenue Recognition</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">The Company has not begun planned principal operations and has not generated any revenue since inception.</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Research and Development Expenses</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Research and development ("R&amp;D") costs are expensed when incurred. These costs may consist of external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, third-party manufacturing organizations and consultants; employee-related expenses, which include salaries, benefits and stock-based compensation for the personnel involved in our preclinical and clinical drug development activities; and facilities expense, depreciation and other allocated expenses; and equipment and laboratory supplies.</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation Expenses</a></td>
<td class="text"><div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Stock-Based Compensation Expenses</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Stock-based compensation cost is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period. We use the Black-Scholes option pricing model for estimating the grant date fair value of stock options and warrants using the following assumptions:</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">
<table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="width: 20.25pt;"></td>
<td style="width: 27pt; font-family: symbol, serif; font-size: 10pt; vertical-align: top;">&#183;</td>
<td style="width: auto; text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">Exercise price - We determined the exercise price based on valuations using the best information available to management at the time of the valuations.</td>
</tr>
</table>
</div>
<div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">
<table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="width: 20.25pt;"></td>
<td style="width: 27pt; font-family: symbol, serif; font-size: 10pt; vertical-align: top;">&#183;</td>
<td style="width: auto; text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">Volatility &#8211; We estimate the stock price volatility based on industry peers who are also in the early development stage given the limited market data available in the public arena.</td>
</tr>
</table>
</div>
<div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">
<table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="width: 20.25pt;"></td>
<td style="width: 27pt; font-family: symbol, serif; font-size: 10pt; vertical-align: top;">&#183;</td>
<td style="width: auto; text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">Expected term - The expected term is based on a simplified method which defines the life as the average of the contractual term of the options and warrants and the weighted-average vesting period for all open awards.</td>
</tr>
</table>
</div>
<div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">
<table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="width: 20.25pt;"></td>
<td style="width: 27pt; font-family: symbol, serif; font-size: 10pt; vertical-align: top;">&#183;</td>
<td style="width: auto; text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">Risk-free rate - The risk-free interest rate for the expected term of the option or warrant is based on the average market rate on U.S. treasury securities in effect during the quarter in which the awards were granted.</td>
</tr>
</table>
</div>
<div style="font: /normal 'times new roman'; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">
<table align="center" style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="width: 20.35pt;"></td>
<td style="width: 27pt; font-family: symbol, serif; font-size: 10pt; vertical-align: top;">&#183;</td>
<td style="width: auto; text-align: justify; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">Dividends &#8211; The dividend yield assumption is based on our history and expectation of paying no dividends.</td>
</tr>
</table>
</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock', window );">Stock-Based Compensation for Non-Employees</a></td>
<td class="text"><div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Stock-Based Compensation for Non-Employees</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">The Company accounts for warrants and options issued to non-employees under ASC 505-50,&#160;<font style="font-family: 'times new roman', times, serif; font-size: 10pt; font-style: italic;">Equity &#8211; Equity Based Payments to Non-Employees,</font>&#160;using the Black-Scholes option-pricing model. The value of such non-employee awards are periodically re-measured over the vesting terms and at each quarter end.</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Segment Information</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">The Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") No. 280, "Segment Reporting" establishes standards for reporting information about reportable segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group ("CODM"), in deciding how to allocate resources and in assessing performance. The CODM evaluates revenues and gross profits based on product lines and routes to market. Based on the early development stage of our operation, we operate in a single reportable segment.</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Comprehensive Income (Loss)</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company is required to record all components of comprehensive loss in the consolidated&#160;financial statements in the period in which they are recognized. Net income (loss) and other comprehensive loss, net of their related tax effect, arrived at a comprehensive loss. For the three and nine months ended September 30, 2015 and 2014, the comprehensive loss was equal to the net loss.</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings per share</a></td>
<td class="text"><div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">Earnings per share</div>
<div style="font: italic bold 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; margin-top: 3pt; margin-bottom: 3pt; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">The Company applies FASB ASC 260, "Earnings per Share." Basic earnings (loss) per share is computed by dividing earnings (loss) available to common stockholders by the weighted-average number of common shares outstanding. Diluted earnings or loss per share would include the dilutive effect of awards granted to employees under stock-based compensation plans, if any. There were no dilutive awards outstanding at September 30, 2015.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_LiquidityAndGoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entire disclosure of policy for liquidity and going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_LiquidityAndGoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents policy for stock based compensation for Non Employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_StockBasedCompensationForNonEmployeesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 305<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Financial Reporting Release (FRR)<br><br><br><br> -Number 203<br><br><br><br> -Paragraph 02-03<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.1(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 305<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Financial Reporting Release (FRR)<br><br><br><br> -Number 203<br><br><br><br> -Paragraph 02-03<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (b),(f(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 19<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6423966&amp;loc=d3e40913-109327<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 954<br><br><br><br> -SubTopic 740<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 17<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32247-109318<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32280-109318<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Research and Development<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18823-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.B.Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section B<br><br><br><br> -Paragraph Question 1<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6061-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6143-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6132-108592<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139753863665184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text"><div style="text-align: left; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">7. Income Taxes</div>
<div style="text-align: left; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">At September 30, 2015, the Company had net operating loss carry forwards ("NOLs") aggregating approximately $4,023,000 which, if not used, expire in 2035. The utilization of these NOLs may become subject to limitations based on past and future changes in ownership of the Company pursuant to Internal Revenue Code Section 382.</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 35.9pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; margin-left: 0.2pt; word-spacing: 0px; -webkit-text-stroke-width: 0px;">The Company records a valuation allowance against deferred tax assets to the extent that it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Due to the substantial doubt related to the Company's ability to utilize its deferred tax assets, a valuation allowance for the full amount of the deferred tax assets has been established at September 30, 2015. As a result of this valuation allowance there are no income tax benefits reflected in the accompanying statement of operations to offset pre-tax losses.</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 35.9pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; margin-left: 0.2pt; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">The Company has no uncertain tax positions as of September 30, 2015.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(h))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139753863713104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">8. Subsequent Events</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: left; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold italic 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; margin-right: 0.1pt; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Restricted Stock Awards</div>
<div style="text-align: left; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold italic 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; margin-right: 0.1pt; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: left; widows: 1; text-transform: none; text-indent: 35.8pt; margin: 5pt 0.3pt 5pt 0.2pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Restricted stock awards ("RSAs") are granted to our board of directors and members of senior management and are issued pursuant to the Company's 2014 Omnibus Incentive Plan. On October 20, 2015, a total of 1,200,000 RSAs were granted to members of the Company's senior management and board of directors with a fair market value of approximately $900,000. These RSAs vest from one to&#160;three years from the grant date.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139753863664896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of future minimum payments under non-cancelable operating leases</a></td>
<td class="text"><table align="center" style="width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; widows: 1; -webkit-text-stroke-width: 0px;"  border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="vertical-align: bottom;" valign="bottom">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">For the year ending December 31,</div>
</td>
<td style="vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="vertical-align: bottom;" valign="bottom" colspan="2"></td>
<td style="text-align: left; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="width: 1337px; vertical-align: bottom; background-color: #cceeff;" valign="bottom">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">2015</div>
</td>
<td style="width: 16px; vertical-align: bottom; background-color: #cceeff;" valign="bottom">&#160;</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div>
</td>
<td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #cceeff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">43,900</div>
</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="width: 1337px; vertical-align: bottom; background-color: #ffffff;" valign="bottom">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">2016</div>
</td>
<td style="width: 16px; vertical-align: bottom; background-color: #ffffff;" valign="bottom">&#160;</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;" valign="bottom">&#160;</td>
<td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #ffffff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">165,700</div>
</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="width: 1337px; vertical-align: bottom; background-color: #cceeff;" valign="bottom">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">2017</div>
</td>
<td style="width: 16px; vertical-align: bottom; background-color: #cceeff;" valign="bottom">&#160;</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom">&#160;</td>
<td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #cceeff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">85,900</div>
</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="width: 1337px; vertical-align: bottom; background-color: #ffffff;" valign="bottom">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">2018</div>
</td>
<td style="width: 16px; vertical-align: bottom; background-color: #ffffff;" valign="bottom">&#160;</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;" valign="bottom">&#160;</td>
<td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #ffffff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div>
</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #ffffff;" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="width: 1337px; vertical-align: bottom; background-color: #cceeff;" valign="bottom">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">2019</div>
</td>
<td style="width: 16px; vertical-align: bottom; background-color: #cceeff;" valign="bottom">&#160;</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom">&#160;</td>
<td style="width: 136px; text-align: right; vertical-align: bottom; background-color: #cceeff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div>
</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; background-color: #cceeff;" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="width: 1337px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;" valign="bottom">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Thereafter</div>
</td>
<td style="width: 16px; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;" valign="bottom">&#160;</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;" valign="bottom">&#160;</td>
<td style="width: 136px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 2px; border-bottom-style: solid; background-color: #ffffff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div>
</td>
<td style="width: 15px; text-align: left; padding-bottom: 2px; vertical-align: bottom; background-color: #ffffff;" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="width: 1337px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;" valign="bottom">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Total</div>
</td>
<td style="width: 16px; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;" valign="bottom">&#160;</td>
<td style="width: 15px; text-align: left; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div>
</td>
<td style="width: 136px; text-align: right; vertical-align: bottom; border-bottom-color: #000000; border-bottom-width: 4px; border-bottom-style: double; background-color: #cceeff;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">295,500</div>
</td>
<td style="width: 15px; text-align: left; padding-bottom: 4px; vertical-align: bottom; background-color: #cceeff;" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>40
<FILENAME>0001640334-15-000301-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001640334-15-000301-xbrl.zip
M4$L#!!0````(`/R*;$<W]`.Z.)X``*AE!@`1`!P`;FUU<RTR,#$U,#DS,"YX
M;6Q55`D``WL1159[$456=7@+``$$)0X```0Y`0``[%UM<Z,XMOX^5?,?V&S5
M[I=VS#LXW>FMO,YFMA-GD\SL3-U[*T5`MK6#P2,@B6>K]K=?26`;S(N-$00G
M='5UER4D/>?HT=&1D`Y?_O8ZM;EG@#SH.L<'PB%_P`''="WHC(\/?GJX[.D'
M?_OZ_7=?_M3K<3\`!R##!Q87>#B?N_BC]\OIW;=%<4X[E`[Y0Y7['T'H"WQ?
MY`6%$X0C03E2-.[V^O^X7F]1U:GAX6IP&5J!>"BL\FC*N6L&4^#XW#6&,H+X
MV1?H3TB+%Q;T7<3]'+4I',JX39Y4=8F@9<P_<3?N,Y@^`<0)TB<N!"$>"?R1
M(G(GUU$[KT_(AD?D7PXKP/&.G&G@'1],?']VU.^_O+P<.@"G/$'7,R%6"#@T
MW2F5B!](6$=A(1LZOR4*D0H/733&3_)2GV0_84$7CY-<"RX+Q!]6^V'F\M%4
MU2\2?588#`9]FKM\U(-9#^)*A?XOU]_NS0F8&CWH>+Z!Y8AC@078UY^'GBN+
M@E94(GQB4<!Q'2>89C]O^:COSV>@CQ_JX:<`@N:RW.9"R0)4<7ZF5I50J_[B
M4=,-'!_-D\]ZP#P<N\_]*)-TLM3CA9XD+(L%"&$.Y)6+<DE!.5G0`C"[#,[(
M>!R\FI/LYTD.95^R`'2>@>=G%PGS,J1Q#&AZV65H%BDB)(MXT,PN@#.R'O=G
M*.=YG)-1(/!Z8\.8+<N,#.^)]F&4D2$ZSB%D\#++T)R,0J]V`7]_^18;5(&/
M<A\=]''N`;$B9!@>>72`W8$11X?ED8%,Y-J@>/#V9\B=`>1#C#-F)F@%!/WQ
M@0>G,WN9-D%@='Q`C%1O880.7SWKH+\PJ&>NXX-7G[L'ID_L8L+.F5$FM(X/
MH@<?3[S'X>A1T!Y_#.Q'7*?XP/./X=^'87;ZO8^-/['*%[\'T)^?N=.9Z^"?
MWLDK]![_92!D./XUM;T'J\;Q`_CAU6]HD11LTQ%'59?4U((I9U?_./C*8QNF
M"*JB"%_ZZX57%7I@3$`M$BS<Y.O,AB:,L'`6Q/GA!!<1ZJA0E(.OB\<2,GWI
M9U9/VNVGD/2SA<=]#ETKI@QJ9DD)HNH>K_4$;55ZE;M(697O)[JVN*_/`L]W
MIX^\4**S[X!-IOI;`_GS!ZP$SZ#$\D[G\1S:\Y?8<EIX/CYQK%`EP]&I:R!K
M/ZBPO:`'7\D`/"H6MPZ68!8@_QQCB?&$%V(UQO*7JK;6"L2)M<IE3"PI02PI
M*_UDC``=>I0[/SF0NH_^?#BZAIY'_LYF</F0%ZKO\1(ZT`??\,/6E8,'Q1@^
MV>#$\X"/.^K:^+>+SFS#"RT1?@#8-C:$@6'?AG9VWFXN4EXE%!-Q;4OU%)!N
MZW%00L,K`YFOZ@;&@51V'-`"DL!^'(23J<1CNCN$[G)R&&2E)X?!O>^:O]T&
MR)Q@1V"9A4L!4BH:`^]@_LTE^C8*8,'R5D[\>!V@]B2>_<0?\5)X/`G&&;S,
M2G\')&M[7^L)&_2&?=W9H,X&L>'EEE[B/9BEJ2D.,M*3U!S.B$N^3/O8/F&F
M,CZF!XA).RCE`=("XH"]!RA=7\2602G_+T7P9EBWLU;+^=54JW'_A956!Y%6
MC6RO>M^T*NRG5M>,\95C@1G&@G^3&I%A^BY*+=AC6:30ZN?0`7MJ>+<2O(HA
MIJTD%1<UG:&^9LSK!Z+LA^-C1Y/'DQ<#60_S&:`TN9C.;'<.`%T(A&Y6NZFQ
M<,(28JQ\LUQY.E(4D8)ZN<-1M/X:HCLXGD1+9`P`>*=13LOMQH(%N>(LEKU9
M0G4,:<PA>GAQVTVD=CM$2_5]*,INV%/9P\71#@OY.A2[W$8=FG[F-FHJO55Z
M7=O3$_AZ]YJW5M+C*3DS"#SOQ/P]@!ZD6UC$#MZ0<W:QQ#,7S=IM#A?S:HY$
MD8'*EZN!K=Q][O;';V!LV!=4X-6CI\N3F%>.^6'YL;%M"\"C-?W%V\O0XOZR
M<34%[J>I3DV!6$_EIL`UQ;+W+3KSW@[SWEJJ7/Y:L'(2'L^!N4\#L+1S+XAU
M'B?*T-]>Z'7=_(OU.B,1^934T</U]/8J*3JG7N<<N9]:6ANB2MDAFE(L^SGR
M$CRE%2OJ&>ELSBML=33BU+#)[9W["0#^-]<TEO/QB6FB`%C?H(GG.W#B6+=8
M&XY_!^#T*4`>K>,2@#W9VFSNQ,)&2,T?U\CKXZC=<CW=@->"QZ)8=O"*/5%G
M/WBEQ'YORB1>&^A]FT2I7J\EI;^]T.OZA"S5Z[5LK:3W<.2RU2<?:^OKE8^P
MGR,B;6FD5ED:_O%DEJ77C/16Z76=?7*=9_]+**FS-/5;FM;T]95CNE.P5%-B
MD1`&>K"QSWAB3;&+[?D(9SZ#B]<9\27W@P$%`J[Z?RM)/Q0OE@J+CHW0LT.Q
MPR\GMPB,`$+`HCG[P85<H59,*)#N8_;_YCG@G7.%S<S1<71K+WD_O;FTERR7
M]9+EFH\(=1[@&WJ`[Y,?[]+BM\;R[@%GKHUYSI;&>GIG4QK@AU*6'TK-K\5V
MX$=G4YJU*2WAS'KPE-0TE$[O3$KMSGZM`4EVZNO./#2YV*NG_^,!P[K!WB+_
M02T[%ZCUWKZ(`BFDCRNETCO[\";V0:O[O%IY`G3VH3[[4"X@2(H?M06<[`Q$
M6PQ$:SD3SBGB,@#:VDG-K/1-E#E]UY3)E*Z).47OB;7.*1T!6D:`M,W0R]J,
M)&>8^Z&9E,E,[]R0!NQ#O3YGU]FM\CEWL`5U^`\\/2W>PR3H94P>&>GM=3A3
M1'E?#N?6A%E-'36^5&5D3/#/J>OLHYM1;%!2<K6,(_4:E4H\Z9S2#\F99(S9
MU,YY%/!G;XY)E=X>J"?@3UFMKMV_O`,>,)`Y6;O@U]9AEWM-,4>.ENX4M80*
MM=SHS>F)QVN,<G+B6+_BW.$H6>::%"#8<F+HY'Q'IMU<W:=;ON6'SW9M%71Z
MU/):UU=I,3]Z4"%_.ANQ%S8"0YYW)N(CFHADSW<6HK,0V18"0_/I4YV9^(AF
M(J/[.UM1KZT8%$4BV;\E?>E().W0:O>UB`;#ON\S3;JO172D*+8=W4<4/]A'
M%-\/D6]MP[DQIJ%Q&TX=^!1X5XY)%/`,2&:,P>_$$L9%7H3K*Q2<!7,[\\N2
MM5T<FS>-8_-^B-2]UNNH$*7?&<X81._57N$TF+ZO66\IWLI^).3L)KFV$;+[
M(EW'D#UYA]"=1/BP[P\^RDF$SD9T)Q$Z$]&=1.@L1'<2H3,3W4F$CVDKMMP,
M*?5:(;;Q@L?'<D.B[8.9X6;'UFV^R:N+K)VC>$=U(^8-1TQ\"Z\;,2T>,5ON
MM;Z_$;.,_I<>&_MPWFT]',&@WA")6RNI.X+RL8^@M):7W8F2CW.BI+4D[-Z=
M[7.'I[Y%OQ9_A<](OP^>//![0`SS,_YG:536TG?PMI-&Z@YX/H*FGXA(\/@`
M?1L,1U>.!9^A%1AVY)T[QCB<J!SKU,75#$?G$`%R"'M/F)>CUEB<ABS][JWG
MGF-4,SN=17N9O%F^6=O(GD86$@)?<B&!"XBU+20$L7?C/O?:OV`(52'T!+&>
M^7"U"R'GS(=RNQ5$V2+7ZS04?/#Y')AKRNL\UP_JN<IXD%:(,OBG7H_[R8$^
M=X]M,T;-<;W>(OW[[Z[^*_SOY<^W?P>OX%Q1-?W7._`[_'J-;&_^`J_^2_)4
M61F8LBR;BJ*8#_^9?+VXU&7MZ/-G05457=!_'.C"\<7QWP7MBZX>?_GA^%(^
M/HH:"=$$I'E"?V]B(("5&J5/@>$%"'R-U$0S%Q(L\A:_21T9-?YT?YZJ#GJN
M+`K:$<XK7]OCC&Q%$"C+>NGL![[&'KX)I@`9>*;;L>E4>9)X#AQW"IVL:K=5
M4***?A)]4O*T[+,@)G*R89)54I/>[R,_55O@HR.24;*N$^L9ZQ6EJ@MW6\+,
MDE5>.<_8:<JK<Y%;LM+[<)QGUQEE;JJ2C,H+F_I5B0'[A;PP#-\5WH$Q/4SO
M^,0V<M%0OP.C*G=X;P`&R9U"US,AP,;U$X=-[.&7?EZS!.LJ[PR0VYLVN<_Y
M^@\P9X0I/K'DMK4`\H`,"SKC^_GTR;49`2`=%S:=J'W1Y%F`$`9S"3W3L,F;
MXXO0EV34>B^T^R&`O+:2_7`);8#.</+81:QZX7YJV+A6[@[,7.1C)7!D5]%P
MYO%.232\QHU54$5J5KUAX)/YB^@S$V*!)\V184(?CF82S@(FQ``]/*1O+@^^
M"@-1TP552A"F`,`"ZKEK!M-H!<E(;WB=\<\01KSR]09OZ<S-ECBKS8]D^XFV
M%D!.<(Y%<B]M([L_R@,8X0X!8=N)ZM>%7['Y$J=X#,5/"K[63C:,4#LL@?Q3
MRH(1:X<`66ZB&1XY@$+^(WOWSX9-M^W],P.A.6;JSX8=9!-D&1@\O6;(64O$
MQA'QGV*#B*I/DPAS2@%C*DF9EW%%DLB2+&JB^(:BE%H%%XDB\*+"BU(%46X1
MF!G0BF[?1=-)$WQ295D?K(!GXJ@$E!5=!HHBZR6`#OT)0.'YN`;5*>$U5VQT
MID'L#I&5(B5!$+:&V+P">5T:Q`A9'1DS>Z7PJA[OW%QHBY.69/>#[+\2$S`C
M4\P-:$2'HB`I<GRHY,-A`9N5@@65E]7M8=-UVSEV>SV(3:MCQ8C<A)(%71E@
M)1>@J`"2F4JW`IEA"FY<QVQNT$<P"W%4`LI8GUL#;8Z.DJQ+LK9NG,IA86<I
M94$14Y8R`<8TW0"[1+?&W'BRFW1X9'X@#^**RD12#2LSNDFB*,DEL:(`6/>&
M;9"W^DWJ55%4-0$U`T@UJ,S4*LM:W%O/QQKN88;9WZ!)7$UL/F_Q`MW!E</I
M4X`\NAMX"4`SLXXPD$4]LNC;`F,J"3-_GA<%=0=!UCKM&S2>H`W]9LDNB(J6
M\%+SP%1&S(SSFL;KPI:(5X<BR0D-$T'Z0FWQ;/;6)6L-\^1/Q(]\*$NTV%M\
MAN15X:6+,"1Z1\=UAJ/D-T"*-5WW)\:+Y-7B\FXG#%/9V;!,PVMTO;00:YP,
MXQ<]&*^-#FF=YU.C(XTD#O=M3(_."_P@!K78YKR-L5&%@2:+.V!L=MFA\THF
MQFQ?OC1,5MH4]8&B"M)N4!NB)(:8B6\'5,SVN11!D93-L,@+*.A/Z0:M8Q$P
MT!D#QZQ/>:\>/'*@?7S@8R-ST&<`IH+."L`D+75C+P8$5>1E);DIO8YC76?1
M&\3&7L,(*A^?+]8A[`J/W3X%K^G;P3NQ+$A<*L.^-2">\<Z,&?0-.U:DD2U+
M[%!K6MP_W0B+G1"LM*[@5:6NZ[L*L3B!CP<^/:._Y:MX=IP>\`E2%^%A@9N9
MTRD)O*2V$G?INR2%8V0@*?HN'70'?`,ZP+HPD(.S/.S=!M/`QDL8ZQR,R*'(
M)NC5$P<"[JJ87=^,BYT4K,C6TWA5$P?JKE+043]Q;0LOA\);@(WH7L:N4/SU
M:1K&[B"9J589R&)\>[T89,R=PP/@;?2ZONN^"1,K_+7MU)<1(.F6W1IHB.B^
MB$5]C%N`Z'FN6KHA=@PX)I!T\)4_Y'DASW/,@\A6*/[Q9(8R^R:=SF`?J=VJ
MV)&F30D5GC@\"?R)B^`?P&)/UO1)R)Y*3G'Q?-+9*L;%1H+=NJ,9":X\+VA&
M__0DZ@;<(9KJF%EIG&)6-JI["7L#\%H=])W1YWBOL=52*^>8+?`Q%2?O3EHJ
M?3_$N3:R)LN,]'T0I_8);W=QWFRJD]3UF:(`%0/P3&<Y=N";F^`(<&$S[O0<
MMP-FIE,$W;6DUT.J@-YZURR*`Y'2=CK]-/#P"M_#2WN\"/+@\G,Q]%I6+/',
M1;.4CYXG[.8>VCPAMDCB5+15^NCJRMJ58VZK&DD0F]9,HR./,?JFQV#N+F,4
M_-6QSL$SL%UZ6#<ZH)^)/_G=XZIW,`9)#[,03C7<R;M&^X.[['>FBW$KHAA_
MU]$BW%M^F:GX!9JJ2>T4KC4AMZM]N*/3_AM^$J%P3UL3DB]I.N77$&V^^/Z.
MG'S!U-!,5O6<DB3JJMA*W`QF!%75XF]ZVB1<:X9%?3-"I_T/,2/LK_+;.2-L
M^,IK_:LR51431U<W`*J*G>G*3)<4-7[[:C/VQ(N7ZKJO>BY*EGF^%'Z&NJ_J
M2PS$0>*&30GPPQF)W@6=<927?7*6*<UU14O0/`6A/#ZVFPR\Q">XS``@4Z[J
M`Q5W>8T*K!PT`1LR52@+,+Q`\LWU&N!@+Y>$*Q2[@&1*Q%X^$ZNA9,K&7BX=
M6:JR*LA\3B91TMM8/QC0(0E#YVQY%XL>&MWBDAA;W>)%XNJFVY:PF(C!5ON#
M'<58=-:JCRZ1.PUO>@2X[Z).=!WO%(Q<!&)WT"Y>\:3G(@LZ!II?87>37O_!
M)9%KV[3;?8"`EWT.MEY;4Z,T;ZFTFFW?.]4:6WLA"+J8,,;O5&MLS9,LR'IB
M<FA4:[AXY!>=8K]]E',TGZE)&L0O<^:@V!4H4S-0)U"F(T^)OY:L5:.5PZ0(
M:BFD-\!OV#/7%2'VKC31?CE@S&<D09$&3)"QM_I:W.HSTQD#RSH8:-H6R!8W
M@A8G\TX-#YIDSP[:@9]SKJH:\;*/$8H8-7_(QPBX`5E5(:J1M$@(06Q,B&I\
M+NP)[8UZ@J40HK*3$/\"9%D$K!.\2C+&X"8@>]_#$2T6.UA4\U!)'WZBFV0*
M+ZI\S!KN!K8F<2L,JDQQ=9W'BSBUI=)6&'W9G:OQJBBU5MP*XS1;7%41!GH\
M"FAU<<_!#.$VZ&*A?M]$DF/@XTU7@%3UA8H8#[R3AVEA`8%%(O%C#[0A=*(J
MX1Z/W9[-Q)&(FC`EGPSX@Z8/1Y=XF>>8F`)GKI<3)Y(E7OI-CDO7]1W7!SWQ
M4<`+#JS?N"=?A&]MX8$`%O0<A/]?.<GHT+63-2F+\"B2PS":HB<6)840&8O#
MLFN$1XGLVB9##U23A\9-C2)!%80E9>NW*[)6*$`:U'+7.?UPB9"^3*VB*@^T
MQ:;SMJB*^V(MIFCCXYYXDZ*JB:I<U#EK*(M%6GP,[`[0*`R;XDXQI=E@("A:
MD23YX`KH5BEP)^L7\V0-5A%G@:@EPTZRW4B*!V$L`VWC$%N+M;D8H,LW=N4X
M6O4T@*HE`J-51=RP]%6W-44]?K"$I?`WP">?_*"1+RU@G<Y_\LBYM&6Q$].'
MSV$8Q(S]]P;V^P:*J*C)C<@*@!L5O?)K9U60I7B8*':RXTF)1NQ[<.G-.`1R
M/UW0P-@6I<3W7+:&5IM`56WR0!>KRI/3U>&'!-LP+M=ZK1K>1B6OO,^?Z%YV
M@N,J3``L^K*37!K&2T<P'&T*",CX9A^>:/1$T(L-F%@+4'F_0^#5`5/\R?,P
MQ$&D">2"<$-"";(L2KRX2:I-0+<89,L-B[<V+RDB5@/<J.@5>UO5%$$3:A$]
M^QMOX?<#UYW*)D[X;O4)NFQX-8I5-4"=("G28.-'`C>+M3BK0@*QUM(;!7&4
M2[9=7F6%;2^/\]0F^A;'6\+6JP&K:O@S#XFD@66&;%V^+@%F@$+S0+Z[B^W'
MA6%.DL\V%JM!7`\T417Y<EN&G//"(XS&%5I66!0.AO&@UW1-B;9ABJ"D8I:&
MR4(#9%+UA.KCK2^UF`1[Y5R\FA/#&8-+%UV\$G<V@-Z$K%6&(_(%:U#S5FP.
MBV+'F"L"WCB*+EX!,J&'%VW0C'5FE.ME]UOTP6EM\2Y83,B<F;X,JQD&+27O
MOUR'QM0GU_"B9K</IBGB_C[<.-`V"5>G=B3A\2089UCOK/2UBXLTEEB`<$][
M8)GU8^``4BJZR?@1%;IU8+H:M",>*JW63HD8MUM*K+2<#SM%]>WX4$T[]<5'
MW@O&[?`],F:,:[MVEA-;RCZGT^N8O02ES=IA'(=T+RS0]A_EZ!P@Q@JM])63
MN@<97=ELLWP9O@#KP?T9.):+&CIK$*V[RJ*+=SPYL.G1_6H/EZ7;E.3+#7#L
MP!$TR4NQL![<P*UK0_(EL0<LS*G-;+?]ZU]L_[,%GSG/G]O@^&"$*SKBGES;
MX@1^YO<=%V&IN;_Z<`H\S@$O''*GAO/73QQ-^<1YF"2CSQQIO6?8&/D19X.1
M_QG#LUUTQ/TYC*@9/>'C+O9&N,XCSL%C,$J%C@5(L_SL]3,N[?L`];R90;9T
MR7,$P6=N:J`Q='J^.SOBE)F_3'AR?=^=1FDO+K)616E]+Q/H`YH&5I6]0,M]
M\8XXX3/7>P%/OT$,C2#Q?.3^!GHXVY^$Y0_^,O8_"X?<C>$'"'#NB%OM*'_B
M%J%6N=76,V<X%G<?3#&\.7D\UIO<JCNY17\2_?=Q!Y!FOO\NLS=:UA$UZ?@O
MQG3V^<^"RG_>0B7D2US0;#U/I0R>2C7R-(NDE(_4T)#TN*GIJ+<+]796R;\#
MSX>C^4Y:D53"FE92CD2*YE:AHC]Q5XYYR&&V&=P3=&?8-YCB^@,?6T`;BSZ=
M&<Z<\R>&S\UL+#+GNWANI7&P*%/Q$U/B%V"E_0$X<G#+F-'2'C?".N:P'76,
M)^BXT,)E)\@-QA/<U,Q`O@.0-X$S+('__^V]:7/;R+DP^OF>JO,?</4Z;^PJ
MDN8B4I(G,U7REN-SQTO9GJ3RR04"31(Q"'#0@&3EU]]GZ6XT0'"3N,K(R8E%
M$DOWT\^^3O!.)^_9A:AO=>UJ.5^7_>P\/?OC_=DSW,1(^-BZ*+QS@*"F08HU
M(+C,D+,D?5R^EX7`_$''U(N#VT`+252CK]*VG%F6S&(I9`L6$*+LB'&7MZ`)
M.7(&6L8H$'[#,1%KZ001[@9^_A"G@@#&FW,S/\#U@/"7($U\3$EU5#`4WF/4
M7G/+V2L&?^/,.;L%C0T6>19GH-+1R_"JZM-L`(`_B!O7=V$?L'CF++A)V!.`
MYGL4WT:.*YW?8]=W_IZYB0]_C@.)QZ80XNG9[W___>P9$$@\%KAA/J8`5G<[
MB0'`37@&K%]F0QGX`0C/!J\&7_X*L`'>%@7%!3P]HRO.GK74PH?"<Z>$->JA
M3OFA>-(+4%8C$][]7B1C6.)3V),O1C@A#IX=QK?/6C6'J+GKP;GK4T-Z0%3/
MG%L7F82F#,!5X!B*7H%*J+&GTQDT'%#].YI4JNZQR`SNPY:43N>";NNVG(]9
MXDR$Z_\)Y`UP`OX.F@88(N;F6*8N$(YT&]:#=DHOM9+QDY#!->FNIDVGTVL3
M5O8;Q*R55',FQ*UOXE1Q_!1,KH!D-_P//@"%C1C!_EDD2HJJ@RTV2V(_\U(M
MU`&RB1M(FMS`0W\;),.'61#2/(<@&B4N+!7N`76;?\271W$*HI0T%Q_^N!%1
M)EAKP3>CNH."9`;O]((9G&QLE/2:3&HS<'LPK/!*U,"L^?;^8?<Q<CYZ:4PL
MNT,L^[R!]@\FZJ;(@MW(,5Y[8J-8"D#6&"G@#8>-&OT0I8V<.T_)G%%:NGD"
MFA>@$#7R(U/*CC7TR,&I1VB.V-]]R89X[R)MZ^P#6A6O*)U&FP;J%ERS,E-*
M#W2F>*'/9@Y>%D3&P#)W@9Q*;K`!-EI/[B)+"`$"^RKL&HV>=V!3P@6I0!$W
M2M&$,[8+0<+A%""?Y$]$IE'LG%5O\\P9WM&:4<+1HJMWW<JA^\DZ2<MJ,N?1
M<(0+JB?E+N6&ET<YYT`WZ,2.K3%):8P<"/[H=!N7E^T&X#_?R]JJ^*%WXP*N
M.)T7%`)1#1L=5&)Q';AK=1-"^78BL'Q_.B0;SG@&>HU.M_`"!>%%:X.#GJ+G
ME@U^T*7A5KJ=UFP>8FTFFU'?@.D,Z!+7!R_`%Q-2)+456;/A/<+N:TZ;`3I)
M$#]=#D4`0J.OBK@/:JR)%$W&42*?1"@-6'5RT-9C(`F;7:[C2N@9(^-Y2L0,
MFS^@9JU\7?0P)+#BC;YV"+;(B27^S`"2X1VK]2Z7Y;.W+:\QQ<_X<ZX\LS?Q
M-@`E?RC0EX5S`M@HQ0LG`9!SHMR/N:<L1ZA\X3)WF8&6'B<EQJ9?D4Y@3SE#
M(SYCW@XFM<\\:N[E,G6&VA&O?5MJ-_;*G,H%,8.?YRCVVL"P"#-?+`.?8G26
MW"HMTX)K88<EF*NW\^]DX^!%N13RPI@L*-Q1<:DU\SL!H^@A<#Q:5?X/IMHW
ML+4IH.7>C*)'"<Q:(#],(,^PYXX*9`!2KA8``?6APMUBQ(I4V3]:7UK.F*=K
MH`W@>>@B\[5P9]\6>9M"@/C3,[K^[]?7G\Z>@:0B$2QAWY$[9@L,Q-W4_2X<
MH2F$F;J4V71FB5IW-`()2RR=13V^DO1CD@M+!+<?2!0,*DCM497>F&R_!??P
M6VPALH:D5-*J:FW:*X?7"-62R6<O8'X+P8VJTEKH0LE(I9%92$V"LA"W,<*`
M&8D]5@8,Q-:1;C53J07=3L'X>P"T[2.;0#S_>XP(#0JV)Y)UDCYJN-8R;S<R
MSX[4@%C"?FV^-BH`14$R:%LQ$F,:$>5@_:`S"N%-S&XM$P3L"P_$0I;@L\2,
M[=/%H:);,'-<GQ](*1GXA\CKD/&^)^>-WGFW<='M6FXNQUXZQI0P>D.9&"@,
M`V5ZLC#+R`E%>X,]I'I+Y/M#`8-=^J405"(XRBA;"V&1FMLI,N7Z-]C)@$6F
M3HYQ(JH&Q67.8NS,A6+/3S*,4D4^"43U(NQM&081F7-^/F,.U()"DB+(/_A'
MDG/0!()+P2T\>F^B#4NI)##VF`2)'6,'3>U64VX%,/F'R#V,8?]/^#'.X.6^
M3[Y16-,H4TXU2_48BC"`I2J@VF$]@BZ&UB8NX(/,1B-,G(1;\#$$KJD0*>TB
MAE>/%7;@HD!E`A)Q[H2;6*8I:1-KJA(`@8`**BEEB*OF>1_2&2-^)IBW@\'$
M/.#H^'$V1)5&NP_43OX*SU/=T#!K2.,+^5[&Q*,]YM&<GH1*'-VG?EFQ5#\F
M(&D7`.&JCZQ$I0`A6*=4XLRZC-9>D()2+*AF!2N03H:+2%U`I;O:5J]EQ(%D
MA,D.M!DKDCQ1NN*K99'`?)T\EIK+`$"%E2JHV%.<H&5$27N"JD+P&U\`V8YT
M-Q$$/`XJ%&-B9V'H#F.3^,VI`L3QL&R!F1CZ\]".<21(%/@PCF^`FHF]C:FV
M`5]"V7Z%NUK._\2WZ'LMIC-@,F&,C-$A>XD(6&:83UCDI-(X']T;-PA)M&!`
M1+@2KL%/<,Y36`[Z>5/,A6@Y[T:%5V&Z`PJ%\H.'=\3]<)L*2M)T(F@461ZV
MG$93%@Y)_`BHX1.'42:@1F*ZT"U93LQ[YA9`7(?7JO(R8#<^O!,/J$IRV#=/
MW3O</>"[Q_$9LF'1GXU9';@HD`,2;#V^%?`/_G1FW(V,@<,B3&:S&4BAA,X7
M-6AZ.UNFMW!J8+0#VN&46G+</@>`RHP>C+"%10/3#*T\CQA.?;K;W(['R0=J
M,W`K8'RE55WZPVJY4T.U%O`'%_"HT@8D&C`];P*J:7BG^"XP;&P:J")QJKS3
MI%(`LPU@P0#1*=:[J/Q]$/!".%.`^H3D+*76@S`8BCE+C_5K#V0PZ=8WV)Z&
M'X&N//O=[@RX^`_E"P69$R3.R(7_`9!]!SG/=_JLF_#/<A(G:;XP=F@J;TS+
M>;70^-1Z._T`(FM"GM?(<EY&H)]0BW"&0VX$!!&@2IHIS80--GT7RD:TIPCS
MQ`]LEF?5-,"=&9K@83`--%AL&QWU#_22)I0GXI-1H30OS)(@9415.K*M&@N^
M25ES:-@&^%X,`ON<\`,ZA%41Y\'KX2*PHK[7<K*6DX<!XV>@]R2@G`$DT!J6
M^T+)A6#[&0`%`$$HV!!IRN`_\,1^JW,.;R[#<[]_X>GAFA:N=>1.@_#NQ6J<
MMW:&M*)2^HTT0[=K[Z+1;[?1%5;IO*7\OR2G4C+[40KZB7L+^$,)^`)H$0Q6
MUQFZT7>=_(-X03%)!WU:)'4XE*C>CC(/))3](ZQ:)622T9^BK*0$)VTQQJ.2
M5T\),5`H?&G[C2V^PEYGVMYKX:G=J918VMV3=FL.Y#7U')'D>WR9[6]1DZ7>
MC,Y[X:(F.-VG<?CX`%I;A@_P57#(86$B2,(&6\"IE62$L?65P=82QV2VM)RW
M^6]!7K[K<NQ*)Y&C]]=33E7V3'+RIJ!D?$J)56LA5S$VN443CX"+[ENSN#OG
M*5PI?@#_IT<^TY+'*O,">Q%S/RFJE[IC$6=26Y#X)I.M26:K>2X"`VU=GPH]
MZ=4NNS.'(KT5(M+/P-IWBDDJ,Y'SS`U!4[RK183.V4:I\"81V*0`UDR99>IR
M&ZY30#-X`QB_JA`?+T;Y%0]10I*S-HAFF3JL:1#-79E%<]>VG&O[)9,`I"N8
M]W>8&(NQX$C9\2&&+4E<\GT-_)--6Q+K00*K2V]C1@SE2<`'Y"_4:4"A*\D*
MM:ZR%]8@Y_-".+RH2;DV`78$*`9)RMB*^_SUS!/8;_Q,PTC=T6FW_Z+TZ/MK
MW8Z'7;A^/?/E;!0&,J7WGH$01PY#T]T\$89JE^;S#*,O_-E:<F+][9<6VVVW
MSOO&?$$,2/TEE_<[K3[U;GK8]IP;5.$]-]08`R>JDJ&0E3B=%ZN7XF9IO`#M
M=K4X0Q7XP;!HJ8HR*D5AB@W&J+J!\CF$$@,J&)H(UP\P%]3$`E$L430NSA)L
M)\)N.^G\F5&E-$DM6?4X6$*`%$1Y)&HQEH0*%B4[KN(!A4-X;N/2<\))ZW/-
M.VK><7C>T3T!WO%Q3BM[RID&H.)&CN*!19I_MA$KD*#>A6Y2S0@:\X_0]W+&
M..A4&!=0SRVREM4/-VD3:FOFF9:ZAQ%X-Z)P3YPD\5"U-1G>V1<IC1DTX@6=
M26K>5?.N1\6[>L?)N_Z8-PUSJL8\'*[<&&)$.$V9O*-8TZ]*9+U3-IZ^S8HK
M4E<Y3.T!LU35=EAFI_+@+N`V'(I5Q3.D.DUC'ZS1!I6OJ*I9DY<,-F,ZB7T@
MS[%.K-7<+#>T6UOE'8>Q-_NMJP=;G.H[=/T!/VAUCL4*K2&Z9O)&,6F"'#28
M@%],1D@RE0UI**FQ..V^P95P@:G'PBQ*G50PX_[)7"?M\FQ?<YV=G6$G9Y2S
M,HHY&:H(FCLJ5JZ[+N$ZK<C,HP2CGHU+F&\&XV*/FK2&Z^,6"T?KV%U<6S6S
ML57DV!H)^!\*;V//G/-!@[WP4I<FP^+1646UP%-0`BD;T'Y$.2?-=YYT.XU>
M_YS*H):]=4&PO>6\^4&IX%C=I/QL*K\<^_X).%\WY$4$4WC!C2JOT3GVIA\*
M!Z*P%JH%;\&2JX##*W1E7I1-!BGMC<(;+A458!U.,PPBH;1'._R1%Q/[&)<8
M92&HIR.CM"8BI)^4\DI%=-@TQ<&"`@0KU_7<QBS],)B"]4^RY;S'DAX1F<HR
M$KN)TKM5^9!*CJ>XB7JI=D-BH&7B4D\K2O+GXFEJL*1K^5K./_&C.A<=MP.M
MF?/_XE&CL`552,:B/9MF_*UO`Q/O3\0TOM%9'ZFJC#(YAX@78XP<HAH?2^I-
M8RJ_=2R.BKGI3SN.EKK?!?5E]$2=?%ASTD-)=\.Y%+;?!.)6!:&!!0&)TF](
M:%@DY&`'`[9:.93-G2&"!"@(RW'8_>9S+E-JJ^R<$TPDK6/;F!ZLBHRP<Q$\
M'M7MEO-9?^!0=,X%.*&:<JUPZ10W!8)3<5.5@$5UBTD@\R9%R]:`S"1G>%&5
MC4TIQ-S4B1?`[%5Y"(PI;\J*RJ_CQ&>N=,W?I>IO%[P2;0X;_LS[F+MX\3@B
M":#?SJ^!3WF(>M$:EK@B:B94,Z$]%V.P"#:U^#H=):$13$ALF,J1#SM`AY;V
M="G96AAS8%>;@Q8`O*C@3\NK)D="Z+R1$"@2J[15>B66,&A=*U<W%KY%ZR%V
M1P$L]P/]3A>"4^5>N5$TU4I3"&)$.47`C4(XH8B[#FC6($6>H:-;UC%LE$LB
M*6J$"]Y,5>3$3ZPW5KZNY7R(N5-<N;[>RJNI/@_<U1#3@NP%H1\4TW]JZJC]
M&`<!(P]K=VA:>PW(6M(=O.S0&(_(V-%W[:LIM#0.`ULDNS\6I=X8*YT;@/%X
M'IV-R7F)\SU0*48%S\2;E_1':ZB^-VFI(0XKDKC:6ZPO4$V@/WS\79X]HUM4
MF!_>D-<A6#?HQB4`Q2G;XT99SZ2.C8G(9>T:GI*8QF^A>UMJK@KR37#S-[+[
MJ9N*!0I\NJVIJXZR[,11-W(Q!B?AH@IAWD@%CNHHEIQ!40$O&_BNZ8`B\XU9
M6;#7V&P`0\V@=%!F+UP0TG/M+&!NX:J>G==YF&XK%/;(NTX4%V&<(=NBTYK^
MMTG_?+S8<^?&9$2[(5A\Y!<CI/4SCQ7&):Q!A9:4<<>(!W9PC$-Q@N_8D9T2
M;U#-9)-5#P8!(Q638[Y32A[FW^@XM6XM8C5%*I9(6RE]6+J$BF.A59:X0?42
M^[GG&K?T)K"=4,TC2:3+2=4%0BLP(=#:_\WTJY12N$(%Z1$$#;J#6EQPAP]N
MD*(8!B;01ZG%!:T))]B9R]6]AU@GYJP@&[A#L.M':*7/=7%>1'L`W'@T0C_"
M+!%-V@X5*-<:;ZUA')##D'A"A+>PFAW8IKL64U(L`V,L1JI>OIJ+Z+YH^A8C
ME"5`U*4B%QHZ('ZXFIO8G``H+^8>/:R$T$)5*&$V$\08,!$F51W4M/V.QUB(
M3G!6"R;N3>%T4],*7*^KIKS:UCQ4'3\W]_W,!+CFC-L:GK5`V'V[4XZRC+-H
MZ1RXPBBY/,C!S)J1F[N>YAU/:PRO&>^AP?C9]LZ_MKSS;U2J7@W=F@T?'C/M
MN-'3L\\$5_S_UV?/="Z*<F!1=*64VJ+[_TK55DME,J'ZBUDS2<1C`I:&J:P@
M%=>MNWI6FM11G@#@@!7=]`(`NY?F3XV3L1NI44PJ1XF:E07*`P`*N*")/OE#
MX-BSD8N]G-$(F'\`[@(L<JP=_\41TUD8WPG1U)9!GI);Z`.-#4[=A/P%QF*G
MQ'=L^-ED:P&3`.!>,RI<N\AD#-(/\VUOXO"&[7OTPMH]JVE=IH$U=KBN[F+]
M"UT)N].^0;7<1BF'R#A)T<_C%3;V2SD#@]R>5#P4)W>Z(VCM3:A%ZX'`^(5(
MZB61U"N;I&K16HO6(\#,"F9/Z0N!G6FE/%?4!)O;[Q<\2A7I4!BZLJ?C\1.M
MP(]KN#V&C]PA9A'?J`;_)!*M&3[_Y,P)_.EEZ,*BOWB3&"<BQ3/EZ;+*O$A6
MJ:7K\)BU\.):U:#062Y/;ZFS=RJMX-HHQO`"A0+S24IU7Y&ZKTA=7[MA?6UW
M@_K:[L5<<:V\FX(,O$>UJL*\R]X:[SU`,>V;'R+Q<`X)-[5J(L/3447AJ[Y7
MA4L,^[W)6X[D#&N(P?&`1LTI#=I$'JF[OHE/*KZ.Z]:<.W_@=FM>:WJNZ?EG
MH>=_Q&!]<^8]K_2RVP%4^6=>&:1"XJA\,$'?Y+<8V@:\AI6"%3L3-(!CPMW2
MW%#&.JHN7.PM9UO7$AO4T6BC2%4!30-4X:S.&18[T)DO/%0%GAZY-=G79%^3
M_?W$N,Z<`\D-4IR2Y@K?!58*HHMM)F8A)Y.K*D)VTG'+2YD7\:G>ERY6](SM
M0:KD7L3QIO1T]7VE-:,ML5N!V>_";^J'%6TMKJ<,*:05L157ZP$U0Z@9PKT8
MPN=`?F^.L(*7)C,R1TC,ER:/E7[5+O8BQRC0-";X*(HNL!*;.2@Y3X^$GZBO
M;II0QK`]_<O*!+;&)_^9N4E*;;JL0CCF`L`Y$N5(T:FQ-4NH6<)"EM"K64+5
M\EX'E.0+]&1;!E\I#Y]_<>X"JLXUKL8"J6.H;0(GA\$M/0/=2\T4^IE+):M1
M;!ZW9?%==XX_DF#9XX/APD@92L8/<=1\HZ+;]82#(X^7W1MNQQN[6%B!5K"P
MM.G%(Z?1V0J;;.JL#*ER1JZ_O'+Z[7ZSWVX4SV-[(WK4%_@H30O*1N4QL+;P
M45\QX7U21=RX]@+--0AAS'0;L^[<ZUP5FFL60G-<1Y8'W[!ZQ@:05C71R\7V
M*,I0;(TCFJ;H;2Y*R`-@J9H[=80+S]1J+(B_G29^/$(\KP79%@29&),K]ET>
M@:F!>=P2ZW$&W)';OC6U?-<LMI!E?DF!71*K?1G#/\[3L[?77UZ>/:N^YA7P
M89JMALK8TS,07W#EA[CE="_;#>=,H_MG73%]AF$.L"H".1%4=*N>@^(R+ZLN
MQ">'<9:JW\@4EOQ,V7(^FF)J_1WW),O'`F'N"IQ*E*JZ*(?L9Q`\V%6$'LR^
M#"EF+GM:K*:A^1JPP4<>)E7UH(+#H51^.<Y"BK:HGD'>)!`CJ];;%UX@\4$X
MO3QI\#QZ_JJIRD7'29S-`(*O/KY^?_8,B[OH$BKOFL2W-%]593A2N1?/>^`T
M4:I;E5*Y:FG9D:<JL_%Y9JE25QKPG?!.*;$6C)(\C1T)7^!P=2<D3S/5?@*D
MA.0`,;J06DHCB)='FE0#65,"T7!NA?I$X25T<T?C4%2<[MY*'WYRKEC#L'IB
M&?"-1$RPH=&-<%2?DZ>_`[D\JX%:B^M#(Z2JJG^*Y?#/*B;AY2TX!!MPRH_O
MFE`>M=O,VV5**Y%>]2"D1/U"YT&Z"6VR^#:"ZY0,*G9QI41.U4R+^BU@0P:*
M&A9%L5?8#_?VC'3H4L9A@`F9?HXQN5PVS0+F>W/D@8D[U6Y1IY2VL+=R"6SY
MCN<7T^!F+2/5>ER73&!5-T=&&@X.++SA_%>WX@DMYZT*VG"?5NKF0$UA>8H]
MV)]P<\4X7+P0F]DV%#3FX(0M=P'$&-GE/A6X5'IE35:UK-P_#-^X"?8+D4B'
MCIP`X=6P/&X1^0A]4P4?+-=U.6BWDD.U.T!;M("G7Q!/6V=HQP`:"OV3$@T&
MDWFVJ.KP#<8=1<Y0DI;O*&31PAW`Y3F';P(8CAEZRC*<R[&),F+_+!+I+GPO
MR,@L)>L87M)R7@<AK<"\5??#SA?*+:YT#1\W[\*6(#>%YESL0U61>NK.6_(_
M+ZSRP\IV[/=)W45(YN-+!7?Y,:]2+[`6C_)Q7LH51-7?GF>R.7;=V0L\#?EQ
M]`F+(B..7%Y'_I=\]D_N@_@$.H('I_P5D.(EV,7??_OO__I;-,WDBS^B`+LA
M@=KS<?0^`+,8_CN;!=>F&M/<0FE2\.&S&/UZ]HK__G;U_LVW=N?;_[K1-USI
MUW;[&__WZ\=OO?8WV$OQ^[/?*HFSYFQ%`NVVG/Q@$!>MHW&>GOWQ'CU,YHC6
MX'XU@&OK:GN-3)W_S<([9$V]1J&=,/D+J9(9'7#.>S&-88]^1ME7?R#+-(SN
MZ?N/?SS+^_G^\9[X:S1VV1+[=PS/L,J]J;(<<S0#'*$$<`]F."2!/G&]=>93
MP@;PO<@=!MP*7K670AA+'H1&3C?*%PNQJQK:!69VQM-WGZP5T80('HX08S])
M],)QF?ATBA4DU,..VK>Y,P'\W'.FPL<0'1IY'P3P5FY+!>8?673O/NG7`X#`
M9A/L`*5&[$:L4*8IWD7[QTJ^JKOUC[K?)K\-[P4PFH>QJ6GGO@'(\S)[%-8C
ME$(T$\.DM=((=5P)7D=Q5S&.4^R^G+M]\U8"><T^-=PBN*G&SIZ52H.09'%O
MMVEV,14.N_E):NOBXZ-T6WN7A_MBGETBU.R3?.G8=&#(>\/^7JQMB(#,4R[V
M5\>(>U`FY&T2`"E1!['`,P.QXOR>VB"LN>@>8?<Q<MX#&N/,H-R!4<U((^<C
MYZ]=Y\2KW3=`\5I!S:C+'N)\DW!>Y[IBM`AT-XQ24'@E(VTW&`O5YE/\`#48
M/2;AG6ZHCL$&'#T)Z@?FQ_FQ1+Z,4"8MT.59DJ^3&'DM$+3S/V(:8!J"1_1H
M^\<DC3)Z>O;ATROG_*)S>?:L)K2:T/8[J\MT6U4QM@()-#`PEQM=W:M*@OPA
M/#(J6:88,BDUK0%JG&6)S-3@U2H2-=360'MT)E`':>#>0Q]6;AY=F!9A!E'@
M0R65F'%WES1>H,L8'VP,K^^W^V!)NOAKDYK(X"F2^J3FT@@XV\F=G\1*>XHP
M81BXQM?_>47<0\4X`9`^CI&5S)P`%'$VGG"F$$+6P[@NWLBCK!/,IPU!KH=H
MR;`9/`\YDZX_HFQ=?$YBW:6+]%0GZWP<!T"UT^5]#8.XZ?H305[?20SZ@0AI
M@%>2H=MX%(13?DL\,UUUIID'3`W^IOLP<HY^$"_ODZ.Z[:BUYP18O0NI^:)1
M.O-Q'AP3OG-#.)=\M(>;QR&H!W`0Z<9*&@-XZRI`4,!&BA4$TR&@&JG.=$:D
M997'F%AXP',^S5&R!T.]BUHQ\ZP>:<JB^#S-7NT%H%>]&+G0JY%9]%VOQ;1Z
M@@<^N6@W!A>7*+C>BF&2N0D9$/U?L$>3U-VC^;E6PV,]Z=0`'&"IGF[>R5@D
M6*.LGG17`&R1:L,PUR-UV]A9D.3$04IQRH<V3!C9J5>^JSA*6HD01$#TO$';
M\=V[.0U4^;BL,_WC?2T::]&X7QWTHY?&2"NY'GK+\\,Q6*>F0*+EIG3)>;:=
M<V2@FQ#[-;/BI[)@J,6Z8N7H!"!A1$T][W!\.3Y.=6L&TGX>4\44F-A#U;>9
MQ:H*/&KA%/CDT\W#D7`IKI&"IEFD)CV@QQ5-2Q#OHDF-&;)9<Y1@9K#N=L/,
MV-B^^FN.D.+-N$D9_#!A2.0,U#T.E7>T@!6+Z;><CQ5*1'].B:#6$SY9_4:@
M$Y"Y7C0R(S@Q=IN_F)DUE;J[4SOO*D_910T_L-I-'%LT9*DK<*<U8=;FYW>R
M_>QP_HY#%^QX78_(5W*S8^1MW?:#>=L>Y[9_5)[+SDJ;6Z4AY,18ML!Q0,0R
M39]]<K8U;A1_4]RPU##7'<%,RRQ>DL4$M4M4+C+BX?YIWG`R2W#V+`^J'VH3
M_NWK:QX>?Z.[35KN36UZZ/<<;:>NT\+"D^K>55?K;E2MNTFI+E?V[JQ`MO/L
M*.MVT6X_OVH7"J<(/[5%;JN+MLKWJ"KE:[(Z5;+J'BU9]=L79;(2;FJ,->R,
M$WA!&(*82P0V[`9-9>]EDU]2=S:Y"V,O]CP,6&2)R&1)(NK:R*?O/W^Y?H:U
M)8+S;FL64+.`(V`!O:-E`9<7)<FJ?+A[D:DGY%Q+V#A7>G[MK3Q=@+[3GCC`
M;/:X!1$8P"+C\:IS?OFE"4O)7&*+">M16LH8IYJGF8_9*V"X>X(23.F)E/P#
MYY2IWI,E0N,DES1H*F%V4T@=8E<`2KMRH&DD:!R\SI6%A>2NP$(J3[&%%994
MWI@AD7,AJ;P8A&=<%JM2K-[B3SJ7C<%%CSP#3P:#QL7Y!3YPY0SZT:IJ#JJ+
MG2_G8#=*@C,K),=GXN0[^74!(?,A[@8(@33-^\J0RZ%#8;2Q[BTQYX?!A]HQ
M+I.C=*<*?S`]+4_&1(0`Z'4N553'7$.>$\`)#?7"$;6<-W9Z$B8PY5&GXF$2
MQO4J8T:/+#Q4<^'%`.VWKM8`J8)@KW59X<,:["$'U'#=[7/5A4PF9ZU^$(?.
MTU<O7S^S4QKD:B:Z.X;9NVAT.E=K,TG`]LG>.67-'VMR/JU*JCY#9#WPM5O=
M"O#M6`G-2?3A+-'U;V@$^X<W[__X\E?8M>M39E<2B!3S9BS%4A4?L2YYYSSE
M^/HS*UG<J&+&&43I3_GH`ECO.'0S($_7Y)LBY4^)H2$_;OIN@`.8;7>29K:M
MO7/8;J=Q?C6H.>SA.>S?GF]80H959[IZ#8YV&A`ZR>O(QWHR.`=8/6@!KP/I
MA3$V*3N!XK.3:Z9K'$I-U\?%ZY4ICVTB4F^2W[@.^^NU'.LTB<0*Y[GS^K3Z
M#.HA@X<`^N\"TV4MW*]A?YP(?T).D>.#M*V(A8+U33&=Q0GJHA-03E674&D/
MH%5#?5G-@EV:DB3=Y8V>9*LG7U&#XF\Q]=(J[N.2?-27*E*[W^-SJ;.II?A9
M.EG^Q"?=1GO0/EX;\9&@2TV8^X)T(>6X,J=1)W)'<X2'II$UWID*]D8CK$N@
M'>B!=N^B*+[A3.S_R88-^"PI;?F3"[:0'B&M3+S%'0L\0(E,%23SZZDL6=LK
M]`23B,[[T#WY`VKO$<U1_H7.\:9!7E&$U4]">BX7A3,WP+1&:ANIRIMO8VWU
MP?IXFHBJI2Q92E0X'6/QDN?*B2G:R3LFTS`A7?K!C"S1@P=\7=G!3\A;EJAW
MJ]?Q;2K77&>@ZSXG"9MA88AESMX$$%`U(%'\C:I0F*-:0T?L1_(FIHHYJO(:
MZTD%=@EL\LE5`\BG9HXU<WPDD'Z7LY1XE(-]OL:EI(@09\0B42].4,?!Z3_,
M&`NJ#O6UQ>Y[@53M<C&+^@?-)`2".V^T+R\<B9>3=RPUS!)N&_3;SE?L[/"*
MW(+.ZX3*0;]D`".G<W'1;@`#ERDVT)`N_'WM7'4'W4'+*5<ATLHM)JDWK'CD
M@-DZ[&5J*TE([?U&[Z+7,#X[[GT(:*8O#")X?QA:I:TE'KOK.I,:A6MFL4<3
MAT4UCONRY:)5/6NU9M8ZE#2^]8U:5;(MT@$JO^IU.+&B<7D.3`F(>,9V3GA7
M;HBY01_,ZJW02_N#QN"RK;(Y&MVK\YJ$'P4)/R2PMDY<<J/2F>[1`/]MEF8@
M?K%EP32;YFI\GD*%_7D]C+5Q-T+JJ,]EWY7TSO7E5>27T&Q1+M;:;9U4?=8;
M$]J*9&B]J'5]IP_(GUX$^[DDWPJ8KH+"%I.NRRG&C`+PBAL%1/YBGS6VA7I:
MIFXE(+%_F0[CVEZ"B@+:ZHSM379;0K.'/1"I&$X)ONBN2FV?!^K:+XGBV\2=
M_7K&_Z[:12$!?&E*?J?7NT"\7+`09^AZWW%.1^0W-;?R/"%&HP/A$5?O`+=>
M&S'T1@=;W.9:"*1?W,<7KWWT#X;X%N#[9&/@]@;E35(:SU'O\KS7N&JW-][J
M[H[SF(A\1/\Y,)$/=D[DR[:Y9R+?VE*V08L;'?\6#KLSZ#<N#D*,BW9Z3,1X
M%!+WHI:X!R+&?0O&RWXM&(];,%[6@O$G$8S-6B0>KTB\JD7B3R(2#T&&!Y.&
MRL=H?,;=DQ.1E%3DCE*1W(]"=PF!G9(M.8_5LIOE\$+Q5]UG`]]0_$4U?*&1
MA,<FD0^_P:-F+[M"W+WSG/.3TP<H^V`[[&:;FS\R=G.^D!K].!N&XBBD_3[\
MWX\4=-VK?J._/>?!KBCC(?RLW%"I+@XZAK2;&NC;RKCUQ4S0GJC^$RNAXV2S
M.87U69Q2WEF=X5>LCIO@L'&[TT-@D827DT1Y;!!<AJ4CF1NJQ'+,)\NSS_2L
M=Q>WRM4UE-2=]W!(A3NE@2/F;CBM&W4O316X"236^21Q*%K.*]5]P5H'9Y%S
MOP<U_S!?TU!X-'8@"T.>I&`-&7Q7O<5R)["U4F0I2?6JC94HE*2ZP<TJK;;7
M[U$=B_/U-E8%.E)8ZY(X409K851GC%[[+_2F3O\OA?Q;#6/.IJ7-^`%F$VZ4
M]'MN#Z*(8JHY4+-Y%Z&&AAM-K@`,\%0OA^K%Y&2^"9SKK-]CXKZUR-M6,?X8
MH/;>Q7W4JL9Q(WL-[_O#^^\B$C@A[_<@#<;YO+K7@9SAQ*7Z$(X.Z6M9^I`B
M#NINA4HGCN6!?QM:'U80!74NX:&%5LU&'$FJ\E23HEW5]8H:;17(AH>(^4P\
M<#E)#YZ$$[K!%!3<5SA)D>9M\TR?`%6Y-'\@M<4P#VW,/0N'_*A'620+.B`N
MC-4];&U!/<P"F60S[@X<Z_T-,XE#Q:6U->QZD0BL1N=R?YYN2L4IW)_L!QS\
MF.>!>D*@'TRJ"G4L9<6YA?#\68(]BU-3)'H3`%(:G5DO'R'H3=R(Y[+32"(N
MJ\$>'50*7X"GN"%SPE3.H?H+[\JB$<C9EG,=X9_N39SP5+DLA04+`T9:-+\9
MCGF$?P)5X(!4.&60TQ,7(66^QLIV'WL."-4C!(M@BUC@J&K>?&0:336FDPJ#
M/[/`)XLJL6%H`;JF[B/BH[7<>KCR@$PC(I_!IYPWU+`_.ERON<I#3,'@N[#'
M@T:!U5]TXL*#/.J[#["%K<,KDSO2%LAQE@VQ_RAW6TF5<$[$6,_+'MXY/)H4
MI9),];1[;.\0.N.<O%S5_%"_]X\H0('X!>\``6Y-)6_0#&_T_YB!IU7/P8$Y
MB5Q3^6DY[ZC1`P@[2;-1N5]%$F!/K5`U@F$]!S9,HX!0-N(\:JDGL7K!30#B
M4L`-U-(+IQZ[4W=,;;I1&JNAZM1_%,6WM>H@NA'2*`8\0EQQ&]I[91EML7?1
MQ/719^:Q^E5096A,+$Z?AF75(OJ8V-96G"J[F3%[.A!_9=1M"J/%(=`*-H9"
MU_RGT(WJ<SA"S*]YS,.:-;T5PR3#CI(L"5`:^_&,.B99]J>G"$(:@I@!09!+
M@/MUHQB,W"EVC?PAO(QL:>[?!+(3;?;`"V8@@ALL$:E%G&]%=?1,<!!0^3N&
M(A(CG-D=C-1`7/7HOTH.M'G40\UJ6:EZ=*>W(KPQ\9A\EF_%EAJ.X/[<.`:8
MFL3KQVFM`(QEQW,S%/>)&IF.(AB0B*_!+8SC&.6R*^'S4XQ&8J,X:K8'Z_,%
MRG??:$(`N6>U^*R9R".!-#`114(R`ZPG3U2#5%Q%Y7Z1>`F<X9WZ0FG#?BS8
MOY>(&W@)D-A8^=L3P?W6T,E&_CQ0S5WLDV9KK0UG0N0IX1_=OQ&6$:2A;KOH
M"7CU"^=I\`Q[SV73&:QV6N@SJ5JQ(0](J?-,ZLC@A]6ZLLR"=-,VM'7`8%%^
MR%F828[]FR'FW#$2^03Q!8SG<_L,XG;,QZC');X/?P!D>QK`2M7NFC,W0&B*
M:9!-S?SR-(@RV-U$@)V`N0PR8ZZ)/[NZPZ794RBB<3K1VZ!]6\R<+X[9^P<+
M"`/T!-Y.1&2=VU"@TQ"MD!M*M="]AM&2@?<0"#E!(0'H\+H\M.U85N`QPZY@
M6P0`,E2`)V,//_@(JXJ:P&K1)J*>(AF9,@+S#G$0@1[>CD\![ILF@9?_Z-ZZ
MB2]+0Q+N-_'`GI7P!1\^`5T.A-@;L'O2NP]Q*O8V)F%>)US9-6>.:\SKA\SQ
MC(:ZFM]5<I0J;K2(E95YXSV:[.")GK<<^T#^ZKP&N>H%[$C_+'PAIN3<!OA3
MOBG^_46@K>J\=#XE8B22A#P!\(RE,J&&^WTD::58W#+@+&_HZ<`/^0^HA9OA
M70W!X\!`5M)R+?%T@/91C0KL7)"7KUOT\@52HO)PT<"VMYCW)R<N=;.E4";B
M*TM6<HM&,9IPF)&?L=<5Q"U/57HJ!2@<02(I,.N.$W<V47J!N68HP/IZACH(
MFG*CF'YF00X'`&@)LMN9LDLRH"E-;*-ITU!I2-)2)V,'-`!@]@%H,10=;O#B
MJ,UOL2/PD\[J!MLUXM34]D"@T6#.2*@I=.5Q`"3T&Y?MAY":4NNS!,@#V\TG
M9#6,,'&7'_L47WE&JZ#$7!(XSB=]@ZD'.'O&?@XLO)GA$^!1-QA/X>!!G$A0
MM'!D6V[`^*#R9E)23"$J479-6C5I[9JTKK,Q@&$)<74;W=T05Z?140^N:::F
MF9,!6F$*0P71*/4/L+NS(=F@[H6%LD)$5JU*3@?LW\<@LN7U)]^WBT2#/C#T
MR]TI19"FMI`*]U=R`5EQ9R$#G\;"?"&W(M^%I3Y#?C<0_HV>JXJ>P[QP1P9Y
M-8TG>-:GSQ,E^%T\I06!0.XODWRGH(!E(Y6:*-:1*)?5NGY)U'D_Z;TTS,09
M1$*A83$_=#7Q*0"C?:!XE^MC0VTX;Y><<;I@!9G4^6"`_,\D"L99`L>F9F9H
M!&`WZ"BD)`N\R@VPEBGY+E)UM-HW:".`0I0J:,P!0,VDW>2Y"&E?<,0%/MX$
M+KI.[1J==!(`!7#6)SY.I7'&D9^1`Y![@Y<F<*QHL%_SBIK!;D'?=R,*G%8.
MGF:MY+S3&`QZ2YEKSEF1DMNM=KNS6!NYZ)XWKBZO5NHB]4'6V+]C[']/$\`K
M<5_Q=L#559I%%?)S#!ZYOLKU+\L>XP^"*X<4NR)AZMMC8Q(WD!3PS_5QSYVA
M\W.AK`6%@\)LMF#M#"YI#UJPDJ-+R]6'R%,4Z('$^7"@(_V'!\D%,G^W'GBG
M*U1-F%!%ZCCI(I#D0<.(X2+96Q*P61J$^GT&"G^5#@:T2'.B13+#<:6]`S/@
M7"M22Y:73]%9IRRVB#P*)#AQOM/I-2[;`P3T:D6HYGDUS]N3&X*1EE.(_IU%
M5OXP(O*BD*,CW5`X3Y5;``T?\HL7L1_Y%J)^O]5VID$84GE/JIS82%W,3E4*
ML-6DP,T`$$`0'BZ*QH'R/!UK1==S*P+"LIF3F@7,S\[SE8H/[%^6#<:%C\>%
M=UM]>]U82X99%']FH+*$*N&KT[CL=+$'T0)949/V29#VHP@UWC=/H`;B<2#A
MZ5)NN:$-</1)G)`FU"666V*[,X.IED+M5JK4AO_6G+1&XMT"#8"#Z]YB?T)\
M9(9_+-(S>.Q?IJ]]CD\I'J"#NAL8->%"1TU_H5)326951(:FB7J,"?9@M;?V
MXI0,+MLH)'\/MH4:)V*,YE6%ZV?0[1,3P"S7)Z@MY52=;W1EC`J9S&(68I1(
M*O%FO8\J\A;8\"KM%_0\3JNU$T$I75*7?RN?N4ZK97660`6[H4S7XAAZ+$1`
M"Q<35-'*51FIO'X#750HQ0^1>('D28,IQQ@4Q$"'ME7/?+`]K.J&K6;)172I
M'0Q`^Q;;:SGOW;M%^-(IX@L^NE<Z>K+P50H./Z5S.7_3H'A3/B%38N,O--M5
M4X0X8D=&[=NK6?CN]9"%W$^[KT(9LY+BG`&8HB;U<#W##*U4L#T\$BZUJ["3
MMC@BIP.%JJC'$)9A'J%R(5+!J<21FE3FJNB&(HGT/J3R=?D,AQYA#25&DU<P
MI0766.!S[&AT/2Q]Q=TG!5X38I.0=`(,O&3M%EV-9%FK)V`N'.[0]D\N?G<)
M;-Q9<(K=]+CB@B*NM'P`H9<$'/#DQ:%+4R7R4ZR6`ZXTX)H'5F=3%236X%6!
M.2RB4(7&ZHU>FE%K$_U8B[?."09==4#K"^-;D?"-RL5@NQ0\BOA2("_WC;C#
M^$9L[F+)T8!VAW\472F1OU7W!NSPT,Z+3G=/O(=?M`?]D32Y^^3S9[O60%=K
MFF4GX9SFT*_&KI>%7<YAFIVJ9.N4@\:\YOI`/7.IIQ%42REU2P"IM2Q-7BU+
MXWZ#A4Z&.<R+$:U=TGZI9VL'][(P6D0L6O<*8H;$K8=0E;-(.-](NW7)^]`/
M,EJ@Z@&E5I!S1"XL(=8.QX6(P1S<G-%Q2$-;&);@U"@62Y&Q8`-:"F"V`765
MJ!1@)7ZX`I@,G;GK`UDR)+C04&"1WVVD=VZ>S6``?I!1>&DH"-<(LLMRZ@`'
ML!C+Z:N,NN))*?!0WRIN-^4JH8@G*")=<,?-2JQSS77S`O[A%_2PFYAH@68%
MR%S.4:S+B%(;2)*QFQ&8RO\8S?XJ5U%%'G_C**6R3+X2\(IW3KC/+4MXE'&T
M/+!B1N8[U8A,>*'+_8;G8I,-BPC,J\MO@CW-5U=:F5YX+B3T\_?&K#[(9C"R
M:<Z5@=S,H.NT0%^[KT&W&).0%R:^BHE*:SD:Q09UTN8]@F44Y[E1(1YNUF?H
MD+KU@3S,=)N:VT`5?<Y*(LR4Y]_`U5%*^398)F(^-A:R9XW)JO;7TIIS'"H0
M\$+.U["[$^4<7C$V9%N-7/1-45S.PB"7*V745^C+:X%WY%*\P#@:U4JL+66!
MOJDA`3<$M,#+KY5"$146!V,SAH`RZF($P#1(=>&SU``PD%2@LW:%5*\>2-T"
MD:W?N$%(=*HKKGV,R@?#S$KXQ%2,U&5JQRVKS`/]IOP%^K0"!'X\PR2`V`@+
M*AAF@%'WPSO`2^R$1.S[-I!B0;TW-C[$)(^I&U#BI@42>ZUFF?D";<:HEE;3
M?^UYV2G0ON1,QE.3`@!%QV/,$^;VGFPLPU,;17J=TP<4,9'*0AH$*@3X8("C
M5_!%,[6@L57R@,PYAW-A/)O7F8J<%.P+5Z4>/[U^YG2PS7^>,J29K.*`U!?@
MY3.E;L28UTLW=IZ5;TB4@J&:CKK:_X%=:NDIW6?6Z\$(,VE-F'I1T#CMHES'
MSQ*=$J7RJX8"#I]SO9F[4M93,)T*/^"ZPAFR&))9O`8^*/PL3%:Z8*%F/X(N
M5H:&+\(`MZ8:RZ5J>7@:4U+@5>I[^=G()+TP\\6+FKAJCK1+H*T'GG5:U5B/
MHV%<Y6EB[?9??GGH3#\L0Y#RUS-?SD8AB'=Z$7R+'F3>^J]G;?ZLII3A9VMA
MR\8>TB$:=]"*V6B7^L#OOYNYF6D`WE^LT9/5"UB$OK@J-,IWMZJWH`QFB>&O
M1C1]!D[*N9K$;H$'3I42.K3,T=R7HW3F+V]>.;J#I?+<&QY*_FYL!QY$(KV#
M[^Y`I1NE*G+V1C^*FG>_%JX/*K38<$+<9ORA)H":`$![D]13/L^[5!H62Y[+
M;N?BE[(_EGP5B4M:0J%M$^H_H,R`[B--URQU':)[C<TU-N^5G5O&@M):==.N
M4N2A@-\Q%B-\9W.#NG(`+T<&;G==4P%=U1,.%AT)U65Q82*S%?WY.0@A\'\]
M$R.W?W[9=Z_..[WSCC]T>]U!QSN_=(?>5=]K7]3D<DAR03>3#T>$X7)`5M3\
MAZGP407Y>5#4O^IY[<O!Y84WZ)SW+^'_NKV+H7<Y\D>=P:!W6:/HH5%T%(0J
M1V:1.]T9NM%W'(;CW6E57/'^GP>/W79[>-4_'W3ZH][YR.U=#B_]3L=SW:M^
M?^`-:U9[6#RF+)\0WNJ/U<P#K`^E24T8)%0)7PF6&U)>T7Q7AI\'E477[YQW
M^ZXG+KKG5T/A]B]'?5_T1FU_V.N>NS4J'Q*57R:4$$`^7^QW`MCLYEUN51S:
MFF6RJ*/7SX'/N\745J?&U74,0JX9G8&M-I^.B?.M:<XR5XB_MIKD@Y;Q.0/$
MZ)R?ZS18LOY:>T7=S8!3Y7"?`YBZB`)L+YQVRY##0P(.!UWXM33A1],8:3X$
MA3$_=$\%+&79GXO]N^&+O#=`',[E<RP-7'(*5/&AGN[8C:EPB<D+S>%;2)J*
M?)[AK6<\F891Q#X`.SG5>"K^\Q^7NA.H#'+%8JM\=D,WI$0B.1&"&U-I1EV1
M$K#-KM*+*D,?$$0Z9,`(9ZJ+9#_835_<"D9NK*1=391UG>^FI_U/E2E70Z^.
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MB84**`U;OV80-8/87\^O<T1S+'71@FS[;**_G$UPBY=($[]83/24(J6H/K`V
ML3[-=]KG-=&?.O[61/^0YJ;S);SDP"#%'B4V5M(J0M?=EU0!.G:J9%OAC@<A
M9D.T3ZE!*:F[2`NJK'84)%/=SY/3NOUB_1J0]Q*6<75?CE'JS*<V0#-+X>>\
MHHX8ALT=R`Y8V)0U;\>:Y]!7MD\EZA8\^;U4ZDJ64]ZPI\BR<&S@E/N\YDI1
MWIP>3)(G@XO&%6RNPLIQM)43YTT2\(+<U+'ZCUXUNMW^`M,NG8"V-IY4M#.M
M^5/-GW:NE"QH9K6"/\4\H(@F*N?S&F*-U3G/,OB.53IA"+O$'>FZ$^9:JM,&
MM4JJL*)0:5A3#4)=!5=3J*^Q.5UGC=DNU4RNU`.JQ.12$5D\;A,.T^MRYZ9[
ML1BC0:66:K56DV,S>T$S436TFN2%!IZ>K%HSHITRHOO$<'K]UM560'0X%J.H
MESP6:HB):?[-;"0I`M-NQC($^AA3[713KW1$_]DT!E3>9V7?EI*.0B<[W[+%
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M6,T>Q3JLVH(;-PGB#&B0>JYQ?TA?]WG$CR.7[FDX;HA-`5D81[,L9:L;X.".
M=70CSO,B.=*)<Q@KN4,CCZ'4W;M.P@=V?S7G8`V[3K,&K]MN=?OK%^%U+^;X
ML[R;`C^]1W&;0J_+WK+W'J[V[A5<*::S&!!7(,_*4[1I:&W"K6;7&IPN9P+3
M4^#LK)Y;W&F:O"TJB^&\,3=2G6?7LU/53.FAK[2VJ+[<945?3<M;;G5P?CX2
M%X.^Z[5'YU>COCOJ]Z]ZE\.+JXLK5UR<UQ1_&(I_ETHS[:!0-=*P4LQFL21U
M7Y=H8,%%FDFN)Y>"<MCP)U_<@.T_(_,+B#Y.E,??]28!_*2CGZ0"`WF#,03[
MP>R0"-9>4_-I4'--IX>@4QZ`,364&(]8)K)G`WT!C5(P,;<;`)G=*5T];ZG4
M9'<B9(="U!/M0;_O^IV+B]'YX%*X%U?]P977:0_/>^?]8;<FSL,1)_G;@+)X
M.@(6^JL\GV*E`78,@%=B7V].U?94NX*:#D^##FL*.Q2%Y:(-U,\Q.;PLA;/A
M##,94"MF2F85XSNCKJ(C/4%%%G3.[Y*K(]1P1"!0<Q\GI_BPL:2FQYH>:WI<
M3H^YKP=+B4F:A7=-2OOTE5BS6HH-`YQ1-XD`J\:8]U]KGS65U52V?'EO?@#.
M8)`5,.J[2*T42,=EGZJ*]A:)2\NPFLI.C,JHM_&@,[SJ7@Y'7L<_]X1[V1/B
MJG/E#=L>&']NKZ;%`]IXP7<1!I.8YR:P5Q-)T+6L/A[*I,NGK"&795NPP2.:
M.+4BB("NT=/*1J%.OZ"YJN\^?:1_79XN56YSQVUP9HG`*7F4W5%F%N0IJGG`
M:?"`'5/W>4W=BZ@;@QJ&O(#H-"%1UE@`KW23$&1JD&9D/19EKM%W:V%[(H2&
MPG8X'(ZZW?-+T1^-SD?N\.IB,.I=N1<]M^-=]KS=.U1K<JQ<WFN35RR=B0A]
M3HKBC$YXW@PH+R)Y::K+.1H"4C`,L$<<*+]49$"=5&7>`\9JK)/'1[#RBK,7
MG<3%J*2*7>ZT97"=8557&6Z4<(BU>=C$!"!"K:]!R]23"=AUJ5.&T>6"E_/$
M`AIFIW(&C;>F.G4P=[#J)$+=DF7QBZP^,L`H,QXG*JU1Y]3?,N.VC)Q<`%^J
MWBU82-C(VS'JCM^"K@&M&(4P"%\:OCRG8FOG;N7F["%05I])D4YBG\?5V]GF
M$]>'0\5JY0`5;WIZOID&[<&N0N*G>309FO*[J>^S=3*@)YA'U=6*)\$;'D6G
M7ZY/^,C9_I]"`,`+[AOW<1H%PTPZ[R),0,=4//RU!O*)(>GI4C8:6$LPT7F*
M_/B,KL#/9\^HRY_KQS,5J3.M@X"+`\PP#Y6;4,0CX+FD%@($FP+D1WPGA)7A
MPC)+?4^N&%5.CEEONI#&%@<4!TS)QQJ$`0DZYO5#W708BV%F,]`1LP@%$A8(
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M'B>*'<PCPE_ARTZ[W"K'5SR`1PPXZSQYZMZADB$"LG@#HR(!?:*>\&<&YT0=
MC]78XYD:\/`VMJ]&:E]\N2)QMKNMPF`:L`RJR9`Z!(7"!=4%/:U5_H)H?H.H
MLDA[:D-QJ"=PNGG63H8XMB/"@<_D`;"XVEAW#%*+S/D>?S;J4DBC1;$N*4T3
MT"W9#W`;2;7M62RED)(+G[EE-1Z7V9AN&CT=TKIO8G91Q+=P!*AW`4S("\S<
M6X&R8M;4*EAV*F%)Q:!T<12G=/A6JZ9\O58OIER.%C&LIO):J3LT:U0,S&Z"
M8.-S,$+7WS1(4VMH#18*@C7$S\VU/<4_JA3"R&_@HW1+!3"4*#2G7JY*J]$(
M2H3I%D'VH\SGX6@EB.TV7_=$A<=0&X>8)L_C:@..]E<U0RMQ^*]E[I6KB,5N
M2F6E<'&/Y\;#-+$::7?7HF5M3]=I`0R1>!2'87Q+WGNL5Y#9=$H#O#'G!30,
M]&Y4$;];-*88@Y<W'_B9`MK+4+$<YM[4<GI`9'S1KN>,CGML&VR3!/#$Q,@?
M$#-7EYH3Z^+[RP'D:>#[H8#WWM`7OY[QU57@KPYYK_46_G'7;UFT%T1'@"-\
MT5V5.##/U1ZT/T"-V\2=_7K&_QX;5!G7S$L4N>++'!F'@7\?$'?:ZQO^#TR&
M6&#3:ZWK8^[.J3#NC_'\"\D2U42]=?K=.E+=ERH/B#%?6*F\UNZ]!Z#+SCG#
MT9S7<8-E]2YZ)["+GY$8_TG?@"%X#8MWQT=(C#6;/@QF8-#E[^3RB$?'AQ7U
M6=EG]2$CK\QI'50M-$X5W=XHQ^;Q8=L:PN(Q&>J[,"D/CEW*HCP1*[(^\JV9
MA"=WXKLXB]ZAS^(3Q8>Q[3>=RLD=2DV&#SOZ$SGP-21]Q9`"SQ,"AQ2H(,#%
M57M3Z;]&:*X0_NBT6^W^YFE6ZQ[92S>D<5=NZKP6'L6U<J#IW,:UCW0UQ#J#
MG9#3/!"/8BD)@GNMM?0N-EW,'"(]L&`4G]EIG%]0Y/X!1+QMP-]?NAX#!JP-
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M[`2]MB:2'R?R[]4VW`+R'X54-<T]#X#\A]%'=[*Z(W(X'Z7J>3+T@%KF%E*U
M:I*H2>+QD,2@]\A(8>E@S+K?[]QA_Z0@P>;2M[HCGLL=\9Q$3-T@PF[3'FPC
M<;TT<T,G#$8TN(I;KJNY"96S;1:,\*$!8E>MSB4_8O]-TT^V!?B:B%LWFK>!
M=FW&/@6`Q$$D`P]Y:B:PASK-.0#2U--)I\"H4VN&'7[Y9Q8C5:BAXSQ%9&Y:
M%$\?$3^`M>NQJSK5M'A+84!,P>>3$PAV($PGL2Q?C=\O7Q>25A#1.J0ASM)"
MGI[A,4]$<PKG?J<??O:LY2P>ND7`60A(N*F*`>!BGG3.+]#H6O;P**Z<QI`/
MYBJ,XKK%@;O6[(IZZ,))#5TXW?&B/,/UI8MS39#P121YWO";'_AW1?^@&J2U
M0-N-KJ:GV23"B\<1F#%*`C6'A)Z>C9Z"T=/AG]2(L/*0<1!$.#953>HNBAWZ
M%<>89F%*\\5I>-!,>&H"+,WE\3.:LXC/YMD\+>?+JA69U9N90SA'%?-0W)2&
MH\$_.-V<!0S-*,?UJ.'FLOJA*"1M6+BW;N++XN[UH'1?S3:B>4$V2&[4#)4$
M9\9*.'=$@AO5'XXV]S;F*T`_QG%@43J1CHA0]B^2GW-GYJ\^,]CXD^Z@U[BZ
M["O)CT(5GY#@JW`2KQZ01`/+7'\*&CL@CDL#Y_1C-H#N1CL[;ZS>`FD![5I*
M'[^4/EV(?373`EF#1Y3.(HO0"ICIQ<"O$A&ZBG_A2$;D8>7QC4J!;9Q?7#0Z
MY[V%!BT.&,-Y3/SJVX#G"UIO5S/+Y@SL?(C9>:MSOJDY7*L1AR:81P&\?X#$
M8[JXEF`*+^I!7,.QUF5W--2NH(K:O#=7TT`!G9OKZ&12:YPO0Q>4D"_>)`[1
M8Y#/>^79LKX(6V2ED<9Z$P/G#T(<EA>4]$)@XVF<H!O>OFKY:'#2-X-I$+J@
M-HEDJL98Y@HR?%?:3;YPN'&F1@%/13J)2:7+)W'R,+\OUR^=#W$+!]7"`>(X
MX=*4<8DN%)`WJ,P99P^.#H^3D0AH?#CO[(YU^0!5R!D.9H]25A0MP.L!F99"
MCX+)FLT^OSWS-%E2KW,)I\8(P]M+'K!$%(P)D)R6#ZFAM%Y8<8@>+1JYJU19
MXY%F".OK\GFAJ5!>:CZ1))#?FZ-$D/]*)&BT).3-*B'!'ZTO<$,B7)D!P.X"
M$?JE(P5R#H#R?/X1'_`?D<0T9]D^&#]&&HQQC'(*J#C#E\W<.X2J?H+4JGD$
MZU2CWOEE<\J"FW-GPCD!F!/?"5&`I"O5C$BY?+QCS87VHS_L(.ZP8UBH,&=I
M[&4^PU)E"<';0G<F85WZKP=7PVUQ)J5><>>\LRPY=,U3WD)D^1YM@%:7ZJA=
M]BXNEV;`'D^'?>U9^(">A??L67B#G@4+/.:OHJ&U`FQKY!?_5#C1N:I,J%A[
MDRIS8S=HL%$ZLT;RI5G>C^30^DM'\AS\T%:UT]_*9(+CH<_7!2UO_>->O<5C
M($Z5\`0R?8L[.V4J72-/ZPC(DU[SX7HGE%@N"#H:2OQ';HN/P.:+DX><:GF7
M1T.,%_V'4F-I:X^+&N?*U1XY-1ZM7/Q<[4=YE`*RTQI<-CNMRWXM)6LI>>12
M\DW!)?N4/)];;1!^-%0Y:'7[S4&KOW[=2BTLC^3H?C9AJ<?,-[4;OSK:51%T
MX=#)^K-!3TFL/NFV!NNW3ZXEZI$<VV;$6ZXVTO?][7DFFV/7G;V@!,%)'/HB
MD6_^S,"^^Q"GXG4@O3"662*^PBY>AG#-;__]7W_3-WU*Q$@DB?#I;G,)103A
MPV<Q^O7L%?_][>K]FV_MSK?_=:-OZ'3\VFY_X_]^_?BMU_[V1<R*WY_]5H*C
ME92`8'C.P9;5X*N,KY4C-.N&C!9%?.;"<56ALXHP4&58R0IEK1,FZK><3TE\
M$TB,M&,X$D`.&"I5`JDY)$X"71I6JV'\L+`DPT_ES#P,C,P('Q,,O\`F8?O7
M98RT\?7WP!V2=ZD&\UY0=?]PZ_5;E\OR"-8"G?J.F\NV6]T=@O,=)JE&$9AS
MB)^W0<H57P:99P:950Y2$+F11_DRY4QSSA-W0HWC=N(KK"EJDNX!3P3)ZZF\
MJ1@#'W2%J5A34EJGJX@;S#6B=)ZYC!<WBN&[!,0`K!&UV7(%US@1L(*$DWF>
M=+`\#/\?D[Q<5:,V%&%\ZX":V&_31':J!>/$F.*BE002/V8!%HNI]:#^H-[L
M.C(;2O%GA@LV<'+X`2"W/GIIC#'FCBY.Q3PB@0F[@73`A`X#D;2<?^HC<*4,
M,#F)"_I<^"X`#)BY"4#VQF122K#$`T!:F18/A/1^7R<P:?Z3G\TL2V2&J6T*
M]*[G84XQ+GB<!;Y^[?675\YEM]WLM!M%PD/ZVDX]O/H"'Z69GHKAH_WR#[)?
MWE.*%-40L)F"]^`U#94J;1^%3MVCXI,@0:<A'\'(.I6\Q.$:\"#4A[(\)[IF
M*L?$HQ^BB0%$K[8-T<X.(<HEK?^;16)AJ4]3,%=05!\&WT483&),]`3DSSD&
M,9,9\&"@=@"YQ>3&`?!:9K4`>W?,-3N8]#D4\(/K80)GJ'@'%>N[,R18)W$#
MHCRP)>,DE2WG'?-N%]BAYE_(LP707T!9H"YP9GI\<1=@='I9:/90+ATK\+(1
ML';,-^5,SB<7BK4/\3WHE^1^`IQK.YY@[`"8^%#S/X:"YO=*%I@,R1]V)J5?
MP3^`[XQ0L&"=$T@P$CYN"-`$BS*3DO.*D9,/W>@[++AA03R(L`0DQB]=$BUP
M3K!:%W-FT9\J)T*DLE3J@8<0`V:H2BPO`YD,W^<,W9W'$'H\WNG!'L?Z5JQ!
M4458>&16+9M545?3;<T)CQ.BP%K^-PN)@.>Y8!!YF$V-59ZIK-;?@#\\Z5X.
MF%?8R=BV)@?,SO<#9)?(W33UJZYNN7+,?0-VH0[-9T65,$DK0(^7W6FFI<KF
M%K.L=((1XA6%L35'^YDXVDEIRZS;76=CV+/3[6CM+IO-,R;+-'\YYV>2;BB8
M"H'RL3N,Y$I5O/=)O]5V@".%0*HEEBDE&HJ=1K?79=LXYWP+^J*`?OBDW;JT
M[&5\8B*`%RG:3ID782U-8+&@)U>*\;K$7T823@BO#,@,O<Y?_,D-?#C/YBM6
M,"N80ZXH5G!`/T"'`*F>P..*;`^O&8KT5HBHZ.DH@S.W%:DTON`?H`TL/8RW
MA;M+T)IB>X-9&/#J\3E])5JXM%C!774?,"T+S%*UO^.8F=I)D6#-U+8-T9U'
M0:O<1A6ZTUJ`L?WW\Z2\L?_^Z+?ZD`+B2N7E@?N[+_)6B$_C'`F6.K9?GH9C
MFT1ZG)"0UBY96Q0W2B6N<:(\)&E`577"RQ*0J?#$6Q30O!;;`I#:_UV44+4;
M>MMN:(5<'%C0T'%#&2/0D>L3BB7B)H`5SSN[<H@Q7O\[BRS$)O``TN\=-J_A
M^ANJZY:D$OV/\(%&Q\]?J9II0O8W<)XI%K-_O(4/E'Q1!A[<JG4XPA9%$S;%
MP7VH$PV#499XC'1X6R*:T_Q4$(W(::A:%;+O4#U-L%$K7&^"9>38@PJ.27=9
MHH"/V0XIF0IY4=V]Z#?.+R^-0VT=5UQU]Q9A^S,Q[@-7^,@I2N^VP)%A0<)_
MR.3FXZ95P!]QENI:_B&3FLGH*C&WN=M2%=YRRJRK0J6<SZ99D!ACY\Z\BX!/
MB:_NCXH<F]TDT.R\5\AI59I?H!<>S\"!0Q`';K-R6J"K^ZO<I_EM57_9HC(P
M<7W82.KDKCQ@#&C+)\D=>O.X?=[3LP\??Y=GSTP76.)\,V!1/W1+P"?GC7:W
M1P8SQ7%!VQM1^XM,"K^A0O0H>KKMGN*ZS$1-!`R6)86#+P)8W8$21)0BL^&_
M@0VB%$$_1JJZ`!HW\<R5*;%1;I^!+LIH3(:Z`[P41/4DF)5ZN!0TG'=8Q8+^
MC<^H_&5XD8\J*8ORWF6W[EUW&E1JF3T'`]N:QOQ]^GPB&;J6=N]BGQ>>'#9V
M@PA[<&K](G5_H(D@4JE5>'B/,6P"Z@`TC1,5C[[C3!PD56[0@U2GNH$VT'K!
MH$(\8K91]0YJ>8>W4]L[.-;_"-#=7F?"6%K9$*T5%=K.AH7V>\7>2EI=@Q^8
M.PB.&LV_MK$`&CH",<I"NQ_@HL6;2+J0F+`<R`EKEU6:XK4D<T!F86ITQ:HE
MD..5&O)$,3H,$:#XRJ&(Q`BW`ZI:R,4ZRNY$$XM`@'QU4>-3@`G[9U&5;.(#
MD56+`[30?VRT5BL7#V10J@D9&,`B25U$:L#.&=C<JC?5(N.KVI199J?8]LP7
MD]KW!OTV<H_&S`Z&49R@4G[9<O(S</@0]DY!IPW"NGFIQ<L3]IPO#I:O`]'/
M(,F3@*0KQPJNR8:IP;L=\.ZI6YZ.K?'27SA]`%R[!;M6?W6W(C9W3-P6*JHH
MO3:G/W^Y)G,:=$1=_(GJ798`NL`E*"Y]L)>QVPE[<:<D.4F.2A$%<6*G@U+O
M=[2N.6^@[,#/U6MLX^1\G$;!,)/HBL)TH!OA?`K=J.5\C$PZ?!ZR<57X&U.M
M&EV5SXFKYTDLUN*M%9:&XU2NMV*?[!&M<!9CD*/H;+CBE9`?00I>$`TB&,'I
M.X!.L*(<4SD;B4=6T06XP+SW_P(U9*%Z8>L@?TCQ<?1&=3R5NRQ#W$KMT:.L
ME/N#1R684]A7(=>C!.8)I%T,'IQTL2/8?>4PS\Q-C%.S,'1#A1PQFTC;^%(%
M#W&WZ/@@'D@]B/-.QJ[GH>GDVY'861+`DV;8\/KI&5W_]^OK3R!23%3.XK?(
MG=WO>6=F%BEV2V$>\C(:D:>5)I^@!PA?J6:B(0MFCPG>JN-J@7J4;PPUM6=<
M(W'Z!?<4&WK/32>I!)3.[ZI:6Z*<MWB-SD6UNBG,AQ:ON7DT>W.0;V>AKW+4
MM(C`"6P&8@MD1)']HV"(IIE\\7L`A^##>5Y'_M]C>"_(`C"-HT^P0^]NQW9J
MS>&64ZDY',(6.AY'G4\M.6K)<3#)83O3@+EGY*HNQN44NXTH!`>*N^?*B3/"
MAN]*\<V]Q3PI`"T*_(/8_+(IC+>"0H'T0'P%_8&B!#1PH9CLD_-&[[S;N.AV
MK7$`Q>094[$@3;"!P@,L$C@D0'NCH*/:4A`I0P4.#K1Y0=W'53@/89&:V\D)
M[OHW'/>@#)4;$<8S+*'*:$>P3*N.+LFP("[R2:RH%X&`]L(@HC$/ZG8V2K"4
M+A=I($5<ZM!/TB$!^<&S+T>)"V>8>;0Z-79`3R1C.2915DD9@_Q"*<4U&()S
M16;9$+F'\O9S2A?F?E@)WJ-,S3ZP!/A0A(&XT4"U0YDF^#)Q;S#2,AK!`5"Q
M<Q91LCG892*E7<3PZK'"#EP41D@C-HM4*8F1R6L*9&-R:CL,[O&5SQ<+%W'H
M`AWY?`3(E4N#/P9?>,89\6B/>33'C@L1D]5+]6,"DCHIJGQT?60E4S6V`NLK
MT3VBXSO&3(33H0".#O@8'W=Z=[RIWD?+YVH9L1T9,0M=C@C:C!5)GBA=\=6R
M2&"^SN7!BLL`0*DF99+$V7BBV5.<H'UQ@YQ`4&X@?N.+H=5"`0&/<P;%F-A9
M&+K#6+VG`:J^!QHX<;PDP70,HK(&6P.40`L?QC@7+2+V1JX8RI3E%%O[KI;S
M/_$M=F0H5R5'*N1,5@='KC-@QB5.*LU$-O?&#4(2+6"9844B7(.?:&H/![I3
M#.*VG'?%;!&LI$:A4'[PD`MUJ/R-H93G]C:*+"\(,S((X9#$CT"F'.:U\H]O
MR?Y@WC.W`.(ZO-:8WP&[\>&=>$!5DL.^F5-I4+1ZRD^'EB#&L?V,<UP"2A56
MMU*F@(^#:MAR1."P")/9#,MC$CI?U*#I[2H%@"+>,T`[S'&FY-'G.!@IHP=3
M"G2&3#,DQ,4$RED2PZE/RW;5)M:3[89[!>H*7(W_O,F5EMK<.@*V]4JKE/2'
M=3JUL54+TH,+4ET]+2G-"<NTPSO%WU25-&N(>BZ]K_.V@:D%L&"`Z!1[7IA)
M<5;=,[`]'EM&W3#*%A7KL91HB>+`2D&/:69O_FXK]D$V1I!4Q$A\DV\58,%(
MG*3YPMC]IIAJRWFUT,C3^C']`*)A0G["R'*U1:`'4&('PR%7MC$%+4@SI0&P
M8:3O0AF$=@MAGOB!=;#.2/C*O0EW9FCJ4GJG+%9C<&))2CZ]),#J49^4=Z7A
M8)4+"7UVC"IGI!Z\IJPFE?$&CX@EBT!\@@0$#\!8PB"0!Z^'BW!$W`(_WUKR
MQ19(6*%"!2I6?0I??FI"Z?&UJUM6/53W_ZN%T7[5(Y4QMRA2DK","#@MU>J^
MQ--!3>BGY;S-?PLD-W;B>BC.`.;$>%5D2/82&QT\K%H$-\B4T0I2:R$KT`TX
M29>`2V.L\Y*JIRYVW@M2?N0SG<NJ(E.8,P`B"H=MD\,N=<<BSJ066CI-U[RJ
M4$U'XA6VA\G)^&J7+17=(T`]`PL>R=VH)!,^SRX\H]B^DT\X3H4WB4`,`E@S
MJ9,6Z'(;KE.L69VZ(&\Q^QB?F7%\.1X"4MZ0'19$LTP=%K8X*%^917/7MIQK
M^R43,*1<T"CN['XWJ#J$Z)$D;RO?U\`_69KFO?/2VY@10RDO^(#\A3I.%F)E
M1"#MJ^R%-<BN7`B'Y1-$:U)^*!M<"+>?P'A17=`96W&?OY[QZ,FSRJ&C#YTL
MZ@$ER%_/?#D;834TO7<'\T:[[=9YWY3S+^[YKB[O=UK]_A8*]<N=X>%$59P3
M68G3>;%Z*6Z6Q@O0;E>+,U2!'PR+YMG&"T0A(+MJO,)=#Y484'[.1+A^@,D2
MQLVG.\O(&&PWN)\M!>G\F<4TG!JEEJQZ'!;W(P51B$@MQI)0P:*2BXUF`*S5
M++_F'37O."#OZ)X`[_@XIY4]Y2`"5;4I'EBD^6<;L0()ZEWH)M6,H#'_"'TO
MIU11$5BJGUMD+:L?;B(B:FOFF9:ZA\YU-R(/4YPD,85AN(F5=9'2F$$C=FO>
M5?.NGX!W]8Z3=_TQ;QKF5(TA-DYM'*(3.DV9O*-8TZ_*4;E3-IZ^S7)E8ONC
M4N>]^8[-"[@->W]5=BFI3M/8!VNT0?F=Z&`5?IYRI-J<`'F.=<Z,YF:YH=W:
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MU3EJ*CL/.ZA@M`=SB5OP%DQ9#ES56Q"NS$N#R.JCO5$,P:6D/,QC;89!)$PG
M.KNGOBYI\='Y/\I"T`%'1C/4C5F4AJCZZ(68!!=A%T&5%WL;LX@Q994MYSVF
MQ(K(9&:3;$N4<JO2;U5R&;<1Y)=J7Q]W;M+-Y74)S^U$1"87ON7\$S^J<]'!
M,5!-.:ZO6]3H+:A$;):?V51UIO9M8.+](,]B"GWIA-]"+@'B!;;7(5T9&V,%
M,J\_T@$O*BGBMO=6L"IUO\,29R'01)TH7'/20TEWP[D4MF,S4Q7I!18$)$J_
M(:'1V#/J@,M-:_-&:EZ0``5QQUG\P@=;4U<):+TX;[5D`LB8]F/Z0GF8[HLZ
M;<OYK#_D<S!,MRJX=B)"3CJBX"3VJF*]DZQBEVLGDD":IG%+UX#,)&=X494A
M2ZE!:G8Z+8#9:YIW@J='F;3<\NLXH8DK1?)WJ?J5!:]$Q=Z&/_,^YBY>#.;\
M?ZRW\VO@4QX'7K2&)?9^S81J)K3G)$L6P::63>=\4!\2HG;,E^!B`20^]!II
M=Y*2K5@/AGD2=K$7$0R-TY`%IU5>=3`20B=GA#CG!C0AE=".J8E:U\K5C85O
MT7J(79&'Z?*@W^E"*M/#NYRRR'[^$27N8'<X:C/)40#%&JQY.:Y'5=N^@DW#
MM/2P-<(%;Z8J+.(GUALK7]=R/L1T*'/U:5;R2O5YF#YY]H+0V;BX?\:Z+H#*
M%L6UF^`(:'CM9L4U(&M!LH]L?6.;(=]$_ZMIZ6FUV5R0/F*,X'P2D2Q,'<I]
MHGF["(JS8.M.5XHE33`:JBQ[91]E?(_II8R541RJAC>H'/3B#;JN%J`X97/7
MZ,*9U/$=,+I9>86G)*:[1^C>*N-;"SP0'X([?)!971S*Q$^W%6%LJ9%(-799
MW4C3)E0BJ>KRR&^DNH#Y[JKE,RCJMV7[V34%NC+?F)7)>4W3!`%!L=$39J?"
M!2%/TK`R67DTB'JVU85J05?5XB*,KZ&FTYK''8;'+6_V3(3I9]QE>!G[T\-;
MV#YDXEK4]CDNMFY^ATDLWREU#O-D=#Q95_=:?0F*U5-6ZAVU?KT1Q6X5`N?O
MP"9LI5UZ$]A.B)HO\1N7DY\+S*3`:$'Q_S?S**77PA4JF(X@:'#K6:PRY2);
MKE%63!$3W?-!\)B"8QA!L;WSYBV<M]NUN::2FL/LE,.0"$:$M[":?>"+FCBS
M+WY%\W@2I>H6HWA(@*C+8W-P?J;XX6IN8G,"H+R8R^2E'DYNHA&SF2#&@`DK
MJ6IBHET`>(R%``=GGV""W11.-S4=*?6Z5G6=7F*>JAD1GQF`^+#:3CT"Y-:C
M.ZQSJ<W5FM$>G-%J5^!0C+/(:GUA"N2*O5GTY7G\@9D@(S<W],J;>55SL94<
MJLC.V.]Y'?FO<Z_G&W9Z\GTU0SL,0[,<TM;1..IL:F]<S=Z.`#/M4,G3L\\$
M5_S_UV?/=/J%<BI10*&4S:%;QDG5(4(E[]`\R!]J*->JR(P5E^%Z:'><")-4
M0X&-?#2JIR9@YD^-D[$;J1%D*BV'^FX$RF(%A1%/UWX(''LV<K']'RJM\P_`
M78`%B37)OSAB.@OC.R&:6I/-4ST+K0.Q)Y:;D'UK+$Q*J,8>44W6;C'N#?>R
M[JOC1B!`)$[4Q3S.FSB\87L4/:-VFT-:E^EYB$T1JQL?_L*#U`!GE+].+;=1
M2ILQCDOT2WB%C?U23CH@5R05I<3)G6XBM2C5=`V!5.CZ9('D,T/X%:)3K90?
M`:>@X1O-EX2[]D'5,JR68<>`F15<E4+C@9W%HUP:^:R(HJNA(M4&XS8-TX-!
M/]&*>KB&K6+LQ!UBANJ-:KY*LL?J4OY/CLKC3R]#%Q;]Q9O$V/.=AXL7ZW1(
M**BEZ]B0M?#B6HLSRGF&<L)M&//(TBA&OS/%P?)>\75CB+HQ1%T@N6&!9'>#
M`LGNQ5QUI+R;@@R\1[FAPKS+WAKO/4`UY)L?(O&P1S1W)6HBPRL,G4?KH7")
M8;\W><^(G&$-,3(<T#`-I:J:D!1U/LTG$#%?QW5KSIT_<+M%BS4]U_3\L]#S
M/V(PPCBKFU=ZV>T`JOPSKSI1L5)4/IB@;_);#&T#7L-*P5R<"6J./.%V5VXH
M8QUN!3,1%"?;C)7888S:SD>JPF0:H`IGM3ZPV(%.^^"&U_#TR*W)OB;[FNSO
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M>2#8[2-X`+_G+_!1FA:42<@3L6Q>K[YBPONDZG%Q[06::Q#"X&.+>)0[>:LB
M8<U")(QKEO)8%U8QV`#2FATZE=C\0Y&%74Y$TQ18S07E>!86%>:FCG#AF5IK
M!&E3-<?J/O+`3F_X(L8(H\^Z&JV>'W(<-*K.Q7F7!QIJ27'<DN)QQI61R[TU
MM4S7^73X+RFP*6)Q+V/XQWEZ]O;ZR\NS9]77O`+^A^U#20EZ>@9B`Z[\$+><
M[F6[X9QI=#=\Z`R]^:`\!W(BJ+!2/0?%5%XZ6PC##7'(+?]&%I_D9\J6\]$4
MS.KON*U3/KX$4S3@5/04>C#?T4R<T6Q9?C";[%+,7'8H6,T-\S5@CX0\&JCJ
MX01'_:C\;)R%%%10;5>\22!&5CVO+[Q`XH-P@&+2X)&8_%53E<N-DSB;`01?
M?7S]_NP9%K?0)53>,HEO:?24RIBC<A?N2\]IAU2W)Z7R2-*R(T]5W^+SS%*E
MS@CG.^&=4F(M#"4-&G,)OL#YCDY(#E6J?0-(\0!E]I2TE"2.EP=45*-+DZI.
MHZ+Y$T51T)L;C4-1<;H+DOS6$FOE-+]$3+"YQXW@,IU:%!X'!RH<C:/Z13S]
M'5#R62T2:Y%X:(14E;M/L>3V6<54K+R5@9K@JUS"KHD*45?`O*N?M)*?5:LT
M2JXN-$BCF]#>B&\CN$[Q^6*S2<H)5#U_J*8;B[XI`%44=UYA/]R",)J;SYYC
M3.7T\W*/@]S'?:>ZPNGLQ!:V@"V!+=_Q_&(:W/1BI-H0ZS1WK!QE)WL#ASG3
M;#%L5E[QA);S5OG_N9TD58Q3[TH>H@FV%=P\WQ:4+L2>FPT%C3DX86=0')(<
MZEIX7"J]<K&[;QTQ8XNF-VZ"=>;RDTB^3`"4M40Z-`/0)X+8[D@\DUH0';<@
M>NQ>/*YX<=`"(Y=<=X!650%/B7>TSE`C!S04^B?%@`TF\S0_U>X7S!0*=:"\
M*M]12'N$.Z8X*->>-Z]LG+FDB"@C)LN"A^["]X(DRE*R\^`E+><UCK/'FA_]
M5MT<-U\H-^31U4W<:@B+^V\*K838"Z="J]2JL^3!7%C_A+6TV/R/^@209,67
M"N[785ZE7F`M'J70O"Q9(!!6,/>"JTZU,?DX>DM=2=[C5,AL^AGPU`VUKQ,$
MG;%V?Q?84>HKGM$NI,7:<=6'LJ<'NH^KZ&]]4G.V&,`M!RZ93<`[;A04^8NS
M2@XXS\ZVX59GZGQ!8HGYBE:5L.<V:D:(T783\GDVO2`.O,EN2U+@80]$/@^G
M!%]T5\7(YX&Z]DNB^#9Q9[^>\;^K=E$("R\-[W=ZO0O$T04+<8:N]QV=0)'?
MU/+,\P1PO`/A$;T%V</:B*$W.MCB-M="(/WB/KYX[:-_,,2W`-\G&P.W-RAO
MDMJ^'O4NSWN-JW9[XZWN[CB/B<A'])\#$_E@YT2^;)M[)O*M+64;M+C1\6_A
ML#N#?N/B(,2X:*?'1(Q'(7$O:HE[(&+<MV"\[->"\;@%XV4M&'\2P=BL1>+Q
MBL2K6B3^)"+Q$&1X,&FH?(PFKM`].1%)WG-WE(KD?A2Z2PCLE&S)>:R6W2P'
MH(J_ZH(=?$/Q%Y7\3+'X8Y/(A]_@4;.772'NWGG.^<GI`U_CU`VWPVZVN?DC
M8S?G"ZG1C[-A*(Y"VN_#__U(0=>]ZC?ZVW,>[(HR'L+/\C)+*P-X&]'RZO`[
M!>KG:FZH$N<C%TU=<[O3NSKV?C2Q][7D\#3P?2#;^[/M3:3]CM^R:"\/BHX_
M:'\;DOB^H;H`@+O0<)<<2J>]6D-B@M]5`HCB8<['/*5I;>%Q6(Q90\G=.L7O
M"PU7TO$!,>8+)_!=ZXS`!Z#+SGG)T9S7<8-E]2YZ)["+GY$8_ZGR;8$<*=_V
M^(BQ9M.'P0RLG?T[];>*1\>'%?59V6?U02?)G])!U4+C5-%--\D^/FQ;0U@\
M)M/^.(S0@^.CLD%/Q.ZLD>2`9N?)X<AQG%[OT*?WB5JSF\K$DSO&FM3WC2PG
M@B+KA]HOKMI+5)4=!-4+<9].N]7NS_6&W=J1O71#;%6!U;"Z?#`'6J]#5;'G
M&T<E#Y:N-Q=./F"ZWL7II>MU&N<7[4;['G'HW0'^WJS_X,A8YXYNCHS__5\%
M=+SHW0\=CR:+=,'2'A\ZGFH^T>%WV6Z==VL$KQ&\1O"C1/`-#(7N%8Z!L1)3
M<<TOG$&[=5%)%$M,B,/7`N@$$]649^<VP-:2XQ^NBFXO3W\+-L"^<^J?=NZI
M<^T.[E44NXNM5W0J/58DK\M#'V;H'LRNV%*ER,/5KA-!17/ZK"\MZ4/X&-&T
MU>D[3>=)KU7CZBGAZLF;"/O>9;?5W;PH_&@0_#`FPN%+][2)H">S[]Y(J`,%
MQV'2;UYX6P<(Z@#!P9'P:)Q*/XW7]*B0\$C@4N-*C2M'Z*PN9-T\)@^VAQDN
M87A?]?1HFMI4JU#__5_'W/5EQYKPX3>X"\5F<+E5#_R1-+<Y=O*J>T8=W09W
M$M^Z+W4=0>NHXPAZ+=8:CHAL]]J,[[C\O*>V]6WFAQRMK*N)IB::FFBV6Y*Q
M5I>S1U>G8::6684::GS9=@S<@[51W#1&<`2]`(_.OCV-;H>-=G>G)NZ!^AT>
M.X&=8)_2H[-Q3X+`.HW.;JW<HR&P2KWZ9`CL\)CR\Y0@;#N1KB:)FB1.FB0&
MO4=&"ANTF[YO=^A5O:95S^IKG#=M/^T?;IC1*ZZES*;\W<[Z3B^U6JW.SNNV
MG4;\8=19C6N50],7]:TN*UP5C:C7FDX/>QXFCA>Z4OYZAF/6!6P`WNA-W&@L
MFK#:,(C$F>,\MY";FG.7\)NZ<2OE#A87NC,)V]!_/3@J[6RO4[9><>>\L\3K
ML<=H^SU2\PM:M$$#=#_I>)':9>_B<MDFCZA?CI[+_0'PS7D/UTRD\P9HR;?`
M8_XJ#J!?`;8-9H/\%#C1N:K,VUQ[DTI"[P8-[N.,ZRUK,_-8#JV_M.W?P0]M
M5:N;-8APL7KC'!U]O@8-!^2\[]P%(EP_/6J-+1X#<2HU%V3Z%G=VRE2Z^MB.
M@3SI-1^N=T*)*E)U?)3XCS@$\R`$>\,9N5X:KS^`;XU='@TQ7O0?2HVEK3TN
M:BR?VV.GQJ.5BY\#^;TY2H1PR(P4,G42-UV_M>$I"<A.:W#9[+0N^[64K*7D
MD4O)-S]FPL.I&4"44^?IG7`3N7[^XBE)RD&KVV\.6OWUHQ6UL#R2H_O9A*4>
M9=-T;VB4#2BP08*>_$PX\<B)BWVD'#]+@FA,3K(9/#7VU^\-?DIB]4FW-5B_
MI4$M48_DV#8CWCS&I#ZK^Y9'G.X?(\+H4S3-Y`L>/*,>*M_\X$"'7QE#>I7)
M-)YB&.FCEV*XZ+P81JKZ_F4F@TA(>>W]F04RH$7]".2W#P+>;GWY*DYF[\F#
M?>9D4<`OEK2H,\<77C!U0_GKV;L/;\]^ZW0O+]$M^+?GR[9@!]A>84#GX^B?
M;H*\XV/R&8_9W"<\X"1I(.0K%XO[7MZIZZ2Z4%9"XUI^^SCZUKGX]K]9B)ON
M%H!1^?V7%'1_/+$WL._T#@.&<82#:0DDZJWK0J''OM$<0QZXR?W`J]<&N$05
MR%/U_?48+"?"<(0/8?BG#&-Q4IB?X"Z!=S'8M@OBSN5)@KCS[3H;5]+G_/=;
MA5>W^^CA=6B4[/=/$\+OW:0B\:#J^ZV"Z^H4H058-JN"5L7W:_"PDR3)#4"P
M7809G"2PE.B<`];\]]N5CZ>(6H:KS_&B^>^WBUK=D^3=%<EABY+&#BX=SW<'
MX4])/`.K\NY3"%=<1SXN=X;K?BUF":R"[*WW(IW$?C4X-\_`^Y(F+JZCB3EG
MSI2>G>]MDP6MM9$W$LQ:.`S_#RE&6?A[<".VM9/T-G92^.\$(R'D;%UC'U7K
M,7;K5Y%,/XX`+V(X,3^#O_^(?)'H"?8&VU88LLI&ZY59P?SW1=3^(X+5)&"Z
MWL$B`BGQO[-98"Z2"KO?!H"Q`I?NOXM@;>,`K'"PRD4J7]Z]=_\=)X2B]$RX
M`)O+>&GFAAHH"O%_^]3_E[)VU]WXG(7_>^")R*+#ZK/-0:..L:@3=Z\JOB^"
MAGT0YKOM`B+G`&H[WUS]HGD#N>0?F`-`#J(XA=\^D1/Q;9P@B(.(Z.<48?3;
MIT'[M=[[PIW==_.;$O^6=E4"X&<A@8MXDS((*5$2F,B_X->/H^(][_$&7)NZ
M]G<Q=L,W40I$O(RF#51[-50KH`J<\JX&ZI:!:M)Y]P79SR*8#K-$TA)`-<JB
M[Y]`]((0_H$U#0L4@9P1OA7#>1AW+RN^WPF,J_FI*G7_,A$B_3WV7.-\OO:\
M)!.^%@B1SWLM`.&M$').Z/SQY;4M9D"SN6@/+BX5G%<"T5;#/L)N8$71^'<!
MVK%\FZ59(MX#<*;95/GUY>M,O,J29)$:L[F"OG0KY[TK6W?>;('WV-J[Z.MM
MC-B_+?-CZ>XZ@_[%/;:7+_)^.T2-=V][O.S?YP3M5=YKDV_C+-GE'G_(X$44
MA+^>I4"U9\_OMT9@.,>]QJ\3D0AWE(KD:)>X#QSN7J&+>V,D-I(,Q!P6YKAC
M\7&$2TPH"59S8!1_<0IR%#_[`3YK'1MW+E:U2L%_!S89O@$^YXN8LPZMG_"F
M_./'2,S)GAFLU895]^RW=JNG@Z";;_MQ00RX]'H0Z_0?!#&-EM=`JV!2@M&]
MW->X=J3<=F[].4K+LKE]>9'31/[R)43\.5<\/HAJ!:*GCHR=':N/;"GA#KI7
MYPO)MKB8AZUZ4T1;ONK+\PU6_:!UKW`;;+STJ_82/KE-@-\C[V/IPON]B]Y>
M%O[V7TLPI?/MM?`V6'6W/=@/N(M4^4!QVA\,+O>S[(V]PDNU]8OV5:^S$6$2
M4^<<H.L;-P@QWPFX^-_)\S]2F5'PG`B>HIN@;<5K@([K#^Y4L"4ZC8)A)M]%
M*%M`Y\0?K6@'I6I]O9OQQ6^FLS"^$\+*W5H[]'9^8:5`;;;MWU9!BV_ZN\JS
M/&$@]=:`46&S:X+FC9Y3=$K`J=#_U]CJ*]WS_I2V6HZ\7JZ-!V:[*\&C:>L-
MQ5U.GZ-TV]T-.$IAUX5>)I7]4*XQL#HF5?[E774"JV956:IC61RXV59L^C`<
MJ'-9C$AO'3R'@OU"A*[0JPX$^XO>"<&>R`N`PF[ZOR>QW$[P_8AQN6++)P'1
M@^HR/SOP/^,"5#SW!SH!CYYEKX(T+O&=E)GP7U-%$U_'`MBNZG@L2N>VX`HZ
MR4BP9TX#]Y0@LT!'W2%TC$H[+\\^)1PAID>>GI'\QY?7WV:83(C+GW/YGG>5
M4KO1OM>'UO:MY34AL!%4+<;)T9-5T6V`72=WEV\$A4<,.UOH+(4==HC=)>QV
M8'<>#.VV0+QS!NGCA.%B]%L(P_41<1]&O2[RON8:;ZW4T#I.P]1?CJ^#WDX,
MSF5@.ZZ3.B+'P&K.<LPG)3>R*S8^K1-2X;JM[M4&9[4]P&V%LMZZ08(5^<*J
MQM?]9W3?Q,]NNLXIK9-5L3'D.4UB%X;:%G>^$T=7.4'D'-G"ELRP=?>^<T#G
M#0%_/B3;>._[0[.+_L[1K+C[G0$;>]R]383`;&WL<'>,:%;>^W#UWH>;@!IS
MZCO[Q:_?/@W^U7M?0J&=[&L.<XX8>@]U#R-4!X>!ZM9<S"6-AGY\#41IEG0H
MZBSI>#OT#6\?(#N1#,N5WL$F2N]V`5*JLU6%T2NR`]?O6O';ITZ[6-"JWK#;
M]VY4;#Y7<_N0)>ZF0</*)>K2UVO_)I#QTN*'/32R4JN8SSPI%>KJU9IM$$IB
MEO9TJD;KE"OV3Z[C5'4ZKW'4K=[QEH"S^UY1%<F=G0-M===-B"K2RR^N^GO?
MZ.Z;YU2<Z2%.=).-OHN\>"K,=@OUH'\7$<C!\#KRK_UI$`4RQ63C&Z%2C-?8
M?J\[.,C^=]WXI^*@SR\.R*5VUK.GHI@2^_7L_T2W4T6W.=]9*QV%OW\;)U]$
M<A-X*\O"U]<H/HL06[U\<I/T[BLL2KH>Z:TO[^Q?Z`C?8@-8D4@@5S[&CZ.7
M,6BZZV9:7%Q<E'Q\&VUY9\"Z5ZG8HARFSE%N<6T!O$:Z\OD#-VC3!D<_=>?8
M4\'O:BE<I/J%.UOCC.D1ZQUQ;YFMO/Q\JTKU+]<YV^KEK8V['\0M_;3RC!?L
M:>[[=7"V,RC$A]=:W]9W=*#6BOT-6-)1;5YUD:/7J_8L22#D]:=$C$22".Z]
MO7:=Q7'`X;U[MX!4R]]OOVOU*6Y^NTC0.0XDJ*XQK?I^NT@P.-'-;QD)RBF_
MZ\)A3=&]2PE7T0FI>WYU>;6>U"YMQE98M$W"=QY8DE5U.>C/Z5C%)9=UR\TV
MM'<S=UYE?/!V-@^<',[K>LG=9M;8O_9.OXMN!!Q7=6W<PZPY_>@*3E%RD>LK
MS>I4<BVN&9,W]32,=Q'#YVT0P=<X+N=8M*,%+D1S&.MN:-L0V)]4J&@Q<3EX
M"``XX*UO*&3VK@>%A_B/[P^$)1%0X\/::&^%QMBVUVL6I&[(8,2NC,D-68[<
M4DH_^C1RD!<I5G,#.#;=_E:"\,6)/'-%Y"<-8E,FOVLH;27KYLV/69#0Q<=>
M(*=2`K:^X\HV9_QFXB+7*;:423^.3.[#QPA3(3Z._K[86W\4$%O:Z*R3%WW<
M<^,&<!8/^4><LB*O'GBBP&FW.AHX2S97B3DYL&Q(/@J$Z50AS.K]EO4/E4"/
MK(PIT'Z(0L#CA9&54K/!?K8B->E__@%JO;&5MY03N3LX[6+/>X7EG+U6!&>W
M7?']EVPHQ9\9VIXW\#\&6*7O[U'G5P0^Z&@ID%M:4)V_?0U2'`+Y+O*QB"!S
M0Y7L&KD,D>O(IVC1Q]'K(!'8TE*:(^OMZ\CN([A75E)]%E,WP`)M/#SLU@F;
MQ[2W[C%3R=6_NN_[K[>@U]P?/-O,J\5SAS=&ODEECO$KBT=>C\>)&(-\>`>K
M""(9>(LS;(].YU^0[K+%M@SW!F"A^6P88OJ2\*M7H]*6=M\\U8++>DO:R2;6
MP)K=)G]U![VKR_Y#8&%PDX/8U?=]B,GI)Y@#2VI/;/_^*I;IASC]EX!U>O$X
M"OXC"E.!]])E__SBHG-NA;CWLK.]@-+,SU!?X77;4=!`3)S_J_.^VWZ]![A5
M;J.Z\VLLY2LW2>Y&<4+/W\L0BG:WMZ"O<7DY]J)S7>F5*W&J"OZ#;L$;-Z2H
M0$JWPF.V*8V6IX06*_PV7*&]N=?*@XI=;U_!OP$<:N2M'@Q257!_G\['EVV+
MN2U;S#86O37P=[N=^ZPZ@0-!]O][X`ZQ=C(0<K\+[UY>=7M777OM2]>T_^5_
MJQRK:#G]7^H0VEHQC_MO%\1Z@OV@`9WIWW=1D<J`RQGV<>W!(^E9N^]>72+]
M^RTS=S\EL2>$+]\F\53!MQA461JZV.K&SON7E[W>E?83K;NPO)=N$3V^P@)?
M@J[T?4MB]/^&Z2]@%CLRO0O%KV<C>-`+9QB'OM-IS]+G49S`3IR_IL$4L"`2
MMPXLW(W^VG#HFX8C87FC7QQ\>],-@W'TPOEW!H;NZ.X76&$8)R^<_\-!2G51
MBIF<((^F+YPHCH3Z-J`I%B^<]NS'+TXHTE0D33ES,32%U^$B?G&F;C(.HF8:
MSUXXO5EJOAC&:1I/U7>W<>+GM]+S;B=!*N@[D3_L-O#C6_G"Z?SB-&_%\'L`
M2\.5`);%WT43?DXG?/_9_QVGOPQ:#I^$\]+19X&P>P[`P]__^[]J2*X'R?_K
M3F>__)_.H/W+&O`[".AZ`]S^,<+N';F!_YU%E`D-=Z<3)YV('#4-,W&(FS@C
M'>!MT'6HZ;K1G1-P)LJ@<=Z[:`#C=6YUH44Z<5,'%&='Y.:U@U\Y,VJ+$X^<
M)]CBS@'NZU"\S\&!+@)#2`)>=Z.&U3HC."-Z9Z!9K0_V7<OY"E^9M]T*N.D&
ME3<?7_*DV[CJ]1N7L*`,NS#\!Z/N^(R7H>M];W[Q)G$(V\25X"_3V!<AO1ZO
M&<5@0][B]VY>/OYBES@6BE%Z/P3KMZX>C&+J.UP$8$BKLT.T8\"EC`NX]U_/
MT'V$:HJ"I+JCTV[_Y1<'P=H<N=,@O'NQ&J)TM00[BT_BES-@FHDO$I2>#C:6
M5_LQGV>N[ZO/UN(2ZV^_O*Q.MX>PN!%)&GANJ`]P&OA^*"K94NHO>5[O:K#D
M<6K]ZK2:9?PH_JJ>V,7G%7^A5[YP9!P&/@`%'@.``,CWSBIQV49,/IR''@1_
M<4LN4Y9D#"G0O8C@/N"(;1K)*9TW@-F^!4+SEV/F<CJ]=F.>&@N`?EXXQ7V>
M:.>JO^\377F*"0)^5X>(:N"*TY@#4K^S59#WVS\=R,_W10#.$`3F.,&R*`,[
M#RR/T6@-*+!<>R`7Q[?HIEW.72!"?U-T6T63#]CA5LZ97H/-S_ZR54):M;%M
MTMA1@/##]2&I8D3_V2=5Y#W&G!$-4-P]8:R]R>V=ZL5^*,/>V6XIXP`P/"QE
M[%]>8%N\YB@18#2JQGA.`D;CHQ0<G=9%OQ8<)TP>^Q<<.O_!`=J8.D_)S_+L
M40J/\]:@4XN.TZ6-_8L.G=G5=#FU"U2K(&'7(OHLC<=QK.9F^%1?27Z,&87W
M*[SYCT#*/&FWS@>UE-D?)3TG+ZGUN?8]GT*XZ*<!9R'\4H[S!)'CN7+BD(,7
M"&\\<5SZ)A12ZBN!82;Q32"#..)HC@D^Y<\-9>Q,@!/#[6>PO*A)5'R&=Z:"
M8U<CX6(1'3_,1Z4FYG"1*M.53C`JQ*RDR14/50!+XD*E"#$&=,?!*(G,WJ,"
M%<",V/O>X'^<F.-!#8>KD(GEX):E\$`24(Z#%>6B_:83-Z(56!N?"X$)UYOH
MC3,X^.D('G5]`(_.X+!=8G*P>-?'Z"0*(0"-WK=Y-@,!CB_#O$MG*%!.<<"N
ME1/#5PLRB;@)Q*W@,)B'B2;!*.!T3?W`_&BD$^8Y(@@-096@#C50HFO'6>!3
MP`[NO?[RRCF_;#<[[4:1$)'>;-I[J+M4.6JQW#+PM/>0$N:S0$X0!%9J"P<7
MN825N`(^`F]I4#003L`+,\(IC&:FE3@J)W$6^@!>`S&,00*`#'SN^#PUE.$Q
MD>/.9F&@()U@%RH,>%JJALMYK`CYJ4@GL0\<97P'6TS,3UKK4)D@A$[]5AND
M7ACB?8GP!#S5SR.H9O$FF@O+3F^%8/2T$,XLW41%\U"KCA4#D5`1A.-.@2@U
M@KDZ`5?C8RF2W'*N`6:9-VG8C]6[IET4(CT.!AC@,HE!W<NK;J-WU:5%W<(V
M$>I`SO\&5H"OL^"7B.94N!(8`R&_.CUT(<,+B-82,8L3@B+K;2U;+.A)S`MR
M9NQ$*+O9N$BQ<YB%8.]Y#?['Z#/R!U05X8(/<93HCR]=&4B\GP[[J_`F40#,
M27Y%1KJ+))V]15_K\&L=?JW#KW7X]1&"O`Z_/C;_1AU^/7%/81U^K<.OQPK#
MG\V'7H=?:\%Q,N11AU_K\.OQ0O!G$QUU^+4.OQX#)>7AU[R6="^>WD(#S<IJ
M]575[)_B,/#N=EG6R<&5NB9Q/BJ:GXV#I[)&I+F&Y58"]@O!]C,`JBJ,RNRO
MW^J<4S"F!-#]_F5'5K<;\Z7]7SN^F,4R2"D$J@I1EX82DYQ,*3B*,4T_<6]=
MK@*="`SHWCDNB*[H.V8S<%TH:.OP3-?Q4-!19)R4$O5VC/(&LO`C-_K%M0"^
MX:BA!-Z`,=P9=Z?24745&OXK7$<-,AP/FZQ847K'8BR46<';>RT\M;L.[>Z<
M`Z7MUAS(\\#F-H3+5MJ:<=C]G<E0D!\!%,G7B1M5SLW]Z7L(KIYI4>Y`O:^C
M610.+\_>UG&$[4VIOW\WE$73ZG>QD9VV=2GWDSW''KM%/%AW*^MN/_=\G_Q)
M;KR5_9_EQ=IG6=S,*A"@E_9M(K#7(?EH3_8L[[F1`U!EYZ*__"2KMK(N*F/#
MT<-L&WOH7;SOV#WT5BWT$!I$J6DK_8C=M,U:#XW]I8$<2\C@E$"VZZ9F"V>8
MH,]L_\K02I#-335:8ZS37AO%+5`O!^>JM]J2Q=LX:K<HRR?I%+N4\2<!O_#P
MFLA?.JEYQ;"N[M)A70NFY+S<;%10LZ^F:=I"^6%;+4V5L\;F+N\P>7Q#]*RE
MSW&KU5NJ/+Y='>M"&XKF^*S>T_ZQ>_DHNBUA]V`7V&V`IIG&9\J]1K_W%S$F
MGKKM_HGJN?/GFV]K\6(,AYYO_%Z8?J5^?H4`P:GNQ]L,?VV!V57L?<.=;Z2;
MR!5]VM_&R4@$6-2S2*BJENT\B^QQ0/U0T"/A4QC:IHM`%#-A!LA?PS.JVVZW
M"=Q-X$_-"O9=\?V.)%*_))%6[J8H>XLO_2Q\P:8+6BR'YMF_/;U^YG0Z_;]H
MI[%5KJ,J<-!W_?3E,UT6Y&<>>9B?=IZ5;\!T+/1KB]$(:V?<E$IRR-G.3^GR
M+>-$P)4R=;PPEAAHEVY8*C'C*4ZJ3>1<.-X9BG$0X6@,)V8WND^OGDZ%'\!?
MX1T\37C"IX?3&I)@/!;T&'$CU*X$L:#"(^CB21QBM9DOP@"W1K]&<:J6EY@#
M;-G2;,D96S-Q<]19Z$\PFMC:`T>_O<P`C$+*:P^L"AF820@?!+S3^O)5G,Q6
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MD=T%B^RNO<@-3ZGSK;OLE/#GHS^EXB(W!D!O.0!ZIP``7B1QB,)""ZL$7A)G
MB2<V80'Y^@HP*BQK&L+76+DJHN8?7\Y^>YUK/1$64TZYF)+83T4*0F4+;5A!
MHUUHH!T[,S6(W6I)`/LIM"6@;`(0.#(+J999\LP:N:(_]GGGHG%YT2\6IE.W
M!;6<ZB8(B]YF/[HSN,2-M)POJ*"Q9JH6`&("#UV5QX,B-G,#W]'3IE#/PT82
MJHY\BM79_X&+XQO53T"]3==K_^UYX>3G<':;J%`Z\06X`<;<U_F3'13/%;M#
M1%6M('#D-IZZFV^46UHDI*G_`%2(QI2&`A]T0P.=1?*DP^B#2GGB^@!-SV/(
MS]P[JOB.;W5-?@#G!;@9)PM!N+'D6\I3NWOCJ4M$1G>1F+'8$"VR"!)4*W*'
M/5D69HH36@Q!Y"X<JCHWV+ZWP%-K?7\-%A>K5ZAM_1&161.D=Q]'[P&=\+^S
M66`N4AK7M[<!:%RPUAOAOXM20!-L2<)9JB_OWKO_CA-2M.F9&%H,0T$S"C\E
M,1!3>I=/J7ROW?L+MXK0P,,(7J":YP3^KV>_PZ5`P=]<O:ZSW]0EJ@?#;_3,
MN<O^]KQXE?Z,#X;7_#\,==!`Q4Q0$IX>KQ@G6QU15P1ZY?O*(%^MY"I`+EN]
M0:P';G&-H.2VM]CK]];?8Y4OO>!./):@P'(WW>6"L$!A*^9,7\>WT6=,>O^D
MNQS)?#[Z6@ZE65*)O_/?W\^9IG.[5V9EEI(R&_3YES,'\S`1-/@`$6!0%(7;
MT^`9BC!CH^J^0'G/&<RA3)T0)Z"#W$*QQ:(K@7OA9C"$8U27.*6QOR25<4TX
MEWU\6P_<[#?>O<=X#0XQ!'126MXUJV2+!=Z1S0;M='J7[8'M#%ZT&T.T]I?F
M?-0=>/ONQWQ==;M]A=FK%I-+8K4J$L9Z53UVR0,U-2M<D\W7PBM^;V0V>HS2
M._T)DP,QGQFG]'@3.*:"5B:%UQK'-\]?O?O_@$.V89>=0;_?T8(\O]G(]N+3
M6977GV3J)I0K\1NNK-EI-]OF4?EO9IF^=6FWV>ODK^!?]&?]DN<%8)&"H5%C
M!;)5'OO&`%XZW6TPZ-HTO&)!RX^^LR0:T]M>-&;'"*/.G6.R_-&'E_V8A8$7
M**^GXX,LBI#I_WIF1/.BS9S]9BY9O"M>R=R+#/:8]6R*S_UF^W)-?*9+'X3/
M]XOB[0EO=A7%6TP0]P]/<O(76O1Q1*-B<7,<\CHE4JC:1DX.<_LY&B+H[H`(
M6&G?=AQ[3419(Z>JT^VO@?QJ%[_-ARL7)T7L<7>K+:FJ5>?#2DM**>^6_:SL
ME&`H%/G+,298+6)QN?7\X+W^MCI]8QG./P@J6T-[0/J=X/Q^=[<0[=$<R8^\
M`NT7"R^=97`/^;L@D^3(A=4JO:UR5]L46=@U&0BK0A73OZPAA>B@W[L_@FEF
MK/""I^A=Q.CUUCA&EN68;.WT-^;1&^UA$\-DSF2:_[[HMF3/A0J*F9_^-XN$
ME=NPG'@5SSQ.2F"KW][RV6^YB%BQ\84$L&UML0#"G6F*Y^MKBN?W-I<(N"KW
M9(TJC&-#WZ7.K_9Y7JQ1N<6U2/6]FU3:@O/?GS#='24!@.3IK6\J]1Y``.@D
M-\BQ#/%WA`R?^O]2>%I822%RA*2S2#'^(&[?\1B'_2B`BXAPH45W43#HUMM+
ML=;$EN-\H969OSPW];7P*G-3Y[Y?O9/VHBS:N245#3FM.J#3NOJ0-J]O6^Y-
M[70&@XYM7Q66<,_5W0^6\ZMK+UU8-81_#_[$:1HIF0PZ=+.X`G.;\%P08UIO
M=84=<::MUE17PWVK@97>5==>_Y*UY.A1Y<3<\[(O+G)'P<KEE%;^\J`K+Q+A
MR@7MSZK?K;DT;]OO*AE_=WT//N-R5+XW&7_W+GQ:T`?ALK^C;/U%#106*[H,
MG"8`IT*W:3<!.,V%P`FB>P#G2)5?LZU<T2WL;Y&BJX"[UCL*(,K?LQ!62]Y9
M4J_S;S91L#OK*]A7S5[[`;&(0Q+^'G%[)>$/+O=,^(67#5>_;+C.R^Q.)M5.
M]?USE4^#?V'VYN[WNYR=M@M9$<6-=ZZJOK]OG=%:54R;5$5M5&]UK&R\$IS*
MC;@&4!_N15S`XRN/Y^%OL\]7[7+Y*6_!35J-)E:4H@I?=N@G6CM/BB[M7!U"
MC-'__$/0($;V=RP-P/\$[.-3YU];$(45<+5T(?Q?^/C_`U!+`P04````"`#\
MBFQ'$6$-\_L(``#*=P``%0`<`&YM=7,M,C`Q-3`Y,S!?8V%L+GAM;%54"0`#
M>Q%%5GL1159U>`L``00E#@``!#D!``#E76USXC80_MZ9_@>7?CT")'=MD[FT
M0R!T,I,[,I#KRZ<;82]!<[;$23()_?65C)WP8LMR<+"`N9E+0K32[O.L5BM[
MI7S\XRGPG1DPCBFYK+5.FC4'B$L]3!XN:U_N>_7?:G_\_N,/'W^JU_^Y&MPZ
M7>J&`1#A?))MQA@\YQ&+B7/]7_W:PX(RYZ]%7T[KY/U)\Z3IR&][#'MH_L[Y
M3&<0C(`YK;-WSFFS]<%IG5ZTFA<?SISV)Z=>5^/XF'P;(0Z.U(OPR]I$B.E%
MH_'X^'CR-&+^"64/C=-F\ZR1-*PM6EX\<;S2^O$L:=MJ_//I=NA.($!U3+A`
MQ'V14MVDR;7.S\\;T6]E4XXO>"1_2UTD(J1R]7(R6ZB?ZDFSNOJHWCJMG[5.
MGKA74Q@PZL,`QDXT_(683^&RQG$P]97:T6<3!N/+&@E"7E<X-L_/FDKZYPXE
MG/H2;0'>%?*5I<,)@.`U1W7Z97"SHCD!V<,(4^YB23J<N#1HJ':-['X:2D$7
M^6[H1TC<2G56%(4G`<0#+U%5];?MH)%C4'=E'%]10=DJ(O$P$=YCQ$<1Z!*D
M!X2F#854`WS!DT\B[.K-5HS]S_''7]N<RU$[(6/2T9,!?#0"/QKV:WJ[QHZU
M["`^:1-/?;G^'N(9\J46O"TZB+&YG+Y_(3\$C?9F\NM\M]FJ@8BYR1CRVPVR
M5ST_;M'@81!$O=6Q@""1'S,:Z`!.QJ6OL<.AS`,F(YP,<"&72M*I4@#Y-><1
M\,-$R%_MG,(!<,&P*_U]6S*+]F0_K86QB0D^M8G@.P93A+WKIRD0#OD1);V]
M_61EV!E3<F83)7TQ`68:X5,:VT]&FH4Q$^\M9>(S)6X1,I;:-WXWTWDS65*?
M?.W"E'(LPPGQEOI/T4+76NI0E4=H04P\0VNIV<*X^_PK-_&J$O95%==G8/KD
MLPCA.T:GP,3\3F;90CJ$6E>G:EOW&?3+DT;,6C;TQIJE#9::EC'[S=;=73K<
M+48C[&.!P6#536F\XP#DNC24.>8=FJ.1;Y"W90A4Z#?9@&\$JPQC[8M:4E,6
M@C=$/F)&CI0AL"^TI!IK&*^VR8GBH6^QJ[)Y&3'OD)!C#P`'HY!Q4+&S!Y"9
M)1G+6TU$02CLB[G/NA<(O=DR5G-E8++9#FBK>3,4U/TV#$?<97BZ>#BZT&.>
M-5,T$E;CG6MNC/:'-T1;IG4SK%XU]"CK4!*_P^B/[Z002*V]2+\LY`VE[6?!
M%(:8D5^LBT\WQ*4!W*.G`O$I1<9JI@Q,COGYU1Y^ELPR2]8MX2`+?,VJ8%&2
MNZ2ET5.Q]/9[PT3*MK64U+8<,J+8.:&^U(NKQP:I*[FF\6ZU[=`@H"12(_?E
MWWK3"ATF&^2-5WT;!MHW?]N>AQ<ZW"$L(WT'3;%`_I+JNN4M7W@OB#(!P;[9
M_C=B#)'H"?E`:<#[H5#E(JH81D.:5FPOZ-(;;M_.=@`"80+>-6)$JLAE6A4&
M"F+PNC#&+M8MF`;">T&:"0AE;GI+3V^DMQ5:7W-%[4AZM&9I,B$;%S,5L+$(
M8!$;Y/922$\#XNJW!#JI/>1("X)]J]CJQC\O$4QKO8<<I1IMN'#MFZUI+>T+
M]-V8D(&<-QWY%0NC[:Q6K-+:&^W&?)TCO?4Q6S85XW2!X9F$809%'T#D2>X3
M:3D8)`MT'F^-M0)I^=GROY(*O(="_A\M2_UQ?PHL&HY_(2B4[J8*L%]=\IW7
M\XZ*P//4V'6]VD(%\A"7.>I2H,VV%=06@YPMJG*V"S/P:53R$JNCW1[IY"J=
MS)D$I-0.ZVRWL13\3R#2.%]JW/8"3#`7+(I$^83E2>X'9;GVVUC>_6S=XH7.
M+>5&,6&I=965H]G*;Y29;;*8/X?JN\XX7^SH26,7^[10*OVR=%S!F#)8>OMV
M_23=3)J""6+S&PE7M-Q+28FD'T$C@`'7I3]O.6J%WK$#,#.];-DARWPFDE%(
M\"?"1`W6)R_OSZ/'H&:5!*;BQT%F,43M>WKR&811,%]M5R&WJ0JO3ZTW=0#[
M'EL^FQ&O5U<RN1AK7PID2>P'L2F6YL^LQ?J<N55]@TVJ.L'7\^ECZ7O4E(XK
MV**F:+'C?%2ZC%(B*@F3IEW-OW!5;/2\L+9=F5(O"F!20H`^VFW3\:[S\M<&
M\0HW2N50MQX>UH"P<>/;A2D#%T=V:)\R+C4[0*968;!QLSN<(`972!K;H8%:
M;/(HRQ`X0/*RH+'Q_',[H$S@_R(-^^.>3.^(*XWL4*X_<JD3.T!*]3"5>YRZ
MZGWIP9#WJLVGYHQ"???34R[7#&0DZ<+BZPU9O0BC1UD*./J=S6LZ/""OV!;:
M_),35OC)ZAT<A3QB3?0HN%^'*__\A14L1R>^X^,+N?<D&(D?!=MIL,6,_U82
MXQFK^*8NQ:X<,98_(!X+`A<3>6[YU%T[:%]HWJ[+'A#9!0![?GYATX9J4^_K
M8.K3.<``HFILLW-TA;HY"OIU,":>4-*C+./8O>W5"%OT>$"<;PUN0G_>ZXW2
M^2]^Q+]0'X?/L<&E`2W-\S);%O*U6R:2C.09J]?&_()='Y"_E`=WXD9677:8
M`=8-F0%_BU=SIAWO^&P*FD<O2^]IV_T>8@:9=[-I+"[02;6O[TL@?..<2P$`
M+2S1RP#E^?%ZV;/`M..=W[[H`GA1+<X-YZ&ZZ;P_-CLAGB]KG\\7I#?E_L8\
MN.PK04I7>O45A,IPHP]4?<GKB,_M\$B\(1_8'=R;MZS:$-2M?5>K>B7Z9NT5
MS#LX&%J+`F??903IU]/?23.HMY[,:N9WH6XJI/\UYJ:4)6VU<S`,]P<(D7'Z
M:/FUQF\(D7$@,@PE;U,AFWFEP%`AR.;]<2\4(8-/F.`@#)*\OZLN_?"+_SF?
M+8=[TVK:+76KZLS7K?)-GJZ:]LH%TQXJ.\VFU\O@KV84Z\B.`XIF=&:>63+$
MS,8*7$,;;LC](_T7$#,ZXVC<UQ&POXR<C96]YF;(4:$\%WCI[3B<8`D]&RN#
MC0WIT9"5Y@4OG1V%$RQA9^7?9#*V`\_*BP0OG1V'#[Q@9W9/NI4^<#\!N3T;
M"V#;N\!27T?@`<O(F5W+GGZGT,?G/S8K?_@?4$L#!!0````(`/R*;$=:V7__
MS1L``([6`0`5`!P`;FUU<RTR,#$U,#DS,%]D968N>&UL550)``-[$456>Q%%
M5G5X"P`!!"4.```$.0$``.U=6W/;R+%^3]7Y#SK*:V2)DKR[=L5)43>74I*I
MHF0[>4)!Q(A"#`):#$!+^^LS`Q`@0<X5F,$TM2JGLA0YE^ZO>VX]/=U__^?S
M+-J9HQ2'2?QI=_#N8'<'Q9,D"./II]VO=Q=[O^W^\Q__]Y>____>WK]/QE<[
M9\DDGZ$XV[DF91Y"%.S\#+/'G?,_]LZ#,$O2G6]E6SN#=\?O#MX=[)"/%VD8
M^"]_V_F2S-'L'J4[@Z._[1P>#-[O#`X_#@X^OC_:&5[O[.W1?J(P_G'O8[1#
MZ(KQI]W'+'OZN+__\^?/=\_W:?0N2:?[AP<'1_M5P=VRY,=G'#9*_SRJR@[V
M_WU]=3MY1#-_+XQQYL>392W:#*O>X,.'#_O%KZ0H#C_BHOY5,O&S`BDI73O<
M$O2OO:K8'OUJ;W"X=S1X]XR#FBY2)LCJ;E8;>+]?_KA+X?+329I$:(P>=A8?
MOXXO-ZN%<;8?A+/]19E]/XI(3Y2&C]G+$_JTB\/94X2J[QY3],!EL>J?4OZ>
MTOQ7VMI^!VK(9Q13I=D+T(.?1YE!VC;;-D1I,O/#V`ZA9=.=Z"R:V)L5P\TD
MD8UVNU#X2(A))_D]VJL9-T@GJ_4NU,9)-C0Z9!8-%C15!,D:CV<YWJ/3YL&'
MHX.BE2]^EJ=H]#`BW!;S$C[)<1@CC(>3+)R'68CP,`YN\]G,3U]&#[?A-":3
M]L2/L^%DDN1Q1J;YFR0*)Z3@&<K\,+I#SUGN1WAW9QT<RE2,"`WW88))!3*+
MOILDL_T"()N4=`3I:QP6ZUM&NKT.,:;_>WH*O\Z&TQ0ANI9U8UV__8X,G2:S
M69@5#1-(3Y,".T)35QFJMRME0*O?VRR9_'A,HH"@>(:(4H09Z?^&<(_2%`7%
MS[?Y_7_1)+M+QBA`LR>J8;4NC8H_%WKV\C4F[1"\CF\B/R[IQC)$>Z``%F3?
M43A]S%`P))KK3]$0X[PL@2^2])P0E+P@5'*U8&!@&\,V)($`=7W,68$)X@!L
MTF1+0=9[,<OZ39K,0[H]($I&9KS%06CTT"1+3\2MVNRX)MRBE$S3)]_]-/7K
M!4=W`>`T8H.TEDN4N*VNA.;W&/V>D_7O?-YY5R!IK""5G$C".*1*?D7H:E!,
MRB&RC`05S;1-]SNQXH">3!J41O1(G*0R<.DWGE':"&;H,D.S>CQ&_CV*"H(\
MB[UY!Z7PP.!PY]\O==LJ!D5/WF!=>8=I$PER:*K(69R?M`P2#VDRZT.*%<V)
M;;AVDI2L>9]V!Z3/'!,PDF)A\RG'Q;'PXX3LM<D8.X^*XP*9K]"4?EC^'B48
M!9]VLS1'!?KK_]2T<54(#SZ^+R1!%'3J^T_[5$OW493AZIM";_<.!@O+U%\7
M7WM+1'[/R3)7:,!SR!J%DAK>>QN:)#`LV-2L6MA-K9)#P-<.]6G&GF#I1W**
M/6M8NQ1%W*CK_6)#V#Q[W%+2"@)0E]@Z1Y7L7KOHO+-5VZDU$3:-O_W(L&;-
M@"QYJSW=JJV0<)JD3]<-R^S&JLVMX?UJ108L<[$:_AM#@K6JBM@Q/(8PFKR;
M)O/]`(5T^!S3#U0FQRNCAGSE7:&I'YV3*3Q[X:Q>C%+>;Z]_Q6*S74GIL&<Q
ME41PY[#U(MX'-ZL,![1-9->(=:3\VJ@Z7@!:PMO7W'Y2'\,OXXG"S,XH[PT.
M'$SL+(WDS=\<HBU"F],^R"3VZ*<(GS]/'OUXNK2(;"#++NX-K)Q7)<`Z.+GR
MV3<]=[??II[Z^)%>+9'_G)/=P-R/BLNF[-1/TQ?"[#<_REFF#*WZWN#PM4M<
M&X]*!8Z<J\`8X2P-)QD*NBJ#9DO>X.C/HA8MD*D4Y-BY@M!;Z"0N;X.*N6R4
M9]1GBWJDB:8&035O</QG$;T,ADK.'\ROU\NKKK&?<0W2S5+>P(H-$))D.%PO
MS7Y,2;@R[MZD"<$C>Z&N"_1ZELX:3]06_05E@M$GJN8-[!S*`,E8%89*Z.^=
MS[)<2L_04XHF88'6-<H>DT!DV==IQCMT<<2!I0<<6"J]^`6N7ISC+)R1N2OX
MBM%#'EV%<]1*,5CM>(>O_HS6&I=*-7YUKAK5"7.,GI(TH\;#V_*:4J0'_$K>
MX9_FF"8&H9+P;VP)[S>]1*SYC>B[L7;=,')Z7/970\O;3*JW8,)K0]J;T!-#
MK7;?WA5:"+)VMLIL<0V%K9T@^IS\+J@T$)V5@\N8G*>F(>%JB#'*\,G+M?_?
M)#V-?#)_B!TA-%KQK,R.ZE=-ZG)ESWEZK,*Q3PGH7E+]Q9_)[]4U6_+LF*>4
M'20T!:8M=0[/8%PH'`H>B'N%&PTP>4EG1A,(W2B*T(3N<JK].O=63U[)<V%\
M[#`@V7(5\F?O$K!>;S@KZV8AUUZ%;1=.)B<FG`-ER'+G,U8Q5VY\;'1$")IT
MTC,,H>/YOCV6/3A42(>/V+]"L;H3-SJ>?K8Y59ETG^-(8O&HL>I2C#NSL!UW
M.7,H\XBV..N.$4:$D4=%6#G%+;FY&0.63S8<7Y03/Z*!0&X?$<JN%F$]9.\8
M.%4L.6_U=U@7,0;',X!%I=R[G5O)EF>8^I,$$>KJ@EIR`^8$95Y20([(ID76
MPX9J.)FD.0JNP@EA$M$7UWY&IH0Q"F?W>8J+^>$"(<F^2J\5-RYXBH.$M='5
MYLZ>O*Z3.*,^6_\A*^CH0>G\*ZABR>NMI^.PA#$3[A1Z4A`?](25;#FAJ1V=
M94BJ@[_DIO<QT`U]"*=N"V+H80FYIGMY^K5XC5@KYM"W3ZZZ+*`WR;<'Z;_R
MZ$6.:+.4-[!C?+,%Z";U%@_6M^@I*_J1H\HHZ@V<&81:0<MAP=4KO7:/*0>.
M7U.VW9IP>-F6)Y*6W'%;O9$<R%_Q#;;FE>0`XC-))83=V?5;6?,7$YX3?V*F
M?JI;\)>DVX/Z#J4STBF:):D?!SGY7$0DK)Z!U/,;#W75^@[==CN[K>GP:''7
M4GF&5I:'FGZ>;+@5'+K3=A:&D"D3RRH/_20C/=Z@-$R"BR2E.A'&A;F("S^W
MAG?H['EA=_R%7(E]\]0?*'%OQ%:,;*.'VSS^45K?SI^?J#9PAX*THG?H[`#:
M621*S,%Y3E1?^,7!&9JC*"G?-)2T"FS^PGK>H;/S;A?Y*?,F>?73E^._>MCG
MGI5J\3PCGEXA'Z.@]%J[$KP)4*NH]13`#"<T^4201\LG)TW2>.\&=*KW^'!`
M&6;.P%!DQ]6#`7.>B.Y<^'6A9MV)K;$"SHW.D;\\&QP1@"9]W0U#".%.I!66
M/5@L+LER^D37U#BCBV+J3TA-53]$I<I./,-YNLE`794)>S)8Z58PZS9+.70`
M-S#M;O!BT?JP[$L\;:R7<^H$O@F0$,4>W,#;PPAA^FV)9P\3\++348S$TRVC
MJ#L7;Y;R"3%=I;D/..]^)JIPUD7=^7)KP[E*L\79\X:L!V09]*=DFE]V7MEG
MJ!TMR?RH^#L(:<`![OJEWY(3!_"VY[[V/,*)C3Y,D3]ZN/)C5OS)S4)NPGEV
M/9@WZ8?CJM_D!X^79C1Q5"IA/3>!0;N*2,J2B9?T.@<BOHU76L>MEW"K64S&
MCN2Q1%\FW1[RV?5M0:7!#$^HH$Z3&86[=+VG::"FQ6GTY&59Y,9_*>P)/_TT
M4+$7=V_<J4U92C[FT:]N>.[8AP/KM!&A2BW8W7'9[K@X)2ND%\G3N48Y4(9Q
M`Q+D[*;66`;S.JL]QTN6R&I"%@.E<"@VNG,=+&=#MIQYP@[K;YID$DX@3PN=
MJA2\(#Q5QM]BKUKN1Z4Q>+AUG(;@L34)L/5#A`$8X5;,2#8-J\5`W>I8VS.L
M<0S'_J4\1Z_IJ>.L?^MXBE&'E]>O->Q`%K5V^/=PMS2:Q>%]CB]C:I0.YXB2
M0$T<DB@WPEI.<_-MZC##?"6E'XSBC^E,*ED>ZC(.T_+UN#:LL@O'-E]0)=V9
MK91RE:*/":,`Z8V01=L(-9!E0!=S>,>1:P+<+)])T6^4<WL+N*;%;-@WZ(6#
MN/^LAOAJ.;>7>FJ(K]-K\U%\D0)J./?#B*XM%TGZF2Q#677!@\=)%)$OZ>+#
MV_)H-.'V/L^&O;\-`@[%.2)LA_%T$?^HK42;K3A,FZ<+?`O9;?(JG/\Z/W;C
MT5-24WSF9SA5JNPPZHI%>6VP:/%5J)B&\V=R*`AQ6RG5U1T&<[$NIP:3%AU2
MQ%2<TB$=16TE55=W&!O&NJ0:3)J(]-ERY3HO7MUW7+@:C5B*+@-DW=I@%<Y3
MX-;[L&I)7B8L%6]/[7;H)FME+\XKUO""8Y4RR&,9G*(?_2O[<A/8I@?UL*Z/
M2_S`F#&Z<E?,^_@R+J-S?$X3;,63D=^;FR@_6ZN-'`3AW.06C@&7&.<H.,M3
MFLBRH+3<<:QX#0A/.NT;<Q.GR)TZM0+H]2RD!*$'5+[GJ<:$Q>F+T9N;N$Q;
M.WUQ$+1XB-_D]"8MHU$5A"J8J-5;\`Y!.X*UM5#K`>!.EFKV::U&',;XTD1=
M7VZ;G-I.]B0@1<5`K=6(P^A>/4ANG5.+MT)JM$BMH9K->(?.K*)]B:_!J\4+
M!PDU2K91G3:\0V>F4>NBVV`43F9I@WO![RB</I*993A'J3]%U=FA0()B^-"G
MT521&._PS:!J$DLX>=EZXM^]-GM'K\0PJZ-F3G6>(KX]IERN9R_3-FA+U\U1
MX1V]$M-O#_IN%G5`YN*NC#,L2JXT7Y,4[^B5F*H!J'\+Z"4GKFV)I;+&YA#C
M?%9C4KW6+%%:Q%89O`57>0NN\A9<Y2VXREMPE;?@*F_!5<SO2=Z"J[P%5^E1
MI>"]9GP+KO**@ZNTWIM=^&'ZS8_RU3,*C6TY(:>7LW`>!N0$-?8S*X98U;[M
MA('9YDL$#>2VR*K4AMMO242:B<+LQ866-GNW%/CFE>KI!G:OP`&2Q>\XQ#\N
M4H0NR:$S13CK4T]9?3N-6+,U6LI!#IAGP;V<VWN=,4FS@`YDRFFE4R>I)GK3
M2EN0O1Y_`.%56?'C&1F!-2:]/8>14N(T*P?(Z;0UCN+WK-4_L!')_@PFV!5`
MJG.%2%:K_T!'S0(2GDP(>\5/M4UV/>6W#-8$(U83#^EU8L%8>%H&(P..]AJQ
MPDD%]`0"Q.:M,Y-LF*B/ML+)HFU^<HXC_OGO>9B]B)P:6,6TW!.$/?,\!M:+
M]'CASV%X3:,8!/)MC5MQ]7Z;D0TI):?DBFZ=DIANEB0[0&$]AU?S+`EQ]OH2
M#L"L@FOT22\XF>5=WW5+T>9<1'%X>6W"`;*4FI42O/O@[SX]#F;234ZCG--[
M7^X`8$MBG7`PR!,.9DE<[&^DZ&^4=7H9JBD!%O%P[B/'*"(C/+CQ4[(^$DW!
M_J0P7)V\K/XBL_XH-V+G=M#P1D"+'9BBE"X[FX4M78FIVW^T4)=+KN8*S)37
M64!`-@6V)-5#]I.+)*<Y73$Y8Y>3\>CA)/'30)S]1%S+Z:T=6^,9AU0I#_9`
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M##+Z=U=,F#EF8"8;8`9+=Y$`6:J,R0;>ZG2+TA#A8=,Y1+HF"6JY2?`C&1&<
MF4W,!3`9G;22$;.6FW0^'63$Y0+.3<F"J\7=Z"@=4[?L,H4&X15-\I3@C/"I
M3V.@GKPLRN%%0='^H6/+;G+OJ+DZ&601SB,W)C.-@$SUCS4'HK=!K=ISD_;&
M@-15&+,8=)T^`*I[Y9D9&X7<I'31<"7<H-9B:KIJS`Z#>8B3E'LSLU[.32(3
M#1!9!)M($\?!L7BY,WI8\?-8G_MXR,IKNDGBH8&U&@L5^K]8N-B9)6D6_E$8
M,>J10W8B<S(EG2:8.R_(ZKG)F*&!O`H#%>Z_.E]HA>F`RN\ODG1!OMA"H].0
MPRP9RDNK/D>56'^S-IF5(>6?)X_TI81$,DKU'":]T)K(A`Q4N'^`.IP*)@R,
M)G8[#C-?=!U,?(:6IU*H0BTG@B_H9_%3Z[FQ;L!A%@PS<V*#DUI^[@^3(MWK
M(+YF?3?9),P-P@8CM?#<W[O3+1.U7Y0SP^KF2G3<YU9RDS%!\TPOI+Z6#8#[
MHN7IXL9/1VEAXR_5J4I_(Q22M+:;>/^ZTE)BHQ:;O9-N=;(K1[AD1]@L[":R
MO/XV<)/J&E<+9]C*8'$9SQ%>J<2SQ%3EO"/@U@$6P360[@^E$I^&]HX>WA%<
MXX$&"[6HNAPTS8AJ[45\L0\<YMECDH9_"!,UBRMZ1_#M`W(.:CFY/Y@VB6VQ
M6JLUX!W!-2?H<[*\#S._MBRBB]"%C&8&7%@X\&5<\G$1QN1KLD7GK3FJ];TC
MN,8!;49J@5C(6KH(KE/1T4CBJ"X5G4:\([@'_G;<U/)A'_KUHFUQY'2:D$U+
M2IV.>.F96,6\8[@G"1Z]-9H03N$5=0NGDW*0EE^3J5-X]RZKZQW#/7QH,5$+
M#,+1G$EO>6YJ(:U%1>\8[LE&G8-:3EW.XJ;V9<D$H0!?$&:72^#:%J7XB\:G
M*ITFXT!P@6VF8>\8_D&I.X>U'G2Q'=C8GR\#BE''$[&8!?6\XVT[13$8J(7$
MMDMTWD^L*P;O=J-)J'@0&FH8JNQ,X58=CSF[^:V*]:>1(_$MV%]OP?ZV,]9?
ME?U'\BAJM=A61/);(QC,XP#EE&2PTM*MPRD&'5Y(OM:P`WG2U`[_'L(_C&9Q
M>)_C2[+*Q?3J@)(@#_P@KN4TN)XL'9H:_6`4OUT:U6UXZ+I.,9RW1:\A>:7C
MY[4;PF7K@"76P8S>5Z%)0)90IRH%[R6QV32HH'.IM9P$V/HAP@",<+7R]=@)
M7F@Z(.L*M7#>CNJGQ[#CN:N?88?"*$"ZIA:62NM!#63AT<4<WEK1,L.1"_=G
MCA:S8=^@%PSB%D+T63&E]AFB;VEJ=>^D8"G8FQWG!#,A^G2%MN0)^JCJ+#4@
M"XT=\<%;CGH*T>?"_41]3+&%J<P:&&$VP@8\A9D?E7>Y8X11.B_>:E[D69ZB
MRN]"Z%"DV9:;.(RM'_VH,[5%QE"M]+F?TP0+WT^:[\U2V$>SKRWML`WGH-V:
MP3HJ5?EF8NZ'$=V"DD'SF1,RR':7MD)7@M`G!=[A;.);IZ0GJVF8%H7+`2/3
M(A-]N`G4V$)M3#%K,>P5Z81>W/I3-'HH9\#"$7Z872&?OH>ND[&/8IJ;??3P
M6>A]U[(Y-V$=-?R<.O!E,=;6RG[H6Y*5'H`+,GD"$E2!'&Y1A7:+8;56Q;\4
M]:H>Z`X.>2N0XR"V9,=$`"[Q.[)%#$:ZT);3YRIIBY'+$X]&$^`C)VKR8B*$
MEN/=;?%_WQ#.:D=HT7L;D]U`C@!IBU]`L;_:;K06Y[U1GN',CP/"WW=$`[6B
M8#A'*9G5QH@*@'Q_FL19ZD^HPSE]'W%H8X_;GAK(03$=PP(IFEE'LP0=@H3I
MF)X/T(1\O$OH5RL3_'`Z3=&4K+B7!(@PQN&DF.8M6HA:TP0YFB@(<&1O=/KT
MFHV*QE'`!D0>'$:M@6T(3:K.":`P?+635AG8C$WZEZ0(283*Y1[?)9D?K?Y.
M8Z-]2;+_H&R,)LDTIJ%65KR^1&;H7OJ''$^U=R``A1&TQG.Y%;U(TL57M)QH
MO]\O(=L0&K9_1`"%4&R]'ZU/ST.,\_)!*JX7>++ME)XYK72Z%3%LK7)O),ZC
MXYV^B-&S<!X&*`[&9/MA8T>OVO=6Q-OM`P19`,R^7M'?I,D\I#Y19,)=#<'2
M?$???#2O_F;>4E2<*\%K>WDEK;?WECC@O=H75^CQ#;\2C%PW&P[Q?%>:K7C@
M;S8%JKNG_W(Y<29&`2]PG.`ZIMYT'!U`B#%GN+&8>#WR`.(1;$@P\%R`S>=!
M=1ES@#T8./.9D`=@`C*9!-6%J;2]@'@\F'#,=1WFUX79L<W63I<K$^ZN<"+^
M.LWKK"TE3=8LIA0]2W[&XR2G4=D6ITR\=$_DQ4A4K&GGJ;4MH2CQ8]--4^F8
MSW4\4ZIMZ4&V)8DH\V3"_]*@99"?)X95S.W+X3;&@W7JX23=A!KTU\YS9(LB
M[LZO15?=SX3KJX1L4>,E:T4";K6I4K&ZK??)EB9+#:[@>/;9C7[O]$VK$:LL
MBR4C'F]F4T`X>5?:>J0PJ`?DC+6ZN#8.!HK;B6:=[1"+`N]B[_7>`EJ7UHYJ
MG2OOW/J_;"OM,PLJ1FDQS5^I7+@)*[JX=&,1)+UXXU9R<?DF@U1L>&8SL=U!
MMIFL2>[@N'4@W,$)1:4A7J#W<$TB52^`6+5<W\P)4=<0%-@K.I.B`G)I9UIF
M/40!7]L%B(-_,PM#N'_CJ3QCQ\SC`<SP,.!7I^P9!N!F3GNWH<$<G%@Z(J*_
M)9&?A5&8O700:[,1MQ=]%@2[P1Z<`#<LLL<A_G&1(OI4"I%38-9"L*PFW-X,
M&A0KASDX`69D7MPM1RFMZO8FT<+87#!EXCK1L4M[>5M]&6-RUBS"CX^R1Y3>
M/?HQ,]K6VMO>XD<:0Z(&2V;F@D"CVVO4ENH("3W)A:U3<YXS%_HWJ]Z;5>_-
MJO=FU8-G*GJSZFV-J-ZL>F]6/?=6/0[$5;S49F9C'L;LTEME?Q/S`<?4QN1K
M$<>F=$]>DK_X%0M]<]JTMY4&N+:<PK'%5=0-XZ`D;R42ET#$HFI;:7.3,`3'
MSF;T\?LURAZ3X"N6NRN;[W$KK7KVL(!C#(3J1KV-9K?.+,-YW'!&-HSS(L'*
M5>C?TYLELG_\DL23G'`BS"X@J>GX"41+R2HP)7&"[\W.F=]C]'M.B#J?(^>&
MSC5J5$R<O"H.C)MKI,C,FJSB#@R:`@!YZQR;\.TV8JXS]2+-%,^I`<"`R1.0
MFCB7?("QAC%(E.?PYM5Q;;04X*TL('@&2\,B`F*L-"DK@,%#FL3*HU*PRCLU
M;0J'AI*$X'DL5@G8)<O/:C$[ED^+:\X:\7#,G15ATKFK6="2@5)Y35G'4XQZ
M33,XG=>&'<@ZT0[_'JZN1K,XO,_Q94R3]9#S*"6!E#H6WV&):SFUX6[J,.->
M14H_&,4O['\*AXU&.3O648O3_3KU<*XXI#9;+,R-4_`4!\K3EXWN+-D^E=>>
M#>&VM(ZW8QW,2'X5F@1D.76J4O#.:6.$LS2DSN%JT0.9Y=U:TFV-?K9B<`$`
M(]*[,(O0Z.$R#N@;J]R/).L_L[REX$$6-P)<-N#<H6^0^#W,'L<H*A06/X9/
M=\DYV51F+](I6K,E6U&%E!=ROG`4A2GG#^[XZU'*0!99^^+NX7Q[[<=^N8"0
MY>$DH1G8'L["%$U(`Q)'386J;N-$M1E?C,.P(I]@AF9?KY%L>#5IDN`V/%:+
MF]\><;$8()KZ6UW[Z0^4+7(AE]&E"AKX3L?B6M[`I?>QNB@56=DB"PW`G-`#
ME_[*/0YK#N^2S3S#MVF?TD63?Y$__@=02P,$%`````@`_(IL1[:3N&&H4P``
M<=\$`!4`'`!N;75S+3(P,34P.3,P7VQA8BYX;6Q55`D``WL1159[$456=7@+
M``$$)0X```0Y`0``Y;U[;^4VEB_Z_P7N=^#-::`38#M53E62KIZ9/O`S[1E7
MV7`YZ=,(#@)9XK8UT99V)&U7N3_]Y2+UVA+?>I"[!MU(')M<XH]<+RXN+O[[
M__Z\2=`SSHLX2__CJ^-O7W^%<!IF49P^_L=7/]]?'OWEJ__]M__W__GW_^_H
MZ/^<WEVC\RS<;7!:HO>DS3K&$?H4ET_HXE]'%U%<9CGZA=%"Q]^^_?;UMZ\1
M^?$RCZ/@984^9,]X\X!S=/QFA;Y[??P].O[NK\>O__K]&W3R'AT=P7>2./W]
M(2@P(N-*B__XZJDLMW]]]>K3IT_??G[(DV^S_/'5=Z]?OWE5-_R*M?SKYR+>
M:_WI3=WV^-7_>7_],7S"F^`H3HLR2,.V%Y#A]3M^]^[=*_I7TK2(_UK0_M=9
M&)1TII3C0L(6\%]'=;,C^-71\7=';XZ__5Q$7\$<Y%F"[_`:T<__M7S9XO_X
MJH@WVP2&37_WE.,U?PQ)GK^"_J]2_!B4.`+Z[X#^\0]`_W]5O[X.'G#R%8*6
M/]]=">&\VZ/%.KWZ&UIBA+<XC[/H(K4;:J_WHF/^6`9Y.6+4G?X+C?L^*X/$
M:L2=G@N-]0.VF]NFWU)S2O0@MIO3MN>$8RV'XS2>R'8&05/#S]?D^WLCPY]+
MG$8XJL<&/27:DA*F6I8J_RS<(Y:`NLWR?9SI9E<<@?5X_>[-:X:$_.:WVC"=
MI$3LR[A\N4K76;ZAZOKDH2CS("QK0G3HE/QO?WGS[L>W;_[^]J?OWQ[_ID_H
MU=_J&=@;<(Z+;)>'V`@]6X3]D04/O[W^_OC=#]__YP]7/_[PQF!D8-@(&3#?
M.#WZ^>-7?VM,=I!&B'5$G9[HU[KO__UW-ICIL!''XB%KQ,!'B"?Y/LL%>5@/
ME/RHP%BU>!5FQ*78ED=[2[G.L\TH'JO'E8V:K%?:@E7!I!`+''[[F#V_BG!,
MH!Z_A1]`Z-X>O3ZN7)7_17[U&_ON'7Z,X7-I^2'88(Z47?[T[ON_''_WW8\_
M_O#NW7^]?O?V\NW5;\+^"PC7WZ^.?WS]YNW;=^_^<GS\_KOC'_[^PW^)!S1D
MN(K'VG8(&BXM/\N@6$)$S!BD)QEFT["$0)P1J<R#Y(I8PL__A5]4=D?<<6D[
M(X,@X)ZJ(:(M$6GJU(K,`6!Q&Z%D)*Y-4''17"Q_GP<0+OCXLGG(!NLCD^W]
MCBZU?A]"GU.JOR/6P!LU/V[83O4ZEVF4"IW',7.Q]=DNSXD<7<9%&"3_Q$%^
MD4;G9'^FH\R%?5WH<PF0/L-431%KBZ`Q<:<C!,V=J_69<#C1[BKF$BIX!6?-
MZ]9<Q@G.S\C7'K.<Y]0HO+C][NZ]_#X<@7]`FZ&ZG3?*?T(,'GCX7-;2=/!Y
M?#6S?Y]M-EGZL<S"WS\^!635;W8E'"R`<3)P]F54''K^<G`B+YKV0K3;"K&.
MJ-/3N?E8$IS+'8,&:ZJV#VJ^G$N\ZI#6/2%K8F#V^KFT+#T`PD`E_-T;4S)F
MT$YM!X]=E$:#PRMSLW-S'*F[@>!W=&$31!"$3,(:^K-MF!J`$]TN922A.I=Q
MT5PL?T(^&,%'+Y.`YPL)97F_HTL=WH?0YY3F[P@:>*/%QPW;J1[G,HU2D?,X
M9FY-WFZ\+\EO"A-=WN_J4IL/80C583>&0AM[H]&G!.%4JPN82JG7^1RUC`@P
MFR(2`J7'-B3B@]?.@Z;BJ<I=<"(:BP/RPML7,J"VZR_B/E/160?%`\6W*XX>
M@V`+\O/]*YR41?T;FJG4$:3JU[]]+(DK!D.Y65_&:9"&,1E/5L0FZ4I&M):V
M-H9`^TS9=$,W:]1T1'5/7Y*6)D.9&:)<W%[9,"[7@%EP[7)B>5(4N"PD`LA5
M3H+>KBR:$,Q@1T`;.)2ED</_^/'B_J,W)DK.0U+;)&6@I;F_.F(TM4+\SJ[,
MC@@*7P16J#XQ]LRNZ,*HAQ_0]MX8"RE#2:V#C)N6$XBSH'@Z22/XU\4?N_@Y
M2,AHBI/R+,CSESA]_"5(=MKG%&9$71L/7>@#3B0=:!HV_:'3=85.2E3W1K2[
M5^9F-.`0?L!MU\G1;0?7BQPC7*$'_!BG*2PH<6#9^&:"W=X$<PX:D]\*X3IW
M/XQTEI978J*PEM/-=Y@8A3@L<62KI;DFRY2L*P?'''Z?PUL*2**T*Q/LA3<T
M*6:0:V\<)4MFEKI0=IR\G`#?YG@;Q-'%YRU."USQF:DSQ2?BVGD20>NS8]4.
M50V=2=ND8#!KZ$_L6(OAM"RAC-N6$YR;\@GG>QLD7>/&Z>G*?G%!]%F*-D*]
M/?KDPE%VKFI//OC0SYVYF(>D-D7(0(Z"5'816E_,A(J#YF;\\=%9\=AI90@%
M]X^7W$[ABN6'[]R@2>77`/[RGE]&-L_ERRV9<GI[G3BE6S@*^H"U39F4ABNC
MI@`V])A8\Q6B'5CU@KK+"I%.'M@Z0TSDMS1:0IMXL6NT7!2Z&KA=C72.U9#I
MK]E7PYGSH2/_4C=$0_B=N..V!\<\$JZ=$SXLF8?NZT&R"1)/+;V$Q[3LO9C!
MQI1<PEO(URB(`';HJPRXK*N;LDHB&(-$N:HA(BU1E_$]J)MDC`&L6R9A^=$8
MHBK7CI8CFA;$'=Z2$4$,$P6/CSDMFX;"^F@QV&0[,-A!`:<TA!!Z"!(H^HB*
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M-.1_)P)OF<4LH>#*PDI!2<36VZ1F(T`UAJ3MY(T%5+.;U"HJ>6U!ES,,8=-<
MW`8OP4-BFXPCH.+:"@K!#5S6JB&J6GIZ\FH,9\M:>F><Y%RG=Y`I8[E%Y2??
MX>ACD`1Y*\[:6SA^;V=;.A$8#H-!0U2W]"M;U!@&$1/RL82ZNSE.X"T&I\EL
M)KRBM0N3L=F(<X"*[G4<PE01C_"63%U:WN%X\[#+"WK)\Q)C[3H!9D1=61=3
MZ"*NJ_K20P76&^UU1]!_V3R`6?$F%5Z0LBW#F^_A7<^!5W4:,0ODSCE%<SKQ
M#+G6TK,)^$OVD,2/=*P%BED@,B+-\VSW^$3^'50MV1Q2RX?668X"DSEV<LHQ
M@<#KN`<V*F1Q;V'H_QLZ#!P"CGT&+B2QYAON57WR'(S`^.HHB)E,QU<0<M@(
M=X$5%MT]%&$>;T'%U1_1+BFM(N/4)9#"&Q8`(8U1MW4C%7Y4FK:%5'0A);-!
MLC?K1ICL#7DAF0W/#+!:+M4F5RF4(_3&;9X]Q_"VZ&66GV5I]6CIS?J6=,+@
M(-&/:Z4?:9)RDHZD#9.3N,HZ(M(3M5VA@E+3F=6P=IA6/`[C91#GE>158A>V
M.-<X*'>YVXJS4RTA>/,=:`3L1PR;=G2*MLU:%K.LI7GBEC7>CEZ%M6296TWL
MI<P(5O&$].:A4L5#->Q)-I>9^A)G=QGIKL7W-%=IF&WP??!9MJ=1!84%A#PX
M1Q!"%&T+6&-$6WM[G*"-JD)30BN?3Q7DG*A[L"!E0Y>'VO:'V1X=8FL>7GN0
MEJ4U]OT+@X=Q6FUY2NU2`MJTS`F2MSC$7-L8%52IR+0]#B!/2PM>!Y%CD1K!
M4R9F1X<[EQ.\\\JEO".#."/_CDMI)C]7[4AIN#)'"F##6S/53@/:(]9AUGQ^
MFZBU+28>`&=&2H?CI.9*@]V6E)\\?B;[Z&?,E6M3TZ4BY]IXJ>$.F;#NT<:]
M70K6Q/":F,VG((<'R/VS7)H<JF6[]-C3L=MHL7?RP%[I,IS`'?3"/NEB8#NI
M5,OSDP*Q'9#=5G(,#!_VA(9VUCL1'[$/=&XX]V%(A-JCBZ/R,3/N/Y`]F^T.
M;?EZY-EF$Y=P.`,7;\ZRM(S31YR&?/;G2KR,A"OK)H<UN!'2MF8U:[OMO;!T
MX_"$W?;HZP]9B=&;;[PQ&1H\*#4<:@9<M`1MY\S,JIH_CX1K<\*'Q:G7VLT)
M6+&:_"MT510[/'T9]Y$E:#4`W>$(XPU-AF4'HV4,/S>;L`'@/[W^]O7K8[0-
MJIR"%?KN-=K$20(GS`5[Y3O8E4]9'O\+1_^&OE^]?OT:Q71^6-&0]F'LZOCY
M(Q$GO'G`.7KS&L@=?T\;$C<0RSN>X[#J=TS[O:45Q^`O?WI[?+SZX8=C%*>4
M!#W>#K.B+/X-_>G[;]L1)_$?NSBBQ_;5X3B&IJ*!3;?"[]@*I[00BUV9?KT5
M%N5`0(+5?^.PA)0!\DN\H;E'GB_PMUJK)\G\$(WHK7>^ED3/ZM9=%BC9)5_L
M,R@?('@ZS66A`,$C;`8WY;N-_UP7!#@IRSQ^V)54[1+QNPU\O'(\`F>$UW$8
M^Q,AU[_#;SH3+G8S66KO>@WZN_:[.(!XSCY1\-Y[7/I0"KXO]6_HNS<_R&SM
M\5]6KW_\R^KXAS=6!O>X)6YF=KTSCB(QT'N;AR\#"^;]11%]LC-(;H,XNDK/
M@FU<!DEG7+KF48.2L]M-.B`'*8!-)P2]P'VO^JU05PUX82#'(H1G,8[B]"AD
M_;RQEOKL*;\.I<N;RPG>/ZHCQ9,TNHL?G\KBIM5]II942LNU554`[3-EW9S:
M`]8!=7IX964MH7EGPG1X4<N<:3#BDB_,E4&<XN@BR.&)P^(D#'>;';V;<,XV
M!;JF38.2NW?D-$`.(VVL$ZI[H:\[_5#5<1"S'G]:9?QZ@16\+A;!]L^)D1ZW
M5KA>JVB7@W\,-VXB_(R3C);.)XY\\#CAY2F]H."BB^;P>3]=3:)XT4]3C;B,
MBIGZ'AP*KCT.+J@1T3"O?`XM<.SXGN[:&XB8-O8H`\$$B4Y(;S24L0\T:P$Z
M91<</7MF><S0G;NO8B6FY;0*-9@_E8YU'54E'0\2($4`]2H8>^'(6:!A>JR/
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M]/:`3JW^J%4^U$VO@42;YB!ZL]WMC,EVKRLCX?*FI!B67!OYN<6U0N3]YE:#
M_927).6\YU"4[/:T(C(>&7K%KH\G3KXG[^M!.HA=K((/34V5T_WK8!P6FU<I
M#6\,E'QSQQ>I.3>MYBF$=I"8)RS9I/IA;?6QZ&R\1V/2R*"9`E>5B$(==H9J
M^FV),I]F(2#^^$"FD1`-!;><QF:%H.G69C.B^JR(C&LO2`Q/4`.\:>IKJ=E9
M$#EW@A1LJ.4$R7EP.9&Z(2HR@.HO%]7;6:87ZL4$7+D_,DA]MFO:HKJQ;[?F
M[=!X]Q*:DL^D5DC%9$O>1RHPF8>GDS0Z;^]M5,,R-41R8J[-D0KJ\)(+:T^3
M!CL]:M'R*-@^"EKWO@Z>"=H8HSL5.._LKI;L:5E?'<%;3J?\A%.BWA(RF)-H
M$Z<QJ#:HX"O6*EP5JR+CRAZKX?4YLNI!&7*_SVRZQ,8TCP,6[/69M*BN)D,9
MZUA]."+%Z,S_T)P2J1>B)V`.?7=3_V-(P+7/P8.D]MF],K\Z$-A%BTSIKH]W
MD:PO]DT)P[GG()04+6]!)"8.))V%#:ZS0KO6,*^K\YWY'@RQ?%=!H:^AX>(Y
M*R,0P*\1L&8M&UDZO6AOLR*F[SP<Z/C-;[29LD]"&GCC@$A$6"_T,9#?Y=3/
MARS-]H=1:4+;"+R:H&M'1`<RYZ&T;*"[JF[?^!JBMP%Z4S[AW*6+/Y*Y3(R_
M+JN.>%3]IR!.0:YOTO8M85IYR>)5=5U:3IY5UP<ZV&F2GHB:I9NT^ZPZ[3W[
MR^K&CX_;`Z48";#.,]LYQ=C6H#[Q\/5Q>\#*Y\<?8>FSG%IST<STBW)WJBNQ
M%(#!^^/V<V114VGD%)T]D?_"4+MR'<1[^=[[,U&8,,GBCI"-JA._P&ZFYY9.
M48"179)I8"]K[`@OWC2.]"E>9SGNO&E]\9G8D2R/XC3(7ZY*O*&/.9&>9(H3
M:G5*3#C4,LUAGJ&X=L_FG69!<@+;A[*-4?M)U'X3/="/]AZ<W_LPHE]F[\*U
MWT;UQ[UR#9>=Y`^X9#J^FL2X\\Z]1W$Q?R?%N>.]@.XSR*V94_$M;4_(&*M=
MQRE.\5J_Z*FHNZL(H!B.0.>2IG68'WU=M?8C%*@/Y3;/GF/JIA&N<ZC7IED1
M,O!ZZT\OV#UDV>\3`AE1LG2.%7$6+U0(OC1F*)?Z!>.&N)0>6,C#.'N=73N<
M?2@\0[WO)BY4AM0^"4H'$O4]0$9@*_V"@]PK!U47P>)G+Z-&[?[TQ;-);TR"
M7457G0%7)N#KA'?2Z-RQYNI1O>@U1XDNI__K&MGU#?33H(A#R+F+DUVI?PE<
M1<:5,ZN&UV>UIE1_4X%BA6@OEC/+^GEPW<X<V4"(VN(+Q&^'[M]X4HMB(L#M
MLD6L#;.5@*NNP\'`SPQZA+_L&K0SWUI3+TE];#VEM.!31!BBWS@Z(>P?/.(/
M.WAP[69-Q]:YLZ=6P?)'9NR^XMI[MYZ<P>L_%2%444*,%+I9<XI].=?M"\])
M4,U)5Q7L756N+8%7FXC)YJ%B@%V!Z3MS9!:V.YH*\B#6FJVZ='AS>`Z)-W%2
M1RF5)9]9J2YKWJS/@N+I,LD^&=^6E-)P]P"Q%-CPT97ZCFZV1M`!T1Z^79R<
M'97#UX?5C*AX?UC)A8L&"6$0-"0;X>CTY6>B0*_2)N_Q)"SC9UJ:GW>28YV!
M.,U773LVDTT>;S]'I:`FC4Y?T-=`'5VEWZ`VR;;]PDIP*.YKXN-<4T>G;4V5
M1S>*!Z\A-R3_ZIV=GU8,=8-3T\G@DJ\M__>N*$%]%O?9'89)CQ.\%VF[SS2!
MF?H/LWS;W8O.LTSD\(7DYC/H/D/-A]#PS(;\V5#I^>;U.)C3,D-Y,Z=I?6A$
M?@L_AS"=]9;(&TVXG&SIN&,S"O5R6O$<\GC#F)LRK+(]>WU=NU0]('W.[_[9
M*W]FQ+B=.Q\\YM%R(3B<LV!`H(K[XN@LVT"BA8CY^;LX?F]G00`1&&Z8Z^@!
M6J)N4P^.K?0Q0&YXA2'L-*6I#GBS3;(7O/RU\IDP^5:*02XV\L"%3&86W`%L
MLKR,_T4_?K.^C-.`6.ST\2PK2N,T)RDMU[90`73@%7::0QBMZ8!H#Z_,Y4AH
MGX(\#\#[;5[(K%]<`!52X/PY#CU,T=;A7"W#J\&VBR9)YYAHA7/,_MWUC(L"
ME\;;;'V"#A.IM2%S$GEI'_1UW?L;LK_M;F\I!=^VMF,@LRMT!6Q"`P8.Y+;S
MTJT_VU!C9E:E`AMQLDNAO<-D*'%8$NL.IQ)9SMG?FII7RZ^X-KS6DZ,CZT0(
M6FHLX`5&BQ?>\LID3S8I'?00G[*MO3;/8&U3O@Q!.G=%QDV0[D4P>^%WJ0EO
M<[P-XLBP`*22CC_.R@"@IMZJ^DU?!G+<M2-3=#4,[\HTZ[*BH<_!Y4.G^P.H
M8'.VR^%*#O.#QCL6')K^N1%<X)K"Q\K^5)VK3<+2$C@'7(8KK'`%7%P>FDLQ
M#UL:1R$#CZAM-/S*.::WIXJ3-*(?%(K?L'J(-C$GU8T,H`H%KNX+^_&Z-R+=
M*]F;6N:LZ_V,P-HI^%,5^\G6<'6DTCA15^-$]13`;CVC4\#$TX-Z/B.FX%P$
MR[D?8"6SXBH]A@+KTB,X"4-@QN(V>($;N^/=@3Y!_WR!(61-1Z#NB*J>GD<)
MU#@;0%L^(`^MOX!?+4T_GUE=RN-%=0I[QRK!7;>A6OOML(2F/UMC*7!-`:UI
MH(H(ZE#Q-)9O!)NP:PYG;41<H4`/M:-UR<`#V%.K>=MP?ZUD[$D]^&KVK^.0
MUD%-HUORT;2\P_'F89<7]&;!)=:/U8_]C"O+.GYZM/8!-;-7!.EV@)%$>S31
MI8.<E84FIIZ#I)H#$/@MFX-\;P[6<\R!:G^TT"28[)P"DPE;?#=U"%SCS.>;
M2.M*/<%I5.ZD5H6],;M[*,(\WH*@U5;LQ3(V)"'H27Q("EG+-E`*J$NB<?5>
M'"9D3H&702NZT)+9H$T1`3-"9Z++ARL?UV^;\Z?'3)]/"7.JPVN3Q?<E2*:>
M&)-`F5)[.0Z6,3O1[#/J>%YSGB[?L)L'.TR^YV6HS6S"]"-QU=Z@Z4R]''9<
MT&;T.-S_+SU3]934<8!.D#T1SX*?$3X+(;,/`)I+V*$4"="-&([\BJL8XNC)
MF>_ROQ?!QLGGIW/#?UO/D'_/I<W"%LK[O,Z]LVE5AC00.XF^<*Y$K])G7"Q>
M:<7TJZY]NLDFSU#9-A_XXBJMC)^Z?J65N)FK`ZRT8BF&8RJMV,G@<@KK-GBI
MJB*<A'_LXAP3`&14Y<LM88.2.*@7Y+=;:*+KX1E0=.7-&8$>)!97G:&22=4=
MU?U7B%)8T0U10\0+#VT<9C+"IP!V>MD:X>EQC4@-GP[7MNI(%T\(TIFS92ZI
M4L?*6$P/Q8E:UGDZ<*=I5F?I"_*09%NU9G_Z0.:IVK=]@];-Q7SQQFW>':NC
MZ:AWKCQ/\0MS%!=T$'U1PDT9`NN=K$DDP?1KGH4'S2?+4!FWU3]\WKDN.V7]
M'2M/$?M3BF!:,;,)I=G)V(([U#P+,8[H0Y-71;$C@\4WZS-:`%_T:+M4YZL)
MNO;I="`/RT5&,2Q4D*`\B`OZ>O5ZET;L;;$V:LZ*Y.-GG&3;NA9W@H,(W)AH
M%\YP]<G^_821\P#PV61,_RC$&%?4!E;=A^FT^OF'IB@2D%C1:J!D.?_T9O7N
MN]?-[TEK3F4HYZZ7MEQK>5>Z0NU:;^V_G0[I?_07F/Q1I,SXT0`[ZLXB;K:3
M(9>#FA1P?4.LRM@#/=?28[_TPO.9:2X^XAQ24TZ((J\G0J0??ES]^-H'_3`E
M9VO%O,8(S8A,W.YWV3*=[G^T'HRN*V-(U>GM#1/P0@Z_['#XZ4#4:PI>6/GI
M0*_W0*O%^NWQ\>J''XX5@CUZ4NRO:HR9E2NXBE,E]';R>0TG:Y"VZ_8*@K%B
M4-\X,-4*AQ)16B:2=*`1I%DC1UXX3;/,SR!\[SYH[SGX`XV3+1`?6UR=PEB)
MLPK_@J/:YR"!X]Q;HO*SJ)]\;!HB,Z+M.EIF.!'<>#%L%ND/'0HKQ&@@SL4`
M+SS-B2:@>E>:=RTJK.>&_H!;XAZ=9$Z)W@2R\P":C0+0BJ592/^"+X+LMMN$
MWI(-DOIEQ0OV"_.G0G5H.7LM1`_HX%I?IUO[R":J>_IV##@%RB@NPB0K=CG+
MXP+!/8(#0"+.ZRS?4/OLSXF?"0/+7^K0Y]X1L2OJ$@5Q=+[+B;_#E,!EEINF
MJFO1<AJG4@/E>@[0!;$^M;]`>J&ZFQ>.PAA\M(ANQ/"53QB>U`:,1+#\2?LV
M851U!$6/2Y>\&UQBPBDEC$G7LNWU<5=X:V_@P_NV[,]4A+PP1IH#]L:4\#A#
M4=9JP!:+WG'/-O@^^(P+`2NK;N_N=7>][1S"X5PHAX=/:1,G3#[-^$MHXHVN
M5W"3[MUL#BLM&+I)@J*X6?^#/7!UD]_%CT_EA]WF`><WZX\X)(:'AIF")($X
MU$40/NVWU34#XS_DRG9,,44#?P9HP@ZA:HF(GT;;KA"C#']K:2-&'$*C0'[0
MRPN3-<<\_:-^>*UZ;JW,T+:Z*(,*>!Z0;;.Z.4B08T:DN=@E-..[?IP-?0UE
M=&B70<C,F=6<3/JDIG8JT1NQ=?M`)H?XLK\$R0XW(RFNZ*(:[=NDA)QNVA00
M!\$^UAS1]NBFT00%8EV\,-`VP!B@[J.)HV77H[P!P\GH%/Y*JP5_GGY^/$LE
MT!%V]=Y70](7#/76Z0HX.M8.Z7;[.`O=[@^<7WG-C<:Q&6^C7`9IQ]5;K!K:
MPUVXE<-$\K#JD(-&V.!]$;I*+SZ'])W,RRR_^`PSMHN+)]"*-^O[/(BPY1L)
MDWS+J24?/U%"-Y:1A%J>-5$:HMTG"]X`)>SGTPMSSU$ES3&\95[-$7VH?7^.
MB`XHZ1P%BM<<'#H+TT]2QY^`"'C:[!7[SH3M[*'L$W-%GG$:9;EGGL5$*DSM
M?$RCOQR'<2X^XSR,"WR;QV''A:K^6F@[,G;$O0K7:$R%08BFIH8HN4Z;HFFT
M\-VU66=BS]?:!CG;PGCA+DX%L5YC7*_LEJXLQ(RB+$F"O(#31K8M\SQ\I"OU
MYB$C39$?X:+JZ-8;8J#NLU^H>3+R28V).W5"+::BS]2Z7B4".E!#BE'RQ\G\
M@N;`WHF<8!)Z7F-U9:5^0HDX>U^&=VBK/=3NH*7J6,[_J\8"22)9$H=0T-DP
M`5%"P94G)P4E>-2/YCY5K7U+,)P1CS,71,UX4C]#R77+B=!I4,0%O8);U'KZ
M)(T^QH]IO(Y#*$0W&.L]T9NGB47=CU'?<IUM,G*B^HQ.R56WYAN"-.V]0Q)Q
MQ0'((DK7KQ*X$\_0AZ#<Y72;V=[Q6:'371&GF&Q1V\M`;-9VFTV0O]`$`OD$
M>F.]IQ1!K:R;">1OQ"[GYS0FW%7$Y<O-^GU<%/#_[38^><RQV>4!0VI.WL$R
M`=MG_+8O..Z=WJCM[I-1M%M=\3M!IDL[)T\:VSI3LDYWVT;P[=C4-V,U*>YL
M'_?77_W\_JMO.O`]VD^/@MS929-_0+WM]L8//6<QF!//=L_F&D"];S86_P5/
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M\:6OML8$4BV&ZWTQ'-8$]\YV*/A2L_*]C"E'V(6J>FR=<6AD`$1]G6AZ,9"!
MEU(['4UJL6^*6[$H8@TM7Y'IV,3NR$I$Y+=%4MK%L70).`W>\4VYCH;DC0)5
M,8WV88EP-E[]S?FAF<%*W3]AP=E84:]A?5FI<P+FJ/Z/_5&/C(2[*E<R6.*:
M0'IG-DY":O-"<E@N2\F`BNI9*NYS*DS6VQHI+==[&P5036;TS1*/0^=Y1:ZQ
ML2\-?ERRWO!#@?_8$>-Z\6Q78UC0WUU=82&@897=NBEB;7W4ZJH%4M30E:Z.
M.S:S/T@1$G*MR640-3C/5Q4^"I9W2ES)AWJG%PHF7$ZN?B[PS?JB*.--4&+M
M1X1ZO5RIZL'@!\F@!:UBUC19L6L&+^C7ZM\.A<8>4=9!Y(V9X3.2U+APN6A$
MI.TZ_F,71W#\GT8_97'Z>`8X\I2MM5W@39>FTRB</O`^.S4]$>F*:%]4=?9!
M1N:%'/0A>Y00;H_O8A#F(OIBRY82`E[)'OY'BC]DQ#U+_C:49W4PTTR8G3]5
MI51;_&1B+6+.TKPUH9J\0N6W29\<L3<FWXAMY>GJ!CSK6BSO,-D"QV&)(]FH
M3;>EH[[E>N<Z<J(,9+VEB0Y"(RPY;;VY\<:63RE.(]YG,Y*EY93,91#GM(#L
M>QR`MP;N(AN*I?W7)^C*!S"!W&=RZ%N5)^_T]DGD%X+LCQM@S,%25\"4?9=,
MDLRV."]?;A.HQ9!&H#NV[?!&9$UJTG5MY@TF@).$2+L2087.U&XWW7V2WKDG
MH(_\`W;R7-8T#&EBE`VYW$&F@*6]%?9WGG"CYLHV&\`G&9P(E;,L`#,VT3&*
M"AY;3ECN\#-.=_@.A]EC&D-4<Z3Q4Q-T;?5T(`^W8K0/ZG3R2<"6P.N=5=-F
M72USILNW2XIF@<D\P<[VG`PNR:AUO?B\Q6F!A4$IKJ[2(>7*NNG!Y,1&:"_J
M?G7ZH:JC3]*Y(&Q_S*,!]THMI3[K+EKN!#Y/#P'O6'WCLZS0.>!1E9'0(NO:
M@.K#YY3U:'JBJBNB?7V2UYG`T^MJ1Z=!03%W)L*E[$["D$:Q7",F'W--"Z:;
MSG;WDY=9_B%++S;;)'O!V/1(UIZPFWN`=E/`?[Z-P[AP#?P#,'!-RP?IG7<:
M>/*[9M-PU-!:/.UD-LR=2H2=C!/V1LL#G8F0,Q,M0SA)0)E(9&7>R5A%L&">
M-7X$SB$+F>5-I6&-HRAYTJP64==^BB[TX2U0V@\U'0_&.1F+^"HE$KP)O-SN
M&S&R7M*V`1<ON[G(\1-1)_$S9G'"4<?'VO0<%@K5!<S;3S1=$>OKD[`N@1=]
M?9T5/KTV;\B_JK*G)LR[8.'#($^)RBAN<?X1GFL;:5!5Y%R;4C7<0=9RU0.1
M+HCV\4DPYP+;/-_GG?G49%@MPZG'K0OZN.$3CG8)OEE?[N`1D_=Q&F]VFSO8
M,26WP0M-KR%^>?6P2?IXC8G77MQ##3YC>SK-QYQ=AIUHJ@8>9$47[B8PRJ@B
MC1AM5!.GF\2&/&+TT:_T"][9ZB6F:\VF:U--U[:>IUT:$6V29NE1&!"Y3]C3
M>,W$)?1+WIC]2650?H5Y0@%TH:.HRAR$#6@PX69+GUVJWEIZ42HH^89I_!==
MNQV33)I,]BC9HX=!3&]5E0NL:*_JYZ]>/%!4;F>L:!_^8F'`;,N>4JN(>>?X
M3"=X>D&%J:3.K6JJ].C)IR"/ND.&3%[VDEE!.('];JP?-<E7W3M4$TV>KKJJ
M/H+H5P;ZJOD4ZGS+`^7E?@X_87A'G$Q@0(8:/&(4="8(?%-<A>XKS>:CBS6E
MG&KZ6A,*J8.[.&1(F+Z@<1T'#W%"W[&L[B-$-^D=#G=Y3CQ%TN!#EN;U?]('
M'!M8]SA\2N,_=AH;1ZE!6F90KEVWI:9>\W(-W#2L2-/<J>ZWNMJR_9('RM++
M"2ZZ]LC;>JE.-("6@[BD^(](GV'/`=^LV\>`ZZ>`VY>`X35;MAT@]D'ZK"T,
M3BNY9H;/.DF]F67Z!$\VWW2?;.:^V'S2>;'Y1OEB<Z7YIE=WYFDLBTQC)\F%
M--DE0=XKMI(V3V-GG:>Q'^J)#H1/8Q>=B0[:B=Y6`_(D.V8^41?GSLPFY\XJ
M&-Z3[YU\CGDEUTP*T#5D7#MP8GBJ(G\(VJ)?H;63JIE6TVT4XY$NF5,./,\V
M03S0K9JE1#L$/"G6N@=)D^]8>V_KM0Y7R:1@ZV")G'';>[QYP/E(;5<1\4S7
M-="4'/<K:^K7SM`6C>^Z>I_C;#3U'KLM)SFM:_/'+B[HY4*!I\!5(*+NKG2T
M&$Z?PSI[D::I0\?`:'9UE+-\9=PR&/R88[%#()4\-4'7*EL'L@X[KE#=S:GG
M,'(U3'2B[MJ."1YA\L\._;,LWPK]!<Z&5-S=33!'!F<0E('&>PH/FCOS%&9!
MXT-DR`1%)\(3MU<<($+#Q^=+8$8I1I(`BTJ&3*U3@<-O'[/G5Q&.P3"]A1]`
M]-]V[!'YU6_7^#%(H&9Q^6(2#N%U=65C^#`&=:>A!6)-?(MV2!9":B/$JS`7
MN[`/Z84M!NV7M@:<`?.J=0,_^!*%$,TQ5W,()GBL)W`:9T488S+HJS0TBQO(
MB3@MTB^!QK>B;5NXNN-7[&`LHA5`\JC<O@$4@7.0$S681W!<P\7J66E]E9RI
M:^DKA,R7H^1KTO&JQ!ME]&3.3Q_^D7)W&A<[5H:/(OI5'[9!"T]GUIW.%7<^
M>Z?'3N?3\5F];$(I[!C^2)1TI;O1.DZ#-(R)1U[I4-#F8;*+<$1^0`$JX9#X
M6W3_1-JW;0*R,CM(IRVS^M`?`]4LI^WW+$)0%!GY`N2.?HK+)Q11'PEMJ)HL
M4(3)&-C7,C+`+$>;('U!4+02J)=/N!J#<Y]P`:V\T,E_7R6/L5([6,8JT;6X
M^!P^$9[#D9FC*J#AUD\5`AMH*MJ2JG+:%C6-/?)13=%`&@Y#@V=#,\)/U89S
M_Q03"`E-9VWU7H%2(4S?7%2Y@&EXJ%+I&B'Z9UE*^+&`BF1$NVLYEKTN3AS"
MP;"'Y2+J!@A:N/>Y3$:<SS%B<Z]&.63E]C'<Q^2)^>?SO-AL<QE^P:HX"?&^
M;M95GOE-?@>7>!J%`,G1U'$X"Y($1Z<O=3YZU=`X*6_LYUR?CHZ?KH%D`D6P
M,E5;\&]IXQ5J#6U+&3'2Z.&EN1O0])B^/EY).-.RG.?D$]7`)3[_E@!Y"LB.
MHC+-9(K";+,AFH#=G8V+8@<WT<B^+]N514E^(!K#"V=KO@D:^&5APRJ??+U&
M,I'ZT:N0.HGN\>`9G7.PC+!A)D;C/2Z?LD@[Y<F(IJL\*$/@AD_H=(F@BHH7
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MC^^!D+_7C2Q90Z_ZC15?+/EX<(F3!(?E+DCJ79G>S24-"NX>$):`&CZVVS9&
MS:[=B^M+T^'QQN2H^4WQCK""V4;L<AK_R^0:#Z>GTSU+'T2?.YJ_"WP1A]L/
MU="5B0?M!@*V%D&*,+W:X=EN@LMFZDT#C\>F8':]FTC</DZ2@(8#E["XP.-P
MD%:C'K8^>[OG;C5O*/-K^,PT9Y#*XB*6+DV_PU1"5T$O3N7=M:U)`/>"3U]_
M]?/[K[[IX/;(,-KC5>H4@PGQS(P:BOL$4;FI_$Q6/KJA:U`G@M_3B1D6@>AS
M(&N'.C;9AXW5*`@>>!.Z0U?*?_V814W)$V]"*B)BGT(F'R,$]HY,(8'RI!99
ML;H2T7#J.8B!#1F)M?1`D.>!XY&Y-X'!%>_@(=O!E9D*8[MOH+?X?G[OF257
MB)?:<LME:\&J9$$"#Y=]?,*XO(;/F-:]$_5W5OA.#&A0:HPU1;0MJAO[=N"E
M6B%Y\3OY\KCE,\NR=V)*K@^HI"!UN<_7$R?U"NI5ME,MWY@`81CF.QQ=QR%.
M"WR21K=!B>'Q\'CSL,L+JF<O,19'53@Q(C.2;L*+IK`'T4=&`%44:,T(1@/M
M$4%`93XG2GI#:$;8204;\EVW#':^!WN-9TCTM8C'C@7<\;VV>4Q+6+0E&0HR
M$@8W#-@."\-;WMN@*&#79319GFS)[/2!)/YKHPQ&Z+/W65H^D<_\D[B*-VO[
MLSX9':>;.3G`/OO2UE0Y07L(_WI\,F@&[8H;Z=A0P"!I+P`8CE"<!CWL.$Q[
M3Z1FT^EER>`H44[!B>57@3*2('\.'DUA=>R:1&2@Z,^GISA\0M2LI2]P&HES
M6@VHS#PQ65IL*K90.CPZ1H@@9`&_MH@F]ONZ-3P#(`-1H7$H:.)AU-!D^#[9
M1.6PNY+<+D!0=*1X7\)]LX-\`=&P?5SI&"&J_[E+7J22.M0]O2Y.+-I@V'T.
M@09NQ7+,H#TPKLK!=F2PG6S?1%#)O4I3R>7V$0+WD8R6DK*TC[S^3FTD']#@
M@:*ZE:^VT@:&1S93;_@=F>TMB&^":R8`VO93+#W3I^<9F%0Y!2<65@5*/^'.
M'P,\`M-^"ID']MD4BS)?9K<'=M.2],1P:TF9V([KB-B<*;K7DF+G(U(!KY<L
M9#XBP_!:4@1:+U?WVF&%[)F`7]?5K[M%8/_GW"T?B,0$F:Q]>1@ATO<XWY"O
MX$V6$U=H1W[^.8W(QZO2?LTWM2R\-C$GQMX`ZJ!``NE*Q;;I#/^UUWW&5#1C
M%V`L4C"-+5+R7[L]I,%L2,T]A#%0!06JHUW>/+<6=')K5Q`T__-M^L_T?7I^
MG_Z=_.OCGQ'38ROX-\*?@\TVP2O2ZOB?W[\_?G/^YRYAJ*C/"MC@"*V#D%X$
M@M+[L`$A%(C4LUU)L:+[DO(I)DUQBJ+@I?@6'G&!YP'('Q]V)4JS$B7Q)B[I
M6P`K]`GCWPOV<@"+]N?HCUU`^OL2DS#5-&(OQU#-3%!COS[E;C2PD7\CIN)%
MG7T>.'&E_28O9KZ;-J-K[1L@(A+89''X>'?(!-(=K\C^$)UG'I12QO0+[8L$
M;(P&R$I"]!;G<19=9CFHGCCE+B/_T1)Q=S=O,LG@#$2$-D:L-2+-4:>]>R_'
M!LN680%C7<Z(Q>(Q(A,P(L_E4QZ7)?$74AE8YLQU`J$/+PC'Q#?)T9;X"[Y<
M2%8+GN3)'KG4M?\;>:VHD^IVL_ZX2W]G.7`7G[>@AO1>?%-3<:(H=,`-[4\W
M]Q%>Y2&]ZN39NI][O3$>&I2"!VA5SB>>"YJY&K'!)M(FP08>KV)5-S70>Z(W
MM*52K#YT17*Y&R/5VV/IXS4.R/<O=_`DV?LXC3>[S6WP0GV=\QT^V^4Y/U8C
MO<U@2-WUS1+CR1A>"*X(($9AA1@-5!%!-15$R*S0!_RY1/>?<$*VYS2GS(\=
MSV33P3OD=7[#QH[CM6[=6+&[=[)^E=Y_RB"U4?MZHCEA5_<6;:;`6LA7(.40
M."/$:"JP'P6RIY@#PF$_.+?*H_E:>JG3EJE]E&?R52R2Z"F4Y=XG#L2*]Z9E
M`BD'<F[D?('Y(#SXXZ':<IX$3&G0.>SOH1:X)%PWCUEO*7MOU[N3,%[D@=HA
M6G;9+!`V^\OAF?8!<T]CV_N<[:-8Q\\SV_;V"P=CVKN3,H&8P_GY`1MVV6P0
M]GMWN'9]P/S3FO4^YWLG_O=/.,?!NM0ORFY.V'.;OC<%(V6]I75(]EPZ`V)(
MOAOU(6]/8=,'C.V=3,]DQP_%>(\-JT]?,"<K@V1.`\V36OCFH9KE.6SQXL+Z
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MAN^5^9$-6^R>=5RR+,7>&:"!+.A8H;X@3"*5]Y\RBRT<K[\G!JD+2,+FD`WG
MWU[,!H:75E4V?"VI+3^Y*=-IQO,6AK4O,*XB_U64Z%I2TD3CW&1`Q8]S.@XX
M13B_#1=>BVN4>')8)5HZ@Y,IP;J-,"FWF"PO41J/^&;=<GM]I02NJ<%I`OWO
M*(;PNMDE<POR3@V2U73T>;0E`M?-.FJ_IL-NK0(EU"7ECT&;>AKVC41]-XO=
M`:73@.><!GO+.,D\B&ZR;;GST\X.1"('D^.9=;57'VKC:ZT[EK/-)SD.;M;7
M01KIVN%.#U<V=V_0@Q=7R!^!\^#/#I^/,1IKF.7;C%A)D*,U7#%_PD%4E9GQ
M([E6"T;"F7)GKLN0LZ5NRH"MG67&W+4W8C_@L9=.>\0\RX(90%7GOMQU+KW#
M'=+%RX)-BN^N<]/;&[MHQ)<V:2Y<IIPZ5:#Z@%;05TK`2?17`4GS3/R"SUG+
M1X-'P!FZW1Z$B0WQ[$6>9-`\"1CK")0X<JPA32XRV3X^!3D^A1C$6;:!P;"7
M2O.<K!3+%SA]:=M4V7<GGX(\$J6[2;7G=!]V;;2GG$)9(AWM>?1`@V)=^JC[
M`2BKU&U8?031K[C,N5N(&4S,[M0LN."VE'Z:?,7DG>C]3LXVI[VA#S9+E%&A
M@6^O0',G7;YIXLSX@JK=FJG;<:?1+5F=#\$&V[T4/<L8G"O\>2:V+PD7?^R@
M)'FEN7U]DWI.+M/3XO.QV'*R>K'9)MD+QA_++/S]AK[]JY>4HR;@2M'+(`U8
MO6J+:&/$6ON1K6,#IXO"&_.E9#&I*5/QUW*B4DNJR1/,W+ZNS4@/R.!TC?P7
M@K\[](/T)]-$8W-687GVT7MU6-#+E4Y5^@P=IG'H,.A,H8[2L3;*@D#HS2:-
M'W;%50K'CO$S!OJDU5N+3#L%*:<Y#DJ8@V,$U@$U/1#E(^CC83+>E/`\2D4P
MAB7.UY,`]BR]0$\BU:D$6N*XG)&Y@[V'26RF[>#*M'2'/.`T^)MOX9C!'$M-
M27^"%^8%,PO#Z^K:6]V'(>`07X,4G#70\E2'"[`<WU1E#LS"`/N=7.F2_M#[
MW%)7YO!J@Z\Y:&_T'Y<_I#J0QQP+\G/P6<K/4@'>[^Q:%_:A#%B%_=TOW]EP
M\-[I<"[_:&EQ'O-X=`PC"D]?FUX!F>!+SNK,3#%)@S"LQH&YXKS\VL-+)],Q
ME+R,S53<-")@0S]0G#P'<0+G[)=9_A/Y?`F5=6`PQ5V6).27\%6CZ(T)7:>A
M'+,)X`I`@9KN]%H*)0#W5BH2Z%<@@BHJ?MBJI;![%/X9A_8$Y;"(:]8`Q04*
M4(Y!N\1)W#XKBRI]@T#%T#(X#_@Q3E/((*9_K]YN*[.J1D[4_;5GL2,+Y:`.
M))EKAAG5VPU1NV1I3@.RUJ%>JJXA22?)N\:P[?1:1095=-QG^8[&7?T%!>6^
M['J0\3L:F^@27<'6.FC6&NX4/M*UAF>L&75/\H+MY%F<*6PAS!,],BGZ,OLN
M_1DKK\094/)*#_5!FJB?2O=4G?W5.2J,-9#'F8!,IV%42$2*I7VKNH=UH$SL
MP;YC8%/\&!#"SE?-+ZW(U27FRI"G2&;3?!>?<1[&!5?WF7NJ?9I>;C6'P"WT
M8=/=_^VE&F\-"L\&:OIMI!J5OIYL<!_(AE`@NO:;0;[<SJ9TSL"[2Y))'*Z6
MEH<N5Q>HA9)INOON=LEPUF#"V<!,[7K)T*B52M;'Z_E>3B"2MGY+7QYGC"9=
MI)$TF&0?:=NG[*47(YH$N]`2H^(JLC0?^EZ`"=/F!^#=Z.([O"#35$(Y60"<
M)^L'<)A>1\QV95$&%(+\['#:DU?YUP_NT%TUF9,?Q*]JS4M^:#_J^.32[9Q^
M:#PH)K'.O:9E1'2>E`4=^3Q()<>XQ#3;;OH!N,[8FV-*%])R*\2^.+EZ8X?Z
M'\L@+XT\S27G=+$33S89Q+DYE*G@^^;.LS1GTUW3U`*P5%R'H_NILUY<I;>4
MGW_*LV+^]%')IP_5M>5/X]*'I.;E5)?!??+XF-,CS4X<K]I"SS45+GQQ,R8H
M,[0EJ)X(L7HRPFRS(?:_H.4@?#F374#3S.JDB]7,@EH:5O2J*'8X.M_EQ%JP
MP;"=6*=$AOEY\8@O./>Q;29E3B>Z_@[<CT9L,,NJZ/FG2WD4[=XAM!85/8_/
M5DX.QZ6[S/(U9O7O:ZVWE$O'^_2ANG3\:9Q3_W2^Z$H#.9S)<0?9;C#89O09
M8S]8KT\R;[-Z?6)--*8>T&#7?YO'(2;DZ5AL;Y<9D'5;)\@$OHC%N^<QM#OH
M.:8>O;U9-@IX#Z1'I^.C8/U/O$%F+O\:E8A,A7\^_65Q?<R,HI,40E/0-HK+
MNZMC8T%[?'-L+#113D^=6)AUUGE+UYGH(A:A\R35T$J,Q0F'-C(\IQ+B7?.8
MPH]:_@J9M=;7OK@C5TJLC:.[9?.#=W77;#YDAZ:;II+%J;REJ2]WZ7W.[+Z%
M*4T_G:8!\#$:RJ.+&-,!]^E"QGA4AZ:9QLO=>+^)*\CS:2/[^QI&A'WVFU3Y
M_#I*R=>[&B.A^WY58R2\0]-/$PGC5([3%W-+XQ\X?GPBOM\)D;/@$=>GN!0L
MQ-+6SFYPZ([L4,]+K19AL9SH>DBH&E.3[%'I_U]/'@KZM.87=RW$?C$4<^;<
MK7.O/I:Z76*F.[XXQ6V<#+?0L)QGT"TV_;[HZ2_Y4HOA$OS/N^HR;H*^_`LP
M.BITZ6LQ&OK3(W,E?/J3FTMN:++L?)<)A^3MSF+2:;<Q5?)GT#NVBHVDS<Y<
MWF#-LIN8=0$4QW7^;ANFUP;C]@N3JX(#TKR<?,Y%=PQ3C\_[K</T"S*K8N;F
MSGNGG7U?$B_RT/T2U$G]YGFTB$=J7(3O,HCS7X)DAT^*8K>I;UAM<4B0G<?/
M<41V9W=!.9W;/'H@WCK+$TSQ#-$<^#JBGT>=[\.=2C8"5`\!P1@.PRN>8::;
M67B)<7)`KO!4<CU/P-Q0J`]<7_Z2)81,$I<O`HTY3[S)8$C>.[>33+L++=H.
MPHD>]7#6.S.R#D(BQX?GLDZG!.:-[AIK@`-5M'=Q\?MECO%56F(B1*4SQY0[
MD"_",15,\8(J%4:`8`BH'L,7ZIEJ3C4T.UK#?,3U?.2<^?@R7%29A"_GHDK$
M>V'-^:!&]&!B#>YQOCFV\DSG&8D7#NE<D^S"#X5O^U0;:<GY/<M2FBFX"Q)$
MAKQI2[YWLXS]<\V7FI^&2>CD?/V"@[SXQD^O?%:]I^^,SZGT#L`'USF^I'\\
M)P:RP;U4"K?IL`[./[>>_CF3`C42+=@K*S"HCKTZ;/]]LJ6H^QP%U62M88:>
MJ47O/*)4I62@B);"HVER+-OORWD>P%*K+%B25%>EC+@Y>/''+BY?[N&!%J.+
M@=U^3N_][0,8>!STK^A7^O?I+W#87VJ3#_NNO:96!@^[),A1%!=ADA6[G(HI
MZ^[9_30.+ZFOGPT9:<GBNT288/W8($!DLQ1F_>1SK%_L7$K$F<U70!,(2ML.
M_0HM/;GS-!,8=Z9+A_'DAD:#ZY83I-X@SK--$`_TH6K?Q2?B.D`C@J;B.?0K
M:^I'L<+9T#C?K4M93VNC+>.[Y43H'P$XB>5[+'AFB:M']CNYLC7]H0^V'.SO
MZ%?6P@^;HCEH?[8[7`:1V@@>=RS'T&?TR0I:.%W(U%+)'A)P;0MXD(8Q8/I2
M!VWDC.,G1>&=RA=REI:Z%['5<I)QAQ,H^7T;Y&3C0R2T"$*Z^3]]Z?[%9`]B
M0-&5D3`"/=P/TR:(MO'-F3=?3JG6-EY+-XQKY^-S*+A6ZEQ0"@;TU1D6+Y"6
M:A2NSH@`XV6V2R.<%R=IQ-3MS?HT"_)(S]'5(>&D#*(25I^#Z@Z(]$"L%;P#
M3SOYX1F/Q!407`S-!L_RRJAY<4-C,)VX:YRNLWS#3JFV."^),-"#D`RMNXBK
ME<S6Z`$H>U+14$_HQ`4,M21NA%*@WM=M]<;=R6..:2CK/W<I)FW?FFT7]`DZ
M/:?0A#PX.:7[B+H?:CHBZ(F@JU^;C'FQ>G2`8XE1H&'@\74E>L^.>TR$6'T.
M9"#!RSF\5VF8;7`3:[^&+\%YKL'63$;"U5Y,#JO/LJPU:IJCNKUO&S&-U9+N
MO-1+Y9SS['9=<F*N-V`JJ`;\Z.N^3&LUM;9H.DNY')?^A%.<!PEQ$T^B#7&0
MH5!F&3]C2#=,"VQVF*%'S)7.U(7:Y]:J']TL[/=$55<_=G]3X@SV<6+6U1L[
M8<2U4HMAPK(.TEK.DJ`H;M;4M1+X+(H7=T6$7-L,&<3!608T:3UL=TZ+Y5R;
MF`?5BBUX_-<9@-!KX8HGIZ<KI<\%H>(OATZ([GSJZ#;A,BRHR'`>X^+DEI#$
M>8ZC$8?),E+.E9D4YB!*0ENC$]2T]_FPV1+;ML%6>'D$K<&9>OI:R99+2]NI
MIK3Q\QHE))QEPDIA"3CPU!OIFA&3-Q9*@_/DR;!*MAM]0^(Z3O$5<:VT?6AN
M7P]N2G2!B&Y+0!M$&_EW94(V?CKN&/[8/O2#UG$:I&%,MJ85:T+D/4QV$1&#
M.$4!W+!(\+?H_HFT;]L$.48[N(=69O7="PQ4LYRVWXO>$T<I(U^`!(%/<?F$
M(NHN5>>@!8HP&0/[6D8&F.5H$Z0O*/A,A+)ZW9J-P1LS)V-\W2L=?:X?(8)P
M:_5F7:4S:J4,[/=PDB'0'_3@72JX`WVS1E4+]T?_6@,FVYQ/,PW8_'Q?->+N
M-:K]P7MR3L]E;/&Q/(^K1XC5AQT[VC^)GN,BR\U,VZ"S4]O&@=)G!M8$)*YN
MY,5&R7#XA(6#N89O;YHUQM^1Q70`Q3/+)Q(,M>D32,4((:7W?&_6G:SELP#J
M+Y^^U#<4M`RB!ADG5E(+WJ"R'[VM3B1Y+]F>=42G+TAT=V-YFSH"'A&/D,&C
M(1`4,G@/+[4-6UX!3(2OHPJ"3;8C/KH:JR<&6U\:Q59<6Q1':(V3#=FGQ/^B
M"]EX#&2;_!R'^"PK>$ZT6!TJB3DU_1I0^PS8[=)QP5'5"T$W?YR#L0!;KQ<5
M%<!P#H#V[H,%PGT=H@3KF8.A*YYJAT-3-I<\?"8*[:HH=C@ZI[5C6"D36O6D
M8+^_S/)JA`9%%HRHNJNZ8`B>GP++6B)&HBESQ*BLZK^NL[Q66--[`M*">_-`
M;S<X!>V#XA9G,1=.NVH4DR&MG9X]P/TK!A`S?)!<K'!8Q<)&U!5E+2SD?/SN
MBM*_^!P^09DFA7X2:W4E,:=^D@94X3Z+=D)-+WA3:3[=8^TH62-L=0YN(,ZJ
M=NQ=)0N,'5?I>0^N`*UGOI*NB*I])4WY=.XKT7%.[2H)B'KF*0FAFSA*E,B!
M^4G:P&E!RTV0_X[+5ISW@B>5&Y'C,,OAD#,H()UF&\21*!/7)S=*>R(&4;(O
MRHF2ZP`;'TJJ`)SK/.;A?<"?Z)\L,I6UJ#K/]-,%K[LY(FS^F&>[+?QEF\?/
M4/(V3I\QT00S'!"-*,-N"QS^0-]J[VLY@KP!"ID5!#U1],3+@0R6K^-:'PS*
MBSMQ3R=<?Y&VB],(WC.#TO-"!G"?-FDD_)H9[P:2[US-424LTW+&-F)1Y69L
M;V0\K>'"D>ZL@>^>FPQG?X_I1'5/[:%-KK,/PB$3JJ@1\[=\7;ZB))O@RO_K
MGA^8.ET22JX=+2G(8;&[@AY!U\U7J-O!*P?""%?_%#"L<%:!'N^\`S5G:A;X
M4[#E^'AQ?5#/A-LD`:?7TV7.S0"$T'#521B5Z7)HBXW&?Q)%,2P[<8G7NS1"
M>1`7,XS>-BG(G_FWSOM10KA_B@N$$U:G(><$HGO0_$KSX8NY,K.'*^,3Y.E>
M5;Z3T:'4H+,7>;H=*.(\W;J1%Q;8</B$M3D[<H\.DC2@B(0WE4'T[?A()#SZ
MN;P]R1DAR._C--[L-O7^J#J**JY2=F/FDMU42A^U'`IM8DY\#`.H?;:KNJ)F
M&UD?0!=$(U0OWZ"&@'MS/@%4S$"MZZ:(GER@*/N4'N5PC$&VREF):2%@M,9!
MN<NG/\0Q]P)&(.<=2F^JV8@[\8,J9L+FHS]-GG@+IF(M=B`,97J,*@H^=[]T
MFY.]TBW.Z?=T])%8X9I1=NJ-F$["0'Q9_U9340H0Q*PR9CS05_.C'QP^TZG8
MTJG8DJE@N29P)!-E21+D1?O;Z4]G[!VBL=/1T6B;:F:$D^&1.IM*D+7=*AO]
M,$+1G1,;>@<F]#;/GN.B>@PWSBF#P(5*O?M3&F2<^%E:\/JL"IT0[87:;JCM
M1Q_Q]N#VE#VXQFFJP>$67#D+.'/OR0X=+L(\WM8AW4@+K"=^DKXHBCTD33FL
M_S=*=9QE9.>7PS>HDM+2$_T^3I3"<."<E^JK%LQG<2_K1F/>SC)F<Q%6#[KC
M%82]\;?^@"?R*>!WL3#RF7W)H\SZ^U6=.K9=8K\N<71L?J*I(NC^8%,-62(X
M=97"^C81:CIZL2\9@W*0(A>*H'EPT*G)MYKGG7I,ZUPNV7D(3RCY=2OE5)S5
M!%6!,Q&_JWD.]&RR?8QQB7)2R4:_-77.+9L93\HKHNHPY')21CS@$..HN"3`
MVXCA?A$\]E^8_(55`DXC2=40J<X:^377=G/T9/6YOR:(@._:"""1AEZ5Q15J
MZ=:_@1L)KHJ4.)JF'(<X?H;[.#!?4/.N*4NY%L5&G1OJ:41,RXI/(E]+*I_N
MP.YPA#=;[8B:'A%7!EX%;<CB/7EONU@$TL:.SE9-B%$5#%7>HN)&T)Q9=JT9
MD1IV-1^:1I2F\J,[)8*V<1DDS..XPY#"2>]Q7>[@++A6&/JNM2EA=]ZV^13(
M'K->H8I,[8'7A.@]44:JL>:>^.7C9V#@JN==U&N&^M&O]^ZMF5_AP]MQ_H(W
MAV`\IT&!(S)6N*[+'B$#._](4[%.7]HFM\$+_.KD4Y!'=;X2`W3R',0)5!4F
MB'X2U,V5W]6::QRNMP(S3O#@BA.T/'H`0JC[,=3Y&E2YZ[:KOHCH)U>H%=U*
M837?I;+[DXO:P;Y,[T"M!7MST]5KWFTMYA9SO<N3\\KXPDKS00WDH0^D/3QD
ME[-T/:CI/NCLVN:$4S:#WNMD([#/>.&,S3EIM,D+G`J2OX-2R^@FI&`*S,TQ
MQLR\K^.Q32UI(Q("")T0SH<?\<WZABX./?<\*:]Q`'?.H#8+NP.2G@<E:?23
M4:AUU#><)E+:3\P@[-!0@K1O1JM*JSPI$24'?Z!5<*KR9"D"FO#;G_P)J,XW
M+8UBJ+((@A(E=%K(']8P+54^=8HBF!;R6_[&;O9TB27F171%92N>+\%D041Z
M?\(\2\<<J7S4B9GC-,^H/*MF3_Y+5K)[\M5(-'.NQ/T=Y5_)`,G"4XBU1VT'
M'S*S3-!4`/8%L)LB[D7:E@FB?=T+=\$`8+WIK+S7L.OE!N!^^))UJ2%=L@PO
ME6A-Y$ZURJ6K>2;QHC1(>^,\:4V#W&?JND8]]^D0_*2Q,]`S[#U/Z2!<(JLI
M^!_J">GK#3,'2%MIC+^#=_&9?#<N('[&-JK=KU>>F)8?9$+/S:5@(\"B^V:=
M[E5HJ*_VZHVC>]]I&L2X@[@-#W6EMI9L#YRK<9!%:FQC/!6>N%\60BZY'VPL
MX0=P;DG_\0MSJQD<X[S]2;]]L.>3_(F<(39/_X6J+\T5GA]1;';>"80&9$Y:
M[5,=/@K"](=Y&#MN*H+PCUV<>WCS8@XE->])JUA#'<#I*C-%Q<VN+,H@C0B$
M?^#X\8GPS`GA:N)HWV%X*9O\_BQ+RSP(RUV00-;==[.?PXX8VL&=V(Y:AAGL
M1S4>\D,[HA6JQX2J0:%F5*@S+)I2>]AGP9,N1SM)86>2DGB-NT?(6?LMYVZQ
M!UIEG@/GT2KE`)SU"B,S_"<I'++CD/QXG\&O.AN3D\?''#\&);XB4..TB$.Z
M/5G,LQ\]T(/=!DRP1'/J_,IGA"M0]<B@,#C\>M6-[9!M1CT^U`R017B^#!=[
MAG5J9RQN9JP7%O'P40C7NFA>!WXB1;2<;3A)*'$<\2%?L#>D=!UT36JN?&IM
ML`-1JSLBH7*\F.FU+?.G*ZQ1WN$P>TSC?]77P'BGW8)'Q9SYE6;\*W4%C9AW
M.0F]V&R3[`7CJL8]?W`?,EJW%K,(0G&?E4'2_3N4R?^0E?_$9;O(]*"_4EBF
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M1)7KM/`)D/@!.W7$=L$G[-2!6?$+9.S/*T>5%L>,O*UN$+0/V>V56O1.)_.8
M2C^Z;OY@VC2B<$,\PP#R:ZZSHC@+\OR%N-+4@='5OQ(*KO2O%%2?U9K&"%JC
MO>9>[".,T'P@^Z.L090`HA"Z(!$D9^9$S7E2<Z)DNP5]F"0HBN;IPYO\#A(?
M['QH,277ID8*<N#30&/0WE5S!-MSZ."O1ZU<0SVO6K6`CKGRY'.L[U@+"3CS
MJR60#%@0>GCD5JO62>Y5*Q;),;^=9Y#U-8D:K$AYJ0<;F`9<R/H<B";<7T=[
M5;BWB".N#[+ZR:=U">#W&+8+*L4FZ>GD2J`(Q&`;5Q>+KENB7UG;`?,LZI^.
MP^#!;3W]L8>['%ZK*Y^"$CW&SP0(7!1^RA)XR@Y^S*E,EQG:DF$_!06N-ZMP
M+X0]#IBB(`RS/**ETC_%Y1/M2,L)0ROXCS@MRIR"6*%=L0N2Y`7MMG!GN<HG
MA/TP*K8XC-<QY!'2(UI/+OM)15)\K4\FCXZ-ERP4::Y"%PU+FFMF:8A2;,4<
M!RK'+,-H8^8N@-G<>#TIBAVKUUW4N97G\"HY3J.[H-1.5-2FY\KS-P#<9][.
MY?A.YU6;@%WW1T#`BXC/"+0-F)<8)_Z4331E6.F>QY!;_1#+7[*$>"8)<2,$
M@BE590:475L7HTDP%M:6@A-QG0]Y!]@Z"`F#>F=.S;E;R[0:L[9;>;Z+B]\O
M<PP7%3!AL'*LF>72\\G,"@#K2BYT1]`?U03\MK.:<*'9T1I@Q36LG`/+*X,K
M8UUC@ROA6S\,+EPNG=+,4GH^&]<*L+%)=7&I?&J0[6U*\G?T]0L.\N*;@[*@
M778=;3<[O'H`]ZHO_M@1"W_5!+^*F_()Y_=/05JEK;.B<U=5+?/>Q7+Z1RA.
MUTR(KCGV9\!.JVIX,0/SO*-`1XDZPT1TG!#(3=M;V6RL$*%EH^64XZ!-6`W1
M5I]ZX</XO(1UGZ.@FL;]6G6?ZN.,JGH4BG8Y9*U`*)PEK/N3K>+3-*L=-G]&
M._JDKWYMISX@,,O:E)%P6OA8"$N0"7FS;D__/$KGM,+2%7U^,N?LAX$3@+EK
M"W2F(ERU1F/:S+-2PG+)4I<,EHK5`;B=/`?Z/2Z?LNCG@JMAIC4,BL\?G$NH
MG,X9'#S1WI9]%\&'#]M),Y[4"OFNJ-XW!6>+S6I'.QV^5Z4GN_/X2%J"NZ#^
MVST4^(\=&=W%,_F'5=XQEX;K6)<`V$"--,T0;>=MBK%LH?0NBHA7:3EVN\-D
M;Q!#D(E>XM++O)-W=F7J1%"&GE[=KKZ>YT/ZW0@4+",M\.L^B)2QI)I<QE7+
M"<9]7";X9GV51I""L`L20:Z]5$?PB;C6Q")H@\(QT`X<C;:EPVQ[BXDVT<:R
MI7+(=?^(RZ<[J,@#;LE3O+W/+M(R+E^$F?A<830EZTJ%F\,?JL6V,23PLN9.
MT_,G61$=Q6FWRJ->_4D#YER?I-%I!A4BU^=QCB'?19S$+PYAZ-!S&N;3`SQ\
M^Z;NA4@W1/M!!+#IZ<P#F1KI1YS&9)>Z:0%#;=P'"IC8D:@FX%&`T`[H+<X+
MV(3G$`LLH"PY+5F>)0G$!P$TPUJ??P1K."NA2==!BC!32M",=4<%E**!IQC9
MFV7#&?,LV&@@^>K(H[[8.]N&7YN6,1'V=Q8(%`-2;\&O/:Q?HEHA>;1(OCP'
M$.XV/-HS#B$M-2[7FZ$%%\"?E`@O_`P/5J`]P90_?.5\?[NTFIBWCKR=CABQ
M48$8__L@_QV7U<."K$C/3VRU539=AX23&\=*6-SD4=:C?6"4=4(_N7GS;2I4
M&X:JR4::^24[\^O)=K`$>#RY)*PG5^+;PEI"Y::0''TFF>@?^CN.AE#WT50)
M':;1'H>)&N%7D:NRCE;5B^KD`TP/&`G*7$/OJ0P!@KA"P%X`)QMI)B/H:^+F
M1&0G'N1%^ULGV>/:DU)+B!Y3M?\;5W0#3E?(CGL_X>><IC@QP\N&<4N(X#RO
MCF,Z'3A2,0WAW[2+;'<X<%I,HR2,GL=!J*^7XX?80.HJUQ4?-V-!PXZVXKC\
M9"ADMO6TMPW<ZMR2P&WR[(K,S2WGR?BV)]`3K<.KORWDMDS&-Y;K#SE.8;;9
M0$B4U5FAW^ZX.U,H/0`$=5N@AK=<B^VU'*F6N%\=KV=JLK2H_@0*PWJ8>V\Y
M]<?:C#+DC7)9$>\OJE!F]Z?"@1#VUT*2M-R^[](*3COA%@(TC4N]KR.N8[+S
MCRAN]@=,1BBZY&5,PM[A-AWE&*GMF?L5ZGP.M=];65Q*6@B95-"[:+;--]@^
MUJ4/;CH1?9?<D`L7E#`66"NJ,NPJVZ;5;80D:8QFE/14]-OB^M/8OZG'+Y61
MVSP+,8Z(NT/8=.CO!%3\4TRU^9_>K-Y]][JGSGU!J7#ZSWC(W'D`)N@'XJ\6
ME]'U+T_V=8R>EZKL.<)KU1[5*"^6E9(\&>R#IW1L)T4BE>T&3G^?XY[_]1F&
MZQ&KYW!A#UEG40<YK4]Q@7#"SE9SGONLN8`3;DE9R4QKX9?U'"O\.J.:0/A/
MYQ?^J9#H"/^IW\*O8!BQ\$OGT(7P*Q;56OA5"[@G_":A>`_OR/(J/[T//L>;
M':_>TN)#&'F*MN`LC3Z4F^?RK*!BVPI5PW=^,+;@$G'/V1;C8C;1UV0@?R,_
MDW_!.I(__/]02P,$%`````@`_(IL1[U(EN`M+@``SS8#`!4`'`!N;75S+3(P
M,34P.3,P7W!R92YX;6Q55`D``WL1159[$456=7@+``$$)0X```0Y`0``[5U;
M<^.X<GY/5?Z#,WG-7&3/GG-F*YN4?)MR8ELN6;.;\Z2B)5C&+D5J0=)C[Z\/
M0(H42>%.4$UR7.?4SHP-@/CZ:]P:C>[__.^7M7_TC$B$P^"7=Z,/G]X=H6`1
M+G&P^N7=M]GE^W^\^^__^M=_^<]_>__^_TZGUT?GX2)9HR`^NJ%E'C%:'GW'
M\=/1Q5_O+Y8X#LG1KUE;1Z,/GS]\^O#IB/[UDN"E]_H?1[?A,UH_('(T.OF/
MH^-/HY^.1L<_CS[]_-/)T?CFZ/U[]AT?!W\\>!$ZHOT*HE_>/<7QYN>/'[]_
M__[AY8'X'T*R^GC\Z=/)Q[S@NZSDSR\1KI3^?I*7'7W\OYOK^\436GOO<1#%
M7K#8U6+-\.J-OGSY\C']+2T:X9^CM/YUN/#B5%+*?AT)2[!_O<^+O6<_>C\Z
M?G\R^O`2+=\Q&9#01U/T>)1^_N?X=8-^>1?A]<9GW4Y_]D30XR_O@G42O6=R
M_/3EY!.K_>\Y.^-@>1'$.'Z]"AY#LD[[_.Z(M?MM>E7I?(!H(P\XC!:8\HX^
M+,+U1U;NH[2IC\VZ>18&4>A3I8C1\M3S&2'W3PC%D6$?Q>TX[.!#UG"4-KSQ
M")7)$XKQPO.;=%?6JL/.W\?TOXS&:/(XV2"2TA=]"[R$CE:T;`!`U7)+(,Z\
MZ.G2#[\[Q\!I^&`0[EQIE=%G&L*[]>*$H#+YITF$`Q1%XT6,GW&,440GC_MD
MO?;(Z^3Q'J\"NF(L/#JG+!9A0B>58'5'>TX!F6)V^^V&@O@6X'0!C>F';G`4
ML?]O-OC;>KPB*&/#$)Y.BTV5<W)S<S6[N;B=W8]OS\\FM[.KVZ\7MV=7%_>F
M^B=I2=E)HR_=Q^'BCZ?07U+9G"-*)V:KTQU%B`AARD]_?9\\_(X6\2R<HB5:
M;[*%3RX*VV;=@KLCX3-F.Z?+D-`AO=V231ZK_5!AT6REH?+<(T+'S>EO'B&>
MN7;7:S?LS!7=KJ[1S'LQGD7*-9M*)'F(T)\)'9D7SQ8#?J]ZE^;F+LS1KN;J
MLW"]QG$Z@WK!DHX0]A':;]KTS'OPC4&JV^O$%)AC:V4BU`5J-*=8L<%OHTMC
MZ1S%'O9GZ"5.S'=Z;?:D_3U0(^CF[;N;*,:U@5W(]S)A?-S@`*^3]9WW6NI&
M@WG$[G/MP6W$FWZ[G9@G"UE/TG]NA]7KMX"V0^7U^8X>V@N"6YE,37K0+9']
MAO#JB9XRQW2@>BLTCJ(D*Q'1O>@%[5#XBE"&:@M@U+8,;;K4":'6QUPK8NKB
M`*SVJ2T%J7\%XB1G1K%5F^X.5HW6`'$[;K>,=BNOH)$VNF8I/WE;C@^NS7HJ
M;\RHJ[SK$Y^0[$,!6C%S)[L\^<(N3T9_2\%L?WSM/2"?W_7R3<R72EM9I8__
M=72('MY12L/E16#7U5KM@_;Y/O9(W*#7I?H'ZO<LC#W?JL>EF@?JZRVRDVU1
M[U`RI>L/LI/IKJ;#OL;[_306Y$Z"=);:$!31&2P]95_3;E0Z2.<S1/?CR[R+
MK`$'EZKI]7>XJ'S*9Q?.(5'-XNPG<UGCXX<H)MXBSAOR&=:T^;EVW?FG;`;7
MZN-6&JFD([3XL`J?/RX1_LC.,.POK/^?WW\:;>^]_YW^:)Y]>8I6F'TPB&^]
M->)T6%1TOMW(E;D;DVI?/;+(6Z1_W2.N>E&_+?$QNYY]OWC"?L'Y(PG7YO++
M^Q(JD1R%A&YJ?WE'ZR01[628;EP]_R`4G%$DQ/.OJ)*__"]ZE7)0*SL_[B\)
M^U!R%D8'IF%&/.:!<_^Z?@A]@?@K9>8G?11['4(N[N,#B_LL(0SE)8X6GO]/
MY!&ZMSJGJY5`\J+B\\]])$&")N?C!&06NL0^(F>T)ZN0R.>@2LGY3WUD@0\D
M)^`SS#(0KM=AD!E1GBCX:)+$S'V.C5GYFB"I./];?^E1X,K9^NG`;.6P9K19
M`2_E(O._]Y&!&H)<UG\#DG5Q!I>L$]RR\W_T6?IU*#D-?S\P#6/:F27KT*7O
MB>:B2IGYESZ*O0XA%_<_@+1^MTFXI#^)%'I?*ST??>HC!Q(T.1U?0.G(QJ0^
M(:7R\U$OS\Q2/+LS&Y^5CW7;3AV_0WN/V$'=2C\>O>@A%742O5]YWH8IR4\?
MD1]'^4]2LU!)6[8_GA>.P9/'2QS0?F`JMS#""MN0275K\Y`]JG$445EJ]+]:
M$,A09"C,FMX+H0@M14>;_'+P.I.(L/]IYY\1>0AWMED()K='46U":^6!;$]B
M9F0,[O=]$$2R5P?,TX?^<?%G@I\]/_7]B<\\0E[I,>E7ST]X^V6C^D#6+B6!
M?+YU(8F-C7U2@"FB\L`+NN`U507#EH"L;Y9*80Y.;!SMDWK<$;3Q\/+B98."
M"&W%)5$";GD@$Y\EU2((8NMJGPB=Q$^(5"0B87._,)`YT))*;O_%1EI#'N/R
MW3C@_DMWWP5D2+3DKMYUL;76E+:RF\BA9]-P@TC\RKR"TW,T74`V[&AQB^23
MJK@:D'W2=!.M@#",O51INM$X$W%*`UD]3<GD]QQZPR-RLT$;=EAG[QE*_18Z
MUG!+0YE"%0*OLJ/H_R".JR5,MV&P,-G`[,I#65&-V%0B<#9E`JZ'PK%8+3`?
M]<E2Q'KK[*P`2,XU]AZP7[Q2+#W=8(MW_*JQQ.DV,1_!6HB:F7A-4`YCHU-"
MK&\#%E>:CV!M048$*G6``VX0:^_V37)TY[VRA]H:AT]NA?D(UAJD8$HPLPNA
M#(5:DJ#EO>=[9"<7.;6<"O,1K'7(EEH!%.BY6G"@V7;X&B^8?9*]GZ2+5Q!/
M$5X_)"1*U[%+A(1''-WZ\Q&LO<B(36-DSDZKD%;`'&]=4.J1NU]G/H*U)#49
MO'PTT`9[P?C-7SE'"X(WF0-+UGN>T[2BQGP$:S$R'Z-R+,YL\VXI,POV5:=/
MK_;\&-;&9$ZE/BYGMOLN[))*[^.UI]O].O-C6"-4D^F6CT;LXMTGDHT64\ZZ
M<PQKJK*BE0]#["O>2QO6SGIJ9JO8KS<_AK56N357\/%!GWW<T'^^[>F4HCNC
M?^)8Z]9`5FU^W!E;E8`Y/N,J3(.P8YPC@I\I(\^(*R8IY=*:\^/.&*T,65?"
M&L9(-^5;(([.V*^,6!:"<6?DZ,02KL?G_+@S=BL'RS-#,P0:)9$E9>[EXEKS
MX\[8JVQI5J"#ME\Y\R`N60-43N2<TO/CSMBX;(D6H(*V=KEZJV;A&2`1XTEG
M[&"V=,O!#<,85HJMH'PC5"LZ/X%^T">E1SQ7UT$,XLPT7BYQUNT[#R^O@C-O
M@^DNH8179MY45IZ?P!K$K,C6@S6,DU,>IY1.=E,6?ED1-4:GVOP$VIW+@G,5
M(&CW9E?/_6(/!VAYX9&``HO&BT6R3GSVX'T;D%G"N;KR_`36.F;%O!XL=RZ=
M<`X#^^(QVJ+-3V"M8%;L\F&X>P36"<L(=Z?:P#%W?M(92Y@#&XH0HK,KR[H6
M0`4MD:6I?`MAXMR:<>>1"4E[NDP/!7>(I('FM`T<H@9Z'?)$&^(P-M"U]!5I
MH,%Q$C^%!/^U&\]*5:A7!(Z.XE(%.-"&L9OFP;R*HL28]JP2<)P4]Y07L(9H
MRM:)L:I9$S@6BGOBJ]B&8><N67\LUGV-VL!A4III@1X^9SYE7=$$@^5>4@LX
MJHHSYCFXQ"%0>\VX<I47U`".P>*8Z0*3.+)JKUG66]RE8<9AG10<\UT%)HG<
M"O_`AJDF,X6<A9$XV@>G9/_8$F)V%C`)SF!=W5M>XS\39N>B*+)?,$.8F4>)
MI(G^,6\N)6?VSII*0-D["[E%Y33;WP(O66+ZZT/;/+.',46G-,R<@AH`ELVM
M^(+5-O"A5@@K41U@^Z58JH(1)`,R""^/*>6!RI!%+CU'S\@/T^!K6[32*U])
M/6`3I90TT56O',X@N/Z*`BH8GV(<+]<X2!/5L2<`:K85-8'MDQ9\JP$-XPYB
M3S0FDS:P]=&"5AZ$(3C)%[BR!>PZC+2(W)4&-B':K[L5"$,(;7<;!F$5W%97
M-;95RKK`]D)CFG4`0=\("HP)7ST<,+6<!+L0!ZE_H%[L!\WJP&9!+7XX5@=]
M=(TW5OSL[Q#'.P;XDHHP>Z^34)'M3IZGZ#$DJ!0?X>*%RH]BIX=Z\GI%QTOZ
M0H_6I&C\5-KT*(TB]1&QE:\"6R>-YY%V13&$H)T%\NT`/J4;X$>I4Z^@!G`H
M:DO5X,$8QNWS+8JU-H65<M!QJ\TW"O7>#R'J?^Y7GM^#GWH17C`+!/:36'J)
MJ*@)'<C:F%X-/,.((O0;8KL@M!S37G@K=)NL'Q"9/*:@2Y=H^II@UR!TX&QC
M!;&'V:)G21<N-UBZJ4L__`YWMU&ZHBHZ8^;'O5<-X):#+C"L&VGH.DK0Z>NW
MB,4S*^P0XT6,G[-(6)S=I<[9W<D'NN/_S2--O'B[@3X(*[S=A@UVOG;'H,[V
M;B#7+>/E[TF41?&8A5-$SY8+[*,*U%FH*5:=5*HM?`[X8J=MM6M)9,.X.CI'
MM+,+G,I2HG;E8M"I.UNBDZ\\->"#F++RPQ=:GH5K9BY1L<^O`)W7\Z!Z(!2!
MN]LJP$CRZY#$^*\44N&"%JQ$SI,ZU:`SA1Y4.12">+O;&KHB6%Z'V5\U=.0^
MC"`Z(YZC[,^RS'2S8&JW`9WH]*#SB8E4AG&_L8^XFG+],B0<21HIEDZ#\-=>
M^KSKJHXF[J%<T=?0WU72N1LI3+5J!R[3W.O&/L3FV]ENZD&:2#7/B:#*.ZI3
MO0.W;^[U@0^S^?ZUF4X(]J_[W3=+]JQ;OP/7:+9,&^,<ZLZTEL'1:.S7ZD)G
MJVUEX',P#G5C>;'>^.$K0E.4QOC3"S!OT@QT/MM6%$0.%SJHL?8*T31[IGV+
MT(EOW:\B)LB;^_4<:`MAGI[1I`WH%+GNE4".M;E;3F>W$[7$H_E6JI"G[;IB
MUC1TEMZV-B.&(AA&F)EF%^&M>25!IP8^@%M*0^D,X?&A0`I7P3.*VG2-,_P`
M=,ICI[YQ%MB'X75"CYG;NY3QXL\$$T0E0^'&KW>^%\1TMF=!FM/'^1*%TF\$
M.KFR0_KY^F4FBD&8^IO)M+5Y"CJQ<^NJUEP\@WC?S9="X?K1UFII^`'H?-1.
M5TL+[-">-Z["H(4+A);IJ]<\R!L5J%:*)F5=Z'36#LD6K(TZ$AB$7R<?:=7[
MB)GIBK!P=LJC:A`Z1S:01NF(!7KW+C"#E@'=(T(E<UI%DZ,4V4"U&X#.I-V:
M;IB+81AK4S.!MK8!@L[EW?H<U%P\0XAWP43`<B?3/]@)]]GSV2GXC@Z]<%FW
M*TMTS:09Z/SB=EMJ4X3#58XQ'3>$O-+AH$Q<JU,?.@^Y2W7@0'/F!+))58WV
MEL2#UH8^6J>UH3ES\\BTX2(`LAW>)YN-G\K)\W,Y760_T`IJH%$=.H^YG2;H
M(H,.TR(XQZ0[(@\OSQ-"U39;W2Y#(J%4IQIXPG)=4C@G$@UH@S!]Y''<&%:I
MN\6N&%1J<FU>1.X250@#H:^(V*=DL%(2*M=X8Q+W4+1H&NIF!*.[KN2G[7$\
MHS/?BZAPM\GK)R1];EJ$S4(+JIBI"<#S?68CN/`63]6RL@UOT[9[&<7(!6IH
MSWG![HA%/J6"2'?S!4)Q*C-EG>ZDJ-7@5P<-M!>[JYEM:VA&RY%T)ML5ZT[F
M69.S2A5`1X\D526["BY>%D]>L$)TGW#QPOPE$AP]9=AGQ%LB]4,E%\UV)^.L
M[M!M#G@@R4=YZ]/%"R(+'*$[@A>EB6W[VT@V#5BUUYU4M4U7=@VDT+[E@HE%
M1^LGW]%R%OY*M_*[1NLSB6D[W4E6JSMU6"`<1D+3W"N4;EQU<F)J5>L/]WI2
MZ*9#1N8\,.8[#\ASFJIK]H=";5DX>W]A$X--RJ'``42#0VG-7G(HEX6S&V?`
MY*2W7IP05$Y&>II$.$!15`K_%"SOD_7:(Z]T1L*K`#_B!7/2SQ8D9D@,?;Q@
MSP8/'05PKP<Z\6B%E0#,82PP?)1ZXNW&!96V3,@S2O:I+W>#;-(LL!%,2H]@
MP6P(M[T+B4..Y&\!3D/XQ724WN`H8O_?;/"W]7A%4&;4UA^?@A5"\(W=%U07
ME]H-&(U%V][*AI)A"T"CQEBHO+7.".4P!LO9Y.;F:G9S<3N[']^>GTUN9U>W
M7R]NSZXN[@^]B#&_?IP%:F0N+:GOXXKVEDY2YSA:^&%$%VB-=<VH'8B;'YW^
MZ2QN9@T!+V>FK(A,0::8AS%,TUWW4^A3*-$YHFLYCHMG"OFF_#YY^!TM8A;D
M=(G6*<Q##V'F@Q:_:HS1:D&`05@6:-:9VS!&9N-/NPW@H;<G;-FUC":>80RK
MU`>?!7N^#,DN\G/]05#CW:+>9U1;1K-6`,94M2,Z(TA0`W(/:2QED>U2"&T8
M0V=K%\JO71J/D5I[JL$@*.[BM%1K6GDV$I6'U&*Q>"0V/AZ"82AKR6GOT%NB
MXM-&9QA)+8")G=,;G=E=5@UX2R27KV!*5^`9QE!A`0'1GPEM^>+9S%3FZH%'
M]?M:CSKX52".%;6N:!TC1'6@O3#%8A4=("1(AC$ZG-X2O=T6V2+X%E$.+J(8
MK[U8&J2S6K"'-SI[`(`?C0CVS-?XSP0OF94A6'X-TP1:=-R0(`7ZJMQ":U8'
M=ELVX<\0%K0S2ZMO^I4Z8%0?V./99A#KXAI&7!$^VFHN(Y$TC)5#KUGHO*?.
M=$8;KC.?'%!5NO0P29]\W""/';?8O4\&47]2T6X#.BFJA9*88(-^VN0L4!H_
M.JJ^0N@V`9T'U4(?#*`-X\5489+1IU]4!3K;J07=$BC0;ZK<T#M%SRA($,O:
M2<_1#(`^S\JZT'E)+0C7P32,QU)THX.H/-D6YYR"]L-T&MMF.U3N%35J`^<+
MM6-?!Q7THR=G3E)%JO9MXJK4V=S@,*G7`G1R4*NS@3XTZ.=0HCM6=BE^ZD6L
MXSLLER&Y#8M\91I<6[<%G0+4V)1D"W)G6.KU='"/5FRNFZ)-2`JI&1P"M>I#
M9PNUF0JT@16*T',3(]5^@I[H`,#/*-O_FNJ";A/0V4)M5P9=;(5&]-O<>.&1
M@,J(142]?Z*"U5<$14WH9*`V_&M`*FAOP31XV'!5A2>X5_,$G[%WX0>_5OU1
MWB_<+Y[0,O'1Y/$R8;?A-SC`ZV0]91S[^9-MNC/99?QCH8DS4K36:A?M#^.U
M@RM1#,/YPO(1!,QLT*.G$(62I4O&WB$CE>MDDX6WS[Q<7BT&LVWC?7D\X0+H
M("*"\B2QG:O&WSVR+$N"75YEC$91D@U7FX7"Q8>`G4N:Z%DCT`.)7EKW83><
M]+OS*L'QS?DVEW-0SLF\O2U>3H(I"XO)0N#2`K=A0/)_IH$$"O69H<53@/],
M##9Q!_E^+UY8'%HBP]CK.76T/4>QAWTFI`0@7C&DNZTHGJQ+Z<YDT2[=?ZE'
M3KSM2<#5(/>+T5W^WT$#_Q3"H!N@*+W3'K]@F4^WH`:0^U:+'//7$3%\9SLY
M'^3<P`.6I<1&Y^':PX&A3E3J`CMS24C39[D.R/TDT&Q186MYJ;]G(=G<(!9^
M7;@X"&L`.V-I29\WU\L`=>AP'Z'%AU7X_'&),!N?G]E?&*.?2\.2_FA^C5:>
M?T%G)WHRY4_*G%)`?E4'FXCYD,6^^^U2E'5".$'6BP"Y/0EDMB_86E^%8\;-
M;'5:G#RN@H7&7,4I#^4_Q!.6:$82=+N;3\F<#F%Z(D57,5H+`[:V\S4H]Z*#
MS8$MRP[Z]8I(-?-D,LSR&N5Y#,096/C%H=R,VN:,IR%B"0SYQ:/KU*1`CDB'
M51ACD0SCM:3J19^^+AFV!.7>!*-5%L*!7H3<>25M;Y^S67B2Q%'L!4L*5>&$
M)*HV'PW%U*8U'RDDX>R]A<L,!KO(=5,O%AKGJZ7F(Q@;&<"^9!]X>^\DH`SK
MPK>@MTAV\22K-C^&.>O"#'R5)`;^H/H<410+G(KZ!L5/X5*:><B@F?GQ4$['
MC=1(()EA/,P6HLYC&2V_1>@Q\:_QLS2`DU$[\^,?X61M+9IAO`G/;0K9DR=F
MGMJ^@9*ID;C2_/A'.ES+Y=#BT_&.)8"Q]0CZ0=+!R#QZ]&H/.PU,:UXX!W41
MQ0&.$5L=EE>4H6"%*:K,.?'T]<;[/21IWE6%-XY!*T`>UH:<\B=.,YC.3$>=
MTXP=U%MOK?;+,6P).+:?(<G&FB*`W.]IA()$OH\6;"7-MZ3"JW1U)>!0?1;L
M\=5`BK";-^_%9"B8\O<+0?I<VL[H7!1@KI,J*H0S+*\8D),C7Z(RJ7?5A5&I
M4W(?(<WJ0,Z-(@IL=L!=<6H4\)B]?RNZ*V>-6QC2B5&/(U&WH1TK!)04P<OT
M2!$4!W)?-*!%W/%A^"N<>C[+_'W_A%!\S3ZC\6!#4`7*==+)@5`&RMG-$-!#
M#`XT]0L,827H6&M2IO3)W8'IV*9EO%B0A'X2+U@<2!81PXL1"PF&UP\)B5)M
MOD1(L7<Q:P4Z5)J"(-[>TQB?*YI=^G7<A$',O)?^2=>8R:/6@4U2!=2QL-'Y
M30'*V1VJHR$JZ*[\<">M!.J]IY*^/F$[,!V;5&_8'H[]6#YKUHJ!>L:I1<SC
M91]`-X]T_Y/XKVH^JJ5`/=JLZ-CO?T>/<_=H$Z=]5'/"*3H?`9I`K(@1@.C2
MF:[=1YTC0(.([59!@*,O3S5'W7FK.5(_UARU^5I3H`%6YMCMZ`7R9>7*3=\$
MN^M\-Y=IY5"]5KW(U&\!U(^TT?'%#*,SOSU'>^,9(FO:;[0.B1<L$_KW;P&+
MR;E]%%&@$#&L6Q_4G=.0(@[))C"[.9AS;\'<:%)@%S$KK`#J9=F<2BFNCN[0
M;\.8]O8.$1PN+T/"M!$'J=R%[`EKS(\!K0T.Z),":V\/K__D1WAI5K).3A[O
MD^"/S&RY3?HC'(C*BO-CP*-Q<T:U\`WC@8XTZY/D0D9:;WX,>`!O1+\V/&<V
MX+K]'BC)03V.?/$HH!(:/@\*GSFXO^5`:`EG+>`^GX($G26$\#?"=@T-(ZN!
M,>8.14YK766N@MGWD)DF91X5QFT!!S<_K.)48$/OS@^M//2KR)WZ%*T!>^8?
M7('*P+MDY#^`"EV&"7&F045CP'[]AU:@,NYA!)+1ATYW]^[T)V\,Z*D!F/Z4
M<`_C'*L)??:$"/(>8^GS(>.V@,,_'U9[*K"'$4Y"$WESE0$./'U812F]WVA\
MMQ2'L>=WSTH"F_KC1S&'[))2535OF;V<%,43,*D^#-.')M*..4-:/`R%M3?H
MBIESLU"'T54JS!Z&`MZ^[@E4)G3P-_$"L5_1A6G#5J<@9F.?#?*0Z#X+U:H,
M=#X6B9]#DBZ,;OHRE+HLF<2JI8#/G`UFL3T<77O@ONN@?"*KEX-\XKXO5*GD
MN_K(?=?#28#D,Q>G*.3C=9YLI124>]WU:6GV/=0EHR@*^4K=F(QRKX=X*[.=
MEJ\E#JYZ%8$>N3=;=K2A.;M-<30=WB&R8%)>4<`[9<W]B)B[&+-LI/]>8F9'
M$6X>S%N">@&O3Q9G1-O!',0=_I@@;_)X[06\G"_[A:!?OIO2RT?@;*ZV>@C=
MBOUXNG,5DT=#E]:#?@1O2Z\2%/2%M\DA7.P(J:P#]?R]T>RK`M3B9?,A3?II
MOHVGT&</)L[1(UY@%N+Z+D>0I>-('GY'BW@63M$2K5.8A5/D-CI2%D7Y-7UX
MP5[DL5C90*Z1+#QW_*IA[*\6!+7FIPE/3IERGH5KIF+;(4)8&J_4ZG/ZNBNS
MO5D:?_?(4M_DW_`;P/<">V0I#?_-\?8[7F@&A7Y%$36J4JXS]PD.V!/LN6IP
M^TVRO9AV<J#3/9VMM<(,M_$Y8(_'/7T0S"OM(.^W]EVL-W[XBE"Z2\AV`LJ(
MQ,(ZP(Z+;1',5R>9%`9Q@L\%H5A\RL4Z<PO4VMI30PMV5^268N6J41L4L"Z"
M=0[D3'7U;FFR#O!#$ET%S$*(GQ'K+SMW*2+P2FL!N^3MBYQS*E<B&,3D.643
MC6+F+,H`W4T=<-HL0P6[U7#(K'*/5"H%?$=5$;V$G;W@R_VD9^NZJR2H4@[Z
M<JE&`)^EO1X/8J*\\5[T^"J7@[XMTN.KWN-AW.0KUPC1$J%SV]^\<>B;I@,L
MIFZ$!)9X2Q0F,\T8/G[VL,_@7X;D*P44Y_<3T33T??I#AD.T.39H`OI"RQ&'
MG/VUH1"ZZ>NE`C&A(L/!:AO;W%8?JJV`QHDV9<V"^'VTK7'?.)J3"$N&)/T[
M,IX&*I5!`QZWR/8>R.;'K2\9RP%:L4S)+8_PK/\7+X@L<&3+<5$=-'IRZRQ7
M8$(_G;?B^8Q-1;YORW-1'33F<NL\5V!"/W&W7+$OTDB>#1?L2B-009\/M5[O
M@1W&^W3KG6^^C4GB/"ZL_$C0[@>A@F*W>H!H7V0_N`UD7SY9O-S#J&_V+:A8
MX`=0KM:U>2=!5V>G31IJ]S[V2-Q/74X7K>@JR&(&?R5AU(J!3_PUJ-CGO=5G
M@0Q[[LN0^N%<15&"EN<)H<+,X&6[K)*3CO1L:=\85-AV."VT$I&SRU_`%S)-
M14UE^XBRYU[Y(&QQQN1\#2I&?6]G3($,FYM<FIG6NJ'.P)M98)?#OJDR5X+.
M;$K9;O8B<&4EWN_T'<GR4Z0@->X$]5N`RO/0_I6@F0PZ^J11`4+O1M"H$=#,
M#X:<F;.^C[6;5\%*&#I7@D:-S(\!+Q,.P'L=*[1-KA'QRALDPV;FQX"W"H<B
MOX*VG_.]UGV221OS$QB#_F&(WX,*?5W<N;/+;PBOGNB,.*:`O!7*K1:I%)G\
M'P]YT:39F?E)3TWY![Z$,A#GV[@PD!W\8)B?#,;X;Z*DH".&R?S'N?X2>FES
M;U/:&BWN>C$_&<Q%Q0%&C%NY0Y^T.C)D..9TJ'%CV)7YR6!N3CHP>"R$#WU8
M?=N>&6X5!G,]TZ/MV4_N3C&\"YT^!;>K"6H<1<FZF'SR$"Z9?+?![D9OT>[>
MHMV]1;M[BW;7D=>^HFAW?773LY;36[@[@4*XWIV_A;NKSN1OX>Y^A'!WS>\R
MVCAN[2Y*!A]:SXF,P*):`"OAI8?)KYZ?E$\X+-3Y@IY]SO$S7M+SU]2+6S$)
MZ'X;.&R@&_URK+L&LOM!C,<VDOHU]&DS/CUP0>AX]>O`,1A[I^5[TOO!3;P\
M64UQ],<E0>@JB!%5J_B06L[[-G3`RK[HN$!V`WK(_Z"6U(/);#!#9#U2J78K
M'X5.)=>V3K<EM%R9_]9_97;VIK9VZY#^\IR._4*>!WLAK>P)=.C33L[E]J+,
M1\/?6XFIIA]7#2"*]=#M$R5A"'>HG0]&#1\VMZQ.DD#48J-B+R(4P\NYVE]I
M<.*!'+FL0G]WGJ@JJ/9L0#WPZL@\-&;TNXDWS*R$@K=068LBUXEZD8Y[/G"Z
MV^]+Q7LJXG1GD8%BVXXP8!L-Q<Y)6@_(L8%'CF!SK>A]OSFM@5+Z&7#+`SL*
M*!D2W/0*H/2;T-\\=@*(E9N#2CG@&WXA$WSBZET?Q+4\1;\.@W1'H.1NKRSP
MI;DA?[SN#^/2;XI\%M_HSB-T6:$Z&M&-`3.PG+Z6?Z,R-&@W`G31K+]V&D'I
MN<-?&9%R&=TO#'R=:L:4FNT"5,>R$5Z&"4O\'M%C6#;W3!Y/0X\LY=D(Y;6`
M;PGY8N><190HNAD89[PB*-W>">;-_4)`5USJ>9';5;`\@2IY"V<Q7C&H^Q6^
M2&5BW_6W8W-3NB.Z2\CBR8M0T=W_20*DSI>J4Q<JFYQ0_!R6='$,8L]_%2S"
M-2J.K]?L2XP2^?Y04@LJ*9S^CE#1^9Z[M0K0*;>#TGK0*=Q4E!D1O8/4;S/+
M5Q0@XOET*S5>KG&`F1&897EF7B-!I+ZJU*H/E:E-GT,^]]K@!C&+%_(Y\[TH
MFCRF2YBN2;Q>9SZ",>58V,-Y77<68!=F5)<A*2?M_<)0N?;TJ!$8X[@H^CTY
MWR."432NWK,JIV1)+:CT>@J2!`-4CF,8<VZ*\=2*86XMJ,1Z#1@6XH"VI4LO
M]Z\EKPAYQ4"SWZF-.9S>.O-Z!UT#MY=L$S)EWJ!9"'VJGVB1$!Q3[3OS6%S=
MT]=MN6A;4+;I:=@R5"8Z(<_2!;4)2N@!W*(B52+X%+\LT,N>1%BU!Y4$SH72
MZ&"#]F@4S/7LT4318]%,7RD$E=U,DRA^AZ&#Z`JDG\\VX^4SCD(B7&KKY:!R
M>YEPP.MS1U,%IX\E)H\E=X?ZI"\B1ET3*K65"55Z**`?"8INP=8AB?%?J5R+
M,4\WWL]T+CX+(^&DIJH'E<C)A#@=#`-Y#B=+[I?]_#(D6^AR@YY)0U`IF`QW
M)>:@G#T+LTI[*)^'L_P0+XLG]AA!0:M6/="\269SL!1#3MH_ACB44P$X&,G\
M=D!3*#4>R&),N4I\Z7/Z4MGL=8N^I[^RGM.+!D`3*3F:RRM@"NM#3QTQ9<K>
M@/9J?=`L2FX&?@5+07J?$Q:SO2FSL67S6'D7*S,K"2M!91TRM1U)`13$]CO1
M3^D0>>>1"4FO.C,]SE-_23E6UH9*L&-,MA:2@O7&)I$6-N+YZ3^;EQ2[[VIA
MJ*0N%EON_8X7I'3,U)&;U*Z"9Q25*HG,A7DYJ"0A-N;"<I\+'OIMNU!X6=D[
MGT$ELS"<"C50%$S#V"/<\%P+%Y!NV,=)_!02_!=W^M2K.#_IA0U*#:(@N=_V
MBRI0BTV.7@/SDTX;K<S!%/0WME6X756W`4W8\L]RT6YM<-%5D`GA$@?TQ_1$
M)EIM=>O/3SIM@C+&LKO1[AB?622A'$,EZ[`^J2:-S$\Z;5FR`U30Z]ZYQ2QR
MG(#FLY#N%$E$>R1*+<8K-O_<Z=.CJ,L%&7TW#N3(MAZ4V?22_9BN&5*O(E7=
M^>=.'SF-<!1\0WE*M,IW=M*V('M;<?ZYT^=9?1`%S?T.O'Q'P@5"R^B22FJW
M=:CM#--_L:AKV6.'8"GQK7'3\/QS+X['S4$6:M1O.TD5\B[*'O/FDVN)I-[\
M<P]/SQP,!<?M!/)M_AZ^I).BV\LJ2/D4X*CA#E/O2G2%#_I;",YAYDI]B\'9
M0^>&/(V=XGUQN5CG(VS6.CL,@I3/ASN5:[-.@9PH\%"9@JEKL@[P0Q)=T04@
M8#=!K+_JT#GR6L"A,55I*_40#.+-KUW>9/"SFE':8X>!,(&<[P:0]A@VB,.>
M0O#UIB7D_5Y\W:8][GB"0TN"^>HDD\(@5@^C%#]`$3T-`NN6>@H6/](A,2:I
M?8`3V%5$+V&GZ&R_IU2KK$#0R=9J!/!9VNOQ(.:Y%F)*@GO!-XDIN3/XO,64
M+`?O@S$*Z5)F1/0.4K^GV@/%E.QD--$2AWSNM<%U,XBY;?`K<(\$H^!7.TM3
M7P-`EF-5;'#L^=D]V92*GSRGSV0ODS@A*+]1ESJ;&+;5@=B?52[Y(]$*UR#V
M5F[S['XE821]A^K^:U`!2@TUK"7DSDRKD(_:;4531*#+7E`\>]AG,SL=K%\%
M,;K:_B144-5#*:,&?.CH;0YU\D$MH8>ZA.C>#9.T<#9254KHXAM0@5YMM,X5
MWHZ&J:,=9!>6W@I-'K.9.W5,'\?7R&-/VHN$\Y.`Y9^?/'Z5>G59-M>!`+,R
MA6@*K:.Q\4J;R%_#./-*VT(4/[D05NE6:%@^AXKN=S0,7EGS=EI65D'3H:EN
MI5LQ6]4C4@\1=,`\^;.V;:Q9MD')UHTRK.V<(V+7H(EN17GE4VL(QUG(._@]
MG,TN-_W/KRB*"\]BV0,<EY_I5K1:]^<'`>2!1.NSW=]NC_B3)(YB+UA2V?R&
M6#ALM!Q30'0^GB)F2:8_/PN#U"LX\7SVW.&XC=.%?6^Z%<#7_3FDF62<Q1^$
M5_(&=BPV^*F\`G:H0POZUUG(?E1:F<:K%4$KNM.XHC+$0807Z?K4HE71ND_=
M"GS<FNVQD7S:?'1S2$]=/VT<+?G"5`<HTFN@6U&4A1JE#\9=Y$U`"W7A29@%
M).2#O@W3>%PHV^1$LS#V_/+O64S#VS#^)XJG:!&N`A;KI^2:*+LV.<CWNQ7Z
M6:AZ!Y.%N_"AH!-7:_+*]N^7(=G^B)63G9,.VY%N1;$^O#8+A3*0X*G6F_C"
MX#&.HB1[&!L5^QJZ5U<>]5OY:+<B;KL_.FD)`#C"*_`!22:B<_R,ERA83NF>
MJXV#D.ZWNQ4BW/V!QT0.;8:^/60T@3L2/F,6>H<N%N4X/-5X`M7@`?JQ`T1W
M,%H?E00+L&C%*))`2U&=1#$(Y!6`(A+8R5CH8B=`UF\'9[>9TF$]V,44":99
M"8Y^L]HT:3JL/[J4%\'HY&'H-X?N,Z;#ADW@4R08F5(4PW!<=IXN'<:6;T^O
M",5`4BW7%Z-KR4,3=27@"`BF2ZL4"%@\#>BPX+#1"^2<\+QN]'%!C]GN!`B'
M,=O:<VP(#MH]7D#T>?@]F(8)BR*X/>Y%.Z]K4511S9K`P0V,*=5"U%7_<ZW3
M>C-["G0D!&-"]6$Y\RR'-D"+$Y'QBD'%0[!A5-1_:%_D8<<'!XZM8*,@S1%W
M]/W"5WHVO`[I83'8B67*_!#U)GG-ZM!!%8QG>0-<S?V-OV3$!JG3V[(C)V2G
M*4*`PC0T&?%:H*#=<-WFZ`$*KV`]2#G];]%!5#]<O_NM5^4DJ+D/J];I"[$:
MZ-M[3W3(F_(LSL_,>T&1[76XR_A9M"/G.%KX8900I!%77U(+X&I\LD'L1!VL
MV)I]1G==KX\A2?W;)!#$E8"#]LME*Q@P4C3M7=(<-%5%=E.1[ZJS8=/<?:36
MK,I/1%`<PB$DN^79]F1"T@VJTBE$6`G2,40L5/D=,Q]&O^^:N=`47B#".M!>
M(%*:#*@=DB=(%9FN2PBO%K!OB)0I`W+!G43T5@9YF@QNX6ZX>8BDS3E3B5`,
MPLV#*XYK'5<`:<5N.'LTGV/+@'J>9L.!_[NV^S:P,XB22;X&&,`;Q-B7X?TU
M]"EM/HY?&^A$M1%H]Y(6M&(/(+2?27N*,<71'Y<$L1?HB!(86Z@%KPEH?Q2'
M2B&`!^V1TOY<P7PV+&<(5A7:?Z6%>6$+"]J)!?C%7>:==15$,4G2[$.3^`F1
MV9,7<(/NUH*]I+]D$=$*0:NL_%WH([CSCJ4V=TJ`+0:@!#?..GOB]V:C?;/1
M=NE\^6:C?;/1OMEHWVRT;S;:-QOMCV>C%0S%/*%#KIA"MW%)Z9Y94^5(ACL@
MM^$:LR=*.^3;WT92;U&;]GIJ3K7%.@S+:G%2")89M%*P6XF"R*KUU(*J@#0,
MJZG30$DW*'X*E]\B];,C]U_LJ8VV/6D,P[3;V>=0_32B-D<-G7K'C5J=T]/8
M<YIJ]1I[#^Q^E![.;L-@D1`F?HG>*&J"/Z2T5`P-6"T^ACNHS3MYB-"?"6WY
MXADU,'H[6G]KO='PXA=5`3"4U[JB,I'SB@.[[4N$*5JQ^2#Z;4"M@Z+?4X6P
MX]<`-HN+R-&C<H=A<&PJC>'".M"A[,0<:9,*;@9OA59UJ#->>6##N90=+4*'
M93F_\[W@UENK9MMR,6"KN-D46^MXSSV4<S3*V;1:$-@^7N=`SE31Y8[=&4[6
M`7Y(HJN`I:BDYQ367UKJL_SR4%X+V$*]+W+.1842P2#FP=2FI;'MK)0#-BR;
MS83UGCNS'P-M1E2&RTB:`C(51+#4GE#;^!RPR7A/(2PMQ';(^[T5GB)Z3,?,
MD5DOZB^W/+01MRUF^7HD%,$@UH\9CGTT>;P*ENP95.+YBG6$6Q[:>&NVH`@A
M.+OY@1G;>[A^P_'3%/DI&]$3WLS""[H3BE^5BX9A2]`Q[L2$:BJ`&E[']O0W
M7N!E4QV=R$Y#EG#T\1P3M*`-*+P"-:I"!["SX8=S`-!$.HAIO#8#7FNX$(JJ
M0,>O:V2*KJ!P=N7:T9."HX<[;?B<&'8!.AJ?5(L<.Z!8B`9XBA(L0LR3YL8C
M?Z`X]:?)@_2GW1=[PLIKS4>P)C\#1=!$,PSO1FMM3__#<I[C8)4IM#)-J*//
MS$>P1LI#SBD"^,Y,9?6@[%R_DX\,$\M?2O_Q_U!+`P04````"`#\BFQ'(.Y/
M&`X/``"BEP``$0`<`&YM=7,M,C`Q-3`Y,S`N>'-D550)``-[$456>Q%%5G5X
M"P`!!"4.```$.0$``.T=77/;-O+]9NX_\/QRZ4QE67&2:SQ).[(MI^K8EL=2
MTMY3!R(A"Q<24`#0EOKKNP"_29`B+3FF3I[I-!2QW[M8+$``_O#+TG.M>\P%
M8?3C0>_PZ,#"U&8.H7<?#SY/+CH_'?SR\S__\>%?G<X?I[>7UCFS?0]3:5T!
MS(Q@QWH@<FX-_NH,'"(9M[X$M*S>X9O#H\,C"QXO.''0ZD?KFMUC;XJYU3O^
MT7I]U'MK]5Z?](Y.WAY;_2NKTU%\A#W''K(DXG=87B,/BP6R\<>#N92+DV[W
MX>'AD&+/%U/"A$U`5'QH,Z^KJ!V]/U;2NUC)=\&X=XYGR'?EQX-O/G*UL`<6
MJ$O%"04*#6AJI`S\P_$AXW<`<M3K_G%U.=921]1=0K]FH)=3[D;PQUW5/$4"
M1^"JU9$Q0AKX;3=HC$'="KI_7`+A-%%2`4RHD`@T32CGA0Y5[+U__[ZK6V/C
MX3LDL5-*_'V7,Q=W0[`(RQ>=.X06,=8,B:G&"!NTN3M'O<YQ+X?205*6HT$C
M)U-?8A&AV<RGDJ^R!A78/KQC]]VP47$[SG*S?<[!]V5X8:M"?)-%=#`QXT"#
M`1PO[;D97K48S$#H/1;2C!*T&;2AB-C"C*.;%$HOBR*(;4:`!@,X.$"N%E@8
M7:-;#+H(N>`E3*#%P(7C66F@O>M":^*%!<?VFL!$W-:Q.4.V[.#EPD440=):
M7<#OV'*,4M\S$W$D[RK5N@#4`2C,B1WCK4<*$52>0Y0RB21DRI\_H,6"T!E3
MKU4_.U$B3@#!4@^?;X=K,Y76*<K,?>H,J"1R-02:W-,\#BP"9JF$B+D[>$8H
MT9)!=K,Z2<I//2+J6`$-*T7D0S=/(2+J"^R,Z,_Z&?PD@(;&4"DKQ`I!3!@)
MP7KP-G)MWRUGT,V8>4.[GS$JF`LC'(3>*7)54AW/,98B,'IYL]GBK\',8S`.
M#DU^-KH>CRZ'Y_W)X-PZ[5_VK\\&UOC7P6`RWGMS3P-["FW/!8($+>=8$I#'
M8/PJ8+,KCNN[PGIUDZ'XP][[)C:<&,U&"\RU".(S13[4B:HLR/MG'8+91V^J
M?#2>P#]7@VOPS^C"&MT,;ON3(0!8K_R([(NCTG8_0V)^X;*'NGXRP)O=]+:^
MF\[ZXU^MB\O1[R]NJF_VFS7)KQ&VV87O-G7A2XY4/KU&TN<XG>).?4$H%J)O
M2W(/8F,!!=K8]SS$5Z/9F-Q1F+O:".HV6\]>8&I^`WX%PJ&CMTO2[/W_J.J/
M"-ME`GC!CX"IQ696PO9'*V)L)9QUK1CR5N`I[E;"WHKX[V50?*9$K\%(\,X5
M$4+]!Y."SU[_CN.@WP:NK@-H=N!/>0<FI)174L2L5P>?KPY^L!*2>^F3L]'5
MU7"B<UK_^ARRW61X_6EP?38<C,/\6@%@]L'[O`_.F.<1J6VLNPFD;-490)!]
M[0ECR>RO<^8Z$)KG(*A-U'3U!B;ZF',UCD'SV)_^#]MRPFZQ@[U%,L%]+++1
M6[VCO+?2Y/]MA0RTWQ0M[*&IBY4+H5M)HI[',-V'!'AJQ2($-/;2LS><W1.U
M-'S!>&`D]6,TR[HG<&1-6+/?>GF_Q=2L&>-60D_EO1?/0)_387KZ.^(<Q2--
M_J79UJ\+?20*^0AQ+RTZI/"()V@9E6CI%V9+'N<M&:!8&F<OC0B96N!O/F@T
MN$\JH,);LSG?%`(SQK,"Q+VTZ5:G"D\X"ZF>C?3>?J_9",Q9PZ?]G*VF"E0P
M7*8\G:AR)UYJ6`=F]N.[1@6Q]2H@MI^N>&1QFW;39B3,+BPL#&2JY'21G"NU
MK)"3)9F5\-IS'V>+KHSOC$UFGQ3F^H6J;+_-O-6AZAQ+1-P)7DH_7GI]2@9F
MEQ>6%IYN1`SDL2*!]C.$:BS$F0*C.9K1W:\+:Q,-5O->/)@O;?JYFB7NEQ>^
MZD17H(3G>S=HE7)0L?)Y'!6S?PMK&-6%42?=@0-VEA?PLQ8AP\CM+^[..\K4
M4>N#FQU86!A94]F^=,G'E[AQ1QOIG^'0MOI,@8[:?W?C(IKIM-^!CSDJ"HL\
M&Q;+F7[/@G<H%,ORE5QJG^T;2TFVY_U_4Y__CLG=7&*G#\,LNL-](?P`0EPP
M/O`6+EMA'`1&:.?>=H+M,8S-T5=<$]MB]#V$8EHHD--"B:!ZW1V'HD9Q&H6C
MU7L)R`9Q81JLMD/*'#2%I;9-Y_<O(]VVG+]9@LG3,KN_L$*W9??O:^^O]X73
MU-D?A6EV;F'MKL&7TI>.G/_29W)6>;/1(\>%>7WZ*^"+R4V+I-G*WMQF#O\Z
MRZ3[73.;K)DK/2I!S'8OK%66VGW?(SWWK=OH@&H8<YHI+"\5OH[_WWE`_4^=
MNKS%,TL?9SQ19[(^'@@"\Q)U#%*_F^OS9NIX:"<Z_ODGJ'2X]-P(1%&N.%BI
M'9>W0L@X(A$>0ZL^;@E$V$+M),.B&PE_T-V"/F#PIOID?=0J;5PT;:H-H&"W
M=8I`7#=5)-<5MJM.-SJ6"$_)845H`$T8EQ8U'LXN.V4<G.N^9+8F4X&B?G4B
MO(YZU>F][ASW#I?""01KP#_6J"'_"*\9?_/)[9J<(P3%\FT-9I7GITMX:GY&
MQ"YVI8C>=!)2=;6N.(]<)8L!+7SN)"2:RF`ZXEU'B#1>]&,3,4PGQFO)D4:,
M?W42,DTE*9PKKR-%C*2?-@B)XG'S.NP3K."QDQ!H*D#^^'H=]A&.>MB$=?Y0
M>RW>$9)^:L9]W5T,=9*1RWD&2V6D]RH)]MYM(D'-5)CB+C?E7'W<OZXT:2J#
MA$@SX2HOAJ@3%1&.>FB6"ZHO(ZAEACS6!HXQ7Z'03`A&KQ\C1_4%%8\?,S4M
M8X8,+Z/1LE3?O]"?"LEU6*I)G:H,_ZP''I27^KJ7$WA'Z-U08D]-?0XL%$)]
M/)#<5\6GAH)RCS!GHO$<GX<71%#BNFI+6`0K8$8(3'W5^HDS?Q$Q(4`>M+.*
MZN$%$T1_+Q_).>9](>);$`*%2@#2*G@,^CWB*Y,2,YB&&K4(RD49-84G_4$[
M/"5R&ZKU;1LPG4MB8RJP6EV'Q$CE+2;>U.<BN'$(X[2R]5&>3'V;8V<[^D??
M$(3-R2*8;J`I<2$F4QI7`>V`CDW.)VE]ZR+L@.Z?$*&73(@1312Y5=]S2Y6O
MC;&Q]DF*>C+UAQ1HP73O'`?_#NG:7%8?93<-\(B,MPF1W312K;38#&T7#`&)
MS\;8$1><>>'Z?[;7#X7P@V6?=+*LB_-T)MA:/:"NT+A!Q#GW5<%UHWG#*&`H
MXM9"MJ=^NV;4!FF_(-?'HUGT*4;Y);H&1FM4#;9%YVVN45:X(1TL[3FB=UAM
MG%JJW9<^$7,%/YI-.')PN-U=W*"58IQ2>F-*&3?/$<?BV:Q21^#1`W8F[`NF
M#N,I,S1'W8'.7+(G/]DP;^C6#7#:T\'7"JV^]9VZV4*O"5*@:G"!XHF,WC];
MH-<KT`W>;8K8'A?G/L<;="N%:*T2IJ@L!VE9#%Z2;SZ!NFL%U>\G!D:%>+(Q
MI_HXU<JD6FV,EFFJ^\0I%+C.&?,64/!KRM"#H&"(MBF+<K4?A]XR&VSUW-\D
M5X,\!?'OW.D=>3('3&[[4SPL-:+:#M.WH1<(O>7@C/'%E;XX/&V,"J!,4#C,
M0X0^6TVMQ#R-M_;`7-"LB1&D37IL,_8N`5$I(IXJN%,,VC.J7?O*JR"YKOZC
M"41F9E4&T:+)0VJU#\ET=LHWI&5>@&L?M^+Y/8K>7)JMB]#&U!D+V5^2S,>(
M[/OO+[I#@+L*CO6BG^M$9Q(^:FE17EP;+(5T7QNC15J&YQTC$0LZE;2W2(-;
M+##B]KQ<AU*(%FE1=SV]H%Q3Q!;I?,6HG(/$_P7OC&9E":X2JHWIKD3@0O);
M`]<F1ZG>HS9!%**OT-(BJ7_SW951Z'Q#BV0>XX744AD%-[:V2/J2`;#N0+D[
M&B5#NFG"TP2I/9.8">8>R(L]QA%U?'C6MQ^H:EW]R;!8^I2B]5'2:D9"/]]2
M3C@9B\;,W$7<F0F;`2:M"Z$2WV'^?*HP"0+&WQZ50P@-J:<^ZY4#/:]C3-5<
MJFZ!^;)/OP8%S6"I5@XSNQ)JP.[`-ZHA=!D0UX$WZN(8)0_C%;.,FO`M2J(I
M,;.E7;ZAC=5<(F.A@"LVM=+H(XH+061L;:7TDP=6(7VJM4720ZJUU1G!.SR:
M);)&64FE8":1JW\[1"V.ICO%8Y!#W4'Q18#];`.2,3N%PJ]+8C'8#F3MD4?)
MU!=#JJP-Y9ZZADEMW2\NH*P!;%'8!HO3_7M$-"$(M4_J$VQT*9:X9:X++Q\0
M3R]M-\)J3[F[3NP1Q"*(%_Y=OP;ZYA&?<X6_OMJ![/H9U_%N#KY%GS&J)1XL
M(4$2T4#'%,;.:'FF0L]U&VB9PM@!+:.^-M#SS.9]-(?7(HVC).++:!9]PX/)
MF];)G(*;(+4G`Z^1NC0!-\3+U$8:HJW.+4W"#?&V6#Y]+YU-":LQYNYXNBQO
M-4-KD;Z#;SZ1J_SW]LS;-GY4OV#Z)E6U_22HQT>S4P9ILE#%KP-L4Q6O=MO=
M^-R>H]2ZY6\^Q<;Y23WP%ND7!)5IW;W0TIZQ+E@I#_>T%E;0X_>M7";O._=$
M,&Y:'4^:-ET4W^*VH/#XBKJ5FP4'LLZ0&B!.5]D_@Z8UJ0.\\7BZ1>7Z'N.2
M_*6='`?.&/-[&";.F$C'UGK0'5AG"?T3#'_1MCDH9D,]#*ZL`-T=?4N/:#W]
MV:R<9ML[6Q@EC:&^!2AS^*C8U*:/;.&?=XB.,4:[.(<T&'`N"(77,+BD]T74
M1MD%SUVA95J;3$U::85F>!O6LUO,LN?L@=ZJDB\^+B0&RP4)#*W&[,S=%S6`
MZU4BWWF;K_:'<9]OV/*<$XSJKRK!1$F+V9>7&`DYFET@PH/T2,^1!*!/^<'^
MT13:\WTE5:A\83(X=QSJE/%D!51[E$G[([%]VC$U'%D'L3TJARDQ7%16M()]
M&6D]PM@L)M)Z6*V:1.1.\QFVM!G;6S3?C&J3\E/S)0`;KBIO<3B[0A2ZBMXU
M2QV];C&:G1..U4?7HDMJ0;?(0:H+7"'^%<OT#,"PC+H.<`>F!\'I9.ID8RU]
M`T6@4^XX<X*07_G9C%95B%<K5VF]@JESAC-<P):Y:$3-;@N:YAJKG=U8^+BW
MKI/='!HFC71F[)NO4BEH6`-XRQK7=U=#E4MNCS&K7`W<1I6[P6V$\/@W4$L!
M`AX#%`````@`_(IL1S?T`[HXG@``J&4&`!$`&````````0```*2!`````&YM
M=7,M,C`Q-3`Y,S`N>&UL550%``-[$456=7@+``$$)0X```0Y`0``4$L!`AX#
M%`````@`_(IL1Q%A#?/["```RG<``!4`&````````0```*2!@YX``&YM=7,M
M,C`Q-3`Y,S!?8V%L+GAM;%54!0`#>Q%%5G5X"P`!!"4.```$.0$``%!+`0(>
M`Q0````(`/R*;$=:V7__S1L``([6`0`5`!@```````$```"D@<VG``!N;75S
M+3(P,34P.3,P7V1E9BYX;6Q55`4``WL1159U>`L``00E#@``!#D!``!02P$"
M'@,4````"`#\BFQ'MI.X8:A3``!QWP0`%0`8```````!````I('IPP``;FUU
M<RTR,#$U,#DS,%]L86(N>&UL550%``-[$456=7@+``$$)0X```0Y`0``4$L!
M`AX#%`````@`_(IL1[U(EN`M+@``SS8#`!4`&````````0```*2!X!<!`&YM
M=7,M,C`Q-3`Y,S!?<')E+GAM;%54!0`#>Q%%5G5X"P`!!"4.```$.0$``%!+
M`0(>`Q0````(`/R*;$<@[D\8#@\``**7```1`!@```````$```"D@5Q&`0!N
M;75S+3(P,34P.3,P+GAS9%54!0`#>Q%%5G5X"P`!!"4.```$.0$``%!+!08`
1````!@`&`!H"``"U50$`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139753865463664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Future minimum payments (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2015</a></td>
<td class="nump">$ 43,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2016</a></td>
<td class="nump">165,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2017</a></td>
<td class="nump">$ 85,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2018</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2019</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="nump">$ 295,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 40<br><br><br><br> -Subparagraph (Note 3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 40<br><br><br><br> -Subparagraph (Note 3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 40<br><br><br><br> -Subparagraph (Note 3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 40<br><br><br><br> -Subparagraph (Note 3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 40<br><br><br><br> -Subparagraph (Note 3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 40<br><br><br><br> -Subparagraph (Note 3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 40<br><br><br><br> -Subparagraph (Note 3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139753851533440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders'Deficit and Preferred Stock Subject to Redemption (Detail Textuals 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Recognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total amount of unrecognized compensation cost related to non-vested stock options</a></td>
<td class="nump">$ 1,477,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Recognized period of non-vested stock options</a></td>
<td class="text">4 years 1 month 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Recognized stock-based compensation expense</a></td>
<td class="nump">$ 263,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Aggregate number of shares granted</a></td>
<td class="nump">1,180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Contractual term of option outstanding</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Aggregate number of shares granted</a></td>
<td class="nump">1,180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Contractual term of option outstanding</a></td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nmus_OmnibusIncentivePlan2014Member', window );">Omnibus Incentive Plan 2014 | Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future grants</a></td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Aggregate number of shares granted</a></td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future grant</a></td>
<td class="nump">2,020,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiry period of options granted</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants', window );">Percentage of option price at least of fair value on date of grants</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_CommonStockVotingPercentage', window );">Voting percentage of common stock</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_PercentageOfFairValueOptionPriceAtDateOfGrants', window );">Percentage of fair value option price at date of grants</a></td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_MaximumExercisablePeriodOfFairValueOfOption', window );">Maximum exercisable period of fair value of option</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vested period of shares acquired</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining contractual life of options outstanding</a></td>
<td class="text">9 years 2 months 5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value of options</a></td>
<td class="nump">$ 147,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_CommonStockVotingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_CommonStockVotingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_EquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_EquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_MaximumExercisablePeriodOfFairValueOfOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents maximum exercisable period of fair value of option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_MaximumExercisablePeriodOfFairValueOfOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_PercentageOfFairValueOptionPriceAtDateOfGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents percentage of option price least of fair value on the date of grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_PercentageOfFairValueOptionPriceAtDateOfGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents percentage of option price least of fair value on the date of grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_PercentageOfOptionPriceAtLeastOfFairValueOnDateOfGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 14.F)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(1)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br> -Section F<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)(iii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of fully vested and expected to vest options that are exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (f)(2)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br> -Section D<br><br><br><br> -Subsection 2<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nmus_OmnibusIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nmus_OmnibusIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139753851695776">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (4,149,977)<span></span>
</td>
<td class="num">$ (1,031,539)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,290<span></span>
</td>
<td class="nump">344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation for employees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">263,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of warrants and stock issued for services</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">529,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_GainLossOnConversionRightPreferredStock', window );">Change in fair value of conversion rights of Series A preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">986,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(37,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">25,800<span></span>
</td>
<td class="num">(23,758)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_IncreaseDecreaseInDepositsAndOtherAssets', window );">Deposits and other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64,970)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(267,264)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued payroll and related expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">99,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees', window );">Accrued license and patent reimbursement fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(29,212)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_IncreaseDecreaseInStockSubscriptionLiability', window );">Stock subscription liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">52,899<span></span>
</td>
<td class="nump">167,355<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,614,336)<span></span>
</td>
<td class="num">(952,568)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,982)<span></span>
</td>
<td class="num">(12,389)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,982)<span></span>
</td>
<td class="num">(12,389)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common stock issuance, net of $3,920 issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">721,069<span></span>
</td>
<td class="nump">1,989,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from Series A preferred stock issuance, net of $7,700 issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,442,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ProceedsFromSeriesBPreferredStockIssuance', window );">Proceeds from Series B preferred stock issuance, net of $411,661 issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,588,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,751,710<span></span>
</td>
<td class="nump">1,989,980<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase in cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,135,392<span></span>
</td>
<td class="nump">1,025,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">207,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,342,722<span></span>
</td>
<td class="nump">$ 1,025,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_CashPaidDuringPeriodForAbstract', window );"><strong>Cash paid during the period for:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 116<span></span>
</td>
<td class="nump">$ 905<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">During the nine months ended September 30, 2015, the Company issued 200,000 warrants to purchase shares of our common stock for consulting services. The warrants were valued at $417,875. The Company also issued shares of common stock for consulting services valued at $168,000. Such amounts were recorded as a Prepaid Expense and are being amortized over the service period.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The Company issued 6,000 warrants at an exercise price of $2.50 to a service provider in exchange for extinguishment of $10,000 of trade accounts payable owed to this vendor.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_CashPaidDuringPeriodForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_CashPaidDuringPeriodForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_GainLossOnConversionRightPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount related to gain or loss on conversion right of preferred stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_GainLossOnConversionRightPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of increase (decrease) in accrued license and patent reimbursement fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_IncreaseDecreaseInAccruedLicenseAndPatentReimbursementFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_IncreaseDecreaseInDepositsAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of increase (decrease) in deposits and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_IncreaseDecreaseInDepositsAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_IncreaseDecreaseInStockSubscriptionLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of increase (decrease) in Increase Decrease in stock subscription liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_IncreaseDecreaseInStockSubscriptionLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ProceedsFromSeriesBPreferredStockIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It Represent amount of Proceeds from Series B preferred stock issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ProceedsFromSeriesBPreferredStockIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 230<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -Subparagraph (f)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of accrued expenses and other operating obligations not separately disclosed in the statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other current operating assets not separately disclosed in the statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as operating activities. This may include cash restricted for regulatory purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 26<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 26<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139753863672608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit and Redeemable Convertible Series B Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Deficit and Redeemable Convertible Series B Preferred Stock</a></td>
<td class="text"><div style="text-align: left; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">4. Stockholders' Deficit and Redeemable Convertible Series B Preferred Stock</div>
<div style="text-align: left; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold italic 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Common Stock</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold italic 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">On July 17, 2012, the Company issued 7,770,000 shares of common stock with no par value and warrants (see first paragraph under warrants below) to its founders and one board member in exchange for the services provided to establish Nemus, valued at approximately $1,000.</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">In June of 2014, the Company sold 1,800,000 shares of common stock with no par value and warrants for a purchase price of $900,000 (the "June 2014 Stock Purchase Agreement") to a group of private investors. See additional discussion on warrants below.</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">In August of 2014, the Company sold 2,200,000 shares of common stock with no par value and warrants for a purchase price of $1,100,000 to a group of private investors. See additional discussion on warrants below.</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">In October of 2014, the Company issued 1,110,000 shares of common stock with no par value to eighteen individual investors that had participated in a prior entity founded by Nemus' then current president. Such entity has been insolvent and not operating since the inception date of Nemus. The issuance of these shares was in exchange for the signing of a release of claims against the Company, its President, and the former entity. The Company recorded a general and administrative expense of $466,200 in the fourth quarter of 2014 to reflect the fair market value of the common stock issued in exchange for the release of claims. The fair market value of the common stock issued was determined via an independent third-party valuation conducted as of October 31, 2014.</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">In January of 2015, the Company sold 241,663 shares of common stock with par value of $0.001 for a purchase price of $724,989 to a group of private investors.</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">In March of 2015, the Company issued 24,000 shares of common stock with par value of $0.001 to a third party in exchange for services to be performed related to raising additional capital. The Company recorded a prepaid expense of $168,000 in the first quarter to reflect the fair market value of the common stock issued and is amortizing this expense over the contract service period which is one year. The fair market value was determined utilizing the Company's closing stock price as of the commencement date of the contract service period. For the nine months ended September 30, 2015, the Company amortized $113,806 to general and administrative expense.</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">In August 2015, in conjunction with the Series B Preferred Stock sale (discussed below), the Company raised $5.0 million at $1,000 per share resulting in the automatic conversion of the Series A Preferred Stock to common stock. This resulted in the conversion of 580,000 shares of Series A Preferred Stock at $2.50 per share to the equivalent of 1,812,500 shares of common stock.</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold italic 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Preferred Stock</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold italic 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">The Company has authorized 20,000,000 shares of preferred stock with a par value of $0.001 per share.</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><u>Series A Preferred Stock:</u></font>&#160; In April 2015, the Company sold 250,000 shares of Series A preferred stock with par value of $0.001 and 50,000 warrants to purchase the Company's common stock for an aggregate purchase price of $625,000, or $2,50 per share&#160;to a group of private investors. The shares of preferred stock automatically convert to shares of common stock either at (i) a subsequent equity financing of at least $1,000,000 or (ii) October 1, 2015, whichever is earlier. The warrants are exercisable at a price of $5.00 per share and expire five years from the issuance date. In May 2015, the Company sold 150,000 shares and 30,000 warrants and in July 2015, 180,000 shares and 36,000 warrants under the same terms and conditions.</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">The Series A preferred stock issued also has a "down-round" protection feature provided to the investors if the Company subsequently issues or sells any shares in a round of equity financing of at least $1,000,000 prior to October 1, 2015 in which the shares of common stock to be acquired are at a price less than $2.50 per share. The Company is required to issue additional shares of common stock to the investors in an amount such that the subscription price paid, when divided by the total number of shares issued will result in an actual price paid per share of common stock equal to such lower price. This conversion occurred as discussed above in conjunction with the Series B Preferred Stock financing totaling $5.0 million and resulted in the conversion of 580,000 shares of Series A Preferred Stock at to 1,812,500 shares of common stock.</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 12pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 12pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"><u>Redeemable Convertible Series B Preferred Stock</u><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><u>:</u></font>&#160;In August 2015, the Company sold 5,000 shares of Series B Convertible Preferred Stock and warrants to purchase 6,250,000 shares of the Company's common stock for an aggregate purchase price of $1,000 per share resulting in gross proceeds of $5.0 million.&#160; Each share of preferred stock is convertible into 1,250 shares of common stock which results in an effective conversion price of $0.80 per common share and can be converted by the holder at any time. The Series B preferred stock issued also has a "down-round" protection feature provided to the investors if the Company subsequently issues or sell any shares of common stock, stock options, or convertible securities at a price less than the conversion price of $0.80 per common share. The conversion price is automatically adjusted down to the price of the instrument being issued. See additional discussion in Note 5 below. The Series B shares have liquidation preference over other preferred shares and common stock and have voting rights equal to the number of common shares into which each holder's preferred stock is convertible as of the record date. The preferred stock has no dividend rights. If dividends are declared on the common stock, the holders of the preferred stock shall be entitled to participate in such dividends on an as-if converted basis. The warrants are exercisable at a price of $1.15 per share and expire five years from the issuance date. See additional discussion regarding these warrants in Note 6 below.</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">In the event of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary, Series B preferred stockholders receive an amount per share equal to the conversion price of $0.80, subject to down-round adjustment,&#160;multiplied by the as-if converted share amount of 6,250,000 common shares, totaling $5.0 million.&#160; If upon the liquidation, the assets are insufficient to permit payments to the Series B holders,&#160;all assets legally available will be distributed in a pro rata basis among the Series B&#160;holders in proportion to the full amounts they would otherwise be entitled to receive. Any remaining assets are distributed pro rata among the common stockholders.</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Subject to certain trigger events occurring, the Series B preferred stock holders have the right to force the Company to redeem the shares of preferred stock at a price per preferred share equal to the greater of (A) 115% of the conversion amount and (B) the product of (1) the conversion rate in effect at such time and (2) the greatest closing sale price of the Common Stock during the period beginning on the date immediately preceding such triggering event and ending on the date such holder delivers the notice of redemption. Such triggering events include:</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">
<div style="text-align: justify; margin-top: 3pt; margin-bottom: 3pt;">
<table style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" cellspacing="0" cellpadding="0">
<tr>
<td style="width: 36pt;"></td>
<td style="width: 18pt; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">-</td>
<td style="text-align: justify; width: auto; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">Failure of the Series B Registration Statement to be declared effective by the SEC on or prior to the date that is ninety days after the Effectiveness Deadline;</td>
</tr>
</table>
</div>
<div style="text-align: justify; margin-top: 3pt; margin-bottom: 3pt;">
<table style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" cellspacing="0" cellpadding="0">
<tr>
<td style="width: 36pt;"></td>
<td style="width: 18pt; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">-</td>
<td style="text-align: justify; width: auto; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">Suspension of the Company&#8217;s common stock from trading for a period of (2) consecutive trading days;</td>
</tr>
</table>
</div>
<div style="text-align: justify; margin-top: 3pt; margin-bottom: 3pt;">
<table style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" cellspacing="0" cellpadding="0">
<tr>
<td style="width: 36pt;"></td>
<td style="width: 18pt; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">-</td>
<td style="text-align: justify; width: auto; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">Failure of the Company to deliver all the shares of the common stock or make the appropriate cash payments in a timely manner upon conversion of the Series B Preferred;</td>
</tr>
</table>
</div>
<div style="text-align: justify; margin-top: 3pt; margin-bottom: 3pt;">
<table style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" id="efa5485a941341dba3261c48abc95c07" class="dspflisttable" cellspacing="0" cellpadding="0">
<tr>
<td style="width: 36pt;"></td>
<td style="width: 18pt; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">-</td>
<td style="text-align: justify; width: auto; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">Any default of indebtedness;</td>
</tr>
</table>
</div>
<div style="text-align: justify; margin-top: 3pt; margin-bottom: 3pt;">
<table style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" id="d93c08687c61458585237bc8fdf16638" class="dspflisttable" cellspacing="0" cellpadding="0">
<tr>
<td style="width: 36pt;"></td>
<td style="width: 18pt; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">-</td>
<td style="text-align: justify; width: auto; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">Any filing of voluntary or involuntary bankruptcy by the Company;</td>
</tr>
</table>
</div>
<div style="text-align: justify; margin-top: 3pt; margin-bottom: 3pt;">
<table style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" id="a00b954615f34fa38b8d11caa9556cb7" class="dspflisttable" cellspacing="0" cellpadding="0">
<tr>
<td style="width: 36pt;"></td>
<td style="width: 18pt; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">-</td>
<td style="text-align: justify; width: auto; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">A final judgment in excess of $100,000 rendered against the Company;</td>
</tr>
</table>
</div>
<div style="text-align: justify; margin-top: 3pt; margin-bottom: 3pt;">
<table style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" id="e2d1425ace7249bea58f5de3f0db324a" class="dspflisttable" cellspacing="0" cellpadding="0">
<tr>
<td style="width: 36pt;"></td>
<td style="width: 18pt; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">-</td>
<td style="text-align: justify; width: auto; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">Breach of representations and warranties in the Stock Purchase Agreement;</td>
</tr>
</table>
</div>
<div style="text-align: justify; margin-top: 3pt; margin-bottom: 3pt;">
<table style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" cellspacing="0" cellpadding="0">
<tr>
<td style="width: 36.1pt;"></td>
<td style="width: 18pt; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">-</td>
<td style="text-align: justify; width: auto; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">Failure to comply with the Series B Certificate of Designation or Rule 144 requirements.</td>
</tr>
</table>
</div>
<div style="text-align: justify; margin-top: 3pt; font-family: 'times new roman', times, serif; margin-bottom: 3pt; font-size: 10pt; margin-right: 0.3pt;">&#160;</div>
<div style="text-align: justify; margin-top: 3pt; font-family: 'times new roman', times, serif; margin-bottom: 3pt; font-size: 10pt; margin-right: 0.3pt;">As certain of these triggering events are considered to be outside the control of the Company, the Series B preferred stock is considered to be contingently redeemable&#160;convertible and as a result, has been classified as mezzanine equity in the Company&#8217;s balance sheet presentation.</div>
</div>
<div style="text-align: left; widows: 1; text-transform: none; text-indent: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">
<div style="text-align: center; margin-top: 3pt; font-family: 'times new roman', times, serif; margin-bottom: 3pt; font-size: 10pt; font-weight: bold;">&#160;</div>
</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold italic 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Warrants</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold italic 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">On July 17, 2012, the Company issued warrants to purchase up to 3,000,000 shares of our common stock to its founders and two advisors in consideration for services provided in the start-up of operations. The warrants are exercisable at a price of $1.00 per share and expire on June 20, 2023. The Company valued these warrants utilizing the Black-Scholes valuation model and they were determined to be of nominal value given the start-up nature of the Company's operations at the time of grant.</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">In conjunction with the June 2014 Stock Purchase Agreement, the Company issued warrants to purchase up to 450,000 shares of common stock to a group of private investors. The warrants are exercisable at a price of $1.00 per share and expire on June 12, 2020. The Company valued these warrants at $85,500. This amount was recorded as warrants and was reclassified from the total consideration received for both the common stock and warrants purchased.</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">In August 2014 as part of the June 2014 Stock Purchase Agreement, the Company issued warrants to purchase up to 550,000 shares of common stock with an exercise price of $1.00 per share that expire in August 2020. The Company valued these warrants at $104,500. This amount was recorded as warrants and was reclassified from the total consideration received for both the common stock and warrants purchased.</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">In March 2015, the Company entered into an agreement with a financial advisory and public relations consulting firm which included the issuance of warrants to purchase up to 90,000 shares of common stock with an exercise price of $2.50 per share with a term of five years. These warrants were in exchange for services performed beginning in the first quarter and were subsequently issued in April 2015. The Company estimated the warrant value to be $67,950 utilizing the Black Scholes option pricing model and amortized $9,225 for services provided through September 30, 2015.</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">In April 2015, the Company entered into an agreement with one of its investors to provide advisory services on all matters including financing. In conjunction with this agreement, the Company issued warrants that vest immediately to purchase 100,000 shares of common stock with an exercise price of $5.00 per share with a term of ten years. The Company estimated the warrant value to be $326,000 utilizing the Black Scholes option pricing model and recorded this amount to general and administrative expense for the quarter due to the immediate vesting.</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: left; widows: 1; text-transform: none; text-indent: 35.9pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">In April 2015, the Company issued to a former service provider&#160;<font style="background-color: #ffffff; font-family: 'times new roman', times, serif; color: #000000; font-size: 10pt;">in exchange for</font>&#160;payment of its outstanding invoice warrants that vest immediately to purchase 6,000 shares of common stock with an exercise price of $2.50 per share. The Company estimated the warrant value to be $10,000 which represented the value of the trade debt extinguished<font style="background-color: #ffffff; font-family: 'times new roman', times, serif; color: #000000; font-size: 10pt;">.&#160;</font></div>
<div style="text-align: left; widows: 1; text-transform: none; text-indent: 35.9pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">In April 2015, the Company issued 50,000 warrants to purchase the Company's common stock in conjunction with its Series A Preferred Stock financing. The warrants are exercisable at a price of $5.00 per share and expire five years from the issuance date. In May 2015, the Company issued 30,000 warrants and in July 2015, 36,000 warrants under the same terms and conditions.</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: left; widows: 1; text-transform: none; text-indent: 35.9pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; margin-left: 0.3pt; word-spacing: 0px; -webkit-text-stroke-width: 0px;">In June 2015, the Company issued to a service provider&#160;<font style="background-color: #ffffff; font-family: 'times new roman', times, serif; color: #000000; font-size: 10pt;">in exchange for consulting</font>&#160;services warrants that vest immediately to purchase 10,000 shares of common stock with an exercise price of $5.00 per share with a term of five years. The Company estimated the warrant value to be $14,700 utilizing the Black Scholes option pricing model<font style="background-color: #ffffff; font-family: 'times new roman', times, serif; color: #000000; font-size: 10pt;">.&#160;</font></div>
<div style="widows: 1; text-transform: none; text-indent: 0px; font: medium 'times new roman'; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: left; widows: 1; text-transform: none; background-color: #ffffff; text-indent: 35.9pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; margin-left: 0.3pt; word-spacing: 0px; -webkit-text-stroke-width: 0px;">In August 2015, the Company issued 6,250,000 warrants to purchase common stock in conjunction with its Series B Preferred Stock financing. See further discussion in Note 6 below.</div>
<div style="widows: 1; text-transform: none; text-indent: 0px; font: medium 'times new roman'; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: left; widows: 1; text-transform: none; background-color: #ffffff; text-indent: 35.9pt; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; margin-left: 0.4pt; word-spacing: 0px; -webkit-text-stroke-width: 0px;">In August 2015, the Company issued 187,500 warrants to purchase common stock to its investment banker in exchange for services rendered in conjunction with the Series B Preferred Stock financing. The warrants vest immediately and have an exercise price of $1.15 per share. The Company estimated the value of the warrants to be $86,250 utilizing the Black Scholes option pricing model and recorded this amount to offering costs as an offset to Additional Paid-in-Capital.</div>
<div style="text-align: left; widows: 1; text-transform: none; text-indent: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">
<div style="text-align: center; margin-top: 3pt; font-family: 'times new roman', times, serif; margin-bottom: 3pt; font-size: 10pt; font-weight: bold;">&#160;</div>
</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">The Company's board of directors considered various objective and subjective factors, along with input from management, to determine the fair value of the warrants, including:</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: medium 'times new roman'; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">
<table style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" cellspacing="0" cellpadding="0">
<tr>
<td style="width: 20.25pt;"></td>
<td style="width: 27pt; font-family: symbol, serif; font-size: 10pt; vertical-align: top;">&#183;</td>
<td style="text-align: justify; width: auto; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">Contemporaneous valuation prepared by an independent third-party valuation specialist effective as of June 30, 2014, October 31, 2014, and April 1, 2015, and August 20, 2015,</td>
</tr>
</table>
</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: medium 'times new roman'; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">
<table style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" id="a44fe765ac0f49f5af55938b7979ae74" class="dspflisttable" cellspacing="0" cellpadding="0">
<tr>
<td style="width: 20.25pt;"></td>
<td style="width: 27pt; font-family: symbol, serif; font-size: 10pt; vertical-align: top;">&#183;</td>
<td style="text-align: justify; width: auto; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">Its results of operations, financial position and the status of research and development efforts and achievement of enterprise milestones,</td>
</tr>
</table>
</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: medium 'times new roman'; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">
<table style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" cellspacing="0" cellpadding="0">
<tr>
<td style="width: 20.25pt;"></td>
<td style="width: 27pt; font-family: symbol, serif; font-size: 10pt; vertical-align: top;">&#183;</td>
<td style="text-align: justify; width: auto; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">The composition of, and changes to, the Company's management team and board of directors,</td>
</tr>
</table>
</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: medium 'times new roman'; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">
<table style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" id="ce0655ad177f468ea79569c10b4345b2" class="dspflisttable" cellspacing="0" cellpadding="0">
<tr>
<td style="width: 20.25pt;"></td>
<td style="width: 27pt; font-family: symbol, serif; font-size: 10pt; vertical-align: top;">&#183;</td>
<td style="text-align: justify; width: auto; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">The lack of liquidity of its common stock as a newly public company,</td>
</tr>
</table>
</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: medium 'times new roman'; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">
<table style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" cellspacing="0" cellpadding="0">
<tr>
<td style="width: 20.25pt;"></td>
<td style="width: 27pt; font-family: symbol, serif; font-size: 10pt; vertical-align: top;">&#183;</td>
<td style="text-align: justify; width: auto; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">The Company's stage of development, business strategy and the material risks related to its business and industry,</td>
</tr>
</table>
</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: medium 'times new roman'; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">
<table style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" cellspacing="0" cellpadding="0">
<tr>
<td style="width: 20.25pt;"></td>
<td style="width: 27pt; font-family: symbol, serif; font-size: 10pt; vertical-align: top;">&#183;</td>
<td style="text-align: justify; width: auto; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">The valuation of publicly-traded companies in the biotechnology sectors,</td>
</tr>
</table>
</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: medium 'times new roman'; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">
<table style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" cellspacing="0" cellpadding="0">
<tr>
<td style="width: 20.25pt;"></td>
<td style="width: 27pt; font-family: symbol, serif; font-size: 10pt; vertical-align: top;">&#183;</td>
<td style="text-align: justify; width: auto; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">External market conditions affecting the biotechnology industry sectors,</td>
</tr>
</table>
</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: medium 'times new roman'; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">
<table style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" id="d61b928bfc1d4cea83ee919cb0c065a3" class="dspflisttable" cellspacing="0" cellpadding="0">
<tr>
<td style="width: 20.25pt;"></td>
<td style="width: 27pt; font-family: symbol, serif; font-size: 10pt; vertical-align: top;">&#183;</td>
<td style="text-align: justify; width: auto; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">The likelihood of achieving a liquidity event for the holders of its common stock, such as an initial public offering, or IPO, or a sale of the Company, given prevailing market conditions, and</td>
</tr>
</table>
</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: medium 'times new roman'; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">
<table style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" class="dspflisttable" cellspacing="0" cellpadding="0">
<tr>
<td style="width: 20.45pt;"></td>
<td style="width: 27pt; font-family: symbol, serif; font-size: 10pt; vertical-align: top;">&#183;</td>
<td style="text-align: justify; width: auto; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">The state of the IPO market for similarly situated biotechnology companies,</td>
</tr>
</table>
</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: medium 'times new roman'; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">
<table style="width: 100%; font-family: 'times new roman', times, serif; font-size: 10pt;" id="bbbf2248e5ff4fab976f39a73a1c83c2" class="dspflisttable" cellspacing="0" cellpadding="0">
<tr>
<td style="width: 20.45pt;"></td>
<td style="width: 27pt; font-family: symbol, serif; font-size: 10pt; vertical-align: top;">&#183;</td>
<td style="text-align: justify; width: auto; font-family: 'times new roman', times, serif; font-size: 10pt; vertical-align: top;">Discussions held with bankers, potential investors, and preliminary term sheets received as part of management's capital raise efforts.</td>
</tr>
</table>
</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">There are significant judgments and estimates inherent in the determination of the fair value of the Company's warrants. These judgments and estimates included the assumptions regarding its future operating performance, the time to completing an IPO or other liquidity event and the determination of the appropriate valuation methods. If the Company had made different assumptions, its warrant valuation could have been significantly different.</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold italic 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Stock Option Plans: 2014 Omnibus Incentive Plan</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold italic 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">The 2014 Omnibus Incentive Plan (the "2014 Plan") was adopted to provide a means by which officers, non-employee directors, and employees of and consultants to the Company and its affiliates could be given an opportunity to acquire an equity interest in the Company. All officers, non-employee directors, and employees of and consultants to the Company are eligible to participate in the 2014 Plan.</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">On October 31, 2014, after the closing of the Merger, our Board of Directors approved the 2014 Plan. The 2014 Plan reserved 3,200,000 shares for future grants.&#160;As of September 30, 2015, options (net of canceled or expired options) covering an aggregate of 1,180,000 shares of the Company's common stock had been granted under the 2014 Plan, and the Company had 1,180,000 options outstanding and 2,020,000 shares available for future grants under the 2014 Plan.</div>
<div style="text-align: left; widows: 1; text-transform: none; text-indent: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">
<div style="text-align: center; margin-top: 3pt; font-family: 'times new roman', times, serif; margin-bottom: 3pt; font-size: 10pt; font-weight: bold;">&#160;</div>
</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Options granted under the 2014 Plan expire no later than 10 years from the date of grant. Options granted under the 2014 Plan may be either incentive or non-qualified stock options. For incentive and non-qualified stock option grants, the option price shall be at least 100% of the fair value on the date of grants, as determined by the Company's Board of Directors. If at any time the Company grants an option, and the optionee directly or by attribution owns stock possessing more than 10% of the total combined voting power of all classes of stock of the Company, the option price shall be at least 110% of the fair value and shall not be exercisable more than five years after the date of grant.</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Options granted under the 2014 Plan may be immediately exercisable if permitted in the specific grant approved by the Board of Directors and, if exercised early may be subject to repurchase provisions. The shares acquired generally vest over a period of five years from the date of grant. The Company granted options to purchase 1,180,000 shares through September 30, 2015, under the 2014 Plan.</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: left; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">The following is a summary of activity under the 2014 Plan as of September, 2015:</div>
<div style="widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: medium 'times new roman'; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<table style="widows: 1; text-transform: none; text-indent: 0px; width: 100%; font-family: 'times new roman', times, serif; letter-spacing: normal; font-size: 10pt; word-spacing: 0px; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="padding-bottom: 2px; vertical-align: middle;" valign="bottom">&#160;</td>
<td style="padding-bottom: 2px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="padding-bottom: 2px; vertical-align: middle;" valign="bottom" colspan="2"></td>
<td style="text-align: left; padding-bottom: 2px; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 2px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="border-bottom: #000000 2px solid; vertical-align: middle;" valign="bottom" colspan="10">
<div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Options Outstanding</div>
</td>
<td style="text-align: left; padding-bottom: 2px; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="vertical-align: middle;" valign="bottom">&#160;</td>
<td style="vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="vertical-align: middle;" valign="bottom" colspan="2">
<div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Shares Available</div>
</td>
<td style="text-align: left; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="vertical-align: middle;" valign="bottom" colspan="2"></td>
<td style="text-align: left; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="vertical-align: middle;" valign="bottom" colspan="3"></td>
<td style="text-align: left; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="vertical-align: middle;" valign="bottom" colspan="2">
<div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Weighted Average</div>
</td>
<td style="text-align: left; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="vertical-align: middle;" valign="bottom">&#160;</td>
<td style="vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="vertical-align: middle;" valign="bottom" colspan="2">
<div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">for Grant of</div>
</td>
<td style="text-align: left; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="vertical-align: middle;" valign="bottom" colspan="2">
<div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Number of</div>
</td>
<td style="text-align: left; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="vertical-align: middle;" valign="bottom" colspan="3"></td>
<td style="text-align: left; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="vertical-align: middle;" valign="bottom" colspan="2">
<div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Exercise</div>
</td>
<td style="text-align: left; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="padding-bottom: 2px; vertical-align: middle;" valign="bottom">&#160;</td>
<td style="padding-bottom: 2px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="border-bottom: #000000 2px solid; vertical-align: middle;" valign="bottom" colspan="2">
<div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Options</div>
</td>
<td style="text-align: left; padding-bottom: 2px; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 2px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="border-bottom: #000000 2px solid; vertical-align: middle;" valign="bottom" colspan="2">
<div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Shares</div>
</td>
<td style="text-align: left; padding-bottom: 2px; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="border-bottom: #000000 2px solid; vertical-align: middle;" valign="bottom" colspan="3">
<div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Price per Share</div>
</td>
<td style="text-align: left; padding-bottom: 2px; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 2px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="border-bottom: #000000 2px solid; vertical-align: middle;" valign="bottom" colspan="2">
<div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Price</div>
</td>
<td style="text-align: left; padding-bottom: 2px; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="background-color: #cceeff; width: 790px; vertical-align: middle;" valign="bottom">
<div style="text-align: left; text-indent: 10.05pt; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Balance at December&#160;31, 2014</div>
</td>
<td style="background-color: #cceeff; width: 16px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="text-align: left; background-color: #cceeff; width: 16px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="text-align: right; background-color: #cceeff; width: 137px; vertical-align: bottom;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1,470,000</div>
</td>
<td style="text-align: left; background-color: #cceeff; width: 16px; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="background-color: #cceeff; width: 16px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="text-align: left; background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="text-align: right; background-color: #cceeff; width: 136px; vertical-align: bottom;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1,730,000</div>
</td>
<td style="text-align: left; background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="text-align: left; background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div>
</td>
<td style="text-align: right; background-color: #cceeff; width: 136px; vertical-align: bottom;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">0.42</div>
</td>
<td style="text-align: left; background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="text-align: left; background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div>
</td>
<td style="text-align: right; background-color: #cceeff; width: 136px; vertical-align: bottom;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">0.42</div>
</td>
<td style="text-align: left; background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="background-color: #ffffff; padding-left: 60px; width: 729px; vertical-align: middle;" valign="bottom">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Options granted</div>
</td>
<td style="background-color: #ffffff; width: 16px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="text-align: left; background-color: #ffffff; width: 16px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="text-align: right; background-color: #ffffff; width: 137px; vertical-align: bottom;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(130,000</div>
</td>
<td style="text-align: left; background-color: #ffffff; width: 16px; vertical-align: bottom;" valign="bottom" nowrap="nowrap">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div>
</td>
<td style="background-color: #ffffff; width: 16px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="text-align: left; background-color: #ffffff; width: 15px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="text-align: right; background-color: #ffffff; width: 136px; vertical-align: bottom;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">130,000</div>
</td>
<td style="text-align: left; background-color: #ffffff; width: 15px; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="background-color: #ffffff; width: 15px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="text-align: left; background-color: #ffffff; width: 15px; vertical-align: bottom;" valign="bottom">
<div>$&#160;</div>
</td>
<td style="text-align: right; background-color: #ffffff; width: 136px; vertical-align: bottom;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1.15 - $3.00</div>
</td>
<td style="text-align: left; background-color: #ffffff; width: 15px; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="background-color: #ffffff; width: 15px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="text-align: left; background-color: #ffffff; width: 15px; vertical-align: bottom;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div>
</td>
<td style="text-align: right; background-color: #ffffff; width: 136px; vertical-align: bottom;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">2.29</div>
</td>
<td style="text-align: left; background-color: #ffffff; width: 15px; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="background-color: #cceeff; padding-left: 60px; width: 729px; vertical-align: middle;" valign="bottom">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Options exercised</div>
</td>
<td style="background-color: #cceeff; width: 16px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="text-align: left; background-color: #cceeff; width: 16px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="text-align: right; background-color: #cceeff; width: 137px; vertical-align: bottom;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div>
</td>
<td style="text-align: left; background-color: #cceeff; width: 16px; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="background-color: #cceeff; width: 16px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="text-align: left; background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="text-align: right; background-color: #cceeff; width: 136px; vertical-align: bottom;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</div>
</td>
<td style="text-align: left; background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="text-align: left; background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="text-align: right; background-color: #cceeff; width: 136px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="text-align: left; background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="text-align: left; background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="text-align: right; background-color: #cceeff; width: 136px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="text-align: left; background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="padding-bottom: 2px; background-color: #ffffff; padding-left: 60px; width: 729px; vertical-align: middle;" valign="bottom">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Options cancelled</div>
</td>
<td style="padding-bottom: 2px; background-color: #ffffff; width: 16px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 16px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 137px; vertical-align: bottom;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">680,000</div>
</td>
<td style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 16px; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 2px; background-color: #ffffff; width: 16px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff; width: 15px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff; width: 136px; vertical-align: bottom;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">(680,000</div>
</td>
<td style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 15px; vertical-align: bottom;" valign="bottom" nowrap="nowrap">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</div>
</td>
<td style="padding-bottom: 2px; background-color: #ffffff; width: 15px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 15px; vertical-align: bottom;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div>
</td>
<td style="text-align: right; padding-bottom: 2px; background-color: #ffffff; width: 136px; vertical-align: bottom;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">0.42</div>
</td>
<td style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 15px; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 2px; background-color: #ffffff; width: 15px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 15px; vertical-align: bottom;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div>
</td>
<td style="text-align: right; padding-bottom: 2px; background-color: #ffffff; width: 136px; vertical-align: bottom;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">0.42</div>
</td>
<td style="text-align: left; padding-bottom: 2px; background-color: #ffffff; width: 15px; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
<tr>
<td style="padding-bottom: 4px; background-color: #cceeff; width: 790px; vertical-align: middle;" valign="bottom">
<div style="text-align: left; text-indent: 10.05pt; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">Balance at September&#160;30, 2015</div>
</td>
<td style="padding-bottom: 4px; background-color: #cceeff; width: 16px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 16px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 137px; vertical-align: bottom;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">2,020,000</div>
</td>
<td style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 16px; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 4px; background-color: #cceeff; width: 16px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="border-bottom: #000000 4px double; text-align: left; background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="border-bottom: #000000 4px double; text-align: right; background-color: #cceeff; width: 136px; vertical-align: bottom;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">1,180,000</div>
</td>
<td style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 4px; background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="text-align: left; background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div>
</td>
<td style="text-align: right; background-color: #cceeff; width: 136px; vertical-align: bottom;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">0.42 - $3.00</div>
</td>
<td style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 4px; background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom">&#160;</td>
<td style="text-align: left; background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</div>
</td>
<td style="text-align: right; background-color: #cceeff; width: 136px; vertical-align: bottom;" valign="bottom">
<div style="font-family: 'times new roman', times, serif; font-size: 10pt;">0.63</div>
</td>
<td style="text-align: left; padding-bottom: 4px; background-color: #cceeff; width: 15px; vertical-align: bottom;" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
<div style="widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: medium 'times new roman'; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: medium 'times new roman'; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">The weighted average remaining contractual life in years of the options outstanding as of September 30, 2015 was 9.18 years.</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Aggregate intrinsic value is the sum of the amounts by which the quoted market price of the Company's stock exceeded the exercise price of the stock options at September 30, 2015 for those stock options for which the quoted market price was in excess of the exercise price ("in-the-money options"). As of September 30, 2015, the aggregate intrinsic value of options outstanding was $147,000. As of September 30, 2015, no options to purchase shares of common stock were exercisable.</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: left; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold italic 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Stock Based Compensation Expense</div>
<div style="text-align: left; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold italic 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">The Company recognizes stock-based compensation expense based on the fair value of that portion of stock options that are ultimately expected to vest during the period. Stock-based compensation expense recognized in the consolidated statement of operations includes compensation expense for stock-based awards based on the estimated grant date fair value over the requisite service period. For the nine months ended September 30, 2015, the Company recognized stock-based compensation expense of $263,985 which was recorded as a general and administrative expense in the consolidated statement of operations. For the nine months ended September 30, 2014, stock-based compensation expense was $0.</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: left; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">The total amount of unrecognized compensation cost related to non-vested stock options was $1,477,143 as of September 30, 2015. This amount will be recognized over a weighted average period of 4.14 years.</div>
<div style="text-align: left; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold italic 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: left; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold italic 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Valuation Assumptions</div>
<div style="text-align: left; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 0px; font: bold italic 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">The fair value of options was estimated at the date of grant using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company's common stock for similar terms. The expected term was estimated using the simplified method as permitted under SAB No. 110, since the Company has no recent exercise or forfeiture history that is representative of options granted during the year.&#160;The expected term represents the estimated period of time that stock options are expected to be outstanding, which is less than the contractual term which is generally ten years. The risk-free interest rate is based on the U.S. Treasury yield. The expected dividend yield is zero, as the Company does not anticipate paying dividends in the near future. The weighted average assumptions for employee options are as follows:</div>
<div style="text-align: justify; widows: 1; text-transform: none; margin-top: 3pt; text-indent: 36pt; font: 10pt 'times new roman', times, serif; white-space: normal; margin-bottom: 3pt; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</div>
<div style="text-align: left; widows: 1; text-transform: none; text-indent: 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">
<table style="width: 100%; border-collapse: collapse; font-family: 'times new roman', times, serif; font-size: 10pt;" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="width: 1141px; vertical-align: middle;">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div>
</td>
<td style="border-bottom: #000000 2px solid; width: 378px; vertical-align: middle;" colspan="3">
<div style="text-align: center; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">For the Nine Months Ended&#160;&#160; September 30,</div>
</td>
</tr>
<tr>
<td style="width: 1141px; vertical-align: middle;">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div>
</td>
<td style="border-bottom: #000000 2px solid; width: 196px; vertical-align: middle;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">2015</div>
</td>
<td style="width: 30px; vertical-align: middle;">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div>
</td>
<td style="border-bottom: #000000 2px solid; width: 152px; vertical-align: middle;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt; font-weight: bold;">2014</div>
</td>
</tr>
<tr>
<td style="background-color: #cceeff; width: 1141px; vertical-align: middle;">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Dividend yield</div>
</td>
<td style="background-color: #cceeff; width: 196px; vertical-align: middle;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">0.00%</div>
</td>
<td style="background-color: #cceeff; width: 30px; vertical-align: middle;">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div>
</td>
<td style="background-color: #cceeff; width: 152px; vertical-align: middle;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">NA</div>
</td>
</tr>
<tr>
<td style="background-color: #ffffff; width: 1141px; vertical-align: middle;">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Volatility factor</div>
</td>
<td style="background-color: #ffffff; width: 196px; vertical-align: middle;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">75.00%</div>
</td>
<td style="background-color: #ffffff; width: 30px; vertical-align: middle;">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div>
</td>
<td style="background-color: #ffffff; width: 152px; vertical-align: middle;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">NA</div>
</td>
</tr>
<tr>
<td style="background-color: #cceeff; width: 1141px; vertical-align: middle;">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Risk-free interest rate</div>
</td>
<td style="background-color: #cceeff; width: 196px; vertical-align: middle;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">1.68-1.85%</div>
</td>
<td style="background-color: #cceeff; width: 30px; vertical-align: middle;">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div>
</td>
<td style="background-color: #cceeff; width: 152px; vertical-align: middle;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">NA</div>
</td>
</tr>
<tr>
<td style="background-color: #ffffff; width: 1141px; vertical-align: middle;">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Expected term (years)</div>
</td>
<td style="background-color: #ffffff; width: 196px; vertical-align: middle;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">6.25-6.50</div>
</td>
<td style="background-color: #ffffff; width: 30px; vertical-align: middle;">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div>
</td>
<td style="background-color: #ffffff; width: 152px; vertical-align: middle;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">NA</div>
</td>
</tr>
<tr>
<td style="background-color: #cceeff; width: 1141px; vertical-align: middle;">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">Weighted-average fair value of options granted during the periods</div>
</td>
<td style="background-color: #cceeff; width: 196px; vertical-align: middle;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">$2.69</div>
</td>
<td style="background-color: #cceeff; width: 30px; vertical-align: middle;">
<div style="text-align: left; font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</div>
</td>
<td style="background-color: #cceeff; width: 152px; vertical-align: middle;">
<div style="text-align: right; font-family: 'times new roman', times, serif; font-size: 10pt;">NA</div>
</td>
</tr>
</table>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph (SAB TOPIC 4.C)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Preferred Stock<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section C<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139753857799648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision for Conversion of Preferred Stock (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2015</div></th>
<th class="th"><div>Aug. 21, 2015</div></th>
<th class="th"><div>Jul. 31, 2015</div></th>
<th class="th"><div>Apr. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ProvisionForConversionOfPreferredStock', window );">Fair value of the conversion feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,488<span></span>
</td>
<td class="nump">$ 75,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_GainLossOnConversionRightPreferredStock', window );">Change in fair value of conversion rights of Series A preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 286,000<span></span>
</td>
<td class="nump">$ 986,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_MinimumIssuanceOfSharesInEquityFinancing', window );">Minimum equity financing under down-round protection feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 286,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_MaximumIssuancePricePerShareInEquityFinancing', window );">Maximum common stock issuance price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_DownRoundProvisionsExpirationTerms', window );">Down round provisions expiration terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div><font style="font-family: times new roman,times;" size="2">either at (i) a subsequent equity financing of at least $1,000,000 or (ii) October 1, 2015</font></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ProvisionForConversionOfPreferredStock', window );">Fair value of the conversion feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of additional shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted</a></td>
<td class="nump">580,000<span></span>
</td>
<td class="nump">580,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockLineItems', window );"><strong>Conversion of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_MaximumIssuancePricePerShareInEquityFinancing', window );">Maximum common stock issuance price per share (in dollars per share)</a></td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants', window );">Proceeds received from the Series B financing</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of additional shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,232,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ConversionPrice', window );">Conversion price</a></td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents conversion price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_DownRoundProvisionsExpirationTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of down round provisions expiration terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_DownRoundProvisionsExpirationTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_GainLossOnConversionRightPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount related to gain or loss on conversion right of preferred stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_GainLossOnConversionRightPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_MaximumIssuancePricePerShareInEquityFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents maximum issuance price per share under equity financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_MaximumIssuancePricePerShareInEquityFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_MinimumIssuanceOfSharesInEquityFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents value of minimum issuance of shares under equity financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_MinimumIssuanceOfSharesInEquityFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ProvisionForConversionOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount related to provision for conversion of preferred stock as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ProvisionForConversionOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.3.0.814</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>87</ContextCount>
  <ElementCount>205</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>29</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="nmus-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nmus-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nmus-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>003 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/Consolidatedbalancesheetsparentheticals</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nmus-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/ConsolidatedStatementsOfOperationsUnaudited</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nmus-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/ConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nmus-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/ConsolidatedStatementsOfCashFlowsUnauditedParentheticals</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nmus-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>007 - Disclosure - Nature of Operations, Business Activities and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Nature of Operations, Business Activities and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nmus-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>008 - Disclosure - University of Mississippi ("UM") Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/UniversityOfMississippiUmAgreements</Role>
      <ShortName>University of Mississippi ("UM") Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nmus-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>009 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nmus-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>010 - Disclosure - Stockholders' Deficit and Redeemable Convertible Series B Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemption</Role>
      <ShortName>Stockholders' Deficit and Redeemable Convertible Series B Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nmus-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>011 - Disclosure - Provision for Conversion of Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/ProvisionForConversionOfPreferredStock</Role>
      <ShortName>Provision for Conversion of Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nmus-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>012 - Disclosure - Series B Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/SeriesBWarrants</Role>
      <ShortName>Series B Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nmus-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>013 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nmus-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>014 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nmus-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>015 - Disclosure - Nature of Operations, Business Activities and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Nature of Operations, Business Activities and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="nmus-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>016 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="nmus-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>017 - Disclosure - Stockholders'Deficit and Preferred Stock Subject to Redemption (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionTables</Role>
      <ShortName>Stockholders'Deficit and Preferred Stock Subject to Redemption (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nmus-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>018 - Disclosure - Series B Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/SeriesBWarrantsTables</Role>
      <ShortName>Series B Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/SeriesBWarrants</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="nmus-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>019 - Disclosure - Nature of Operations, Business Activities and Summary of Significant Accounting Policies (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesDetailTextuals</Role>
      <ShortName>Nature of Operations, Business Activities and Summary of Significant Accounting Policies (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="nmus-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>020 - Disclosure - University of Mississippi ("UM") Agreements (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/UniversityOfMississippiUmAgreementsDetailTextuals</Role>
      <ShortName>University of Mississippi ("UM") Agreements (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/UniversityOfMississippiUmAgreements</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="nmus-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>021 - Disclosure - Commitments and Contingencies - Summary of Future minimum payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/CommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Future minimum payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="nmus-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>022 - Disclosure - Commitments and Contingencies (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/CommitmentsAndContingenciesDetailTextuals</Role>
      <ShortName>Commitments and Contingencies (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="nmus-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>023 - Disclosure - Stockholders'Deficit and Preferred Stock Subject to Redemption - Summary of option activity under 2014 Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionSummaryOfOptionActivityUnder2014PlanDetails</Role>
      <ShortName>Stockholders'Deficit and Preferred Stock Subject to Redemption - Summary of option activity under 2014 Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="nmus-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>024 - Disclosure - Stockholders'Deficit and Preferred Stock Subject to Redemption - Summary of weighted average assumptions for employee option (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionSummaryOfWeightedAverageAssumptionsForEmployeeOptionDetails1</Role>
      <ShortName>Stockholders'Deficit and Preferred Stock Subject to Redemption - Summary of weighted average assumptions for employee option (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="nmus-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>025 - Disclosure - Stockholders'Deficit and Preferred Stock Subject to Redemption (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals</Role>
      <ShortName>Stockholders'Deficit and Preferred Stock Subject to Redemption (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="nmus-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>026 - Disclosure - Stockholders'Deficit and Preferred Stock Subject to Redemption (Detail Textuals 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionDetailTextuals1</Role>
      <ShortName>Stockholders'Deficit and Preferred Stock Subject to Redemption (Detail Textuals 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/StockholdersDeficitAndPreferredStockSubjectToRedemptionTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="nmus-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>027 - Disclosure - Provision for Conversion of Preferred Stock (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/ProvisionForConversionOfPreferredStockDetailTextuals</Role>
      <ShortName>Provision for Conversion of Preferred Stock (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/ProvisionForConversionOfPreferredStock</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="nmus-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>028 - Disclosure - Series B Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/SeriesBWarrantsDetails</Role>
      <ShortName>Series B Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/SeriesBWarrantsTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="nmus-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>029 - Disclosure - Series B Warrants (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/SeriesBWarrantsDetailTextuals</Role>
      <ShortName>Series B Warrants (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/SeriesBWarrantsTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="nmus-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>030 - Disclosure - Income Taxes (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/IncomeTaxesDetailTextuals</Role>
      <ShortName>Income Taxes (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/IncomeTaxes</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="nmus-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>031 - Disclosure - Subsequent Events (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nemusbioscience.com/role/SubsequentEventsDetailTextuals</Role>
      <ShortName>Subsequent Events (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nemusbioscience.com/role/SubsequentEvents</ParentRole>
      <Position>31</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">In ''CONSOLIDATED BALANCE SHEETS'', column(s) 3 are contained in other reports, so were removed by flow through suppression.</Log>
    <Log type="Info">In ''CONSOLIDATED BALANCE SHEETS (Parentheticals)'', column(s) 4, 5 are contained in other reports, so were removed by flow through suppression.</Log>
    <Log type="Info">In ''CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)'', column(s) 4 are contained in other reports, so were removed by flow through suppression.</Log>
    <Log type="Info">In ''CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)'', column(s) 1, 2 are contained in other reports, so were removed by flow through suppression.</Log>
    <Log type="Info">In ''CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (Parentheticals)'', column(s) 5 are contained in other reports, so were removed by flow through suppression.</Log>
  </Logs>
  <InputFiles>
    <File>nmus-20150930.xml</File>
    <File>nmus-20150930_cal.xml</File>
    <File>nmus-20150930_def.xml</File>
    <File>nmus-20150930_lab.xml</File>
    <File>nmus-20150930_pre.xml</File>
    <File>nmus-20150930.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139753846229456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>University of Mississippi ("UM") Agreements (Detail Textuals)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 29, 2014 </div>
<div>License_agreement</div>
</th>
<th class="th"><div>Jul. 31, 2013</div></th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152,288<span></span>
</td>
<td class="nump">$ 195,000<span></span>
</td>
<td class="nump">$ 232,862<span></span>
</td>
<td class="nump">$ 195,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_AgreementAxis=nmus_UniversityOfMississippiAgreementsMember', window );">University of Mississippi ("UM") Agreements | Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_TermOfMemorandumOfUnderstandingAgreement', window );">Term of memorandum of understanding agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NoticePeriodForTermination', window );">Notice period for termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_AgreementAxis=nmus_OptionAgreementMember', window );">Option Agreement | Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NumberOfLicenseAgreements', window );">Number of license agreements | License_agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NoticePeriodForTermination', window );">Notice period for termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_AgreementAxis=nmus_OptionAgreementMember', window );">Option Agreement | Intellectual Property | Accrued license and patent reimbursement fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_ReimbursementOfSunkPatentExpenses', window );">Reimbursement of sunk patent expenses</a></td>
<td class="nump">$ 70,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_AgreementAxis=nmus_ResearchAgreementMember', window );">Research Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_AgreementAxis=nmus_ResearchAgreementMember', window );">Research Agreement | University of Mississippi | Intellectual Property | March 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NoticePeriodForTermination', window );">Notice period for termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_AgreementAxis=nmus_ResearchAgreementMember', window );">Research Agreement | University of Mississippi | Intellectual Property | July 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NoticePeriodForTermination', window );">Notice period for termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_AgreementAxis=nmus_ResearchAgreementMember', window );">Research Agreement | University of Mississippi | Intellectual Property | September 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmus_NoticePeriodForTermination', window );">Notice period for termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_NoticePeriodForTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents written notice period for termination under agreement by either party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_NoticePeriodForTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_NumberOfLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_NumberOfLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_ReimbursementOfSunkPatentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents amount of reimbursement of sunk patent expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_ReimbursementOfSunkPatentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_TermOfMemorandumOfUnderstandingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents duration of an agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but not limited to, weeks in a year or quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_TermOfMemorandumOfUnderstandingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_UniversityOfMississippiAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line item represents information regarding University of Mississippi agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_UniversityOfMississippiAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 985<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_AgreementAxis=nmus_UniversityOfMississippiAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_AgreementAxis=nmus_UniversityOfMississippiAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_AgreementAxis=nmus_OptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_AgreementAxis=nmus_OptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=nmus_AccruedLicenseAndPatentReimbursementFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=nmus_AccruedLicenseAndPatentReimbursementFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_AgreementAxis=nmus_ResearchAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_AgreementAxis=nmus_ResearchAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nmus_UniversityOfMississippiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nmus_UniversityOfMississippiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_MonthAndYearOfAgreementAxis=nmus_March2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_MonthAndYearOfAgreementAxis=nmus_March2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_MonthAndYearOfAgreementAxis=nmus_July2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_MonthAndYearOfAgreementAxis=nmus_July2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmus_MonthAndYearOfAgreementAxis=nmus_September2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmus_MonthAndYearOfAgreementAxis=nmus_September2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
